{
    "0": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the criteria of \"Women of any age with clinical stage II breast cancer\".\n\nThe tumor is 3 cm invasive ductal carcinoma, which falls under \"primary tumor less than or equal to 5 cm in size\". \n\nShe has 5 positive axillary lymph nodes, meeting the criteria of \"axillary lymph nodes which are clinically [N0 or N1] [T1N1, T2N0, T2N1]\".\n\nThe tumor is HER2-positive and ER/PR negative, which is allowed as \"Estrogen receptor (ER) status can include ER positive, negative, or unknown\".\n\nThere is no mention of previous cancer history.\n\nThe patient has no other chronic diseases mentioned that would exclude her based on the criteria.\n\nBased on the information provided, this patient meets all the inclusion criteria and does not violate any of the exclusion criteria for this breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed nonlobular invasive breast cancer - The patient has invasive ductal breast carcinoma, which meets this criteria.\n- Stage I/II (T1-2 N0-1 M0) tumor no greater than 3 cm - The patient has a 3 cm tumor, meeting this criteria. \n- Prior lumpectomy and axillary lymph node dissection required - The patient had a core biopsy, not a lumpectomy, so this criteria is not met.\n- No more than 3 positive axillary lymph nodes and no extracapsular extension - The patient had 5 positive lymph nodes, not meeting this criteria.\n- Other criteria regarding surgical margins, mammogram findings, intraductal carcinoma, etc. - Unable to assess based on the information provided.\n\nPATIENT CHARACTERISTICS:\n- Age: Any age - Met\n- Sex: Female - Met\n- Other criteria (menopausal status, performance status, hematopoietic, hepatic, renal, etc.) - Unable to assess based on information provided.\n\nPRIOR CONCURRENT THERAPY:\n- No prior chemotherapy for breast cancer - Met\n- Planned chemotherapy may begin after brachytherapy - Unclear if chemotherapy is planned based on information provided.\n- Concurrent tamoxifen permitted - Unclear if the patient will receive tamoxifen.\n- No prior radiotherapy for breast cancer - Met\n\nBased on the information provided, the key criteria that are not met are the requirement for prior lumpectomy, and having no more than 3 positive lymph nodes. There is also insufficient information to assess some other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "2": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has a 3 cm invasive ductal breast carcinoma, which meets the \"Primary invasive adenocarcinoma of the unilateral or bilateral breast\" criteria.\n- The tumor is stage II (5 positive lymph nodes) which meets the \"Stage I, IIA, or IIB (T1-3, N0-1, M0)\" criteria.\n- There is no evidence of recurrent or distant metastatic disease based on the CXR findings of metastatic lesions.\n- The patient had a core biopsy, meeting the requirement for prior definitive local treatment and axillary node biopsy.\n- There is no mention of endometrial hyperplasia or carcinoma.\n- The patient is a candidate for adjuvant tamoxifen therapy based on her ER/PR negative, HER2-positive status.\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, meeting the age and menopausal status criteria.\n- There is no information provided about performance status or life expectancy.\n- There are no concerns mentioned about hematopoietic, hepatic or renal function.\n- There is no mention of other malignancies.\n- The patient is not currently sexually active, so contraception is not a concern.\n\nPRIOR CONCURRENT THERAPY:\n- The patient has not received any prior treatment yet, so chemotherapy and radiotherapy criteria are met.\n- There is no mention of prior hormonal breast cancer treatment besides planned tamoxifen.\n- The patient has not had a hysterectomy.\n- There is no information about participation in other adjuvant trials.\n\nBased on the information provided, the patient meets all of the key inclusion criteria for this tamoxifen trial in postmenopausal breast cancer patients.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "3": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of being a female aged 18 or over with histologically confirmed breast cancer.\n\nThe tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative, with 5 positive lymph nodes. This meets the criteria of resectable adenocarcinoma of the breast with 1-3 positive lymph nodes.\n\nThe patient is a candidate for tumor resection prior to chemotherapy, which meets the criteria of having the tumor removed before starting treatment on the trial protocol.\n\nThere is no mention of prior chemotherapy, radiotherapy or endocrine therapy for this malignancy, meeting those criteria.\n\nThe patient's health status like hematopoietic, hepatic, renal and cardiac function are not mentioned, so it's unclear if she meets those criteria.\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria for this breast cancer chemotherapy trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "4": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically or cytologically proven stage I or IIA invasive breast cancer - The patient has cytologically confirmed invasive ductal breast carcinoma, which meets this criteria.\n- T0, T1, or T2 (no greater than 3 cm) - The tumor is 3 cm, which meets this criteria. \n- N0 - The patient has 5 positive lymph nodes, so does not meet this criteria.\n- Noninflammatory - No information provided, but assuming it is non-inflammatory based on the details given.\n- Nonmetastatic - The patient has metastatic lesions noted on CXR, so does not meet this criteria.\n- No ductal carcinoma in situ - No information provided, but assuming no DCIS based on invasive ductal carcinoma diagnosis.\n- Eligible for breast-conserving surgery - The patient is a candidate for tumor resection, which suggests breast-conserving surgery is an option.\n- Hormone receptor status: Positive or negative - The tumor is HER2-positive and ER/PR negative, which meets this criteria.\n\nPATIENT CHARACTERISTICS:\n- Age: Any age - The patient is 45 years old, which meets this criteria.\n- Sex: Female - The patient is female, which meets this criteria. \n- Menopausal status: Pre- and postmenopausal - The patient is postmenopausal, which meets this criteria.\n- Performance status: Not specified\n- Life expectancy: Not specified\n- Hematopoietic: Not specified\n- Hepatic: Not specified \n- Renal: Not specified\n- Other: Not pregnant, no allergy or sensitivity to radiopharmaceuticals or patent blue V dye - No information provided about pregnancy or allergies.\n\nPRIOR CONCURRENT THERAPY:\n- No prior biologic, chemotherapy, endocrine therapy, or radiotherapy - Meets these criteria based on information given.\n- No prior breast surgical biopsy or axillary surgery - The patient had a core biopsy, so does not meet this criteria.\n\nIn summary, the patient meets some but not all of the key inclusion criteria for this trial due to having positive lymph nodes, evidence of metastatic disease, and a prior core biopsy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "5": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has resectable invasive ductal breast carcinoma, which is confirmed by core biopsy. This meets the criteria.\n- The tumor is 3 cm, which implies it is clinically node-negative based on the criteria of \"No positive ipsilateral axillary lymph nodes\".\n- There is no mention of ulceration, erythema, or skin involvement, meeting that criteria.\n- It is a single tumor in one quadrant of the breast, meeting the criteria of \"No diffuse tumors or multiple malignant tumors in different quadrants of the breast\".\n- There is no mention of prior breast malignancy.\n- There is no mention of prior or concurrent breast implants.\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, meeting the age and sex criteria.\n- There is no information provided about performance status or life expectancy.\n- There is no mention of any hematopoietic, hepatic, renal, or cardiovascular systemic diseases.\n- There is no mention of any prior malignancy or psychiatric/addictive disorder.\n\nPRIOR CONCURRENT THERAPY:\n- There is no mention of any prior biologic therapy, chemotherapy, endocrine therapy, or radiotherapy for this cancer.\n- The patient is a candidate for tumor resection, meeting the surgery criteria.\n\nBased on the information provided, the patient meets all the stated inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "6": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative tumor\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria state:\n- Histologically confirmed resectable adenocarcinoma of the breast\n- pT1, pT2, pT3, or minimal dermal involvement\n- pN0, pN1, pN2, or M0 (no distant metastases)\n- Must have had total mastectomy, lumpectomy, or quadrantectomy\n- Stage I, II, or IIIa if tumor completely removed\n- Postmenopausal\n- At least 10% hormone receptor-positive tumor cells\n\nBased on the information provided, the patient meets most of the key inclusion criteria:\n- Postmenopausal\n- Resectable breast cancer\n- Has undergone or is a candidate for tumor resection\n\nHowever, there are a couple potential issues:\n1) The tumor is ER/PR negative, while the criteria require at least 10% hormone receptor positivity.\n2) The patient has metastatic lesions on CXR, which may exclude her if considered M1 disease rather than M0.\n\nWithout more details on staging and whether the metastases are confirmed, it's difficult to make a definitive assessment. But given the ER/PR negative status, she likely does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "7": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- HER2 overexpressing (3+) metastatic breast cancer by immunohistochemistry, or amplified by FISH - The patient has HER2-positive metastatic breast cancer, meeting this criteria.\n- No prior chemotherapy for breast cancer metastases - Not mentioned if the patient had prior chemotherapy for metastases.\n- No bilateral disease - No mention of bilateral disease.\n- Bidimensionally measurable disease At least 1 target lesion greater than 1 cm2 - The patient has a 3 cm tumor, meeting this criteria. \n- No significant lymphedema in the arm ipsilateral to mastectomy site, unless patient has an indwelling catheter for the purpose of chemotherapy infusion - No mention of lymphedema.\n- No CNS metastases - No mention of CNS metastases.\n- Hormone receptor status: Not specified - Meets this criteria.\n\nPATIENT CHARACTERISTICS:\n- Age: 18 and over - The patient is 45 years old, meeting this criteria.\n- Sex: Female - The patient is female, meeting this criteria. \n- Menopausal status: Not specified - Meets this criteria as it is not specified.\n- Performance status: Karnofsky 70-100% - Not mentioned.\n- Life expectancy: Not specified - Meets this criteria.\n- Hematopoietic criteria - Not mentioned, so not enough information.\n- Hepatic criteria - Not mentioned, so not enough information. \n- Renal criteria - Not mentioned, so not enough information.\n- Cardiovascular criteria - Not mentioned, so not enough information.\n- Other criteria - Not mentioned, so not enough information.\n\nPRIOR CONCURRENT THERAPY criteria are not mentioned, so there is not enough information.\n\nIn summary, the patient meets some of the key inclusion criteria like HER2-positive metastatic breast cancer, age, sex. However, there is insufficient information provided about several other criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "8": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, meeting the age requirement.\n\n2. She has cytologically confirmed invasive ductal breast carcinoma, which is an adenocarcinoma of the female breast as required.\n\n3. The tumor is HER2-positive and ER/PR negative, meeting the HER2 and hormone receptor status criteria.\n\n4. She has 5 positive lymph nodes, meeting the node-positive disease criteria.\n\n5. The tumor size is 3 cm, meeting the tumor size criteria for node-positive disease.\n\n6. She is a candidate for tumor resection prior to chemotherapy, meeting the surgical eligibility criteria.\n\n7. Her lab values (ANC, platelets, bilirubin, AST) are not mentioned but can be assumed to be within normal limits based on the information provided.\n\n8. Her left ventricular ejection fraction is not mentioned but can also be assumed to be within normal limits.\n\n9. There is no mention of prior hormonal therapies, so she meets that criteria.\n\n10. There is no mention of other malignancies, so she meets that criteria.\n\n11. She agrees to receive radiation therapy after chemotherapy if indicated, meeting that criteria.\n\nBased on the information provided in the patient note, this patient meets all the key inclusion criteria for this HER2-positive breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "9": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast\n- The patient has cytologically confirmed invasive ductal breast carcinoma, which is stage IV based on the metastatic lesions seen on CXR. This meets the inclusion criteria.\n\n2. Fine needle aspiration, core needle biopsy, or incisional biopsy allowed, no excisional biopsy\n- The patient had a core biopsy, which is allowed. This meets the inclusion criteria.\n\n3. Any of the following:\n    - Tumor size \u22652 cm, Nodes \u22651 (T2N1) or tumor size \u22653 cm nodes 0 (T3N0)\n    - Any T with N2 (including matted axillary nodes) or N3  \n    - Any T4, including inflammatory breast cancer\n    - Adjuvant patients with \u22654 positive lymph nodes and HER-2 overexpressing tumor\n    - Supraclavicular or infraclavicular positive lymph nodes without distant metastases\n    - Distant metastases with measurable disease in breast or lymph nodes\n- The patient has a 3 cm tumor (T3) with 5 positive axillary lymph nodes, as well as metastatic lesions, meeting the criteria for T4 and distant metastases with measurable disease.\n\n4. Measurable or evaluable disease\n- The patient has measurable disease based on the primary tumor and metastatic lesions.\n\n5. Patient characteristics like age, sex, menopausal status, performance status, life expectancy are not specified as inclusion criteria.\n\n6. The patient meets the hematologic criteria based on the limited information provided.\n\n7. The patient is not pregnant or nursing based on the information provided.\n\nBased on the information in the patient note, this patient meets all of the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "10": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma in left breast\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial state:\n- Must be at least 25 years old (or 5 years younger than youngest family member with BRCA-associated cancer) and less than 46 years old\n- Must be premenopausal \n- Must be a known BRCA mutation carrier or first/second-degree relative of someone with BRCA-associated cancer in a family with known mutation\n- Willing to use non-hormonal contraception\n- ECOG performance status 0-1\n- Able to provide informed consent\n\nBased on the information provided, the patient does not meet several of the key inclusion criteria:\n1) She is postmenopausal, whereas the trial requires premenopausal status\n2) There is no mention of her being a BRCA mutation carrier or having a relevant family history\n\nTherefore, there is insufficient information to determine if she would be eligible for this particular clinical trial studying breast imaging modalities in high-risk women.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "11": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically or triple diagnosis confirmed operable invasive breast cancer - The patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which meets this criteria.\n- T0-2, N0 - The patient has axillary lymph node involvement (5 positive nodes), so does not meet this criteria.\n- Only 1 tumor in 1 breast - The patient has only 1 tumor in the left breast, meeting this criteria. \n- Tumor between 5 and 50 mm - The patient's tumor is 3 cm (30 mm), meeting this criteria.\n- Clinically negative axillary lymph nodes - The patient has 5 positive axillary lymph nodes, not meeting this criteria.\n- No metastatic disease - The patient has metastatic lesions on CXR, not meeting this criteria.\n\nPATIENT CHARACTERISTICS:\n- Age: Any age - The patient is 45 years old, meeting this criteria.\n- Sex: Female - The patient is female, meeting this criteria.\n- Other criteria like menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal are not specified.\n\nThe key exclusion criteria the patient does not meet are:\n1) Clinically negative axillary lymph nodes (patient has 5 positive nodes)\n2) No metastatic disease (patient has metastatic lesions on CXR)\n\nTherefore, despite meeting some inclusion criteria, the patient would be excluded from this clinical trial based on the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "12": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically or cytologically confirmed metastatic breast cancer with HER2 overexpression\nThe patient note mentions that the patient has cytologically confirmed breast cancer that is HER2-positive and metastatic, so this criterion is met.\n\n- Radiographically or physically measurable disease that can be biopsied safely under local anesthesia\nThe patient note does not explicitly mention if the disease is radiographically or physically measurable, but it does state that a core biopsy was performed, so this criterion is likely met.\n\nPATIENT CHARACTERISTICS:\n- Age: 18 and over\nThe patient is 45 years old, so this criterion is met.\n\n- Sex: Male or female \nThe patient is female, so this criterion is met.\n\n- Performance status: ECOG 0-2\nThe patient's performance status is not mentioned, so there is not enough information to determine if this criterion is met.\n\n- Hematopoietic, hepatic, and renal function criteria are not mentioned, so there is not enough information to determine if these are met.\n\n- Not pregnant or nursing, negative pregnancy test, fertile patients must use effective contraception\nThe patient is postmenopausal and not sexually active, so these criteria are likely met.\n\nPRIOR CONCURRENT THERAPY:\n- No prior trastuzumab\nThis is not mentioned, so there is not enough information.\n\n- At least 2 weeks since prior hormonal therapy, no concurrent hormone receptor therapy\nThis is not mentioned, so there is not enough information.\n\n- Localized palliative external beam radiotherapy allowed, concurrent bisphosphonates allowed\nThese are permissible, but not mentioned if applicable to the patient.\n\nIn summary, while some of the key inclusion criteria are met based on the information provided, there are several criteria where information is lacking to make a definitive assessment.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "13": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Postmenopausal women: The patient note states that the patient is a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n2. Metastatic breast cancer suitable for endocrine therapy: The patient has \"cytologically confirmed breast cancer\" and the note mentions \"metastatic lesions\", so this criterion is met. \n\n3. Positive hormone receptor status: The note states that the tumor is \"ER/PR negative\", which means the hormone receptor status is negative. This criterion is not met.\n\n4. Human epidermal growth factor receptor 2 (HER2) overexpression: The note mentions that the tumor is \"HER2-positive\", so this criterion is met.\n\nSince the patient does not meet one of the key inclusion criteria (positive hormone receptor status), she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "14": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the inclusion criteria of \"Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.\"\n\nShe has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is HER2-positive and ER/PR negative. This provides additional details about her breast cancer diagnosis.\n\nThe tumor has metastasized to lymph nodes (5 positive lymph nodes) and lungs (metastatic lesions on CXR). This does not explicitly exclude her from the trial.\n\nHer medical history of using multivitamins and iron supplements is not a contraindication based on the listed inclusion/exclusion criteria.\n\nShe does not smoke or consume alcohol, which is not mentioned in the criteria.\n\nShe is not sexually active and has no children, which is also not mentioned.\n\nShe is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not explicitly required or excluded by the criteria.\n\nBased on the information provided, the patient meets the key inclusion criteria of being a woman with breast cancer, being postmenopausal, and having acceptable WBC and platelet counts (not mentioned but assumed normal). None of the exclusion criteria seem to apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "15": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must have histologically confirmed invasive carcinoma of the female breast, with 0-3 positive axillary lymph nodes\"\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and axillary sampling revealed 5 positive lymph nodes. This does not meet the criteria of 0-3 positive axillary lymph nodes.\n\n2. The other inclusion criteria relate to details like tumor characteristics, previous treatments, adequate organ function, etc. Since the patient does not meet the first key criteria of 0-3 positive lymph nodes, we don't need to evaluate the other criteria.\n\nIn summary, while the patient has breast cancer which would make them potentially relevant for this trial, the specific criteria of 0-3 positive lymph nodes is not met (the patient has 5 positive nodes).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "16": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients with histologic confirmation of invasive, but non-inflammatory carcinoma of the breast.\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and \"a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. Stage criteria:\nThe patient does not have stage I (T1N0) disease, which is excluded. \nThe note mentions 5 positive lymph nodes, so the patient likely has at least stage IIB or IIIA disease, which is allowed.\n\n3. The tumor types listed as eligible (mucinous, tubular, medullary) do not apply here as it is an invasive ductal carcinoma.\n\n4. The patient has unilateral breast cancer, so the criterion about bilateral cancers does not apply.\n\n5. The lymph node involvement specified (pN2a, pN3a) is allowed. Infraclavicular nodes are not mentioned.\n\n6. The patient has a measurable 3 cm primary tumor, meeting this criterion.\n\n7. Histologic confirmation by core biopsy is noted.\n\n8. Consent is not mentioned but can be assumed to have been obtained.\n\n9. No prior breast cancer history is mentioned.\n\n10. No specific lab values are given, but can be assumed to be adequate based on no mentioned abnormalities.\n\n11. The patient has not had prior surgical therapy yet.\n\n12. HER2 positivity is noted, meeting this criterion.\n\nBased on the information provided, this patient appears to meet all of the key inclusion criteria for this breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "17": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed breast cancer - Yes, the patient has cytologically confirmed invasive ductal breast carcinoma.\n- Stage IV or locally advanced disease - Yes, the patient has metastatic lesions noted on CXR.\n- HER2/neu positive - Yes, the tumor is HER2-positive.\n- Measurable disease - Yes, the 3 cm breast tumor meets the criteria.\n\nPATIENT CHARACTERISTICS:\n- Age 18 and over - Yes, the patient is 45 years old.\n- Female sex - Yes\n- Postmenopausal - Yes, the patient is described as postmenopausal.\n\nPRIOR CONCURRENT THERAPY:\n- No prior trastuzumab - Not mentioned, but likely no prior trastuzumab given.\n- Prior chemotherapy allowed - Not mentioned.\n- No prior exemestane - Not mentioned, but likely no prior exemestane.\n- No other prior hormonal agent except tamoxifen - Not mentioned.\n\nThe patient meets all the key inclusion criteria based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "18": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed breast cancer confined to the breast and axillary nodes - Met (3 cm invasive ductal breast carcinoma with 5 positive axillary lymph nodes)\n- No distant metastatic disease - Not met (CXR was remarkable for metastatic lesions)\n- Tumor detected in the internal mammary chain by sentinel node procedure allowed - No information provided\n\nMust have undergone 1 of the following procedures for primary breast cancer within the past 12 weeks and have no known clinical residual locoregional disease:\n- Total mastectomy with or without adjuvant radiotherapy\n- Breast-conserving surgery followed by radiotherapy \nThe patient is a candidate for tumor resection, so this criterion is potentially met pending the surgery.\n\n- Prior axillary lymph node dissection or negative axillary sentinel node biopsy required - Met (Axillary sampling revealed 5 positive lymph nodes)\n- No locally advanced, inoperable breast cancer - Likely met based on information provided\n- No prior ipsilateral or contralateral invasive breast cancer - Assumed met, no information suggesting otherwise\n- Histologically diagnosed synchronous bilateral invasive breast cancer within the past 2 months allowed if criteria met - Not applicable\n\nHormone receptor status:\n- Estrogen receptor and/or progesterone receptor positive - Not met (ER/PR negative)\n\nPATIENT CHARACTERISTICS:\n- Age: Premenopausal - Not met (Patient is 45 years old and postmenopausal)\n- Female - Met\n- Premenopausal with estradiol in premenopausal range after surgery - Not met (Postmenopausal)\n- Other criteria likely met based on information provided\n\nPRIOR CONCURRENT THERAPY:\n- No prior neoadjuvant or adjuvant chemotherapy - Potentially met pending surgery/treatment\n- No prior neoadjuvant or adjuvant endocrine therapy after breast cancer diagnosis - Potentially met \n- No prior hormone therapies as listed - Potentially met based on information provided\n- No prior ovarian irradiation - Potentially met\n- No prior bilateral oophorectomy - Potentially met\n- No other prior neoadjuvant therapy - Potentially met\n- No concurrent investigational agents - Potentially met\n- No concurrent bisphosphonates unless criteria met - Potentially met\n\nBased on the information provided, the key reasons this patient does not meet the inclusion criteria are:\n1) Presence of metastatic lesions on CXR\n2) ER/PR negative tumor\n3) Postmenopausal status\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "19": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically confirmed invasive ductal breast cancer, which meets the \"histologically confirmed stage I-III invasive breast cancer\" criteria.\n- The disease is operable.\n- The tumor is 3 cm, meeting the \"Tumor \u2265 2 cm in greatest diameter\" high-risk criteria.\n- The patient has 5 positive lymph nodes, meeting the \"One or more axillary or intramammary nodes are involved by metastatic breast cancer\" criteria.\n- The tumor is HER2-positive, which is allowed.\n- The patient has undergone tumor resection, meeting the \"Prior modified radical mastectomy OR local excision of all tumors with axillary lymph node dissection or sentinel node resection required\" criteria.\n\nPATIENT CHARACTERISTICS:\n- The patient is 45 years old, meeting the \"Age 18 and over\" criteria.\n- Gender is not specified, but both males and females are allowed.\n- Menopausal status is stated as postmenopausal.\n- No performance status is given, but Zubrod 0-2 is required.\n- No hematopoietic, hepatic, or renal function details are provided.\n- No cardiovascular issues like congestive heart failure or angina are mentioned.\n- Pregnancy status is not given, but the patient is postmenopausal.\n- No other malignancies in the past 5 years are mentioned.\n- HIV status is not stated.\n\nPRIOR CONCURRENT THERAPY:\n- No prior cytotoxic chemotherapy, anthracyclines, anthracenediones, or taxanes are mentioned, meeting criteria.\n- No prior radiotherapy for this malignancy is stated.\n- Surgery for tumor resection has been performed, as required.\n\nBased on the information provided, the patient meets the key inclusion criteria for disease characteristics and prior therapy. However, some patient characteristics like performance status, organ function, pregnancy status, and HIV status are not clearly stated.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "20": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma\nThe patient has a 3 cm invasive ductal breast carcinoma, which meets this criteria.\n\n- Largest tumor lesion \u2264 5 cm  \nThe patient's tumor is 3 cm, which meets this criteria.\n\n- Palpable or nonpalpable breast lesion\nThe note doesn't specify if the lesion was palpable or not, but this criteria is met regardless.\n\n- Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions\nThis is not mentioned in the note, but may have been done prior to the biopsy.\n\n- Prior (preoperative) or planned (intraoperative) sentinel node biopsy required\nThe patient had axillary sampling which revealed 5 positive lymph nodes, so a sentinel node biopsy was likely done.\n\n- At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension\nThis criteria is not met, as the patient had 5 positive lymph nodes rather than micrometastases.\n\n- No clinical evidence of distant metastases\nThe patient had metastatic lesions on CXR, so this criteria is not met.\n\n- No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including skeletal pain, elevated alkaline phosphatase, bone scan hot spots\nThis is not mentioned, but the metastatic lesions violate this criteria.\n\n- No palpable axillary lymph node(s)  \nThe patient had 5 positive axillary lymph nodes, so this criteria is not met.\n\n- No Paget's disease without invasive cancer\nThis is not mentioned.\n\n- Hormone receptor status: Estrogen receptor and progesterone receptor known\nThe patient's tumor is ER/PR negative, so this criteria is met.\n\nPATIENT CHARACTERISTICS:\nThese are all met based on the information given.\n\nPRIOR CONCURRENT THERAPY:\nThese are all met based on the information given.\n\nOverall, while the patient meets some of the inclusion criteria, they are excluded based on having metastatic disease, more than micrometastatic lymph node involvement, and palpable axillary lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "21": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has a diagnosis of invasive ductal carcinoma in the breast, not ductal carcinoma in situ as required. This does not meet the inclusion criteria.\n\nPATIENT CHARACTERISTICS:\n- Age: The patient is 45 years old, which meets the 40-70 year age criteria.\n- Sex: The patient is female, which meets the criteria. \n- Menopausal status: The patient is postmenopausal, which meets the criteria.\n- Other criteria like performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, pulmonary are not mentioned but can be assumed to meet criteria based on the limited information provided.\n\nPRIOR CONCURRENT THERAPY:\n- The patient has not received any prior therapy like chemotherapy, radiotherapy or endocrine therapy, meeting this criteria.\n- The patient is a candidate for tumor resection prior to chemotherapy, meeting the surgery criteria.\n\nOverall, while the patient meets some of the key inclusion criteria like age, sex, menopausal status and prior therapy status, the key disease characteristic of having ductal carcinoma in situ is not met as the patient has invasive ductal carcinoma.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "22": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)\"\nThe patient note states that the patient is a \"45-year-old postmenopausal woman with cytologically confirmed breast cancer\" and that \"CXR was remarkable for metastatic lesions.\" This meets the inclusion criterion of having metastatic breast cancer.\n\n2. \"Adequate bone marrow, liver, and renal function\"\nThe patient note does not provide information about the patient's bone marrow, liver, and renal function. Therefore, we cannot determine if the patient meets this inclusion criterion.\n\nSince one of the inclusion criteria cannot be evaluated based on the provided information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "23": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically or cytologically confirmed breast cancer - The patient has cytologically confirmed breast cancer, meeting this criteria.\n- Locally advanced disease (stage II or III) - The patient has locally advanced breast cancer, meeting this criteria. \n- Not amenable to breast-conserving therapy at the time of diagnosis - This is not explicitly stated, but the patient is a \"candidate for tumor resection\" implying breast-conserving therapy is not an option.\n- Measurable disease meeting criteria - The 3 cm tumor meets the \"bidimensionally measurable palpable lesion at least 1 cm\" criteria.\n- No evidence of disease outside breast/chest wall except ipsilateral axillary lymph nodes - The patient has 5 positive axillary lymph nodes, meeting this criteria. No other metastases mentioned.\n- Hormone receptor status: Estrogen and/or progesterone receptor positive - The tumor is ER/PR negative, not meeting this criteria.\n\nPATIENT CHARACTERISTICS:\n- Age: Postmenopausal - The patient is a 45-year-old postmenopausal woman, meeting this criteria.\n- Sex: Female - The patient is female, meeting this criteria.\n- Menopausal status requirements met based on age.\n- Performance status ECOG 0-3 - Not mentioned, assume eligible.\n- Life expectancy - Not mentioned, assume eligible.  \n- Hematopoietic - Not mentioned, assume eligible.\n- Hepatic - Bilirubin not mentioned, assume eligible.\n- Renal - Creatinine not mentioned, assume eligible.\n- No other prior/concurrent cancer except allowed types - Not mentioned, assume eligible.\n\nPRIOR CONCURRENT THERAPY:\n- No prior biologic/chemotherapy/endocrine therapy for breast cancer - Met, no prior therapies mentioned.\n- No prior radiotherapy for breast cancer - Met.\n- Surgery status not specified - Assume tumor resection planned meets criteria.\n\nWhile the patient meets most of the inclusion criteria, the key criteria of estrogen and/or progesterone receptor positive tumor status is not met (the tumor is ER/PR negative).\n\nTherefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "24": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of being 18 years or older.\n\nThe tumor is a 3 cm invasive ductal breast carcinoma, which is an eligible tumor type (not pure tubular or mucinous adenocarcinoma).\n\nThe tumor is HER2-positive and ER/PR negative, which is allowed.\n\nThere are 5 positive lymph nodes, but the criteria specifies that lymph nodes must be pN0 (no positive nodes), so this patient does not meet that criteria.\n\nThe patient has metastatic lesions noted on CXR, which excludes her based on the criteria of \"no clinical or radiologic evidence of metastatic disease.\"\n\nThe patient has not received any prior treatment like radiation, chemotherapy, etc. for this breast cancer diagnosis.\n\nThe other criteria regarding menopausal status, prior testing, adequate organ function, etc. are either met or not clearly excluded based on the patient note.\n\nHowever, due to the positive lymph nodes and presence of metastatic disease, this patient would be excluded from enrolling in this clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "25": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is studying sentinel lymph node mapping in detecting cancer spread to lymph nodes in patients with non-small cell lung cancer.\n\nLooking at the inclusion criteria for the trial:\n1. Patients with clinical stage I lung cancer for whom surgical resection is planned are eligible. The patient has breast cancer, not lung cancer, so this criterion is not met.\n2. No prior therapy for this diagnosis. The patient is a candidate for tumor resection, so it seems no prior therapy has been given, meeting this criterion.\n3. No prior treatment with mediastinal radiation therapy. There is no mention of prior radiation therapy, so this criterion is likely met.\n4. Age \u2265 18 years of age. The patient is 45 years old, so this criterion is met.\n5. ECOG performance status: 0-2. There is no information provided about the patient's performance status.\n\nOverall, while the patient meets some of the criteria, the key criterion of having non-small cell lung cancer is not met. The patient has breast cancer instead.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "26": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which does not match the inclusion criteria for a clinical trial on malignant glioma (brain tumor).\n\n2. The clinical trial requires patients to have undergone gross total resection of a malignant glioma tumor, but the patient has breast cancer.\n\n3. The inclusion criteria specifically mention histopathologic confirmation of malignant glioma from the resection specimen, which this patient does not have.\n\n4. Other inclusion criteria like Karnofsky Performance Scale score, adequate hematologic status, etc. are not relevant since the patient does not have the primary condition being studied (malignant glioma).\n\nTherefore, based on the information provided, this patient does not meet the key inclusion criteria for the clinical trial on malignant glioma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "27": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the inclusion criteria of being a woman with invasive breast cancer.\n\nThe tumor is 3 cm invasive ductal carcinoma, HER2-positive and ER/PR negative. This meets the inclusion criteria of having an invasive carcinoma of the breast, and not being HER2-positive (which is an exclusion criteria). \n\nAxillary sampling revealed 5 positive lymph nodes, meeting the criteria of pN1, pN2a, pN3a or pN3b nodal status.\n\nCXR was remarkable for metastatic lesions. This would exclude the patient as the criteria specifies \"no clinical or radiologic evidence of metastatic disease.\"\n\nThe patient has no other conditions mentioned that would exclude her based on the criteria listed.\n\nSo in summary, while the patient meets some inclusion criteria, the presence of metastatic lesions on CXR is an exclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "28": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Diagnosis of invasive breast cancer - Yes, the patient has cytologically confirmed invasive ductal breast carcinoma.\n- Tumor \u2265 3 cm and palpable - Yes, the tumor is 3 cm.\n- Multiple masses allowed if at least 1 is \u2265 3 cm - Not applicable, only one mass mentioned.\n- Clinically positive axillary or supraclavicular lymph nodes allowed - Yes, 5 positive axillary lymph nodes.\n- Fine needle aspiration or core biopsy positive for invasive breast cancer AND/OR lymph node positive - Yes, core biopsy confirmed invasive ductal carcinoma.\n- HER2/neu-positive OR negative - Yes, HER2-positive.\n- No inflammatory breast cancer - Not mentioned, assumed no.\n- No distant metastases - No, CXR showed metastatic lesions, so this criteria is not met.\n\nPATIENT CHARACTERISTICS:\n- Age 18 and over - Yes, patient is 45 years old.\n- Female - Yes\n- Menopausal status premenopausal or postmenopausal - Yes, postmenopausal\n- Performance status Karnofsky 60-100% - Not mentioned\n- Life expectancy - Not mentioned\n- Granulocyte count \u2265 1,000/mm3 - Not mentioned\n- Platelet count \u2265 100,000/mm3 - Not mentioned\n- Bilirubin \u2264 2 times ULN, SGOT \u2264 2 times ULN - Not mentioned\n- LVEF \u2265 50%, no congestive heart failure, no serious conduction abnormality, no significant cardiovascular disease - Not mentioned\n- Not pregnant/nursing, negative pregnancy test, fertile patients using contraception - Not pregnant/nursing mentioned, fertility status unknown\n- No other prior/concurrent malignancies or must have received no prior chemo and likely cured - Not mentioned\n- No severe medical/psychiatric condition precluding compliance - Not mentioned\n- No known HIV positivity - Not mentioned\n\nPRIOR CONCURRENT THERAPY:\n- No prior chemotherapy - Yes\n- No prior hormonal therapy for breast cancer - Yes \n- No prior radiotherapy for this malignancy - Assumed no prior radiation\n- Surgery status not specified\n\nWhile the patient meets many of the key inclusion criteria like tumor size, node positivity, HER2 status, no prior therapy, the presence of metastatic lesions on CXR would exclude the patient from this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 2
    },
    "29": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically confirmed invasive ductal breast carcinoma, which meets the \"invasive adenocarcinoma of the breast\" criteria.\n- The tumor is 3 cm, which meets the \"Stage II tumors must be \u2264 3 cm\" criteria. \n- The tumor is described as unifocal, meeting the \"Gross disease must be unifocal\" criteria.\n- No mention of multicentric carcinoma, meeting the \"No proven multicentric carcinoma\" criteria.\n- The patient has 5 positive axillary lymph nodes, meeting the \"No more than 3 positive axillary nodes\" criteria.\n- No mention of extracapsular extension, meeting the \"No axillary nodes with definite evidence of microscopic or macroscopic extracapsular extension\" criteria.\n- The patient underwent lumpectomy with clear resected margins, meeting the \"Must have undergone lumpectomy\" and \"Resected margins histologically free of tumor\" criteria.\n- No mention of suspicious microcalcifications, densities or palpable abnormalities, meeting that criteria.\n- No mention of Paget's disease of the nipple.\n- No prior history of invasive breast cancer or DCIS.\n- The tumor is HER2-positive and ER/PR negative, so hormone receptor status is known.\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, meeting the age and sex criteria.\n- No information on performance status or life expectancy.\n- No information on hematopoietic, hepatic or renal function.\n- No mention of pregnancy/nursing status or need for contraception.\n- No mention of other prior malignancies.\n- No mention of collagen vascular disease or psychiatric/addictive disorders.\n\nPRIOR CONCURRENT THERAPY:\n- No mention of prior biologic, chemotherapy, endocrine therapy or radiotherapy for this malignancy.\n- The patient is a candidate for surgery prior to chemotherapy, meeting the surgery criteria.\n- No mention of prior breast implants.\n- No mention of other concurrent anticancer therapy.\n\nBased on the information provided, this patient meets the key inclusion criteria for histology, stage, lymph node status, surgical status and hormone receptor status. There are a few criteria lacking information, but none that clearly exclude her.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "30": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histological or cytological diagnoses of breast cancer, with metastases.\nThe patient note mentions that the patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR, so this criterion is met.\n\n2. Metastatic lesions should not be curable with surgery or radiotherapy. \nThe patient note does not provide information about whether the metastatic lesions are curable with surgery or radiotherapy, so this cannot be definitively assessed.\n\n3. Women of age > 18.\nThe patient is a 45-year-old woman, so this criterion is met.\n\n4. To have received a previous treatment with anthracyclines and taxanes.\nThe patient note does not mention any previous treatments, so this criterion cannot be assessed.\n\n5. A maximum of 2 previous chemotherapy treatment lines for metastatic disease.\nAgain, no information is provided about previous treatments.\n\n6. Previous radiotherapy is allowed, whenever the radiated area is not the only disease location.\nNo information about previous radiotherapy is given.\n\n7. At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities.\nNo information about previous treatments or recovery from toxicities.\n\n8. Performance status < 2 in World Health Organization (WHO) scale.\nNo information about performance status is provided.\n\n9. Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which would likely be considered measurable disease.\n\n10. Life expectancy of at least 12 weeks.\nNo information about life expectancy is given.\n\n11. Patients able to comply and to receive an adequate follow-up.\nThe patient agrees to tumor resection prior to chemotherapy, suggesting ability to comply with treatment.\n\n12. Adequate bone marrow function: neutrophils \u2265 2 x 10^9/L; platelets \u2265 100 x 10^9/L; hemoglobin \u2265 100 g/L.\nNo information about bone marrow function or lab values is provided.\n\n13. Calcium within normal limits. \nNo information about calcium levels.\n\n14. Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization.\nThe patient is noted to be postmenopausal, so this criterion does not apply.\n\nIn summary, while some of the inclusion criteria are met based on the information provided, there are several key criteria that cannot be assessed due to lack of information in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "31": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- 3 cm invasive ductal breast carcinoma in the left breast\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR (indicating metastatic disease)\n\nThe clinical trial is titled \"Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer\".\n\nThe inclusion criteria are:\n1) Clinically node negative operable breast cancer\n2) No prior incision or excision biopsy\n\nLooking at the patient details, she does not meet the first inclusion criteria of being clinically node negative, as she has 5 positive axillary lymph nodes. She also has metastatic lesions, indicating inoperable/metastatic disease.\n\nTherefore, based on the inclusion criteria, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "32": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Written informed consent: Not mentioned, but can be obtained if the patient agrees to participate.\n2. Age >= 18 years old: The patient is 45 years old, so this criterion is met.\n3. Metastatic breast cancer patients with lytic, sclerotic or mixed bone lesions: The patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR, so this criterion is met.\n4. Non-symptomatic bone lesions, defined as pain absence, lack of bone complications: This is not explicitly stated, but the note does not mention any bone pain or complications.\n5. A maximum of two chemotherapy lines for metastatic disease: The note does not mention any prior chemotherapy for metastatic disease.\n6. A maximum of two hormone therapy lines for metastatic disease: The note does not mention any prior hormone therapy for metastatic disease.\n7. Normal, minimally altered renal function (serum creatinine < 1.5 x Upper Normal Limit (UNL)): Renal function is not mentioned, but can be checked.\n8. Normal serum calcium levels: Serum calcium levels are not mentioned, but can be checked.\n9. Performance status 0,1 (World Health Organization (WHO)): Performance status is not mentioned, but the patient is a candidate for tumor resection, suggesting good performance status.\n10. Negative pregnancy test before study recruitment: The patient is postmenopausal, so this criterion is likely met.\n\nBased on the information provided, the patient appears to meet most of the inclusion criteria, with a few criteria that need to be checked (renal function, serum calcium, performance status). However, there is no information provided about the exclusion criteria, which could potentially exclude the patient.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "33": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets disease criteria) \n- HER2-positive and ER/PR negative breast cancer (meets HER2 status criteria)\n- Has metastatic lesions seen on CXR (meets criteria for non-operable locally advanced or metastatic disease)\n- Previously treated with trastuzumab and taxanes (meets prior treatment criteria)\n- Has measurable disease (meets criteria for measurable disease per RECIST)\n- Disease has progressed during or after trastuzumab and taxane treatment (meets disease progression criteria)\n- No mention of prior chemotherapy lines for advanced/metastatic disease beyond trastuzumab and taxanes (assumed to meet maximum 1 prior line criteria)\n- ECOG performance status not mentioned but is a candidate for surgery (assumed to meet ECOG >=2 criteria)\n- No mention of LVEF but criteria is within previous 4 weeks which is reasonable to assume\n- No lab values mentioned but is a surgical candidate so can assume meets hematologic criteria\n- No liver or kidney function values mentioned but is a surgical candidate so can assume meets those criteria\n\nBased on the information provided, this patient meets all of the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "34": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent: Not mentioned in the patient note.\n2. Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3): The patient has a 3 cm invasive ductal breast carcinoma, which meets this criteria.\n3. Tumors must be HER2 negative: The patient's tumor is HER2-positive, which excludes them from this trial.\n4. Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks: The patient has not started chemotherapy yet, so this criteria is not applicable.\n5. Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection: The patient is a candidate for tumor resection, which meets this criteria.\n6. Node negative patients with tumor size > 2 cm or positive axillary lymph nodes: The patient has 5 positive axillary lymph nodes, which meets this criteria.\n7. Status of hormone receptors in primary tumor: The tumor is ER/PR negative, which meets this criteria.\n8. Patients must not present evidence of metastatic disease: The patient has metastatic lesions on CXR, which excludes them from this trial.\n9. Negative status of HER2 in primary tumor: The patient's tumor is HER2-positive, which excludes them from this trial.\n10. Adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines and/or taxanes: The patient has not started chemotherapy yet, so this criteria is not applicable.\n11. Age >= 18 and <= 70 years old: The patient is 45 years old, which meets this criteria.\n12. Performance status (Karnofsky index) >= 80: Not mentioned in the patient note.\n13. Laboratory results within normal limits: Not mentioned in the patient note.\n14. Patients able to comply with treatment and study follow-up: Not mentioned in the patient note.\n15. Negative pregnancy test done in the 14 previous days to randomization: The patient is postmenopausal, so this criteria is not applicable.\n\nBased on the information provided, the patient meets some of the inclusion criteria but is excluded due to having a HER2-positive tumor and evidence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "35": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female patient, postmenopausal: The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Histologically or cytologically proven adenocarcinoma of the breast: The patient note mentions that the patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma, which is a type of adenocarcinoma. This criterion is met.\n\n3. HER2-positive disease: The patient note states that the tumor is HER2-positive, so this criterion is met.\n\n4. ER-positive and/or PR-positive disease: The patient note states that the tumor is ER/PR negative, so this criterion is not met.\n\n5. ECOG performance status 0-2: There is no information provided about the patient's ECOG performance status, so it is unclear if this criterion is met or not.\n\n6. Life expectancy > 24 weeks: There is no information provided about the patient's life expectancy, so it is unclear if this criterion is met or not.\n\n7. Left ventricular ejection fraction > lower limit of normal: There is no information provided about the patient's left ventricular ejection fraction, so it is unclear if this criterion is met or not.\n\n8. No prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer: The patient note does not mention any prior treatment for metastatic breast cancer, so this criterion is likely met.\n\n9. Other criteria related to prior treatments and washout periods: The patient note does not provide enough information to determine if these criteria are met or not.\n\nSince the patient does not meet the ER/PR-positive criterion, and there is insufficient information to determine if several other criteria are met, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "36": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- With cytologically confirmed breast cancer (meets cancer type criteria)\n- HER2-positive and ER/PR negative (meets HER2 criteria)\n- Has metastatic lesions seen on CXR (meets metastatic disease criteria)\n- No prior chemotherapy for metastatic disease (meets prior treatment criteria)\n- Karnofsky performance status not mentioned but presumably \u226570 to be a candidate for treatment\n- No lab values for ANC, Hgb, plt provided\n\nBased on the information provided, this patient meets most of the key inclusion criteria except we don't have confirmation that her lab values meet the ANC, Hgb, plt requirements. \n\nHowever, since she is a candidate for tumor resection and chemotherapy, it can be reasonably assumed her lab values are adequate unless stated otherwise.\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "37": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with breast cancer, which is not the target disease (cervical cancer) for the given clinical trial. The trial is specifically recruiting cervical cancer patients receiving radiotherapy or chemo-radiotherapy.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "38": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, meeting the age criteria of >= 40 years.\n\nShe has invasive ductal breast carcinoma, which meets the criteria of having invasive ductal carcinoma or ductal carcinoma in situ.\n\nThe tumor size is 3 cm, which exceeds the criteria of tumor < 2.5 cm in size.\n\nThere is no information provided about the margin of normal breast tissue between the cancer and edge of the specimen, so we cannot determine if that criteria is met.\n\nThe patient has chosen to undergo lumpectomy rather than mastectomy, meeting that criteria.\n\nOverall, while the patient meets some of the key inclusion criteria like age, cancer type, and choice of lumpectomy, the tumor size exceeds the limit set in the trial. There is also missing information about the margin status.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "39": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nFemale gender: The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\nAge >= 18 years: The patient is 45 years old, so this criterion is met. \n\nECOG performance status < 2: No information is provided about the patient's performance status.\n\nHistologically proven diagnosis of breast cancer: The patient has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\nLocally advanced and/or metastatic disease: The patient has metastatic lesions noted on CXR, so this criterion is met.\n\nLife expectancy of three months or longer: No information is provided about the patient's life expectancy.\n\nNo concurrent second malignancy: No information is provided about any other malignancies.\n\nNo other serious illness or medical condition: No information is provided about other medical conditions.\n\nNo symptomatic central nervous system (CNS) metastases: No information is provided about CNS metastases.\n\nNo rapidly progressive visceral metastases requiring immediate chemotherapy: No information is provided about the rate of progression of the metastases.\n\nNo concurrent anti-cancer treatment is allowed: The patient has not started any treatment yet, so this criterion is met.\n\nPrevious therapies allowed with some exceptions: No information is provided about previous therapies.\n\nAdequate organ function: No information is provided about organ function.\n\nOverexpression of HER-2: The tumor is noted to be HER2-positive, so this criterion is met.\n\nBaseline LVEF > 50%: No information is provided about the patient's LVEF.\n\nEvaluable or uni-dimensionally measurable disease: The primary tumor is 3 cm, so this criterion is met.\n\nBirth control for women of childbearing potential: The patient is postmenopausal, so this criterion is not applicable.\n\nAbility to comply with study protocol: No information is provided about potential issues with compliance.\n\nInformed consent: No information is provided about whether informed consent was obtained.\n\nIn summary, while some criteria are met based on the information provided, there are several criteria for which information is lacking to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "40": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of being 18 years or older and having a solid tumor.\n\nThe note does not mention the patient's hemoglobin levels, so it is unclear if she meets the criteria of having moderate anemia (Hb 9-12 g/dL for women).\n\nThe patient is a candidate for tumor resection followed by chemotherapy, which implies at least 4 cycles of chemotherapy are planned after inclusion in the study.\n\nThe note states the patient has a life expectancy compatible with the study follow-up, though an exact timeframe is not provided.\n\nThe note does not mention any issues with the patient's general condition that would make study follow-up incompatible.\n\nBased on the available information, there are no clear exclusion criteria that would prevent the patient from participating. However, the lack of hemoglobin levels makes it difficult to definitively assess eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "41": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of having invasive breast cancer.\n\nThe tumor size is 3 cm, which falls within the inclusion criteria of tumor stage Tis, T1, or T2 if lesion is < 3 cm.\n\nThe patient has 5 positive lymph nodes, which matches the inclusion criteria of N0 or N1 if 1-3 positive nodes with no extracapsular extension.\n\nBased on the information provided, the patient meets all the listed inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "42": {
        "output": "To determine the patient's eligibility for the clinical trial \"Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery\", let's go through the inclusion criteria:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed invasive breast cancer by fine needle aspiration or biopsy\nThe patient note mentions \"cytologically confirmed breast cancer\" and \"a core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n- Locally advanced or early metastatic disease\nThe patient note states \"CXR was remarkable for metastatic lesions\", indicating metastatic disease, so this criterion is met.\n\n- Clinically or radiographically measurable disease\nThe tumor size of 3 cm is mentioned, so this criterion is met.\n\n- Planning to receive neoadjuvant chemotherapy for locally advanced or early metastatic disease\nThe patient note mentions \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy\", indicating neoadjuvant chemotherapy, so this criterion is met.\n\nHormone receptor status:\n- Not specified, so this criterion is not applicable.\n\nPATIENT CHARACTERISTICS:\n- Age, sex, menopausal status, performance status, life expectancy, hematopoietic, hepatic, and renal status are not specified in the inclusion criteria, so these are not applicable.\n\nPRIOR CONCURRENT THERAPY:\n- Biologic therapy, chemotherapy, endocrine therapy, radiotherapy, and surgery are not specified in the inclusion criteria, so these are not applicable.\n\nBased on the information provided in the patient note, the patient meets all the specified inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "43": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Histologically confirmed advanced or metastatic breast cancer\n- The patient note mentions that the patient has cytologically confirmed breast cancer with metastatic lesions, so this criterion is met.\n\n2. Postmenopausal females with amenorrhoea > 12 months and an intact uterus\n- The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n3. FSH levels within postmenopausal range or have undergone a bilateral oophorectomy\n- There is no information about FSH levels or oophorectomy in the patient note.\n\n4. ER &/or PR positive\n- The patient note states that the tumor is ER/PR negative, so this criterion is not met.\n\n5. Previous adjuvant hormone therapy > 12 months prior to enrolment\n- There is no information about previous adjuvant hormone therapy in the patient note.\n\n6. Previous adjuvant chemotherapy > 6 months prior to enrolment\n- There is no information about previous adjuvant chemotherapy in the patient note.\n\n7. Measurable disease according to RECIST and/or non measurable bone disease\n- The patient note mentions metastatic lesions, so this criterion is likely met.\n\n8. Life expectancy of at least 12 weeks\n- There is no information about life expectancy in the patient note.\n\n9. World Health Organisation (WHO) performance status (PS) of 0 to 1\n- There is no information about performance status in the patient note.\n\nSince the patient does not meet the ER &/or PR positive criterion, which is a key inclusion criterion, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "44": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, which does not meet the inclusion criteria of \"premenopausal women 18 years or older\".\n\n2. The patient has cytologically confirmed breast cancer, which meets the inclusion criteria of \"histologically or cytologically confirmed locally advanced or metastatic breast cancer\".\n\n3. The patient has metastatic lesions on CXR, indicating advanced or metastatic breast cancer, which meets the inclusion criteria of \"locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available\".\n\n4. The patient has measurable lesions (3 cm invasive ductal carcinoma), which meets the inclusion criteria of \"one or more measurable lesions\".\n\n5. There is no information provided about the patient's life expectancy or biological parameters, so it is unclear if the patient meets those inclusion criteria.\n\nBased on the information provided, the patient does not meet all of the inclusion criteria due to being postmenopausal instead of premenopausal.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "45": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of \"Patients with pathological diagnoses of breast...adenocarcinomas\".\n\n2. The note mentions that this is a newly diagnosed case (\"cytologically confirmed breast cancer\"), so the patient meets the criteria of \"Patients with de novo malignancies and no previous chemotherapy\".\n\n3. There is no mention of the patient having received prior chemotherapy, so she would not fall under the criteria of \"Patients with advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols\".\n\n4. The patient's age of 45 years meets the criteria of \"Patients of any age group\".\n\n5. The note states that a core biopsy was performed, indicating that the tumor is accessible for biopsy, meeting the criteria of \"Patients must have tumor which is accessible and agree to undergo biopsies, or drainage of effusions\".\n\n6. The note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, indicating that chemotherapy is a treatment option for her, meeting the criteria of \"Patients for whom chemotherapy is a treatment option\".\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "46": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically confirmed invasive ductal breast carcinoma, which meets the criteria of \"Invasive carcinoma\" and \"Stage I-III disease\" based on the 3 cm tumor size and positive lymph nodes.\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, meeting the menopausal status criteria.\n- No information is provided about performance status.\n\nPRIOR CONCURRENT THERAPY:\n- No prior chemotherapy or aromatase inhibitor therapy is mentioned, meeting those criteria.\n- No prior tamoxifen or hormone replacement therapy is mentioned, meeting those criteria. \n- No information about prior radiation therapy or surgery is provided, so it's unclear if those criteria are met.\n- No information about concurrent bisphosphonates or soy supplements is provided.\n\nBased on the information given, the patient meets several of the key inclusion criteria like menopausal status, hormone receptor positive tumor, and no prior chemotherapy or endocrine therapy. However, there are some unclear areas like performance status, prior radiation/surgery details, and use of bisphosphonates/soy supplements.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "47": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Recurrent or metastatic breast cancer\nThe patient note mentions that the patient has cytologically confirmed breast cancer with metastatic lesions on CXR, so this criterion is met.\n\n2. Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n3. Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting\nThere is no information provided about prior treatment, so we cannot determine if this criterion is met or not.\n\n4. Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease\nAgain, there is no information about prior treatment, so we cannot determine if this criterion is met or not.\n\nSince the patient does not meet the second inclusion criterion (ER, PR and HER2 negative status), and there is not enough information to determine if the other criteria are met, the patient would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "48": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of \"Women or men > 18 years old with histologically confirmed, by needle core biopsy (not FNA), locally advanced or inflammatory breast cancer.\"\n\nThe tumor is 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative, with 5 positive lymph nodes - this matches \"T2 lesion...or with a T3 N0-N2; T4 any N; or any T with N2 or N3 clinical evidence of disease.\"\n\nThere are metastatic lesions noted on CXR - this would exclude the patient based on the criteria \"Bone scan and CAT scan of chest and abdomen negative for metastatic disease.\"\n\nThe patient is a candidate for tumor resection prior to chemotherapy, which aligns with the trial evaluating neoadjuvant chemotherapy before surgery.\n\nBased on the information provided, the patient meets most of the key inclusion criteria except for the presence of metastatic disease on imaging.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "49": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has a diagnosis of breast cancer (meets criteria)\n- The tumor is 3 cm, which falls under T2-T4c disease (meets criteria)\n- No information on clinical staging as T4a-c, T2 or T3 (unable to assess this criteria)\n- The primary tumor is palpable and measures 3 cm (meets criteria)\n- The patient agrees to undergo tumor resection after neoadjuvant therapy (meets criteria)\n- No inflammatory breast cancer (meets criteria)\n- No distant metastasis, though axillary lymph node involvement is present (meets criteria)\n- Diagnosis not established by incisional biopsy (meets criteria)\n- The tumor is ER positive (meets criteria)\n\nPATIENT CHARACTERISTICS:\n- No performance status given (unable to assess)\n- The patient is a postmenopausal woman (meets criteria)\n- No other malignancies in the past 5 years (meets criteria)\n\nPRIOR CONCURRENT THERAPY:\n- No prior treatment for invasive breast cancer (meets criteria)\n- No prior sentinel lymph node biopsy (meets criteria)\n- No information on prior estrogenic agents/herbal preparations (unable to assess)\n- No information on prior hormone replacement therapy (unable to assess)\n- Not enrolled in another neoadjuvant trial (meets criteria)\n- No concurrent anti-neoplastic therapy (meets criteria)\n- No information on concurrent agents altering ER function (unable to assess)\n\nIn summary, the patient meets several key inclusion criteria like breast cancer diagnosis, tumor characteristics, ER positivity, postmenopausal status and no prior treatment. However, there are some criteria I cannot assess due to lack of information.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "50": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria for the clinical trial state:\n\n- Moderate to severe fatigue >6 months after last chemotherapy or radiation treatment\n- >5 years from diagnosis\n\nFrom the patient note, we don't have information about when her last chemotherapy/radiation treatment was or how long she has had fatigue symptoms. We also don't know how long ago she was diagnosed (only that she is a candidate for tumor resection prior to chemotherapy).\n\nSince we don't have sufficient information to determine if she meets the key inclusion criteria around fatigue duration and time since diagnosis, I would assess her as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "51": {
        "output": "To determine the patient's eligibility for the clinical trial \"Detection of Genetic Markers of Lung Cancer\", let's go through the inclusion criteria one by one:\n\n1. \"Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy\"\n   - The patient note mentions that the patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR. This does not meet the inclusion criteria of having lung cancer, lung metastases from a non-lung primary site, mesothelioma, or a suspicious lung lesion.\n\n2. \"Written informed consent.\"\n   - There is no information provided about whether the patient has given written informed consent or not.\n\n3. \"Must be scheduled for a biopsy or surgical resection\"\n   - The patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is met.\n\nSince the patient does not meet the first inclusion criterion of having lung cancer or related conditions, and there is no information about written informed consent, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "52": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed breast cancer - Yes, the patient has cytologically confirmed invasive ductal breast carcinoma.\n- Disease confined to breast and axillary nodes without masses elsewhere - Yes, no mention of metastases except for CXR lesions.\n- No prior ipsilateral or contralateral invasive breast cancer - Meets this criteria based on information given.\n- Resected disease - Yes, the patient is a candidate for tumor resection prior to chemotherapy.\n- No more than 16 weeks since last surgery - Meets this criteria based on information given.\n- No known clinical residual locoregional disease - Meets this based on information given.\n- Negative margins for invasive cancer and DCIS - Meets this based on information given.\n- No locally advanced, inoperable breast cancer - No evidence of this based on information given.\n- Hormone receptor-negative disease - Yes, the tumor is ER/PR negative.\n\nPATIENT CHARACTERISTICS:\n- Female - Yes\n- Postmenopausal - Yes\n- ECOG 0-2 - Meets this based on information given\n- Adequate blood counts and organ function - Meets this based on information given\n- No other conditions listed as exclusions - Meets this based on information given\n\nPRIOR/CONCURRENT THERAPY:\n- No prior neoadjuvant/adjuvant therapy except radiotherapy - Meets this criteria\n- Allowed concurrent trastuzumab - No mention of this\n- No prior anthracyclines or within cumulative dose limits - Meets this based on information given\n\nBased on the inclusion criteria provided, this patient appears to meet all of the key eligibility requirements for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "53": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the disease characteristics of \"Diagnosis of stage IIB HER2/neu-expressing breast cancer 6\u00bd years ago\".\n\nShe has cytologically confirmed invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative. This aligns with the requirement of \"HER2/neu-expressing breast cancer\".\n\nThe patient has metastatic lesions in the lungs, fitting the criteria of \"Developed pulmonary metastases during adjuvant chemotherapy following modified radical mastectomy\" and \"Pulmonary metastases progressed after prior allogeneic SCT\".\n\nThe note mentions she is a candidate for tumor resection and agrees to do so prior to chemotherapy, which satisfies the criteria of \"Operable tumor with at least 1 cm of surgically accessible lesion\".\n\nThere is no information provided about her undergoing a prior stem cell transplant or receiving prior allogeneic lymphocyte infusion, chemotherapy, and trastuzumab treatment.\n\nThe patient characteristics like gender, ECOG performance status, life expectancy, pregnancy status, and pulmonary reserve are not explicitly stated.\n\nBased on the available information, there are some criteria met but also some missing details that would be needed to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "54": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Has metastatic breast cancer with documented HER2- or HER2+ (IHC3+ or FISH+) disease\nThe patient note states that the patient has cytologically confirmed breast cancer and that the tumor is HER2-positive, so this criterion is met.\n\n2. Has measurable MBC, with at least 1 measurable lesion per RECIST criteria\nThe patient note mentions metastatic lesions on CXR, so this criterion is likely met.\n\n3. Has had no prior treatment with Doxil or carboplatin\nThe patient note does not mention any prior treatment, so this criterion is likely met.\n\n4. Has had no adjuvant chemotherapy within 1 year prior to study, but may have received prior anthracyclines as adjuvant chemotherapy\nThe patient note does not mention any prior chemotherapy, so this criterion is likely met.\n\n5. For taxane-pretreated patients (adjuvant or metastatic), has had no more than 1 prior chemotherapy regimen for MBC\nThe patient note does not mention any prior chemotherapy for MBC, so this criterion is met.\n\n6. For taxane-na\u00efve patients, has had no prior chemotherapy for MBC\nThe patient note does not mention any prior chemotherapy for MBC, so this criterion is met.\n\n7. Has had cumulative doses of < 300 mg/m2 prior doxorubicin or < 450 mg/m2 prior epirubicin\nThe patient note does not mention any prior doxorubicin or epirubicin treatment, so this criterion is likely met.\n\n8. Has normal cardiac function as evidenced by a LVEF within institutional normal limits\nThe patient note does not provide information about the patient's cardiac function or LVEF, so this criterion cannot be assessed.\n\n9. Has an ECOG Performance Status (PS) 0-2\nThe patient note does not provide information about the patient's ECOG Performance Status, so this criterion cannot be assessed.\n\n10. Is a male or female greater than or equal to 18 years of age\nThe patient note states that the patient is a 45-year-old woman, so this criterion is met.\n\n11. Laboratory Values - Please refer to protocol section 4.2 for specific laboratory values.\nThe patient note does not provide any laboratory values, so this criterion cannot be assessed.\n\n12. Has a negative serum pregnancy test within 7 days prior to registration (woman of childbearing potential [WOCBP; not surgically sterilized and between menarche and 1 year postmenopause])\nThe patient note states that the patient is postmenopausal, so this criterion is likely met.\n\n13. If fertile, patient (male or female) has agreed to use an acceptable method of birth control\nThe patient note states that the patient is postmenopausal, so this criterion is likely not applicable.\n\n14. Has signed a Patient Informed Consent Form\nThe patient note does not provide information about whether the patient has signed an informed consent form, so this criterion cannot be assessed.\n\n15. Has signed a Patient Authorization Form (HIPAA Form)\nThe patient note does not provide information about whether the patient has signed a HIPAA form, so this criterion cannot be assessed.\n\n16. Has a life expectancy of > 3 months\nThe patient note does not provide information about the patient's life expectancy, so this criterion cannot be assessed.\n\nBased on the information provided in the patient note, several of the inclusion criteria cannot be assessed due to lack of information. However, the criteria that can be assessed appear to be met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "55": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of \"patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy)\".\n\nThe note also mentions that the patient agrees to tumor resection prior to chemotherapy, which implies consent for the procedure.\n\nThere is no information provided that would exclude the patient based on the given inclusion criteria.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for the clinical trial \"Identification of Sentinel Lymph Nodes With Methylene Blue and Isotope\", the patient appears to be eligible for this trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "56": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS\" and check if the patient meets them:\n\nDISEASE CHARACTERISTICS:\n- Diagnosis of ductal carcinoma in situ within the past 6 months (Met: The patient has a 3 cm invasive ductal breast carcinoma)\n- Locally excised with tumor-free margins at least 1 mm (Not mentioned)\n- Currently enrolled in protocol CRUK-IBIS-II-DCIS AND randomized to receive either anastrozole or placebo (Not mentioned)\n- No T-score < -4.0 and/or > 2 low trauma vertebral fractures by dual-energy x-ray absorptiometry (DXA) (Not mentioned)\n- Hormone receptor status: Estrogen or progesterone receptor positive tumor (Not met: The tumor is ER/PR negative)\n\nPATIENT CHARACTERISTICS:\n- Female patient (Met)\n- Postmenopausal (Met)\n- No prior bilateral hip fracture or bilateral hip prostheses (Not mentioned)\n- No concurrent metabolic bone disease (Not mentioned)\n\nPRIOR CONCURRENT THERAPY:\n- More than 12 months since prior medication affecting bone metabolism (Not mentioned)\n\nBased on the information provided, the patient does not meet the inclusion criteria for hormone receptor status (ER/PR negative tumor). There is also some missing information regarding other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "57": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Histologically confirmed unicentric Stage I (T1 N0 M0) invasive ductal breast cancer - The patient meets this criterion as she has a 3 cm invasive ductal breast carcinoma.\n\n2. Histologically negative tumor margin 2 mm or more / Low-grade DCIS 2 cm or less with negative margins - No information provided about tumor margins.\n\n3. Tubular, mucinous and medullary variant histologies permitted - Not applicable as the patient has invasive ductal carcinoma.\n\n4. Women age 70 or older with T1 ER+ tumors and clinically negative nodes eligible without node evaluation if taking hormonal therapy - The patient is 45 years old, so this does not apply.\n\n5. T1N0(i+) tumors eligible if completion axillary dissection confirms N0 status - The patient has 5 positive lymph nodes, so this does not apply.\n\n6. Prior adjuvant chemotherapy permitted. Can be on hormonal therapy. - No information provided about prior treatments.\n\n7. Radiation therapy to begin within 4-12 weeks of surgery or 2-6 weeks after chemotherapy - No information provided about timing of radiation therapy.\n\n8. Age >= 18 years - The patient is 45 years old, so she meets this criterion.\n\n9. ECOG Performance Status 0-2 - No information provided about performance status.\n\n10. Signed informed consent - No information provided about consent.\n\nExclusion Criteria:\n1. Multicentric or multifocal invasive ductal carcinoma - No information provided, but the note states it is a unicentric tumor.\n\n2. Tumor > 2.0 cm, nodal involvement, or metastatic disease - The tumor is 3 cm, and the patient has 5 positive lymph nodes and metastatic lesions on CXR, so she is excluded based on this criterion.\n\n3. Lymphovascular invasion, extensive intraductal component, invasive lobular carcinoma, mixed ductal/lobular features, infiltrating papillary carcinoma - No information provided about these histologic features.\n\n4. Margins < 2 mm - No information provided about margins.\n\n5. History of cosmetic/reconstructive breast surgery - No information provided.\n\n6. Psychiatric illness preventing informed consent - No information provided.\n\n7. Uncontrolled infection, diabetes mellitus, connective tissue disease - No information provided.\n\n8. Currently active second malignancy - No information provided.\n\n9. Diffuse suspicious microcalcifications - No information provided.\n\n10. Pregnancy - The patient is postmenopausal, so she is not pregnant.\n\nBased on the information provided, the patient meets some of the inclusion criteria but is excluded due to having a 3 cm tumor, positive lymph nodes, and metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "58": {
        "output": "To determine the patient's eligibility for the clinical trial \"AZD1152 in Patients With Advanced Solid Malignancies\", I will go through the inclusion criteria one by one:\n\n1. \"Histological or cytological confirmation of a solid, malignant tumour\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and a \"3 cm invasive ductal breast carcinoma\", which satisfies this criterion.\n\n2. \"At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\"\nThe patient note mentions a 3 cm tumor in the left breast, as well as metastatic lesions seen on CXR, which would qualify as measurable disease.\n\nSince the patient meets both of the listed inclusion criteria and there are no explicit exclusion criteria provided, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "59": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria for the clinical trial state:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the breast and appropriate for treatment with Doxorubicin and Cyclophosphamide. \n   - The patient has cytologically confirmed invasive ductal breast carcinoma, which is a type of adenocarcinoma, so this criterion is met.\n\n2. Age > 18 years and <45 years.\n   - The patient is 45 years old, which does not meet this age criterion.\n\n3. ECOG performance status of 0 to 2.\n   - There is no information provided about the patient's ECOG performance status.\n\n4. Signed informed consent.\n   - There is no information provided about whether the patient has signed informed consent.\n\n5. Premenopausal: defined as regularly occurring menstrual cycles or serologic estradiol and FSH levels consistent with premenopausal status.\n   - The patient is described as postmenopausal, which does not meet this criterion.\n\nSince the patient does not meet the age criterion and is postmenopausal, which is an exclusion criterion, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "60": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women \u2265 18 years of age: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically proven breast cancer with an interval between definitive breast surgery and study registration of < 60 days: The patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, and it doesn't specify how long ago the biopsy was done, so there is not enough information to confirm this criterion.\n\n3. Definitive surgical treatment must be either mastectomy or breast conserving surgery with axillary lymph node dissection/evaluation: The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is potentially met pending the surgery.\n\n4. Lymph node positive or high-risk lymph node negative: The patient has 5 positive axillary lymph nodes, so she meets this criterion.\n\n5. HER2/neu positive or negative tumors are eligible, with HER2 positivity confirmed by FISH: The patient's tumor is HER2-positive, meeting this criterion.\n\n6. ER and PR status must be known: The patient's tumor is ER/PR negative, so this is known.\n\n7. Normal cardiac function confirmed by LVEF/shortening fraction: There is no information provided about the patient's cardiac function.\n\n8. Meeting hematologic criteria for ANC, platelets, and hemoglobin within 2 weeks: No hematologic values are provided.\n\n9. Meeting hepatic criteria for bilirubin, AST, ALT within 2 weeks: No hepatic values are provided.\n\n10. Complete staging workup done: It mentions the patient has metastatic lesions on CXR, suggesting some staging has been done, but the full extent is unclear.\n\nIn summary, while the patient meets some key inclusion criteria like being a woman \u226518 with HER2+ breast cancer and positive lymph nodes, there are several criteria where information is missing to make a definitive assessment of eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "61": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.\"\nThe patient note mentions that the patient has a 3 cm invasive ductal breast carcinoma with axillary lymph node involvement and metastatic lesions on CXR, so this criterion is met.\n\n2. \"Tumors over-expressing Her-2\"\nThe patient note states that the tumor is HER2-positive, so this criterion is also met.\n\n3. \"Candidate for treatment with docetaxel/trastuzumab\"\nThe patient note does not explicitly mention if the patient is a candidate for docetaxel/trastuzumab treatment, but it does state that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. Since the trial is evaluating the combination of SU011248 with docetaxel and trastuzumab, it can be assumed that the patient would be a candidate for this treatment regimen after tumor resection.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient appears to meet all the necessary criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "62": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Confirmed diagnosis of Breast Cancer with at least one breast cancer-related bone lesion\n- The patient note states that the patient has cytologically confirmed breast cancer and metastatic bone lesions, so this criterion is met.\n\n2) No treatment with bisphosphonates within 6 months prior to inclusion into the study\n- There is no mention of the patient receiving bisphosphonate treatment, so we can assume this criterion is met for now.\n\n3) Good health status (ECOG Performance status 0-2)\n- There is no information provided about the patient's ECOG performance status, so this cannot be definitively assessed.\n\nExclusion Criteria:\n1) Patients who do not have at least one breast cancer-related bone lesion that is detectable on conventional radiographs of bone (plain film) at screening\n- This criterion is met, as the patient has metastatic bone lesions detected.\n\n2) Abnormal renal function\n- There is no information about the patient's renal function, so this cannot be assessed.\n\n3) History of diseases with influence on bone metabolism such as Paget's disease and primary hyperparathyroidism\n- There is no mention of the patient having these conditions, so we can assume this criterion is met for now.\n\n4) Pregnancy and lactation\n- The patient is noted to be postmenopausal, so pregnancy and lactation are not applicable.\n\n5) Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures, recent (within 6 weeks) or planned dental or jaw surgery (e.g..extraction, implants)\n- There is no information provided about the patient's dental status, so this cannot be definitively assessed.\n\nBased on the information provided, the patient meets the key inclusion criterion of having breast cancer with metastatic bone lesions. However, there is not enough information to definitively assess all inclusion/exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "63": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. High risk lymph node positive breast cancer defined as 5 or more involved axillary lymph nodes\n- The patient has 5 positive lymph nodes, so this criterion is met.\n\n2. Must have undergone surgical local therapy (modified radical mastectomy or breast conserving surgery).\n- The patient is a candidate for tumor resection, so this criterion is likely to be met after surgery.\n\n3. Negative tumor margins for invasive cancer\n- There is no information about tumor margins in the patient note.\n\n4. No evidence of distant metastasis\n- The patient has metastatic lesions on CXR, so this criterion is not met.\n\n5. Normal cardiac ejection fraction\n- There is no information about cardiac ejection fraction.\n\n6. Adequate organ function defined as specific lab values\n- There is no information about the patient's lab values.\n\n7. Performance status 0-1\n- There is no information about the patient's performance status.\n\n8. Age 18 years or older\n- The patient is 45 years old, so this criterion is met.\n\n9. No prior chemotherapy, hormonal therapy or radiation therapy for treatment of the primary breast cancer\n- There is no information about prior treatments.\n\n10. Bilateral synchronous breast cancer is allowed if other criteria are met.\n- This is not applicable as there is no mention of bilateral breast cancer.\n\n11. Patients may be ER/PR+ and receive treatment with hormonal therapy\n- The patient's tumor is ER/PR negative, so this is not applicable.\n\n12. Use of effective means of contraception in subjects of child-bearing potential\n- The patient is postmenopausal, so this is not applicable.\n\n13. Signed informed consent\n- There is no information about informed consent.\n\nBased on the information provided, the patient meets at least one inclusion criterion (lymph node involvement) but does not meet the criterion of no evidence of distant metastasis. There is also insufficient information to determine if several other criteria are met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "64": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nFor Patients:\n1) Being a female patient diagnosed with metastatic breast cancer.\nThe patient note states that the patient is a \"45-year-old postmenopausal woman with cytologically confirmed breast cancer\" and that \"CXR was remarkable for metastatic lesions.\" So this criterion is met.\n\n2) Initiating treatment for metastatic breast cancer\nThe patient note does not explicitly state whether the patient is initiating treatment or not. There is not enough information to determine if this criterion is met.\n\n3) Having an ECOG Performance Status Score of 2 or less\nThe patient note does not provide the ECOG Performance Status Score, so there is not enough information to determine if this criterion is met.\n\nFor Spouses: \n4) Being the male spouse or significant other of a female patient diagnosed with metastatic breast cancer\nThe patient note does not mention whether the patient has a spouse/significant other, so there is not enough information to determine if this criterion is met.\n\n5) Having the patient's consent to be contacted\nSince it is unknown if the patient has a spouse/significant other, there is not enough information to determine if this criterion is met.\n\nFor Patients and Spouses:\n6) Having the ability to read and speak English well enough to understand the consent form and complete the questionnaires\nThe patient note does not provide any information about the patient's or potential spouse's English proficiency.\n\n7) Being able to provide informed consent\nThe patient note does not indicate whether the patient is able to provide informed consent.\n\nIn summary, while one of the inclusion criteria is met (being a female with metastatic breast cancer), there is not enough information provided in the patient note to determine if the other criteria are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "65": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologic, pathologic or cytologic diagnosis of cancer of the female breast in either primary or metastatic setting - The patient has cytologically confirmed breast cancer, so this criterion is met.\n\n2. Stage IV breast cancer or locally advanced (stage III) breast cancer not considered amenable to curative therapy - The patient has stage III breast cancer with positive lymph nodes and metastatic lesions on CXR, so this criterion is met. \n\n3. Tumors must be potentially sensitive to endocrine therapy, defined as expressing estrogen receptor (ER) and/or progesterone receptor (PgR) - The tumor is ER/PR negative, so this criterion is not met.\n\n4. The protocol permits tumors with any HER2 status - The tumor is HER2-positive, so this criterion is met.\n\n5. At least one measurable lesion >= 2 cm - The primary tumor is 3 cm, so this criterion is met.\n\n6. Prior endocrine therapy requirements - No information is provided about prior endocrine therapies.\n\n7. Prior chemotherapy allowed - No information is provided about prior chemotherapy.\n\n8. No prior trastuzumab, EGFR inhibitors, or fulvestrant - No information provided.\n\n9. Postmenopausal woman criteria - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n10. ECOG performance status 0-2 - No information provided.\n\n11. Absence of visceral crisis - No information provided.\n\n12. Absence of bleeding disorder - No contraindication mentioned.\n\n13. Lab value criteria - No relevant lab values provided.\n\nSince the key inclusion criterion of ER/PR positivity is not met, despite meeting some other criteria, I would assess this patient as:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "66": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, invasive ductal carcinoma, HER2-positive, and ER/PR negative. There are 5 positive axillary lymph nodes and metastatic lesions seen on CXR.\n\nThe clinical trial inclusion criteria are:\n1. Breast cancer with evidence of unresectable locally recurrent, or metastatic disease - The patient meets this criteria with metastatic lesions seen on CXR.\n2. Her-2 negative tumors - The patient's tumor is HER2-positive, so she does not meet this criteria.\n\nSince the patient does not meet one of the key inclusion criteria (HER2-negative tumor), she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "67": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Metastatic or locally advanced breast cancer not amenable to curative surgery\n- The patient note mentions that the patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR, so this criterion is met.\n\n2. Life expectance of greater than 12 months\n- There is no information provided about the patient's life expectancy, so this cannot be definitively assessed.\n\n3. English speaking\n- This is not mentioned in the patient note, but we can reasonably assume the patient is English speaking since the note is written in English.\n\n4. Pre- and postmenopausal\n- The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n5. Performance status 0-1\n- There is no information provided about the patient's performance status.\n\nSince there is insufficient information to definitively assess criteria 2 and 5, I would determine the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "68": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically confirmed breast adenocarcinoma.\nThe patient note confirms that the patient has cytologically confirmed invasive ductal breast carcinoma, which meets this criteria.\n\n2. Within 20-45 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed.\nThe patient note does not mention if surgery has been performed yet, so this criteria cannot be evaluated.\n\n3. Absence of lymph node involvement after excision and hormone (E&H) staining and light microscopy evaluation.\nThe patient note states that axillary sampling revealed 5 positive lymph nodes, so the patient does not meet this criteria.\n\n4. Premenopausal or postmenopausal women with at least one of the following tumor characteristics is required in order to characterize the tumor as high risk:\n- Estrogen receptor (ER) (-) and progesterone receptor (PR)(-)\n- Ki-67 + > 30%\n- Grade III\n- HER2 (3+) \n- Perineural infiltration or presence of tumor emboli in blood or lymph vessels.\n\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so the patient meets this high-risk criteria.\n\n5. Postmenopausal women with tumors 1-2 cm are eligible if the tumor has at least 2 of the above mentioned high risk criteria.\nThe patient is a 45-year-old postmenopausal woman with a 3 cm tumor, so this criteria does not apply.\n\n6. Premenopausal and postmenopausal women with tumors measuring > 2 cm are eligible irrespectively of the expression of the above adverse prognostic tumor criteria.\nThe patient has a 3 cm tumor, so she meets this criteria.\n\n7. Absence of any clinical or radiological evidence of local or metastatic disease.\nThe patient note mentions metastatic lesions on CXR, so the patient does not meet this criteria.\n\n8. Age > 18 years.\nThe patient is 45 years old, so she meets this criteria.\n\nThe remaining criteria (performance status, adequate bone marrow/liver/renal/cardiac function, pregnancy test, informed consent) cannot be evaluated based on the information provided in the patient note.\n\nOverall, while the patient meets some of the key inclusion criteria like tumor type, size and HER2 status, she is excluded based on having positive lymph nodes and evidence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "69": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma\n- The patient note states the patient has \"cytologically confirmed breast cancer\" and \"a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed.\n- The patient has not had surgery yet, but \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\". This criterion cannot be evaluated definitively yet.\n\n3. Tumor involvement of at least one axillary lymph node\n- The patient note states \"Axillary sampling revealed 5 positive lymph nodes\", so this criterion is met.\n\n4. Absence of any clinical or radiological evidence of local or metastatic disease\n- The patient note mentions \"CXR was remarkable for metastatic lesions\", indicating presence of metastatic disease, so this criterion is not met.\n\n5. Premenopausal or postmenopausal women aged 18-75 years old\n- The patient is described as a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n6. Adequate bone marrow, liver, and renal function\n- There is no information provided about these laboratory values.\n\n7. Adequate cardiac function (LVEF>50%) \n- There is no information provided about cardiac function.\n\n8. Written informed consent\n- This is assumed but not explicitly stated.\n\nOverall, while some criteria are met, the presence of metastatic disease excludes the patient from this trial. Additionally, there is insufficient information to evaluate some other criteria definitively.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "70": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Signed and dated informed consent form - There is no information about this in the patient note.\n2. Women \u2265 18 years, negative pregnancy test at screening life expectancy of at least 6 months - The patient is a 45-year-old postmenopausal woman, so she meets this criteria.\n3. Locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma of the breast - The patient has metastatic breast cancer, so she meets this criteria.\n4. Measurable disease, defined as at least one lesion that is measurable in one dimension (RECIST) - The patient has a 3 cm tumor, which is measurable, so she meets this criteria.\n5. HER-2/neu expression 1+ or 2+ / FISH negative - The patient's tumor is HER2-positive, so she meets this criteria.\n6. Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive - The patient's tumor is ER/PR negative, so she does not meet this criteria.\n7. Prior adequate endocrine therapy for advanced or metastatic disease - There is no information about prior endocrine therapy in the patient note.\n8. Disease progression during or after endocrine therapy - There is no information about disease progression during or after endocrine therapy in the patient note.\n9. No prior treatment with mouse or rat antibodies - There is no information about prior treatment with mouse or rat antibodies in the patient note.\n10. ECOG performance score of \u2264 1 - There is no information about the patient's ECOG performance score in the patient note.\n11. Adequate hematological, liver and kidney function - There is no information about the patient's hematological, liver and kidney function in the patient note.\n\nBased on the information provided, the patient does not meet the inclusion criteria for ER/PR positivity. There is also not enough information to determine if she meets several other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "71": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"TAC Versus TC for Adjuvant Breast Cancer\" and assess the eligibility of the patient based on the provided patient note.\n\n1. Age >18 to <70 years old: The patient is a 45-year-old postmenopausal woman, which meets this criterion.\n\n2. Has known ER and PR status: The patient note states that the tumor is ER/PR negative, so this criterion is met.\n\n3. Has HER2 nonamplified disease, confirmed by FISH: The patient note mentions that the tumor is HER2-positive, which does not meet this criterion.\n\n4. Has known menopausal status: The patient is described as postmenopausal, so this criterion is met.\n\n5. Has operable, histologically confirmed, Stage I, IIA, IIB, or IIIA, IIIB, or IIIC invasive carcinoma of the breast: The patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, which suggests Stage III breast cancer. This criterion is met.\n\n6. Meets one of the three criteria (T1-3N1-3M0 if ER positive or negative, T2-3N0M0 if ER positive or negative, or T1N0M0 if ER and PR negative): The patient has a T3N1M0 tumor (based on the 3 cm size and positive lymph nodes), and the tumor is ER/PR negative, so this criterion is met.\n\n7. Has complete surgical resection of the primary breast tumor: The patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is potentially met.\n\n8. Has had no prior chemotherapy unless >5 years ago: The patient note does not mention any prior chemotherapy, so this criterion is assumed to be met.\n\n9. Has an ECOG Performance Status (PS) 0-1: The patient note does not provide information about the ECOG Performance Status, so this criterion cannot be assessed.\n\n10. Has laboratory values within specified ranges: The patient note does not provide laboratory values, so this criterion cannot be assessed.\n\n11. Has normal cardiac function as evidenced by a LVEF >50%: The patient note does not provide information about the patient's cardiac function or LVEF, so this criterion cannot be assessed.\n\n12. Has no evidence of metastatic disease outside of breast: The patient note mentions metastatic lesions on the CXR, which suggests metastatic disease outside of the breast. This criterion is not met.\n\n13. Has had baseline bilateral mammography: The patient note does not mention whether bilateral mammography has been performed, so this criterion cannot be assessed.\n\n14. It has been <84 days since the date of definitive surgery: The patient note does not provide information about the timing of surgery, so this criterion cannot be assessed.\n\n15. Has a negative serum pregnancy test within 7 calendar days prior to registration: The patient note states that the patient is postmenopausal, so this criterion is likely met.\n\n16. If fertile, patient has agreed to use an acceptable method of birth control: The patient is described as postmenopausal, so this criterion is not applicable.\n\n17. Has adequate tumor specimen available for FISH analysis of TOP2A status: The patient note does not mention the availability of a tumor specimen for FISH analysis, so this criterion cannot be assessed.\n\n18. Has signed a Patient Informed Consent Form: The patient note does not provide information about signing a consent form, so this criterion cannot be assessed.\n\n19. Has signed a Patient Authorization Form: The patient note does not provide information about signing an authorization form, so this criterion cannot be assessed.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria but does not meet the criterion for HER2 nonamplified disease and has evidence of metastatic disease outside of the breast, which is an exclusion criterion. Additionally, there are several criteria that cannot be assessed due to lack of information in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "72": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Females age 18 years or older - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Ability to provide written informed consent - Not mentioned in the patient note, but presumably she can provide consent. \n\n3. Histologically confirmed infiltrating (invasive) breast cancer by core needle biopsy, with no evidence of metastatic disease except to the ipsilateral axillary lymph nodes - The patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, with 5 positive axillary lymph nodes, meeting this criterion.\n\n4. Clinical stage IIB - IIIC breast cancer, with primary tumor \u2265 2 cm or pathologically proven axillary nodal involvement - The 3 cm tumor and positive axillary nodes satisfy this.\n\n5. Clinically palpable tumor meeting RECIST criteria for measurable disease - The 3 cm tumor would be palpable and measurable.\n\n6. Primary tumor may be ER/PR negative or positive, and HER-2 positive - The tumor is HER2-positive and ER/PR negative, meeting this.\n\n7. Normal cardiac ejection fraction and no prior heart issues - Not mentioned, but presumably met to be a surgical candidate.\n\n8. ECOG Performance Status 0-1 - Not explicitly stated but implied by being a surgical candidate.\n\n9. Able to self-administer injections - Not mentioned but presumably able to do so.\n\n10. Life expectancy > 6 months - Not explicitly stated but implied by being a surgical candidate.\n\nBased on the information provided, the patient appears to meet all the key inclusion criteria for this breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "73": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, not lung cancer. This clinical trial is specifically for patients with stage IA non-small cell lung cancer.\n\n2. The inclusion criteria require a peripheral lung nodule \u2264 2 cm on preoperative CT scan, presumed to be lung cancer. The patient does not have a lung nodule, but rather breast cancer.\n\n3. Other inclusion criteria like ECOG performance status, no prior malignancy within 3 years, no prior chemotherapy or radiation therapy, no evidence of locally advanced or metastatic disease, and age \u2265 18 years are not relevant since the patient does not have lung cancer.\n\n4. The intra-operative randomization eligibility criteria, which require histologic confirmation of NSCLC and confirmation of N0 status by frozen section examination, are also not applicable to this patient with breast cancer.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for this clinical trial on different types of surgery for stage IA non-small cell lung cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "74": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Histologically or cytologically confirmed invasive breast carcinoma - Yes, the patient has cytologically confirmed invasive ductal breast carcinoma.\n\n2. Early stage breast cancer - stage I (tumor size greater than 1 cm), II and IIA - Yes, the tumor size is 3 cm which falls under stage II.\n\n3. 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity - Yes, the tumor is HER2-positive.\n\n4. Patients must have measurable disease as defined by palpable lesion with both diameters greater than or equal to 1 cm measurable with caliper and/or a positive mammogram or ultrasound with at least one dimension greater than or equal to 1 cm - Yes, the 3 cm tumor satisfies this criteria.\n\n5. ECOG performance status 0 to 2 within 14 days of study entry - There is no information provided about the ECOG performance status.\n\n6. Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography - There is no information about LVEF.\n\n7. Must be 18 years of age or older - Yes, the patient is 45 years old.\n\n8. Women or men of childbearing potential must use a reliable and appropriate contraceptive method. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential - Yes, the patient is postmenopausal.\n\nSince there is no information about ECOG performance status and LVEF, I cannot definitively determine eligibility. However, based on the information provided, the patient seems to meet most of the key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "75": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Patients must be female and 18 years of age or older.\nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Patients must have a clinical T1, T2, or T3 tumor size. \nThe patient has a 3 cm invasive ductal breast carcinoma, which would likely be classified as T2.\n\n3. Patients must have a histopathologic tissue diagnosis of breast cancer by a core-type of breast biopsy\nThe patient had a core biopsy that confirmed invasive ductal breast carcinoma.\n\n4. Patients must have had biopsy-proven involvement of the axillary lymph nodes at initial presentation based on fine needle aspiration (FNA) cytology, core/Tru-cut biopsy, or pre-treatment SLN biopsy that will require an axillary lymph node dissection to be performed at the time of the definitive breast cancer surgery.\nThe patient had axillary sampling that revealed 5 positive lymph nodes.\n\n5. Patients will have had to undergone preoperative neoadjuvant systemic chemotherapy.\nThe note mentions the patient is a candidate for tumor resection prior to chemotherapy, so this criterion is not met yet.\n\n6. Patients may be candidates for either lumpectomy or mastectomy.\nThe note does not specify the planned surgery, but presumably the patient would be a candidate for either.\n\n7. Patients may have a history of a previously treated metachronous contralateral breast cancer in the past.\nThere is no mention of a previous breast cancer.\n\n8. Patients may have synchronous bilateral breast cancer.\nThere is no mention of bilateral breast cancer.\n\nBased on the information provided, the patient meets most of the key inclusion criteria except having already received neoadjuvant chemotherapy prior to surgery.\n\nTrial-level eligibility: 1) Not relevant, as the patient has not yet received the required neoadjuvant chemotherapy.",
        "label": 2
    },
    "76": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must have pathologically confirmed ER, PR and HER2/neu negative (FISH ratio of <2.0 or IHC <1+) metastatic breast cancer. Locally advanced or recurrent disease is also eligible.\"\n- The patient note states that the tumor is HER2-positive and ER/PR negative, which does not meet this criteria.\n\n2. \"Patients must have measurable disease\"\n- The patient has a 3 cm tumor, which is measurable disease, meeting this criteria. \n\n3. \"Patients must not have received prior chemotherapy for metastatic breast cancer (not including adjuvant therapy). Patients should be > 4 weeks from their most recent chemotherapy or radiation therapy treatment.\"\n- There is no mention of prior chemotherapy for metastatic disease in the patient note, so this criteria is met.\n\n4. \"Age >18 years\" \n- The patient is 45 years old, meeting this criteria.\n\n5. \"ECOG performance status <1 (Karnofsky >80%).\"\n- No ECOG or Karnofsky score is provided, so this cannot be evaluated.\n\n6. Normal organ and marrow function criteria\n- No lab values are provided, so these cannot be evaluated.\n\n7. \"Tissue from the primary tumor must be available for correlative studies\"\n- It is not stated if tumor tissue is available, so this cannot be evaluated.\n\n8. \"Women of child-bearing potential must agree to use adequate contraception\"\n- The patient is postmenopausal, so this does not apply.\n\n9. \"Ability to understand and the willingness to sign a written informed consent document.\"\n- This is typically assumed unless stated otherwise.\n\nSince the key criteria of HER2-negativity is not met, the patient would be excluded from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "77": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"probable or definite localization-related, primary generalized or symptomatic generalized epilepsy that is medically-refractory, as defined by treatment failure of at least 2 anti-epilepsy drugs at standard doses, despite medication compliance as determined by the treating neurologist\"\n- The patient note does not mention the patient having epilepsy or being treated with anti-epilepsy drugs, so this criterion is not met.\n\n2. \"at least 3 seizures/month in the 3-month period prior to randomization. Seizures that will be considered include generalized tonic clonic, complex partial, myoclonic and absence seizures. Simple partial seizures must have an observable motor component or have been otherwise been documented by videoEEG to be a definite seizure.\"\n- Again, no mention of the patient having seizures.\n\n3. \"Patients with prior epilepsy brain surgery or vagal nerve stimulator implantation will be allowed if medication and seizure frequency has been stable for the prior 3 months.\"\n- Not applicable since the patient does not have epilepsy.\n\n4. \"Ages between 10 and 75 years will be eligible for inclusion. Elderly patients without a history or symptoms of cardiovascular disease may be eligible on a case-by-case basis. No patients older than 75 will be included due to the possible cardiovascular side-effects.\"\n- The patient is 45 years old, so meets this age criterion.\n\n5. \"Pre-menopausal women must be utilizing two reliable forms of birth control or abstinence\"\n- The patient is described as postmenopausal, so this does not apply.\n\n6. \"ability of the patient to understand the concept of a clinical trial by answering the following questions appropriately: o will your seizures get better, worse or stay the same? Response in the spirit of: Any of the 3 could happen.\"\n- Cannot assess this from the patient note provided.\n\nSince the patient does not have epilepsy or seizures, they do not meet the key inclusion criteria for this epilepsy clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "78": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed breast cancer, including invasive ductal carcinoma - Meets this criteria based on \"a 3 cm invasive ductal breast carcinoma\"\n- Stage I or II disease (T1, N0; T1, N1a; T2, N0; or T2, N1a) - Meets this criteria based on having 5 positive lymph nodes, which would be T2, N1a\n- Lesion \u2264 3 cm - Meets this criteria with a 3 cm lesion\n- No more than 3 positive lymph nodes - Does not meet this criteria with 5 positive lymph nodes\n- Has undergone lumpectomy and axillary lymph node sampling - Meets this based on \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy\"\n- Negative resection margins with \u2265 2 mm margin or a negative re-excision margin - No information provided\n- Unifocal breast cancer - Meets this criteria based on no mention of multicentric carcinoma\n- No multicentric carcinoma - Meets this criteria \n- No palpable or radiographically suspicious lymph nodes unless confirmed negative - Meets this based on no mention of this\n- No skin involvement of disease - Meets this based on no mention \n- No Paget's disease of the nipple - Meets this based on no mention\n- No distant metastatic disease - Does not meet this based on \"CXR was remarkable for metastatic lesions\"\n\nPATIENT CHARACTERISTICS:\n- Female - Meets this criteria\n- Menopausal status not specified - Meets this based on being postmenopausal\n- Not pregnant/lactating, negative pregnancy test - Meets this based on no mention of pregnancy\n- Must use contraception if fertile - Meets this based on being postmenopausal\n- No collagen vascular disorders - Meets this based on no mention\n- No psychiatric/neurological/addictive disorders precluding consent - Meets this based on no mention\n- No other malignancy in past 5 years except non-melanoma skin cancer - Meets this based on no mention\n\nPRIOR/CONCURRENT THERAPY:\n- No prior radiotherapy to the breast - Meets this based on no mention\n- No chemo 2 weeks before/after study radiotherapy - Potentially does not meet since planning chemo after surgery\n- Concurrent hormonal therapy allowed - Meets this based on no mention of hormonal therapy\n\nOverall, the patient meets several of the key inclusion criteria like cancer type, stage, lesion size. However, there are a few criteria the patient does not meet - having more than 3 positive lymph nodes and evidence of distant metastatic disease based on the CXR findings. There is also unclear information about the resection margins and whether the patient will receive chemotherapy overlapping with the study radiation.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "79": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"All patients must have histologically confirmed and newly diagnosed breast cancer: node-positive stage IIA and any stage IIB, III.\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and \"Axillary sampling revealed 5 positive lymph nodes\", which suggests node-positive disease. However, the stage is not explicitly mentioned.\n\n2. \"No prior hormonal, chemotherapy or radiotherapy is allowed.\"\nThe patient note does not mention any prior treatment, so this criterion is likely met.\n\n3. \"No breast operation other than biopsy to make diagnosis is allowed.\"\nThe patient note states that a core biopsy was performed, but no other breast operation is mentioned, so this criterion is likely met.\n\n4. \"Age: 18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)\"\nThe patient note states that the patient is a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n5. Adequate hematopoietic, renal, hepatic, cardiac, and mental function criteria are not explicitly mentioned in the patient note.\n\nBased on the information provided, the patient meets some of the key inclusion criteria, but there is not enough information to definitively determine eligibility. More details about the disease stage, organ function, and performance status would be needed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "80": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Women with histologically/cytologically confirmed locally advanced or metastatic breast cancer\"\nThe patient note states that the patient is a \"45-year-old postmenopausal woman with cytologically confirmed breast cancer\" and that \"CXR was remarkable for metastatic lesions.\" This meets the criterion.\n\n2. \"Primary tumor or metastases are HER2-ICH3+ or FISH+\"\nThe patient note mentions that the tumor is \"HER2-positive.\" This meets the criterion.\n\n3. \"Measurable or non-measurable disease\"\nThe patient note states that there is a \"3 cm invasive ductal breast carcinoma in the left upper outer quadrant\" and metastatic lesions, indicating measurable disease. This meets the criterion.\n\n4. \"The patients must not have received treatment with the combination trastuzumab and vinorelbine previously\"\nThere is no information provided about previous treatments, so we cannot confirm or deny this criterion.\n\n5. \"Expected lifetime of more than 12 weeks\"\nNo information is provided about the patient's expected lifetime.\n\n6. \"Age \u2265 18 years\"\nThe patient is stated to be 45 years old, meeting this criterion.\n\n7. \"Performance status \u2264 2 according to World Health Organization (WHO) scale\"\nNo information is provided about the patient's performance status.\n\n8. \"The patient must be able to comply with the protocol\"\nNo information is provided about the patient's ability to comply with the protocol.\n\n9. \"Verbal and written informed consent\"\nNo information is provided about whether the patient has provided informed consent.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to confirm eligibility for all criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "81": {
        "output": "Okay, let's go through the inclusion criteria for this neoadjuvant chemotherapy trial in triple-negative breast cancer step-by-step:\n\n1. Women with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 negative invasive breast cancer confirmed on core biopsy.\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n2. Primary tumor size 2cm or greater by physical exam or radiographic measurements.  \nThe patient note mentions the tumor is 3cm, so this criterion is met.\n\n3. Assessment of pre-treatment axillary lymph nodal status\nThe patient note states that axillary sampling revealed 5 positive lymph nodes, so this criterion is met.\n\n4. Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3\nThere is no information provided about blood counts, so this cannot be assessed.\n\n5. Normal myocardial left ventricular function\nThere is no information about cardiac function.\n\n6. Serum creatinine < 2.0 mg/dl \nNo creatinine value given.\n\n7. Total bilirubin and AST < 3X upper limits normal\nNo liver function tests provided.\n\nSince the key inclusion criterion of triple-negative breast cancer is not met, despite meeting some other criteria, this patient would be excluded from this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "82": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of \"Histologically confirmed breast cancer\".\n\nThe tumor is 3 cm invasive ductal carcinoma, which meets the criteria of \"Primary tumor \u22652 cm acc. to clinical measurement or manifestation of an inflammatory breast cancer.\"\n\nThere are metastatic lesions noted on CXR, which would exclude the patient based on the criteria \"No systemic metastasis, exclusion by chest x-ray, sonogram of the upper abdomen and skeletal scintiscan.\"\n\nThe patient's age of 45 falls within the range specified in \"Age \u226518 years and \u226465 years.\"\n\nNo information is provided about ECOG/WHO performance status to assess \"ECOG < 2/WHO 0-1\".\n\nNo lab values are given to evaluate the criteria for adequate organ function.\n\nNo information about heart echo or hepatitis status.\n\nSince the patient has metastatic disease noted on CXR, she would be excluded from this trial despite meeting some of the other inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "83": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Postmenopausal women defined as: aged >/= 50 years with amenorrhea for at least 12 months or aged < 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or having undergone bilateral oophorectomy\nThe patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Histologically or cytologically confirmed breast cancer\nThe patient note mentions that the patient has cytologically confirmed breast cancer, so this criterion is met.\n\n3. Metastatic breast cancer (Stage IV according to UICC - Union Internationale Contre Cancer - criteria, Version 6)\nThe patient note states that the patient has metastatic lesions on CXR, indicating metastatic breast cancer, so this criterion is met.\n\n4. Progesterone receptor-positive tumors\nThe patient note does not mention the progesterone receptor status of the tumor.\n\n5. Patients must be considered candidates for endocrine therapy (no other therapies for breast cancer are required)\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so it is unclear if she would be considered a candidate for endocrine therapy alone.\n\n6. Disease progression after first-line endocrine therapy for advanced breast cancer (i.e. with tumor remission or stabilization lasting at least 3 months under endocrine therapy)\nThe patient note does not mention any previous endocrine therapy or disease progression.\n\n7. At least one measurable or non-measurable tumor lesion (according to RECIST criteria)\nThe patient note mentions a 3 cm invasive ductal breast carcinoma, which would likely be considered a measurable lesion.\n\n8. WHO Performance status 1\nThe patient note does not mention the patient's performance status.\n\n9. Adequate function of major organs and systems (hematopoietic, hepatic, renal, gynecological)\nThe patient note does not provide enough information to determine if the patient meets these criteria.\n\n10. No other uncontrolled concurrent illness\nThe patient note does not mention any other concurrent illnesses.\n\n11. Adequate recovery from previous surgery, radiation and chemotherapy\nThe patient note does not mention any previous surgery, radiation or chemotherapy.\n\n12. Written informed consent\nThe patient note does not mention whether the patient has provided written informed consent.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all the inclusion criteria for this clinical trial. The progesterone receptor status, performance status, organ function, and previous therapies are not clearly stated.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "84": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria specify female patients aged \u226540 years with localized ductal carcinoma in situ (DCIS). So far the patient meets these criteria.\n\n2. The patient has a 3cm invasive ductal breast carcinoma, which is not DCIS. The inclusion criteria specify biopsy-proven DCIS only. An invasive carcinoma would make the patient ineligible.\n\n3. The patient also has axillary lymph node metastases, which is an exclusion criterion of \"clinically and/or histologically negative axillary lymph nodes\".\n\n4. The patient has metastatic lesions seen on CXR, which would likely exclude her as the trial is for localized DCIS only.\n\nIn summary, while the patient meets some inclusion criteria like age and gender, the presence of invasive carcinoma, lymph node metastases, and distant metastases would exclude her from this clinical trial for DCIS.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "85": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically/cytologically confirmed breast cancer, meeting this criteria.\n- The patient has metastatic disease with measurable lesions, meeting this criteria. \n- The patient's tumor is HER2-positive, which is allowed but not required for this trial focused on ER/PR positive disease.\n- The patient has ER/PR negative disease, not meeting the \"ER and/or PR positive disease\" criteria.\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, meeting the gender and menopausal status criteria.\n- No information is provided about ECOG performance status, so unable to assess that criteria.\n- No lab values like hemoglobin, platelets, liver/kidney function are provided to assess those criteria.\n- No information about pregnancy/nursing status.\n- No information about other medical conditions like cardiac disease, infections, hepatitis, HIV status, etc.\n\nPRIOR/CONCURRENT THERAPY:\n- No information about prior therapies for metastatic disease.\n- No information about timing of any prior radiation or surgeries.\n- No information about concurrent medications.\n\nOverall, while the patient meets some of the inclusion criteria like having metastatic measurable breast cancer and being postmenopausal, the ER/PR negative status excludes the patient from this trial focused on ER/PR positive disease. There is also insufficient information provided to fully assess several other inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "86": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of 18 years or older)\n- Postmenopausal woman\n- Diagnosed with breast cancer\n- 3 cm invasive ductal carcinoma in left breast \n- HER2-positive (meets criteria of ER-, PR-, HER2-negative)\n- ER/PR negative (meets criteria)\n- 5 positive lymph nodes (meets criteria of clinical stage T2/T3, N0-3, M0)\n- Has metastatic lesions on CXR (this would make her M1 and ineligible based on the M0 criteria)\n\nThe key inclusion criteria she does not meet is having M0 (no metastatic) disease. Since she has metastatic lesions, she would be classified as M1 and therefore ineligible.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "87": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patient with unifocal histologically proven breast cancer, with or without calcifications in mammogram.\"\nThe patient note states that the patient has a \"3 cm invasive ductal breast carcinoma\", which meets this criterion.\n\n2. \"DCIS (Ductal carcinoma in situ) (Tis, Stage 0)\" or \"Non-lobular infiltrating carcinoma, maximum of 2 cm in diameter. (T1, Stage I)\"\nThe patient has an invasive ductal carcinoma, which is a non-lobular infiltrating carcinoma. However, the tumor size is 3 cm, which exceeds the 2 cm maximum stated in the criteria.\n\n3. \"The patient was operated on and the tumor was excised with lumpectomy\"\nThe patient note mentions that the patient \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\", which implies that the tumor has not yet been excised with lumpectomy.\n\n4. \"The tumor is reported with negative margins >3 mm, as per our hospital protocol.\"\nThere is no information provided about the tumor margins in the patient note.\n\n5. \"For invasive carcinoma, axillary lymph nodes are negative by sentinel lymph node (SLN) mapping and biopsy or by formal axillary lymph node dissection.\"\nThe patient note states that \"Axillary sampling revealed 5 positive lymph nodes\", which does not meet this criterion.\n\n6. \"The patient is over 40 years old with life expectancy of at least 5 years\"\nThe patient is a 45-year-old woman, which meets this criterion.\n\n7. \"Karnofsky status must be at least 70. See appendix I.\"\nThere is no information provided about the patient's Karnofsky status in the note.\n\n8. \"Pre- and post-menopausal women are eligible for entry.\"\nThe patient note states that the patient is postmenopausal, which meets this criterion.\n\n9. \"The patient must be aware of the neoplastic nature of her disease and must be willing to consent after being informed of the potential benefits, side effects and risks of radiotherapy. Institutional Review Board approval of this protocol and a consent form is required.\"\nThere is no information provided about the patient's awareness or willingness to consent in the note.\n\nBased on the information provided in the patient note, the patient does not meet all of the inclusion criteria for this clinical trial. Specifically, the tumor size exceeds the maximum allowed, the tumor has not yet been excised with lumpectomy, and the patient has positive axillary lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "88": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criteria.\n\nShe has a 3 cm invasive ductal breast carcinoma, which is an allowed histology type per the inclusion criteria. \n\nThe tumor is HER2-positive and ER/PR negative, which is not an exclusion criterion.\n\nShe has 5 positive lymph nodes, which would exclude her based on the criteria \"For patients with invasive cancer, no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\"\n\nShe is a candidate for tumor resection prior to chemotherapy, which aligns with the criteria.\n\nThere is no information provided about pregnancy status, margins, mammography findings, or chemotherapy/hormonal therapy timing in relation to brachytherapy.\n\nOverall, based on the positive lymph node involvement, this patient would not be eligible for this particular breast brachytherapy trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "89": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman with breast cancer, meeting the criteria of \"Women who have chosen to undergo breast conservation therapy, including lumpectomy and breast irradiation, for any invasive mammary carcinoma or intraductal breast cancer\"\n- She has a 3 cm invasive ductal breast carcinoma, meeting the criteria of \"Stage I-II invasive or intraductal breast cancer\" and \"Unifocal tumor \u2264 3.0 cm in size\"\n- There is no mention of multicentric disease, meeting \"No proven multicentric carcinoma in more than 1 quadrant or separated by 4 or more centimeters\"\n- It is not mentioned if margins are negative after biopsy\n- She has 5 positive lymph nodes, which meets \"fewer than 4 positive nodes on adequate axillary lymph node dissection (i.e., 10 or more lymph nodes removed)\"\n- There is no mention of sentinel lymph node status\n- There are no nodes >2 cm or with extracapsular extension mentioned\n- It is not mentioned if surgical clips were placed or if the lumpectomy cavity can be visualized on CT\n- Hormone receptor status is provided (ER/PR negative)\n\nPATIENT CHARACTERISTICS:\n- The patient is female\n- Menopausal status is postmenopausal, meeting criteria\n- No history of other cancers mentioned\n- No contraindications to MRI mentioned\n- Not pregnant or nursing status not mentioned\n\nPRIOR CONCURRENT THERAPY:\n- No prior radiation mentioned\n- No breast implant mentioned\n- No prior breast reconstructive surgery mentioned\n- No prior neoadjuvant chemo or hormonal therapy mentioned\n\nBased on the information provided, the key missing details are the margin status after biopsy/lumpectomy and if the lumpectomy cavity can be visualized on imaging to meet target volume requirements.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "90": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed primary invasive breast carcinoma - The patient has cytologically confirmed invasive ductal breast carcinoma, which meets this criteria.\n- Stage I-IIA disease (T1, N0, M0 or T2, N0, M0) - The patient has a 3 cm tumor (T2) with 5 positive lymph nodes, so does not meet this criteria.\n- Pathologically determined single, discrete, and well-defined primary tumor \u2264 5 cm in diameter - The 3 cm tumor meets this criteria. \n- Pathologically negative surgical margins - No information provided about surgical margins.\n- No multicentric disease and/or diffuse malignant appearing microcalcifications - No information provided about this.\n- Micro-calcifications must be focal - No information provided.\n- Specimen radiograph required/optional - No information provided.\n- No axillary lymph node involvement - The patient has 5 positive lymph nodes, so does not meet this criteria.\n- No evidence of metastatic breast cancer - The patient has metastatic lesions on CXR, so does not meet this criteria.\n- Hormone receptor status not specified - Meets this criteria.\n\nPATIENT CHARACTERISTICS:  \n- ECOG performance status 0-2 - No information provided.\n- Menopausal status not specified - The patient is postmenopausal, so meets this criteria.\n- No pre-existing collagen vascular disease except rheumatoid arthritis that does not require immunosuppressive therapy - No information provided about this.\n- Not pregnant or nursing - The patient is not noted to be pregnant or nursing, so meets this criteria.\n\nPRIOR CONCURRENT THERAPY:\n- No prior irradiation to the area of planned radiation field - No information provided about prior radiation.\n- No prior placement of breast prosthesis in the treated breast - No information provided about this.\n- Concurrent hormonal therapy with external-beam irradiation allowed - No information provided about planned therapies.\n\nBased on the information provided, the patient does not meet several of the key inclusion criteria, specifically regarding stage, lymph node involvement, and presence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "91": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must have estrogen (ER) and/or progesterone receptor (PgR)-positive, histologically confirmed adenocarcinoma of the breast with measurable (but not operable) locally recurrent disease, or measurable and/or evaluable metastatic disease.\n- The patient note states that the patient has a 3 cm invasive ductal breast carcinoma that is ER/PR negative, so this criterion is not met.\n\n2. Patients with available paraffin tissue blocks from either the primary or the metastatic site must submit tissue blocks for retrospective EGFR and HER2 analysis. \n- There is no information provided about tissue blocks, so this cannot be evaluated.\n\n3. All patients must be post-menopausal females.\n- The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. Patients must not have had more than 1 prior chemotherapy regimen for metastatic disease.\n- There is no information provided about prior chemotherapy regimens.\n\n5. Patients may have had 1 prior hormonal therapy for metastatic disease.\n- There is no information provided about prior hormonal therapies.\n\n6. Patients must not have had prior therapy with EGF receptor inhibitors.\n- There is no information provided about prior EGF receptor inhibitor therapy.\n\n7. Previous but not concomitant therapy with trastuzumab (Herceptin) is allowed.\n- There is no information provided about prior trastuzumab therapy.\n\n8. Patients must have an ECOG performance status of 0, 1, or 2.\n- There is no information provided about the patient's ECOG performance status.\n\n9. Patients must have adequate hematologic, hepatic, and renal function.\n- There is no information provided about the patient's lab values.\n\n10. Must be 18 years of age or older.\n- The patient is 45 years old, so this criterion is met.\n\n11. Patients must not have a history of central nervous system metastases or unevaluated CNS symptoms suggestive of possible brain metastases.\n- There is no information provided about CNS metastases or symptoms.\n\n12. Patients may receive concurrent radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is initiated prior to study entry and sites of evaluable disease outside the radiation port(s) are available for follow-up.\n- There is no information provided about radiation therapy.\n\n13. Patients < 55 years of age must not have received Luteinizing hormone releasing hormone (LHRH) antagonists within 3 months prior to protocol therapy.\n- This criterion is met since the patient is 45 years old and there is no information about LHRH antagonist use.\n\n14. Patients must not suffer from medical or psychiatric conditions that would interfere with ability to provide informed consent, communicate side effects, or comply with protocol requirements including maintenance of a compliance/pill diary.\n- There is no information provided about the patient's ability to provide consent or comply with requirements.\n\n15. Patients must be disease-free of prior invasive cancers for > 5 years with the exception of basal or squamous cancer of the skin or cervical carcinoma in situ.\n- There is no information provided about prior cancers.\n\nBased on the information given in the patient note, the key inclusion criterion that is not met is that the patient's breast cancer is ER/PR negative, while the trial requires ER and/or PR positive disease.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "92": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma\"\n   - The patient note states that the patient has \"cytologically confirmed breast cancer\" and \"a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. \"HER2/c-neu over expression should be documented by either immunohistochemistry (score 3+) or FISH/CISH positivity. A score of 2+ by immunohistochemistry is acceptable only if FISH/CISH positive\"\n   - The patient note mentions that the tumor is \"HER2-positive\", so this criterion is met.\n\n3. \"Within 60 days after the surgical excision of the primary tumor with tumor-free operation margins; at least 10 axillary lymph nodes have to be removed.\"\n   - The patient note does not provide information about the timing of the surgery or the number of lymph nodes removed, so this criterion cannot be evaluated.\n\n4. \"Tumor involvement of at least one axillary lymph node (N0 with HER2/c-neu over expression are also eligible)\"\n   - The patient note states that \"Axillary sampling revealed 5 positive lymph nodes\", so this criterion is met.\n\n5. \"Absence of any clinical or radiological evidence of local or metastatic disease\"\n   - The patient note mentions \"CXR was remarkable for metastatic lesions\", indicating the presence of metastatic disease, so this criterion is not met.\n\n6. \"Premenopausal or postmenopausal women aged 18-75 years old\"\n   - The patient note states that the patient is a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n7. \"Adequate bone marrow function (absolute neutrophil count >1500/mm3, platelet count >100.000/mm3, hemoglobin >10gr/mm3)\"\n   - The patient note does not provide information about the patient's bone marrow function, so this criterion cannot be evaluated.\n\n8. \"Adequate liver (bilirubin <1.0 times upper limit of normal and SGOT/SGPT <2.5 times upper limit of normal) and renal function (creatinine <1.5mg/dl)\"\n   - The patient note does not provide information about the patient's liver and renal function, so this criterion cannot be evaluated.\n\n9. \"Adequate cardiac function (LVEF>50%). Normal electrocardiogram and absence of significant heart disease\"\n   - The patient note does not provide information about the patient's cardiac function or electrocardiogram results, so this criterion cannot be evaluated.\n\n10. \"Written informed consent\"\n    - The patient note does not mention whether the patient provided written informed consent, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria but does not meet the criterion of \"Absence of any clinical or radiological evidence of local or metastatic disease\" due to the presence of metastatic lesions on CXR. Additionally, there are several criteria that cannot be evaluated due to lack of information in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "93": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must be women with a histologically confirmed diagnosis of breast cancer that is more than 1 cm and or lymph node positive\"\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, a 3 cm invasive ductal breast carcinoma, and 5 positive lymph nodes. This meets the criteria.\n\n2. \"Physical examination, and scans needed for tumor assessment must be performed within 90 days prior to registration\"\nThe patient note does not explicitly mention when the examinations/scans were performed, so this cannot be confirmed.\n\n3. \"Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible\"\nThere is no mention of the patient having these conditions, so this exclusion criteria does not apply.\n\n4. \"Serum creatinine within normal limits within 90 days prior to registration\"\nNo information is provided about serum creatinine levels.\n\n5. \"Bilirubin within normal limits within 90 days prior to registration\" \nNo information about bilirubin levels.\n\n6. \"Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) =< 2 x the institutional upper limit of normal within 90 days prior to registration\"\nNo information about SGOT or SGPT levels.\n\n7. \"Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration\"\nNo information about ANC.\n\n8. \"Platelet count of >= 100,000/microliters within 90 days prior to registration\"\nNo platelet count information provided.\n\n9. \"Patients must have a performance status of 0-2 by Zubrod criteria\"\nNo mention of the patient's performance status.\n\n10. Pregnancy/contraception requirements are met, as the patient is postmenopausal.\n\n11. Timing of tests is not an issue, as no dates are provided.\n\n12. Informed consent requirement is not mentioned.\n\nIn summary, while the patient meets some of the key inclusion criteria like being a woman with breast cancer over 1 cm and lymph node positive, there is insufficient information provided to fully assess eligibility based on the listed criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "94": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is titled \"Molecular Breast Imaging in Women With Atypia and LCIS\".\n\nThe inclusion criteria for the surveillance arm are:\n- Diagnosis of biopsy-proven ADH, ALH, or LCIS within the past 5 years confirmed by Mayo pathologist\n\nThe inclusion criteria for the diagnostic arm are: \n- Recent core needle biopsy demonstrating ADH, ALH, or LCIS confirmed by Mayo pathologist\n\nBased on the patient note, this patient has invasive ductal breast carcinoma, which is not atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS).\n\nTherefore, this patient does not meet the inclusion criteria for either the surveillance or diagnostic arm of this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "95": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nDisease Characteristics:\n- The patient has histologically proven invasive unilateral breast cancer, meeting this criteria.\n- The tumor is 3cm, meeting the criteria of pT >20mm.\n- The tumor is HER2-positive and ER/PR negative, meeting the criteria of triple-negative for node-positive patients.\n- There are positive lymph nodes, meeting the node-positive criteria.\n\nPatient Characteristics:\n- The patient is a 45-year-old postmenopausal woman, meeting the female criteria.\n- No information is given about ECOG performance status, so cannot confirm if this criteria is met.\n- No information about peripheral neuropathy, neutrophil count, platelet count, hemoglobin, liver function tests, creatinine, or LVEF is provided.\n- It is not stated if the patient is pregnant/nursing or using contraception.\n\nExclusion Criteria:\n- No information about previous cancers is provided.\n- No information about concurrent severe/uncontrolled medical diseases is given.\n- No cardiovascular disease history is mentioned.\n- No information about prior hypersensitivity reactions is given.\n- No psychological/sociological conditions that could hamper compliance are noted.\n\nPrior/Concurrent Therapy:\n- It is stated the patient is a candidate for tumor resection prior to chemotherapy, meeting the criteria of no prior chemotherapy, hormonal therapy or radiotherapy.\n- No information is provided about the timing since any prior surgeries.\n- No information is given about use of strong CYP3A4 inhibitors.\n- It is not stated if the patient is participating in any other clinical trials.\n\nIn summary, while some of the key inclusion criteria are met (invasive breast cancer, triple-negative, node-positive), there is insufficient information provided to fully assess eligibility against all the criteria listed.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "96": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which is not relevant to the clinical trial on cervical cancer and parametrial lymph node mapping.\n\nLooking at the inclusion criteria:\n1. Patients who are dispositioned to undergo radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy.\n   - The patient note does not mention anything about cervical cancer or plans for a hysterectomy/trachelectomy, so this criterion is not met.\n\n2. No evidence of metastases on computed tomography, magnetic resonance imaging, or PET/CT scan.\n   - The patient note mentions metastatic lesions seen on CXR, so this criterion is not met.\n\n3. Patients must be good surgical candidates.\n   - There is no information provided about the patient's surgical risk factors, so this cannot be determined.\n\n4. Patients who have signed an approved informed consent and authorization permitting release of personal health information.\n   - This is not mentioned in the patient note.\n\n5. For patients of child-bearing age, a negative serum pregnancy test within 72 hours prior to injection of radiocolloid. \n   - The patient is described as postmenopausal, so this criterion does not apply.\n\nSince the patient has confirmed metastatic disease and there is no mention of cervical cancer or plans for a hysterectomy/trachelectomy, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "97": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is HER2-positive and ER/PR negative, which does not meet the \"triple negative\" criteria for this trial.\n\nThe trial inclusion criteria state:\n1. Female subjects with triple negative (ER, PR, and HER2 negative) locally advanced non-resectable and/or metastatic breast cancer\n2. Prior adjuvant or neoadjuvant anthracycline-based chemotherapy\n\nSince the patient's tumor is HER2-positive, she does not meet the first inclusion criteria for this triple negative breast cancer trial.\n\nThere is no information provided about whether the patient received prior adjuvant/neoadjuvant anthracycline chemotherapy.\n\nBased on the information given, the patient does not fully meet the stated inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "98": {
        "output": "To determine the patient's eligibility for the clinical trial \"Axillary Reverse Mapping for Invasive Carcinoma of the Breast\", let's go through the inclusion criteria:\n\n1. Patients with invasive carcinoma of the breast planning to undergo axillary lymph node dissection at M. D. Anderson Cancer Center.\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer and is a candidate for tumor resection, which likely includes axillary lymph node dissection. This criterion is met.\n\n2. Eastern Cooperative Oncology Group (ECOG) performance status of equal to or less than 3.\nThe patient note does not provide information about the patient's ECOG performance status. Without this information, it is not possible to determine if this criterion is met.\n\nSince one of the inclusion criteria cannot be evaluated due to lack of information, the patient's eligibility cannot be fully determined.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "99": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Signed study-specific Informed Consent Form(s)\n   - No information provided about this in the patient note.\n\n2. Age \u2265 18 years\n   - The patient is 45 years old, so this criterion is met.\n\n3. Histologically documented breast cancer\n   - The patient has \"cytologically confirmed breast cancer\", so this criterion is met.\n\n4. HER2-positive disease\n   - The patient's tumor is described as \"HER2-positive\", so this criterion is met.\n\n5. Metastatic breast cancer\n   - The patient note mentions \"metastatic lesions\" on CXR, indicating metastatic disease. This criterion is met.\n\n6. Disease progression on the last chemotherapy regimen received in the metastatic setting\n   - No information provided about prior chemotherapy regimens or disease progression.\n\n7. Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting and prior treatment with at least two lines of therapy in the metastatic setting\n   - No information provided about prior treatments.\n\n8. At least two lines of anti-HER2 therapy must have been given in the metastatic setting as monotherapy or combined with chemotherapy or hormonal therapy.\n   - No information provided about prior anti-HER2 therapies.\n\n9. A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease is required\n   - No information provided about prior trastuzumab treatment.\n\n10. Patients must have had at least 14 days of exposure in the metastatic setting to lapatinib and capecitabine unless they were intolerant of lapatinib and/or capecitabine\n    - No information provided about prior lapatinib or capecitabine treatment.\n\nBased on the information provided in the patient note, there is insufficient information to determine eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "100": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm tumor\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial inclusion criteria are:\n- Histologically proven breast cancer with at least 1 positive axillary lymph node among minimum 6 resected nodes\n- Definitive surgical treatment must be mastectomy or breast conserving surgery with axillary lymph node dissection\n- Margins of resected specimen must be free of invasive cancer\n\nThe patient meets the inclusion criteria of having breast cancer with positive lymph nodes and being a candidate for surgical resection prior to chemotherapy.\n\nThe exclusion criteria are:\n- Prior systemic anticancer therapy\n- Prior anthracycline or taxane therapy\n\nBased on the patient note, there is no mention of any prior systemic therapy, so the patient does not meet any of the exclusion criteria.\n\nTherefore, this patient appears to be eligible for the docetaxel adjuvant breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "101": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with newly diagnosed invasive ductal breast carcinoma, which meets the inclusion criteria of \"Women with newly diagnosis of infiltrative breast cancer\".\n\nShe is also over 18 years old, satisfying the \"Women > or = 18 years old\" criteria.\n\nThere is no information suggesting she would not agree to take part in the study.\n\nTherefore, based on the provided patient note and inclusion criteria, this patient appears to be eligible for the \"National Survey on Infiltrative Breast Cancer\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "102": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman\n- She has cytologically confirmed breast cancer\n- The tumor is 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative\n- She has 5 positive lymph nodes and metastatic lesions on CXR\n- She is a candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n1) Women with histologically confirmed invasive primary breast cancer grades I to III\n2) Age up to and including 75 years old\n\nBased on the information provided, the patient meets both of the inclusion criteria:\n1) She has cytologically confirmed invasive breast cancer\n2) She is 45 years old, which falls within the age range\n\nThere is no information provided about exclusion criteria, so we cannot definitively rule out exclusion. However, based solely on the inclusion criteria, this patient appears eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "103": {
        "output": "To determine the patient's eligibility for the clinical trial \"Upper Extremity Lymphatic Mapping for Breast Cancer Patients\", let's go through the inclusion criteria one by one:\n\n1. \"Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration who are scheduled to undergo an ALND.\"\n\nThe patient note mentions that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma, and axillary sampling revealed 5 positive lymph nodes. This satisfies the criteria of having Stage II invasive breast cancer with documented axillary metastases.\n\n2. \"Females > 21 years of age\"\n\nThe patient is a 45-year-old woman, which meets this age criterion.\n\nSince the patient meets both inclusion criteria and no exclusion criteria are provided, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "104": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with confirmed breast cancer. The tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial is studying the use of optical spectroscopy during breast cancer surgery and core needle biopsy.\n\nThe inclusion criteria for the trial are:\n\"Patients having a needle biopsy of a breast mass\"\n\nBased on the patient note, it states that a core biopsy has already been done to confirm the breast cancer diagnosis. However, it does not explicitly mention if the patient will be undergoing an additional needle biopsy.\n\nSince there is not enough information to definitively determine if the patient meets the inclusion criteria of having a needle biopsy of a breast mass, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "105": {
        "output": "To determine the patient's eligibility for the clinical trial, I will go through the inclusion criteria one by one:\n\n\"Clinical diagnosis of Breast Cancer\"\nThe patient note states \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\" This meets the inclusion criteria.\n\nThere are no other inclusion criteria listed, so based on the information provided, this patient meets the eligibility requirements for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "106": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman\n- She has cytologically confirmed breast cancer\n- The tumor is 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative\n- She has 5 positive axillary lymph nodes\n- There are metastatic lesions on CXR\n\nThe inclusion criteria for the clinical trial are:\n- Postmenopausal women\n- With hormone receptor-positive locally advanced or metastatic breast cancer\n\nBased on the information provided, the patient meets the inclusion criteria of being a postmenopausal woman with metastatic breast cancer.\n\nHowever, the note states that her tumor is ER/PR negative, while the trial requires hormone receptor-positive disease.\n\nSince the patient does not meet this key inclusion criterion, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "107": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient major at the time of breast surgery.\nThe patient note states that the patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Patient affiliated with a social security. \nThere is no information about the patient's social security affiliation in the note.\n\n3. Consent dated and signed by the investigator and the subject.\nThere is no information about consent in the patient note.\n\n4. Subject having been informed of the sentinel lymph node procedure during the visit prior to breast surgery.\nThere is no information about this in the patient note.\n\n5. Patient having a unifocal infiltrative breast cancer (less than 2 cm) diagnosed preoperatively by core biopsy or cytology.\nThe patient note states that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, so the patient does not meet this criterion.\n\n6. Patient having a ductal carcinoma in situ (DCIS), diagnosed preoperatively by core biopsy or cytology.\nThe patient does not have ductal carcinoma in situ, so this criterion is not met.\n\nSince the patient does not meet the tumor size criterion (less than 2 cm) and does not have ductal carcinoma in situ, she would not be eligible for this clinical trial based on the information provided in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "108": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female patients greater than or equal to18 years of age.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically confirmed invasive unilateral breast cancer (regardless of histology). \nThe patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n3. Early-stage breast cancer, defined as node-positive disease or node-negative with primary tumor >1.0 cm.\nThe patient has node-positive disease with 5 positive lymph nodes, so she meets this criterion.\n\n4. Definitive loco-regional surgery must have been completed, including breast conservation surgery or mastectomy with clear surgical margins.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so she potentially meets this criterion pending the surgery.\n\n5. Axillary lymph node sampling or dissection must have been done.\nThis is not mentioned in the patient note, but could potentially be done during the planned surgery.\n\n6. Multicentric/multifocal invasive breast cancer is eligible if loco-regional surgery has been completed.\nThis does not apply to the patient.\n\n7. HER2 negative tumors confirmed by FISH or IHC.\nThe patient's tumor is HER2-positive, so she does not meet this criterion.\n\n8. Estrogen receptor negative (<10% staining by IHC).\nThe patient's tumor is ER/PR negative, so she meets this criterion.\n\n9. ECOG Performance Status of 0 or 1.\nThis is not mentioned in the patient note.\n\n10. Patient must be <= 84 days from having completed definitive primary breast surgery.\nThe patient has not had surgery yet, but plans to have it prior to chemotherapy.\n\n11. Adequate hematologic, liver, and renal function based on specified lab values.\nThis is not mentioned in the patient note.\n\n12. Complete staging work-up <=12 weeks prior to initiation of study treatment.\nThe patient has had a CXR showing metastatic lesions, but it's unclear if she has had the required CT scans and PET/bone scan.\n\n13. Adequate cardiac function with LVEF >50%.\nThis is not mentioned in the patient note.\n\n14. Adequate recovery from recent surgery.\nThe patient has not had surgery yet.\n\n15. No evidence of recurrent disease if previous history of invasive cancers.\nThis does not apply to the patient.\n\n16. Negative pregnancy test for women of childbearing potential.\nThe patient is postmenopausal, so this does not apply.\n\n17. Patient must be accessible for treatment and follow-up.\nThis is assumed to be the case.\n\n18. Women of childbearing potential must use birth control during and after treatment.\nThe patient is postmenopausal, so this does not apply.\n\n19. Able to understand the study and give informed consent.\nThis is assumed to be the case.\n\nBased on the information provided, the patient does not meet all the inclusion criteria due to her HER2-positive status and potentially having metastatic disease (though staging is incomplete). However, there is also some missing information that could impact eligibility, such as performance status, lab values, cardiac function, and whether she will meet the surgical criteria after her planned operation.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "109": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has biopsy-proven invasive ductal breast carcinoma, which meets the criterion of \"Biopsy proven ductal carcinoma in situ (DCIS) of the breast.\"\n\nPATIENT CHARACTERISTICS:\n- The patient is referred through a breast care clinician (implied).\n- No information is given about pregnancy or nursing status.\n- No information is given about contraindications to MRI.\n\nPRIOR CONCURRENT THERAPY:\n- No information is given about prior surgery or radiotherapy to the ipsilateral breast.\n- No information is given about prior cytotoxic regimens.\n\nBased on the available information, the patient meets the disease characteristic inclusion criterion. However, there is not enough information provided to determine if the patient meets all of the other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "110": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically confirmed metastatic carcinoma of the breast\n- The patient note confirms she has cytologically confirmed invasive ductal breast carcinoma with metastatic lesions seen on CXR, so this criterion is met.\n\n2. Hormone receptor (estrogen receptor [ER] and/or progesterone receptor [PR]) positive disease\n- The patient note states the tumor is ER/PR negative, so this criterion is not met.\n\n3. Postmenopausal\n- The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. Criteria related to prior hormonal therapies\n- There is no information provided about prior therapies, so cannot evaluate this.\n\n5. Measurable or non-measurable disease\n- The 3 cm primary tumor is measurable disease, so this is met.\n\n6. ECOG performance status 0-1\n- No performance status provided, so cannot evaluate.\n\n7. Laboratory value criteria\n- No lab values provided, so cannot evaluate.\n\nSince the tumor is hormone receptor negative, which is an inclusion criterion for this trial, the patient would be excluded despite meeting some of the other criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "111": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is for the compassionate use of mifepristone in brain/nervous system and other cancers.\n\nLooking at the inclusion criteria:\n1) \"All patients 18 years of age or older.\" - The patient is 45 years old, so she meets this criterion.\n2) \"Patients must sign an informed consent.\" - This is not mentioned in the patient note, so we cannot determine if she meets this criterion or not.\n3) \"Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks.\" - Again, there is no information about the attending physician's opinion, so we cannot determine if she meets this criterion.\n\nSince there is not enough information provided to definitively determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "112": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Diagnostic mammogram - The patient note mentions the patient had a core biopsy which revealed invasive ductal breast carcinoma, so this criterion is met.\n2. English speaking - No information is provided about the patient's language, so I will assume this criterion is met.\n\nExclusion Criteria:\n1. Pregnancy - The patient is described as postmenopausal, so she is not pregnant.\n2. No biopsy referral after diagnostic mammogram - The patient had a core biopsy, so this does not apply.\n3. Patient reported breast feeding - The patient is postmenopausal, so she is not breastfeeding.\n4. Significant active medical illness which would preclude protocol treatment - No such illness is mentioned.\n5. History of or active liver disease or baseline total bilirubin greater than institutional upper limit of normal - No liver disease is mentioned.\n6. Patient reported allergy or sensitivity to cruciferous vegetables - No such allergy is mentioned.\n7. Use of oral antibiotics within three months prior to randomization - No antibiotic use is mentioned.\n8. Oral steroid therapy at enrollment - No steroid use is mentioned.\n9. Current therapy with valproate acid or SAHA - No mention of these therapies.\n10. Current use of nutrient supplements or herbal remedies containing sulforaphane and unwillingness or inability to quit 72 hours prior to randomization and for the duration of the trial - No mention of such supplements.\n11. Radiation for currently-diagnosed disease prior to or during study supplementation - No prior radiation mentioned.\n12. Chemotherapy for currently-diagnosed disease prior to or during study supplementation - No prior chemotherapy mentioned.\n\nBased on the information provided, the patient meets the inclusion criteria and does not seem to be excluded by any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "113": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Genetic Susceptibility to Bladder Cancer,\" the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The patient has been diagnosed with breast cancer, not bladder cancer.\n2. The inclusion criteria specifically state that the subject must have a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer.\n\nSince the patient does not have bladder cancer, which is a key inclusion criterion for this particular trial, the patient would not be eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "114": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed invasive ductal breast cancer (meets criteria for invasive breast cancer)\n- The tumor is 3 cm (meets criteria of tumor >= 1 cm)\n- HER2-positive (meets criteria of HER2-negative)\n- ER/PR negative (meets criteria of hormone receptor-poor)\n- Has 5 positive lymph nodes (meets criteria of clinical stage II-III)\n- No prior chemotherapy, hormone therapy or radiation therapy (meets criteria)\n- Is a candidate for tumor resection after neoadjuvant therapy (meets criteria)\n\nThe only potential exclusion is that the tumor is HER2-positive, while the criteria specifies HER2-negative.\n\nBased on the information provided, this patient meets most of the key inclusion criteria except for the HER2 status.\n\nTrial-level eligibility: 0) Excluded (due to being HER2-positive which is an exclusion criteria for this trial)",
        "label": 1
    },
    "115": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Histologically or cytologically confirmed metastatic breast carcinoma that is HER2 positive\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and that the tumor is \"HER2-positive\". This criterion is met.\n\n2. \"Measurable disease as defined by the RECIST criteria\"\nThe patient note mentions that the tumor is 3 cm in size, which would be considered measurable disease. This criterion is met.\n\n3. \"Life expectancy greater than or equal to 6 months\"\nThere is no information provided about the patient's life expectancy, so we cannot determine if this criterion is met or not.\n\n4. \"Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\"\nThere is no information provided about the patient's ECOG performance status, so we cannot determine if this criterion is met or not.\n\nSince there is not enough information to confirm that the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "116": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman\n- She has been diagnosed with breast cancer\n- The tumor is 3cm, invasive ductal carcinoma, HER2-positive, ER/PR negative\n- She has 5 positive axillary lymph nodes\n- She is a candidate for tumor resection and agrees to undergo it prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n1) Diagnosed previously as breast cancer\n2) Patient scheduled for sentinel lymph node dissection  \n3) 18 years or older\n4) Female or male\n5) Able and willing to give consent to participate in the study\n\nChecking each criteria against the patient note:\n1) The patient has been diagnosed with breast cancer, so meets this criteria\n2) The patient is a candidate for tumor resection, which would involve lymph node dissection, so meets this criteria\n3) The patient is 45 years old, so meets the age criteria\n4) The patient is female, so meets this criteria\n5) The note states the patient agrees to the tumor resection prior to chemotherapy, implying consent to participate\n\nSince the patient meets all the inclusion criteria listed, and there are no explicit exclusion criteria violating her eligibility mentioned:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "117": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n\u2265 18 years old: The patient is 45 years old, so this criterion is met.\n\nECOG/Zubrod Performance Status 0-1: There is no information provided about the patient's performance status, so this cannot be evaluated.\n\nFemale: The patient is a postmenopausal woman, so this criterion is met. \n\nHistologic diagnosis of invasive breast cancer, clinical stage T0-4 N1-2 M0 (excluding inflammatory breast cancer): The patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, so this criterion is met. There is no mention of inflammatory breast cancer.\n\nFNA biopsy or core needle biopsy of an axillary node documenting nodal disease at time of diagnosis and prior to preoperative chemotherapy: The patient had axillary sampling that revealed 5 positive lymph nodes, so this criterion is met.\n\nPreoperative chemotherapy must be completed or planned for patient: The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is met.\n\nNo prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or treatment of hidradenitis: There is no mention of any prior axillary surgery, so this criterion is assumed to be met.\n\nNo prior SLN surgery/excisional lymph node biopsy for pathological confirmation of axillary status: There is no mention of any prior SLN surgery or lymph node biopsy, so this criterion is assumed to be met.\n\nBased on the information provided, the patient appears to meet all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "118": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients with invasive breast cancer are required to have axillary staging which can include sentinel node biopsy alone if sentinel node is negative or axillary dissection or sampling with a minimum total of 6 axillary nodes if sentinel node is positive. Axillary staging is not required for patients with DCIS.\"\n- The patient note states that axillary sampling revealed 5 positive lymph nodes, so this criterion is met.\n\n2. \"Estrogen receptor (ER) and progesterone receptor (PR) analysis must be negative.\"\n- The patient note states that the tumor is ER/PR negative, so this criterion is met. \n\n3. \"The patient must be \u2265 18 years old.\"\n- The patient is 45 years old, so this criterion is met.\n\n4. \"If the patient is older than 49 years, she must meet at least one of the following 2 conditions: i. 1-3 histologically positive axillary nodes ii. negative ER and PR analysis\"\n- This criterion does not apply since the patient is 45 years old.\n\n5. \"The patient should have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer.\"\n- There is no information about life expectancy in the patient note, so this cannot be evaluated.\n\n6. \"The tumor must be DCIS or invasive adenocarcinoma of the breast.\"\n- The patient has invasive ductal breast carcinoma, so this criterion is met.\n\n7. \"Gross disease must be unifocal with pathologic tumor size 3.0 cm or less. Patients with microscopic multifocality are eligible as long as total pathologic tumor size is 3.0 cm or less.\"\n- The tumor size is 3 cm, so this criterion is met.\n\n8. \"The patient must have pathological stage 0, I, or II breast cancer.\"\n- There is no information about the pathological stage in the patient note.\n\n9. \"Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (DCIS and invasive). Re-excision of surgical margins is permitted.\"\n- The patient is a candidate for tumor resection, but it is not clear if this has already been done.\n\n10. \"The patient must be registered within 42 days following the last surgery for breast cancer.\"\n- There is no information about when the patient would be registered relative to surgery.\n\n11. \"The target lumpectomy cavity/whole breast reference volume must be \u2264 30% based on the postoperative CT scan.\"\n- There is no information about breast volume in the patient note.\n\nIn summary, several of the key inclusion criteria are met based on the information provided, but there are some criteria that cannot be evaluated due to missing information in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "119": {
        "output": "To determine the patient's eligibility for the clinical trial \"Detection of Aggressive Breast Tumors Using Tc-99m-NC100692\", let's go through the inclusion criteria one by one:\n\n1. \"Have a lesion on mammogram, ultrasound or breast MRI that measured < 15 mm in diameter, is considered suggestive or highly suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas criteria (BIRADS 4b, 4c or 5), and is scheduled for biopsy (needle biopsy and/or surgical biopsy).\"\n- The patient has a 3 cm (30 mm) invasive ductal breast carcinoma, which is larger than 15 mm. This criterion is not met.\n\n2. \"OR Have a lesion on mammogram, ultrasound or breast MRI that measured > 15 mm in diameter, is known to be malignant and is scheduled for surgery.\"\n- The patient has a 3 cm (30 mm) invasive ductal breast carcinoma, which is known to be malignant, and is scheduled for tumor resection (surgery). This criterion is met.\n\n3. \"Patient age > 18 years of age.\"\n- The patient is a 45-year-old woman, which meets this criterion.\n\n4. \"Have a negative pregnancy test on the first day of the study, or must be postmenopausal or surgically sterilized.\"\n- The patient is described as postmenopausal, which meets this criterion.\n\nSince the patient meets criteria 2, 3, and 4, she is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "120": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has newly diagnosed (within 30 days) stage II breast cancer, which meets the criteria of \"Newly diagnosed (within 30 calendar days of diagnosis) stage I or II breast cancer\".\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman, which meets the criteria of \"Pre- or post-menopausal\".\n\nPRIOR CONCURRENT THERAPY:\n- The patient has not received any prior chemotherapy, which meets the criteria of \"No prior chemotherapy for breast cancer or any other cancer\".\n- There is no information provided about estrogen, oral contraceptives, selective estrogen receptor modulators, or aromatase inhibitors, so we cannot determine if she meets those criteria.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for this clinical trial of studying biomarkers in nipple fluid, urine, and blood samples from women with newly diagnosed ductal carcinoma in situ or stage I or stage II breast cancer.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "121": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Biopsy-confirmed diagnosis of one of the following:\n    - Stage I-IV infiltrating ductal or infiltrating lobular carcinoma\n        - The patient has a 3 cm invasive ductal breast carcinoma, which meets this criteria\n    - Patients with early-stage disease must not have started systemic treatment; if no systemic treatment is planned, patients must be either preoperative or \u2264 120 days since definitive breast surgery\n        - The patient has not started systemic treatment yet and is a candidate for tumor resection prior to chemotherapy, so meets this criteria\n    - Patients with locally advanced disease must be scheduled for neoadjuvant chemotherapy prior to initiation of systemic treatment\n        - This does not apply as the patient does not have locally advanced disease\n    - Ductal carcinoma in situ\n    - Lobular carcinoma in situ  \n    - Benign breast disease\n\nPATIENT CHARACTERISTICS:\n- Karnofsky performance status 50-100%\n    - No information provided about Karnofsky score\n- Not pregnant\n    - No mention of pregnancy status\n- No prior invasive cancer diagnosis within the past 5 years except for squamous cell or basal cell carcinoma of the skin\n    - Meets this criteria based on the information given\n\nPRIOR CONCURRENT THERAPY:\n- See Disease Characteristics \n- No prior systemic therapy (chemotherapy or hormonal therapy) for patients with stage I-III disease\n    - The patient has not received any prior systemic therapy, so meets this criteria\n\nBased on the information provided in the patient note, the patient meets the key inclusion criteria for having invasive ductal breast cancer and being scheduled for surgery prior to systemic treatment. There is no exclusionary information provided.\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "122": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm size\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe clinical trial inclusion criteria state:\n- Undergoing surgery for breast cancer OR core biopsy sampling of the breast\n\nSince the patient is a candidate for tumor resection (surgery) for her breast cancer, she meets this inclusion criteria.\n\nThere are no other specific inclusion/exclusion criteria listed for the trial regarding age, tumor type, stage, etc.\n\nBased on the information provided, this patient appears eligible for the clinical trial studying gene expression in tumor tissue from breast cancer surgery/biopsy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "123": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Provision of written informed consent - Not mentioned in the patient note, so cannot assess this criteria.\n2. Patient must be female - Yes, the patient is a 45-year-old postmenopausal woman.\n3. Patient must have undergone primary breast cancer surgery with institutional standard axillary dissection - Yes, the note mentions the patient had a core biopsy and is a candidate for tumor resection prior to chemotherapy.\n4. The tumor must have been pathologic primary invasive carcinoma by core needle or open biopsy - Yes, a 3 cm invasive ductal breast carcinoma was found on core biopsy.\n5. The beginning of endocrine therapy must be no more than 6 weeks from the end day of chemotherapy or radiotherapy - The patient has not started any treatment yet, so this criteria is not applicable.\n6. The date of randomization must be no less than 2 years of letrozole and no more than 3 years letrozole treatment - The patient has not started any treatment, so this is not applicable.\n7. Positive node is defined as defined as the presence of at least micro metastasis greater than 0.2 mm - Yes, the note mentions 5 positive lymph nodes on axillary sampling.\n8. Patients who have had neoadjuvant chemotherapy are eligible with conditions - The patient has not had neoadjuvant chemotherapy yet.\n9. Bilateral, synchronous breast cancer is allowed if one tumor meets criteria - Only one tumor is mentioned.\n10. Hormone receptor-positive tumors - Yes, the tumor is ER/PR negative but HER2 positive, which meets criteria.\n11. HER2 status must be known - Yes, it is mentioned the tumor is HER2 positive.\n12. No evidence of metastatic or recurrent disease on examination - There are metastatic lesions seen on CXR, so this criteria is not met.\n13. Patients must be postmenopausal - Yes, the patient is described as postmenopausal.\n14. WHO performance status 0-1 - Not mentioned, so cannot assess.\n15. Lab values within range - WBC, platelets, LFTs, Cr not provided.\n16. Can swallow pills - Not mentioned.\n\nBased on the information provided, while the patient meets several key inclusion criteria like being postmenopausal with invasive breast cancer, hormone receptor status known, and lymph node positive disease, the presence of metastatic lesions on CXR would exclude the patient from this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "124": {
        "output": "Okay, let's go through the inclusion criteria for this breast cancer clinical trial and assess the patient's eligibility:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed breast cancer (invasive ductal carcinoma) - Met\n- Pathological stage 0-IIIA disease (pT1-2, N0-N2a, M0) - Met (3 cm tumor, 5 positive lymph nodes)\n- Tumor size \u2264 5 cm - Met (3 cm)\n- Has undergone lumpectomy or mastectomy and either sentinel node biopsy or axillary dissection - Met (axillary sampling done)\n- Negative inked histological margins or confirmed negative re-excision specimen - Not mentioned\n- Unifocal or multifocal disease with 1 or 2 foci that can be encompassed by 1 lumpectomy - Assumed met\n- No multicentric carcinoma - Assumed met \n- No evidence of suspicious microcalcifications before radiotherapy start - Not mentioned\n- No more than 9 positive axillary lymph nodes - Met (5 positive)\n- No palpable/suspicious contralateral nodes unless biopsy confirmed negative - Assumed met\n- No previously treated contralateral breast cancer or synchronous ipsilateral breast cancer - Assumed met\n- No lobular carcinoma in situ alone, non-epithelial malignancies, Paget's disease, skin involvement - Assumed met\n- No distant metastases - Not met (CXR showed metastatic lesions)\n- Hormone receptor status not specified - Met\n\nPATIENT CHARACTERISTICS:\n- Pre- or post-menopausal - Met (postmenopausal)\n- ECOG performance status 0-1 - Not mentioned\n- No limiting co-existing medical conditions - Assumed met\n- Not pregnant/nursing, fertile patients using contraception - Met (not sexually active)\n- No other malignancy in past 5 years except non-melanoma skin cancer - Assumed met\n- No collagen vascular disease - Assumed met\n- No psychiatric/addictive disorder precluding informed consent - Assumed met\n\nPRIOR/CONCURRENT THERAPY:\n- See Disease Characteristics \n- No prior radiotherapy for current breast cancer - Met (assuming)\n- No extensive tylectomies impacting cosmetic result before radiotherapy - Assumed met\n- Chemotherapy timing criteria met - Not mentioned\n- Concurrent tamoxifen/anastrozole/hormonal therapy allowed - Not mentioned\n- No other concurrent chemo/immuno/experimental therapy - Assumed met\n\nBased on the information provided, the key issue is the presence of metastatic lesions on CXR, which would exclude the patient from this trial focused on early stage breast cancer.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "125": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\nWomen aged \u2265 18 years and < 70 years\n- The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\nKarnofsky performance status (KPS) \u2265 70\n- There is no information provided about the patient's KPS.\n\nAt least one measurable disease according to the RECIST. histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), T2N1 or locally advanced breast cancer (T3-4N0-3 or T0-4N2-3)\n- The patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, so she meets this criterion.\n\nBiopsy specimens are available for ER, PgR and Her2 detection, patients should be with triple negative or Her2 positive breast cancer, Her2 positivity is defined as FISH/CISH Her2 positive or IHC Her2 3+, Triple-negative disease defined as negativity for ER, PgR and Her2\n- The patient's tumor is HER2-positive and ER/PR negative, so she meets this criterion.\n\nAdequate bone marrow function: Neutrophil \u2265 1.5*109/L; Hb \u2265 100g/L; PLT \u2265 100*109/L\n- There is no information provided about the patient's bone marrow function.\n\nAn estimated life expectancy of at least 12 months\n- There is no information provided about the patient's estimated life expectancy.\n\nWilling to take biopsy before neoadjuvant chemotherapy and patients must be accessible for treatment and follow-up\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so she likely meets this criterion.\n\nWomen with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study\n- The patient is postmenopausal, so this criterion does not apply to her.\n\nWritten informed consent according to the GCP\n- There is no information provided about whether the patient has provided written informed consent.\n\nIn summary, the patient meets some of the key inclusion criteria such as age, tumor type and status. However, there is not enough information provided about her performance status, bone marrow function, estimated life expectancy, and whether she has provided informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "126": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Histologically or cytologically confirmed invasive breast cancer.\" - The patient note states that the patient has \"cytologically confirmed breast cancer\" with a \"3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. \"HER2 positive disease is not allowed.\" - The patient note mentions that the tumor is \"HER2-positive\", so this is an exclusion criterion and the patient would be excluded based on this.\n\n3. \"Metastatic breast cancer (Stage IV) is not allowed.\" - The patient note states that the \"CXR was remarkable for metastatic lesions\", indicating metastatic (Stage IV) disease, which is another exclusion criterion.\n\n4. The next few criteria relate to residual disease after neoadjuvant chemotherapy, which does not apply to this patient based on the information provided.\n\n5. The criteria about triple-negative breast cancer also do not apply since the patient's tumor is HER2-positive.\n\n6. There are no details provided about the patient's prior chemotherapy regimen or timing, so those criteria cannot be evaluated.\n\n7. The patient is a candidate for tumor resection, which meets the criteria of \"Patients must have completed definitive resection of primary tumor.\"\n\n8. There are no details about margins or radiotherapy in the patient note.\n\n9. The criteria about residual disease after neoadjuvant chemotherapy do not apply to this patient.\n\n10. There are no details about the patient's LVEF or ECOG performance status.\n\n11. The patient is 45 years old, meeting the age criterion of \"18 years of age or greater\".\n\nOverall, while the patient meets some of the inclusion criteria, they are excluded based on having HER2-positive and metastatic disease, which are exclusion criteria for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "127": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Value of Percutaneous Cholangioscopy After Placement of a Percutaneous Transhepatic Biliary Drainage\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe patient note describes a 45-year-old postmenopausal woman with breast cancer, including details about the tumor characteristics, lymph node involvement, and metastatic lesions. However, the inclusion criteria for the clinical trial specifically mentions patients who have received a percutaneous transhepatic biliary drainage (PTBD) with at least 14 French in diameter.\n\nThere is no information provided in the patient note about the patient having received a PTBD or any biliary drainage procedure. Therefore, based on the available information, the patient does not qualify for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "128": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies.\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and \"a core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. \"Lesion size \u2264 3 cm treated with a tylectomy and whole breast irradiation (with or without tumor bed boost)\"\nThe patient note mentions a \"3 cm invasive ductal breast carcinoma\", so the lesion size criterion is met. However, there is no mention of the patient receiving a tylectomy or whole breast irradiation yet.\n\n3. \"Unifocal breast cancer recurrence\"\nThe patient note does not specify if this is a recurrence or the initial diagnosis, so there is not enough information to determine if this criterion is met.\n\n4. \"Negative resection margins with at least a 2 mm margin from invasive and in situ cancer or a negative re-excision\"\nThe patient note does not provide information about the resection margins.\n\n5. \"Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation.\"\nThe patient note does not mention any planned therapies.\n\n6. \"Signed study-specific informed consent prior to study entry.\"\nThere is no information about consent in the patient note.\n\nBased on the information provided in the patient note, there are several inclusion criteria that cannot be determined due to lack of details. Therefore, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "129": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient is at least 18 years old (45 years old, meets criteria)\n2. Written informed consent has been obtained (not mentioned, cannot assess)\n3. The patient is diagnosed with confirmed invasive breast cancer with stage IV disease (metastatic breast cancer, meets criteria)\n4. The patient has documented disease progression or relapse following at least one prior standard therapy with trastuzumab (not mentioned, cannot assess)\n5. Criteria regarding prior lapatinib use and chemotherapy (not mentioned, cannot assess)\n6. Criteria for ER+/PR+ metastatic patients (ER/PR negative, does not apply)\n7. Tumor lesion shows HER2 overexpression/amplification (HER2-positive, meets criteria) \n8. The patient has at least one measurable lesion according to RECIST criteria (not mentioned, cannot assess)\n9. The patient has ECOG status of 0 or 1 (not mentioned, cannot assess)\n10. The patient has adequate bone marrow reserve (not mentioned, cannot assess)\n11. The patient has adequate renal function (not mentioned, cannot assess)\n12. The patient has adequate hepatic function (not mentioned, cannot assess)\n13. The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN (not mentioned, cannot assess)\n14. Criteria regarding childbearing potential/contraception (postmenopausal, meets criteria)\n15. Able to swallow and retain oral medication (not mentioned, cannot assess)\n16. In the view of the investigator, the patient can and will comply with the protocol (not mentioned, cannot assess)\n\nBased on the information provided in the patient note, the patient meets some of the key inclusion criteria like age, metastatic HER2-positive breast cancer, and postmenopausal status. However, there is insufficient information to assess several other important criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "130": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically proven primary invasive breast cancer that is thought to be suitable for neoadjuvant treatment (meets criteria)\n- The tumor is 3 cm which meets the criteria of T2 tumor or greater (\u2265 20 mm) (meets criteria)\n- No evidence of distant metastatic disease except for metastatic lesions noted on CXR (does not meet criteria)\n- Primary tumor amenable to biopsy (core biopsy done, meets criteria)\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman (meets criteria)\n- No information on performance status\n- No information on blood counts/chemistry values\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. The presence of metastatic lesions on CXR would likely exclude the patient from this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "131": {
        "output": "To determine the patient's eligibility for the clinical trial \"Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer\", I will go through the inclusion criteria provided:\n\nInclusion criteria: \"The NSABP B-28 trial enrolled women from 1995 to 1998 with operable breast cancer with pathologically positive axillary lymph nodes.\"\n\nFrom the patient note, we know that:\n- The patient is a 45-year-old postmenopausal woman\n- She has cytologically confirmed breast cancer\n- The tumor is invasive ductal breast carcinoma\n- Axillary sampling revealed 5 positive lymph nodes\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nBased on this information, the patient meets the inclusion criteria of being a woman with operable breast cancer and pathologically positive axillary lymph nodes.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "132": {
        "output": "Okay, let's go through the inclusion criteria step-by-step:\n\n1. DISEASE CHARACTERISTICS:\n   - Histologically or cytologically confirmed invasive breast cancer - The patient has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n   - Complete resection of primary tumor - The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is met.\n   - Stage I-III (T1-3, N0-3, M0) disease - The patient has axillary lymph node involvement (N+) and metastatic lesions on CXR, so the stage is likely IV (M1), not meeting this criterion.\n   - Enrolled in clinical trial CAN-NCIC-MA27 - No information is provided about enrollment in this specific trial.\n   - No locally recurrent or metastatic breast cancer - The patient has metastatic lesions on CXR, not meeting this criterion.\n\n2. Hormone receptor status:\n   - Estrogen receptor- or progesterone receptor-positive disease - The patient's tumor is ER/PR negative, not meeting this criterion.\n\n3. PATIENT CHARACTERISTICS:\n   - Postmenopausal status, defined as one of the following criteria - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. PRIOR CONCURRENT THERAPY:\n   - See Disease Characteristics - No specific criteria are listed under this section.\n\nBased on the information provided, the patient does not meet all the inclusion criteria for this clinical trial due to having metastatic disease, ER/PR negative status, and potentially not being enrolled in the specific trial CAN-NCIC-MA27.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "133": {
        "output": "Okay, let's go through the inclusion criteria for this breast cancer clinical trial step-by-step:\n\n1. Age between 40 and 75 years.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Clinical, mammographic or ultrasonographic diagnosis of a unicentric carcinoma with an ultrasonographic diameter of equal or less than 2.0 cm.\nThe patient has a 3 cm invasive ductal breast carcinoma, which exceeds the 2.0 cm size limit, so she does not meet this criterion.\n\n3. Axillary lymph nodes that cannot be palpated or that are not clinically suspicious for metastasis.\nThe patient had 5 positive axillary lymph nodes on sampling, so she does not meet this criterion.\n\n4. No previously executed therapy (including biopsy) at any outside institution. \nThe patient had a core biopsy done, so she does not meet this criterion.\n\n5. Those patients with nonpalpable lesions will be subjected to preoperative radioactive occult lesion localization (ROLL) or stereotactic biopsy.\nThis criterion is not applicable since the patient's lesion was palpable.\n\n6. Adequate patient information and signature of the informed consent.\nThere is no information provided about informed consent, so this cannot be evaluated.\n\nBased on the information given, the patient does not meet several of the key inclusion criteria for this breast cancer clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "134": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with newly diagnosed breast cancer. This matches the inclusion criteria of \"Newly diagnosed biopsy proven breast cancer\".\n\n2. The tumor is 3 cm invasive ductal carcinoma, which is greater than the 1 cm minimum size required.\n\n3. The tumor is HER2-positive and ER/PR negative. This matches the inclusion criteria for Phase I selection of \"ER+, HER2+\" and \"ER-, HER2+\".\n\n4. The patient has not received any prior treatment for this breast cancer.\n\n5. The patient has a good performance status (Karnofsky >70% implied).\n\n6. There is no mention of the patient being pregnant, lactating, HIV positive, diabetic, or having pre-existing gastrointestinal issues.\n\n7. There is no mention of the patient being on any contraindicated medications.\n\nBased on the information provided, the patient meets the key inclusion criteria and there are no obvious exclusion criteria that would prevent enrollment.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "135": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female patients, age \u226665 years\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Biopsy proven lymph node positive, estrogen receptor- positive primary breast cancer\nThe patient has cytologically confirmed breast cancer with 5 positive lymph nodes. However, the tumor is ER/PR negative, so she does not meet this criterion.\n\n3. Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard regimen(containing anthracycline or paclitaxel)\nThere is no information provided about prior chemotherapy, so this criterion cannot be evaluated.\n\n4. Must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so she potentially meets this criterion.\n\n5. Postoperative residual positive lymph nodes or G1/G2/G3 of Miller & Payne Grading System\nThere is no information provided about postoperative residual disease or grading, so this criterion cannot be evaluated.\n\n6-12. Other criteria related to medical history, pregnancy status, cardiovascular function, hematologic function, hepatic and renal function, ability to provide informed consent, and comply with study procedures.\nThere is insufficient information provided to evaluate these criteria.\n\nSince the patient does not meet the criterion for ER-positive breast cancer, which is a key inclusion criterion, she would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "136": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, which meets the age inclusion criteria of 18-55 years old.\n\n2. The patient has breast cancer, which is not relevant to the trial's inclusion criteria of inducing muscle pain through eccentric exercise.\n\n3. There is no information provided about the patient's willingness to abstain from physical therapy, hard physical work, exercise, or sauna during the study period.\n\n4. There is no information provided about the patient's use of birth control methods.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, and the patient's condition is not relevant to the trial's purpose.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "137": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is studying the pharmacokinetics of Raltegravir in patients with end-stage liver disease and liver transplant recipients.\n\nLooking at the inclusion criteria:\n1. Age \u2265 18 - The patient is 45 years old, so meets this criteria.\n2. Documented HIV-1 infection - There is no mention of the patient having HIV in the note, so this criteria is not met.\n3. Plasma viral load criteria - There is no information provided about viral load.\n4. Patient with severe liver failure or eligible for liver transplant - There is no mention of the patient having liver disease or being eligible for a liver transplant.\n5. Abstinence from alcohol for \u22656 months - There is no information provided about alcohol use.\n6. Withdrawal from IV drug use for \u22656 months - There is no information provided about IV drug use.\n7. No ongoing opportunistic infection - There is no mention of any opportunistic infections.\n8. Able to take triple therapy regimen - There is no mention of the patient's HIV treatment regimen.\n9. HIV population sensitive to study drugs - There is no information provided about the patient's HIV drug resistance profile.\n10. No viral escape on certain drugs - There is no information about prior treatment failures.\n11. Registered with social security - There is no information provided about this.\n12. Contraceptive use for women of child-bearing potential - The patient is postmenopausal, so this does not apply.\n13. Signed informed consent - There is no information about whether consent was obtained.\n\nOverall, there is insufficient information provided in the patient note to determine if the patient meets all the inclusion criteria for this HIV clinical trial studying Raltegravir in liver disease patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "138": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is studying vaccine responses to influenza A H1N1 immunization in high-risk patients.\n\nThe inclusion criteria for the trial are:\n1. Medically recommended influenza A(H1N1) immunization\n2. Signed informed consent\n\nFrom the patient note, there is no information provided about whether the patient is recommended for influenza A(H1N1) immunization or if she has provided informed consent.\n\nTherefore, based on the information given, the patient does not have sufficient details to determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "139": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 45-year-old postmenopausal woman with breast cancer. The clinical trial is investigating the efficacy and safety of aripiprazole in patients with first episode psychosis.\n\nLooking at the inclusion criteria for the trial:\n\"Aged 18-59 years and meet DSM-IV diagnostic criteria for first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychotic disorder NOS as assessed by using the Structured Clinical Interview for DSM-IV, research version.\"\n\nThe patient note does not mention any psychotic disorder or first episode psychosis diagnosis. The patient has breast cancer, which is not relevant to the trial's inclusion criteria.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "140": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Locally advanced or metastatic melanoma - The patient has metastatic breast cancer, not melanoma, so this criterion is not met.\n- Measurable - No information provided about measurable disease.\n- Histologically or cytologically confirmed - The breast cancer was cytologically confirmed by core biopsy.\n- Surgically incurable - It is not explicitly stated that the cancer is surgically incurable, but the presence of metastatic lesions on CXR suggests it may be incurable.\n- HLA-A2 positive and tumors that present HLA-A2.1/p53aa264-272 complexes - No information provided about HLA type or tumor antigen presentation.\n\nPRIOR/CONCURRENT THERAPY:\n- If prior Proleukin treatment, must have had clinical benefit - No information provided about prior Proleukin.\n- No prior systemic cytotoxic chemotherapy for melanoma - The patient has not received prior chemotherapy for melanoma, but this trial is specifically for melanoma patients.\n- No concurrent radiotherapy, chemotherapy, or other immunotherapy - No information provided about current treatments.\n- More than 4 weeks since prior major radiotherapy - No information provided about prior radiotherapy.\n- More than 8 weeks since prior CTLA-4 antagonist immunotherapy - No information provided about this.\n- Not receiving other investigational agents - No information provided.\n\nPATIENT CHARACTERISTICS:\n- Life expectancy > 3 months - No specific information, but metastatic cancer suggests life expectancy may be < 3 months.\n- Performance status ECOG 0 or 1 - No information provided.\n- Adequate bone marrow reserve (ANC, platelets, hemoglobin) - No specific lab values given.\n- Adequate renal function (serum creatinine) - No values given.\n- Adequate hepatic function (bilirubin, AST, alk phos, coags) - No values given.\n- Cardiovascular criteria - No information provided.\n- Pulmonary criteria - No information provided.\n- No known autoimmune disease - Not mentioned.\n- No known HIV positive - Not mentioned.\n- No psychiatric/social issues limiting compliance - Not mentioned.\n- No history or evidence of CNS disease - Not mentioned.\n- No active systemic infection requiring IV antibiotics - Not mentioned.\n- No systemic steroid therapy required - Not mentioned.\n- No prior organ transplant - Not mentioned.\n- Not receiving chronic asthma medication - Not mentioned.\n- Not pregnant or nursing; use contraception if fertile - No information provided.\n\nBased on the limited information in the patient note, the key reasons why this patient does not appear eligible are:\n1) The trial is specifically for metastatic melanoma, while the patient has metastatic breast cancer.\n2) There is insufficient information provided about many of the inclusion criteria to determine if they are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "141": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. This meets the inclusion criteria of \"Known or suspected malignancy involving the breast as determined by biopsy, physical examination or noninvasive imaging studies including plain films, CT, MR, ultrasound or nuclear medicine imaging.\"\n\n2. The patient is scheduled for tumor resection, which likely means she will be undergoing routine clinical imaging. This meets the inclusion criteria of \"Scheduled for routine clinical imaging at the ACB PET/CT facility.\"\n\n3. The patient is 45 years old, which meets the inclusion criteria of \"Participant must be at least 18 years of age.\"\n\n4. There is no information provided that would exclude the patient based on the trial's exclusion criteria.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "142": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n- Postmenopausal women with breast cancer eligible for hormonal therapy.\n\nBased on the patient note, the patient is:\n1) A 45-year-old postmenopausal woman (meets the \"postmenopausal women\" criteria)\n2) Has cytologically confirmed breast cancer (meets the \"with breast cancer\" criteria)\n3) Is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests she may be eligible for hormonal therapy after surgery (meets the \"eligible for hormonal therapy\" criteria)\n\nSince the patient meets all the inclusion criteria mentioned, and there are no exclusion criteria provided, we can conclude that the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "143": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed, American Joint Committee on Cancer (AJCC) stage II or III breast cancer\n- The patient note states that the patient has a 3 cm invasive ductal breast carcinoma, which would likely be stage II or III. This criterion is met.\n\n2. High risk of breast cancer recurrence, defined as:\n    i) Biopsy evidence of breast cancer in regional lymph node(s) \n    ii) Tumor size > 5 cm (T3) or locally advanced disease (T4)\n- The patient has 5 positive lymph nodes, meeting criterion i. This criterion is met.\n\n3. Documented pathological evaluation of the breast cancer for hormone receptor (ER and PR) status and HER-2 status\n- The patient note states the tumor is HER2-positive and ER/PR negative, meeting this criterion.\n\n4. Receiving or scheduled to receive standard systemic adjuvant/neoadjuvant chemo, endocrine, or HER2 therapy\n- The patient is a candidate for tumor resection prior to chemotherapy, meeting this criterion. \n\n5. For adjuvant therapy patients: underwent complete tumor resection, scheduled for definitive curative treatment within 9 months, randomization within 12 weeks of surgery, axillary node treatment if node positive.\n- This section applies as the patient is receiving adjuvant therapy after planned resection.\n\n6. For neoadjuvant therapy patients: randomization within 8 weeks of starting neoadjuvant treatment, scheduled for definitive curative treatment within 9 months.\n- This does not apply as the patient is not receiving neoadjuvant therapy.\n\n7. Female, age \u226518 years\n- The patient is a 45-year-old postmenopausal woman, meeting this.\n\n8. Negative pregnancy test if reproductive potential \n- No information on pregnancy potential, cannot assess.\n\n9. Serum calcium and albumin-adjusted calcium levels within range\n- No information provided, cannot assess.\n\n10. ECOG performance status 0 or 1 \n- No information provided, cannot assess.\n\n11. Provided written informed consent\n- No information provided, cannot assess.\n\nIn summary, the patient meets criteria 1-4 based on the information given. For criteria 5-11, there is insufficient information to make a full assessment.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "144": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Histologically confirmed locally recurrent breast carcinoma consistent with invasive ductal breast carcinoma - Met (patient has 3 cm invasive ductal breast carcinoma)\n- No Paget disease of the nipple - Assumed met (not mentioned)\n- Target lumpectomy cavity must be clearly defined and < 30% based on CT scan - Met (3 cm tumor size)\n- Tumor size \u2264 3 cm - Met (3 cm tumor)\n- Negative histologic margins after breast-conserving surgery - Assumed met (not mentioned)\n- Axilla negative or \u2264 3 positive lymph nodes without extracapsular extension - Met (5 positive lymph nodes)\n- No multicentric ipsilateral breast recurrence or regional recurrence - Assumed met (not mentioned)\n- Patients must have a breast technically amenable to partial-breast irradiation - Assumed met (not mentioned)\n- No metastatic disease documented by exam or imaging - Not met (CXR remarkable for metastatic lesions)\n- No skin involvement - Assumed met (not mentioned)\n- No prior contralateral mastectomy - Assumed met (not mentioned)\n- Estrogen and progesterone status must be known - Met (ER/PR negative)\n\nPATIENT CHARACTERISTICS:\n- Zubrod performance status 0-1 - Assumed met (not mentioned)\n- Menopausal status not specified - Met (postmenopausal)\n- Not pregnant or nursing - Assumed met (not mentioned)\n- Negative pregnancy test - Assumed met (not mentioned)\n- Fertile patients must use effective contraception - Not applicable (postmenopausal)\n- No other invasive malignancy within past 3 years except breast cancer - Assumed met (not mentioned)\n- No collagenous diseases like lupus, scleroderma, dermatomyositis - Assumed met (not mentioned)\n- No psychiatric/addictive disorders precluding informed consent - Assumed met (not mentioned)\n\nPRIOR CONCURRENT THERAPY:\n- More than 2 weeks since prior chemotherapy and recovered - Assumed met (no prior chemo mentioned)\n- No concurrent intensity-modulated radiotherapy - Assumed met (not mentioned)\n- No concurrent chemotherapeutic agents including trastuzumab - Assumed met (not mentioned)\n\nWhile the patient meets most of the inclusion criteria, the presence of metastatic lesions on CXR excludes them from this trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "145": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women or men \u226518 years of age - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically or cytologically confirmed adenocarcinoma of the breast and clinical evidence of metastatic breast cancer - The patient has cytologically confirmed invasive ductal breast carcinoma with metastatic lesions seen on CXR, so she meets this criterion. \n\n3. Pre-treatment requirements:\n   3.1 Must have been previously treated in neoadjuvant, adjuvant or metastatic setting with anthracycline and/or taxane - No information provided about prior treatment.\n   3.2 Must have received 2-3 prior chemotherapy treatment regimens - No information provided about prior treatment regimens.\n   3.3 Prior hormonal therapy allowed - No information provided about prior hormonal therapy.\n\n4. Patients must have measurable disease as defined in the protocol - The patient has a 3 cm primary tumor, so she likely has measurable disease.\n\n5. Negative pregnancy test for women of childbearing potential only - The patient is postmenopausal, so this does not apply.\n\n6. Required laboratory values within 15 days prior - No recent laboratory values provided.\n\n7. LVEF \u226550% and EKG within normal limits within 22 days prior - No information provided about LVEF or EKG.\n\n8. ECOG Performance Status of 0, 1 or 2 - No information provided about performance status.\n\n9. Life expectancy >3 months - No information provided about life expectancy.\n\n10. Ability to complete questionnaires - Likely able to do so, but not explicitly stated.\n\n11. Provided written informed consent - Not mentioned if consent was provided.\n\n12. Willingness to return for follow-up - Not mentioned.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all of the inclusion criteria for this clinical trial. More details are needed, particularly regarding prior treatment history, laboratory values, cardiac function, performance status, and consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "146": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm)\n    - The patient has a 3 cm invasive ductal carcinoma in the left upper outer quadrant, so this criterion is not met.\n- All radiographically suspicious lesions must be biopsied and have histologically confirmed ductal carcinoma in-situ, invasive ductal, invasive lobular, medullary, papillary, colloid (mucinous), or tubular histologies\n    - The patient has a confirmed 3 cm invasive ductal carcinoma, so this criterion is met.\n- A maximum of two radiographically detected malignant lesions\n    - Only one lesion is mentioned, so this criterion is met.\n- Clinical Stage I-II breast carcinoma, with lesion size =< 5 cm for the dominant mass and the second lesion detected only on MRI, treated with lumpectomies; the MRI detected lesion must be pathologically =< 1 cm\n    - The patient has a 3 cm lesion, which meets the stage I-II and lesion size criteria. No second MRI-detected lesion is mentioned.\n- Axillary lymph node evaluation, either sentinel lymph node biopsy or axillary dissection as deemed appropriate by the treating surgeon for all patients with invasive cancer\n    - The patient had axillary sampling that revealed 5 positive lymph nodes, so this criterion is met.\n- Negative resection margins with at least a 2 mm margin from invasive and in-situ cancer or a negative re-excision\n    - No information is provided about the resection margins.\n- Patients are eligible regardless of estrogen receptor, progesterone receptor, or Her-2/neu amplification\n    - The patient's tumor is HER2-positive and ER/PR negative, so this criterion is met.\n- Hormonal therapy is allowed; if adjuvant chemotherapy is planned, the chemotherapy should be delivered first and radiation must begin no earlier than three weeks and no later than eight weeks following completion of chemotherapy\n    - No information is provided about planned therapies.\n\nExclusion Criteria:\n- Extensive intraductal component by the Harvard definition (i.e., more than 25% of the invasive tumor is DCIS and DCIS present in adjacent breast tissue)\n    - No information about intraductal component is provided.\n- Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically confirmed negative\n    - No information about other lymph node involvement is provided.\n- Patients receiving neoadjuvant chemotherapy\n    - No information about neoadjuvant chemotherapy is provided.\n- Patients with distant metastatic disease detected by radiographic imaging\n    - The patient has metastatic lesions on CXR, so this exclusion criterion applies.\n- Patients with known BRCA 1/BRCA 2 mutations or those with predicted risk of carrying the mutation by BRCAPRO (44) risk assessment >= 50%\n    - No information about BRCA mutation status is provided.\n- Diffuse calcifications throughout the breast \n    - No information about diffuse calcifications is provided.\n- Patients with skin involvement or inflammatory breast cancer\n    - No information about skin involvement or inflammatory breast cancer is provided.\n- Patients with Paget's disease of the nipple\n    - No information about Paget's disease is provided.\n- Patients with nonepithelial breast malignancies such as lymphoma or sarcoma\n    - The patient has an epithelial breast cancer (invasive ductal carcinoma).\n- Patients with collagen vascular disorders\n    - No information about collagen vascular disorders is provided.\n- Patients with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent\n    - No information about psychiatric/neurologic/addictive disorders is provided.\n- Other malignancy, except non-melanomatous skin cancer, < 5 years prior to participation in this study\n    - No information about other malignancies is provided.\n- Patients who are pregnant or lactating\n    - The patient is described as postmenopausal",
        "label": 1
    },
    "147": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has histologically confirmed breast cancer (meets criteria)\n- The patient has metastatic disease amenable to biopsy (meets criteria) \n- The patient has an unresected tumor with no intention to undergo resection during the study (meets criteria)\n- Archival tissue or fresh biopsy is available (meets criteria)\n- The patient has measurable disease (meets criteria for phase II)\n- ER, PR, and HER2 status from metastatic site is available (HER2-positive and ER/PR negative meets criteria for phase II)\n- The patient has triple-negative breast cancer (meets criteria for phase II)\n- No CNS metastasis (meets criteria)\n\nPATIENT CHARACTERISTICS:\n- The patient is a 45-year-old postmenopausal woman (meets criteria)\n- No information on ECOG performance status\n- Life expectancy not mentioned but likely \u2265 12 weeks\n- No lab values mentioned \n- Not pregnant or nursing (meets criteria)\n- No other medical conditions mentioned that would exclude her\n\nPRIOR CONCURRENT THERAPY:\n- No prior chemotherapy mentioned (meets criteria for phase II)\n- No prior aromatase inhibitor therapy mentioned (meets criteria)\n- No concurrent investigational agents mentioned (meets criteria)\n\nBased on the information provided, the patient meets the key inclusion criteria for the phase II portion of this breast cancer clinical trial evaluating panobinostat and letrozole in metastatic triple-negative breast cancer. There is no information provided that would definitively exclude her.\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "148": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Histologically confirmed breast cancer - The patient note mentions \"cytologically confirmed breast cancer\", which satisfies this criterion.\n\n2. T1c N1-2 or T2 N0-2 disease - The patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, which corresponds to T2 N1 disease, satisfying this criterion.\n\n3. HER2-positive tumors - The patient note states that the tumor is HER2-positive, satisfying this criterion.\n\n4. No prior systemic treatment regimens for breast cancer - The patient has not received any prior treatment, satisfying this criterion.\n\n5. Adequate hematologic function - There is no information provided about the patient's hematologic function.\n\n6. Serum creatinine concentration and creatinine clearance within specified limits - No information provided.\n\n7. Bilirubin level within specified limit - No information provided. \n\n8. Normal cardiac function with specified left ventricular ejection fraction - No information provided.\n\n9. Karnofsky performance status \u226580% - No information provided.\n\n10. Age \u226518 years - The patient is 45 years old, satisfying this criterion.\n\n11. Adequate contraception if of childbearing potential - The patient is postmenopausal, so this criterion is not applicable.\n\n12. Written informed consent - The patient agrees to tumor resection prior to chemotherapy, implying consent.\n\nSince there is no information provided about some key criteria like hematologic function, renal function, liver function, cardiac function, and performance status, I cannot definitively conclude that the patient is eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "149": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Histologically or cytologically confirmed metastatic invasive mammary carcinoma. The primary cancer must be HER2 negative by fluorescence in situ hybridization and/or immunohistochemistry.\"\n- The patient note states that the patient has cytologically confirmed invasive ductal breast carcinoma, which is a type of mammary carcinoma. It also mentions that the tumor is HER2-positive, which meets this criteria.\n\n2. \"Patients must have CTCs with HER2 amplification by FISH.\"\n- There is no information provided about the patient's circulating tumor cells (CTCs) and their HER2 status.\n\n3. \"Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 20mm or greater with conventional techniques of as 10mm or greater with spiral CT scan.\"\n- The patient note mentions a 3 cm (30 mm) tumor in the left breast, which meets this criteria.\n\n4. \"Study participants must have either archival primary tumor or metastatic tumor tissue available to allow analysis to confirm their HER2 status.\"\n- There is no information provided about availability of tumor tissue samples.\n\n5. \"Patients must have received at least 1 prior chemotherapy regimen for metastatic breast cancer or evidence of disease progression within 6 months of completing adjuvant chemotherapy. Patients can receive any number of biological or hormonal regimens and remain eligible.\"\n- The patient note does not mention any prior chemotherapy regimens.\n\n6. \"18 years of age or older\"\n- The patient is 45 years old, meeting this criteria.\n\n7. \"Life expectancy of greater than 3 months\"\n- There is no information about the patient's life expectancy.\n\n8. \"ECOG Performance Status of 0, 1 or 2\" \n- There is no information about the patient's performance status.\n\n9. \"Normal organ and marrow function as outlined in the protocol\"\n- There is no information about the patient's organ or marrow function.\n\n10. \"Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\"\n- The patient note states that the patient is postmenopausal, so this criteria is not applicable.\n\nBased on the information provided in the patient note, the patient meets some of the key inclusion criteria like having metastatic HER2-positive breast cancer and a measurable lesion. However, there are several criteria for which information is lacking, such as CTC HER2 status, availability of tumor samples, prior treatment history, life expectancy, performance status, and organ/marrow function.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "150": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with metastatic breast cancer. The tumor is HER2-positive and ER/PR negative. She has not received any treatment yet and is a candidate for tumor resection followed by chemotherapy.\n\nThe clinical trial is an observational study assessing the treatment duration and safety of Avastin (bevacizumab) as first-line treatment in patients with metastatic breast cancer.\n\nThe key inclusion criterion for this trial is \"Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin\".\n\nSince the patient has not yet received any treatment, including Avastin, she does not meet this key inclusion criterion.\n\nTherefore, based on the information provided, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "151": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of having a histologically or cytologically confirmed diagnosis of breast cancer.\n\nThe patient's age is given as 45 years old, which meets the inclusion criteria of being 18 years or older.\n\nThe patient note does not explicitly state her ethnicity/race, but the trial is specifically looking for Hispanic/Latino women with breast cancer.\n\nThere is no information given about whether the patient is able to understand and sign an informed consent document.\n\nThe patient note states that she is a candidate for tumor resection and agrees to do so prior to chemotherapy, suggesting she would likely be willing and able to provide a saliva sample and answer questionnaires as required by the trial.\n\nNo exclusion criteria are mentioned that would exclude this patient.\n\nThe only potential issue is the lack of information about the patient's ethnicity matching the Hispanic/Latino requirement.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, due to lack of ethnicity information).",
        "label": 2
    },
    "152": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criteria of \u2265 18 years.\n\nThe tumor is a 3 cm invasive ductal breast carcinoma, which is a histologically confirmed invasive breast carcinoma.\n\nThe tumor is HER2-positive, which does not meet the inclusion criteria of HER2-negative status.\n\nThe tumor is ER/PR negative, which does not meet the inclusion criteria of positive estrogen and/or progesterone receptor status.\n\nAxillary sampling revealed 5 positive lymph nodes, which meets the criteria of 1-3 positive lymph nodes.\n\nThe patient has not received any prior treatment like aromatase inhibitors or selective estrogen receptor modulators.\n\nBased on the information provided, the patient does not meet all the key inclusion criteria for this clinical trial due to the HER2-positive and ER/PR negative status of the tumor.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "153": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients should have a life expectancy of at least 10 years, excluding their diagnosis of breast cancer.\n- The patient note does not mention any comorbidities that would limit life expectancy, so this criterion is likely met.\n\n2. Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy and for a period after.\n- The patient is described as postmenopausal, so this criterion does not apply.\n\n3. Submission of tumor samples from breast surgery is required.\n- This is a requirement for participation, but not an inclusion criterion per se. Assuming the patient agrees, this would be satisfied.\n\n4. Signed IRB-approved consent form.\n- Again, a requirement but not an inclusion criterion. Assuming consent is obtained, this would be satisfied.\n\n5. ECOG performance status of 0 or 1.\n- The patient's performance status is not mentioned, so there is insufficient information to assess this criterion.\n\n6. Unilateral invasive adenocarcinoma of the breast on histologic examination.\n- The patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n7. Specific staging criteria based on tumor size, nodal status, ER/PR/HER2 status.\n- The tumor is 3 cm (pT2) with 5 positive lymph nodes (pN1)\n- HER2 is positive \n- ER/PR is negative\nThis matches the criteria of pT2, pN1, HER2-positive, ER/PR-negative.\n\n8. Various laboratory value criteria related to blood counts, liver/kidney function.\n- There is no information provided about the patient's lab values, so these criteria cannot be assessed.\n\n9. LVEF criteria based on planned chemotherapy regimen.\n- There is no information about the patient's LVEF, so this criterion cannot be assessed.\n\nIn summary, based on the information provided, the patient meets some of the key inclusion criteria related to breast cancer type, staging, and HER2/ER/PR status. However, there is insufficient information to fully assess performance status, laboratory values, and cardiac function criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "154": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge \u226518: The patient is 45 years old, so this criterion is met.\n\nStage IV HER2 (+) breast cancer: The patient has cytologically confirmed breast cancer that is HER2-positive and has metastatic lesions, meeting this criterion.\n\nHistologically documented HER2 (+) breast cancer: This is met based on the HER2-positive status mentioned.\n\nECOG performance 0-1: No ECOG performance status is given, so this cannot be evaluated.\n\n0-1 prior treatment in the metastatic setting: It is not mentioned if the patient has received any prior treatment in the metastatic setting, so this cannot be evaluated.\n\nMeasurable or non-measurable disease: The primary tumor is 3 cm, which would qualify as measurable disease, meeting this criterion.\n\nLVEF \u2265 50%: No LVEF value is provided, so this cannot be evaluated.\n\nHematologic parameters: No lab values are given, so these cannot be evaluated.\n\nNon-hematologic parameters: No lab values are given, so these cannot be evaluated.\n\nCreatinine \u2264 1.5 mg/dl: No creatinine value is provided, so this cannot be evaluated.\n\nPatients with stable and treated brain lesions may be enrolled: No information about brain lesions is provided.\n\nIn summary, some key inclusion criteria are met (age, cancer type/stage, measurable disease), but several others cannot be evaluated due to lack of information in the patient note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "155": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The treating surgeon must determine that breast conservation therapy (BCT) would be made more feasible by reducing tumor size using neoadjuvant systemic therapy\n- The patient note does not mention if BCT is feasible after neoadjuvant therapy, so this criterion cannot be evaluated.\n\n2. The patient must have signed and dated an institutional review board (IRB) approved consent form that conforms to federal and institutional guidelines\n- This is not mentioned in the patient note.\n\n3. The patient must be female\n- The patient note states the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. The patient must be greater than or equal to 18 years old  \n- The patient is 45 years old, so this criterion is met.\n\n5. The patient must have an Eastern Cooperative Oncology Group Score (ECOG) performance status of 0 or 1\n- The ECOG performance status is not provided.\n\n6. The diagnosis of invasive carcinoma of the breast must have been made by core needle biopsy\n- The patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n7. The primary breast tumor must be >= 2 cm by physical exam or imaging\n- The tumor size is 3 cm, so this criterion is met.\n\n8. Ipsilateral axillary lymph nodes must be evaluated by imaging (MRI or ultrasound) within 6 weeks prior to randomization; If indicated for abnormal lymph nodes, fine needle aspirate (FNA) or core biopsy must be performed.\n- The patient note mentions \"Axillary sampling revealed 5 positive lymph nodes\", so this criterion is likely met but the timing and method are not specified.\n\n9. The tumor must have been determined to be HER2-negative\n- The patient note states the tumor is \"HER2-positive\", so this exclusion criterion applies.\n\n10. The tumor must have been determined to be ER+ and/or progesterone positive (PgR+) defined as > 10% tumor staining by immunohistochemistry\n- The tumor is described as \"ER/PR negative\", so this criterion is not met.\n\n11. The patient must have been evaluated by a treating physician, reviewed and discussed by the multi-disciplinary breast team, and considered to be a candidate for chemotherapy\n- This is not mentioned in the patient note.\n\nIn summary, while some criteria are met, the key criteria of being HER2-negative and ER/PR-positive are not met for this patient based on the information provided.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "156": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must be \u2265 18 years of age\nThe patient is 45 years old, so this criterion is met.\n\n2. Patient must be a postmenopausal woman, defined by one of the following criteria:\n- Women \u2265 60 years\n- Women aged 45-59 years with spontaneous cessation of menses \u2265 12 months prior to registration\n- Women aged 45-59 years with cessation of menses of duration < 12 months or secondary to hysterectomy AND an follicle-stimulating hormone (FSH) level in the postmenopausal range\n- Women aged 45-59 years on hormonal replacement therapy who have discontinued hormonal therapy AND an FSH level in the postmenopausal range\n- Status post bilateral surgical oophorectomy\n\nThe patient note states that the patient is a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n3. Patient must have a negative serum pregnancy test within 48 hours before starting study treatment (if a woman of childbearing potential)\nThis is not mentioned in the patient note, so we cannot determine if this criterion is met or not.\n\n4. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2\nThe patient's performance status is not mentioned, so we cannot determine if this criterion is met.\n\n5. Patient must have histologically or cytologically confirmed invasive breast cancer that is stage IV or metastatic\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and that \"CXR was remarkable for metastatic lesions\", so this criterion is met.\n\n6. Patient must have a representative tumor tissue specimen available; archival tissue is allowed\nThis is not mentioned in the patient note.\n\n7. Either the primary or the metastatic tumor must be positive for estrogen receptor (>= 1% tumor cell staining by immunohistochemistry or an Allred Score of >= 3 by immunohistochemistry)\nThe patient note states that the tumor is \"ER/PR negative\", so this criterion is not met.\n\n8. Patient must have at least one site of measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria\nThis is not mentioned in the patient note.\n\n9. Other criteria related to prior lines of therapy, life expectancy, adequate organ function, etc.\nThese are not mentioned in the patient note.\n\nSince the tumor is ER/PR negative, which is an exclusion criterion for this trial, the patient would be excluded from participating.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "157": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. All patients must have signed and dated an informed consent form\n   - There is no information about this in the patient note.\n\n2. Patients must be female\n   - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n3. Primary invasive breast cancer pathologically approved by core needle or open biopsy\n   - The patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, so this criterion is met.\n\n4. Ipsilateral axillary or internal mammary nodes positive, or tumor size is equal to or larger than 4cm\n   - The patient has 5 positive axillary lymph nodes and the tumor size is 3 cm, so this criterion is met.\n\n5. Patients must have undergone standard surgery for primary breast cancer\n   - The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is potentially met.\n\n6. Treatment for confirmed breast cancer including the surgery modality listed above, loco-regional radiotherapy after lumpectomy, adjuvant chemotherapy\n   - There is no information about radiotherapy or chemotherapy in the patient note.\n\n7. Adjuvant endocrine therapy of TAM or Fareston must be started within 6 weeks when adjuvant chemotherapy or radiotherapy was finished\n   - There is no information about prior endocrine therapy in the patient note.\n\n8. The date of randomization must be processed after taking TAM or Fareston for 2 or more than 2 years, but not more than 3 years of time\n   - There is no information about prior endocrine therapy duration in the patient note.\n\n9. Patients taking neo-chemotherapy are eligible...\n   - There is no information about neo-adjuvant chemotherapy in the patient note.\n\n10. Patients diagnosed as occult breast cancer...\n    - The patient does not have occult breast cancer.\n\n11. Patients with synchronous bilateral cancers are eligible...\n    - There is no information about bilateral breast cancer in the patient note.\n\n12. Hormone receptor positive (\u2265\uff0b) is defined as detecting ER or PR expression at any time is eligible\n    - The tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n13. According to the standard operation principles for clinical practice of local cancer center, patients must be randomized within 4 weeks after definitive physical examination, imaging examination and laboratory testing show no evidence of recurrence or metastasis\n    - The patient has metastatic lesions on CXR, so this criterion is not met.\n\n14. Based on the study objective, all patients are required to be premenopausal...\n    - The patient is described as postmenopausal, so this criterion is not met.\n\n15. Patients must have an ECOG performance status of 0 or 1\n    - There is no information about ECOG performance status in the patient note.\n\n16. Blood count and chemistry criteria\n    - There is no information about these lab values in the patient note.\n\n17. Patients can swallow pills\n    - This is likely but not explicitly stated in the patient note.\n\n18. Pregnancy testing is negative and are willing to do contraception during the treatment period\n    - The patient is postmenopausal, so this criterion is met.\n\nIn summary, while some criteria are potentially met, the key exclusion criteria of being ER/PR negative, having metastatic disease, and being postmenopausal make this patient ineligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "158": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histopathologic evidence of urothelial carcinoma, based on local pathology report.\n   - The patient note mentions the patient has cytologically confirmed breast cancer, which is not urothelial carcinoma. This criterion is not met.\n\n2. High risk urothelial carcinoma, in subjects with or without prior neoadjuvant chemotherapy, defined as positive lymph node status (N+), or pathological stage \u2265 pathological tumor (pT2) in patients who either have negative lymph node status (N0) or have no evaluable lymph nodes (Nx).\n   - The patient has breast cancer, not urothelial carcinoma, so this criterion is not applicable.\n\n3. Radical surgical resection was performed \u2264 84 days (12 weeks) prior to registration.\n   - The patient note mentions the patient is a candidate for tumor resection, but it has not been performed yet. This criterion is not met.\n\n4. No evidence of residual disease or metastasis following surgical resection which includes: absence of invasive cancer at the margins in the surgical specimens and confirmation by CT scan of chest, abdomen and pelvis obtained at least 28 days following surgical resection and \u2264 28 days prior to registration.\n   - Since the surgical resection has not been performed yet, this criterion cannot be evaluated.\n\n5. HER2/neu tissue expression \u2265 1+ by immunohistochemistry (IHC). Available biopsy specimens from the primary tumor and involved lymph nodes are be submitted to the central pathology laboratory prior to registration for confirmation of HER2/neu tissue expression.\n   - The patient note mentions the tumor is HER2-positive, so this criterion is met.\n\n6. Last neoadjuvant chemotherapy treatment administered at least 60 days prior to registration.\n   - The patient note does not mention any prior neoadjuvant chemotherapy, so this criterion is not applicable.\n\n7. Left ventricular ejection fraction \u2265 50% on multigated acquisition (MUGA) scan or echocardiogram obtained at least 28 days following surgery and \u2264 28 days prior to registration.\n   - There is no information provided about the patient's left ventricular ejection fraction, so this criterion cannot be evaluated.\n\n8. Women of child-bearing potential have a negative serum pregnancy test result \u2264 28 days prior to registration and agree not to breastfeed during investigational treatment with DN24-02 and for 28 days following the final infusion of DN24-02.\n   - The patient note mentions the patient is postmenopausal, so this criterion is not applicable.\n\n9. All males and premenopausal females who have not been surgically sterilized have agreed to practice a method of birth control considered by the Investigator to be effective and medically acceptable for at least 14 days prior to registration, throughout treatment, and for 28 days following the final infusion of DN24-02.\n   - The patient is postmenopausal, so this criterion is not applicable.\n\n10. Adequate hematologic, renal, and liver function.\n    - There is no information provided about the patient's hematologic, renal, and liver function, so this criterion cannot be evaluated.\n\n11. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2.\n    - There is no information provided about the patient's ECOG performance status, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for this clinical trial because she has breast cancer, not urothelial carcinoma, and has not undergone surgical resection yet. Additionally, there is not enough information to evaluate some of the other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "159": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must have histological or cytological confirmed invasive breast cancer\n- The patient note confirms she has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\n2. Patient must be premenopausal confirmed by serum estradiol level in the premenopausal range (> 25 pg/ml) at the beginning of the study\n- The patient note states the patient is a 45-year-old postmenopausal woman, so this criterion is not met.\n\n3. Patient must have a negative serum pregnancy test within 7 days of registration\n- There is no information about a pregnancy test in the patient note.\n\n4. Patient's tumor must be ER+ with or without concomitant progesterone receptor-positive (PR+) with an Allred score of 6, 7 or 8\n- The patient note states the tumor is ER/PR negative, so this criterion is not met.\n\n5. Patient's tumors must be HER2 negative\n- The patient note states the tumor is HER2-positive, so this criterion is not met.\n\n6. Patient must have T2-T4c, any N, M0 breast cancer, by clinical staging\n- The patient has a 3 cm tumor (T2) with 5 positive lymph nodes, but also metastatic lesions on CXR, so this criterion is not met.\n\nSince multiple key inclusion criteria are not met, particularly being premenopausal and ER+/HER2-, this patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "160": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) 21 years of age and older\n- The patient is 45 years old, so this criterion is met.\n\n2) Must sign informed consent, witnessed, and dated prior to entry\n- There is no information about whether the patient has signed informed consent, so this cannot be evaluated.\n\n3) The participant has breast biopsy consistent with Ductal Carcinoma in situ (DCIS)\n- The patient has invasive ductal breast carcinoma, not DCIS, so this criterion is not met.\n\n4) Performance Status: ECOG 0-1 unless mobility is limited from chronic physical handicap\n- There is no information about the patient's performance status, so this cannot be evaluated.\n\n5) No clinical evidence of other malignancies (except Basal Cell carcinoma)\n- The patient has metastatic lesions on CXR, indicating the presence of another malignancy, so this criterion is not met.\n\n6) Complete blood count, differential and platelet count must be WNL or verified by the study chair to be related to conditions not interfering with normal health status\n- There is no information about the patient's blood counts, so this cannot be evaluated.\n\n7) Adequate hepatic and renal function (these must be WNL or verified by study chair to be related to conditions not interfering with normal health status)\n- There is no information about the patient's hepatic and renal function, so this cannot be evaluated.\n\n8) Normal fasting glucose\n- There is no information about the patient's fasting glucose levels, so this cannot be evaluated.\n\n9) No history of diabetes\n- There is no information about whether the patient has a history of diabetes, so this cannot be evaluated.\n\n10) Medically and Psychologically able to comply with all study requirements\n- There is no information about the patient's ability to comply with study requirements, so this cannot be evaluated.\n\n11) Accessible for Follow up\n- There is no information about the patient's accessibility for follow-up, so this cannot be evaluated.\n\nSince the patient does not meet the inclusion criteria of having DCIS and having no evidence of other malignancies, and there is insufficient information to evaluate several other criteria, I would assess the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "161": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with newly diagnosed invasive ductal breast cancer. This meets the inclusion criteria of \"Diagnosis of invasive breast cancer or DCIS\" and \"Female age \u226518\".\n\nThe tumor is HER2-positive and ER/PR negative. There are no specific criteria related to tumor subtype.\n\nThe patient has 5 positive lymph nodes. There are no criteria specifying lymph node status.\n\nThe patient has metastatic lesions noted on CXR. There are no explicit exclusion criteria for metastatic disease.\n\nThe patient is a candidate for tumor resection and agrees to undergo it prior to chemotherapy. This meets the criteria of \"Have not completed definitive surgical treatment\" and the relevant sub-criteria for planned surgery type.\n\nBased on the information provided, this patient meets all of the stated inclusion criteria for the clinical trial on genetic testing decision making in newly diagnosed breast cancer patients.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "162": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy. \nThe patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n2. Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required.\nThe patient has not yet received neoadjuvant therapy, but is a candidate for it prior to tumor resection.\n\n3. Residual tumor size </= 2.0 cm in greatest diameter. \nThe tumor size is 3 cm, which exceeds the 2.0 cm limit.\n\n4. Tumor enhancement on pre-registration MRI.\nNo information is provided about tumor enhancement on MRI.\n\n5. Tumor with <25% intraductal components in the aggregate.\nNo information is provided about the intraductal component percentage.\n\n6. Adequate breast size for safe cryoablation. \nNo information is provided about the patient's breast size.\n\n7. Patients with prior in-situ or invasive breast carcinomas are eligible if the prior carcinomas occurred in the contralateral breast.\nNo information is provided about any prior breast carcinomas.\n\nBased on the information given, the key exclusion criterion appears to be the tumor size exceeding 2.0 cm. There is also insufficient information to determine eligibility for some of the other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "163": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female patients >=18 years-of-age.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically confirmed breast cancer prior to surgery with the following staging criteria: T1-T3, T4a, T4b, N0-N2, N3a and M0 (T1N0M0 patients are excluded). Inflammatory disease is excluded.\nThe patient has a 3 cm invasive ductal breast carcinoma and 5 positive lymph nodes, which falls under the allowed staging criteria. It is not mentioned if she has inflammatory disease.\n\n3. Previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or taxane containing chemotherapy (+trastuzumab in HER2-positive patients).\nThis is not mentioned in the patient note.\n\n4. Patients must be \u2265 21 days and \u2264 84 days from breast surgery and fully recovered. Patients may have had mastectomy or breast conservation surgery with axillary node dissection.\nThe patient is a candidate for tumor resection, so it seems she has not had surgery yet.\n\n5. Pathologic CR (pCR) not achieved following neoadjuvant treatment (i.e., residual invasive breast cancer (>5 mm) in the breast or presence of nodal disease at surgery [ypT0/T1a, N1-N3a, M0 or ypT1b-T4, N0-N3a, M0].\nThis is not mentioned, as the patient has not received neoadjuvant treatment yet.\n\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\nThe patient's performance status is not provided.\n\n7. Recovery from any toxic effects of prior therapy to <=Grade 1 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v4.0) except fatigue or alopecia.\nThe patient has not received prior therapy yet.\n\n8. Peripheral neuropathy Grade <=2 per NCI CTCAE v4.0 at trial entry.\nThis is not mentioned.\n\n9. Normal left ventricular ejection fraction (LVEF), within the institutional limits of normal, as measured by echocardiography (ECHO) or multi-gated (MUGA) scan in patients to receive trastuzumab with eribulin (HER2-positive).\nThe patient is HER2-positive, but her LVEF is not provided.\n\n10. Adequate hematologic, hepatic, and renal function\nThis is not mentioned.\n\n11. Complete staging work-up to confirm localized disease should include computed tomography (CT) scans of the chest and abdomen/pelvis...\nThe patient has metastatic lesions on CXR, so she may not meet this criterion.\n\n12. Female patients who are not of child-bearing potential and female patients of child-bearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test performed within 7 days prior to start of trial treatment.\nThe patient is postmenopausal, so she is not of child-bearing potential.\n\n13. Willingness and ability to comply with trial and follow-up procedures.\nThis is not mentioned, but can be assumed unless stated otherwise.\n\n14. Ability to understand the investigative nature of this trial and give written informed consent.\nThis is not mentioned, but can be assumed unless stated otherwise.\n\n15. Agree to delay in reconstruction in terms of implants placed in setting of expanders until chemotherapy is completed and the patient has recovered. Expansion of expanders may continue during trial treatment.\nThis does not apply, as the patient has not had reconstruction yet.\n\nBased on the information provided, there are a few key criteria that are not met or not mentioned:\n- Prior neoadjuvant chemotherapy treatment and response\n- ECOG performance status\n- Staging workup results\n- Laboratory values for hematologic, hepatic and renal function\n- HER2-positive patients require LVEF testing\n\nSo while the patient meets some of the major criteria like age, cancer type and stage, there is insufficient information to fully determine eligibility.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "164": {
        "output": "To determine the patient's eligibility for the clinical trial \"Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid\", let's go through the inclusion criteria one by one:\n\n1. Postmenopausal women: The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Diagnosis of early stage, invasive ductal carcinoma (for which a lumpectomy or mastectomy is planned prior to systemic therapy): The patient note mentions that the patient has a 3 cm invasive ductal breast carcinoma and is a candidate for tumor resection (lumpectomy or mastectomy) prior to chemotherapy, so this criterion is met.\n\n3. Estrogen receptor (ER)/progesterone receptor (PR) positive tumor: The patient note states that the tumor is ER/PR negative, so this criterion is not met.\n\n4. Ability to provide informed consent: There is no information provided about the patient's ability to provide informed consent, but we can assume that as a standard procedure, the patient would be able to provide informed consent if eligible for the trial.\n\nSince the patient does not meet the criterion of having an ER/PR positive tumor, which is one of the inclusion criteria, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "165": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) \"All patients selected for this imaging study are patients scheduled to start trastuzumab-based therapy for advanced HER2 positive breast cancer\" - The patient note states that the patient has HER2-positive metastatic breast cancer and is a candidate for trastuzumab therapy, so this criterion is met.\n\n2) \"Histologically confirmed HER 2 positive (defined as FISH amplification ratio more than 2.2) invasive carcinoma of the breast (primary tumor at diagnosis) with locally recurrent or metastatic disease.\" - The patient has a confirmed HER2-positive invasive ductal breast carcinoma with metastatic disease, meeting this criterion.\n\n3) \"Patients with FDG-PET positive metastatic lesions.\" - There is no mention of FDG-PET imaging in the patient note, so this criterion cannot be evaluated.\n\n4) \"Brain metastases are allowed provided they are controlled and they are not the sole site of metastatic disease.\" - There is no mention of brain metastases in the patient note.\n\n5) \"Patient planned to have metastatic site biopsy for HER2 status control.\" - This is not mentioned in the patient note.\n\n6) \"Age \u2265 18 years\" - The patient is 45 years old, meeting this criterion.\n\n7) \"Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1\" - The patient's performance status is not provided.\n\n8) \"For women of childbearing potential a pregnancy test will be done and an agreement to use a highly-effective non hormonal form of contraception.\" - The patient is postmenopausal, so this criterion does not apply.\n\n9) \"Agreement from the patient to participate in this imaging study and if indicated agreement to biopsy one or two accessible lesions.\" - This is not mentioned in the patient note.\n\n10) \"Signed written informed consent (approved by the Ethics Committee) obtained prior to any study procedure\" - This is not mentioned in the patient note.\n\nExclusion Criteria:\n1) \"Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)\" - There is no mention of any severe uncontrolled systemic diseases in the patient note.\n\n2) \"Pregnant or lactating women\" - The patient is postmenopausal, so this criterion does not apply.\n\n3) \"Current known infection with HIV, HBV, or HCV\" - There is no mention of any such infections in the patient note.\n\n4) \"Known severe hypersensitivity to trastuzumab\" - This is not mentioned in the patient note.\n\n5) \"Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol\" - There is no information provided about the patient's ability or willingness to comply with the protocol.\n\n6) \"Patients with bone only metastases are not eligible\" - The patient has metastatic lesions noted on CXR, but it is unclear if these are bone metastases or other sites.\n\n7) \"Psychiatric illness/social situations that would limit compliance with study requirements\" - There is no mention of any psychiatric illness or social situations that could limit compliance.\n\n8) \"Patients who received lapatinib within the 7 days prior to HER immunoPET/CT.\" - There is no mention of the patient receiving lapatinib.\n\nBased on the information provided in the patient note, the patient meets some of the key inclusion criteria for the trial, such as having HER2-positive metastatic breast cancer and being a candidate for trastuzumab therapy. However, there are several inclusion and exclusion criteria that cannot be evaluated due to lack of information in the patient note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "166": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women or men with histologic evidence of invasive breast cancer (ductal, lobular or mixed disease).\nThe patient note states the patient has \"cytologically confirmed breast cancer\" and \"a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. Surgical resection including breast conserving surgery or modified radical mastectomy or simple mastectomy, within the last four months.\nThe patient note mentions the patient \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\", so this criterion is potentially met depending on when the surgery occurs.\n\n3. Axillary lymph nodes assessed for tumor by: (i) sentinel node biopsy, or (ii) axillary node dissection, or (iii) both\nThe patient note states \"Axillary sampling revealed 5 positive lymph nodes\", so this criterion is met.\n\n4. Axillary lymph node assessment negative for cancer, or positive only for micrometastases (i.e., cancer <2mm by H&E stain).\nThe patient has 5 positive lymph nodes, so this criterion is not met.\n\n5. Tumor is estrogen receptor (ER) positive.\nThe patient note states the tumor is \"ER/PR negative\", so this criterion is not met.\n\n6. Receiving or to receive adjuvant endocrine therapy (i.e., tamoxifen or aromatase inhibitor).\nThere is no mention of the patient receiving endocrine therapy in the note.\n\n7. Being considered for adjuvant chemotherapy.\nThe patient note states the patient agrees to have tumor resection \"prior to chemotherapy\", so this criterion is potentially met.\n\nOverall, while some criteria are potentially met, the key criteria of ER positive status and no/micro lymph node metastases are not met for this patient.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "167": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically proven adenocarcinoma of the colon expressing non-mutated (wild-type) KRAS.\n   - The patient has cytologically confirmed invasive ductal breast carcinoma, which is not a colon cancer. This criterion is not met.\n\n2. Progressive metastatic disease after first-line treatment with chemotherapy alone: based on 5-FU (iv or per os) with irinotecan or oxaliplatin associated to bevacizumab.\n   - There is no mention of the patient receiving any prior chemotherapy treatment. This criterion cannot be evaluated.\n\n3. Prior adjuvant chemotherapy (of the primary tumor) with fluoropyrimidine and oxaliplatin is allowed if the time interval between the end of this chemotherapy and the beginning of the first-line metastatic treatment is \u2265 6 months.\n   - There is no mention of the patient receiving any prior adjuvant chemotherapy. This criterion is not applicable.\n\n4. Measurable disease (at least one measurable metastatic lesion) according to the RECIST V1.1 criteria (the lesion should not be located in a previous field of radiation).\n   - The patient has a 3 cm primary breast tumor and axillary lymph node metastases, which would likely be considered measurable disease. This criterion is likely met.\n\n5. Previous radiotherapy is authorized if discontinued \u2265 15 days prior to randomization and if the measurable metastatic lesions are outside the radiation area.\n   - There is no mention of the patient receiving prior radiotherapy. This criterion is not applicable.\n\n6. Sites of disease evaluated within 28 days prior to randomization with thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI plus Chest Xray)\n   - The patient had a CXR showing metastatic lesions, but it is unclear if a full CT/MRI evaluation was done within 28 days. This criterion cannot be definitively evaluated.\n\n7. Age \u226518 years\n   - The patient is 45 years old, so this criterion is met.\n\n8. Patient with ECOG 0 or 1\n   - There is no information provided about the patient's ECOG performance status. This criterion cannot be evaluated.\n\n9. Life Expectancy \u2265 3 months\n   - There is no information provided about the patient's life expectancy. This criterion cannot be evaluated.\n\n10. Hematologic function criteria\n    - There is no information provided about the patient's hematologic function. This criterion cannot be evaluated.\n\n11. Hepatic function criteria\n    - There is no information provided about the patient's hepatic function. This criterion cannot be evaluated.  \n\n12. Renal function criteria\n    - There is no information provided about the patient's renal function. This criterion cannot be evaluated.\n\n13. Completion of the EORTC QLQ-C30 quality of life form\n    - There is no mention of the patient completing this form. This criterion is not met.\n\n14. Negative pregnancy test for women of child-bearing age\n    - The patient is described as postmenopausal, so this criterion is likely met.\n\n15. Information given to the patient and signed informed consent\n    - There is no mention of the patient providing informed consent. This criterion cannot be evaluated.\n\n16. Public Health insurance coverage\n    - There is no information provided about the patient's insurance coverage. This criterion cannot be evaluated.\n\nIn summary, while some criteria are likely met (e.g. measurable disease, age), there are many criteria that cannot be definitively evaluated based on the provided patient information. Additionally, the key criterion of having colon cancer with wild-type KRAS is not met, as the patient has breast cancer.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "168": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman undergoing treatment for breast cancer. This meets the age criteria of <=85 years old for the trial.\n\n2. However, the trial is specifically for patients undergoing staged bilateral total knee arthroplasty (BTKA). The patient note does not mention anything about knee surgery or BTKA.\n\n3. The trial also excludes patients with severe heart, liver or renal disease, as well as those with inflammatory joint disease or previous knee surgery/trauma. While the patient note does not explicitly state the absence of these conditions, it also does not provide enough information to confirm the patient meets the inclusion criteria.\n\n4. Additionally, the trial requires patients to be ASA physical status I or II, but the patient's ASA status is not provided in the note.\n\n5. Overall, while the patient's age meets the inclusion criteria, there is insufficient information in the note to determine if they meet all the other criteria for staged BTKA, and the primary condition (breast cancer) is not relevant to the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "169": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which is not relevant to the inclusion criteria for this bladder cancer trial.\n\n2. The trial is specifically for patients with muscle-invasive urothelial (bladder) cancer, stages pT2-pT3, without lymph node or distant metastases. The patient note does not mention bladder cancer or staging information.\n\n3. The other inclusion criteria relate to age \u2265 18 years, life expectancy \u2265 6 months, performance status, adequate organ function, no prior radiotherapy or chemotherapy for bladder cancer, ability to use contraception if premenopausal, and willingness to participate. However, without knowing if the patient has bladder cancer that meets the staging criteria, the other criteria are not relevant.\n\nTherefore, based on the information provided in the patient note, there is insufficient evidence to determine if this patient would be eligible for the bladder cancer trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "170": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Women with histologically proven invasive breast cancer and no distant metastases and;\n   - The patient has cytologically confirmed invasive ductal breast carcinoma, which satisfies this criterion.\n   - However, the patient has metastatic lesions noted on CXR, which would exclude them based on the \"no distant metastases\" part of this criterion.\n\n2. Lymphnode negative and a clinical tumor classification of T2 (\u22653.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level.\n   - The patient has 5 positive lymph nodes, which is outside the allowed range of 1-3 positive lymph nodes.\n\n3. Age \u2265 18 years.\n   - The patient is 45 years old, satisfying this criterion.\n\n4. At least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or MRI images to define specific size and validate complete pathologic response.\n   - The patient has a 3 cm tumor, which can likely be measured, satisfying this criterion.\n\n5. Adequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100 x109/l), adequate renal function (serum creatinine \u2264 1.5 x upper limit of normal) and hepatic function (ALAT, ASAT \u2264 2.5 x upper limit of normal, alkaline phosphatase \u2264 2.5 x upper limit of normal and total bilirubin \u2264 2.0 x upper limit of normal).\n   - There is no information provided about the patient's lab values, so this criterion cannot be evaluated.\n\n6. Signed informed consent of the patient\n   - It is mentioned that the patient agrees to tumor resection prior to chemotherapy, implying consent, so this criterion is likely satisfied.\n\nOverall, while the patient meets some of the inclusion criteria, they are excluded based on having distant metastases and having more than 3 positive lymph nodes.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "171": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n1) Patients aged over 18 years old with invasive breast cancer with an indication of SN procedure as recommended by Saint-Paul de VENCE in 2005 amended in 2009\n- The patient is 45 years old and has invasive breast cancer, meeting this criteria.\n\n2) T1-2 breast cancer \n- The tumor size is 3 cm, which likely falls into the T2 category, meeting this criteria.\n\n3) Patients having social security coverage.\n- There is no information provided about the patient's insurance coverage.\n\nBased on the available information, the patient meets criteria 1 and 2, but there is insufficient information to determine if they meet criteria 3 regarding social security/insurance coverage.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "172": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of \"Age between 18 and 80 years\" and \"Histologically proven breast cancer, regardless of histological type or molecular subtype\".\n\nThe tumor is 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative with 5 positive lymph nodes. This matches the criteria of \"Localised breast cancer with or without axillary or subclavicular lymph node involvement\" and \"Absence of bone or visceral metastasis on further evaluation\".\n\nThe patient is a candidate for tumor resection and agrees to neoadjuvant chemotherapy, which matches the criteria of \"Treatment by neoadjuvant chemotherapy\" and \"Breast surgery (breast-sparing or not) planned after neoadjuvant chemotherapy\".\n\nThere is no information suggesting the patient meets any of the exclusion criteria.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria and does not meet any of the exclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "173": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative (does not meet HER2-negative, HR-positive criteria)\n- Has metastatic lesions (meets metastatic disease criteria)\n- Has progressed after prior endocrine therapy (meets this criteria)\n- Has measurable disease (3cm tumor, meets criteria)\n- No ECOG performance status mentioned\n\nSince the patient does not meet the HER2-negative and HR-positive criteria, she would be excluded from this clinical trial despite meeting some of the other inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "174": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR (indicating stage IV disease)\n\nThe inclusion criteria for the breast cancer registry trial are:\n1) Male or Female > 18 years \n   - The patient is a 45-year-old woman, so meets this criteria\n2) Newly diagnosed stage I-IV breast cancer per AJCC criteria\n   - The patient has newly diagnosed stage IV breast cancer based on metastatic lesions, so meets this criteria\n3) No prior therapy (other than surgery) for current disease\n   - The note mentions the patient is a candidate for tumor resection prior to chemotherapy, so it seems she has not received any systemic therapy yet. This meets the criteria.\n4) Written informed consent (if required by local regulations)\n   - There is no information about consent, so we cannot determine if this criteria is met or not.\n\nSince the patient meets criteria 1-3 and there is no exclusion information provided, the most appropriate assessment is:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "175": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u2265 40 years per National Comprehensive Cancer Network (NCCN) recommendations for breast conservation.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Life Expectancy of at least 5 years, excluding diagnosis of breast cancer (Comorbid conditions should be taken into consideration, but breast cancer diagnosis is not a consideration)\nThere is no information provided about the patient's life expectancy or comorbid conditions, so I cannot determine if she meets this criterion.\n\n3. Female Gender - Men are excluded from this study. Male breast cancer is a rare event.\nThe patient is a woman, so she meets this criterion.\n\n4. Foci of Breast Cancer\n4.1 Upon clinical exam and pre-operative imaging by mammogram +/- MRI, two or three foci of biopsy proven breast cancer separated by > 2 cm of normal breast tissue.\n4.2 Foci must include at least one focus of invasive breast carcinoma with another focus of either invasive breast carcinoma or ductal carcinoma in situ (DCIS).\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which meets the requirement of having at least one focus of invasive breast carcinoma. However, there is no mention of additional foci of either invasive breast carcinoma or DCIS separated by > 2 cm of normal breast tissue.\n\n5. No more than 2 quadrants with biopsy proven breast cancer.\nThe note only mentions one quadrant (left upper outer quadrant) with biopsy-proven breast cancer, so this criterion is met.\n\n6. Mammogram Imaging - Bilateral mammogram \u2264 90 days prior to date of surgery.\nThere is no information provided about mammogram imaging, so I cannot determine if this criterion is met.\n\n7. Staging of Cancer - cN0 or cN1 disease\nThe note mentions that axillary sampling revealed 5 positive lymph nodes, which would likely correspond to cN1 disease, so this criterion is met.\n\n8. ECOG Performance Status (PS) - 0, 1, or 2.\nThere is no information provided about the patient's ECOG Performance Status, so I cannot determine if this criterion is met.\n\n9. Ability to Complete Questionnaires - Ability to complete questionnaire(s) by themselves or with assistance\nThere is no information provided about the patient's ability to complete questionnaires, so I cannot determine if this criterion is met.\n\n10. Ability to Provide Written Informed Consent\nThere is no information provided about the patient's ability to provide written informed consent, so I cannot determine if this criterion is met.\n\n11. Willing to Return to Enrolling Institution - Willing to return to enrolling institution for follow-up during the Active Monitoring Phase (the active treatment and observation portions) of the study. Patients are encouraged to return to the enrolling institution; however, patients may receive radiation therapy at a different institution other than the enrolling institution.\nThere is no information provided about the patient's willingness to return to the enrolling institution for follow-up, so I cannot determine if this criterion is met.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria (age, gender, staging of cancer), but there is not enough information to determine if she meets all of the criteria. Additionally, the note does not mention whether she has multiple ipsilateral breast cancer foci separated by > 2 cm of normal breast tissue, which is a key requirement for this trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "176": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age criteria of 18-75 years old.\n\nShe has cytologically confirmed invasive ductal breast cancer, which is a pathologically confirmed diagnosis of primary invasive operable breast cancer as required.\n\nThe tumor is 3 cm and has positive lymph node involvement, corresponding to stage II or III breast cancer as specified in the inclusion criteria.\n\nThe tumor is HER2-positive and ER/PR negative, meeting the criteria for triple negative phenotype.\n\nThere is no information provided about performance status, renal/liver function, or bone marrow reserve, so we cannot definitively confirm those criteria are met.\n\nHowever, based on the information given, this patient appears to meet the key inclusion criteria for this triple negative breast cancer clinical trial evaluating neoadjuvant docetaxel-carboplatin chemotherapy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "177": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must have histologically confirmed HER2 positive invasive carcinoma of the breast in the reference laboratory of the participating center.\n- The patient note states that the patient has \"cytologically confirmed breast cancer\" and that \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative.\"\n- This criterion is met.\n\n2. The patient must have documented progressive disease and present with at least 2 non-bone target metastatic lesions, unequivocally of neoplastic origin with a transaxial diameter greater than 2 cm on the screening diagnostic CT/MRI for all non-bone lesions except lymphnodes, a short axis greater than 1.5 cm for lymphnodes on the screening diagnostic CT/MRI. These two lesions should not be confluent with adjacent lesions and not have been irradiated previously.\n- The patient note mentions \"Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\"\n- This criterion is likely met, though the sizes of the metastatic lesions are not specified.\n\n3. A concurrent biopsy of a metastatic site is mandatory with tumor samples collected as specified.\n- This is not mentioned in the patient note, so it is unclear if this criterion is met.\n\n4. Primary tumor blocks or slides must be available for central HER2 testing.\n- This is not mentioned, so it is unclear if met.\n\n5. Age \u2265 18 years\n- The patient is 45 years old, so this is met.\n\n6. ECOG performance status 0-1\n- This is not mentioned, so unclear if met.\n\n7. No significant cardiac history and LVEF \u2265 50%\n- Cardiac history/LVEF not mentioned, so unclear if met.\n\n8. Adequate organ function based on specified lab values\n- No relevant lab values provided, so unclear if met.\n\n9. Absence of conditions hampering compliance\n- Not mentioned, so unclear if met.  \n\n10. Negative pregnancy test and contraception for women of childbearing potential\n- The patient is postmenopausal, so this is not applicable.\n\n11. Signed informed consent\n- Not mentioned, so unclear if met.\n\n12. Completion of baseline procedures\n- Not mentioned, so unclear if met.\n\nIn summary, some of the key inclusion criteria are clearly met based on the patient information provided (HER2+ breast cancer, metastatic disease). However, there are several other criteria where information is lacking to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "178": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women older than 18 years old and younger than 70 years old\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Invasive breast cancer confirmed by core biopsy, any histology\nThe patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, so she meets this criterion.\n\n3. Tumor \u22652 cm and/or lymph node positive (proven by FNA)(T2-4b, N0-3, M0)\nThe patient has a 3 cm tumor and 5 positive lymph nodes, so she meets this criterion.\n\n4. Must have ER/PR positive and HER2 negative\nThe patient's tumor is HER2-positive and ER/PR negative, so she does not meet this criterion.\n\n5. Must have full staging and extent disease and clinically and radiographically tumor measure\nThe patient has had axillary sampling and a CXR showing metastatic lesions, so it seems she has had full staging done. This criterion is met.\n\n6. Without previous treatment for breast cancer (including surgery, hormonotherapy or chemotherapy)\nThe note mentions the patient is a candidate for tumor resection prior to chemotherapy, so she has not had any previous treatment. This criterion is met.\n\n7. Normal liver, kidney and blood tests\nThere is no information provided about the patient's liver, kidney or blood test results.\n\n8. Performance Status ECOG 0-2 o Karnofsky \u226570%\nThere is no information provided about the patient's performance status.\n\n9. Fasten glucose levels <125 mg/dl \nThere is no information provided about the patient's fasting glucose levels.\n\n10. Signed consent\nThere is no information provided about whether the patient has provided signed consent.\n\nSince the patient does not meet the ER/PR positive and HER2 negative criterion, which is a key inclusion criterion, she would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "179": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the Bristol Bladder Trial step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This trial is for patients with transitional cell carcinoma of the urinary bladder, so the patient does not have the target disease.\n\nThe inclusion criteria specifically state:\n1) Age \u226518 years (met)\n2) Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary bladder (not met - patient has breast cancer)\n3) T2 to T4 disease, N0 M0 determined by CT imaging and biopsy (not applicable since patient doesn't have bladder cancer)\n4) ECOG Performance status 0 or 1 (no information provided)\n5) GFR \u226560ml/min (no information provided)\n\nSince the patient does not have transitional cell carcinoma of the bladder, which is a key inclusion criteria, she would not be eligible for this clinical trial.\n\nLooking at the exclusion criteria, there are several that may potentially apply like having a secondary cancer (breast cancer) and being postmenopausal, but we don't need to evaluate those since the primary inclusion criteria of having bladder cancer is not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "180": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in left upper outer quadrant\n- HER2-positive \n- ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria state:\n- Women or men > age 18 (met)\n- Archived tumor tissue available for genetic analysis (not mentioned)\n- Early-stage or locally advanced/metastatic breast cancer (met)\n- Histologic documentation of invasive breast cancer (met)\n- HER2-positive or triple-negative (HER2-positive met)\n- For early-stage:\n    - Clinical stage II-III \n    - Neoadjuvant chemo planned\n    - Post-chemo breast MRI\n    - Surgical resection planned\n- For advanced/metastatic:\n    - Stage III-IV\n    - Chemo +/- HER2 therapy planned\n    - Restaging scans every 8 weeks\n\nBased on the HER2-positive, metastatic breast cancer with planned surgery and chemotherapy, this patient meets the inclusion criteria for the advanced/metastatic cohort.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "181": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is HER2-positive and ER/PR negative. The patient has metastatic lesions in the lungs based on the CXR findings.\n\nThe clinical trial is looking to analyze breast tumor specimens using advanced mass spectrometry to identify potential biomarkers. The inclusion criteria states \"Patients with breast cancer\".\n\nSince the patient has been diagnosed with breast cancer, she meets the inclusion criteria for this trial.\n\nThere is no information provided about any exclusion criteria that may disqualify the patient.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "182": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of \"Invasive non-lobular breast cancer, histologically proven by biopsy\".\n\nThe tumor is 3 cm invasive ductal breast carcinoma, which is T2-T3 based on the TNM staging system. This matches the inclusion criteria of \"Tumour T2 - T3 regardless of nodal status, stemming from a primary surgery\".\n\nThe patient is a candidate for tumor resection prior to chemotherapy, which implies the trial is for pre-operative staging. This matches the criteria \"in whom FDG-PET is performed for staging\".\n\nThe patient's age of 45 years matches the criteria \"Age greater than or equal to 18 years\".\n\nThere is no information provided about the patient's overall condition, but it is stated that she is a candidate for surgery, implying a good overall condition matching \"Good condition: WHO lower 2.\"\n\nThere is no information about contraception use.\n\nBased on the available information, the patient appears to meet most of the key inclusion criteria except for the contraception use, which is not mentioned.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "183": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histological confirmation of primary breast cancer, stage II or III, completely resected: The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n2. Prior diagnosis of HER-2 positive primary breast cancer: The patient's tumor is HER2-positive, meeting this criterion. \n\n3. Completion of surgery +/- radiation at least 30 days prior to registration: The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is likely met.\n\n4. Must have received mastectomy or lumpectomy plus radiation: This is not explicitly stated, but can be inferred from the previous point.\n\n5. Must have received either neoadjuvant and/or adjuvant chemotherapy for treatment of breast cancer: The patient has not yet received chemotherapy, but is a candidate for it after tumor resection.\n\n6. Must have received either neoadjuvant and/or adjuvant trastuzumab for treatment of breast cancer: This is not mentioned in the patient note.\n\n7. All chemotherapy, trastuzumab, and/or corticosteroids must be completed at least 90 days prior to registration: Since the patient has not received these treatments yet, this criterion is not applicable at this point.\n\n8. Clinically without any evidence of disease recurrence/progression: The patient has metastatic lesions noted on CXR, so this criterion is not met.\n\n9-13. The patient note does not provide enough information to assess these criteria related to lab values and performance status.\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. The presence of metastatic lesions would likely exclude the patient from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "184": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of being an adult female with invasive breast cancer.\n\nThe tumor is 3 cm, HER2-positive, and ER/PR negative. This meets the inclusion criteria of having a tumor \u2265 1.0 cm.\n\nThe patient has 5 positive lymph nodes, which is allowed under the inclusion criteria.\n\nThe patient has not received any prior chemotherapy, hormonal therapy, or radiation therapy, meeting the criteria of being previously untreated.\n\nThe patient's performance status is not mentioned, but assuming it meets the ECOG \u2264 2 or Karnofsky \u2265 50% criteria.\n\nNo information is provided about peripheral neuropathy, hematologic values, hepatic function, renal function, or pregnancy status. However, since the patient is postmenopausal, the pregnancy criteria likely does not apply.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "185": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Diagnosed with breast cancer (invasive ductal carcinoma, HER2-positive, ER/PR negative)\n- Has metastatic lesions seen on CXR\n- No other major medical conditions mentioned\n- Candidate for tumor resection prior to chemotherapy\n\nThe clinical trial inclusion criteria are:\n1) Patients who are diagnosed with gastric adenocarcinoma\n   - The patient has breast cancer, not gastric cancer, so this criterion is not met.\n2) 65 years old and below\n   - The patient is 45 years old, so this criterion is met.\n3) Patients are expected to be undergone distal subtotal gastrectomy\n   - The patient is a candidate for tumor resection, but not a gastric resection, so this criterion is not met.\n4) No complication by gastric cancer\n   - The patient does not have gastric cancer, so this is not applicable.\n5) No synchronous metastatic lesions\n   - The patient has metastatic lesions seen on CXR, so this criterion is not met.\n6) Laparoscopic or robotic surgery\n   - No information is provided about the type of surgery.\n7) Informed consent\n   - No information is provided about consent.\n\nBased on the above, the patient does not meet several of the key inclusion criteria for this gastric cancer surgery trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "186": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must consent to be in the study and must have a signed an approved consent form conforming with institutional guidelines.\n   - No information provided about consent.\n\n2. Patient must be > 50 years old.\n   - The patient is 45 years old, so this criterion is not met.\n\n3. The patient should have a life expectancy of at least two years with a karnofsky performance status > 70.\n   - No information provided about life expectancy or performance status.\n\n4. The patient must have stage 0 or I breast cancer.\n   - The patient has cytologically confirmed breast cancer, but the stage is not specified.\n\n5. On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the breast.\n   - The tumor is confirmed as invasive ductal breast carcinoma.\n\n6. Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (>2mm, DCIS and invasive). Re-excision of surgical margins is permitted.\n   - The patient is a candidate for tumor resection, but it has not been performed yet.\n\n7. Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 2 cm or less.\n   - The tumor size is 3 cm, so this criterion is not met.\n\n8. Patients with invasive breast cancer are required to have axillary staging...\n   - Axillary sampling revealed 5 positive lymph nodes.\n\n9. The patient must have simulation within 8 weeks/56 days of the final surgery for their breast cancer.\n   - No information provided about timing of simulation.\n\n10. Patients with a history of non-ipsilateral breast malignancies are eligible if they have been disease-free for 2 or more years prior to enrollment.\n    - No information provided about history of other breast malignancies.\n\n11. Chemotherapy is permitted if planned for \u2265 2 weeks after radiation.\n    - No information provided about chemotherapy timing.\n\n12. Urine pregnancy test must be performed and be negative on all women younger than 60 who have not had a tubal ligation, oophorectomy, or hysterectomy.\n    - The patient is 45 years old and postmenopausal, but no information about pregnancy test.\n\n13. Separate incisions for the lumpectomy and sentinel node biopsy should be present.\n    - No information provided about incisions.\n\n14. The patient must have a cavity which is able to be targeted with external beam APBI, either through surgical clip placement, or CVS 3 or higher. The cavity to whole breast ratio must be 30% or less.\n    - No information provided about cavity or cavity to whole breast ratio.\n\nBased on the information provided, the patient does not meet at least two of the inclusion criteria (age and tumor size). There is also insufficient information to determine eligibility for several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "187": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of being a postmenopausal woman with invasive ductal carcinoma.\n\nThe tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR. This matches the inclusion criteria of tumor stage T2-4bN0-3M0.\n\nThe patient has not received any previous treatment like chemotherapy or bisphosphonates.\n\nThe patient's laboratory values are not provided, but it is mentioned that she is using multivitamins and iron supplements, suggesting her blood counts are likely within normal limits.\n\nThe only potential exclusion criteria is the Karnofsky performance status, which is not mentioned in the patient note.\n\nOverall, based on the information provided, this patient appears to meet most of the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "188": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria do not mention anything about gender or menopausal status, so this is not relevant for determining eligibility.\n\n2. The patient has cytologically confirmed invasive ductal breast carcinoma, which is not a criterion for this trial. This trial is focused on metastatic brain tumors that have failed stereotactic radiosurgery.\n\n3. The patient has HER2-positive, ER/PR negative breast cancer with positive lymph nodes and metastatic lesions on CXR. Again, this breast cancer information is not relevant for a trial on brain metastases.\n\n4. There is no mention of the patient having brain metastases that have failed stereotactic radiosurgery, which is a key inclusion criterion.\n\n5. The other inclusion criteria like signing informed consent, Karnofsky Performance Status, etc. cannot be evaluated based on the given patient note.\n\nBased on the information provided, this patient does not appear to meet the key inclusion criteria for this clinical trial on laser ablation after failed stereotactic radiosurgery for brain metastases.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "189": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria which states \"Patients must have histologically or cytologically confirmed unresectable (stage III) and/or metastatic (stage IV) melanoma or unresectable and/or metastatic Merkel cell carcinoma.\"\n\nHowever, the trial specifically excludes breast cancer patients. The inclusion criteria state \"Melanoma patients should have no mutation in BRAF and NRAS genes\" and \"Patients must have histologically or cytologically confirmed unresectable (stage III) and/or metastatic (stage IV) melanoma or unresectable and/or metastatic Merkel cell carcinoma.\"\n\nBased on the information provided, this patient does not meet the inclusion criteria for this particular clinical trial as she has breast cancer instead of melanoma or Merkel cell carcinoma.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "190": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. This matches the inclusion criteria of \"Histological confirmation of malignancy (non-small cell lung cancer, breast cancer (hormone refractory), prostate cancer (hormone refractory), lymphoma, renal cell carcinoma, myeloma by either biopsy or cytology of the primary or metastatic lesion.\"\n\n2. The patient has metastatic lesions seen on CXR, indicating metastatic disease. This matches the inclusion criteria of \"Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine including both positron emitted tomography (PET) or nuclear medicine bone scan (NMBS) and Magnetic Resonance Imaging (MRI) within 4 weeks prior to study entry.\"\n\n3. The note does not specify the number of spinal metastases, but it does mention metastatic lesions, which could potentially include spinal metastases fitting the criteria of \"Patients with one to three spinal metastases to the thoracic or lumbar spine will be included.\"\n\n4. There is no information provided about the size or location of the spinal metastases in relation to the spinal cord.\n\n5. There is no information provided about the patient's ability to fit into the specified immobilization devices.\n\n6. The patient's age of 45 meets the criteria of \"Must be \u2265 18 years of age.\"\n\n7. There is no information provided about the patient's ECOG status.\n\n8. There is no information provided about the patient's use of contraception.\n\n9. There is no information provided about a pregnancy test for this patient.\n\n10. It is assumed the patient would sign an informed consent form if enrolled.\n\nBased on the available information, there is not sufficient evidence to definitively determine eligibility, as several key criteria are not addressed in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "191": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of \"Patients with histologically proven invasive breast cancer\".\n\nThe tumor is 3 cm invasive ductal carcinoma and there are 5 positive axillary lymph nodes - this matches the criteria of \"the primary tumor size is at least 5cm or cytologically proven axillary node metastasis\".\n\nThere are metastatic lesions noted on CXR - this would exclude the patient based on the criteria \"no evidence of systemic metastasis pathologically or radiologically\".\n\nThe patient's age of 45 falls within the range of \"age at the time of diagnosis between 20 and 70 years\".\n\nThere is no mention of prior chemotherapy, so she likely meets the criteria of \"patients with previously untreated primary breast cancer including chemotherapy\".\n\nThere is no performance status mentioned, so it's unclear if she meets the ECOG 0-2 criteria.\n\nNo details are provided about hematologic, renal, liver or cardiac function to assess those criteria.\n\nIt states the patient agrees to tumor resection prior to chemotherapy, suggesting she would consent to the trial.\n\nOverall, while the patient meets some key inclusion criteria like tumor size and nodal status, the presence of metastatic lesions would likely exclude her from this particular neoadjuvant chemotherapy trial based on the criteria provided.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "192": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. \"histologically confirmed invasive carcinoma of the female breast, status post definitive surgery (lumpectomy or mastectomy plus nodal evaluation if feasible).\"\nThe patient note mentions that the patient has a \"3 cm invasive ductal breast carcinoma\" and has undergone axillary sampling, so this criterion is met.\n\n2. \"Patients must initiate therapy with ddTC within 84 days of the last breast or axillary surgery performed for curative intent\"\nThere is no information provided about the timing of the surgery, so this cannot be evaluated.\n\n3. \"candidate for chemotherapy by the treating oncologist\"\nIt is mentioned that the patient \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\", so this criterion is likely met.\n\n4. Criteria related to nodal status (pN2 or pN3) are not applicable since the patient has 5 positive lymph nodes.\n\n5. \"Patients with bilateral, synchronous invasive breast cancer are eligible as long as both primary tumors meet the eligibility criteria.\"\nThe patient has a single tumor, so this criterion is not applicable.\n\n6. Criteria related to ER, PR, and HER2 status are met since the tumor is described as \"HER2-positive and ER/PR negative\".\n\n7. \"There must be negative surgical margins for invasive cancer and DCIS. LCIS is acceptable at the margin.\"\nThere is no information provided about surgical margins.\n\n8. \"Patients with multi-centric breast cancer are eligible as long as all known disease is resected from the breast with negative margins.\"\nThe patient has a single tumor, so this criterion is not applicable.\n\n9. \"Age >18 years.\"\nThe patient is 45 years old, so this criterion is met.\n\n10. \"ECOG performance status \u2264 1\"\nThere is no information provided about the patient's performance status.\n\n11. Criteria related to pregnancy and contraception are likely not applicable since the patient is described as postmenopausal.\n\n12. \"Ability to understand and the willingness to sign a written informed consent document.\"\nThis cannot be evaluated based on the provided information.\n\n13-17. The criteria related to laboratory values (platelets, ANC, bilirubin, alkaline phosphatase, AST/ALT, creatinine) cannot be evaluated since no laboratory results are provided.\n\n18. \"If patient has received tamoxifen or another selective estrogen receptor modulator (SERM) for prevention or other indications (not for treatment of this cancer), they have been discontinued prior to enrollment.\"\nThere is no information provided about prior SERM use.\n\nIn summary, while some of the inclusion criteria are met based on the provided information, there are several criteria that cannot be evaluated due to missing information.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "193": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient has a histologically confirmed diagnosis of invasive ductal breast carcinoma, which is a type of invasive breast carcinoma. This meets the criteria.\n- The tumor is ER/PR negative, which does not meet the criteria of being ER and/or PR positive.\n- The tumor is HER2-positive, which meets the criteria of being HER2 negative.\n\nSince the patient does not meet all the disease characteristics criteria, they are not eligible for this trial.\n\nPATIENT CHARACTERISTICS:\nThere is no information provided about the patient's lab values, performance status, cardiac status, etc. So it's not possible to assess if they meet these criteria.\n\nPRIOR CONCURRENT THERAPY:\n- The patient has not received chemotherapy yet, whereas the criteria requires completion of standard neoadjuvant or adjuvant chemotherapy prior to randomization.\n- There is no information about prior exposure to mTOR inhibitors or other investigational drugs.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "194": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Pathologically confirmed diagnosis of invasive breast cancer - Yes, the patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma.\n\n2. Stage IV disease - Yes, the patient has metastatic lesions noted on CXR, indicating stage IV disease.\n\n3. Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be refractory to at least one prior hormonal treatment - Yes, the tumor is noted to be HER2-positive and ER/PR negative, so this criterion is met.\n\n4. ECOG Performance status 0-1 - This is not explicitly stated, but the patient is a candidate for tumor resection, implying a relatively good performance status.\n\n5. Measurable disease per RECIST (1.1) - Yes, the 3 cm primary tumor and metastatic lesions would qualify as measurable disease.\n\n6. Adequate hematological function per protocol - Not explicitly stated, but no concerning hematological issues are mentioned.\n\n7. Adequate hepatic function per protocol - Not stated.\n\n8. Adequate renal function per protocol - Not stated. \n\n9. Negative serum pregnancy test at study entry for patients of childbearing potential - The patient is noted to be postmenopausal, so this is likely not applicable.\n\n10. Ability to understand and sign written consent and to comply with the study protocol - Not explicitly stated, but there is no indication that the patient would be unable to do so.\n\nBased on the information provided, the patient meets most of the key inclusion criteria, but there is not enough information to definitively confirm adequate hepatic and renal function per protocol requirements.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "195": {
        "output": "To determine the patient's eligibility for the clinical trial \"Single Fraction Intraoperative Radiotherapy\", let's go through the inclusion criteria one by one:\n\n1. Histological proven invasive breast carcinoma ductal, lobular and/or Ductal Carcinoma in situ\n   - The patient has cytologically confirmed invasive ductal breast carcinoma, which meets this criterion.\n\n2. Age > 40 years\n   - The patient is 45 years old, which meets this criterion.\n\n3. Karnofsky performance status > 70%\n   - There is no information provided about the patient's Karnofsky performance status.\n\n4. Tumor. Single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm\n   - The patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which exceeds the maximum dimension of 2.5 cm.\n\n5. Nodal Status: preoperatively N0\n   - The patient has 5 positive lymph nodes, which does not meet this criterion.\n\n6. Clear surgical margins: R0\n   - There is no information provided about the surgical margins.\n\n7. All grades G1 - G3\n   - There is no information provided about the tumor grade.\n\n8. Any hormonal receptor and HER-2 status\n   - The patient's tumor is HER2-positive and ER/PR negative, which meets this criterion.\n\n9. Informed consent\n   - There is no information provided about whether the patient has given informed consent.\n\nBased on the information provided, the patient does not meet all the inclusion criteria due to the tumor size exceeding 2.5 cm and the presence of positive lymph nodes. Additionally, there is insufficient information about the patient's Karnofsky performance status, surgical margins, tumor grade, and informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "196": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman\n- Diagnosed with metastatic breast cancer\n- HER2-positive and ER/PR negative\n- Has metastatic lesions seen on CXR\n- Is a candidate for tumor resection prior to chemotherapy\n\nThe clinical trial inclusion criteria are:\n- Female patients with metastatic breast cancer\n- At least 18 years old (no upper age limit)\n\nBased on the information provided, the patient meets the inclusion criteria for this clinical trial of nab-paclitaxel (Abraxane) in metastatic breast cancer.\n\nThere is no exclusion criteria mentioned, so we can assume the patient is not excluded.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "197": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is for metastatic melanoma. The key inclusion criteria are:\n- Histologic diagnosis of locally unresectable, metastatic melanoma\n- At least 2 distinct measurable metastatic sites, with one \u2265 1 cm\n- Adequate organ/marrow function based on lab values\n- ECOG 0-1 or Karnofsky > 50%\n- Age > 18 years\n- Life expectancy > 3 months\n\nSince the patient has metastatic breast cancer and not metastatic melanoma, she does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "198": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which does not directly match or contradict any of the inclusion criteria listed.\n\nThe tumor details provided (3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative, 5 positive lymph nodes, metastatic lesions on CXR) do not match the criteria which is looking for melanoma patients.\n\nThere are no details provided about previous treatments received, which is a key criteria \"Previously untreated (adjuvant interferon is acceptable), and histologically confirmed Stage III (unresectable) or Stage IV melanoma\".\n\nThe patient's ECOG status, life expectancy, and baseline lab values are not mentioned, which are required per the criteria.\n\nThe only other relevant detail is that the patient is willing to undergo tumor resection prior to chemotherapy, but this trial is specifically for the drug ipilimumab.\n\nOverall, while some details are missing, the key factor is that this is a breast cancer patient, whereas the trial is specifically recruiting melanoma patients.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "199": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Core needle biopsy showing invasive mammary cancer or ductal carcinoma in situ: The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n2. Age >= 50 years and postmenopausal: The patient is a 45-year-old postmenopausal woman, meeting this criterion.\n\n3. Age and tumor size criteria: The patient is 45 years old with a 3 cm tumor, meeting the criterion of age > 70 years with tumor <= 3 cm.\n\n4. Hormone receptor status: The tumor is ER/PR negative and HER2-positive. Since the tumor size is <= 1.0 cm, the ER/PR negative status meets this criterion.\n\n5. HER2/neu negative: The tumor is HER2-positive, which does not meet this criterion.\n\n6. Tumor >= 0.5 cm from skin: No information is provided about the distance from the skin.\n\n7. Unicentric tumor: The note mentions a single tumor in the left upper outer quadrant, suggesting a unicentric tumor, meeting this criterion.\n\n8. Axillary lymph node status: The patient has 5 positive axillary lymph nodes, which does not meet the criterion of negative axillary lymph nodes.\n\n9. Negative surgical margins: No information is provided about surgical margins.\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. The HER2-positive status and positive axillary lymph nodes exclude the patient from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "200": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman\n- With cytologically confirmed invasive ductal breast cancer\n- 3 cm tumor in the left breast \n- HER2-positive\n- ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR (indicating metastatic disease)\n\nThe key inclusion criteria are:\n- Histologically confirmed HER2-negative primary invasive ductal or lobular breast cancer\n- For adjuvant treatment, must be pathologic stage IIA to IIIC\n- Planning to receive standard chemotherapy \n- At least 18 years old\n- ECOG performance status \u2264 1\n- Able to provide informed consent\n\nThe key exclusion criteria are:\n- Evidence of distant metastasis\n- Prior chemotherapy for this cancer\n- Prior trastuzumab or HER2 targeted therapy\n- Uncontrolled medical conditions\n- For women of childbearing potential, not using effective contraception\n\nBased on the patient details provided, this patient would be excluded from the trial primarily because she has evidence of metastatic disease based on the lung lesions seen on CXR. This violates the exclusion criteria of no distant metastases.\n\nAdditionally, her tumor is HER2-positive, while the trial requires HER2-negative primary tumors.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "201": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI\", the patient does not meet the eligibility criteria for this trial.\n\nThe key reasons are:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, while the trial is focused on patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease.\n\n2. The patient's condition is related to breast cancer, and there is no mention of any cardiac issues or STEMI in the patient note.\n\n3. The inclusion criteria specifically state that eligible participants must have significant stenoses (\u2265 70%) of two or more coronary arteries and require primary percutaneous coronary intervention (PCI) for acute STEMI within 12 hours.\n\nTherefore, based on the provided information, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "202": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n1) Female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer\n   - The patient is 45 years old and has metastatic breast cancer, so meets this criteria.\n\n2) Patients with a diagnosis of breast cancer with documented metastatic disease and with known date of metastatic disease\n   - The patient has documented metastatic disease, so meets this criteria. \n\n3) Patients with a histologically confirmed HER2+ breast cancer \n   - The patient has a cytologically (which is similar to histologically) confirmed HER2+ breast cancer, so meets this criteria.\n\nSince the patient meets all the inclusion criteria listed, and there are no explicit exclusion criteria given, the assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "203": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer \n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive (meets HER2 criteria)\n- ER/PR negative\n- 5 positive lymph nodes (meets N1 criteria)\n- Has metastatic lesions on CXR (does not meet M0 criteria)\n\nThe inclusion criteria state:\n- Female subjects aged 18 years or older (patient meets this)\n- Histologically/cytologically confirmed breast cancer (patient meets this)\n- HER2 positive, T1/T2/T3, N0/N1, resectable T4 or resectable N2, all M0 (patient meets T and N criteria but does not meet M0 criteria due to metastases)\n- Documentation of HER2 positivity (patient meets this)\n- Within normal LVEF range (no information provided)\n- Meeting certain lab value criteria (no information provided)\n\nSince the patient has metastatic lesions and therefore does not meet the M0 (non-metastatic) criteria, she would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "204": {
        "output": "To determine the patient's eligibility for the clinical trial \"Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. Postmenopausal state: The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Histological diagnosis of breast invasive ductal carcinoma with receptor profiles obtained: The patient note mentions that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, and the tumor is HER2-positive and ER/PR negative, so this criterion is met.\n\n3. MRI visible breast lesion: The patient note does not explicitly mention an MRI, but it does state that the tumor is 3 cm in size, which suggests that it would be visible on an MRI.\n\n4. Unifocal cancer, less than 1.5 cm in maximum diameter (clinical stage T1), with no evidence of extensive in situ cancer surrounding the main tumor: The patient note states that the tumor is 3 cm in size, which is larger than the 1.5 cm maximum diameter specified in the inclusion criteria. Additionally, the patient has 5 positive lymph nodes, which suggests that the cancer may have spread beyond the primary tumor site.\n\n5. Clinical stage N0 (no metastatic axillary lymph node on physical examination or imaging work-up): The patient note mentions that axillary sampling revealed 5 positive lymph nodes, which contradicts this inclusion criterion.\n\n6. Ability to give informed consent: The patient note does not provide any information about the patient's ability to give informed consent.\n\nBased on the information provided in the patient note, the patient does not meet all the inclusion criteria for the clinical trial. Specifically, the tumor size is larger than the specified maximum diameter, and the patient has metastatic lymph nodes, which is excluded by the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "205": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about using ultrasound to detect peripheral IV infiltration.\n\nLooking at the inclusion criteria for the trial:\n1. 18 years or older - The patient is 45, so she meets this criteria.\n2. signed consent - There is no information about whether the patient has provided signed consent.\n3. health form approved by professional practitioner - There is no information about whether the patient has an approved health form.\n\nSince there is not enough information provided about whether the patient meets criteria 2 and 3, I cannot definitively determine if she is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "206": {
        "output": "To determine the patient's eligibility for the clinical trial \"Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. \"female patients with metastatic breast cancer seeing one of the study physicians at one of the identified study clinics\"\nThe patient note mentions that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and the CXR was remarkable for metastatic lesions. This criterion is met.\n\n2. \"age 21 or older\"\nThe patient is 45 years old, which meets this criterion.\n\n3. \"having suspected progression of metastatic disease\"\nThe patient note does not explicitly mention suspected progression of metastatic disease. However, the presence of metastatic lesions on CXR suggests that the patient has metastatic disease.\n\nBased on the information provided in the patient note, the patient appears to meet the inclusion criteria for the clinical trial \"Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "207": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of being an adult female with newly diagnosed invasive ductal breast carcinoma.\n\nThe tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes - this suggests Stage II breast cancer, which is within the included Stage I-II range.\n\nThe patient has undergone a core biopsy and is a candidate for tumor resection surgery prior to chemotherapy - this matches the criteria of having completed surgical therapy.\n\nNo other major health issues are mentioned that would impact eligibility.\n\nBased on the information provided, this patient appears to meet all of the key inclusion criteria for the Vitamin D3 supplementation trial in newly diagnosed operative invasive ductal breast carcinoma patients.\n\nTrial-level eligibility: 2) Eligible",
        "label": 1
    },
    "208": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, meeting the age criteria of \u226518 years.\n\nThe tumor is invasive ductal carcinoma, which is included. It is HER2-positive and ER/PR negative, but the trial requires triple negative (ER-, PR-, HER2-) status.\n\nThe patient has metastatic lesions in the axillary lymph nodes and lung, meeting the criteria of up to 6 sites of extracranial metastatic disease.\n\nThe patient has not started ixabepilone treatment yet, meeting that criteria.\n\nThe patient's performance status is not mentioned but is likely 0-2 given the details provided.\n\nNo details are provided about organ function or prior treatments to assess those criteria.\n\nNo details about contraceptive use.\n\nIn summary, while the patient meets some key criteria like age and metastatic sites, the HER2-positive status is an exclusion criteria for this triple negative breast cancer trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "209": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Patient must be female. \nThe patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Patient must be at least 18 years of age.\nThe patient is 45 years old, so this criterion is met.\n\n3. Patient's clinical stage must be documented as tumor size less than 5 cm, with no palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0). For patients who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be used.\nThe patient note states that the tumor is 3 cm invasive ductal breast carcinoma, and there are 5 positive lymph nodes. However, it also mentions metastatic lesions on CXR, which would exclude the patient based on this criterion.\n\n4. Patient must have a negative (normal) axillary ultrasound performed at Siteman Cancer Center. Lymph nodes will be evaluated based on morphologic features. AUS wil be considered positive (abnormal)if lymph nodes are noted to be completely hypoechoic (absent hilum) or have focal hypoechoic cortical thickening/lobulation greater than 4 mm.\nThere is no information provided about the axillary ultrasound results in the patient note.\n\n5. Patient must have a tissue diagnosis of invasive breast carcinoma\nThe patient note states that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n6. Patient must have Eastern Cooperative Oncology Group (ECOG) status </= 2, as documented in patient's medical record.\nThere is no information provided about the patient's ECOG status in the note.\n\n7. Patient must be available for follow-up.\nThere is no information about the patient's availability for follow-up.\n\n8. A patient with a history of previous malignancy is eligible for this study as long as the patient meets the following criteria for a cancer survivor...\nThe note does not mention any previous malignancies for this patient.\n\n9. Patient, or the patient's legally acceptable representative, must provide a signed and dated written informed consent prior to registration and any study-related procedures.\nThere is no information about informed consent in the note.\n\n10. Patient must provide written authorization to allow the use and disclosure of their protected health information.\nThere is no information about this in the note.\n\n11. Patient must be a candidate for sentinel lymph node biopsy (SLNB).\nThe note states that the patient \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\", but does not specifically mention sentinel lymph node biopsy.\n\nBased on the information provided in the patient note, the patient meets some but not all of the inclusion criteria. The presence of metastatic lesions on CXR would exclude the patient according to criterion 3. There is also insufficient information to determine eligibility for some of the other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "210": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age between 18-70 years female operable breast cancer patients\nThe patient is a 45-year-old postmenopausal woman with breast cancer, so she meets this criterion.\n\n2. Patients were required to register within 60 days from the final surgical procedure required to adequately treat the invasive primary tumor.\nThere is no information provided about when the patient registered relative to her surgery, so I cannot determine if she meets this criterion.\n\n3. Women who had operable, histologically confirmed adenocarcinoma of the breast with:\n    a. histologically involved positive lymph nodes\n    b. or histologic diagnosis for three negative patients\n    c. or lymph node negative, HER2 positive (if HER2 ++, FISH/CISH tests confirmed HER2 amplification is positive), but unable or intolerant to herceptin combined chemotherapy.\nThe patient has a 3 cm invasive ductal breast carcinoma and 5 positive lymph nodes, so she meets criterion 3a.\n\n4. Karnofsky points greater than or equal to 70.\nThere is no information provided about the patient's Karnofsky score, so I cannot determine if she meets this criterion.\n\n5. Postmenopausal women or HCG test results were negative, Women of child-bearing potential willing to use effective contraception during the study.\nThe patient is described as postmenopausal, so she meets this criterion.\n\n6. Hematopoietic criteria (neutrophil and platelet counts within ranges)\nThere is no information provided about the patient's neutrophil or platelet counts, so I cannot determine if she meets these criteria.\n\n7. Hepatic criteria (bilirubin, ALP, AST, ALT within ranges)\nThere is no information provided about the patient's hepatic function, so I cannot determine if she meets these criteria.\n\n8. Renal criteria (creatinine within range)\nThere is no information provided about the patient's renal function, so I cannot determine if she meets this criterion.\n\n9. Cardiovascular criteria (no history of certain conditions)\nThere is no information provided about the patient's cardiovascular history, so I cannot determine if she meets these criteria.\n\n10. No other prior invasive malignancies within the past 5 years (except certain exceptions)\nThere is no information provided about any prior malignancies for the patient, so I cannot determine if she meets this criterion.\n\n11. No hypersensitivity to paclitaxel, docetaxel or similar drugs\nThere is no information provided about any drug hypersensitivities for the patient, so I cannot determine if she meets this criterion.\n\nIn summary, while the patient meets some of the key inclusion criteria related to her breast cancer diagnosis and lymph node involvement, there is insufficient information provided to fully determine her eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "211": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- The tumor is HER2-positive (meets HER2-positive criteria) \n- The tumor is ER/PR negative (meets ER/PR criteria)\n- Has 5 positive axillary lymph nodes\n- Has metastatic lesions on CXR\n\nThe inclusion criteria state:\n- HER2-positive Stage I histologically confirmed invasive breast cancer (Patient meets this)\n- ER/PR determination is required (Patient has ER/PR negative status provided)\n- HER2 positive confirmed by testing (Patient is HER2-positive)\n- Can have bilateral, multifocal or multicentric disease if each tumor meets criteria \n- No prior DCIS except ipsilateral DCIS treated with wide excision alone\n- Must have tumor tissue available to provide slides\n- Less than 90 days since most recent breast surgery (Not stated for patient)\n- All tumor removed by mastectomy or lumpectomy with lymph node evaluation (Patient is a candidate for resection)\n- Clear margins \n- May have received up to 4 weeks hormonal therapy (Not stated for patient)\n- Willing to use contraception if applicable (Not stated for patient)\n- No contraindications to radiation if getting lumpectomy (Not stated for patient)\n\nBased on the information provided, the patient meets the key inclusion criteria of having HER2-positive, ER/PR negative invasive breast cancer. However, some additional details like time since surgery, use of prior hormonal therapy, willingness to use contraception, and potential contraindications to radiation are not provided.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to fully qualify for the trial)",
        "label": 0
    },
    "212": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, which meets the age criteria for the trial.\n\n2. She has cytologically confirmed invasive ductal breast cancer, which meets the inclusion criteria of having an invasive breast cancer.\n\n3. However, the tumor size is 3 cm, which exceeds the 1.5 cm or less criteria for the trial.\n\n4. The tumor is HER2-positive and ER/PR negative, which does not meet the criteria of being estrogen receptor positive and HER2/neu negative.\n\n5. The patient has metastatic lesions noted on CXR, which meets the criteria of allowing patients with metastatic disease at diagnosis.\n\n6. The patient agrees to have the primary tumor resected prior to chemotherapy, which is compatible with the trial.\n\nBased on the information provided, while the patient meets some of the inclusion criteria, she does not meet all of them due to the tumor size being larger than 1.5 cm and the tumor being HER2-positive and ER/PR negative.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "213": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed breast cancer with clinical evidence of stage 4 disease\n- The patient note states that the patient has cytologically confirmed breast cancer and mentions metastatic lesions, indicating stage 4 disease. This criterion is met.\n\n2. Measurable disease and at least one lesion in either liver or lung that is amenable to stereotactic body radiation\n- The patient note does not specify the location of the metastatic lesions. This criterion cannot be definitively assessed based on the information provided.\n\n3. One site of disease that will not receive radiation\n- Again, the location of metastatic lesions is not specified, so it is unclear if this criterion is met.\n\n4. Patients with hormone receptor positive breast cancer must have received prior anti-hormonal therapy for metastatic disease and have progressed and patients with hormone receptor negative breast cancer must have received at least one prior chemotherapy regimen and progressed.\n- The patient note states that the tumor is HER2-positive and ER/PR negative, indicating hormone receptor negative breast cancer. It does not mention any prior chemotherapy regimens. This criterion cannot be assessed definitively.\n\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n- The patient's performance status is not provided in the note.\n\n6. Women of childbearing potential must have a negative pregnancy test on the day treatment starts and must avoid becoming pregnant while on treatment. Men must avoid fathering a child while on treatment.\n- The patient is described as a 45-year-old postmenopausal woman, so this criterion is likely met.\n\n7. Patients must have blood test results within pre-specified range\n- No blood test results are provided in the patient note.\n\n8. No active bleeding\n- The patient note does not mention any active bleeding.\n\n9. No clinical coagulopathy (INR <1.5, PT <16 seconds, PTT < 38 seconds) within 28 days\n- No coagulation test results are provided in the patient note.\n\n10. Anticipated lifespan greater than 12 weeks\n- The patient's anticipated lifespan is not specified in the note.\n\nBased on the information provided in the patient note, there is insufficient information to definitively determine eligibility for this clinical trial. Some criteria are met, some are not met, and some cannot be assessed due to lack of information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "214": {
        "output": "Okay, let's go through the inclusion criteria for this Phase II clinical trial for large ER-negative breast cancers step-by-step:\n\n1. Written informed consent - Not mentioned in patient note\n2. Diagnosis of invasive breast adenocarcinoma by biopsy - Yes, \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma\"\n3. Life expectancy of at least 1 year - Not mentioned\n4. Mass >1 cm confined to breast/ipsilateral axilla - Yes, \"3 cm invasive ductal breast carcinoma\" and \"Axillary sampling revealed 5 positive lymph nodes\"\n5. Can enter before ER/HER2 status known, but if HER2+ then withdrawn - Tumor is HER2-positive, so would be withdrawn\n6. Allows distant mets if local treatment judged necessary - Yes, \"CXR was remarkable for metastatic lesions\"\n7. Allows inflammatory breast cancer - Not mentioned\n8. Prior testing like history, imaging, etc. - Partially mentioned like CXR\n9. Baseline labs like WBC, platelets, LFTs, Cr Cl - Not mentioned\n\nOverall, while the patient meets some key inclusion criteria like tumor size, lymph node involvement, and allowing metastatic disease, the HER2-positive status would lead to withdrawal from this trial specifically for ER-negative breast cancers. There is also incomplete information provided about other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "215": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must have signed an IRB-approved consent form - This is not mentioned in the patient note, so there is not enough information to assess this criteria. \n\n2. The patient must have an ECOG performance status of 0 or 1 - This is not mentioned, so there is not enough information.\n\n3. The patient must have clinically T1-3, N1 breast cancer at diagnosis before neoadjuvant therapy - The note states the patient had a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, so this criteria is met.\n\n4. Pathologic confirmation of axillary nodal involvement before neoadjuvant therapy - This is met as the note mentions 5 positive lymph nodes on axillary sampling.\n\n5. ER analysis performed before neoadjuvant therapy - This is met, the note states the tumor is ER/PR negative.\n\n6. HER2 testing performed before neoadjuvant chemotherapy - This is met, the note states the tumor is HER2 positive.\n\n7. Completed at least 8 weeks of neoadjuvant chemo with anthracycline and/or taxane - This is not mentioned, so not enough information.\n\n8. For adjuvant chemo after surgery, maximum 12 weeks completed before randomization - This is not mentioned.\n\n9. HER2+ patients must have received neoadjuvant anti-HER2 therapy - This is not mentioned for this HER2+ patient.\n\n10. At surgery, all removed axillary nodes must be histologically free of cancer - This is not mentioned.\n\n11. Residual invasive carcinoma or pathologic complete response is allowed - This is not mentioned. \n\n12. ypN0(i+) or ypN0(mol+) staging is allowed - This is not mentioned.\n\n13. Total mastectomy or lumpectomy is allowed - The note states the patient is a candidate for tumor resection prior to chemo.\n\n14. For lumpectomy, margins must be free of invasive tumor and DCIS - This is not mentioned.\n\n15. For mastectomy, margins must be free of residual tumor - This is not mentioned.\n\n16. Interval between last surgery and randomization must be <= 70 days - This is not mentioned.\n\n17. Patient must have recovered from surgery - This is not mentioned.\n\n18. Chemo-related toxicity resolved if adjuvant chemo given - This is not mentioned.\n\nIn summary, while some key criteria like tumor stage, nodal status, ER/PR/HER2 status are provided, there is insufficient information to fully assess eligibility as many other criteria are not addressed in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "216": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Greater than or equal to 18 years old.\nThe patient is 45 years old, so this criterion is met.\n\n2. Histologic diagnosis of invasive breast cancer, clinical stage T0-3 N1 (maximum one or two abnormal axillary nodes on ultrasound exam) M0.\nThe patient has a histologic diagnosis of invasive ductal breast carcinoma with 5 positive axillary lymph nodes, which meets the N1 criteria. There is no mention of metastatic disease, so the M0 criterion is assumed to be met.\n\n3. FNA biopsy (or core needle biopsy) of an axillary node documenting nodal disease at time of diagnosis and prior to preoperative chemotherapy or surgery.\nThe patient had axillary sampling that revealed 5 positive lymph nodes, meeting this criterion.\n\n4. Marker clip placed in the one or two abnormal axillary nodes identified at ultrasound.\nThere is no mention of a marker clip being placed, so this criterion is not explicitly met based on the information provided.\n\nOverall, the patient meets most of the key inclusion criteria, except for the marker clip placement which is not mentioned. However, this could potentially be done prior to the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "217": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must have histologically confirmed adenocarcinoma of the breast associated with the following clinical stage: IIA, IIB, IIIA, IIIB, or IIIC; patients with stage IV disease are also eligible if there is an intention to perform breast surgery after neoadjuvant therapy is completed, or in patients participating in clinical trials where surgery after neoadjuvant therapy may be an option (eg. E2108)\n- The patient has cytologically confirmed invasive ductal breast carcinoma, which is a type of adenocarcinoma. The stage is not explicitly stated, but the presence of metastatic lesions on CXR suggests stage IV disease. However, the patient agrees to tumor resection prior to chemotherapy, so this criterion is met.\n\n2. Estrogen receptor (ER), progesterone receptor (PR), and HER2/neu status documented by core needle biopsy of the primary tumor and/or regional lymph node must be known prior to beginning systemic therapy\n- The patient's tumor is described as HER2-positive and ER/PR negative, so this criterion is met.\n\n3. Patients must have had a bilateral diagnostic mammogram within 6 months of registration, and may also have a targeted sonography of the breast and/or ipsilateral axilla and magnetic resonance imaging (MRI) if clinically indicated\n- No information is provided about diagnostic imaging, so this criterion cannot be evaluated.\n\n4. Patients with clinically suspicious axillary lymph node involvement must have either aspiration cytology or biopsy prior to beginning therapy\n- The patient had axillary sampling which revealed 5 positive lymph nodes, so this criterion is met.\n\n5. It is strongly encouraged that all patients have metallic clips placed in the tumor prior to neoadjuvant therapy in order to facilitate evaluation for microscopic disease at the time of surgery; placement of clips is particularly encouraged for patients being considered for breast conserving surgery\n- No information is provided about metallic clips, but this is only a recommendation, not a requirement.\n\n6. No prior chemotherapy, irradiation, or definitive therapeutic surgery (eg, mastectomy or lumpectomy or axillary dissection) for this malignancy; patients who have had a prior sentinel lymph node biopsy for this malignancy are eligible\n- The patient has not received any prior treatment, so this criterion is met.\n\n7. Patients who received tamoxifen or another selective estrogen receptor modulator (SERM) for prevention or for other indications (e.g., osteoporosis, prior ductal carcinoma in situ [DCIS]) are eligible; tamoxifen therapy or other SERMs should be discontinued at least 1 week before the patient is enrolled on this study\n- No information is provided about prior SERM use, but the patient is ER/PR negative, so this may not be applicable.\n\n8. The patient is medically suitable candidate for preoperative chemotherapy and surgery in the judgment of the treating physicians\n- No information is provided about the treating physicians' judgment, but the patient agrees to tumor resection prior to chemotherapy.\n\n9. Ability to understand and the willingness to sign a written informed consent document, and willing to provide blood samples before and during preoperative therapy; patients are also asked but not required to have research biopsies performed before and after therapy\n- No information is provided about the patient's ability to provide informed consent or willingness to provide blood samples/biopsies.\n\nOverall, based on the information provided, the patient appears to meet most of the key inclusion criteria, with a few criteria that cannot be evaluated due to lack of information.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "218": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by AJCC staging 7th edition\n- The patient has cytologically confirmed breast cancer and axillary lymph node involvement (N1), meeting this criteria.\n\n2. No inflammatory breast cancer\n- This is not mentioned for the patient, so assume this criteria is met.\n\n3. No other malignancy within 5 years except basal/squamous skin cancer or cervical carcinoma in situ\n- No other malignancies are mentioned, so assume this criteria is met. \n\n4. Had axillary ultrasound with FNA/core biopsy documenting axillary metastasis before or within 14 days of starting neoadjuvant chemo\n- It states \"Axillary sampling revealed 5 positive lymph nodes\", meeting this criteria.\n\n5. ER, PR, HER2 status evaluated on diagnostic core biopsy prior to neoadjuvant chemo\n- It mentions \"The tumor is HER2-positive and ER/PR negative\", meeting this criteria.\n\n6. Completed planned neoadjuvant chemo regimen of at least 4 cycles with anthracycline and/or taxane without progression\n- This is not explicitly stated, but typical for breast cancer treatment. Assume this criteria is met.\n\n7. If HER2+, received neoadjuvant trastuzumab/pertuzumab or other approved anti-HER2 therapy\n- This is not mentioned, but is standard of care for HER2+ breast cancer, so assume it was given and criteria met.\n\n8. Clinically negative axilla after neoadjuvant chemo\n- This is stated: \"All patients must have a clinically negative axilla (no bulky adenopathy) on physical examination documented at the completion of neoadjuvant chemotherapy\"\n\n9. No more than 8 weeks neoadjuvant endocrine therapy before chemo\n- Not mentioned, so assume this criteria is met.\n\n10. No neoadjuvant radiation\n- Not mentioned, so assume no radiation was given yet.\n\n11. No prior sentinel node biopsy to confirm axillary status during neoadjuvant chemo\n- This is not explicitly stated, but is implied by meeting criteria 4 about axillary sampling.\n\n12. No prior ipsilateral invasive breast cancer or DCIS \n- Not mentioned, so assume no prior ipsilateral breast cancer.\n\n13. No prior ipsilateral axillary surgery\n- Not mentioned, so assume criteria met.\n\n14. No prior/concurrent contralateral invasive breast cancer\n- Not mentioned, so assume criteria met. Contralateral benign/LCIS/DCIS allowed.\n\n15. Not pregnant or nursing\n- Stated the patient is postmenopausal, so criteria met.\n\n16. ECOG performance status 0-1\n- Not mentioned, but assume met as patient is a candidate for surgery.\n\nThe intra-operative and post-operative criteria relate to the actual surgery findings, which are not provided in this case.\n\nBased on the information given, this patient appears to meet all of the pre-operative inclusion criteria for this breast cancer clinical trial.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "219": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Females \u2265 18 years of age\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically confirmed invasive breast cancer\nThe patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n3. Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection\nThe patient is a candidate for tumor resection, and axillary sampling revealed 5 positive lymph nodes, so she meets this criterion.\n\n4. Planning neoadjuvant chemotherapy\nThe note does not explicitly mention neoadjuvant chemotherapy, but it does state that the patient agrees to tumor resection prior to chemotherapy, which implies neoadjuvant chemotherapy.\n\n5. HER2 positive disease\nThe tumor is HER2-positive, so this criterion is met.\n\n6. Measurable disease in the breast after diagnostic biopsy, defined as longest diameter \u2265 2.0 cm\nThe tumor is 3 cm, which meets this criterion.\n\n7. Known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry\nThe note states that the tumor is ER/PR negative, so this criterion is met.\n\n8. Normal bone marrow function\nThere is no information about the patient's bone marrow function in the note.\n\n9. Normal hepatic function\nThere is no information about the patient's hepatic function in the note.\n\n10. Normal renal function\nThere is no information about the patient's renal function in the note.\n\n11. Subjects must sign an Institutional Review Board/Ethics Committee (IRB/EC)-approved informed consent form before any study specific procedures\nThis is a procedural requirement and cannot be determined from the patient note.\n\n12. Inclusion Criteria for Randomization:\nLeft ventricular ejection fraction (LVEF) of \u226555% by 2D echocardiogram\nThere is no information about the patient's LVEF in the note.\n\n13. Complete all 4 cycles of run-in chemotherapy\nThere is no information about the patient completing any run-in chemotherapy in the note.\n\nBased on the information provided in the patient note, the patient meets several of the inclusion criteria, but there is not enough information to determine eligibility for some of the other criteria related to normal organ function and procedural requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "220": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Patients have histological confirmation of breast carcinoma.\n   - The patient note states \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\"\n   - This criterion is met.\n\n2. Patients have progressive metastatic disease with predominantly bone metastasis with 1 or more lesions and at least 1 bone lesion has pathological confirmation, have not been treated or have been treated with any prior therapies (including bisphosphonate treatment and/or radiation therapy). Patients can have soft tissue involvement (Lymph node and skin) and/or metastatic lesions at major organ sites (i.e. lung, liver, etc).\n   - The patient note mentions \"CXR was remarkable for metastatic lesions\", indicating metastatic disease.\n   - This criterion is met.\n\n3. Patients have positive ER expression in the primary tumor site by IHC (defined as >/=10%) (PR status is not required)\n   - The patient note states \"The tumor is HER2-positive and ER/PR negative.\"\n   - This criterion is not met.\n\n4. Adequate hematologic function: 1)Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L, 2) Platelet count >/= 50 x 10^9/L, 3) Hemoglobin >/= 9.0 g/dL\n   - There is no information provided about the patient's hematologic function.\n   - This criterion cannot be assessed based on the given information.\n\n5. Adequate cardiac function (LVEF >/= 45%) if patient has known cardiac dysfunction history\n   - There is no information provided about the patient's cardiac function or history of cardiac dysfunction.\n   - This criterion cannot be assessed based on the given information.\n\n6. Adequate Renal function: Calculated creatinine clearance >30 ml/min\n   - There is no information provided about the patient's renal function or creatinine clearance.\n   - This criterion cannot be assessed based on the given information.\n\n7. Adequate Hepatic function: 1) Aspartate aminotransferase (AST) </= 2.5 x ULN; 2) Alanine aminotransferase (ALT) </= 2.5 x ULN; 3) Alkaline phosphatase (Alp) </= 2.5 x ULN; 4) Total bilirubin </= 2.0 x ULN\n   - There is no information provided about the patient's hepatic function or liver enzyme levels.\n   - This criterion cannot be assessed based on the given information.\n\n8. Serum calcium or albumin-adjusted serum calcium >/=2.0mmol/L (8.0mg/dL) and </= 2.9 mmol/L (11.5mg/dL)\n   - There is no information provided about the patient's serum calcium levels.\n   - This criterion cannot be assessed based on the given information.\n\n9. Patients have ability and willingness to sign written informed consent.\n   - There is no information provided about the patient's willingness to sign informed consent.\n   - This criterion cannot be assessed based on the given information.\n\n10. Patients are 18 years of age or older.\n    - The patient note states \"The patient is a 45-year-old postmenopausal woman.\"\n    - This criterion is met.\n\n11. Female patients of childbearing potential (A female not free from menses > 2 years or not surgically sterilized) must be willing to use highly effective contraception to prevent pregnancy or agree to abstain from heterosexual activity throughout the study. Highly effective contraception, defined as male condom with spermicide, diaphragm with spermicide, intra-uterine device. Highly effective contraception must be used by both sexes during the study and must be continued for 5 months after the last dose of denosumab.\n    - The patient note states \"The patient is a 45-year-old postmenopausal woman.\"\n    - This criterion is not applicable as the patient is postmenopausal.\n\n12. Female patients of childbearing potential must have negative serum pregnancy test </= 21 days prior to starting study",
        "label": 0
    },
    "221": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female \u226518 years of age: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0-2: No information is provided about the patient's performance status.\n\n3. Postmenopausal, verified by specific criteria: The patient is described as postmenopausal, so she meets this criterion.\n\n4. Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy: The patient has a core biopsy-confirmed 3 cm invasive ductal breast carcinoma, so she meets this criterion.\n\n5. Clinical T2-T4c, any N, M0 invasive breast cancer, by AJCC 7th edition clinical staging, with the goal being surgery to complete excision of the tumor in the breast and the lymph node: The patient has a 3 cm tumor and positive lymph nodes, but no distant metastases, so she likely meets this criterion.\n\n6. Primary tumor must be palpable and \u2265 2.0 cm: The 3 cm tumor is described as palpable, so this criterion is met.\n\n7. Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7 or 8: The tumor is described as ER/PR negative, so this criterion is not met.\n\n8. Invasive breast cancer is Human Epidermal Growth Factor Receptor 2 (HER2)-positive: The tumor is described as HER2-positive, so this criterion is met.\n\n9. Documentation of mammogram and ultrasound within 56 days prior to registration: No information is provided about recent imaging studies.\n\n10. Laboratory values within specified ranges: No information is provided about the patient's laboratory values.\n\n11. Tissue acquisition: The patient agrees to provide research biopsies, so this criterion is met.\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. The main issue is that the tumor is described as ER/PR negative, while the trial requires ER positivity.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "222": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must have histologically confirmed breast cancer that is ER positive and/or PR positive, and HER2/neu negative and have disease that is metastatic (stage IV).\nThe patient note states that the patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, with metastatic lesions seen on CXR. This does not meet the inclusion criteria.\n\n2. HER2/neu negative disease determined using commercially available/approved assay...\nThe patient is noted to be HER2-positive, which excludes them from this trial.\n\n3. ER/PR expression performed by standard immunohistochemical assay and classified as ER and/or PR-positive according to ASCO/CAP guidelines (1-100% expression)\nThe patient is noted to be ER/PR negative, which excludes them.\n\n4. Histologic and/or cytologic confirmation of metastatic disease is encouraged whenever feasible...\nThe patient has metastatic lesions seen on CXR, meeting this criteria.\n\n5. Measurable disease (RECIST 1.1) or non-measurable (assessable) disease\nThe 3cm primary tumor would qualify as measurable disease.\n\n6. Patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy.\nThere is no mention of prior endocrine therapy in the patient note.\n\n7. Patients taking bisphosphonates for bone disease are permitted...\nNot applicable.\n\n8. Female or male subjects age >= 18 years.\nThe patient is a 45-year-old female, meeting this criteria.\n\n9. ECOG performance status 0, 1, or 2.\nNo ECOG status is provided.\n\n10. Patients must have normal organ and marrow function as defined...\nNo lab values are provided to assess this.\n\n11. Patients must be able to swallow and tolerate oral medications.\nThis is assumed to be true unless stated otherwise.\n\n12. Postmenopausal status, defined as certain criteria.\nThe patient is noted to be postmenopausal.\n\n13. Ability to understand and the willingness to sign a written informed consent document.\nThis is generally assumed unless stated otherwise.\n\nIn summary, while the patient meets some of the inclusion criteria like having metastatic disease, measurable disease, being postmenopausal and able to take oral medications, they are explicitly excluded based on being HER2-positive and ER/PR negative.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "223": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which does not match the inclusion criteria for this melanoma trial.\n\n2. The trial is specifically looking for patients with AJCC Stage IIIB or IIIC BRAF V600 mutation positive melanoma, while this patient has breast cancer.\n\n3. There are no details provided about the patient's BRAF mutation status or melanoma stage.\n\n4. Based on the information given, this patient does not meet the key inclusion criteria for this melanoma trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "224": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial inclusion criteria are:\n1) Informed consent form signed (no information provided)\n2) Adequate performance status (ECOG 0-1) (no information provided)\n3) Female patients with unifocal breast tumors (stages II-III, TN, HER2+ or Luminal B) very sensitive to neoadjuvant medical treatment (5 to 6 months in accordance with the current standard)\n   - The patient meets this criterion as she has a HER2+ stage II/III breast cancer tumor\n4) Patients who submit clinical-radiologic greater response to the treatment administered (equal to or less than 1.5 cm in NMR residual tumor)\n   - There is no information provided about the patient's response to neoadjuvant treatment\n\nBased on the information given, the patient meets some but not all of the key inclusion criteria. There is insufficient information to fully determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "225": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDisease Criteria:\n- The patient has breast cancer, not acute lymphoblastic leukemia (ALL), so this criterion is not met.\n\nAge Criteria: \n- The patient is 45 years old, which falls within the allowed age range of 40-65 years. This criterion is met.\n\nOrgan Function Criteria:\n- There is no information provided about the patient's organ function, so these criteria cannot be evaluated.\n\nPerformance Status:\n- There is no information provided about the patient's performance status, so this criterion cannot be evaluated.\n\nConsent:\n- There is no information provided about whether the patient has provided informed consent, so this criterion cannot be evaluated.\n\nDonor Criteria:\n- There is no information provided about a potential donor, so this criterion cannot be evaluated.\n\nSince the disease criterion is not met, and there is insufficient information to evaluate several other key criteria, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "226": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- With cytologically confirmed breast cancer (meets disease criteria)\n- 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative (meets criteria for tumor type/characteristics)\n- 5 positive lymph nodes, no clinical evidence of metastasis (meets criteria for non-metastatic disease)\n- Untreated and scheduled for tumor resection prior to chemotherapy (meets criteria for untreated patient)\n\nBased on the information provided, this patient meets all of the listed inclusion criteria for the clinical trial \"Chronic Toxicities Related to Treatment in Patients With Localized Cancer\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "227": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which is not relevant to the inclusion criteria for this thyroid cancer trial.\n\n2. The inclusion criteria specify:\n- Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis\n- Willing to participate in the study meetings\n- Age >18 years\n- Alert and capable of giving informed consent\n- Able to speak and read English or French\n\n3. The patient note does not mention anything about a thyroid cancer diagnosis or the patient's language abilities.\n\n4. Therefore, there is not enough information provided in the patient note to determine eligibility for this particular thyroid cancer clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "228": {
        "output": "To determine the patient's eligibility for the clinical trial \"Pain in Women With Chronic Pelvic Pain\", let's go through the inclusion criteria one by one:\n\n1. Women: The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Clinical diagnosis of chronic pelvic pain: The patient note does not mention any chronic pelvic pain diagnosis. The focus is on the patient's breast cancer diagnosis and treatment plan.\n\n3. More than eighteen years: The patient is 45 years old, so this criterion is met.\n\n4. Non-menstrual or noncyclic pelvic pain: There is no information provided about the patient experiencing any pelvic pain, menstrual or otherwise.\n\n5. Duration of pain of at least 6 months: As there is no mention of the patient experiencing pelvic pain, this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, there is no indication that the patient meets the inclusion criteria for the clinical trial \"Pain in Women With Chronic Pelvic Pain\". The note focuses on the patient's breast cancer diagnosis and treatment plan, with no mention of chronic pelvic pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "229": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The trial is for a drug-eluting coronary stent system, so this patient does not have the target disease/condition for this trial.\n\n2. Looking at the inclusion criteria:\n- Age \u226518 years (meets this)\n- Patient with an indication for PCI including angina, silent ischemia, NSTEMI, or recent STEMI (does not meet this, has breast cancer)\n- The other criteria are related to details of the PCI procedure\n\n3. Since the patient does not have a condition requiring a PCI procedure, they would not be eligible for this trial evaluating a coronary stent system.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "230": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Life expectancy of at least 10 years, excluding breast cancer diagnosis: The patient note does not mention any comorbidities that would limit life expectancy, so this criterion is likely met.\n\n2. Women of reproductive potential must agree to use non-hormonal contraception: The patient is described as postmenopausal, so this criterion does not apply.\n\n3. Submission of tumor samples is required: This is likely possible based on the information provided.\n\n4. Signed consent form: Not mentioned in the patient note, but this is a standard requirement.\n\n5. ECOG performance status 0 or 1: Not mentioned in the patient note.\n\n6. Clinical staging criteria: The patient has a 3 cm invasive ductal carcinoma with 5 positive lymph nodes, which meets the staging criteria.\n\n7. Diagnosis by core needle biopsy: This is stated in the patient note.\n\n8. Axillary lymph node evaluation: The patient had 5 positive lymph nodes, meeting this criterion.\n\n9. Menopausal status: The patient is described as postmenopausal.\n\n10. HER2-positive status: The tumor is described as HER2-positive.\n\n11. ER/PR-positive status: The tumor is described as ER/PR-negative, which does not meet this criterion.\n\n12-16. Laboratory values: Not mentioned in the patient note.\n\n17. LVEF assessment: Not mentioned in the patient note.\n\nBased on the information provided, the patient meets most of the inclusion criteria, except for the ER/PR-positive status requirement. However, there is not enough information about some criteria, such as performance status and laboratory values.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "231": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n\u226560 years of age: The patient is 45 years old, so this criterion is not met.\n\nHistological confirmed DLBCL/follicular lymphoma grade IIIb by WHO classification, with any IPI (International Prognostic Index): The patient has cytologically confirmed breast cancer, which is not diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade IIIb.\n\nNewly diagnosed, with no previous treatment: The patient is newly diagnosed, but the trial is specifically for DLBCL/follicular lymphoma.\n\nNon-localised stage, i.e. lymphoma that does not fit into a single radiotherapy field (including clinical stage IA with large tumour mass until stage IV) with at least one measurable lesion: This criterion is not applicable since the patient does not have lymphoma.\n\nECOG performance status 0 to 2: No information is provided about the patient's performance status.\n\nPresent appropriate haematologic, liver (ALT or AST < 2.5 ULN ? upper limit of normal) and renal functions (creatinine < 2.5 ULN), unless changes are secondary to lymphoma: No information is provided about the patient's hematologic, liver, or renal functions.\n\nLVEF at rest ? 55%, with no documented history of congestive heart failure (CHF), serious arrhythmia or acute myocardial infarction: No information is provided about the patient's LVEF or history of heart conditions.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as the trial is specifically for patients with DLBCL or follicular lymphoma grade IIIb, and the patient has breast cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "232": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of \"Histologic diagnosis of invasive breast cancer, clinical stage T1-4, M0 (non-inflammatory T4c)\".\n\n2. The patient has cytologically confirmed breast cancer and is scheduled for tumor resection followed by chemotherapy, which meets the inclusion criteria of \"Patients must consent to documentation of cancer treatment\" and \"Patients scheduled for neoadjuvant chemotherapy\".\n\n3. The patient's tumor is HER2-positive, which does not meet the inclusion criteria of \"Local HER2 status of tumor biopsy must be negative\".\n\n4. The clinical trial requires information on the clinical and sonographical status of lymph nodes, but the patient note does not provide this information.\n\n5. The chemotherapy regimen planned for the patient is not specified, so it is unclear if it meets the inclusion criteria of \"Treatment with a 3-weekly FEC or AC regimen (3-4 cycles) followed by 3-4 cycles of q3 weekly docetaxel or paclitaxel.\"\n\nBased on the available information, the patient meets some but not all of the inclusion criteria. The HER2-positive status of the tumor excludes the patient from the trial. Additionally, there is not enough information provided about the lymph node status and planned chemotherapy regimen to determine eligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "233": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma\", the patient does not meet the inclusion criteria for this trial.\n\nThe patient note indicates that the patient is a 45-year-old postmenopausal woman with breast cancer, but there is no mention of her being a BRCA1/2 mutation carrier or having a strong family history of breast and/or ovarian cancer, which are the inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "234": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria are:\n- Breast cancer patients eligible for sentinel node dissection\n- Invasive ductal or invasive lobular carcinoma  \n- Ductal carcinoma in situ undergoing total mastectomy\n- Clinically node-negative\n- 18-100 years\n\nThis patient meets several of the inclusion criteria:\n- Has invasive ductal breast carcinoma\n- Is between 18-100 years old\n\nHowever, the patient note states she has 5 positive axillary lymph nodes and metastatic lesions, indicating she is not clinically node-negative.\n\nTherefore, based on the inclusion criteria provided, this patient would not be eligible for this particular clinical trial evaluating needle biopsy of the sentinel lymph node in node-negative breast cancer patients.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "235": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Pathologically confirmed diagnosis of breast cancer (central confirmation is not required) - Met, the patient has cytologically confirmed invasive ductal breast carcinoma.\n\n2. Patients must be at least 18 years of age - Met, the patient is 45 years old.\n\n3. Metastatic or advanced breast cancer that is evaluable OR metastatic or advanced breast cancer that is measurable for response as per RECIST 1.1 - Met, the patient has metastatic breast cancer with metastatic lesions seen on CXR.\n\n4. ECOG performance status 0-2 - Not mentioned, so cannot evaluate this criteria.\n\n5. Life expectancy of at least 3 months as assessed by the investigator - Not mentioned.\n\n6. Patients with ER+ breast cancer must have received prior treatment with at least one hormone therapy - Not applicable, as the patient's tumor is ER/PR negative.\n\n7. Adequate hematologic function based on ANC, platelet count, and hemoglobin - Not mentioned, so cannot evaluate.\n\n8. Adequate hepatic function based on bilirubin, AST, ALT, and albumin - Not mentioned, so cannot evaluate. \n\n9. Adequate renal function based on serum creatinine - Not mentioned.\n\n10. Willingness and ability to comply with study procedures - Not mentioned, but can likely be assumed.\n\n11. Use of adequate contraception - Not mentioned, but likely not applicable as patient is postmenopausal.\n\n12. Negative pregnancy test for females of childbearing age - Not applicable as patient is postmenopausal.\n\n13. Allowance for HIV/AIDS patients on stable treatment - Not mentioned, but likely not applicable.\n\n14. HER2+ breast cancer confirmed by FISH or IHC 3+ - Met, the patient's tumor is HER2-positive.\n\n15. Criteria specific to treatment regimens - It appears the patient would be eligible for the triplet regimen of ganetespib, paclitaxel, and trastuzumab, as she has not received prior pertuzumab or ado-trastuzumab emtansine.\n\nWhile some criteria cannot be definitively evaluated due to lack of information in the patient note, based on the available information, the patient appears to meet the key inclusion criteria of having metastatic HER2+ breast cancer without prior pertuzumab or ado-trastuzumab emtansine treatment.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "236": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient has histologically or cytologically confirmed adenocarcinoma of the breast with metastatic disease, which matches the criteria.\n\n2. The primary tumor and metastatic lesions demonstrate HER2-neu overexpression based on the provided criteria, which matches.\n\n3. The patient has progressed on at least two lines of HER2-directed therapy in the metastatic setting, including pertuzumab and ado-trastuzumab, which matches the criteria.\n\n4. The patient has measurable disease, which is allowed.\n\n5. The patient is a 45-year-old postmenopausal woman, which meets the age requirement.\n\n6. The patient's ECOG performance status is not mentioned, but it is stated that she is a candidate for tumor resection, implying a good performance status.\n\n7. The patient's left ventricular ejection fraction is not mentioned.\n\n8. The patient's corrected QT interval is not mentioned.\n\n9. The patient's organ and marrow function details are not provided.\n\n10. The patient's contraception status is not mentioned.\n\n11. The patient is able to swallow, retain, and absorb oral medication, which matches the criteria.\n\n12. The patient agrees to tumor resection, implying her willingness to sign an informed consent document.\n\nBased on the information provided, the patient meets several key inclusion criteria, but there are some missing details regarding performance status, cardiac function, organ function, and contraception status.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 2
    },
    "237": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nFemale gender: The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\nAge \u226518 years: The patient is 45 years old, so this criterion is met. \n\nPerformance Status - ECOG 0-1: No information is provided about the patient's performance status.\n\nHistologically confirmed invasive breast cancer: The patient has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\nPrimary tumor greater than 1 cm: The tumor is 3 cm, so this criterion is met.\n\nAny N: The patient has 5 positive axillary lymph nodes, so this criterion is met. \n\nNo evidence of metastasis (M0): The patient has metastatic lesions on CXR, so this criterion is not met.\n\nOver expression and/or amplification of HER2: The tumor is HER2-positive, so this criterion is met.\n\nKnown hormone receptor status: The tumor is ER/PR negative, so the hormone receptor status is known and this criterion is met.\n\nHematopoietic status: No information is provided about CBC, ANC, platelet count or hemoglobin.\n\nHepatic status: No information is provided about bilirubin, AST, ALT or alkaline phosphatase levels.\n\nRenal status: No information is provided about creatinine level.\n\nCardiovascular status: No information is provided about LVEF.\n\nPregnancy test: No information is provided about pregnancy test.\n\nUse of effective contraception: The patient is not sexually active, so this criterion may not apply. \n\nSigned informed consent: No information is provided about signed consent.\n\nAvailability of tumor samples: No information is provided about this.\n\nSince the patient has metastatic lesions on CXR, which is an exclusion criterion, the patient would be excluded from this clinical trial despite meeting some of the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "238": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy.\"\nThe patient note states that the patient has a 3 cm invasive ductal breast carcinoma, which would be stage II, not stage 0 or I. However, it also mentions that axillary sampling revealed 5 positive lymph nodes, which would make the stage at least IIIA. So this criterion is not met.\n\n2. \"Axillary sampling is required only for cases of invasive cancers. Tumor size is determined by the pathologist. Clinical size may be used if the pathologic size is indeterminate. Patients with invasive cancer must have no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\"\nThe patient has 5 positive axillary lymph nodes, so this criterion is not met.\n\n3. \"Negative histologic margins of partial mastectomy or re-excision specimen.\"\nThere is no information provided about the surgical margins.\n\n4. \"Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm).\"\nThe patient has a 3 cm invasive ductal carcinoma that is HER2-positive and ER/PR negative, so this criterion is not met.\n\n5. Other criteria regarding systemic therapy, being a good candidate per the PI's judgment, postmenopausal status, age \u2265 50 years, ability to provide informed consent, and being an English speaker are either met or not relevant based on the information provided.\n\nIn summary, while some criteria are met or not relevant, the key criteria regarding tumor stage, lymph node status, and tumor biomarkers are not met for this patient.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "239": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Stage I-III breast cancer\n- HER2-positive, ER/PR negative\n- Scheduled for tumor resection prior to chemotherapy (doxorubicin/cyclophosphamide + paclitaxel)\n- May receive adjuvant endocrine therapy subsequently\n\nThe clinical trial inclusion criteria are:\n- Histologically confirmed stage I-III breast carcinoma\n- <65 years old \n- Female\n- Scheduled to receive chemotherapy containing doxorubicin/cyclophosphamide and paclitaxel\n- May receive adjuvant endocrine therapy subsequently\n\nBased on the information provided, this patient meets all of the inclusion criteria for the clinical trial.\n\nThere is no information provided about potential exclusion criteria that the patient may meet.\n\nTherefore, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "240": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial is for patients with newly diagnosed glioblastoma (GBM) brain tumor. It involves tumor resection with Gliadel wafers, followed by either standard radiation or GammaKnife radiosurgery along with temozolomide chemotherapy.\n\nLooking at the inclusion criteria:\n1. Single enhancing brain lesion consistent with GBM - The patient does not have a brain tumor, she has breast cancer. This criterion is not met.\n2. Must be appropriate for Gliadel wafer implant - Not applicable as the patient does not have a brain tumor.\n3. Pathologic confirmation of GBM - The patient has breast cancer, not GBM.\n4. No gross residual tumor on post-op MRI - Not applicable.\n5. Resection cavity volume < 50 cc - Not applicable. \n6. Karnofsky performance status \u2265 80% - No information provided.\n7. Able to undergo MRI with gadolinium - Likely able to, but not relevant.\n8. Willingness for follow-up at Barrow Neurological Institute - Not relevant.\n\nSince the patient does not have the target disease (GBM) for this clinical trial, she does not meet the key inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "241": {
        "output": "To determine the patient's eligibility for the clinical trial \"BIG Molecular Screening Feasibility Study\", let's go through the inclusion criteria one by one:\n\n1. Written informed consent for all study procedures according to local regulatory requirements prior to enrollment into the study.\n   - The patient note does not mention whether the patient has provided written informed consent, so this criterion cannot be evaluated.\n\n2. Age \u2265 18 years.\n   - The patient is a 45-year-old woman, so she meets this age criterion.\n\n3. Histologically proven metastatic or locally recurrent invasive breast cancer.\n   - The patient has cytologically confirmed invasive ductal breast carcinoma with metastatic lesions seen on CXR, so she meets this criterion.\n\n4. Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for research purposes.\n   - The patient note does not mention the availability of tumor tissue for research purposes, so this criterion cannot be evaluated.\n\nSince one of the inclusion criteria cannot be evaluated based on the information provided in the patient note, the patient's eligibility cannot be determined conclusively.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "242": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u2265 18 years at the time of consent - The patient is 45 years old, so this criterion is met.\n\n2. ECOG Performance Status 0 or 1 within 14 days prior to study registration - No information is provided about the patient's performance status.\n\n3. Contraception requirements for women/men of childbearing potential - The patient is postmenopausal, so this does not apply.\n\n4. Negative pregnancy test requirement for women of childbearing potential - The patient is postmenopausal, so this does not apply. \n\n5. Not breastfeeding - No information is provided, but likely not applicable since the patient is postmenopausal.\n\n6. Histologically/cytologically confirmed triple negative invasive breast cancer, clinical stage I-III - The patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, so this criterion is not met as the tumor is not triple negative.\n\n7. Completed preoperative (neoadjuvant) chemotherapy - No information is provided about prior chemotherapy.\n\n8. Completed definitive resection of primary tumor within specified timeframe - The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is not yet met.\n\n9. Significant residual invasive disease criteria - No information is provided about residual disease status.\n\n10. FFPE tumor block with \u226520% tumor cellularity - No information is provided about tumor cellularity.\n\n11. Breast radiotherapy requirements - No information is provided about radiotherapy status.\n\n12. No stage IV disease - The patient has metastatic lesions on CXR, so this criterion is not met.\n\n13. No investigational agent within 30 days - No information is provided.\n\n14. No chronic hepatitis B or untreated hepatitis C - No information is provided.\n\n15. Adequate laboratory values - No relevant laboratory values are provided.\n\n16. Normal LVEF within 30 days - No information is provided about LVEF.\n\n17. No clinically significant infections - No information is provided.\n\n18. Consent to submit tumor tissue and blood samples - No information is provided about consent.\n\n19. No clinically significant arrhythmia or baseline ECG abnormalities - No information is provided about arrhythmia or ECG.\n\nBased on the information provided in the patient note, the key reasons this patient does not meet the inclusion criteria are:\n1) The tumor is not triple negative (HER2-positive)\n2) The patient has metastatic lesions on CXR, indicating stage IV disease which is excluded.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "243": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with metastatic breast cancer. This matches the inclusion criteria of being 18 years or older and having metastatic breast cancer.\n\nThe tumor is HER2-positive and ER/PR negative. There are no specific requirements regarding tumor subtype in the inclusion criteria.\n\nThe patient has metastatic lesions seen on CXR. This matches the inclusion criteria of having metastatic or locally relapsed breast cancer.\n\nThe patient has not received any prior treatment for the metastatic disease, as she is a candidate for tumor resection prior to chemotherapy. This matches the inclusion criteria of not having received more than 1 prior treatment for metastatic disease.\n\nThe patient agrees to provide tumor tissue samples from the primary and metastatic lesions, as well as blood samples. This matches the inclusion criteria.\n\nThe patient's ECOG performance status is not mentioned, but she is a candidate for surgery, suggesting a good performance status of 0 or 1 which meets the inclusion criteria.\n\nBased on the information provided, the patient meets all of the listed inclusion criteria for the AURORA clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "244": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient aged over 18 and under 45\nThe patient is a 45-year-old postmenopausal woman, so she does not meet this criteria.\n\n2. Patient without amenorrhea at diagnosis\nThe patient is postmenopausal, so she likely has amenorrhea. This criteria is not met.\n\n3. Performance status less than 2 (according to WHO criteria )\nThere is no information provided about the patient's performance status, so this cannot be evaluated.\n\n4. Patient diagnosed with histologically proven non-metastatic breast cancer\nThe patient has cytologically confirmed breast cancer, but it is noted that there are metastatic lesions on CXR, so she likely has metastatic disease. This criteria is not met.\n\n5. Clinical Stages I, IIA, IIB and IIIA\nSince the patient has metastatic disease, she would not fall into these clinical stage categories. This criteria is not met.\n\n6. Positive Hormone Receptors or negative\nThe patient's tumor is ER/PR negative, so this criteria is met.\n\n7. Positive or negative HER2 status\nThe patient's tumor is HER2-positive, so this criteria is met.\n\n8. Patients to be treated with neoadjuvant or adjuvant chemotherapy\nThe patient is a candidate for tumor resection prior to chemotherapy, so she would likely receive adjuvant chemotherapy. This criteria is met.\n\n9. Satisfying hematological, renal and hepatic functions\nThere is no information provided about the patient's lab values, so this cannot be evaluated.\n\n10. Obtaining informed consent in writing, signed and dated\nThere is no information about whether the patient provided informed consent.\n\n11. Affiliation to Social Security system\nThere is no information about the patient's insurance status.\n\nOverall, while the patient meets some of the inclusion criteria, there are several key criteria that are not met, primarily related to her age, menopausal status, and presence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "245": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which is not the target disease (gastric cancer) for this clinical trial.\n\n2. The clinical trial is studying the use of carbon nanoparticles for lymph node dissection and harvesting in advanced gastric cancer patients undergoing surgery.\n\n3. The inclusion criteria specifically state:\n   - Histologically and CT confirmed resectable advanced gastric cancer\n   - No prior treatment\n   - No metastases\n\n4. Based on the patient note, this patient has breast cancer, not gastric cancer. Additionally, the patient has metastatic lesions noted on CXR, which would exclude them from this trial.\n\nTherefore, this patient does not meet the inclusion criteria for this clinical trial on lymph node harvesting in advanced gastric cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "246": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of \"Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy.\"\n\nThe tumor is 3 cm, HER2-positive, ER/PR negative, and has 5 positive lymph nodes, which matches the criteria of \"Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter\" and \"Patients must have stage cT1c - cT4a-d disease. Patients with HER2- positive or TNBC are eligible irrespective of nodal status (cN0-cN3).\"\n\nThe patient has no other major medical conditions mentioned that would exclude her from the trial.\n\nThe only potential issue is that her hemoglobin level is not mentioned, which is required for the anemia treatment randomization part of the trial (\"Hemoglobin level <10g/dl\").\n\nOverall, based on the information provided, this patient appears eligible for the main part of the clinical trial evaluating the neoadjuvant chemotherapy regimens.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information about hemoglobin level to qualify for the anemia treatment randomization, but is eligible for the main chemotherapy part of the trial).",
        "label": 0
    },
    "247": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Clinical diagnosis of Ductal carcinoma in situ (DCIS) or invasive breast cancer\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and \"a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\" This meets the inclusion criterion of having invasive breast cancer.\n\n2. Candidate for breast conserving surgery or mastectomy\nThe patient note mentions that \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\" This meets the inclusion criterion of being a candidate for breast surgery.\n\nSince the patient meets both inclusion criteria, and there is no information provided about exclusion criteria, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "248": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) 2 cm\nThe patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\" This meets the criteria.\n\n2. HER2-positive breast cancer  \nThe patient note mentions \"The tumor is HER2-positive and ER/PR negative.\" This meets the criteria.\n\n3. Participants with multifocal tumors are eligible provided all discrete lesions are sampled and centrally confirmed as HER2 positive\nThere is no mention of multifocal tumors, so this criterion is not applicable.\n\n4. Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system\nThe patient note states \"Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\" This suggests the cancer has metastasized, which would exclude the patient from this trial focused on early breast cancer.\n\n5. Known hormone receptor status of the primary tumor\nThe patient note states \"The tumor is HER2-positive and ER/PR negative.\" This meets the criteria.\n\n6. Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy\nThe patient note mentions \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\" This meets the criteria.\n\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nThere is no information provided about the patient's performance status.\n\n8. Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA)  \nThere is no information provided about the patient's LVEF.\n\n9. Effective contraception as defined by protocol\nThere is no information provided about the patient's contraceptive use.\n\nBased on the information provided, the patient meets some of the key inclusion criteria like tumor size, HER2 status, and agreement for surgery. However, the presence of metastatic lesions on CXR suggests more advanced disease, which would exclude the patient from this trial focused on early breast cancer. Additionally, there is insufficient information about performance status, LVEF, and contraceptive use to fully assess eligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "249": {
        "output": "Based on the given patient note and the clinical trial information, the patient does not meet the inclusion criteria for the trial titled \"Common Bile Duct Stone Management: What Have we Learned?\". The patient note describes a 45-year-old postmenopausal woman with breast cancer, while the trial is focused on patients with common bile duct stones (CBDS).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "250": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Stage I-III, HER2-neu positive invasive ductal carcinoma\nThe patient note states that the patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive, so this criterion is met.\n\n2. Scheduled to receive adjuvant/neo-adjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel (FEC-D) chemotherapy\nThe patient note does not explicitly mention the chemotherapy regimen, but it does state that the patient is a candidate for tumor resection and agrees to chemotherapy after resection, so this criterion could potentially be met.\n\n3. Scheduled to receive adjuvant Trastuzumab\nAgain, the specific treatment plan is not mentioned, but since the tumor is HER2-positive, the patient would likely receive Trastuzumab, so this criterion could potentially be met.\n\n4. ECOG Performance status 0-2\nThe patient's performance status is not provided in the note.\n\n5. Adequate baseline imaging on transthoracic echocardiography, and baseline cardiac ejection fraction of \u2265 55%. Additionally, breast cancer patients\u226545 years of age and scheduled to receive whole breast radiation therapy will receive two cardiac PET scans.\nThe patient note does not mention any cardiac imaging or ejection fraction information. However, it does state that the patient is 45 years old and a candidate for tumor resection, which would likely be followed by radiation therapy, so the criterion for receiving cardiac PET scans could potentially be met.\n\nBased on the information provided in the patient note, there is not enough information to definitively determine eligibility, as some key criteria (such as ECOG performance status and cardiac imaging/ejection fraction) are not mentioned. However, the patient appears to potentially meet several of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "251": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must consent to be in the study and must have signed an approved consent form conforming with federal and institutional guidelines.\n- We don't have information about whether the patient has consented, so this is unclear.\n\n2. Patient must be \u2265 50 years\n- The patient is 45 years old, so this criterion is not met.\n\n3. Core biopsy demonstrating breast cancer and receptors that are ER or PR positive.\n- The patient has ER/PR negative breast cancer, so this criterion is not met.\n\n4. Core tissue must have HER 2 negative followed by current ASCO/CAP guidelines.\n- The patient has HER2-positive breast cancer, so this criterion is not met.\n\n5. The patient must have clinical node negative, stage I breast cancer.\n- The patient has axillary lymph node metastases, so this criterion is not met.\n\n6. The surgical treatment must be intended to be a lumpectomy\n- The note mentions the patient is a candidate for tumor resection, which could be a lumpectomy, so this may be met.\n\n7. The biopsy site must have been demarcated by a clip(s)\n- There is no information about biopsy site clips, so this is unclear.\n\n8. Gross disease must be unifocal on Mammo/ MRI imaging\n- There is no information about imaging findings, so this is unclear.\n\n9. Patients must have estrogen receptor (ER) and progesterone receptor (PR) analysis performed on core biopsy\n- This was done and the tumor is ER/PR negative, which does not meet criteria.\n\n10. Patient must be able to tolerate lying in the prone position with arms extended forward.\n- There is no information about this, so it is unclear if met.\n\n11. Must be able to tolerate MRI scan with contrast\n- There is no information about this, so it is unclear if met.\n\n12. At the time of enrollment, patients must have had bilateral mammograms within 6 months.\n- There is no information about recent mammograms, so this is unclear.\n\n13. Patients must be willing to undergo breast cancer surgery minimally 4, maximally 6 weeks post APBI.\n- The patient agrees to tumor resection prior to chemotherapy, but it's unclear if this meets the 4-6 week post-APBI timeframe, so this is unclear.\n\n14. Patients with a history of non-breast malignancies are eligible if they have been disease free for 5 or more years prior to enrollment and are deemed by their physicians to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.\n- There is no mention of any prior non-breast malignancies, so this does not apply.\n\nIn summary, based on the information provided, the patient clearly does not meet criteria 2, 3, 4, and 9 which are required inclusion criteria. There is insufficient information to determine if several other criteria are met.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "252": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Patients must be female. \nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Patients must be 18 years of age or older.\nThe patient is 45 years old, so this criterion is met.\n\n3. Patients with stage I, II, or III breast cancer that is greater or equal to 2 cm on clinical examination.\nThe patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n4. Patients that have biopsy proven invasive breast cancer diagnosed by core needle biopsy\nThe patient had a core biopsy that revealed invasive ductal breast carcinoma, so this criterion is met.\n\n5. Patients who are chemotherapy and radiotherapy na\u00efve for the treatment of the current breast cancer.\nThe note does not mention any prior chemotherapy or radiotherapy for this breast cancer, so this criterion is assumed to be met.\n\n6. Patients that accept to undergo neoadjuvant chemotherapy.\nThe note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is met.\n\n7. Patients with bilateral breast cancer are eligible.\nThe note does not mention bilateral breast cancer, but this criterion is not exclusionary.\n\n8. Patients that understand, accept, and have signed the approved written consent form.\nThe note does not mention consent, but this is typically obtained if the patient agrees to enroll.\n\n9. Patients will need to consent to be part of the study.\nSame as above, consent is typically obtained if the patient agrees to enroll.\n\nBased on the information provided in the patient note, the patient meets all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "253": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women aged \u226518years and \u226470 years\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. At least on measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size \u22652 cm, T2-4 N0-2M0\nThe patient has a 3 cm invasive ductal breast carcinoma, so she meets this criterion.\n\n3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as >1% stained cells and HER2-positive is defined as immuno-histochemistry (IHC) 3+ or FISH ratio \u2265 2.0\nThe patient's tumor is HER2-positive and ER/PR negative, so she meets this criterion.\n\n4. No prior systemic or loco-regional treatment of breast cancer\nThe note does not mention any prior treatment, so this criterion is met.\n\n5. ECOG 0-2\nThe note does not provide the ECOG performance status, so there is not enough information to assess this criterion.\n\n6. Adequate bone marrow function...\nThe note does not provide any lab values, so there is not enough information to assess this criterion.\n\n7. No obvious main organs dysfunction\nThe note does not provide any information about organ function, so there is not enough information to assess this criterion.\n\nSince there are some criteria that cannot be assessed due to lack of information in the patient note, the appropriate trial-level eligibility assessment is:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "254": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. \"Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)\"\n- The patient note states that the patient has a \"3 cm invasive ductal breast carcinoma in the left upper outer quadrant\" confirmed by core biopsy, so this criterion is met.\n\n2. \"Age > 25\" \n- The patient is 45 years old, so this criterion is met.\n\n3. \"Ability and willingness to sign informed consent prior to any study procedure.\"\n- There is no information about this in the patient note, so I cannot determine if this criterion is met or not.\n\n4. \"Positive indication of disease on mammogram or MRI scan.\"\n- There is no mention of mammogram or MRI results in the patient note.\n\n5. \"Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.\"\n- The note states that \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\", so this criterion is met.\n\n6. \"Ability to undergo up to 90 minutes of PEM imaging.\"\n- There is no information about the patient's ability to undergo imaging in the note.\n\nSince there is insufficient information to definitively determine if criteria 3, 4, and 6 are met, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "255": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed invasive ductal breast cancer \n- 3 cm tumor, HER2-positive, ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial state:\n- Histologically confirmed invasive lobular breast cancer\n- Hormone receptor (ER or PR) positive \n- HER2-negative\n- At least 1 cm tumor size\n- Clinical stages I-III\n- Female\n- Fully postmenopausal\n- ECOG performance status 0-2\n- Adequate organ/marrow function\n- Able to provide informed consent\n\nBased on the information provided, this patient does not meet several of the key inclusion criteria:\n- The patient has invasive ductal carcinoma, not invasive lobular carcinoma\n- The tumor is ER/PR negative, not hormone receptor positive\n- The tumor is HER2-positive, not HER2-negative\n\nWhile the patient meets some criteria like tumor size, postmenopausal status, and being a surgical candidate, the tumor subtype and biomarker status make them ineligible for this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "256": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets disease criteria)\n- 3 cm invasive ductal breast carcinoma (meets tumor size criteria) \n- HER2-positive (meets biomarker criteria)\n- ER/PR negative (triple negative, meets biomarker criteria)\n- 5 positive lymph nodes (meets nodal status criteria)\n- No prior systemic or loco-regional treatment (meets prior treatment criteria)\n\nThe inclusion criteria state:\n- Women aged \u226518 years and \u226470 years (patient meets this)\n- Measurable disease per RECIST criteria (3 cm tumor meets this)\n- Histologically confirmed invasive breast cancer, tumor size \u22652 cm (patient meets this)\n- ER/PR/HER-2 and Ki-67 status detected (patient's biomarker status provided)\n- No prior systemic or loco-regional treatment (patient meets this)\n- Adequate bone marrow, liver and kidney function (not mentioned for patient)\n\nBased on the information provided, the patient meets the key inclusion criteria regarding age, disease status, tumor characteristics and prior treatment history. The only potential exclusion is if her organ function labs are not adequate, but this is not mentioned.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "257": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of \"Patients with invasive breast cancer\" and \"Age \u2265 18 years\".\n\nThe tumor is 3 cm and has spread to 5 axillary lymph nodes, which matches \"T1-T3\" and \"N0 on palpation\" as the lymph node involvement was detected by biopsy, not palpation.\n\nThe tumor is HER2-positive and ER/PR negative, which is not an exclusion criteria.\n\nThe patient has metastatic lesions noted on CXR, which is not explicitly mentioned in the inclusion/exclusion criteria. However, this may impact her eligibility for \"breast-conserving therapy or mastectomy\".\n\nThe patient agrees to tumor resection prior to chemotherapy, which matches \"Patients undergo breast-conserving therapy or mastectomy\".\n\nThere is no information provided about preoperative ultrasound or consent, but these could potentially be obtained.\n\nBased on the information provided, the patient appears to meet most of the key inclusion criteria, with the potential issue being the metastatic lesions noted on CXR.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, as preoperative ultrasound and consent status are unknown, and metastatic disease may exclude her from planned surgery)",
        "label": 0
    },
    "258": {
        "output": "To determine the patient's eligibility for the clinical trial \"Core Biopsies for Establishing a Breast Tumor Tissue Repository\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n- Known or suspected breast cancer\n\nBased on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\nSince the patient has a confirmed diagnosis of breast cancer based on a core biopsy, she meets the inclusion criteria for this clinical trial.\n\nThere are no other inclusion criteria provided, and the patient note does not mention any exclusion criteria that would disqualify the patient.\n\nTherefore, based on the information given, the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "259": {
        "output": "To determine the patient's eligibility for the clinical trial \"Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia\", let's go through the inclusion criteria:\n\n1. Female: The patient note states that the patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Age 30-49: The patient is 45 years old, which falls within the age range specified in the inclusion criteria.\n\n3. Able to give informed consent: There is no information provided about the patient's ability to give informed consent, but we can assume that she is able to do so unless stated otherwise.\n\nHowever, this clinical trial is focused on cervical cancer screening, while the patient note indicates that the patient has been diagnosed with breast cancer. The patient does not appear to have cervical cancer or any other condition related to the focus of this particular clinical trial.\n\nTherefore, based on the information provided, the patient does not meet the relevant criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "260": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female participants - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Postmenopausal status - The patient is described as postmenopausal, so this criterion is met. \n\n3. Histologically confirmed invasive breast carcinoma, with criteria on tumor size, stage, and absence of distant metastases - The patient has a 3 cm invasive ductal breast carcinoma, Stage I-III operable breast cancer, and no mention of distant metastases, so these criteria are met.\n\n4. Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer - The patient's tumor is described as HER2-positive and ER/PR negative, so this criterion is not met.\n\n5. Breast cancer eligible for primary surgery - The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is met.\n\n6. Tumor tissue for PIK3CA mutation testing - No information provided, so unable to assess this criterion.\n\n7. ECOG performance status 0 or 1 - No information provided, so unable to assess this criterion. \n\n8. Fasting glucose \u2264125 mg/dL - No information provided, so unable to assess this criterion.\n\n9. Adequate hematological, renal, and hepatic function - No information provided, so unable to assess this criterion.\n\n10. Absence of conditions hampering compliance - No information provided, so unable to assess this criterion.\n\n11. Ability and willingness to comply with study requirements - The patient agrees to tumor resection prior to chemotherapy, suggesting willingness, but no other information provided.\n\nSince the patient's tumor is HER2-positive and the trial requires HER2-negative status, the patient does not meet the key eligibility criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "261": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).\n\n2. The inclusion criteria specifically state that patients must have \"histologically confirmed HNSCC, from any primary site.\" Since the patient has breast cancer and not HNSCC, she does not meet this key inclusion criteria.\n\n3. There are other inclusion criteria related to prior cetuximab treatment, ECOG performance status, age, biopsy requirements, measurable disease, and lab values. However, since the patient does not have the required cancer type, these other criteria are not relevant.\n\n4. Based on the mismatch between the patient's cancer type and the trial's inclusion criteria, the appropriate assessment is:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "262": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologic diagnosis of unresectable, locally recurrent or metastatic breast cancer (MBC). \nThe patient note mentions \"cytologically confirmed breast cancer\" and the presence of metastatic lesions on CXR, so this criterion is met.\n\n2. ER and/or PR-positive tumors with staining by immunohistochemistry (IHC) based on the most recent biopsy.\nThe patient note states that the tumor is ER/PR negative, so this criterion is not met.\n\n3. Only 1 previous chemotherapy regimen for MBC. Patients progressing while receiving adjuvant endocrine therapy or progressing <12 months from completion of adjuvant endocrine therapy are eligible.\nThere is no mention of prior chemotherapy regimens in the patient note.\n\n4. Progressed on anti-estrogen therapy (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy) defined as recurrence while on, or within 12 months of end of anti-estrogen therapy for early stage breast cancer, or progression while on, or within one month of anti-estrogen therapy for locally advanced or metastatic breast cancer.\nThere is no mention of prior anti-estrogen therapy in the patient note.\n\n5. Post-menopausal or pre/peri-menopausal women on tamoxifen. LHRH agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or FSH per institutional guidelines.\nThe patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n6. HER2-negative breast cancer, defined as FISH-negative (FISH ratio <2.0), or IHC 0-1+, or IHC 2-3+ AND FISH-negative (FISH ratio <2.0).\nThe patient note states that the tumor is HER2-positive, so this criterion is not met.\n\n7. Measureable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 or evaluable bone lesions, lytic or mixed, in absence of measureable disease by RECIST criteria.\nThe patient note mentions a 3 cm invasive ductal breast carcinoma, so this criterion is likely met.\n\n8. Adequate hematologic, hepatic and renal function.\nThere is no information provided about the patient's hematologic, hepatic or renal function.\n\n9. International normalized ratio (INR) \u22641.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL) of the institution (if patient is not on anti-coagulation therapy).\nThere is no information provided about the patient's INR, PT or PTT.\n\n10. Age \u2265 18 years.\nThe patient is 45 years old, so this criterion is met.\n\n11. ECOG Performance Status score of 0-2. \nThere is no information provided about the patient's ECOG Performance Status.\n\n12. Life expectancy of \u2265 12 weeks.\nThere is no information provided about the patient's life expectancy.\n\nBased on the information provided in the patient note, the key inclusion criteria that are not met are ER/PR positivity and HER2 negativity. Therefore, the patient would likely be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "263": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Histologically documented invasive adenocarcinoma (any subtype) of the breast with clinical stage T1-2 (0-5 cm) and pathologic stage N0-1, M0 disease\"\n- The patient has a 3 cm invasive ductal breast carcinoma, which falls under the T1-2 clinical stage criteria. The note also mentions 5 positive lymph nodes, which meets the N0-1 pathologic stage criteria. There is no mention of metastatic disease, so the M0 criteria is likely met.\n\n2. \"Lumpectomy with 1-2 cm margin required within 9 weeks of initiation of protocol radiotherapy\"\n- The patient is a \"candidate for tumor resection and agrees to do so prior to chemotherapy\", which implies a lumpectomy will be performed. The margin status is not mentioned.\n\n3. \"Axillary dissection required for premenopausal patients and recommended for postmenopausal patients (Irradiation of clinically negative axilla is an acceptable alternative to axillary dissection in postmenopausal patients)\"\n- The patient is described as postmenopausal. Axillary sampling revealing 5 positive nodes was performed, meeting this criteria.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for clinical stage, pathologic stage, planned surgery, and axillary evaluation. The only potential missing detail is the margin status after lumpectomy.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "264": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of women age >= 18 years with clinical stage II or III breast cancer.\n\nThe tumor is a 3 cm invasive ductal breast carcinoma, which is an adenocarcinoma of the breast as required. It is HER2-positive and ER/PR negative, which meets the criteria of any tumor ER/PgR status and any HER2 status.\n\nThere are 5 positive lymph nodes, indicating clinical stage II or III disease as required.\n\nThe patient has no other prior malignancies, bilateral breast cancer, inflammatory breast cancer, or distant metastases based on the note. She has not received any prior treatment for this cancer.\n\nThere is no mention of pregnancy/lactation status, but it states she is not sexually active and has no children, so likely not pregnant or lactating.\n\nNo other exclusion criteria like psychiatric illness, inability to consent, abnormal organ function, etc. are mentioned.\n\nThe patient is a candidate for surgery followed by chemotherapy, meeting the criteria for Part B.\n\nBased on the information provided, this patient meets all the inclusion criteria for the clinical trial and none of the exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "265": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in left breast\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the advanced/metastatic setting are:\n- Adult women aged \u226518 years (Patient meets this)\n- Diagnosis of invasive breast cancer (Patient meets this)\n- Willing and able to sign informed consent form (Not mentioned, but can be assumed)\n- Metastatic or locally advanced, inoperable disease proven by imaging (Patient meets this with metastatic lesions on CXR)\n\nBased on the information provided, this patient meets all of the stated inclusion criteria for the advanced/metastatic breast cancer setting of the PRAEGNANT clinical trial.\n\nThere are no explicit exclusion criteria mentioned, so there is no basis to exclude the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "266": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria)\n- Postmenopausal woman\n- Has cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma \n- HER2-positive \n- ER/PR negative (does not meet ER+ criteria)\n- 5 positive lymph nodes (meets 1-3 positive nodes criteria)\n- Has metastatic lesions on CXR (does not meet M0 criteria)\n\nThe inclusion criteria state:\n- Patients must have 1-3 positive lymph nodes (patient meets this)\n- ECOG 0 or 1 (no performance status given)\n- Candidate for chemotherapy in addition to hormonal therapy (patient is a candidate)\n- T1-3 N1 M0 staging (patient does not meet M0)\n- ER+ tumor (patient's tumor is ER-)\n- HER2+ tumor (patient meets this)\n\nBased on the mismatch between the patient's ER- and metastatic status compared to the trial's ER+ and M0 requirements, I would assess:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "267": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Women with node positive breast cancer treated with surgery, anthracycline-based or similar cardiotoxic chemotherapy, and regional nodal irradiation between 2000-2007.\n\nThe patient note mentions that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is 3 cm invasive ductal breast carcinoma, and axillary sampling revealed 5 positive lymph nodes. The patient is a candidate for tumor resection (surgery) and agrees to do so prior to chemotherapy.\n\nHowever, the patient note does not mention the specific chemotherapy regimen or whether regional nodal irradiation will be given. It also does not specify the time period when the patient will be treated.\n\nBased on the available information, the patient meets some but not all of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "268": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of \u226518 and \u226470 years)\n- Has cytologically confirmed HER2-positive metastatic breast cancer (meets criteria)\n- Has at least one measurable lesion (meets criteria)\n- No information on ECOG performance status\n- No information on prior capecitabine treatment in the last year\n- No lab values provided to check eligibility criteria\n\nBased on the available information, the patient meets some of the key inclusion criteria like age, HER2-positive metastatic breast cancer, and having a measurable lesion. However, there is insufficient information to fully assess eligibility based on the criteria of ECOG performance status, prior capecitabine use, and lab values.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "269": {
        "output": "To determine the patient's eligibility for the \"Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Female: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Age 45 or greater: The patient is 45 years old, so she meets this criterion.\n\n3. Diagnosed with operable invasive breast cancer, T1 and T2 (< 3.5 cm), N0, M0, confirmed by cytological or histological examination: The patient has a 3 cm invasive ductal breast carcinoma, which falls under the T2 category. However, the patient has 5 positive lymph nodes, which means she is not N0 (no positive lymph nodes). Additionally, the patient has metastatic lesions noted on CXR, which means she is not M0 (no metastases).\n\n4. Suited for breast conserving surgery: The patient is a candidate for tumor resection, which implies she is suited for breast conserving surgery.\n\n5. Have had an ipsilateral (same side as current cancer) diagnostic mammogram within 12 months of enrollment: There is no information provided about a recent mammogram.\n\nBased on the information provided, the patient does not meet all the inclusion criteria due to the positive lymph nodes and metastatic lesions. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "270": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Newly diagnosed Stage 0 or I breast cancer - The patient has cytologically confirmed invasive ductal breast carcinoma, which would likely be Stage II or III given the 3 cm tumor size and positive lymph nodes. This criterion is not met.\n\n2. On histological examination, the tumor must be DCIS or invasive non-lobular carcinoma of the breast - The patient has invasive ductal carcinoma, so this criterion is met.\n\n3. Surgical treatment of the breast must have been wide excision, lumpectomy or partial mastectomy - The patient is a candidate for tumor resection, which would likely involve a lumpectomy or partial mastectomy, so this criterion is potentially met.\n\n4. Age 50 years or greater - The patient is 45 years old, so this criterion is not met.\n\n5. ER positive - The patient's tumor is ER/PR negative, so this criterion is not met.\n\n6. PR positive - The patient's tumor is ER/PR negative, so this criterion is not met. \n\n7. Her2 negative - The patient's tumor is HER2-positive, so this criterion is not met.\n\n8. Subjects with invasive tumors should undergo axillary sentinel lymph node evaluation or axillary lymph node dissection - The patient had axillary sampling with 5 positive lymph nodes, so this criterion is met.\n\n9. Negative inked surgical margins... - This cannot be determined from the patient note as surgery has not occurred yet.\n\n10. Negative post-excision/re-excision mammography... - This cannot be determined from the patient note as surgery has not occurred yet.\n\n11. No involved axillary lymph nodes, N0(i+) allowed - The patient had 5 positive axillary lymph nodes, so this criterion is not met.\n\n12. Enrollment and plan to initiate CyberKnife therapy within 12 weeks of last surgery - This cannot be determined from the patient note.\n\n13. Target lumpectomy cavity/whole breast reference volume must be <30% - This cannot be determined from the patient note as treatment planning has not occurred.\n\n14. Signed informed consent form - This is not mentioned in the patient note.\n\nOverall, while some criteria are potentially met or cannot be determined, several key inclusion criteria are clearly not met based on the provided information.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "271": {
        "output": "Based on the patient note provided, the patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial titled \"Thromboelastogram During Total Knee Replacement\" is studying changes in the coagulation system during total knee replacement surgery with tranexamic acid infusion.\n\nThe inclusion criteria for this trial are:\n1. Osteoarthrosis\n2. Elective total knee replacement (TKR) operation\n3. ASA (American Society of Anesthesiologists) physical status classification I-III\n\nThe patient note does not mention any information about osteoarthrosis or a planned total knee replacement surgery. Therefore, there is insufficient information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "272": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients \u2265 18 years of age with histologically, and radiographically confirmed non-metastatic breast cancer with minimal tumor size over 1 cm (\u2265T1c lesion) to receive neoadjuvant chemotherapy recommended by the treating physician\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed 3 cm invasive ductal breast carcinoma, meeting the age and tumor size criteria. It is also mentioned that she is a candidate for tumor resection and chemotherapy, satisfying this criterion.\n\n2. For estrogen receptor (ER) strongly positive, human epithelial receptor (HER2) negative breast cancer, Oncotype Dx study is required. Patients with low recurrence score will be excluded in the study.\n- The patient's tumor is HER2-positive and ER/PR negative, so this criterion does not apply.\n\n3. Eastern Cooperative Oncology Group (ECOG) performance status score < 1\n- No information is provided about the patient's ECOG performance status score.\n\n4. Absolute neutrophil count > 1500 mm3, platelet count \u2265 100\u00d7109 L, hemoglobin \u2265 8.5 g/dL\n- No information is provided about the patient's lab values.\n\n5. Serum creatinine \u22641.5 times the upper limit of the normal range, total bilirubin \u2264 1.5 X ULN (\u2264 3 mg/dL if clinically diagnosed with Gilbert syndrome) AST/ALT \u2264 2.5 X ULN (AST/ALT \u2264 5X ULN if clinically diagnosed with Gilbert syndrome)\n- No information is provided about the patient's lab values.\n\n6. Willing to provide blood samples for correlative research purposes\n- No information is provided about the patient's willingness to provide blood samples.\n\n7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.\n- The patient is described as postmenopausal, so this criterion does not apply.\n\nBased on the information provided, the patient meets the first inclusion criterion related to tumor type, size, and planned treatment. However, there is insufficient information to determine if the patient meets the other inclusion criteria related to performance status, lab values, and willingness to provide blood samples.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "273": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Newly diagnosed infiltrating ductal carcinoma (IDC) of the breast\"\n   - The patient note mentions that the patient has a \"3 cm invasive ductal breast carcinoma\", which meets this criterion.\n\n2. \">= 1.0 cm primary tumor\"\n   - The patient note states that the tumor is 3 cm, which meets this criterion.\n\n3. \"Calculated creatinine clearance >= 50 mL/min\"\n   - There is no information provided about the patient's creatinine clearance.\n\n4. \"Willing and able to provide informed consent\"\n   - There is no information provided about the patient's willingness or ability to provide informed consent.\n\n5. \"Age \u2265 18 years\"\n   - The patient note states that the patient is 45 years old, which meets this criterion.\n\n6. \"ECOG performance status 0-2\"\n   - There is no information provided about the patient's ECOG performance status.\n\n7. \"Informed of the investigational nature of this study\"\n   - There is no information provided about whether the patient has been informed of the investigational nature of the study.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria, but there is not enough information to determine if they meet all of the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "274": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Tumor diameter \u22643 cm\nThe patient note states the tumor size is 3 cm, so this criterion is met.\n\n2. Tumor from the papilla>2cm\nThere is no information about the distance of the tumor from the papilla, so this criterion cannot be evaluated.\n\n3. Low grade ductal carcinoma in situ\nThe patient has invasive ductal carcinoma, not ductal carcinoma in situ, so this criterion is not met.\n\n4. Candidate for breast-conserving surgery\nThe patient note mentions she is a candidate for tumor resection, which implies breast-conserving surgery, so this criterion is likely met.\n\n5. Must have undergone lumpectomy with negative margins or minimal margin involvement\nThe patient has not undergone surgery yet, so this criterion is not applicable at this stage.\n\n6. Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection\nSame as above, the patient has not undergone any surgical procedure yet.\n\n7. No evidence of metastatic disease\nThe patient note mentions metastatic lesions on CXR, so this criterion is not met.\n\n8. Informed consent\nThere is no information about whether the patient has provided informed consent.\n\nBased on the available information, the patient does not meet at least two of the inclusion criteria (tumor type and presence of metastatic disease). There is also insufficient information to evaluate some other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "275": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Capable and willing to provide informed consent - The patient note does not mention this, so there is not enough information to assess this criteria. \n\n2. Women must not be pregnant or breast-feeding... - The patient is described as a 45-year-old postmenopausal woman, so this criteria is likely met.\n\n3. Women of childbearing potential and sexually active males must use contraception... - Since the patient is postmenopausal, this does not apply.\n\n4. Patient is a postmenopausal woman, man, or premenopausal woman for whom standard endocrine therapy alone is planned after FES-PET/CT - The patient is a postmenopausal woman who is a candidate for endocrine therapy after tumor resection, so this criteria is met.\n\n5. Medically stable as judged by patient's physician - There is no information about the patient's medical stability.\n\n6. Life expectancy > 6 months - No information provided.\n\n7. ECOG performance status 0-3 (0-2 if age > 70) - No performance status mentioned.\n\n8. No history of allergic reaction to compounds similar to 18F-FES - Not mentioned.\n\n9. Not in liver failure - Not mentioned. \n\n10. Histologically confirmed metastatic breast cancer - Yes, the patient has cytologically confirmed metastatic breast cancer.\n\n11. Primary tumor and/or metastatic site must be ER+ - Yes, the primary tumor is ER+.\n\n12. Pathology report and tissue/slides available for central review - Unclear if this is available.\n\n13. Not HER2+ metastatic disease - The primary tumor is HER2+, so this criteria is not met.\n\n14. Not planning molecular targeted or HER2 therapy in addition to endocrine therapy - Unclear based on the note.\n\n15. No prior endocrine therapy for metastatic disease - Criteria met as this would be first-line.\n\n16. Meets criteria around prior adjuvant endocrine therapy - No information provided.\n\n17. No more than 1 line of prior chemo for metastatic disease - Criteria met as no prior chemo mentioned.\n\n18. Disease measurable by RECIST 1.1 in at least one non-liver site - Criteria met as CXR showed metastatic lesions.\n\n19. Able to lie still for 20-30 min PET/CT scan - No information provided.\n\n20. Does not exceed weight limit for PET/CT scanner - No information provided.  \n\n21. Participating at qualified institution - No information provided.\n\nIn summary, while some key criteria are met (metastatic ER+ breast cancer, treatment-naive), the patient's HER2+ status excludes them from this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "276": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women, aged 18 years and older - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Able to give informed consent herself - No information is provided about the patient's ability to give consent, so I cannot determine if this criterion is met or not.\n\n3. World Health Organization (WHO) performance score \u2264 2 - No information is provided about the patient's WHO performance score.\n\n4. Biopsy proven cT1-2 N0-2 MX invasive breast cancer with a size of \u2264 3.0 cm - The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n5. Histological type of tumor: invasive ductal carcinoma (IDC), not otherwise specified (NOS) or no special type (NST) - The patient's tumor is an invasive ductal carcinoma, so this criterion is met.\n\n6. The target breast fits in the cup of the dedicated MR-HIFU breast system - No information is provided about whether the patient's breast would fit in the system.\n\n7. Patient weight is limited to \u2264 90 kg, because of restrictions to the HIFU table top - No information is provided about the patient's weight.\n\n8. Additional inclusion criteria based on DCE-MRI findings:\n   - The distance of the tumor, including a 5 mm margin around the tumor, from the skin, nipple and pectoral wall is at least 1.0 cm measured on MRI.\n   - The tumor is located within the reach of the HIFU beam produced by the transducers in the HIFU breast system.\n   No information is provided about the patient's MRI findings or the location of the tumor relative to the HIFU beam.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to determine if she meets all of them.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "277": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of 18-70 years)\n- Has cytologically confirmed HER2+ metastatic breast cancer (meets criteria of HER2+ advanced breast cancer)\n- Has received prior therapies (anthracycline, taxane - not explicitly stated but can be inferred from \"candidate for tumor resection and agrees to do so prior to chemotherapy\")\n- No information on ECOG performance status, life expectancy, measurable lesions or required laboratory values\n\nBased on the information provided, the patient meets some of the key inclusion criteria like age, HER2+ status, and prior therapies. However, there is insufficient information to fully assess eligibility on criteria like ECOG performance status, life expectancy, measurable lesions, and required laboratory values.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "278": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Women aged 50 and over initially diagnosed with breast cancer by histological tissue diagnosis in 2003 or later.\"\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, so this criterion is not met.\n\n2. \"Currently Stage IV (metastatic) breast cancer on the basis of definitive imaging or biopsy with stable disease (scans within the past 2 months).\"\nThe patient note mentions that the patient has metastatic lesions seen on CXR, indicating stage IV breast cancer, so this criterion is met.\n\n3. \"ECOG (Eastern Cooperative Group) Performance Score of 0 or 1.\"\nThere is no information provided about the patient's ECOG performance score.\n\n4. \"Able to participate occasionally in mildly strenuous physical effort.\"\nThere is no information provided about the patient's ability to participate in physical effort.\n\n5. \"Able to read, speak, and write in English or ability to provide consent or understand questionnaires.\"\nThere is no information provided about the patient's ability to read, speak, and write in English.\n\n6. \"Able to be accompanied by their spouse or significant other partner/friend (spouse, significant other, partner, or friend.\"\nThere is no information provided about whether the patient can be accompanied by a spouse or partner.\n\n7. \"Able to travel to the retreat site.\"\nThere is no information provided about the patient's ability to travel.\n\n8. \"Must be right handed.\"\nThere is no information provided about the patient's handedness.\n\n9. \"Patients must have had a contrast-enhanced computerized tomographic (CT) scan of the chest and abdomen within 2 months of study entry and be willing to have a follow up scan within 2 months of the completion of the retreat.\"\nThe patient note mentions that the patient had a CXR (chest X-ray) but does not specify whether a contrast-enhanced CT scan of the chest and abdomen was performed within the past 2 months.\n\nSince there is insufficient information provided in the patient note to determine if several of the inclusion criteria are met, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "279": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The trial is for evaluating a treatment for active radiographic axial spondyloarthritis (AxSpA).\n\n2. The inclusion criteria for the trial require participants to have a diagnosis of ankylosing spondylitis (AS) confirmed by X-ray, active disease symptoms (BASDAI score >=4, back pain VAS >=4), elevated hsCRP >= 0.3 mg/dL, stable NSAID/analgesic use or no use for 2 weeks prior, and women of childbearing potential must have a negative pregnancy test.\n\n3. The patient note does not mention anything about ankylosing spondylitis, BASDAI, back pain VAS, hsCRP levels or NSAID use. It only describes the patient's breast cancer diagnosis and staging.\n\n4. Based on the information provided, the patient does not meet the key inclusion criteria for this axial spondyloarthritis trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "280": {
        "output": "Okay, let's go through the inclusion criteria for the \"Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)\" and assess the eligibility of the patient based on the provided note.\n\n1) Female patients who are >18 years of age\nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2) ECOG 0 or 1\nNo information is provided about the patient's ECOG performance status.\n\n3) The tumor must be invasive carcinoma of the breast on histologic examination\nThe patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n4) The tumor must be HER2-negative, ER-negative, and PR-negative\nThe note states that the tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n5-8) Staging criteria related to lymph node involvement and tumor size\nThe patient has 5 positive lymph nodes and a 3 cm tumor, meeting these criteria.\n\n9) LVEF assessment by echocardiography or MUGA scan must be >50%\nNo information is provided about the patient's LVEF.\n\n10) Adequate hepatic, renal, and bone marrow function\nNo information is provided about the patient's hepatic, renal, or bone marrow function.\n\n11) Ability and willingness to comply with the study\nThe patient agrees to undergo tumor resection prior to chemotherapy, suggesting willingness to comply with the study.\n\nSince the patient's tumor is HER2-positive, which is an exclusion criterion for this trial, the patient would be excluded from participating in this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "281": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Have postmenopausal status: The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Adenocarcinoma of the breast: The patient note mentions that the patient has cytologically confirmed breast cancer, which is an adenocarcinoma, so this criterion is met.\n\n3. Breast tumor \u22651 centimeter (cm) in diameter, HR+, HER2-: The patient note states that the tumor is 3 cm in size, HER2-positive, and ER/PR negative. Since the tumor is not HR+ (hormone receptor positive), this criterion is not met.\n\n4. Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy: There is no information provided about whether neoadjuvant endocrine monotherapy is suitable for this patient.\n\n5. Primary breast cancer that is suitable for baseline core biopsy: The patient note mentions that a core biopsy was performed, so this criterion is met.\n\n6. Have adequate organ function: There is no information provided about the patient's organ function.\n\nSince the patient's tumor is not HR+ (hormone receptor positive), which is one of the key inclusion criteria, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "282": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 2 weeks prior to screening\n- The patient note does not mention the ECOG performance status, so this cannot be evaluated.\n\n2. Female and male patients must have histologically confirmed invasive breast cancer that meets the following criteria:\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, so this criterion is met.\n\n3. Clinical stage II-III at diagnosis, based on initial evaluation by clinical examination and/or breast imaging; no metastatic disease allowed\n- The patient has a 3 cm invasive ductal breast carcinoma and 5 positive lymph nodes, indicating stage III breast cancer. However, the note mentions metastatic lesions on CXR, which would exclude the patient.\n\n4. ER- and PR- should meet specific criteria\n- The tumor is ER/PR negative, meeting this criterion.\n\n5. HER2 negative \n- The tumor is HER2-positive, so this criterion is not met.\n\n6. Patients must have completed neoadjuvant taxane +/- anthracycline; patients must NOT have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen\n- The patient note does not mention any prior neoadjuvant therapy, so this cannot be evaluated.\n\n7. Must have completed definitive resection of primary tumor\n- The patient is a candidate for tumor resection prior to chemotherapy, so this criterion is not yet met.\n\n8. Specific criteria related to surgical margins, type of surgery, lymph node evaluation\n- These criteria cannot be evaluated based on the provided information.\n\n9. Post neoadjuvant chemotherapy, patients must be found to have residual invasive cancer in the breast at the time of definitive surgery\n- The patient has not yet received neoadjuvant chemotherapy or surgery, so this criterion is not applicable yet.\n\n10. Criteria related to radiotherapy\n- These criteria are not relevant at this point.\n\n11. Specific laboratory value criteria\n- The patient note does not provide any laboratory values, so these criteria cannot be evaluated.\n\n12. Criteria related to neuropathy, adjuvant chemotherapy, and tissue specimen availability\n- These criteria cannot be evaluated based on the provided information.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, and the patient has metastatic disease which would likely exclude them from the trial, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "283": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the criteria of \"Women with histologically confirmed breast cancer\".\n\nShe had a mastectomy and axillary lymph node dissection, meeting the criteria of \"who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection\".\n\nShe has 5 positive lymph nodes, meeting the criteria of \"Lymph node-positive disease with less than 10 involved axillary lymph nodes\".\n\nThere is no mention of when her surgery was performed relative to the 5 week cutoff before randomization.\n\nHer ECOG performance status is not mentioned.\n\nHer lab values (neutrophil count, WBC, platelet count, bilirubin, AST, ALT) are not provided.\n\nShe is a candidate for tumor resection prior to chemotherapy, suggesting she may meet the criteria of \"Postoperative regional radiotherapy limited to the remaining breast admitted for patients who received breast-conserving surgery\".\n\nThere is no mention if she provided written informed consent.\n\nBased on the information provided, there are several inclusion criteria that cannot be definitively assessed, such as ECOG performance status, lab values, timing of surgery, and consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "284": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must provide informed written consent - The patient note does not mention whether the patient has provided consent, so this criterion cannot be evaluated.\n\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - The patient note does not mention the patient's ECOG performance status, so this criterion cannot be evaluated. \n\n3. Clinical stage IV invasive mammary carcinoma - The patient note states that the patient has \"cytologically confirmed breast cancer\" and that \"CXR was remarkable for metastatic lesions\", indicating stage IV disease. This criterion is met.\n\n4. For phase II: ER negative, PR negative, HER2 negative - The patient note states that the tumor is \"HER2-positive and ER/PR negative\". This criterion is met.\n\n5. Androgen receptor positivity, defined as >= 10% of tumor cell nuclei with immunoreactivity for AR on central review at Vanderbilt - The patient note does not mention the androgen receptor status, so this criterion cannot be evaluated.\n\n6. Measurable or bone-only evaluable disease - The patient note states that the tumor is 3 cm, indicating measurable disease. This criterion is met.\n\n7. Criteria related to prior therapies, tissue availability, and laboratory values - The patient note does not provide enough information to evaluate these criteria.\n\n8. Contraception requirements for non-postmenopausal patients - The patient note states that the patient is postmenopausal, so this criterion is met.\n\n9. Requirements related to prior radiation therapy - The patient note does not mention whether the patient has received radiation therapy, so this criterion cannot be evaluated.\n\nSince there are several inclusion criteria that cannot be evaluated based on the information provided in the patient note, the overall trial-level eligibility cannot be definitively determined.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "285": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria for this trial are focused on patients with solid pancreatic tumor masses and suspected lymph node involvement.\n\n2. There is no mention of the patient having a pancreatic tumor or lymph node involvement in the patient note. The note only discusses the patient's breast cancer diagnosis and staging.\n\n3. Since the patient does not appear to have the target condition (pancreatic mass or lymph node involvement) required for this trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "286": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets criteria)\n- 3 cm invasive ductal breast carcinoma (meets staging criteria cT1-2)\n- HER2-positive and ER/PR negative (meets triple-negative criteria)\n- Has 5 positive lymph nodes (meets criteria cN0-1)\n- No evidence of distant metastasis (meets criteria M0)\n- Newly diagnosed and willing to undergo surgery (meets criteria)\n- ECOG performance status not mentioned but likely 0 or 1 given no other details\n\nThe only potential issue is that her HER2 status is positive, while the trial requires triple-negative (ER/PR/HER2 negative). However, since she meets all the other criteria, I would assess her as:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "287": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"invasive mamma carcinoma as verified by core cut biopsy\"\nThe patient note states: \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\" This meets the inclusion criterion.\n\n2. \"extensive ductal carcinoma in situ as verified by core cut biopsy (at least 5 cm or at least 2,5 cm and G3 grading)\"\nThe patient does not have extensive ductal carcinoma in situ, but this is an \"or\" criterion with the previous one, which the patient meets.\n\n3. \"clinical stage tumor T1-T3\"\nThe tumor size is 3 cm, which falls under the T2 stage, meeting this criterion.\n\n4. \"no signs of axillary lymph node metastasis on clinical examination including ultrasound examination\"\nThe patient note mentions: \"Axillary sampling revealed 5 positive lymph nodes.\" This excludes the patient from the trial based on this criterion.\n\n5. \"no signs of distant metastatic disease\"\nThe patient note states: \"CXR was remarkable for metastatic lesions.\" This also excludes the patient from the trial.\n\n6. \"male/ female patient in the age not less than 18 years\"\nThe patient is a 45-year-old woman, meeting this criterion.\n\n7. \"Karnofsky performance status at least 70% or Eastern Cooperative Oncology Group (ECOG) score not higher than 1\"\nThere is no information provided about the patient's performance status or ECOG score.\n\n8. \"written patient informed consent\"\nThere is no information provided about whether the patient has given written informed consent.\n\nBased on the available information, the patient meets some of the inclusion criteria but is excluded due to the presence of axillary lymph node metastasis and distant metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "288": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of having invasive adenocarcinoma of the breast.\n\nThe tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes. This meets the criteria for pathologic staging of T1-3, N1-2a after definitive surgery (lumpectomy with lymph node sampling).\n\nThe patient has not received neoadjuvant chemotherapy, which is allowed under the inclusion criteria.\n\nThe patient has undergone complete resection of the known breast disease by lumpectomy with lymph node sampling, and the margins are clear of invasive tumor and DCIS.\n\nER, PR, and HER2 testing has been performed on the primary tumor.\n\nThe interval between surgery and planned study enrollment is not specified but is assumed to be within 56 days based on the patient being a candidate for chemotherapy after resection.\n\nThe patient is recovering from surgery with no signs of infection or chemotherapy-related toxicity that would interfere with radiation therapy.\n\nAs a postmenopausal woman, the pregnancy test requirement does not apply.\n\nBased on the information provided, the patient meets all of the key inclusion criteria for the hypofractionated regional nodal irradiation clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "289": {
        "output": "To determine the patient's eligibility for the clinical trial \"Staged and Combined Surgery for Cataract Patients With Corneal Endothelial Dysfunction\", let's go through the inclusion criteria one by one:\n\n1. Subjects are older than 18 years.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Subjects have corneal endothelial dysfunction combined with cataract.\nThe patient note does not mention any corneal endothelial dysfunction or cataract, so there is not enough information to determine if she meets this criterion.\n\n3. Subjects have mild to moderate cortical and/or nuclear cataract.\nAgain, the patient note does not mention any cataract, so there is not enough information to determine if she meets this criterion.\n\n4. Subjects are able and willing to provide informed consent.\nThe patient note does not provide any information about the patient's ability or willingness to provide informed consent.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria related to corneal endothelial dysfunction, cataract, and informed consent, we cannot conclude that the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "290": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Must sign informed consent - This is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\n2. Surgical treatment must have been lumpectomy with negative surgical margins - The patient note states that the patient had a core biopsy revealing a 3 cm invasive ductal carcinoma, but it does not mention if a lumpectomy was performed or if the surgical margins were negative.\n\n3. Tumor must be ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma - The patient note states that the tumor is a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n4. For invasive breast cancer, an axillary staging procedure must be performed, and the axillary node(s) must be pathologically negative - The patient note mentions that axillary sampling revealed 5 positive lymph nodes, so this criterion is not met.\n\n5. The T stage must be Tis, T1, or T2 (if T2, tumor must be \u2264 3.0 cm) - The tumor size is 3 cm, which meets this criterion.\n\n6. Estrogen receptor positive tumor and/or progesterone receptor positive tumor - The patient note states that the tumor is ER/PR negative, so this criterion is not met.\n\nBased on the information provided in the patient note, the patient does not meet all the inclusion criteria for this clinical trial due to having positive axillary lymph nodes and a hormone receptor-negative tumor.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "291": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which is not relevant to the inclusion criteria for this rectal cancer trial.\n\nThe inclusion criteria state:\n1. Biopsy proven rectal adenocarcinoma - The patient has breast cancer, not rectal cancer, so this criterion is not met.\n2. Distance between tumor and anal verge \u2264 10cm - No information provided about this for the patient.\n3. Locally advanced tumor (AJCC Cancer Staging: T3, T4 or N+) - The patient has metastatic breast cancer, which would not meet this criterion for locally advanced rectal cancer.\n4. Cancer Staging must be based on pelvic MRI - No pelvic MRI information provided for this patient.\n5. ECOG performance score \u2264 1 - No information provided about the patient's performance status.\n6. Written informed consent - No information provided.\n7. Mentally and physically fit for chemotherapy - Possibly, but no definitive information.\n8. Adequate blood counts within specified ranges - No lab values provided.\n9. No excision of tumor, chemotherapy or other anti-tumor treatment after diagnosis - It's stated the patient is a candidate for tumor resection prior to chemotherapy, so this criterion is not met.\n\nOverall, based on the information provided, this patient does not meet several of the key inclusion criteria for this rectal cancer clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "292": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n- \"Anatomopathological samples (surgical specimens or when a surgical sample is not possible, a core needle biopsy may be used) from female participants with a histopathological diagnosis of invasive breast cancer\"\n\nThe patient note mentions that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma. This meets the inclusion criteria of having a histopathological diagnosis of invasive breast cancer and a core needle biopsy sample.\n\nSince the patient meets the only inclusion criteria listed, and there are no exclusion criteria provided, we can conclude that the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "293": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women aged \u226518 years and < 70 years with life expectancy > 12 months\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Have finished radical operation, pathologically verified no lymph node involvement\nThe patient has had a core biopsy and axillary sampling which revealed 5 positive lymph nodes, so she does not meet this criterion.\n\n3. Operation specimens are available for ER, progesterone receptor (PR) and Her2 detection, patients should be with ER positive, Her2 negative tumor.\nThe patient's tumor is HER2-positive and ER/PR negative, so she does not meet this criterion.\n\n4. Adequate bone marrow function\nThere is no information provided about the patient's bone marrow function.\n\n5. Adequate liver and renal function\nThere is no information provided about the patient's liver and renal function.\n\n6. Has Eastern Cooperative Oncology Group (ECOG0 Performance Score 0-1;\nThere is no information provided about the patient's ECOG performance score.\n\n7. Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study;\nThe patient is postmenopausal, so this criterion is not applicable.\n\n8. Written informed consent according to the local ethics committee requirements.\nThere is no information provided about whether the patient has provided informed consent.\n\nBased on the information given, the patient does not meet at least two of the key inclusion criteria (lymph node status and ER/HER2 status). Therefore, I would assess her as:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "294": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about evaluating a treatment for diabetic foot ulcers.\n\n2. The inclusion criteria for the trial state that participants must have:\n   - Diagnosis of type 1 or type 2 diabetes mellitus\n   - Diabetic foot ulcer persisting for at least 4 weeks\n   - Ulcer meeting certain criteria based on the PEDIS rating system\n\n3. The patient note does not mention diabetes or diabetic foot ulcers. It only discusses the patient's breast cancer diagnosis and details.\n\n4. Since the patient does not have the target condition (diabetic foot ulcer) required for this trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "295": {
        "output": "To determine the patient's eligibility for the clinical trial \"Markers for Predicting Risk of Breast Cancer in Women of Different Races\", let's go through the inclusion criteria one by one:\n\n1. Women: The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. 18 years and older: The patient is 45 years old, so this criterion is met.\n\n3. Histologically proven infiltrating carcinoma of the breast on diagnostic biopsy: The patient has a 3 cm invasive ductal breast carcinoma confirmed by a core biopsy, so this criterion is met.\n\n4. ER-negative, any PR status, and any HER2 status: The patient's tumor is HER2-positive and ER/PR negative, which meets this criterion.\n\n5. Unresected, untreated breast cancer planning surgical management with mastectomy: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is met.\n\n6. Willing and able to sign an informed consent form: There is no information provided about the patient's willingness or ability to sign an informed consent form.\n\nSince the patient meets all the inclusion criteria except for the last one, which is not mentioned, there is not enough information to determine if the patient is eligible or not relevant for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "296": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is HER2-positive and ER/PR negative.\n\nThe clinical trial is looking at evaluating HER2 expression in breast cancer pathology samples using immunohistochemistry (IHC).\n\nThe inclusion criteria are:\n1) Women aged >= 18 and < 75 years (The patient is 45, so meets this criteria)\n2) Tumor samples already diagnosed based on IHC score 0 to +3 (The patient's tumor is HER2-positive, which implies it has been tested by IHC, so likely meets this)\n3) Samples of primary lesions excluding lymph nodes (The patient has a primary breast tumor, so meets this)\n4) 10% neutral buffered formalin-fixed and paraffin embedded tissue samples (This is about the tissue processing method, which is standard for surgical pathology, so the patient's sample likely meets this)\n\nBased on the information provided, the patient appears to meet all of the inclusion criteria for this clinical trial evaluating HER2 status in breast cancer samples.\n\nThere is no exclusion criteria mentioned, so we can assume the patient is not excluded.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "297": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria for the given clinical trial are for thyroid cancer patients undergoing surgery.\n\n2. Since the patient does not have thyroid cancer, she does not meet the key inclusion criteria of \"Subject being operated for a papillary thyroid cancer, re-operated for persistent/relapsed lymphadenopathy, or for benign thyroid pathology\".\n\n3. There is insufficient information provided about the patient to determine if she meets the other inclusion criteria like age, having recent blood tests done etc. \n\n4. However, since the primary inclusion criteria of having thyroid cancer is not met, this patient cannot be considered eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "298": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Diagnosed with invasive ductal breast cancer (meets criteria of invasive breast cancer)\n- 3 cm tumor size (meets T1 or T2 criteria) \n- No information on palpable adenopathy, but 5 positive lymph nodes noted (this may exclude her based on the criteria \"no suspicious palpable adenopathy\")\n- Planning for lumpectomy (breast conserving surgery) and chemotherapy after surgery (meets criteria for planned treatment)\n\nThe main potential exclusion is the 5 positive lymph nodes, as the criteria specifies \"no suspicious palpable adenopathy.\" However, it does allow patients with abnormal nodes on imaging if they have a negative biopsy, which this patient does not seem to have had.\n\nOverall, based on the information provided, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant\n\nThere is insufficient information to definitively determine if the positive lymph nodes would exclude the patient or not based on the criteria provided. More details on lymph node evaluation would be needed.",
        "label": 1
    },
    "299": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm in size\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is evaluating a new method for sentinel lymph node identification in the axilla of breast cancer patients.\n\nThe inclusion criteria are:\n1) Female patients at least 21 years old (The patient meets this criteria at age 45)\n2) Patients with invasive ductal carcinoma staged T1 or T2 with ER+/PR+ (The patient has invasive ductal carcinoma but is ER/PR negative, so does not meet this criteria)\n3) Patients with DCIS scheduled for sentinel lymph node biopsy (The patient does not have DCIS)\n4) Signed consent to participate (No information provided)\n\nBased on the information given, the patient does not meet the key inclusion criteria of having ER+/PR+ invasive ductal carcinoma.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "300": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about using carbon dioxide vs iodinated contrast for cholangiography during ERCP in patients with biliary tract disease.\n\nLooking at the inclusion criteria:\n1. Patients 18 years of age or older - The patient is 45, so meets this criteria.\n2. Patients with choledocholithiasis, benign biliary strictures, malignant biliary strictures - The patient note does not mention any biliary tract disease, only breast cancer.\n3. Biliary pathology suggested or confirmed by imaging - Again, no mention of biliary issues in the patient note.\n\nSince the patient does not appear to have any biliary tract disease or pathology, which is a key requirement for this clinical trial, she would not be eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "301": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age criteria of \"aged 18 years or older\".\n\nShe has cytologically confirmed breast cancer with a 3 cm invasive ductal carcinoma, which meets the criteria of \"histologically confirmed unilateral breast cancer with invasive ductal histology not otherwise specified (NOS) of high proliferation or grade\".\n\nThe tumor is HER2-positive and ER/PR negative, which meets the criteria of \"HER2 negative disease\" and \"Negative estrogen receptor (ER) and progesterone receptor (PgR), both < 1% locally assessed\".\n\nThe patient has a representative paraffin-embedded tumor block taken at diagnostic biopsy, which meets the criteria of \"Representative paraffin-embedded (FFPE) tumor block taken at diagnostic biopsy for confirmation of HER2, ER and PgR eligibility, for assessment of PDL-1 expression and for further exploratory biomarker evaluation is mandatory\".\n\nHer ECOG performance status is not mentioned, but it is reasonable to assume it is 0 or 1 given she is a candidate for tumor resection.\n\nThe other criteria regarding written informed consent, willingness to comply with the protocol, consent for blood samples, and contraceptive use (if applicable) are not mentioned in the patient note but can be assumed to be met if she agrees to participate.\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "302": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which does not match the inclusion criteria for endometrial cancer.\n\nThe tumor is HER2-positive and ER/PR negative breast cancer, which is not one of the included endometrial cancer subtypes (endometrioid, serous, clear cell, or mixed high grade).\n\nThe patient has metastatic lesions noted on CXR, suggesting stage IV disease. The trial includes stage III-IV endometrial cancer, but this is breast cancer.\n\nThere is no mention of the patient undergoing an endometrial biopsy, which is required per the inclusion criteria.\n\nThe patient is a candidate for tumor resection of the breast cancer prior to chemotherapy, but the trial requires resection of the primary endometrial tumor site after pembrolizumab treatment.\n\nBased on the details provided, this patient with metastatic breast cancer does not meet the key inclusion criteria for this endometrial cancer trial evaluating pembrolizumab.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "303": {
        "output": "To determine the patient's eligibility for the clinical trial \"Identification and Semi-Quantification of ER/PR Proteins Expression\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n- Women having breast cancer\n\nBased on the patient note, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, satisfying the inclusion criteria.\n\nThere are no other inclusion criteria mentioned, and no exclusion criteria provided.\n\nTherefore, based on the information given, the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "304": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is:\n- 3 cm invasive ductal carcinoma\n- HER2-positive\n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial inclusion criteria are:\n- Age \u2265 18 years (Patient meets this)\n- Histologically proven invasive stage I and II breast cancer (Patient meets this)\n- Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) and HER2 negative \n    - The patient is ER/PR negative and HER2 positive, so does not meet this criteria\n- OR Triple Negative (ER-, PR-, HER2-) with T1a/T1b and 0-1 positive nodes\n    - The patient does not meet this as she is HER2 positive\n- OR HER2 positive with T1a/T1b and 0-1 positive nodes\n    - The patient has >1 positive node, so does not meet this\n\nBased on the inclusion criteria, the patient does not qualify for this particular clinical trial due to being HER2 positive with >1 positive lymph node.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "305": {
        "output": "To determine the patient's eligibility for the clinical trial \"uPAR PET/CT for Preoperative Staging of Breast Cancer Patients\", let's go through the inclusion criteria one by one:\n\n1. \"Biopsy-verified breast cancer\"\nThe patient note mentions that the patient has \"cytologically confirmed breast cancer\" and a \"core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. \"Primary tumor more than 2 cm (ultrasound or clinically)\"\nThe patient note states that the tumor is \"a 3 cm invasive ductal breast carcinoma\", so this criterion is also met.\n\n3. \"The participants must be capable of understanding and giving full informed written consent\"\nThere is no information provided about the patient's ability to understand and give informed consent, but we can assume that this criterion is likely met unless stated otherwise.\n\nSince all the inclusion criteria are met based on the information provided in the patient note, and there are no exclusion criteria mentioned, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "306": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy - The patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, so this criterion is met.\n\n2. Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter - The tumor is 3 cm, so this criterion is met. \n\n3. Patients must have stage cT1c - cT4a-d disease - The patient has axillary lymph node involvement, so the stage would be at least cT1c, meeting this criterion.\n\n4. Centrally confirmed ER-negative and PR-negative status - The patient's tumor is ER/PR negative, meeting this criterion.\n\n5. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has to be sent to the GBG central pathology laboratory prior to randomization - This is a procedural requirement that cannot be assessed from the patient note.\n\nExclusion Criteria:\n1. Patients with stages cT1a, cT1b, or any M1 - The patient does not have cT1a or cT1b disease, and there is no mention of M1 (metastatic) disease, so this exclusion criterion is not met.\n\n2. Prior chemotherapy for any malignancy - There is no mention of prior chemotherapy, so this exclusion criterion is not met.\n\n3. Prior radiation therapy for breast cancer - There is no mention of prior radiation therapy, so this exclusion criterion is not met.\n\n4. History of disease with influence on bone metabolism, such as osteoporosis, Paget's disease of bone, primary hyperparathyroidism requiring treatment at the time of randomization or considered likely to become necessary within the subsequent six months - There is no mention of any such conditions, so this exclusion criterion is not met.\n\n5. Use of bisphosphonates or denosumab within the past 1 year - There is no mention of the use of these medications, so this exclusion criterion is not met.\n\n6. Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, active dental or jaw condition which requires oral surgery, non-healed dental/oral surgery, planned invasive dental procedure for the course of the study - There is no mention of any dental/oral issues, so this exclusion criterion is not met.\n\n7. Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer) - There is no mention of any previous malignancies, so this exclusion criterion is not met.\n\n8. Known or suspected congestive heart failure (>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP >140 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease - There is no mention of any of these conditions, so this exclusion criterion is not met.\n\n9. Currently active infection - There is no mention of any active infections, so this exclusion criterion is not met.\n\n10. Incomplete wound healing - There is no mention of any incomplete wound healing, so this exclusion criterion is not met.\n\n11. Definite contraindications for the use of corticosteroids - There is no mention of any contraindications for corticosteroid use, so this exclusion criterion is not met.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria and does not meet any of the exclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "307": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is studying quality of life after bladder-preservation chemotherapy and radiation therapy in patients with muscle-invasive bladder cancer.\n\nLooking at the inclusion criteria for the trial:\n1. Histologically confirmed muscle-invasive urothelial cancer (no histology will be excluded)\n- The patient note does not mention the patient having bladder cancer, so this criterion is not met.\n\n2. No pelvic nodal metastases or distant metastases\n- The patient has metastatic lesions noted on CXR, so this criterion is not met.\n\n3. Karnofsky performance status (KPS) >= 70\n- No information is provided about the patient's performance status.\n\n4. Ability to understand, and willingness to sign, the written informed consent\n- No information is provided about the patient's ability to understand or willingness to sign informed consent.\n\n5. Patient will have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable\n- The patient note does not indicate that the patient has opted for bladder-sparing treatment or been deemed medically inoperable for bladder cancer treatment.\n\n6. Following the recent recommendations..., eligible patients will be those with no hydronephrosis, no extensive carcinoma in situ (CIS), and no tumor invasion into the stroma of the prostate\n- No information is provided about these specific criteria.\n\nBased on the information given, the patient does not meet the inclusion criteria for having muscle-invasive bladder cancer and having no metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "308": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. ECOG (Eastern Cooperative Oncology Group): 0-2\n   - The patient's performance status is not mentioned, so this cannot be evaluated.\n\n2. Histologic documentation of invasive duct or lobular adenocarcinoma of the breast\n   - The patient has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\n3. If neoadjuvant chemotherapy was NOT administered: pathologic T1-3, N1-2 following definitive surgery\n   - The patient has not received neoadjuvant chemotherapy, and the tumor is 3 cm (T2) with 5 positive lymph nodes (N2), so this criterion is met.\n\n4. If neoadjuvant chemotherapy was administered, pathology from the definitive surgery must confirm pathologic T1-3, N1-2 disease and also meet one of the following criteria:\n   - Not applicable since the patient did not receive neoadjuvant chemotherapy.\n\n5. Complete resection of known breast disease by one of the following surgeries: Lumpectomy with axillary lymph node dissection with no more than 12 resected lymph nodes, or Mastectomy and axillary lymph node dissection with no more than 12 resected lymph nodes.\n   - The patient is a candidate for tumor resection, so this criterion is likely to be met.\n\n6. ER, PR, and HER2 testing performed on the primary breast tumor; when applicable, testing must have been performed before receiving neoadjuvant chemotherapy.\n   - The patient's tumor is HER2-positive and ER/PR negative, so this criterion is met.\n\n7. Margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the pathologist.\n   - This cannot be evaluated based on the provided information.\n\n8. The surgical wound should be completely healed without any signs of infection.\n   - This cannot be evaluated based on the provided information.\n\n9. Interval between the last surgery for breast cancer or the completion of adjuvant chemotherapy and study enrollment must be \u2264 56 days (ie, a maximum of 8 weeks).\n   - The patient has not received any treatment yet, so this criterion is likely to be met.\n\n10. If adjuvant chemotherapy is received, there should be at least 10 days gap between the last day of chemotherapy and the enrollment in the study to avoid skin toxicity.\n    - Not applicable since the patient has not received adjuvant chemotherapy.\n\n11. Women of child-bearing potential must agree to use a medically accepted form of pregnancy prevention for the duration of study treatment.\n    - The patient is postmenopausal, so this criterion is not applicable.\n\n12. Ability to understand and willingness to sign the consent form written in Arabic.\n    - This cannot be evaluated based on the provided information.\n\nBased on the available information, the patient meets several of the inclusion criteria, but there are some criteria that cannot be evaluated. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "309": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3cm, HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions seen on CXR (indicating metastatic disease)\n\nThe clinical trial is titled \"The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones\"\n\nThe key inclusion criteria are:\n- Age 18 or older (patient is 45, so meets this)\n- Radiographic or histologic proof of metastatic bone disease (patient has metastatic lesions seen on CXR, so meets this)\n- Histologic diagnosis of primary tumor (patient has invasive ductal breast carcinoma, so meets this)\n- Bone metastasis deriving from bones of the extremities (unclear if the metastatic lesions are in the long bones from the note)\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. The location of the metastatic bone lesions is unclear.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "310": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. This meets the age criteria of being 18 or older.\n\nShe has a 3 cm invasive ductal breast carcinoma in the left breast with 5 positive lymph nodes and metastatic lesions seen on CXR. This indicates metastatic bone disease, meeting the inclusion criteria of \"Radiographic or histologic proof of metastatic bone disease\" and \"Histologic diagnosis of the primary tumour\".\n\nHowever, the patient note does not specify if the metastases involve the long bones (humerus, ulna, radius, femur, tibia, fibula) which is an inclusion criteria for this trial. Without this information, it is unclear if the patient meets that key criteria.\n\nAssuming the metastases do involve the long bones, and the patient will receive surgical treatment for a pathologic fracture or impending pathologic fracture, then the patient would meet all the listed inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial based on the location of metastases)",
        "label": 0
    },
    "311": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman\n- Diagnosed with breast cancer\n- 3 cm invasive ductal carcinoma in the left breast\n- HER2-positive \n- ER/PR negative (triple-negative)\n- 5 positive lymph nodes\n- Metastatic lesions on CXR (metastatic disease)\n\nThe key inclusion criteria are:\n1) Histologically/cytologically confirmed diagnosis of breast cancer (Patient meets this)\n2) Radiological evidence of inoperable locally advanced or metastatic breast cancer (Patient meets this)\n3) HER2 negative breast cancer (Patient does not meet this, tumor is HER2-positive)\n4) Received 2-5 prior chemo regimens for advanced/metastatic disease (No information provided)\n5) Prior therapy included anthracycline and taxane (No information provided)\n6) For expansion part: Triple-negative breast cancer, ER/PR <10% (Patient meets this)\n\nSince the patient has HER2-positive disease, she does not meet the key inclusion criteria #3 for the dose escalation part of the trial. However, she does meet the criteria for the triple-negative expansion part.\n\nTrial-level eligibility: 2) Eligible (for the triple-negative expansion cohort)",
        "label": 0
    },
    "312": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets disease criteria)\n- Tumor is 3cm invasive ductal carcinoma, HER2-positive, ER/PR negative (does not meet ER-positive, HER2-negative criteria)\n- Has 5 positive lymph nodes (meets criteria of non-metastatic)\n- No prior hormone therapy, chemotherapy, surgery or radiation (meets criteria)\n- Appears to have normal cardiac, liver and kidney function based on lack of noted abnormalities (meets criteria)\n- ECOG status not mentioned but presumably meets \u22642 criteria\n\nWhile the patient meets several of the key inclusion criteria like age, non-metastatic disease, treatment naive status and organ function, the crucial criteria of ER-positive and HER2-negative breast cancer is not met. The patient has HER2-positive and ER/PR negative disease.\n\nTherefore, based on the inclusion criteria provided:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "313": {
        "output": "Okay, let's go through the inclusion criteria for the Breast Cancer Weight Loss Study (BWEL Study) and assess the eligibility of the patient based on the provided note:\n\n1.1 Histologically confirmed invasive breast cancer within 14 months - Met (3 cm invasive ductal breast carcinoma)\n1.2 HER2 negative tumor - Met (HER2-positive is excluded)\n1.3 Eligible TNM stage:\n    ER/PR negative: T2 or T3 N0, T0-3N1-3 - Met (T3N1)\n    ER/PR positive: T0-3N1-3 or T3N0 - Not applicable (ER/PR negative)\n1.4 No prior invasive breast cancer in 5 years - Met (no mention of prior breast cancer)\n1.5 Bilateral mammogram within 12 months - Likely met (not explicitly stated, but standard practice)\n1.6 Required imaging studies done - Likely met (CXR showed metastatic lesions, other studies not mentioned but likely done)\n\n2.1 Completed adjuvant/neoadjuvant treatment at least 21 days prior - Unclear (timing not specified)\n2.2 Triple negative patients received chemotherapy - Met (ER/PR negative)\n2.3 ER/PR positive patients received chemo or met genomic criteria - Not applicable (ER/PR negative)\n2.4 Breast reconstruction allowed, but definitive surgery completed 21 days prior - Unclear (timing not specified)\n2.5 Clear surgical margins - Unclear (not mentioned)\n2.6 Sentinel node biopsy/axillary dissection done - Met (5 positive lymph nodes)\n     Radiation completed 21 days prior - Unclear (not mentioned)\n     Hormone therapy for ER/PR positive patients - Not applicable (ER/PR negative)\n\nParticipant is a woman - Met\nAge \u2265 18 years - Met (45 years old)\nECOG Performance Status 0 or 1 - Unclear (not mentioned)\n\n6.1 No other malignancy in past 4 years - Unclear (no mention of other cancers)\n6.2 No diabetes treated with insulin/sulfonylureas - Unclear (no mention of diabetes)\n6.3 No digestive/absorptive problems - Unclear (not mentioned)\n6.4 No severe cardiovascular/respiratory/musculoskeletal disease - Unclear (not mentioned)\n6.5 No prior bariatric surgery - Unclear (not mentioned)\n6.6 Life expectancy > 5 years - Likely met (no mention of limited life expectancy)\n6.7 No psychiatric disorders precluding participation - Unclear (not mentioned)\n\n7.1 BMI \u2265 27 kg/m2 within 56 days - Unclear (BMI not provided)\n7.2 Ability to walk at least 2 blocks - Unclear (not mentioned)\n7.3 Not in another weight loss/activity trial - Unclear (not mentioned)\n7.4 Able to read and comprehend English - Likely met (note is in English)\n\nIn summary, the patient meets some of the key inclusion criteria like having invasive breast cancer of an eligible stage, being HER2-negative and ER/PR-negative, and having lymph node involvement. However, there are several criteria that cannot be assessed due to lack of information in the patient note, such as timing of prior treatments, surgical margins, performance status, comorbidities, BMI, and ability to walk.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "314": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy\", let's go through the inclusion criteria:\n\n1. \"Eligible patients will include any patients with biopsy-proven breast cancer and biopsy-proven axillary lymph node metastases at Beth Israel Deaconess Medical Center who are candidates for Neoadjuvant Chemotherapy or Neoadjuvant Endocrine therapy.\"\n\nThe patient note mentions that the patient has a \"3 cm invasive ductal breast carcinoma\" and \"Axillary sampling revealed 5 positive lymph nodes\". This satisfies the requirement of having biopsy-proven breast cancer and axillary lymph node metastases.\n\n2. \"A core needle biopsy or fine needle aspiration is acceptable for diagnosis of metastatic disease in lymph nodes.\"\n\nThe patient note does not specify the type of biopsy used for diagnosing the lymph node metastases, but it is reasonable to assume that a standard biopsy procedure was followed.\n\n3. \"Patients will be identified as possible participants in the Radiology Imaging suites and Breast Surgery Clinics.\"\n\nThe patient note does not provide information about where the patient was identified, but this criterion is not essential for determining eligibility.\n\nBased on the information provided in the patient note and the inclusion criteria, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "315": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, which meets the inclusion criteria of \"Women diagnosed with pathologically confirmed triple negative invasive breast cancer\".\n\n2. The tumor is 3 cm invasive ductal breast carcinoma, HER2-positive and ER/PR negative, which meets the inclusion criteria of \"Hormone receptor status (ER and PR) both \u2264 5% by immunohistochemistry, and HER2 status confirmed by means of immunohistochemistry (with 0 or 1+ indicating negative status) or fluorescence in situ hybridization (with amplification ratio < 2.0 indicating negative status).\"\n\n3. The patient has axillary lymph node metastases and lung metastases, which meets the inclusion criteria of \"Disease stage IV, metastatic unresectable disease.\"\n\n4. The patient has measurable disease as per the inclusion criteria \"Have measurable clinical disease: Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT scan as defined by RECIST (version v1.1).\"\n\n5. The patient has not received any prior treatment for metastatic disease, which meets the inclusion criteria of \"Patients received up to 3 prior regimens for their metastatic disease. Prior hormone therapy will not be counted towards the line of therapies.\"\n\n6. The patient is a candidate for chemotherapy with carboplatin and gemcitabine, meeting the inclusion criteria.\n\n7. The patient's ECOG performance status is not mentioned, but assuming it is 0-2, it would meet the inclusion criteria.\n\n8. The patient's organ function tests and hematologic indices are not mentioned, but assuming they are adequate, it would meet the inclusion criteria.\n\n9. The patient's pregnancy status is not mentioned, but assuming she is not pregnant or breastfeeding, it would meet the inclusion criteria.\n\n10. The patient's consent status is not mentioned, but assuming she provides informed consent, it would meet the inclusion criteria.\n\n11. The patient's tissue sample status is not mentioned, but assuming she provides a tissue sample, it would meet the inclusion criteria.\n\nBased on the information provided, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "316": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must have Stage I to III histologically confirmed invasive carcinoma of the breast. A minimum tumor size of at least 1.5 cm determined by physical exam or imaging (whichever is larger) is required.\"\n- The patient has a 3 cm invasive ductal breast carcinoma, meeting this criteria.\n\n2. \"Patients must have histologically confirmed hormone receptor positive (ER and/or PR), HER2 negative, invasive breast cancer.\"\n- The patient's tumor is HER2-positive and ER/PR negative, not meeting this criteria.\n\nSince the patient does not meet one of the key inclusion criteria (being HER2-negative and hormone receptor positive), they would be ineligible for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "317": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n\"Inclusion Criteria:\n\u2022 histologically confirmed primary invasive breast cancer by core needle biopsy\"\n\nBased on the patient note, it states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\" This satisfies the inclusion criteria of having a histologically confirmed primary invasive breast cancer by core needle biopsy.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria mentioned, the assessment of eligibility would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "318": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n- Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases - The patient meets this criteria as she has cytologically confirmed metastatic breast cancer.\n- Between 18 and 80 years of age - The patient is 45 years old, so she meets this criteria. \n- Who had undergone at least three lines of chemotherapy - It is not mentioned if the patient has undergone prior chemotherapy lines, so this criteria cannot be evaluated.\n- Had an expected survival time of at least 3 months - There is no information provided about the patient's expected survival time.\n\nExclusion Criteria:\n- Abnormal liver function - No information provided about the patient's liver function.\n- Abnormal kidney function - No information provided.\n- Abnormal coagulation capacity - No information provided.\n- Verified metastases to the brain - It is not mentioned if the patient has brain metastases.\n- Synchronous cancer except for specific conditions - No information provided about other cancers.\n- Abnormal hematology status - No information provided about blood counts.\n- Clinically significant abnormal ECG - No ECG results mentioned.\n- Karnofsky performance status score <60% - No performance status mentioned.\n- Pregnant or breastfeeding - The patient is postmenopausal, so not pregnant or breastfeeding.\n- Fertile and not using contraception - The patient is postmenopausal, so this does not apply.\n- Uncontrolled infection - No information about infections provided.\n- Recent corticosteroid/immunosuppressive use - No information provided.\n- Participated in another trial recently - No information provided.\n- Unable to understand information/give consent - No information provided, but presumably she can give consent since she agreed to surgery.\n\nIn summary, the patient meets at least one of the inclusion criteria (having metastatic breast cancer), but there is insufficient information to fully evaluate all inclusion/exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "319": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age criteria of \u226518 years.\n\nShe has cytologically confirmed invasive ductal breast carcinoma, which is an invasive carcinoma of the breast as required.\n\nThe tumor is 3 cm in size, which is above the minimum 11 mm tumor size measured by ultrasound.\n\nThe tumor is ER/PR negative, which does not meet the HR-positive (ER and/or PR >10%) criteria.\n\nThere is no evidence of metastatic disease mentioned, meeting that criteria.\n\nNo performance status or LVEF is mentioned, so those criteria cannot be evaluated.\n\nNo information is provided about pregnancy status or contraceptive use.\n\nNo information is provided about the patient's social security affiliation.\n\nOverall, while the patient meets some of the key inclusion criteria like age, tumor type/size, and lack of metastatic disease, the crucial hormone receptor negativity excludes the patient from this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "320": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women age 18 years or older\n   - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Confirmed histologic diagnosis of invasive adenocarcinoma of the breast, including MSKCC pathology confirmation\n   - The patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which is a type of invasive adenocarcinoma, so she meets this criterion.\n\n3. ER, PR and HER2 testing in progress (i.e. on outside or MSKCC biopsy report)\n   - The patient's tumor is HER2-positive and ER/PR negative, so this criterion is met.\n\n4. HER2-positive pathology is permitted\n   - The patient's tumor is HER2-positive, so she meets this criterion.\n\n5. Operable tumor measuring \u22651.5 cm in maximal diameter\n   - The patient's tumor measures 3 cm, so she meets this criterion.\n\n6. Any nodal status\n   - The patient has 5 positive lymph nodes, so this criterion is met.\n\n7. Multifocal and multicentric disease is permitted\n   - There is no mention of multifocal or multicentric disease, but this criterion is permissive, so it is met.\n\n8. Synchronous bilateral invasive breast cancer is permitted\n   - There is no mention of bilateral breast cancer, but this criterion is permissive, so it is met.\n\n9. The tumor should be more than 5 mm from the skin\n   - There is no information provided about the tumor's distance from the skin, so this criterion cannot be evaluated.\n\n10. No indication of distant metastases\n    - The patient has metastatic lesions noted on CXR, so she does not meet this criterion.\n\n11. Breast surgery planned\n    - The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so she meets this criterion.\n\n12. Tumor amenable to cryoablation as determined by radiologist\n    - There is no information provided about the tumor's amenability to cryoablation, so this criterion cannot be evaluated.\n\n13. ECOG performance status score of 0 or 1\n    - There is no information provided about the patient's ECOG performance status, so this criterion cannot be evaluated.\n\n14. Screening laboratory values must meet certain criteria\n    - There is no information provided about the patient's laboratory values, so these criteria cannot be evaluated.\n\n15. Negative HIV screening test\n    - There is no information provided about the patient's HIV status, so this criterion cannot be evaluated.\n\n16. Negative screening tests for Hepatitis B and Hepatitis C\n    - There is no information provided about the patient's Hepatitis B and C status, so this criterion cannot be evaluated.\n\n17. Women of childbearing potential must use contraception and have a negative pregnancy test\n    - The patient is postmenopausal, so this criterion does not apply.\n\n18. Women must not be breastfeeding\n    - There is no information provided about whether the patient is breastfeeding, but since she is postmenopausal, it is unlikely that she is breastfeeding.\n\n19. Willing to adhere to the study visit schedule and prohibitions/restrictions\n    - There is no information provided about the patient's willingness to adhere to the study requirements, so this criterion cannot be evaluated.\n\nBased on the information provided, the patient meets several of the inclusion criteria, but there are some criteria that cannot be evaluated due to lack of information. Additionally, the patient does not meet the criterion of having no indication of distant metastases, as she has metastatic lesions noted on CXR.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "321": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Participants must have histologically or cytologically confirmed hormone receptor (HR)-positive, Her2-negative metastatic breast cancer.\n- The patient note states that the patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. This does not meet the inclusion criteria.\n\n2. Postmenopausal women or premenopausal women/men on a GnRH agonist for at least 6 weeks prior to study entry.\n- The patient note states that the patient is a 45-year-old postmenopausal woman, meeting this criteria.\n\n3. Participants must have measurable disease as per RECIST 1.1.\n- The patient note does not provide information about measurable disease, so this criteria cannot be evaluated.\n\n4. Prior treatment specifics regarding CDK4/6 inhibitor regimen, NSAI, chemotherapy lines, biologic treatments, and radiotherapy.\n- The patient note does not provide information about prior treatments, so these criteria cannot be evaluated.\n\n5. Age \u226518 years.\n- The patient is 45 years old, meeting this criteria.\n\n6. ECOG performance status \u22642.\n- The patient note does not provide information about performance status, so this criteria cannot be evaluated.\n\n7. Accessible tumor lesion(s) for research biopsy (for phase IIa part of the study).\n- The patient note does not specify if the patient is enrolling in the phase IIa part, so this criteria may not apply.\n\n8. Normal organ and marrow function as defined by specific lab values.\n- The patient note does not provide any lab values, so these criteria cannot be evaluated.\n\n9. Ability to understand and willingness to sign informed consent.\n- The patient note does not provide information about the patient's ability to understand or willingness to sign informed consent, so this criteria cannot be evaluated.\n\nSince the patient does not meet the first inclusion criteria regarding hormone receptor and HER2 status, and there is insufficient information to evaluate several other criteria, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "322": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. Female patient with breast cancer\nThe patient note states that the patient is a \"45-year-old postmenopausal woman with cytologically confirmed breast cancer\". This meets the criterion.\n\n2. Age > 18 years old\nThe patient is 45 years old, which is greater than 18 years old. This criterion is met.\n\n3. Available primary breast tumor sample with adjacent normal epithelial structures\nThe patient note mentions that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, which implies that a primary breast tumor sample is available. It does not explicitly state whether adjacent normal epithelial structures are available, but this information is typically obtained during the biopsy or surgical procedure.\n\n4. Informed consent obtained and signed\nThe patient note does not provide information about whether informed consent has been obtained and signed.\n\nBased on the information provided in the patient note, the patient meets criteria 1 and 2, but there is not enough information to determine if criteria 3 and 4 are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "323": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Newly diagnosed clinical stage II or III ER+/HER2+ breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal.\n- The patient has a 3 cm invasive ductal breast carcinoma which is HER2-positive and ER/PR negative, so this criterion is not met.\n\n2. Tumor size at least 2 cm in one dimension by clinical or radiographic exam. \n- The tumor size is 3 cm, so this criterion is met.\n\n3. At least 18 years of age.\n- The patient is 45 years old, so this criterion is met. \n\n4. ECOG performance status \u2264 1\n- No information about ECOG performance status is provided.\n\n5. Normal bone marrow and organ function based on lab values provided.\n- No lab values are provided, so this cannot be assessed.\n\n6. Left ventricular ejection fraction (LVEF) \u2265 50%\n- No information about LVEF is provided.\n\n7. Baseline corrected QT interval (QTcF) < 480 ms\n- No ECG information is provided.\n\n8. Women of childbearing potential must use contraception.\n- The patient is postmenopausal, so this does not apply.\n\n9. Ability to sign informed consent.\n- No information about ability to provide consent is given.\n\nBased on the information provided, the key inclusion criteria that is not met is that the tumor is ER-negative, when the trial requires ER-positive status. There is also insufficient information to assess several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "324": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criteria of >18 years old.\n\nHer tumor is a 3 cm invasive ductal carcinoma, which is triple negative (HER2-positive and ER/PR negative). This meets the criteria for triple negative breast cancer.\n\nShe has 5 positive lymph nodes, meeting the criteria of 1-3 positive nodes with tumor >2 cm.\n\nShe has metastatic lesions noted on CXR, which would exclude her under the \"Stage IV breast cancer\" exclusion criteria.\n\nNo other exclusion criteria are noted in the patient details provided.\n\nTherefore, based on the information given:\nTrial-level eligibility: 0) Excluded (due to metastatic disease)",
        "label": 0
    },
    "325": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Patient scheduled to undergo lumpectomy for breast cancer at BIDMC.\nThe patient note states that the patient is a candidate for tumor resection (lumpectomy), so this criterion is met.\n\n2. Core needle biopsy revealing invasive breast cancer or DCIS.\nThe patient note mentions that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, which is a type of invasive breast cancer, so this criterion is met.\n\n3. Female.\nThe patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. Minimum age of 21 years.\nThe patient is 45 years old, so this criterion is met.\n\n5. Eligible for breast conserving surgery, lumpectomy and radiation.\nThe patient note states that the patient is a candidate for tumor resection (lumpectomy), so this criterion is met.\n\n6. Estrogen receptor positive (ER+) on core needle biopsy, or if estrogen receptor negative (ER-), have evaluable estrogen receptor status with positive internal control on core biopsy.\nThe patient note mentions that the tumor is ER/PR negative, so this criterion is not met.\n\n7. Progesterone receptor positive (PR+) on core needle biopsy if biopsy indicates invasive cancer, or if progesterone receptor negative (PR-) on biopsy indicating invasive cancer, have evaluable progesterone receptor status with positive internal control on core biopsy.\nThe patient note mentions that the tumor is ER/PR negative, but it does not provide information about whether the progesterone receptor status was evaluable with a positive internal control, so this criterion cannot be fully assessed.\n\n8. HER2 IHC and/or FISH ordered on core biopsy, if biopsy indicates invasive cancer.\nThe patient note states that the tumor is HER2-positive, so this criterion is met.\n\n9. Oncotype DX or other genetic assay performed on core biopsy or not requested.\nThe patient note does not provide information about whether an Oncotype DX or other genetic assay was performed or requested, so this criterion cannot be assessed.\n\n10. Ability to understand and the willingness to sign a written informed consent document.\nThe patient note does not provide information about the patient's ability to understand or willingness to sign an informed consent document, so this criterion cannot be assessed.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria but does not meet the criterion for being estrogen receptor positive. Additionally, there are a few criteria that cannot be fully assessed due to lack of information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "326": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the criteria of being an adult woman over 18 years old.\n\nShe has a confirmed diagnosis of invasive ductal breast carcinoma, which is a type of invasive breast cancer. However, the trial specifically requires the cancer to be cyclin D1 positive, ER positive, PR positive or negative, and HER2 negative. The patient's tumor is HER2 positive and ER/PR negative, so she does not meet those criteria.\n\nThe tumor size is 3 cm, which meets the criteria of being at least 5 mm.\n\nThe patient is a candidate for primary surgery at Mount Sinai, which meets that criteria.\n\nThere is no information provided about the patient's ECOG performance status or a pregnancy test result.\n\nOverall, while the patient meets some of the inclusion criteria, she does not meet the criteria for the specific breast cancer subtype required by the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "327": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n(Cohort A) Pathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (=< 5 cm), N0 or N1 (=< 4 abnormal axillary nodes on initial ultrasound), clinical stage M0\n- The patient has a 3 cm invasive ductal breast carcinoma, which meets the T1/T2 criteria. The note mentions 5 positive lymph nodes, meeting the N1 criteria. There is no mention of metastatic disease, so M0 is assumed.\n\n(Cohort A) HER2 positive (immunohistochemistry [IHC] 3+ and or fluorescence in situ hybridization [FISH] amplified) or triple receptor negative (triple negative [TN], estrogen receptor [ER]/progesterone receptor [PR] < 10% HER2 negative [IHC 1+ or 2+ FISH non-amplified]) receiving any standard routine clinical NST regimen\n- The patient's tumor is described as HER2-positive and ER/PR negative, meeting this criteria.\n\n(Cohort A) Patient desires breast conserving therapy\n- The note states the patient is a candidate for tumor resection, implying breast conserving therapy is desired.\n\n(Cohort A) Age 40 years or older\n- The patient is 45 years old, meeting this criteria.\n\n(Cohort A) Female sex\n- The patient is described as a woman, meeting this criteria.\n\nThe patient meets all the inclusion criteria for Cohort A.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "328": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. ER+ Her2- breast cancer\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n2. Metastatic\nThe patient note mentions metastatic lesions on CXR, so this criterion is met.\n\n3. Female, at least 18 years of age\nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n4. Candidate for fulvestrant therapy - patients who have started fulvestrant may enter this trial if within 3 months of starting fulvestrant\nThere is no mention of the patient receiving fulvestrant therapy, so this criterion cannot be evaluated.\n\n5. Measurable or evaluable by RECIST 1.1\nThe patient note mentions a 3 cm invasive ductal breast carcinoma, which would likely be measurable, so this criterion is likely met.\n\n6. ECOG PS 0-2\nThere is no information provided about the patient's ECOG performance status, so this criterion cannot be evaluated.\n\n7. Able to swallow study drug and comply with study requirements\nThere is no information provided about the patient's ability to swallow or comply with study requirements, so this criterion cannot be evaluated.\n\n8. Tumor available for fresh biopsy (two biopsies - pretreatment as regards enzalutamide, and during treatment at 4 weeks). The patient will be also be asked if they would be willing to provide a third biopsy at time of progression.\nThere is no information provided about the availability of tumor tissue for biopsy, so this criterion cannot be evaluated.\n\n9. If patient is pre- or peri- menopausal, then will need to have concurrent ovarian suppression. Patients may have already gotten the loading dose of ovarian suppression. Pre- or peri- menopausal subjects must have a negative urine pregnancy test confirmed at screening.\nThe patient is described as postmenopausal, so this criterion is not applicable.\n\n10. ANC >1000/uL and platelets >75,000/uL at screening visit\nThere is no information provided about the patient's ANC or platelet count, so this criterion cannot be evaluated.\n\n11. Total bilirubin < 1.5 times upper limit of normal (ULN) at the screening visit unless an alternate nonmalignant etiology exists (eg, Gilbert's disease)\nThere is no information provided about the patient's bilirubin level, so this criterion cannot be evaluated.\n\n12. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases\nThere is no information provided about the patient's AST or ALT levels, so this criterion cannot be evaluated.\n\n13. Creatinine < 1.5 times ULN\nThere is no information provided about the patient's creatinine level, so this criterion cannot be evaluated.\n\n14. INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy\nThere is no information provided about the patient's INR or use of warfarin, so this criterion cannot be evaluated.\n\n15. Willing to donate blood for research at 4 time points\nThere is no information provided about the patient's willingness to donate blood for research, so this criterion cannot be evaluated.\n\n16. Written informed consent obtained prior to biopsies and blood samples\nThere is no information provided about the patient providing written informed consent, so this criterion cannot be evaluated.\n\n17. Agreement to exercise appropriate use of contraception. Subjects should use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at the time of screening for an enzalutamide study and continuing throughout the course of treatment and for at least three months after enzalutamide is discontinued.\nThe patient note states that the patient is not sexually active, so this criterion may not be applicable.\n\nBased on the information provided in the patient note, the only inclusion criterion that is definitively not met is the requirement for ER+ Her2- breast cancer, as the patient has HER2-positive and ER/PR negative disease. However, there is insufficient information to determine if the patient meets many of the other inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "329": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman\n- Diagnosed with breast cancer\n- The tumor is 3 cm invasive ductal carcinoma\n- HER2-positive \n- ER/PR negative\n- Has metastatic lesions in the lungs (based on CXR findings)\n\nThe clinical trial inclusion criteria are:\n1) Initially diagnosed with breast cancer\n2) Has a proven result of HER2 testing by IHC, FISH or other ISH method\n3) Alive or not alive\n\nBased on the information provided, the patient meets all the inclusion criteria:\n1) She is initially diagnosed with breast cancer\n2) Her tumor is HER2-positive, so she likely had HER2 testing done\n3) She is alive\n\nThere is no information provided about exclusion criteria, so we cannot determine if she would be excluded.\n\nTherefore, based on the inclusion criteria alone, this patient appears eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "330": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, meeting the age criteria of \u2265 18 years.\n\n2. She has cytologically confirmed breast cancer that is triple-negative (ER-, PR-, HER2-negative), meeting the criteria for triple-negative breast cancer.\n\n3. She has residual disease \u2265 1 cm and positive lymph nodes after neoadjuvant chemotherapy, meeting the criteria for residual disease.\n\n4. There is no mention of metastatic disease, so she likely meets the criteria of being clinically M0 or Mx.\n\n5. She is a candidate for tumor resection and agrees to do so prior to chemotherapy, meeting the criteria for completing final breast surgery.\n\n6. There is no mention of prior immunotherapy or other exclusion criteria.\n\n7. Her performance status is not mentioned, but assuming it is \u2264 2 to be eligible for the trial.\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for the clinical trial \"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "331": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Invasive adenocarcinoma of the breast diagnosed by core needle biopsy\n- The patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. Breast cancer determined to be HER2-negative\n- The patient note states \"The tumor is HER2-positive\", so this criterion is not met.\n\n3. Breast cancer determined to be hormone receptor-negative (< 10% staining by IHC for both ER and PgR)\n- The patient note states \"The tumor is...ER/PR negative\", so this criterion is met. \n\n4. Locally advanced breast cancer based on tumor size and lymph node involvement\n- The patient has a 3 cm tumor and 5 positive lymph nodes, meeting the criteria for locally advanced disease.\n\n5. Age \u2265 18 years\n- The patient is 45 years old, so this is met.\n\n6. ECOG performance status 0 or 1 \n- This is not mentioned in the patient note, so there is insufficient information.\n\n7. Adequate bone marrow, renal, and hepatic function\n- No relevant lab values provided, so insufficient information.\n\n8. LVEF \u2265 50%\n- No cardiac imaging results provided, so insufficient information. \n\n9. Pregnancy status\n- The patient is postmenopausal, so this criterion is met.\n\n10. Willingness to use contraception\n- Not applicable since the patient is postmenopausal.\n\n11. Ability to understand and sign consent\n- This is not mentioned, so there is insufficient information.\n\nSince the patient does not meet the HER2-negative requirement, which is a key inclusion criterion, they would be excluded from this trial despite meeting some of the other criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "332": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of \u226518 and \u226475 years)\n- Postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR (meets criteria of measurable lesion per RECIST 1.1)\n- ECOG status not mentioned (required to be 0-1)\n- No mention of prior therapies like trastuzumab, anthracyclines, taxanes (required)\n- No mention of lab values like ANC, platelets, bilirubin, LFTs, etc. (required)\n\nThe key inclusion criteria she appears to meet are:\n- Age \n- Metastatic HER2+ breast cancer\n- Measurable disease\n\nHowever, there are several important inclusion criteria that are not mentioned, such as:\n- ECOG performance status\n- Prior therapies \n- Lab values within specified ranges\n\nWithout this key information, it is difficult to definitively determine if she is eligible.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "333": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Estrogen receptor-positive and HER2-negative breast cancer patients, with histological stage of IIa-IIIc.\n   - The patient has HER2-positive and ER/PR negative breast cancer, so this criterion is not met.\n\n2. Without previous chemotherapy or endocrine therapy.\n   - There is no mention of prior chemotherapy or endocrine therapy, so this criterion is likely met.\n\n3. ECOG scores of 0-2 points\n   - There is no information provided about the patient's ECOG score.\n\n4. With measurable and evaluable breast tumor pathologically confirmed as invasive ductal carcinoma\n   - The patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n5. Age: 18-70 years\n   - The patient is 45 years old, so this criterion is met.\n\n6. Lateral breast cancer\n   - The tumor is located in the left upper outer quadrant, so this criterion is met.\n\n7. Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions\n   - There is no information provided about the patient's organ function.\n\nSince the patient does not meet the first inclusion criterion of being ER-positive and HER2-negative, they would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "334": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. \"who sign the informed consent form\" - The note does not mention whether the patient has signed an informed consent form, so this criterion cannot be evaluated.\n\n2. \"pathological diagnosed, without distant metastasis, early stage invasive breast cancer patients\" - The patient has cytologically confirmed invasive ductal breast carcinoma, which is an early-stage invasive breast cancer. However, the note mentions metastatic lesions on CXR, indicating distant metastasis. So this criterion is not met.\n\n3. \"did not undergo neoadjuvant chemotherapy, endocrinotherapy or targeted therapy previously\" - The note does not mention any prior treatment, so this criterion is likely met.\n\n4. \"without breast and axillary surgery history\" - The note does not mention any prior breast or axillary surgery, so this criterion is likely met.\n\n5. \"Ejection fraction score in normal range accord to cardiac doppler\" - The note does not provide any information about the patient's ejection fraction score, so this criterion cannot be evaluated.\n\n6. \"Eastern Cooperative Oncology Group score \u22640-2\" - The note does not provide the patient's ECOG score, so this criterion cannot be evaluated.\n\n7. \"axillary lymph node clinical negative\" - The note mentions that axillary sampling revealed 5 positive lymph nodes, so this criterion is not met.\n\nSince the patient has distant metastatic lesions and positive axillary lymph nodes, which are exclusion criteria for this trial, the patient would be excluded from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "335": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria require patients to have metastatic pancreatic ductal adenocarcinoma, so this patient does not have the target disease.\n\n2. The tumor is HER2-positive and ER/PR negative breast cancer, while the trial is for pancreatic cancer.\n\n3. The patient has metastatic lesions seen on CXR, but the trial requires evaluable metastatic lesions on CT/MRI scans.\n\n4. The patient's ECOG performance status is not mentioned, which is required by the inclusion criteria.\n\n5. There is no information provided about the patient's lab values like ANC, platelets, liver/kidney function etc. which are required by the inclusion criteria.\n\nBased on the information provided, there is insufficient evidence that this patient meets all the key inclusion criteria for the pancreatic cancer trial. More details would be needed to make a definitive assessment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "336": {
        "output": "To determine the patient's eligibility for the clinical trial \"Magseed Magnetic Marker Localization\", let's go through the inclusion criteria one by one:\n\n1. \"Subjects with a breast lesion requiring image-guided localization prior to excision.\"\nThe patient note mentions that the patient has a 3 cm invasive ductal breast carcinoma, which would require localization prior to surgical excision. This criterion is met.\n\n2. \"Subjects aged 18 years or more at the time of consent.\"\nThe patient is described as a 45-year-old postmenopausal woman, so she is over 18 years old. This criterion is also met.\n\nSince the patient meets both inclusion criteria and there are no exclusion criteria provided, we can conclude that the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "337": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease.\" - The patient note confirms that the patient has cytologically confirmed invasive ductal breast carcinoma with metastatic lesions, meeting this criteria.\n\n2. \"Either the primary tumor and/or the metastasis must have been tested for ER, PR and HER2. Patient must have HER2+ breast cancer per ASCO CAP guidelines 2013.\" - The patient note states that the tumor is HER2-positive and ER/PR negative, meeting this criteria. \n\n3. \"History of prior therapy with trastuzumab and a taxane, separately or in combination, is required.\" - There is no mention of prior trastuzumab or taxane therapy in the patient note.\n\n4. \"Patients must have either received one line of prior therapy for metastatic breast cancer, or have developed a disease recurrence during or within 6 months after completing adjuvant therapy.\" - The patient note does not provide information about prior therapies for metastatic disease or disease recurrence after adjuvant therapy.\n\n5. \"No prior treatment with T-DM1 is allowed.\" - There is no mention of prior T-DM1 treatment in the patient note.\n\n6. Other criteria related to prior treatments, radiation, measurable disease, age, performance status, organ function, tissue biopsy, contraception, pregnancy, and LVEF are not addressed in the patient note.\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. There is insufficient information to determine full eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "338": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with metastatic breast cancer. This meets the age criteria of at least 18 years old.\n\n2. She has biopsy-proven metastatic breast cancer with metastatic lesions seen on CXR, meeting the criteria of having at least one lesion outside the liver by standard imaging.\n\n3. It is mentioned that she is a candidate for tumor resection and agrees to do so prior to chemotherapy, suggesting she will start new systemic therapy for her metastatic disease.\n\n4. There is no information provided about whether she has been informed about the investigational nature of the study or has provided written informed consent.\n\nBased on the information given, the patient meets the inclusion criteria of age, metastatic breast cancer with lesions outside the liver, and plans to start new systemic therapy. However, there is no confirmation that she has been informed about the study and provided consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "339": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 18-years or older\nThe patient is 45 years old, so this criterion is met.\n\n2. Patients with histological confirmation of invasive breast cancer with known receptor status suitable for neoadjuvant chemotherapy as assessed by the local investigator\nThe patient has cytologically confirmed invasive ductal breast carcinoma, which meets this criterion.\n\n3. Estrogen receptor (ER)- and progesterone receptor (PR)-negative as defined by \u22641% of positive staining on immunohistochemistry\nThe patient's tumor is ER/PR negative, satisfying this criterion.\n\n4. Human epidermal growth factor receptor 2 (HER2)-negative as defined by American Society of Clinical Oncology / College of American Pathologists guidelines\nThe patient's tumor is HER2-positive, so this criterion is not met.\n\n5. T1c-4 tumours (including inflammatory cancers), with any nodal status non candidate for conservative surgery upfront. Bilateral or multifocal cancer is permitted provided that all sites are HER2-negative and at least one site is ER- and PR-negative.\nThe patient has a 3 cm tumor and positive lymph nodes, making her a non-candidate for conservative surgery upfront. This criterion is met.\n\n6. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses\nThere is no information about consent, so this cannot be evaluated.\n\n7. Patient with social insurance coverage\nThere is no information about insurance coverage, so this cannot be evaluated.\n\nSince the patient's tumor is HER2-positive, which violates one of the key inclusion criteria, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "340": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets adult age criteria)\n- Has cytologically confirmed breast cancer \n- HER2-positive and ER/PR negative (meets HER2-negative criteria)\n- Has metastatic disease (meets metastatic disease criteria)\n- Is a candidate for tumor resection prior to starting 1st line chemotherapy (meets criteria of initiating 1st line cytotoxic chemo for metastatic disease within last 90 days after exhausting hormone therapy if HR+)\n\nBased on the information provided, this patient meets all of the listed inclusion criteria for the BREAKOUT clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "341": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of having histological confirmation of breast cancer.\n\nThe tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative - this matches the inclusion criteria for Cohort 1 of having HER2-positive metastatic or locally advanced breast cancer.\n\nThe patient has 5 positive axillary lymph nodes and metastatic lesions on CXR - this indicates metastatic/Stage IV breast cancer, which matches Cohort 1 inclusion criteria.\n\nThe patient's performance status, blood counts, liver and kidney function are not mentioned but are likely within the specified ranges given that she is a candidate for surgery and chemotherapy.\n\nThe only potential exclusion criteria is that her LVEF is not mentioned, but this is likely assessed prior to chemotherapy.\n\nOverall, based on the provided information, this patient meets the key inclusion criteria for Cohort 1 of the clinical trial.\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "342": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in left upper outer quadrant\n- HER2-positive\n- ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria state:\n- CCI/CLI to be operated (unclear what this acronym means, but she is a candidate for tumor resection)\n- Grade SBR 1, 2 or 3 (no grade provided)\n- Undifferentiated RE/PR status (her tumor is ER/PR negative)\n- HER2 status undifferentiated (her tumor is HER2-positive)\n- Ki 67 indifferent (no information provided)\n- Metastatic or not (she has metastatic lesions)\n- ADP axillary invaded or not (she has 5 positive axillary lymph nodes)\n- Major Patients (unclear requirement)\n\nBased on the information provided, this patient meets several of the key inclusion criteria like HER2-positive status, ER/PR negative, metastatic disease, and positive axillary lymph nodes. There are a few unclear criteria, but overall she appears eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "343": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma in the left breast\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR (indicating metastatic disease)\n- Planned for tumor resection prior to chemotherapy\n\nThe clinical trial is studying a new axillary reverse mapping technique during axillary lymph node surgery for breast cancer.\n\nThe inclusion criteria are:\n- Women diagnosed with invasive breast cancer or ductal carcinoma in situ\n- Receiving mastectomy and sentinel lymph node biopsy, or breast conserving surgery/mastectomy and axillary lymph node dissection, or completion axillary lymph node dissection after positive sentinel node\n- Cases receiving neoadjuvant therapy who are having axillary lymph node dissection\n\nThis patient meets several of the inclusion criteria:\n- Diagnosed with invasive ductal breast cancer\n- Planned for tumor resection (likely mastectomy or breast conserving surgery)\n- Will likely require axillary lymph node surgery given positive nodes\n\nHowever, the presence of metastatic lesions on imaging suggests metastatic disease, which may be an exclusion criterion for this surgical trial focused on axillary mapping.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "344": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparison of Two Types of Biopsy in Suspicious Axillary Lymph Nodes\", let's go through the inclusion criteria one by one:\n\n1. Histologically confirmed invasive breast cancer.\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and a \"core biopsy revealed a 3 cm invasive ductal breast carcinoma\". This meets the inclusion criterion of having histologically confirmed invasive breast cancer.\n\n2. With axillary lymph node with thickened cortex.\nThe patient note mentions that \"Axillary sampling revealed 5 positive lymph nodes\". This suggests that the patient has axillary lymph node involvement, which would likely indicate thickened cortex.\n\n3. Planned for sentinel lymph node biopsy or axillary clearance.\nThe patient note states that \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\". This implies that the patient is planned for axillary lymph node surgery, which could involve sentinel lymph node biopsy or axillary clearance.\n\nBased on the information provided in the patient note, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "345": {
        "output": "To determine the patient's eligibility for the MULTISTARS AMI clinical trial, let's go through the inclusion criteria one by one:\n\nAge \u2265 18 years: The patient's age is not mentioned, so this criterion cannot be evaluated.\n\nSpontaneous acute STEMI (patients presenting within 24 hours of symptom onset): The patient note does not mention any information about a myocardial infarction or related symptoms, so this criterion is not met.\n\nSuitability for PCI from femoral or radial access: No information is provided about the patient's suitability for percutaneous coronary intervention (PCI).\n\nCoronary anatomy suitable for complete coronary revascularization with Synergy\u00ae stent implantation: No information is provided about the patient's coronary anatomy or suitability for stent implantation.\n\nIdentifiable culprit lesion/artery: No information is provided about a culprit lesion or artery.\n\nAt least one non-culprit coronary stenosis \u2265 70% in at least two projections, in a vessel with a lumen diameter \u22652.25 - \u22645.75 mm, other than the culprit artery: No information is provided about the patient's coronary stenosis or vessel lumen diameters.\n\nTIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery: No information is provided about TIMI flow or revascularization of a culprit artery.\n\nStable hemodynamics at the end of the culprit vessel revascularization: No information is provided about the patient's hemodynamic status or revascularization of a culprit vessel.\n\nBased on the provided patient note, there is insufficient information to determine if the patient meets the inclusion criteria for the MULTISTARS AMI clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "346": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Post-menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0).\n- The patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed invasive ductal breast carcinoma, which is a type of invasive breast cancer. However, it also mentions that the tumor is ER/PR negative, which does not meet this inclusion criterion.\n\n2. Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery.\n- The patient note does not provide information about whether the patient has completed local treatment or recovered from side effects.\n\n3. Patient must be on one of AI (steroidal or non-steroidal).\n- The patient note does not mention if the patient is on an aromatase inhibitor (AI) or not.\n\n4. Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish\n- The patient note does not provide information about the patient's ability to complete questionnaires.\n\nSince the patient does not meet the first inclusion criterion of having a hormonal positive (ER and/or PR) tumor, and there is insufficient information to determine if the other criteria are met, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "347": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the inclusion criteria of being a female at least 18 years old.\n\nShe has a 3 cm invasive ductal breast carcinoma, which meets the criteria of having a diagnosis of invasive ductal cancer.\n\nThe tumor is HER2-positive and ER/PR negative, but this is not mentioned in the inclusion criteria.\n\nShe has 5 positive lymph nodes and metastatic lesions on CXR, but this is also not mentioned in the inclusion criteria.\n\nShe is a candidate for tumor resection prior to chemotherapy, which is not explicitly stated in the inclusion criteria but does not exclude her.\n\nBased on the information provided, this patient meets several of the inclusion criteria for the clinical trial on novel molecular targets for ductal carcinoma in situ (DCIS).\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "348": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial is titled \"DTi Diffusion Findings in Breast MRI Screening and Diagnostic\". It is studying the use of diffusion tensor imaging (DTI) in breast MRI to map the milk ducts and detect malignant changes.\n\nThe inclusion criteria state: \"all patients undergoing breast MRI\"\n\nSince this patient is undergoing breast MRI as part of her diagnostic workup and treatment planning, she meets the broad inclusion criteria for this imaging study.\n\nThere are no explicit exclusion criteria listed that would exclude her based on the provided information.\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "349": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge \u2265 18 years of age\n- The patient is 45 years old, so this criterion is met.\n\nFemale gender\n- The patient is a postmenopausal woman, so this criterion is met. \n\nBiopsy proven diagnosis of breast cancer\n- The patient has a cytologically confirmed breast cancer diagnosis, so this criterion is met.\n\nStage IV disease diagnosed either by radiographic studies or biopsy\n- The patient has metastatic lesions seen on CXR, indicating stage IV disease, so this criterion is met.\n\nER+ by immunohistochemistry on primary and/or metastatic tissue biopsy (>10%) \n- The tumor is ER/PR negative, so this criterion is not met.\n\nHER2 non-amplified (1+ or below by immunohistochemistry, and/or Her2 FISH <2 HER2-to-CEP17 ratio)\n- The tumor is HER2-positive, so this criterion is not met.\n\nProgressed on at least one prior line of endocrine therapy for metastatic disease\n- There is no information provided about prior endocrine therapy.\n\nThree or fewer prior endocrine-containing therapies for recurrent/metastatic disease\n- There is no information provided about prior endocrine therapies.\n\nTwo or fewer prior lines of cytotoxic chemotherapy for recurrent/metastatic disease\n- There is no information provided about prior chemotherapies.\n\nPlans to initiate 2nd, 3rd, or 4th line endocrine therapy for metastatic disease\n- There is no information provided about planned endocrine therapies.\n\nRecent re-staging scans within 4 weeks of study enrollment, with radiographically identifiable disease\n- The patient had a recent CXR showing metastatic lesions, so this criterion is met.\n\nNo concurrent or prior diagnosis of malignancy other than breast cancer for the past 5 years...\n- There is no information provided about other malignancies.\n\nIntends to pursue treatment as well as clinical and radiographic follow-up at UNC Health Care\n- There is no information provided about where the patient intends to receive treatment.\n\nSigned an institutional review board (IRB)-approved informed consent document for this protocol and HIPAA consent form\n- There is no information provided about consent.\n\nIn summary, while some criteria are met, there is insufficient information to determine eligibility for several key criteria. Additionally, the tumor being ER/PR negative and HER2 positive excludes the patient from this trial focused on ER+ metastatic breast cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "350": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Signed informed consent - Not mentioned in the patient note, so cannot determine eligibility.\n\n2. Age 18-75 years - The patient is 45 years old, so meets this criteria.\n\n3. Histologically confirmed cancer type:\n   - Colorectal cancer with KRAS/NRAS/BRAF wild type \n   - Esophageal squamous cell carcinoma\n   - Biliary tract cancer\n   - Other digestive system tumor beyond colorectal and gastric/GE junction adenocarcinoma\n\nThe patient has invasive ductal breast carcinoma, which is not one of the listed cancer types. So the patient does not meet this criteria.\n\n4. HER2 positive status - The patient's tumor is HER2 positive, so meets this criteria.\n\n5. Relapsed or metastatic disease with measurable lesion - The patient has metastatic lesions seen on CXR, so meets this criteria.\n\n6. ECOG 0-1 - Not mentioned, so cannot determine eligibility.\n\n7. Failed prior systemic therapy - The patient is a candidate for surgery followed by chemotherapy, so it seems this is the first line of treatment. Does not meet this criteria.\n\n8. Adequate organ function - Some lab values like ANC, platelets, bilirubin are not provided, so cannot fully assess. But the patient does not seem to have any major organ dysfunction mentioned.\n\n9. Able to use contraception if reproductive potential - The patient is postmenopausal, so this is not applicable.\n\nSince the patient does not have one of the listed cancer types and has not failed prior systemic therapy, the patient does not meet all the key inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "351": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must have signed an IRB-approved consent form.\n   - There is no information about this in the patient note, so I cannot determine eligibility for this criterion.\n\n2. The patient must have an ECOG performance status of 0 or 1. \n   - There is no information about performance status in the patient note.\n\n3. ER and PgR analysis must have been performed on the primary tumor prior to neoadjuvant therapy.\n   - The note states that the tumor is \"ER/PR negative\".\n\n4. HER2 testing must have been performed on the primary tumor prior to neoadjuvant chemotherapy. \n   - The note states that the tumor is \"HER2-positive\".\n\n5. A biopsy marker must have been placed in the tumor bed prior to neoadjuvant chemotherapy.\n   - There is no information about this in the patient note.\n\n6. The patient must have operable focal or multifocal invasive ductal carcinoma and completed neoadjuvant chemotherapy with a clinical complete response.\n   - The note states the patient has a 3 cm invasive ductal carcinoma and is a \"candidate for tumor resection and agrees to do so prior to chemotherapy\".\n\n7. Synchronous bilateral breast cancer is allowed if one side meets criteria.\n   - There is no mention of bilateral breast cancer.\n\n8. The patient must have achieved complete or near-complete radiologic tumor response based on imaging criteria.\n   - There is no information about radiologic response in the patient note.\n\n9. The patient must intend to undergo breast conserving therapy at the time of consent.\n   - There is no explicit statement about this in the note.\n\n10. The patient must be able to undergo stereotactic vacuum-assisted breast biopsy after neoadjuvant chemotherapy.\n    - There is no information about this in the note.\n\n11. The patient must have completed neoadjuvant chemotherapy.\n    - The note states the patient is a \"candidate for tumor resection and agrees to do so prior to chemotherapy\", implying neoadjuvant chemotherapy has not yet been given.\n\n12. Patients with HER2-positive tumors must have received neoadjuvant anti-HER2 therapy.\n    - There is no information about the treatment regimen in the note.\n\n13. Patients treated with certain therapies like PD-1/PD-L1 inhibitors are eligible.\n    - There is no information about prior treatments in the note.\n\nIn summary, while some criteria are met (ER/PR and HER2 status), there is insufficient information in the patient note to determine full eligibility for this trial based on the listed inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "352": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer\", let's go through the inclusion and exclusion criteria:\n\nInclusion Criteria:\n1. Age 18 years or older: The patient is 45 years old, so this criterion is met.\n2. Have documented or reported microscopic hematuria within 3 months of study enrollment: There is no information provided about microscopic hematuria in the patient note.\n3. Willing and able to give written informed consent: There is no information provided about the patient's willingness to give consent.\n\nExclusion Criteria:\n1. Have history of BCa: The patient note does not mention any history of bladder cancer.\n2. History of previous cancer (excluding basal and squamous cell skin cancer): The patient has breast cancer, which would exclude them from the trial.\n3. Have a known active urinary tract infection or urinary retention: There is no information provided about urinary tract infections or urinary retention.\n4. Have active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL): There is no information provided about stone disease or renal insufficiency.\n5. Have ureteral stents, nephrostomy tubes or bowel interposition: There is no information provided about these conditions.\n6. Have recent genitourinary instrumentation (within 10 days prior to signing consent): There is no information provided about recent genitourinary instrumentation.\n7. Be unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging): There is no information provided about the patient's ability or willingness to undergo these evaluations.\n\nBased on the information provided in the patient note, the patient meets the age criterion for inclusion but is excluded due to having a history of breast cancer, which is a previous cancer other than basal or squamous cell skin cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "353": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Any patient with histologically confirmed newly diagnosed operable ER+, Her2 negative invasive carcinoma on diagnostic core biopsy that has a radiographic size \u2265 1.5 cm\"\n- The patient has a 3 cm invasive ductal breast carcinoma, which is ER negative and HER2 positive, so this criterion is not met.\n\n2. \"Histology has to be ductal, lobular or mixed\"\n- The patient has invasive ductal carcinoma, so this criterion is met.\n\n3. \"Surgery date planned in the next 2-6 weeks\" \n- It is mentioned that the patient is a candidate for tumor resection prior to chemotherapy, so we can assume this criterion is likely met.\n\n4. \"Negative pregnancy test if of child baring potential\"\n- The patient is postmenopausal, so this criterion is not applicable.\n\n5. \"Post-menopausal status verified by FSH and Estradiol (with 6 months of amenorrhea)\"\n- The patient is described as postmenopausal, so this criterion is met.\n\nSince the patient does not meet the first inclusion criterion of having an ER+, HER2 negative tumor, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "354": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female; age \u226518 years - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II - The patient has a 3 cm invasive ductal breast carcinoma, which would likely be stage II, so this criterion is met.\n\n3. Clinically lymph node negative, confirmed by clinical exam and/or ultrasound imaging - The patient had 5 positive lymph nodes, so this criterion is not met.\n\n4. Estrogen- and/or progesterone-receptor-positive tumor, defined \u22651% positively staining cells by immunohistochemistry - The tumor is ER/PR negative, so this criterion is not met.\n\n5. HER2/neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) - The tumor is HER2-positive, so this criterion is not met.\n\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - No information is provided about the patient's performance status.\n\n7. Other criteria related to pretreatment evaluations, contraception use, adequate organ function, etc. - There is no information provided about these criteria.\n\nSince the patient does not meet criteria 3, 4, and 5, which are key eligibility criteria for this trial, the patient would not be eligible.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "355": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age and menopausal status criteria)\n- With cytologically confirmed breast cancer (meets breast cancer criteria)\n- 3 cm invasive ductal carcinoma, HER2-positive, ER/PR negative (meets criteria for invasive breast cancer and HER2 status, but does not meet ER+ criteria)\n- Has axillary lymph node metastases (no explicit exclusion criteria for this)\n- Has metastatic lesions on CXR (excluded by \"Evidence of metastases\" criteria)\n\nThe key inclusion criteria the patient does not meet are:\n1) ER+ breast cancer \n2) HER2- breast cancer\n\nAnd the key exclusion criteria the patient meets is:\n1) Evidence of metastases\n\nTherefore, despite meeting some inclusion criteria, the patient is excluded from this trial based on not meeting the ER and HER2 status criteria, as well as having metastatic disease which is an exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "356": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1: No information provided, so cannot assess this criteria.\n\n2. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by needle core biopsy: Yes, the patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy.\n\n3. Study participants must be cT1c - cT4a-d, any node (N), no metastases (M0): The patient has axillary lymph node metastases, so this criteria is met. However, the patient also has metastatic lesions on CXR, which would exclude them based on the M0 criteria.\n\n4. Breast tumor must be >1.5 cm: Yes, the tumor is 3 cm.\n\n5. Must be HER2-positive: Yes, the tumor is HER2-positive.\n\n6. Ejection fraction (EF) greater than 50%: No information provided.\n\n7. No prior cancer chemotherapy allowed: Meets this criteria.\n\n8. Adequate organ and marrow function: No information provided on lab values.\n\n9. Women of child-bearing potential must agree to use contraception: The patient is postmenopausal, so this does not apply.\n\n10. Negative pregnancy test within 14 days: The patient is postmenopausal, so this does not apply.\n\nOverall, while the patient meets some key inclusion criteria like tumor size, HER2 status, and no prior chemotherapy, they are excluded based on having metastatic disease per the M0 criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "357": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the \"Diagnosed breast cancer\" inclusion criteria.\n\nShe has received chemotherapy, satisfying the \"received chemotherapy\" criteria.\n\nHer ECOG performance status is not mentioned, so we cannot confirm if she meets the \"ECOG performance status 0 or 1\" criteria.\n\nHer ANC and PLT counts are not provided, so we cannot confirm if she meets the \"ANC\u22651.5\u00d710 9/L, PLT\u2265100\u00d710 9/L\" criteria.\n\nIt is mentioned that she had leukocyte reduction after chemotherapy, which could potentially satisfy the \"WBC\u22643.0x109/L or ANC\u22641.5x109/L\" criteria, but the exact values are not given.\n\nThere is no information about her ECG examination, so we cannot confirm if she meets the \"No obvious abnormal ecg examination\" criteria.\n\nHer liver function tests (TBIL, AST, ALT) and creatinine levels are not provided, so we cannot confirm if she meets the \"Cr, TBIL, AST, ALT\u22641.5\u00d7ULN, no serious underlying disease\" criteria.\n\nIt is not explicitly stated if she has signed an informed consent form.\n\nOverall, while the patient meets some of the inclusion criteria, there is not enough information provided to definitively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "358": {
        "output": "To determine the patient's eligibility for the clinical trial \"Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure\", let's go through the inclusion criteria one by one:\n\n1. \"Invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB).\"\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and \"Axillary sampling revealed 5 positive lymph nodes\", which meets this criterion.\n\n2. \"Underwent computed tomography (CT) reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy (NAC).\"\nThere is no information provided about whether the patient underwent CT reconstruction before and after neoadjuvant chemotherapy.\n\n3. \"Attend the study voluntarily, sign the informed consent.\"\nThere is no information provided about whether the patient has agreed to participate in the study voluntarily and sign the informed consent.\n\nSince there is not enough information to confirm that the patient meets all the inclusion criteria, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "359": {
        "output": "To determine the patient's eligibility for the clinical trial \"Detecting Transitional Cell Carcinoma From Haematuria\", let's go through the inclusion criteria one by one:\n\n1. Capable of giving written informed consent\n   - The patient note does not mention the patient's ability to provide informed consent, so this criterion cannot be evaluated.\n\n2. Age \u226518 years\n   - The patient is 45 years old, so this criterion is met.\n\n3. Referral to haematuria clinic (gross or microscopic haematuria)\n   - The patient note does not mention any referral to a haematuria clinic or the presence of haematuria (blood in urine), so this criterion is not met.\n\nSince the patient does not meet the third inclusion criterion and there is insufficient information to evaluate the first criterion, the patient cannot be considered eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "360": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the \"histologically proven invasive carcinoma of the breast\" inclusion criteria.\n\nShe has 5 positive axillary lymph nodes, which falls within the \"one to three positive axillary lymph nodes (pN1)\" inclusion criteria.\n\nThe patient has undergone breast-conserving surgery and is a candidate for chemotherapy prior to tumor resection, satisfying the \"prior breast-conserving surgery and post-operative adjuvant chemotherapy including taxane\" criteria.\n\nHer tumor is HER2-positive, so she would likely receive \"anti-HER2 therapy in cases with HER2-positive tumor\" per the criteria, though this is not explicitly stated.\n\nHer tumor is ER/PR negative, so the \"administering adjuvant hormonal therapy in cases with hormone receptor-positive tumor\" criteria does not apply.\n\nBased on the information provided, the patient meets all of the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "361": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed breast cancer (infiltrating ductal or lobular breast carcinoma) with evidence of measurable metastatic disease. Metastatic disease must be biopsy proven.\n- The patient note states \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\" This meets the criteria.\n\n2. Measurable lesion \u226510 mm that has not been irradiated.\n- No information is provided about lesion size or irradiation status.\n\n3. Patients must have HER2 status determined by FISH or IHC. HER2 status of positive or negative are both eligible for the study.\n- The patient note states \"The tumor is HER2-positive and ER/PR negative.\" This meets the criteria.\n\n4. Female \u226518 years old\n- The patient is a 45-year-old woman, meeting this criteria.\n\n5. Able to provide written informed consent\n- No information provided.\n\n6. ECOG performance status 0-1\n- No information provided.\n\n7. Life expectancy \u22653 months  \n- No information provided.\n\n8. Eligible for apheresis\n- No information provided.\n\n9. Adequate organ function based on lab values\n- No lab values provided.\n\n10. Negative pregnancy test for women of childbearing potential\n- States the patient is postmenopausal, so this doesn't apply.\n\n11. Willing to use contraception if of childbearing potential\n- Patient is postmenopausal, so this doesn't apply.\n\n12. Had two or more prior lines of therapy in the metastatic setting\n- No information provided about prior therapies.\n\nBased on the information given, the patient meets some but not all of the key inclusion criteria. There is insufficient information to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "362": {
        "output": "To determine the patient's eligibility for the clinical trial \"Role of Oncoplastic Breast Surgery In Breast Cancer Treatment\", I will go through the inclusion criteria one by one:\n\n1. \"The study will include 30 women with early-stage breast cancer treated at general surgery department, Assuit University Hospitals\"\n   - The patient note does not specify where the patient is being treated, so this criterion cannot be evaluated.\n\n2. \"For all patients an informed consent for their inclusion in the study including the use of images will be obtained.\"\n   - The patient note does not mention whether informed consent has been obtained, so this criterion cannot be evaluated.\n\n3. \"Selection criteria include women with a pre-operative diagnosis (clinical examination, imaging and needle biopsy) of Tis, T1 and T2 tumours without extensive skin involvement.\"\n   - The patient note states that the patient has a \"3 cm invasive ductal breast carcinoma\", which would likely correspond to a T2 tumor.\n   - There is no mention of extensive skin involvement.\n\nBased on the information provided in the patient note, the patient appears to meet the tumor size and skin involvement criteria for inclusion in the trial. However, there is not enough information to determine if the other criteria are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "363": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women who have disease that is amenable to biopsy and agree to undergo a standard of care and /or research biopsy\n- The patient note mentions that a core biopsy was done, so this criterion is met.\n\n2. Criteria for prior therapy:\n- The patient has not received any prior endocrine therapy or chemotherapy in the metastatic setting, so she meets the criteria for the first line setting.\n\n3. The intention to begin palbociclib and letrozole (first line) or palbociclib and fulvestrant (second line) as treatment\n- The patient note does not specify the intended treatment, so this cannot be evaluated.\n\n4. Measurable disease as defined by RECIST criteria or bone only disease\n- The patient has metastatic lesions seen on CXR, so this criterion is met.\n\n5. No current evidence of visceral crisis\n- The patient note does not mention any visceral crisis, so this criterion is likely met.\n\n6. History of central nervous system metastasis with certain conditions\n- The patient note does not mention any central nervous system metastasis, so this criterion is met.\n\n7. Premenopausal women must agree to begin or continue an LHRH agonist\n- The patient is described as postmenopausal, so this criterion does not apply.\n\n8. ECOG performance status: 0, 1, or 2\n- The patient's performance status is not mentioned, so this cannot be evaluated.\n\n9. Able to swallow oral formulation of drugs\n- This is not mentioned in the patient note, so it cannot be evaluated.\n\n10. Signed informed consent\n- This is not mentioned in the patient note, so it cannot be evaluated.\n\n11. Willing to submit tissue, blood, stool, saliva and urine for research\n- This is not mentioned in the patient note, so it cannot be evaluated.\n\n12. Histologic confirmation of ER-positive and HER2-negative breast cancer\n- The patient has ER-negative, HER2-positive breast cancer, so this criterion is not met.\n\n13. Adequate blood counts and organ function\n- The patient note does not provide enough information to evaluate this criterion.\n\n14. Willing to return to enrolling institution for follow-up\n- This is not mentioned in the patient note, so it cannot be evaluated.\n\n15. Toxicities from prior therapies have resolved or stabilized\n- The patient has not received any prior therapy, so this criterion is met.\n\nBased on the information provided in the patient note, the key exclusion criterion is that the patient has ER-negative, HER2-positive breast cancer, while the trial requires ER-positive and HER2-negative breast cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "364": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Participants must have histologically or cytologically confirmed inoperable locally advanced or metastatic ER+ breast cancer.\n- The patient note states that the patient has cytologically confirmed invasive ductal breast carcinoma, which is metastatic based on the positive axillary lymph nodes and metastatic lesions on CXR. The tumor is ER negative, so this criterion is not met.\n\n2. Participants must have documented HER2+ disease by overexpression and/or gene amplification on the most recent biopsy, per current ASCO-CAP guidelines. \n- The patient note states that the tumor is HER2-positive, so this criterion is met.\n\n3. Participants must have received prior therapy with trastuzumab, pertuzumab, or ado-trastuzumab emtansine (T-DM1) in any setting.\n- There is no information provided about prior therapies, so it is unclear if this criterion is met.\n\n4. Participants must agree to undergo a research biopsy of a metastatic lesion, or have archived tissue available if a biopsy is not feasible.\n- There is no information about whether the patient agrees to a biopsy or has archived tissue available.\n\n5. Women \u2265 18 years of age.\n- The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n6. ECOG performance status 0-2.\n- There is no information provided about the patient's performance status.\n\n7. Meeting certain laboratory criteria for organ function and marrow function.\n- There is no information provided about the patient's laboratory values.\n\n8. Women of childbearing potential must have a negative pregnancy test and agree to use contraception.\n- The patient is postmenopausal, so this criterion is not applicable.\n\n9. Ability to understand and willingness to sign informed consent.\n- There is no information about whether the patient can provide informed consent.\n\nBased on the information provided in the patient note, the key inclusion criteria that are clearly met are that the patient has HER2-positive metastatic breast cancer and is a woman \u2265 18 years old. However, there is insufficient information to determine if several other important criteria are met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "365": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women age 18 years or older\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Confirmed histologic diagnosis of operable HER2 overexpressing (ER<10%, PR<10%, and HER2 2+ or FISH amplified) OR triple negative (ER<10%, PR<10%, and HER2 0/1+ or 2+/FISH not amplified) OR ER positive invasive ductal or invasive lobular breast cancer including MSKCC pathology confirmation\nThe patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, so she meets this criterion.\n\n3. Operable breast cancer treated with NAC undergoing either breast conservation or total Mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a complete imaging response, which is defined as no residual tumor enhancement.\nThe patient is a candidate for tumor resection (surgery) after receiving neoadjuvant chemotherapy, but there is no mention of a post-NAC MRI showing a complete imaging response.\n\n4. No indication of distant metastases (M0)\nThe patient has metastatic lesions noted on CXR, so she does not meet this criterion.\n\n5. Tumor site amenable to MRI guided biopsy as determined by the radiologist\nThere is no information provided about whether the tumor site is amenable to MRI-guided biopsy.\n\n6. Definitive surgery being performed at MSKCC within within 0-60 days of completing NAC\nThere is no information provided about where the surgery will be performed or the timing relative to completing neoadjuvant chemotherapy.\n\n7. ECOG performance status score of 0 to \u2264 2 and or KPS performance status score of 80% to 100%\nThere is no information provided about the patient's performance status.\n\n8. Women of childbearing potential (WOCBP) must not be pregnant. \nThe patient is postmenopausal, so this criterion is met.\n\n9. Women must not be breastfeeding\nThere is no indication that the patient is breastfeeding.\n\n10. Willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol\nThere is no information provided about the patient's willingness or ability to provide consent and adhere to the study plan.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. The presence of metastatic lesions on CXR would exclude her from participating. There is also insufficient information to determine if she meets several other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "366": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects must have histologically or cytologically confirmed invasive breast cancer which meets the following criteria:\n   - The patient note confirms cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\n2. Estrogen Receptor (ER) and Progesterone Receptor (PR)-negative as defined by local standard clinical immunohistochemistry (IHC) < 1%.\n   - The patient note states the tumor is ER/PR negative, so this criterion is met.\n\n3. HER2-negative using local standard testing. Negative is defined as IHC 0 or 1+ (if 2+, must reflex to ISH method). If ISH method is used, ratio < 2 is considered negative.\n   - The patient note states the tumor is HER2-positive, so this criterion is not met.\n\n4. Clinical tumor size of at least 2.1 cm (T2) by palpation or imaging, regardless of the ipsilateral regional lymph node status, or any tumor size but with ipsilateral regional lymph nodes involved by the tumor (any T if ipsilateral regional node positive).\n   - The patient note mentions a 3 cm tumor size and positive axillary lymph nodes, so this criterion is met.\n\n5. Candidate for neoadjuvant chemotherapy.\n   - The patient note states the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is met.\n\n6. Age > 18 years and < 75 years\n   - The patient is 45 years old, so this criterion is met.\n\n7. ECOG Performance Status < 1.\n   - There is no information about ECOG Performance Status in the patient note.\n\n8. Other criteria related to organ function, pregnancy status, contraception, and ability to provide informed consent.\n   - There is no information about these criteria in the patient note.\n\nSince the patient does not meet the HER2-negative criterion, which is an inclusion criterion for this trial, and there is insufficient information about some other criteria, the patient cannot be determined to be fully eligible based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "367": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which is not relevant to the clinical trial for non-muscle invasive urothelial carcinoma of the bladder.\n\n2. The inclusion criteria specify:\n- Histologically confirmed non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on TURBT obtained within 60 days of registration.\n- ECOG performance status 0 or 1\n- Age \u2265 18 years old\n- Adequate hematologic, hepatic and renal function\n- Provide written informed consent\n\nThe patient note does not mention any of these criteria being met or not met.\n\n3. The exclusion criteria include:\n- Muscle-invasive, locally advanced unresectable, or metastatic urothelial carcinoma\n- Active second malignancy other than non-melanoma skin cancer\n- Recent anti-cancer therapy or unresolved toxicity\n- Prior therapy with PD-1, PD-L1, or CTLA-4 agents\n- Prior radiation to prostate or pelvis (for radiation arms)\n- Recent major surgery or procedures\n- Severe uncontrolled medical conditions\n- Autoimmune or inflammatory disorders\n- Immunosuppressive medication use\n- Pregnancy or breastfeeding\n- Unwilling to use contraception\n- Unwilling to comply with protocol\n- Live attenuated vaccine recently\n- Allergy to study drugs\n\nThe patient note mentions the patient has breast cancer, which would exclude her under the \"active second malignancy\" criteria.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "368": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets criteria of having operable breast cancer diagnosed by histopathology)\n- No history mentioned of prior anti-cancer therapies\n- No information given about cardiac function, ECOG score, or blood test results to assess those criteria\n- Agrees to tumor resection prior to chemotherapy (suggests she is disposed to practice contraception during trial)\n\nThe inclusion criteria state:\n- Operable breast cancer diagnosed by histopathology with no distant metastasis (met)\n- No prior anti-cancer therapies (met based on information given)\n- Normal cardiac function by echocardiography (no information given)\n- ECOG score \u2264 0-1 (no information given)\n- Disposed to practice contraception during trial (suggests this is met based on agreeing to surgery first)\n- Meets blood test criteria (no information given)\n\nBased on the information provided, the patient meets some of the key inclusion criteria like having operable breast cancer, no prior treatments, and suggesting willingness to practice contraception. However, there is no information about cardiac function, performance status, or blood test results to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "369": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria are:\n- Invasive ductal carcinoma diagnosed by biopsy (matches patient)\n- Clinically positive node diagnosed by CECT, number of strengthened nodes at Level I \u2265 1 with longest diameter \u2265 2cm (5 positive nodes mentioned, diameter not specified)\n- Neoadjuvant chemotherapy regimen to follow NCCN guideline (patient is a candidate for chemotherapy after resection)\n- No prior history of breast cancer or other malignancies (not mentioned, so assume no prior history)\n\nBased on the available information, this patient meets most of the key inclusion criteria, except the diameter of the positive nodes is not specified.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "370": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the inclusion criteria of being a female aged \u2265 18 years.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. This meets the inclusion criteria of having a histologically confirmed diagnosis of non-metastatic operable triple negative breast cancer (TNBC) subjected to diagnostic core biopsy.\n\nAxillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. This suggests the patient may have metastatic disease, which would exclude her from this trial focused on non-metastatic operable TNBC.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This aligns with the inclusion criteria of having a clinical indication for a neoadjuvant approach according to the investigator's judgment.\n\nNo other relevant details about ECOG performance status, availability of tumor block, or contraceptive use are provided.\n\nBased on the information given, while the patient meets some key inclusion criteria, the presence of metastatic lesions on imaging would likely exclude her from this trial focused on non-metastatic disease.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "371": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women age \u2265 18 years\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Eastern Cooperative Oncology Group performance status 0-2 (Karnofsky >60%)\nThere is no information provided about the patient's performance status, so this cannot be evaluated.\n\n3. Patients with metastatic breast cancer\nThe patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR, so she meets this criterion.\n\n4. HER2 (human epidermal growth factor receptor 2)-positive breast cancer\nThe patient's tumor is described as HER2-positive, so she meets this criterion.\n\n5. Estrogen/progesterone receptor positive OR negative disease allowed\nThe patient's tumor is described as ER/PR negative, which is allowed.\n\n6. Patients must have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\nThe 3 cm invasive ductal carcinoma would likely be considered measurable disease, but this is not definitively stated.\n\n7. Patients that have failed at least one anti-HER2 therapy in the metastatic setting\nThere is no information provided about prior therapies, so this cannot be evaluated.\n\n8. Patients must have normal organ and marrow function as defined\nThere is no information provided about the patient's lab values or organ function, so this cannot be evaluated.\n\n9. Baseline left ventricular ejection fraction (LVEF) \u2265 50%\nThere is no information provided about the patient's LVEF, so this cannot be evaluated.\n\n10-13. Other criteria regarding willingness to comply, take oral medication, sign consent, use contraception\nThere is no information provided about these criteria.\n\nIn summary, the patient definitely meets criteria 1, 3, 4, and 5. However, there is insufficient information to evaluate criteria 2, 6-13.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "372": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Diagnosed with breast cancer (meets disease criteria)\n- Tumor is 3cm invasive ductal carcinoma, HER2-positive, ER/PR negative (meets ER+, HER2- criteria)\n- Has 5 positive lymph nodes (meets early-stage criteria)\n- No prior anti-cancer therapies mentioned (meets no prior treatment criteria)\n- No issues with blood tests or cardiac function mentioned (meets those criteria)\n\nThe only potential exclusion is that the tumor is ER/PR negative, while the trial specifies ER+.\n\nHowever, since the trial is specifically for the Luminal B1 subtype which is ER+, PR negative or low, this patient appears to meet that criteria.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "373": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Invasive breast cancer diagnosed with core needle needle biopsy;\nThe patient note mentions that a core biopsy revealed a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n2. Staging cT1b-2N0M0;\nThe patient note does not provide the clinical staging information, so it's unclear if this criterion is met.\n\n3. ER/PR positive cells ratio <10%, or HER2 positive (according to ASCO-CAP guidelines),and with chemotherapy indications;\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so this criterion is met.\n\n4. Without chemotherapy contraindications, and planned or has started neoadjuvant chemotherapy (HER2 positive breast cancer neoadjuvant anti-HER2 treatment, or have adjuvant anti-HER2 treatment plan);\nThe patient note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, but it does not specify if neoadjuvant chemotherapy is planned or if there are any contraindications to chemotherapy.\n\n5. With axillary sentinel lymph node biopsy indications confirmed prior to neoadjuvant therapy;\nThe patient note states that axillary sampling revealed 5 positive lymph nodes, but it's unclear if a sentinel lymph node biopsy was performed or indicated prior to neoadjuvant therapy.\n\n6. Voluntarily join the study and sign an informed consent form.\nThe patient note does not provide any information about the patient's willingness to participate in the study or sign an informed consent form.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "374": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative (triple negative), with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial is for recurrent/refractory metastatic breast cancer, with separate cohorts for hormone receptor positive and triple negative breast cancer.\n\nFor the hormone receptor positive cohort, the key inclusion criteria are:\n- Metastatic hormone receptor positive (ER+ and/or PR+) breast cancer\n- HER2 negative \n- Prior treatment with at least 2 lines of hormonal therapy\n- Measurable disease per RECIST 1.1\n- Adequate organ function\n\nThis patient does not meet the criteria for the hormone receptor positive cohort, as her tumor is ER/PR negative (triple negative).\n\nFor the triple negative cohort, the key inclusion criteria are:\n- Metastatic triple negative (ER-, PR-, HER2-) breast cancer\n- At least one prior line of chemotherapy for metastatic disease\n- Measurable disease per RECIST 1.1 \n- Adequate organ function\n\nThe patient meets all of these criteria for the triple negative cohort.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible (for the triple negative breast cancer cohort)",
        "label": 0
    },
    "375": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Two Warming Methods in Knee Arthroplasty\", the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The patient note describes a 45-year-old woman with breast cancer, while the trial is focused on patients undergoing knee arthroplasty (knee replacement surgery).\n\n2. The inclusion criteria specifically mention patients with a BMI between 25-40, undergoing elective primary unilateral knee arthroplasty, and receiving spinal anesthesia. The patient note does not mention any of these criteria.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "376": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n- The patient note does not mention the ECOG performance status, so this criterion cannot be evaluated. \n\n2. The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy.\n- The patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\"\n- This meets the criterion.\n\n3. The primary breast tumor must be palpable and measure greater than or equal 2.0 cm on physical exam. \n- The patient note states the tumor is 3 cm, meeting this criterion.\n\n4. The regional lymph nodes can be cN0, cN1, or cN2a.\n- The patient note states \"Axillary sampling revealed 5 positive lymph nodes.\"\n- This likely meets the cN1 or cN2a criterion, but the specific staging is not provided.\n\n5. Histological grade II or III tumor.\n- The patient note does not mention the histological grade, so this cannot be evaluated.\n\n6. Criteria related to lymph node evaluation and imaging are met based on the information provided.\n\n7. Tumor must be ER and PgR negative.\n- The patient note states \"The tumor is HER2-positive and ER/PR negative.\"\n- This meets the criterion.\n\n8. Tumor must be HER2-negative based on specific testing criteria.\n- The patient note states the tumor is HER2-positive, which does not meet this criterion for the trial.\n\n9-13. The patient note does not provide information on blood counts, hepatic function, bone scans, or LVEF to evaluate these criteria.\n\n14. Reproductive potential and contraception requirement.\n- The patient is described as postmenopausal, so this criterion may not apply.\n\n15. Tumor determined to have abnormal HER2-driven signaling activity based on the CELx HSF test.\n- The patient note does not mention this test, so this criterion cannot be evaluated.\n\nOverall, while the patient meets some of the inclusion criteria, the key criterion of being HER2-negative is not met as the tumor is described as HER2-positive. Additionally, there is insufficient information to evaluate several other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "377": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Provide signed and dated written informed consent before entering the study. (Not mentioned in patient note, so cannot assess)\n\n2. Female, \u226518 and \u226465 years of age. (Yes, the patient is a 45-year-old postmenopausal woman)\n\n3. Histologically-confirmed invasive carcinoma of the breast (AJCC, vs. 8.0) Stage II, IIIa). (Yes, the patient has a 3 cm invasive ductal breast carcinoma)\n\n4. Operable breast cancer, planned surgical resection of breast tumor (mastectomy or lumpectomy) and sentinel or axillary lymph nodes. (Yes, the patient is a candidate for tumor resection)\n\n5. Unilateral, measurable tumor of the breast >2 cm in diameter. (Yes, 3 cm tumor)\n\n6. HER2 positive tumor, defined as 3+ score by IHC or fluorescence positive by FISH, as confirmed by central laboratory. (Yes, HER2-positive)\n\n7. Known estrogen receptor (ER) and progesterone receptor (PrR) status at study entry. (Yes, ER/PR negative)\n\n8. Adequate bone marrow/hepatic/renal function (Not mentioned, so cannot assess)\n\n9. ECOG score of 0 or 1. (Not mentioned, so cannot assess)\n\n10. LVEF \u226555% (Not mentioned, so cannot assess) \n\n11. Negative pregnancy test/using contraceptives if childbearing potential (Not applicable as patient is postmenopausal)\n\nBased on the information provided, the patient meets several key inclusion criteria like cancer type, HER2 status, planned surgery. However, there are some criteria like adequate organ function, ECOG score, LVEF that cannot be assessed from the note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "378": {
        "output": "To determine the patient's eligibility for the clinical trial \"Identification of New Prognostic Markers for Breast Cancer\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Adult female patients with breast cancer\n\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, so she meets this criterion.\n\nSince the inclusion criteria only specify \"Adult female patients with breast cancer\", and the patient meets this criterion, we can conclude that she is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "379": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The inclusion criteria do not mention anything about gender or menopausal status, so this is not relevant for determining eligibility.\n\nThe patient has cytologically confirmed breast cancer, which is not relevant to the trial for treating essential tremor.\n\nThe tumor details like size, HER2 status, ER/PR status, lymph node involvement, and metastatic lesions are also not relevant to this trial.\n\nThe patient's medication use of multivitamins and iron supplements is not relevant.\n\nThe patient does not smoke or consume alcohol, which is not mentioned in the inclusion criteria.\n\nThe patient's sexual activity and child-bearing history are not relevant.\n\nThe patient is a candidate for tumor resection prior to chemotherapy, which is not relevant to this trial.\n\nLooking at the inclusion criteria:\n\n1. The patient has not previously undergone Exablate thalamotomy for essential tremor, so this criterion is not met.\n\n2. The patient does not have essential tremor, so they would not benefit from bilateral Exablate treatment for it.\n\n3-4. The patient's age of 45 falls within the 22-75 year range, but their cognitive status is not mentioned, so these criteria cannot be evaluated.\n\n5. The patient's ability to give consent and attend visits is not mentioned.\n\n6. The patient does not have postural or intention tremor, so this criterion is not met.\n\n7. The patient does not have a thalamus that can be targeted by the Exablate device for essential tremor treatment.\n\n8. The patient's ability to communicate sensations during the procedure is not mentioned.\n\n9. The patient does not have an original CRST score indicating disability from essential tremor.\n\n10. The patient is not on antidepressants, so this criterion is not applicable.\n\n11. The patient remains eligible for the Exablate treatment in terms of medical history is not mentioned.\n\nOverall, based on the information provided, the patient does not meet the key inclusion criteria of having essential tremor and being a candidate for bilateral Exablate thalamotomy treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "380": {
        "output": "To determine the patient's eligibility for the clinical trial \"Breast Cancer Active Surveillance, Alternative Option, Aspirin Included\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Every adult (above 18) y.o.patient with histologic diagnosis of Breast Cancer\n\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, so this criterion is met.\n\n2. that refuse or is not suitable for surgical treatment, or with metastatic disease, remaining this way in an active surveillance\n\nThe patient note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that the patient is suitable for surgical treatment and does not have metastatic disease. Therefore, this criterion is not met.\n\nSince the patient does not meet all the inclusion criteria, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "381": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Germline BRCA 1/2 Mutation Positive\n   - The patient note does not mention the BRCA mutation status, so this criterion cannot be evaluated.\n\n2. Women and men at least 18 years of age or older.\n   - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n3. Histologically confirmed invasive adenocarcinoma of the breast\n   - The patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n4. HER2 negative breast cancer as defined by ASCO-CAP criteria\n   - The patient note states that the tumor is HER2-positive, so she does not meet this criterion.\n\n5. Tumor greater than or equal to T1, N0-3\n   - The patient has a 3 cm tumor (T3) and 5 positive lymph nodes, so she meets this criterion.\n\n6. No evidence of distant metastasis\n   - The patient note mentions metastatic lesions on CXR, so she does not meet this criterion.\n\n7. Adequate bone marrow, hepatic, and renal function\n   - The patient note does not provide information about these functions, so this criterion cannot be evaluated.\n\n8. ECOG performance status 0 or 1\n   - The patient note does not provide the ECOG performance status, so this criterion cannot be evaluated.\n\nSince the patient does not meet at least two of the inclusion criteria (HER2 negative and no distant metastasis), and there is insufficient information to evaluate some other criteria, I would conclude:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "382": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis\", the patient does not meet the inclusion criteria for this trial.\n\nThe patient note states that the patient has cytologically confirmed breast cancer, while the inclusion criteria for the trial specifies \"Non metastatic Pancreatic Cancer\".\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "383": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about studying plasma concentrations of lidocaine and bupivacaine in axillary brachial plexus block mixtures for upper limb surgery in trauma patients.\n\nThe key inclusion criteria for the trial are:\n1) Unpremedicated patient\n2) Scheduled for elective or emergency trauma surgery of hand and forearm\n3) Under ultrasound-guided brachial plexus block\n\nFrom the patient note, we don't have information about whether this is for a trauma surgery of the hand/forearm or if the patient is unpremedicated. The surgery mentioned is for tumor resection prior to chemotherapy for breast cancer.\n\nSince the patient details do not match the key inclusion criteria of the clinical trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "384": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women age 18 years or older\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Confirmed histologic diagnosis of invasive carcinoma of the breast\nThe patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n3. Pathology confirmation of invasive carcinoma (reported or requested and pending)\nThis is implied by the cytological confirmation mentioned earlier.\n\n4. ER, PR and HER2 negative on outside or Cedars Sinai biopsy report\nThe patient's tumor is HER2-positive and ER/PR negative, so she does not meet this criterion for triple-negative breast cancer.\n\n5. Operable tumor measuring \u22651.0 cm in maximal diameter\nThe patient's tumor is 3 cm, so she meets this criterion.\n\n6. Any nodal status allowed, including negative nodal status.\nThe patient has 5 positive lymph nodes, which is allowed.\n\n7. No indication of distant metastases\nThe patient has metastatic lesions on CXR, so she does not meet this criterion.\n\nSince the patient does not meet two of the key inclusion criteria (triple-negative status and no distant metastases), she would be ineligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "385": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one and check if the patient meets them:\n\n1. Written informed consent and any locally required authorization obtained from the patient prior to performing any protocol-related procedures, including screening evaluations\n- No information provided about this.\n\n2. Age \u226518 years at time of study entry\n- The patient is 45 years old, so meets this criteria.\n\n3. Histologically confirmed muscle-invasive urothelial carcinoma (MIUC) of the bladder. Patients with mixed histologies are required to have a dominant transitional cell pattern (urothelial carcinoma must be > 50%)\n- The patient has cytologically confirmed invasive ductal breast carcinoma, not MIUC of the bladder. Does not meet this criteria.\n\n4. Localized MIUC of the bladder with clinical stage T2-T4a and \u2264N1 disease \n- Not applicable since patient does not have MIUC.\n\n5. Patients with urothelial carcinoma of the prostatic urethra\n- Not applicable as patient is a woman.\n\n6. Bodyweight >45kg\n- No information provided.\n\n7. Eligible for cisplatin-based neoadjuvant chemotherapy based on criteria listed\n- Not applicable since patient does not have MIUC.\n\n8. Adequate organ and marrow function as defined\n- No information provided.\n\n9. Evidence of post-menopausal status or negative pregnancy test\n- Patient is stated to be postmenopausal.\n\n10. Willingness to use contraception if applicable\n- Patient is not sexually active.\n\n11. Willing to comply with protocol\n- Stated that patient agrees to tumor resection prior to chemotherapy, so likely willing.\n\nSince the patient does not have muscle-invasive urothelial carcinoma of the bladder, which is a key inclusion criteria, she does not meet the eligibility for this clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "386": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements.\n- No information provided, so cannot assess this criteria.\n\n2. Female patients. \n- The patient note states the patient is a 45-year-old postmenopausal woman, so this criteria is met.\n\n3. Age \u2265 18 years old.\n- The patient is 45 years old, so this criteria is met.\n\n4. Histologically confirmed HER2-/HR+ locally advanced or metastatic invasive breast carcinoma assessed on the primary tumor and/or on the metastatic lesions (preferred).\n- The patient has cytologically confirmed HER2-positive and ER/PR negative (so HR-negative) invasive ductal breast carcinoma with metastatic lesions seen on CXR, so this criteria is not met.\n\n5. Willingness and ability to provide archived formalin fixed paraffin embedded tissue block or a partial block from primary surgery and/or tumor or metastasis biopsy, which will be used for further breast cancer research.\n- No information provided, so cannot assess this criteria.\n\n6. Maintenance endocrine therapy could have already been started up to 6 weeks before randomization, but after achievement of tumor response or stable disease.\n- The patient has not started any therapy yet, so this criteria is not applicable.\n\n7. Maintenance therapy must be preceded prior to randomization by at least 4 cycles of a mono- or polychemotherapy. Tumor response or stable disease needs to be maintained to allow entry into the trial. Study treatment must start within 8 weeks of the last dose of chemotherapy.\n- The patient has not received any chemotherapy yet, so this criteria is not met.\n\n8. Previous therapy with maximum one line of anti-hormonal treatment is allowed.\n- No information on prior anti-hormonal treatment is provided.\n\n9. Previous neoadjuvant/adjuvant therapy is allowed. In case of cancer other than breast cancer, treatment should be completed more than 5 years before study entry.\n- No information on prior neoadjuvant/adjuvant therapy is provided.\n\n10. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\n- No information on ECOG performance status is provided.\n\n11. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.03 Grade \u2264 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).\n- The patient has not received any prior anti-cancer therapy yet.\n\n12. The patient must be accessible for scheduled visits, treatment and follow-up. Patients registered on this trial must be treated at the participating center which could be the Principal or a Co- investigator's site.\n- No information provided, so cannot assess this criteria.\n\n13. Life-expectancy > 6 months.\n- No information on life-expectancy is provided.\n\n14. The subjects need to be either A) of non-childbearing potential (documented postmenopausal or post hysterectomy) or B) childbearing potential with negative urinary pregnancy test (in this case patients need to use highly effective non-hormonal contraceptive).\n- The patient note states the patient is postmenopausal, so this criteria is met.\n\nBased on the information provided in the patient note, the key inclusion criteria that are not met are #4 (HER2-positive and HR-negative disease) and #7 (no prior chemotherapy received).\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "387": {
        "output": "To determine the patient's eligibility for the clinical trial \"Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. Informed Consent as documented by signature: No information provided.\n2. World Health Organization (WHO) performance status\u2264 2: No information provided.\n3. Body weight \u2264 80 kg: No information provided.\n4. Biopsy proven invasive breast cancer with a size of \u22643.0cm (TNM classification: cT1-2 N0-2 MX ): The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n5. Histological type of tumor: invasive ductal carcinoma (IDC): The patient's tumor is an invasive ductal carcinoma, which meets this criterion.\n6. Patient is scheduled for surgical resection of tumor at study site: The patient is a candidate for tumor resection, which meets this criterion.\n7. Tumor location within the reach of the HIFU transducers with the patient in prone position; distance from skin and pectoral muscle to the tumor \u2265 1.0 cm: No information provided.\n8. Target breast fits in the cup of the dedicated MR-HIFU breast system: No information provided.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to determine if they meet all of them. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "388": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Staged Versus Simultaneous Bilateral Knee Arthroplasty\", the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 45-year-old postmenopausal woman with breast cancer, including details about the tumor characteristics, metastatic lesions, and planned treatment. However, the inclusion criteria for the clinical trial are specifically related to patients considering bilateral knee arthroplasty (knee replacement surgery).\n\nThere is no mention of the patient having any knee-related issues or being a candidate for knee arthroplasty in the provided patient note.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "389": {
        "output": "To determine the patient's eligibility for the clinical trial \"BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. \"Female patients with histologically verified metastatic breast cancer (stage IV) with measurable metastases\"\nThe patient note mentions that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and CXR was remarkable for metastatic lesions. This satisfies the criteria of being a female patient with metastatic breast cancer (stage IV) with measurable metastases.\n\n2. \"between 18 and 80 years of age\"\nThe patient is 45 years old, which falls within the age range specified in the inclusion criteria.\n\n3. \"who had undergone at least three lines of chemotherapy\"\nThe patient note does not mention the patient's previous treatment history or the number of lines of chemotherapy undergone.\n\n4. \"and had an expected survival time of at least 3 months\"\nThe patient note does not provide information about the patient's expected survival time.\n\nSince there is insufficient information to determine if the patient has undergone at least three lines of chemotherapy and has an expected survival time of at least 3 months, the patient's eligibility cannot be fully assessed based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "390": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"History of known or suspected solid tumor.\"\nThe patient note mentions that the patient has \"cytologically confirmed breast cancer\" which is a solid tumor. This criterion is met.\n\n2. \"At least one lesion >= 1.0 cm that is seen on standard imaging (e.g. computed tomography [CT], magnetic resonance imaging [MRI], ultrasound, fludeoxyglucose [FDG] PET/CT).\"\nThe patient note states that \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\" This meets the criterion of having at least one lesion >= 1.0 cm seen on imaging.\n\nSince both inclusion criteria are met, and there are no exclusion criteria mentioned in the trial information provided, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "391": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy.\"\n- The patient has a 3 cm invasive ductal breast carcinoma, which meets the T1 criteria. She is a candidate for tumor resection (partial mastectomy). This criterion is met.\n\n2. \"Axillary sampling is required only for cases of invasive cancers. Tumor size is determined by the pathologist. Clinical size may be used if the pathologic size is indeterminate. Patients with invasive cancer must have no positive axillary lymph nodes with at least 6 axillary lymph nodes sampled or a negative sentinel node.\"\n- The patient had axillary sampling which revealed 5 positive lymph nodes. This does not meet the criterion of no positive axillary lymph nodes.\n\n3. \"Negative histologic margins of partial mastectomy or re-excision specimen...\"\n- There is no information provided about the margin status.\n\n4. \"Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm).\"\n- The patient has a 3 cm invasive ductal carcinoma that is HER2-positive and ER/PR negative. This does not meet this criterion.\n\n5. Other criteria regarding neoadjuvant therapy, being a good candidate per PI, postmenopausal status, age, consent, English speaker are met or not applicable based on the information given.\n\nSince the patient has positive axillary lymph nodes and the tumor is HER2-positive/ER/PR-negative, she does not meet all the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "392": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The trial is about determining the minimum anesthesia concentration of lidocaine required for sciatic popliteal block in orthopedic foot or ankle surgery patients.\n\n2. The patient does not seem to be undergoing orthopedic foot or ankle surgery, which is an inclusion criterion for this trial.\n\n3. The patient's age (45 years old) meets the inclusion criteria of being 18 years or older.\n\n4. There is no information provided about the patient's ASA class, BMI, presence of peripheral neuropathy, motor weakness, infection at injection site, or contraindications to medications in the study.\n\n5. Since the patient does not meet the key inclusion criterion of undergoing orthopedic foot or ankle surgery, there is insufficient information to determine eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "393": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. This meets the age criteria of \u226520 years old.\n\nThe tumor is HER2-positive, which meets the \"HER2 positive\" inclusion criteria for this trial on salivary duct carcinoma and other HER2+ cancers.\n\nHowever, the patient has invasive ductal breast carcinoma, not salivary duct carcinoma or a similar salivary gland cancer histology as required.\n\nThe patient also has metastatic disease, meeting the stage IV inclusion criteria.\n\nNo prior systemic chemotherapy is mentioned, meeting that criteria.\n\nBased on the information provided, while the patient meets some inclusion criteria like age, HER2 status, and stage, the breast cancer histology excludes her from eligibility for this particular trial on salivary gland cancers.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "394": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria for Cohort A: \"Recent abnormal mammogram followed by a breast biopsy\" and \"Initial diagnosis of Stage I, II, III or IV invasive breast cancer\".\n\nAdditional details provided:\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This does not conflict with the inclusion criteria.\n\nSince the patient meets the criteria for Cohort A, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "395": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must be premenopausal. Patients with a hysterectomy: menopausal status must be confirmed by estradiol and FSH.\n   - The patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is not met.\n\n2. Operable hormonal receptor (HR) positive (ER/PR greater than or equal to 10%), HER2- negative, invasive early breast cancer, suitable for neoadjuvant AI treatment and ovarian suppression; HR- positive and HER2-negative as determined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP ) guidelines.\n   - The patient has a HER2-positive and ER/PR negative invasive ductal breast carcinoma, so this criterion is not met.\n\n3. Diagnostic breast tissue must have an Oncotype DX Breast Recurrence Score\u00ae of less than 26 as determined by Genomic Health, Inc.\n   - There is no information provided about the Oncotype DX Breast Recurrence Score.\n\n4. No known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib excipients or to endocrine treatments.\n   - There is no information provided about any hypersensitivity reactions.\n\n5. A breast tumor with an ultrasound size of at least 2.0 cm.\n   - The patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n6. Patients must have the ability to swallow oral medication.\n   - There is no information provided about the patient's ability to swallow oral medication.\n\n7. ECOG performance status of 0 or 1.\n   - There is no information provided about the patient's ECOG performance status.\n\n8. Blood count criteria\n   - There is no information provided about the patient's blood counts.\n\n9. Hepatic function criteria\n   - There is no information provided about the patient's hepatic function.\n\n10. Serum creatinine criteria\n    - There is no information provided about the patient's serum creatinine.\n\nBased on the information provided in the patient note, the patient does not meet at least two of the inclusion criteria (criteria 1 and 2). There is also insufficient information to determine eligibility for several other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "396": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age criteria of \u226518 years old.\n\nShe has cytologically confirmed invasive ductal breast cancer, which is an invasive recurrence as required.\n\nThe tumor size is 3 cm, which is \u22645 cm per the inclusion criteria. \n\nShe had a previous breast-conserving surgery (core biopsy), meeting the \"initial conservative surgery\" criteria.\n\nIt is mentioned that axillary sampling revealed 5 positive lymph nodes, indicating she likely had a previous sentinel lymph node biopsy (SLNB) for her initial cancer, meeting that criteria.\n\nThere is no information provided about pregnancy status for this postmenopausal patient.\n\nThere is also no mention of obtaining written informed consent.\n\nOverall, based on the information given, this patient meets most of the key inclusion criteria except the pregnancy test requirement (which may not apply for a postmenopausal patient) and the documented informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, lacking pregnancy test and documented consent)",
        "label": 0
    },
    "397": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the inclusion criteria of having invasive breast cancer and being age \u2265 18.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. This provides additional details about the breast cancer diagnosis.\n\nAxillary sampling revealed 5 positive lymph nodes. This meets the inclusion criteria of patients scheduled to undergo routine fine needle aspiration (FNA) or core biopsy of abnormal axillary lymph node.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not directly relevant to the inclusion criteria.\n\nThe other details about the patient's medications, lifestyle, and reproductive history are not relevant to the inclusion criteria.\n\nBased on the information provided, this patient meets all of the inclusion criteria for the clinical trial \"Carbon Dye Tattooing of Biopsied Axillary Node in Breast Cancer\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "398": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically confirmed invasive breast cancer: The patient has cytologically confirmed invasive ductal breast carcinoma, so this criterion is met.\n\n2. Early breast cancer with tumor size >1 cm: The patient has a 3 cm tumor, so this criterion is met. \n\n3. No clinical evidence of regional lymph node metastasis or limited to movable ipsilateral level I, II axillary lymph nodes: The patient has 5 positive axillary lymph nodes, which meets this criterion.\n\n4. No evidence of metastasis (M0): The patient has metastatic lesions noted on CXR, so this criterion is not met.\n\n5. Postmenopausal status: The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n6. ECOG performance status 0 or 1: No information is provided about performance status.\n\n7. Primary tumor must have positive ER \u226510%: The tumor is ER/PR negative, so this criterion is not met.\n\n8. Primary tumor must be HER2-positive: The tumor is HER2-positive, so this criterion is met.\n\n9. Baseline LVEF \u226555%: No information is provided about LVEF.\n\n10. Normal hematologic, renal, and liver function: No information is provided about these parameters.\n\n11. Written informed consent: No information is provided about consent.\n\nSince the patient has metastatic disease and an ER-negative tumor, which are exclusion criteria for this trial, the patient would be excluded despite meeting some of the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "399": {
        "output": "To determine the patient's eligibility for the \"Sentinel Lymph Node Biopsy in Porocarcinoma\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Patients affected to moderate and high risk porocarcinoma, in according to hystophatological findings, submitted to SNLB.\n- The patient note does not mention porocarcinoma or any details about the histopathological findings. This criterion cannot be evaluated.\n\n2. Thickness greater than or equal to 5mm\n- The patient note mentions a 3 cm (30 mm) invasive ductal breast carcinoma, which meets this criterion.\n\n3. mitoses per 10 high-power field greater than or equal to 7\n- There is no information provided about the mitotic rate in the patient note.\n\n4. Immunohistochemical (IHC) analysis positive for: carcinoembryonic antigen (CEA), cytokeratin (CK) 5,7 and epithelial membrane antigen (EMA).\n- No IHC results are mentioned in the patient note.\n\n5. Informed consent obtained for the SNLB procedure.\n- The patient note does not mention whether informed consent was obtained for SNLB.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets all the inclusion criteria for the \"Sentinel Lymph Node Biopsy in Porocarcinoma\" clinical trial. The patient has a breast cancer diagnosis, which is different from the porocarcinoma condition specified in the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "400": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of \"Patients with invasive ductal carcinoma of the breast\".\n\nThe patient has a 3 cm invasive ductal breast carcinoma, which is also in line with the inclusion criteria.\n\nThe patient received a core biopsy, suggesting she is a candidate for surgery, which is required by the second inclusion criteria \"Patients who received surgery for primary invasive breast cancer between 2010 and 2015\".\n\nThere is no information provided that would exclude the patient based on the listed inclusion criteria.\n\nTherefore, based on the information given, this patient meets all the inclusion criteria for the clinical trial \"Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "401": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with metastatic breast cancer. The tumor is HER2-positive and ER/PR negative. She has metastatic lesions seen on CXR.\n\nThe clinical trial is studying survival endpoints in subjects treated for metastatic breast cancer.\n\nThe key inclusion criterion for this trial is:\n\"Metastatic breast cancer\"\n\nSince the patient has metastatic breast cancer, she meets this main inclusion criterion.\n\nThere are no other inclusion/exclusion criteria listed that would exclude her based on the information provided.\n\nTherefore, based on the patient note and trial criteria:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "402": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\n\"Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not.\"\n\nBased on the patient note, the patient is a 45-year-old postmenopausal woman with newly diagnosed breast cancer. The tumor is 3 cm in size and is operable, as the patient is a candidate for tumor resection. Additionally, the patient has 5 positive lymph nodes, which meets the criteria of having lymph nodes that are suspicious or not.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "403": {
        "output": "To determine the patient's eligibility for the clinical trial \"Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy\", let's go through the inclusion criteria one by one:\n\n1. Subjects must give appropriate written informed consent prior to participation in the study.\n   - This is not mentioned in the patient note, but we can assume the patient would provide consent if enrolled.\n\n2. Subjects must be women or men age 18+.\n   - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n3. Subjects must be receiving neoadjuvant chemotherapy for breast cancer. All chemotherapy types and regimens are acceptable (systemic therapy will determined by the overseeing medical oncologist).\n   - The patient note mentions that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that she will receive neoadjuvant chemotherapy, meeting this criterion.\n\n4. Biopsy-confirmed diagnosis of invasive breast cancer (i.e. ER+/-, PR+/-, HER2+/-).\n   - The patient has a core biopsy-confirmed 3 cm invasive ductal breast carcinoma, which is a type of invasive breast cancer. The note also mentions that the tumor is HER2-positive and ER/PR negative, meeting this criterion.\n\n5. Stage I-III disease according to the AJCC v7 criteria.\n   - The patient note does not explicitly mention the stage, but it states that axillary sampling revealed 5 positive lymph nodes and that CXR was remarkable for metastatic lesions. This suggests that the patient likely has stage III or higher disease, which may exclude her from the trial.\n\nBased on the information provided, the patient meets most of the inclusion criteria, except for the disease stage, which is unclear but may be too advanced for the trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to the unclear disease stage).",
        "label": 1
    },
    "404": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is titled \"Kaffes Stent in the Management of Post-surgical Biliary Strictures\" and is studying the use of metallic stents for treating benign biliary strictures after surgery.\n\nThe inclusion criteria for the trial are:\n1. Confirmed benign postsurgical biliary stricture by presence of all 3 of the following:\n    - Ultrasound imaging or MRCP showing biliary dilatation\n    - Raised bilirubin and/or alkaline phosphatase\n    - History of biliary tree surgery within the previous year\n2. Naive to endoscopic therapy\n3. Age > 18 years\n\nFrom the patient note, we know the patient has breast cancer but there is no mention of a biliary stricture or any biliary surgery history. The patient does not seem to meet the key inclusion criteria for this trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "405": {
        "output": "To determine the patient's eligibility for the clinical trial \"Clinical Significance of Supraclavicular Lymph Node Dissection for Breast Cancer\", let's go through the inclusion criteria one by one:\n\n1. Ability to understand the study procedures and contents, and willingness to voluntarily sign the written informed consent form;\n- The patient note does not mention the patient's ability to understand or willingness to sign a consent form, so this criterion cannot be evaluated.\n\n2. Age\u226475 years old, female;\n- The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n3. Histologically confirmed breast cancer;\n- The patient has cytologically confirmed breast cancer, which meets this criterion.\n\n4. Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis;\n- The patient note does not mention any supraclavicular lymph node involvement, so this criterion cannot be evaluated.\n\n5. cT0-T3;\n- The patient has a 3 cm invasive ductal breast carcinoma, which would likely be classified as cT2, meeting this criterion.\n\n6. low and moderate risk for anesthesia\n- The patient note does not provide information about the patient's anesthesia risk, so this criterion cannot be evaluated.\n\nOverall, based on the information provided in the patient note, the patient meets some of the inclusion criteria, but there is not enough information to determine eligibility for certain criteria. Therefore, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "406": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Has a localized invasive breast ductal adenocarcinoma, confirmed by the local pathologist, that includes either T1c-T2 (tumor size \u22652 cm), clinical node stage (cN)1-cN2, or T3-T4, cN0-cN2. Note: Inflammatory breast cancer is allowed.\"\nThe patient note states that the patient has a 3 cm invasive ductal breast carcinoma, which meets this inclusion criteria.\n\n2. \"Has centrally confirmed ER+/HER2-, Grade 3 breast cancer of ductal histology, according to the most recent American Society of Clinical Oncology/College of American Pathologist guidelines.\"\nThe patient note states that the tumor is HER2-positive and ER/PR negative, which does not meet this inclusion criteria.\n\nSince the patient does not meet one of the key inclusion criteria, we can conclude that the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "407": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Be willing and able to provide written informed consent/assent for the trial. \n   - The patient note does not mention whether the patient is willing to provide consent, so this criterion cannot be evaluated.\n\n2. Be 18 years of age on day of signing informed consent.\n   - The patient is 45 years old, so this criterion is met.\n\n3. Patients must have metastatic confirmed breast cancer\n   - The patient has cytologically confirmed breast cancer with metastatic lesions seen on CXR, so this criterion is met.\n\n4. Disease progression by radiological techniques within 12 months prior to signing informed consent\n   - There is no information about disease progression timing in the patient note.\n\n5. Documented mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious (unknown significance variants)\n   - The patient note does not mention BRCA mutation status.\n\n6. Have measurable disease based on RECIST 1.1.\n   - The patient has a 3 cm primary tumor, so this criterion is likely met.\n\n7. Prior chemotherapy with anthracyclines and taxanes has to be administered in neoadjuvant or adjuvant setting.\n   - The patient note does not mention any prior chemotherapy.\n\n8. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.\n   - This is not mentioned in the patient note.\n\n9. Have a performance status of 0 or 1 on the ECOG Performance Scale.\n   - The patient's performance status is not provided.\n\n10. Life expectancy of greater than 3 months\n    - This is likely met since the patient is a candidate for tumor resection, but not definitively stated.\n\n11. Demonstrate adequate organ function based on screening labs.\n    - No lab results are provided in the patient note.\n\n12-14. Criteria related to pregnancy prevention for females/males of childbearing potential.\n    - The patient is postmenopausal, so these criteria do not apply.\n\nIn summary, while some key criteria are met (metastatic breast cancer, measurable disease), there is insufficient information in the patient note to definitively determine eligibility for this trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "408": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of being \u226518 years old and having histologically confirmed invasive triple negative breast cancer (TNBC).\n\nThe tumor is 3cm, HER2-positive and ER/PR negative, which meets the definition of TNBC in the inclusion criteria. \n\nShe has 5 positive lymph nodes, indicating locally advanced disease, but no definitive evidence of metastatic disease, meeting the inclusion criteria.\n\nShe is planned for tumor resection after neoadjuvant chemotherapy, meeting that inclusion criteria. \n\nThere is no information provided about her ECOG performance status, but she is a candidate for surgery so likely has an ECOG 0-1 as required.\n\nNo other major comorbidities or exclusion criteria are mentioned.\n\nShe meets all the key inclusion criteria listed and no explicit exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "409": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Eligibility waivers are not permitted. Subjects must meet all of the inclusion and exclusion criteria to be registered to the study. Study treatment may not begin until a subject is registered. \n- This is just an instruction, not a criteria to evaluate.\n\n2. Patients must provide informed written consent\n- No information provided, so cannot evaluate this criteria. \n\n3. ECOG performance status 0-2.\n- No information provided about ECOG status.\n\n4. Clinical stage operable I, II or III invasive mammary carcinoma, which is ER-positive by IHC and HER2-negative by Herceptest (0 or 1+) or not amplified by in situ hybridization as per routine clinical testing.\n- The patient has a 3 cm invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative, so does not meet this criteria.\n\n5. Patients who have measurable residual tumor at the primary site\n- Criteria met as patient has a 3 cm tumor.\n\n6. Patients who will undergo surgical treatment with either segmental resection or total mastectomy\n- Patient is a candidate for tumor resection, so meets this criteria.\n\n7. Measurable tumor. Measurable disease: a mass that can be reproducibly measured by physical exam, mammogram or ultrasound and is at least 1 cm in size\n- 3 cm tumor, so meets this criteria.\n\n8. Post-menopausal female subjects \u226518 years of age, as defined by any of the following:\n    - Subjects at least 55 years of age;\n    - Subjects under 55 years of age and amenorrhoeic for at least 12 months or follicle-stimulating hormone (FSH) values \u226540 IU/L and estradiol levels \u226440 pg/mL (140 pmol/L) or in postmenopausal ranges per local or institutional reference ranges;\n    - Prior bilateral oophorectomy or prior radiation castration with amenorrhea for at least 6 months.\n- The patient is a 45-year-old postmenopausal woman, so meets this criteria.\n\n9. No prior chemotherapy for this primary breast cancer.\n- Meets this criteria based on the information given.\n\n10. Patients with a prior history of contralateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer.\n- No information provided about prior contralateral breast cancer.\n\n11. Women may have been taking tamoxifen or raloxifene as a preventive agent prior to study entry but must have discontinued the drug for at least 14 days prior to study enrollment. \n- No information provided about prior tamoxifen or raloxifene use.\n\n12. Subjects must have ended hormone replacement therapy (HRT) (e.g., conjugated estrogens tablets, USP, [Premarin]), at least 7 days prior to receiving the first dose of randomized therapy.\n- No information provided about prior HRT use.\n\n13. Patients must have adequate hepatic and renal function. All tests must be obtained less than 4 weeks from study entry. This includes:\n    - Creatinine <2X upper limits of normal\n    - Bilirubin, SGOT, SGPT <1.5X upper limits of normal\n- No information provided about hepatic and renal function tests.\n\n14. Able to swallow and retain oral medication\n- No specific information provided, but can likely assume this criteria is met.\n\nIn summary, while the patient meets some of the key inclusion criteria like being a postmenopausal woman with operable breast cancer and a measurable tumor, the major exclusion is that her tumor is HER2-positive and ER/PR negative, whereas the trial requires ER-positive and HER2-negative status.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "410": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. ER-positive/HER2-negative in primary tumor\nThe patient note states that the tumor is HER2-positive and ER/PR negative, so this criterion is not met.\n\n2. Oligometastases: \u2264 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)\nThe patient note mentions metastatic lesions on CXR, but does not specify the number or location, so it's unclear if this criterion is met.\n\n3. Recurrent cancer after completion of primary treatment (RFI\u22651year)\nThere is no information provided about previous treatment history or recurrence, so it's unclear if this criterion is met.\n\n4. Metastatic lesions are feasible for resection or radiotherapy (Size\u22643cm)\nThe primary tumor is 3 cm, which meets this size criterion, but there is no information about the size of the metastatic lesions.\n\nOverall, based on the information provided in the patient note, the eligibility for this clinical trial is unclear. The tumor characteristics do not match the ER-positive/HER2-negative requirement, and there is insufficient information about the metastatic lesions and previous treatment history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "411": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about treating distal interphalangeal joint extensor tendon enthesopathy in nail psoriasis patients.\n\n2. The patient does not have any mention of psoriasis or nail involvement. The trial is specifically looking at patients with psoriatic nail changes and associated tendon enthesopathy.\n\n3. Since the patient does not have the condition that the trial is studying, she would not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "412": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with metastatic breast cancer. The tumor is HER2-positive and ER/PR negative.\n\nThe clinical trial is for patients with hormone receptor positive metastatic breast cancer.\n\nSince the patient's tumor is ER/PR negative, she does not meet the inclusion criteria of having hormone receptor positive metastatic breast cancer.\n\nTherefore, based on the information provided, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "413": {
        "output": "To determine the patient's eligibility for the clinical trial \"Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study\", we need to check if the patient meets the inclusion criteria provided.\n\nThe inclusion criteria for this trial are:\n1. Colorectal cancer diagnosis\n2. Medullary carcinoma\n\nBased on the patient note provided, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The note does not mention any colorectal cancer diagnosis or medullary carcinoma.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "414": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal carcinoma in the left breast\n- Tumor is 3cm \n- HER2-positive\n- ER/PR negative (triple negative)\n- 5 positive lymph nodes\n- Metastatic lesions on CXR (metastatic disease)\n\nThe clinical trial inclusion criteria are:\n1) Patients with first treated or recurrent metastatic breast cancer\n2) HER2 positive or triple negative \n3) Have at least one measurable lesion per RECIST 1.1\n\nThis patient meets all the inclusion criteria:\n1) She has metastatic breast cancer (metastatic lesions on CXR)\n2) Her tumor is HER2-positive and triple negative (ER/PR negative)\n3) She likely has measurable disease based on the primary tumor size and lymph node involvement\n\nThere are no clear exclusion criteria listed that would exclude her.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "415": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. ER-positive and/or PR-positive breast cancer.\nThe patient's tumor is ER/PR negative, so this criterion is not met.\n\n2. HER2-negative breast cancer. \nThe patient's tumor is HER2-positive, so this criterion is not met.\n\n3. Unresectable locally advanced or metastatic breast cancer.\nThe patient has metastatic breast cancer with metastatic lesions seen on CXR, so this criterion is met.\n\n4. Confirmed disease progression while in the last aromatase inhibition-containing regimen in the metastatic setting.\nThere is no information provided about prior aromatase inhibitor treatment in the metastatic setting.\n\n5. At least one taxane or anthracycline regimen in either the adjuvant or the neoadjuvant setting.\nThere is no information provided about prior taxane or anthracycline treatment.\n\n6. Patients with no prior line of chemotherapy in the metastatic setting.\nThis criterion is met as there is no mention of prior chemotherapy in the metastatic setting.\n\n7. At least 1 and up to 3 prior lines of endocrine therapy in the metastatic setting.\nThere is no information provided about prior endocrine therapy lines in the metastatic setting.\n\n8. ECOG score 0 or 1.\nThere is no ECOG performance status provided.\n\n9. Patients have adequate bone marrow and organ function.\nThere is no information provided about bone marrow or organ function.\n\n10. Patients must have measurable disease (RECIST v.1.1).\nThe patient has a 3 cm primary breast tumor, which would be considered measurable disease.\n\n11. Premenopausal with LHRH analogues for at least 28 days) and postmenopausal women.\nThe patient is described as postmenopausal, so this criterion is met.\n\n12. Patients must agree to not breastfeed during the study and for 3 months after the last dose of study treatment.\nThis criterion is met as the patient is postmenopausal.\n\n13. Life expectancy greater or equal to 12 weeks.\nThere is no information provided about the patient's life expectancy.\n\n14. Patients agree to collection of blood samples (liquid biopsy) and optional collection of metastatic tumour sample (biopsy) at the time of inclusion and progression (if appropriate).\nThere is no information provided about the patient's willingness to provide samples.\n\nIn summary, while some criteria are met (metastatic disease, no prior chemotherapy in metastatic setting, postmenopausal), there is insufficient information provided to definitively determine eligibility for several key criteria. Additionally, the patient does not meet the ER/PR and HER2 criteria based on the biomarker status provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "416": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the pre-entry research core biopsy for CELx HSF testing and for initiating chemotherapy.\n- No information provided, so cannot determine eligibility for this criteria.\n\n2. Patients must be female. \n- The patient note states the patient is a 45-year-old postmenopausal woman, so this criteria is met.\n\n3. Patients must be \u2265 18 years old.\n- The patient is 45 years old, so this criteria is met. \n\n4. Patient must have an ECOG performance status of 0 or 1\n- No ECOG performance status provided, so cannot determine eligibility.\n\n5. The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy.\n- The patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criteria is met.\n\n6. The primary breast tumor must be palpable and measure \u2265 1.0 cm on physical exam.\n- The tumor measures 3 cm, so this criteria is met.\n\n7. The regional lymph nodes can be cN0 or cN1\n- Axillary sampling revealed 5 positive lymph nodes, so unclear if this meets cN0 or cN1 criteria.\n\n8. The tumor size can be T1c or T2\n- Tumor is 3 cm, which likely meets T2 criteria, but size staging not explicitly provided.\n\n9. Ipsilateral axillary lymph node evaluation criteria\n- Axillary sampling showed 5 positive nodes, meeting the \"nodal status - positive\" criteria.\n\n10. Tumor must be ER/PR < 10%\n- Patient note states the tumor is ER/PR negative, so this criteria is met.\n\n11. Tumor must be HER2-negative by IHC/ISH criteria\n- Patient note states the tumor is HER2-positive, so this criteria is not met.\n\n12-16. Blood count, hepatic function, creatinine, LVEF criteria\n- No information provided, so cannot determine eligibility.\n\n17. Reproductive potential and contraception criteria\n- No information provided on reproductive potential or contraception use.\n\n18. Candidate for weekly paclitaxel and carboplatin \n- Patient is a \"candidate for tumor resection and agrees to do so prior to chemotherapy\", but no information on planned chemotherapy regimen.\n\n19. Multifocal criteria\n- No information provided on multifocal disease.\n\n20. Consent for study treatment\n- No information provided on consent for this specific study.\n\n21. Tumor has abnormal HER2 signaling by CELx HSF test\n- No information provided on this test result.\n\nOverall, based on the information provided, some key inclusion criteria are met (gender, age, core biopsy diagnosis, tumor size) but several important criteria are not met (HER2-positive) or there is insufficient information to determine eligibility (performance status, staging, laboratory values, consent, CELx test).\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "417": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- With cytologically confirmed breast cancer (meets criteria for invasive breast cancer)\n- 3 cm invasive ductal carcinoma in left breast (meets criteria for locoregional recurrence)\n- HER2-positive (does not meet criteria for HER2-negative)\n- ER/PR negative (does not meet criteria for hormone receptor positive)\n- 5 positive lymph nodes (meets criteria for locoregional involvement)\n- Has metastatic lesions on CXR (excludes isolated locoregional recurrence)\n- Is a candidate for tumor resection prior to chemotherapy (could potentially meet criteria after resection)\n\nBased on the provided information, this patient does not currently meet all the inclusion criteria, specifically the requirements for HER2-negative and hormone receptor positive disease, as well as having isolated locoregional recurrence without distant metastases.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "418": {
        "output": "Okay, let's go through the inclusion criteria for the HERPET clinical trial and assess the patient's eligibility:\n\n1. \"Female patients with a histological diagnosis of breast cancer with known HER2 status ((8 positive and 8 negative).\"\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, and that the tumor is HER2-positive, so this criterion is met.\n\n2. \"Written informed consent prior to admission in the study.\"\nThere is no information about whether the patient has provided written informed consent, so this cannot be assessed.\n\n3. \"Target lesion diameter of \u226515mm that has not been previously irradiated.\"\nThe patient note mentions a 3 cm (30 mm) invasive ductal breast carcinoma, meeting this criterion. There is no information about prior radiation.\n\n4. \"Female patients aged \u2265 18 years of age.\"\nThe patient is a 45-year-old woman, so this criterion is met.\n\n5. \"For all patients: histologically confirmed locally advanced/metastatic breast cancer with a biopsy within the last 12 months confirming HER2 status by either immunohistochemistry (IHC), Silver In Situ Hybridization (SISH) or Fluorescent In Situ Hybridization (FISH).\"\nThe patient has a core biopsy confirming invasive ductal breast carcinoma and HER2-positive status, meeting this criterion.\n\n6. \"ECOG performance status 0-2\"\nThere is no information about the patient's ECOG performance status.\n\n7. Other criteria related to pregnancy status, life expectancy, and adequate organ function.\nThere is no information provided about these criteria.\n\nBased on the information given, the patient meets some of the key inclusion criteria related to breast cancer diagnosis, HER2-positive status, and tumor size. However, there is insufficient information to fully assess eligibility according to all the criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "419": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is for studying intraductal papillary neoplasms of the bile duct (IPNB).\n\nLooking at the inclusion criteria for the trial:\n1. Clinical diagnosis of IPNBs - The patient does not have a diagnosis of IPNB, she has breast cancer. This criterion is not met.\n2. ECOG Performance status of 0, 1, or 2 - No information provided about performance status.\n3. Adequate liver function... - No information provided about liver function tests.\n4. Adequate renal function... - No information provided about renal function.\n5. Must be at least 18 - The patient is 45 years old, so this is met.\n\nSince the patient clearly does not have the target disease (IPNB) for this clinical trial, there is insufficient information to determine if she meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "420": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. \"breast cancer in stage I-III, tumor size>0.5cm\" - The patient has a 3 cm invasive ductal breast carcinoma, so this criterion is met.\n\n2. \"lymph nodes negative\" - The patient has 5 positive lymph nodes, so this criterion is not met.\n\n3. \"hormone receptor positive \uff08ER+/PR+,ER+/PR-,ER-/PR+\uff09\" - The patient's tumor is ER/PR negative, so this criterion is not met. \n\n4. \"HER2 negative\uff08IHC 0 or +\uff0c FISH negative\uff09\" - The patient's tumor is HER2-positive, so this criterion is not met.\n\n5. \"receive endocrine therapy only\" - It's not mentioned if the patient will receive endocrine therapy, but they are a candidate for tumor resection and chemotherapy.\n\n6. \"enough FFPE samples within 10 years\uff083 6 10\u03bcm \uff09\" - No information is provided about FFPE samples.\n\n7. \"patients with integrated medical records\" - Assuming the provided note is from integrated medical records, this criterion is likely met.\n\nSince multiple key inclusion criteria are not met (lymph node status, hormone receptor status, HER2 status), this patient does not qualify for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "421": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. Some key details:\n- 3 cm invasive ductal carcinoma in the left breast\n- HER2-positive \n- ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is for testing a combination of immunotherapy drugs (nivolumab and ipilimumab) with a targeted therapy (cabozantinib) in patients with rare genitourinary tumors.\n\nLooking at the inclusion criteria:\n1) The patient does not have a genitourinary tumor, she has breast cancer.\n2) The trial requires metastatic disease, which the patient has (lesions on CXR).\n3) However, the trial specifies certain histologic subtypes that are allowed, and breast cancer is not listed.\n\nSo while the patient meets some criteria like metastatic disease, she does not have an eligible tumor type for this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "422": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which does not meet the inclusion criteria of having a borderline or high-risk, non-malignant breast lesion that requires further excision.\n\nThe inclusion criteria specifically state:\n\"Women over age 18 with a core biopsy proven borderline or high-risk breast lesion that requires further excision for management based on the surgeon's assessment\"\n\nSince the patient has confirmed invasive ductal breast carcinoma, which is malignant, she does not qualify for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "423": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\nAge >= 18 years old: The patient is 45 years old, so this criterion is met.\n\nBreast cancer requiring a treatment by paclitaxel or colorectal cancer requiring a treatment by oxaliplatine: The patient has breast cancer, which meets this criterion. However, the treatment plan is not mentioned, so it's unclear if paclitaxel will be used.\n\nAt least 8 chemotherapy cycles planned: There is no information provided about the planned number of chemotherapy cycles.\n\nAble to understand, read and write French language: There is no information about the patient's language proficiency.\n\nCovered by a social insurance: There is no information about the patient's insurance coverage.\n\nDated and signed informed consent: There is no information about whether the patient has provided informed consent.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "424": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient aged 18 years or older.\nThe patient is 45 years old, so this criterion is met.\n\n2. Written informed consent provided.\nThere is no information about whether consent was provided, so this cannot be evaluated.\n\n3. Triple negative or HER2-positive / ER-negative or HER2-positive / ER-positive breast tumours.\nThe patient has a HER2-positive and ER/PR negative breast cancer, so this criterion is met.\n\n4. Patients eligible for breast conservation after NAC. \nThere is no information about whether the patient is eligible for breast conservation after neoadjuvant chemotherapy.\n\n5. Patients with T2-T3 N0 invasive breast cancer initially treated by NAC to allow breast conservation, who have received a minimum of 6 cycles of adequate NAC +/- anti-HER2.\nThe patient has a 3 cm (T2) invasive ductal carcinoma with 5 positive lymph nodes (N1), so this criterion is not met.\n\n6. Clinical complete response after NAC.\nThere is no information about the patient's clinical response after neoadjuvant chemotherapy.\n\n7. Radiological (mammography, breast US, breast MRI) complete response after NAC.\nThere is no information about the patient's radiological response after neoadjuvant chemotherapy.\n\n8. Patients predicted to be node-negative at treatment initiation.\nThe patient had 5 positive lymph nodes, so this criterion is not met.\n\nIn summary, while the patient meets some of the inclusion criteria, there is not enough information to determine eligibility for several key criteria. Additionally, the patient does not meet criteria 5 and 8 based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "425": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\nWomen ages of 18 to 70 years old\n- The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\nBiopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (\u2265 2cm)\n- The patient has a 3 cm invasive ductal breast carcinoma, so she meets this criterion.\n\nPatients with histologically confirmed carcinoma of the female breast with 3+ positive HER2 status by IHC\n- The patient's tumor is HER2-positive, so she meets this criterion. \n\nClinical stages IIA -IIIC (AJCC 2009)\n- The patient has axillary lymph node involvement, suggesting at least stage IIA, so she likely meets this criterion.\n\nChemotherapy-na\u00efve patients (for this malignancy)  \n- The note states the patient is a candidate for tumor resection prior to chemotherapy, implying she is treatment-naive, so she meets this criterion.\n\nPerformance status: ECOG performance status 0-1\n- No ECOG performance status is provided, so there is insufficient information to assess this.\n\nThe remaining criteria relate to laboratory values and procedures that are not mentioned in the note.\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria related to her cancer type, stage, HER2 status and treatment history. However, there is insufficient information about her performance status and some laboratory values to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "426": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is studying a treatment for psoriatic arthritis.\n\nLooking at the inclusion criteria for the psoriatic arthritis trial:\n1. The patient does not have a diagnosis of psoriatic arthritis, so she does not meet this criteria.\n2. There is no information about prior exposure to biologics or TNF inhibitor treatment failure.\n3. There is no mention of the patient having plaque psoriasis lesions >= 2cm. \n4. There is no information about the patient having active arthritis with >= 3 swollen and >= 3 tender joints.\n5. There is no information about the patient's C-reactive protein level.\n6. The patient is postmenopausal, so the criteria about pregnancy testing does not apply.\n\nOverall, the patient note does not provide sufficient information to determine if she meets the key inclusion criteria for active psoriatic arthritis, plaque psoriasis lesions, and elevated C-reactive protein.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "427": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Effectiveness of Transcranial Direct Current Stimulation for TKR\", the patient does not meet the inclusion criteria for this trial.\n\nThe patient note describes a 45-year-old postmenopausal woman with breast cancer, while the inclusion criteria for the trial specifies \"Subjects who have scheduled elective spine surgery.\"\n\nSince the patient does not have a scheduled elective spine surgery, she does not qualify for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "428": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of being 18 years or older.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. This does not match the inclusion criteria which specifies ductal carcinoma in situ (DCIS), not invasive ductal carcinoma.\n\nAxillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. This suggests advanced/metastatic disease, which is not specified in the inclusion criteria.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This could potentially match the inclusion criteria of planned lumpectomy.\n\nHowever, based on the invasive ductal carcinoma diagnosis and presence of metastatic disease, this patient does not meet the key inclusion criteria of having non-invasive DCIS.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "429": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Ability to comply with the study protocol, in the investigator's judgment - No information provided, so assume met.\n\n2. Histologically confirmed invasive breast carcinoma, with all of the following characteristics: \n   - Primary tumor \u22651.5 cm in largest diameter by ultrasound - Met (3 cm tumor)\n   - Stage I-III operable breast cancer - Likely met (no distant metastasis mentioned)\n   - Documentation confirming the absence of distant metastasis (M0) - Met (CXR remarkable for metastatic lesions, so likely M1 disease)\n\n3. ER-positive tumor and HER2-negative breast cancer - Partially met (HER2-positive, ER/PR negative)\n\n4. Postmenopausal status - Met\n\n5. Breast cancer eligible for primary surgery - Met (candidate for tumor resection)\n\n6. Submission of a representative tumor tissue specimen - No information provided\n\n7. ECOG Performance Status \u22641 - No information provided\n\n8. Adequate organ function - No information provided\n\nBased on the information given, the key exclusion criterion is that the tumor is HER2-positive and ER/PR negative, which does not meet the inclusion criteria of ER-positive and HER2-negative breast cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "430": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. This meets the inclusion criteria of being a female over 50 years old at breast cancer diagnosis.\n\n2. The tumor is 3 cm invasive ductal carcinoma, which meets the inclusion criteria of being unifocal/multifocal, unilateral, and ductal grade 1 or 2.\n\n3. The tumor is HER2-positive and ER/PR negative, which does not meet the inclusion criteria of being HER2-negative and hormone receptor positive.\n\n4. There are 5 positive lymph nodes, which meets the inclusion criteria of stage pT1N0i+ or pT2N0i+ (tumor size \u226420mm or 21-50mm with isolated tumor cells in nodes).\n\n5. The patient has metastatic lesions noted on CXR, which would likely exclude her from having a >5 year life expectancy required for the trial.\n\n6. The patient agrees to undergo tumor resection prior to chemotherapy, which meets the inclusion criteria of undergoing standard locoregional management.\n\nBased on the information provided, while the patient meets some of the key inclusion criteria, she is ultimately excluded due to the tumor being HER2-positive and the presence of metastatic lesions suggesting a poor prognosis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "431": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This matches the inclusion criteria of \"Patients with pathologically confirmed invasive ductal carcinoma\".\n\nThe tumor is a 3 cm invasive ductal breast carcinoma, which is also in line with the inclusion criteria.\n\nThe patient is undergoing tumor resection (wide local excision surgery or mastectomy) prior to chemotherapy, which matches the inclusion criteria.\n\nThere is no information provided about the tumor grade, but the inclusion criteria specifies Grade 2 or 3, so we cannot definitively confirm eligibility based on this.\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "432": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients with stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm, treated with wide excision.\"\n- The patient has a 3 cm invasive ductal breast carcinoma, which meets this criteria.\n\n2. \"Negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm\"\n- There is no information provided about the margin status.\n\n3. \"Negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications; no remaining suspicious microcalcifications in the breast before radiotherapy.\"\n- There is no information provided about mammography findings.\n\n4. \"No involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection.\"\n- The patient had 5 positive axillary lymph nodes, so this criteria is not met.\n\n5. \"Enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment.\"\n- It is not specified when the patient's surgery/treatments occurred in relation to potential enrollment.\n\nOverall, while the patient meets some of the inclusion criteria like tumor size and histology, the positive lymph node status excludes her from this trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "433": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm tumor\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR (indicating metastatic disease)\n\nThe clinical trial inclusion criteria are:\n- Confirmed breast cancer by pathology/histology/cytology\n- Patients with recurrent or metastatic breast cancer, age 18-75 years old\n- Evaluable tumor lesions present\n- ECOG 0-1 (good performance status)\n- Expected survival > 3 months\n- Agree to provide tissue specimen\n- No major organ dysfunction\n- Able to comply with treatment plan\n- Voluntary enrollment and follow-up\n\nBased on the patient details provided, this patient meets all of the key inclusion criteria:\n- Confirmed breast cancer diagnosis\n- Metastatic disease\n- Age 45 within eligible range\n- Evaluable tumor lesions (primary tumor and metastatic lesions)\n- No data on ECOG but likely 0-1 given candidacy for surgery\n- Agrees to surgery to provide tissue \n- No organ dysfunction mentioned\n- Able to comply with planned treatment\n\nTherefore, there is sufficient information to assess that this patient would be eligible for enrollment in this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "434": {
        "output": "To determine the patient's eligibility for the clinical trial, I will go through the inclusion criteria provided:\n\nInclusion Criteria:\nVLE clips featuring indeterminate biliary or pancreatic duct stricture with confirmed diagnosis on pathology\n\nThe patient note does not mention any information about VLE clips, biliary or pancreatic duct strictures, or pathology results related to these conditions. The note is focused on the patient's breast cancer diagnosis and staging.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria for this clinical trial, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "435": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in left upper outer quadrant\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria are:\n- cT1-4c (multifocality/multicentricity permitted) - The 3 cm tumor meets this\n- Female/male patient aged \u226518 years - The 45-year-old woman meets this\n- cN+ based on lymph node criteria like palpable, cortical thickening >3mm, etc. - With 5 positive axillary nodes, this is met\n- Written informed consent\n\nBased on the information provided, this patient meets all of the key inclusion criteria for the clinical trial evaluating the NeoNavia biopsy system in axillary lymph nodes.\n\nThere is no information provided about exclusion criteria, so assuming she meets those as well, this patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "436": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women of age >=18 years\nThe patient note states that the patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. PRE-REGISTRATION: Clinical T1-4, N0-3, M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging version 8.\nThe patient note mentions a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant with 5 positive lymph nodes, which would likely correspond to a clinical stage of T2N1M0 based on the provided information. This criterion is met.\n\n3. PRE-REGISTRATION: Histological confirmation of triple negative invasive breast cancer (defined as estrogen receptor [ER] =< 10%, progesterone receptor [PR] =< 10% and HER2 not amplified by in situ hybridization [ISH] or immunohistochemistry [IHC] 0/1) at diagnosis.\nThe patient note states that the tumor is HER2-positive and ER/PR negative, which does not meet the criteria for triple-negative breast cancer. This criterion is not met.\n\n4. PRE-REGISTRATION: Cohort A or Cohort B criteria for neoadjuvant chemotherapy regimens.\nThe patient note does not provide information about the specific neoadjuvant chemotherapy regimen received, so it is unclear if this criterion is met.\n\n5. PRE-REGISTRATION: Residual lesion/enhancement seen in the breast on breast imaging performed after completion of NAC.\nThe patient note does not mention any information about residual lesions or imaging findings after neoadjuvant chemotherapy, so it is unclear if this criterion is met.\n\n6. Other pre-registration criteria related to ability to swallow oral medication, willingness to undergo biopsy and provide samples, and willingness to stop certain medications.\nThe patient note does not provide information about these criteria, so it is unclear if they are met.\n\nSince the patient does not meet the criterion for triple-negative breast cancer, which is a key inclusion criterion for this trial, and there is insufficient information to determine if some other criteria are met, I would assess the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "437": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned\"\nThe patient note states that the patient has a \"3 cm invasive ductal breast carcinoma\" that is \"HER2-positive and ER/PR negative.\" This meets the criterion of having a HER2-positive breast cancer.\n\n2. \"A biopsy clip placed at the time of diagnostic biopsy\"\nThere is no information provided about a biopsy clip in the patient note.\n\n3. \"18 years of age or older\"\nThe patient is stated to be 45 years old, which meets this criterion.\n\n4. \"Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint - this is justified as there is no individual benefit to study participation\"\nThere is no information provided about the patient's ability to read and write in English.\n\n5. \"Able to provide written consent prior to any research related activities\"\nThere is no information provided about the patient's ability to provide written consent.\n\nBased on the information given, the patient meets at least one of the inclusion criteria (having a HER2-positive breast cancer). However, there is not enough information to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "438": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Women with newly diagnosed human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor (ER) positive or negative, progesterone receptor (PR) positive or negative infiltrating ductal carcinoma (IDC) of the breast\n- The patient note states the patient has cytologically confirmed invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative. This meets the criteria.\n\n2. Clinically stage II-III\n- The patient note mentions a 3 cm tumor size and 5 positive lymph nodes, suggesting stage II or III breast cancer. This meets the criteria.\n\n3. Patients with inflammatory, multifocal, multicentric and synchronous bilateral breast cancers are allowed.\n- No information about this in the patient note.\n\n4. Willing and able to provide informed consent\n- The patient note does not mention this, but we can assume the patient is willing since she agrees to tumor resection prior to chemotherapy.\n\n5. Age \u2265 18 years.\n- The patient is 45 years old, meeting this criteria.\n\n6. Eastern Cooperative Oncology Group (ECOG) Performance status 0 or 1\n- No information about ECOG status in the patient note.\n\n7. Adequate bone marrow, renal, and liver function\n- No information about these lab values in the patient note.\n\n8. Adequate cardiac function\n- No information about cardiac function in the patient note.\n\n9. Women of reproductive potential must agree to use contraception\n- The patient is postmenopausal, so this does not apply.\n\n10. May co-enroll in other trials comparing local or systemic adjuvant therapies\n- No information about this in the patient note.\n\n11. Must have pre-neoadjuvant chemotherapy breast MRI\n- No information about this in the patient note.\n\nIn summary, the patient meets some of the key inclusion criteria like breast cancer type, stage, and age. However, there is insufficient information provided about several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "439": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer, which matches the inclusion criteria of \"Histological diagnosis of breast cancer\".\n\n2. The note mentions that a core biopsy of the primary tumor was done, so primary tumor tissue is available, satisfying the inclusion criteria of \"availability of primary tumor tissue\".\n\n3. The note does not explicitly mention if plasma DNA with high ctDNA content is available. However, it states that the patient has metastatic lesions visible on CXR, suggesting the presence of circulating tumor DNA (ctDNA) in the blood.\n\nBased on the information provided in the patient note, the patient appears to meet the key inclusion criteria for the \"Breast Cancer Liquid Biopsy Stratification\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "440": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Ability to comply with the study protocol, in the investigator's judgment\n- The patient note does not mention anything about ability to comply, so this is unclear from the information given.\n\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status \u22641\n- The patient's performance status is not mentioned.\n\n3. Stage II-IIIC breast cancer, locally advanced, inflammatory, or early-stage\n- The patient has a 3cm invasive ductal carcinoma with 5 positive lymph nodes, which meets this criteria.\n\n4. Primary tumor >2cm or node-positive disease \n- The 3cm tumor size and positive lymph nodes meet this criteria.\n\n5. HER2-positive breast cancer confirmed centrally\n- The patient's tumor is noted to be HER2-positive.\n\n6. Hormone receptor status centrally confirmed\n- The tumor is ER/PR negative per the note.\n\n7. Agreement to undergo surgery after neoadjuvant therapy\n- The patient agrees to tumor resection prior to chemotherapy per the note.\n\n8. Availability of tumor tissue for central testing\n- This is not mentioned in the patient note.\n\n9. Baseline LVEF \u226555%\n- The patient's baseline LVEF is not provided.\n\n10. Contraceptive requirements for women of childbearing potential\n- The patient is postmenopausal, so this does not apply.\n\n11. Contraceptive requirements for men\n- Not applicable\n\n12. Negative pregnancy test for women of childbearing potential\n- The patient is postmenopausal, so this does not apply.\n\n13. No major surgery within 28 days before randomization\n- This is not mentioned, but likely met since surgery is planned.\n\nBased on the information provided in the patient note, the key unclear eligibility criteria are ability to comply, ECOG performance status, availability of tumor tissue, and baseline LVEF. Some criteria are met, but there is insufficient information to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "441": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nFemale: The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\nAge 18-70 years: The patient is 45 years old, which falls within this range.\n\nImaging examination confirmed single lesion: The patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which appears to be a single lesion based on the information provided.\n\nReceive breast conserving surgery with negative margins: The patient is a candidate for tumor resection, which implies breast conserving surgery. The margin status is not mentioned.\n\nAxillary lymph nodes treatment: The patient had axillary sampling which revealed 5 positive lymph nodes. This satisfies the criteria for level I/II axillary lymph node dissection.\n\nThe tumor bed is labeled with clips and it can be drawn on the treatment planning system: This criterion is not addressed in the patient note.\n\nPathologically confirmed invasive breast cancer: The patient has a cytologically confirmed invasive ductal breast carcinoma.\n\nPathologically stage is T1-3N0-3M0: The patient's tumor is 3 cm (T2) and has 5 positive lymph nodes (N1). The presence of metastatic lesions on CXR suggests M1 disease.\n\nImmunohistochemical examination is conducted to determine the status of ER, PR, HER2, Ki67 after surgery: The patient's tumor is HER2-positive and ER/PR negative.\n\nNo distant metastases: The patient has metastatic lesions on CXR, so this criterion is not met.\n\nNo supraclavicular or internal mammary nodes metastases: This is not addressed in the patient note.\n\nNo neoadjuvant chemotherapy: This is not explicitly stated, but the patient is a candidate for tumor resection prior to chemotherapy, implying no neoadjuvant treatment.\n\nFit for postoperative radiotherapy. No contraindications to radiotherapy: This is not directly addressed, but the patient is a candidate for tumor resection and chemotherapy, suggesting no major contraindications.\n\nKPS\u226580: The patient's performance status is not provided.\n\nSigned informed consent: This is not mentioned in the patient note.\n\nBased on the information provided, the patient meets several of the inclusion criteria but is excluded due to the presence of distant metastases.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "442": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Women aged 18-75 years old: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. HR positive and HER2 positive: The patient's tumor is HER2-positive and ER/PR negative, so she meets this criterion.\n\n3. ECOG score \u2264 2, expected survival \u2265 3 months: There is no information provided about the patient's ECOG score or expected survival, so this criterion cannot be evaluated.\n\n4. Histology or cytology confirmed as breast cancer: The patient has cytologically confirmed breast cancer, so she meets this criterion.\n\n5. Prior to trastuzumab and endocrine therapy and progression/recurrence: There is no information provided about the patient's prior treatment history, so this criterion cannot be evaluated.\n\n6. At least one RECIST 1.1 defined measurable lesions: The patient has a 3 cm invasive ductal breast carcinoma, which would likely be considered a measurable lesion, so she meets this criterion.\n\n7. Normal function of major organs: There is no information provided about the patient's organ function, so this criterion cannot be evaluated.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are several criteria that cannot be evaluated due to lack of information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "443": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Confirmed invasive ductal breast carcinoma \n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial inclusion criteria are:\n1) Node-positive breast cancer patients confirmed by biopsy or cytology\n2) Positivity confirmed before the surgical treatment\n\nFor the first criteria, the patient note states she has 5 positive axillary lymph nodes, which were confirmed by biopsy/cytology. So this criteria is met.\n\nFor the second criteria, the positivity (lymph node involvement) was confirmed before the planned surgical treatment of tumor resection. So this criteria is also met.\n\nSince the patient meets both of the listed inclusion criteria for this breast cancer clinical trial, and there are no explicit exclusion criteria mentioned that would rule her out, my assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "444": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman, which matches the inclusion criteria of being a postmenopausal patient.\n\n2. The patient has cytologically confirmed breast cancer, which is required by the inclusion criteria.\n\n3. The tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria of hormone receptor-positive/HER2-negative breast cancer.\n\n4. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which suggests she is eligible to receive treatment strategies as per the inclusion criteria.\n\n5. There is no information provided about whether the patient has provided written informed consent, which is one of the inclusion criteria.\n\nBased on the information given, the patient appears to meet most of the key inclusion criteria, except for the written informed consent which is not mentioned. However, since this is likely a standard requirement, we can assume it would be obtained if the patient is enrolled.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "445": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm size\n- HER2-positive \n- ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial inclusion criteria are:\n- Estrogen receptor (ER) \u2265 10%\n- Progesterone receptor (PR) \u2265 10%  \n- HER2 negative\n- Ki-67 proliferation index < 20%\n- No lymph node metastasis\n\nComparing the patient details to the inclusion criteria:\n- The patient's tumor is ER/PR negative, which does not meet the ER \u2265 10% and PR \u2265 10% criteria\n- The patient's tumor is HER2-positive, which does not meet the HER2 negative criteria\n- Ki-67 status is not provided for the patient\n- The patient has 5 positive lymph nodes, which does not meet the no lymph node metastasis criteria\n\nTherefore, based on the information provided, the patient does not meet several of the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "446": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman (meets age criteria)\n- Has cytologically confirmed breast cancer (meets criteria of having invasive ductal carcinoma)\n- 3 cm tumor size (meets tumor size \u2264 5cm criteria) \n- HER2-positive and ER/PR negative (no criteria specified for biomarker status)\n- 5 positive lymph nodes (no criteria specified for lymph node status)\n- Planning for tumor resection prior to chemotherapy (meets criteria of being accessible for axillary surgery/pathological testing)\n\nThe inclusion criteria specify being in either stage 1 or stage 2. For stage 1, all criteria are met except there is no mention of preoperative axillary assessment being negative.\n\nFor stage 2, the criteria of being female, \u226518 years old, having invasive carcinoma, planning breast conserving surgery and adjuvant radiation are met. However, there is no information provided about preoperative axillary PET mSUV value.\n\nOverall, while several key inclusion criteria are met, there is insufficient information provided about the preoperative axillary assessment findings to definitively determine eligibility for either stage.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "447": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The trial is for pre-emptive scalp infiltration for postoperative pain after craniotomy.\n\n2. The inclusion criteria for the trial are:\n- Patients scheduled for elective craniotomy for resection of tumor under general anesthesia\n- ASA physical status of I, II or III\n- Anticipated full recovery within 2 hours postoperatively\n\n3. From the patient note, we know the patient has breast cancer and is scheduled for tumor resection prior to chemotherapy. However, there is no mention of a craniotomy procedure.\n\n4. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "448": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions seen on CXR\n- Candidate for tumor resection and agrees to it prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n\"Patients with a primary or relapsed solid tumor or lymphoma who require excision of the tumor or metastatic lesions.\"\n\nBased on the patient having breast cancer with metastatic lesions and being a candidate for tumor resection, she meets the inclusion criteria for this clinical trial assessing indocyanine green (ICG) fluorescence imaging during tumor resection surgery.\n\nThere is no information provided about exclusion criteria, so we cannot definitively rule out exclusion.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "449": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female: The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Age \u2265 45 years: The patient is 45 years old, so this criterion is met. \n\n3. Unicentric pathological stage I (pT1 or T2 pN0_M0) invasive ductal breast cancer or DCIS measuring <3 cm: The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n4. Histologically negative tumor margin or no tumor in a re-excision specimen on final shaved specimen: There is no information provided about the tumor margins, so this cannot be assessed.\n\n5. ECOG Performance Status of 0 or 1: There is no information provided about the patient's performance status, so this cannot be assessed.\n\n6. Clips must be placed in the lumpectomy cavity: There is no information provided about whether clips were placed, so this cannot be assessed.\n\n7. Negative serum pregnancy test within 14 days if of child-bearing potential: The patient is postmenopausal, so this criterion is not applicable.\n\n8. Written informed consent and ability to comply with study requirements: There is no information provided about whether the patient provided consent, so this cannot be assessed.\n\n9. Use of birth control if of child-bearing potential: The patient is postmenopausal, so this criterion is not applicable.\n\nBased on the information provided, the patient meets some of the key inclusion criteria (gender, age, tumor type/size), but there is not enough information to definitively determine eligibility for all criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "450": {
        "output": "To determine the patient's eligibility for the clinical trial \"microRNA Profile in Early-stage Cervical Cancer\", I will go through the inclusion criteria one by one:\n\n1. Cervical cancer histopathological diagnosis\nThe patient note does not mention cervical cancer. It states that the patient has breast cancer.\n\n2. Clinical stage IB1 or IIA1 CC\nThe patient note does not provide information about the clinical stage of cervical cancer.\n\n3. Treated with radical hysterectomy (RH) with bilateral pelvic lymphadenectomy (BPL)\nThe patient note does not mention any treatment for cervical cancer. It states that the patient is a candidate for tumor resection (presumably for breast cancer) and agrees to do so prior to chemotherapy.\n\nSince the patient note does not indicate that the patient has cervical cancer or meets any of the inclusion criteria for this clinical trial, there is not sufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "451": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criteria of at least 18 years old.\n\nShe has a 3 cm invasive ductal breast carcinoma, which is an invasive breast cancer as required. The tumor is HER2-positive and ER/PR negative, meeting the criteria of triple-negative or HER2-positive breast cancer.\n\nThere were 5 positive lymph nodes found on axillary sampling. The criteria state that clinically and sonographically tumor-free axilla (cN0/iN0) is required prior to core biopsy. However, it allows cases with cN0 and iN+ if a negative core biopsy or FNA of the suspected lymph node is obtained. Since axillary sampling revealed positive nodes, this would be considered iN+, but it is not explicitly stated if a negative biopsy of those nodes was done.\n\nThere is no evidence of distant metastasis mentioned, meeting the M0 criteria.\n\nThe patient is a candidate for tumor resection (breast-conserving surgery) and agrees to it prior to chemotherapy, meeting the criteria for planned breast-conserving surgery.\n\nThe criteria for standard NAST with radiologic complete response (rCR) is not mentioned in the patient note.\n\nBased on the information provided, the patient potentially meets most of the key inclusion criteria, except it is unclear if she had a negative biopsy of the positive lymph nodes to allow iN+ status, and there is no mention of receiving NAST with rCR.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "452": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. cT1-3N1M0 breast cancer at diagnosis (prior to NACT) by American Joint Committee on Cancer (AJCC) staging 8th edition\n- The patient has cytologically confirmed breast cancer, so this criterion is met.\n\n2. Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at presentation\n- The patient had 5 positive lymph nodes on axillary sampling, so this criterion is met.\n\n3. Oestrogen receptor and HER2 status evaluated on primary tumour\n- The patient's tumor is HER2-positive and ER/PR negative, so this criterion is met.\n\n4. Received standard NACT as per local guidelines (Patients undergoing neoadjuvant endocrine therapy as part of another clinical trial are eligible)\n- There is no information provided about whether the patient received neoadjuvant chemotherapy, so this criterion cannot be evaluated.\n\n5. Imaging of the axilla to assess response to NACT (as per local guidelines)\n- There is no information about axillary imaging after neoadjuvant chemotherapy, so this criterion cannot be evaluated.\n\n6. Undergo dual tracer sentinel node biopsy (SNB) after NACT and at least 3 nodes removed in total (sentinel nodes and marked node).\n- There is no information about whether the patient underwent sentinel node biopsy or had nodes removed, so this criterion cannot be evaluated.\n\n7. Other criteria related to number of nodes removed, marking of involved nodes, evidence of downstaging, etc.\n- There is no information provided about these details, so these criteria cannot be evaluated.\n\nSince there are multiple inclusion criteria that cannot be evaluated based on the information provided in the patient note, I would conclude:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "453": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, invasive ductal carcinoma, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial inclusion criteria are:\n1. Histologically confirmed primary breast cancer (the patient meets this)\n2. No prior chemotherapy (not mentioned, so assume no prior chemo)\n3. Eligible for Oncotype DX testing per Ontario funding criteria:\n    - ER positive (the patient is ER negative, so does not meet this)\n    - PR positive or negative \n    - HER2 negative (the patient is HER2 positive, so does not meet this)\n    - Lymph node negative or micro-invasive disease (the patient has 5 positive nodes, so does not meet this)\n    - Tumor >1 cm or if \u22641 cm, must be grade 2/3 or have lymph node micrometastasis (tumor is 3 cm, so meets this)\n\nSince the patient does not meet several of the key inclusion criteria (ER positive, HER2 negative, lymph node negative/micro-invasive), she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "454": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female patients aged 18-70 years old - The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Histologically confirmed unilateral invasive breast cancer - The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion. \n\n3. Operable breast cancer at first diagnosis, without any absolute surgical contraindication - The patient is a candidate for tumor resection, so she meets this.\n\n4. No gross nor microscopic residual tumor after surgery - This is not mentioned, so there is not enough information.\n\n5. HER2-positive with \u2265 1 positive axillary lymph node; or ER/PR-positive and HER2-negative with \u2265 4 positive axillary lymph nodes - The patient is HER2-positive and has 5 positive lymph nodes, so she meets this criterion.\n\n6. Preoperative examination found no evidence of metastasis in clinical examination nor imaging examination - The patient has metastatic lesions on CXR, so she does not meet this exclusion criterion.\n\n7. No peripheral neuropathy - This is not mentioned, so there is not enough information.\n\n8. Karnofsky score > 70 - This is not provided.\n\n9. Good postoperative recovery, at least 1 week has passed since most recent surgery - The patient is a candidate for surgery, so this criterion is met.\n\n10. Adequate bone marrow, liver and kidney function - These lab values are not provided.\n\n11. Contraception for women of childbearing age - The patient is postmenopausal, so this does not apply.\n\n12. Adequate cardiac function with LVEF > 50% - This is not mentioned.\n\n13. Signed informed consent and agreed to follow-up - This is stated that the patient agrees to surgery prior to chemotherapy.\n\nOverall, while the patient meets some key inclusion criteria like being a woman with HER2-positive breast cancer and lymph node involvement, there is insufficient information provided about residual disease after surgery, metastases, lab values and functional status to fully determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "455": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Newly treated female patients aged \u226518 years and \u226460 years\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. ECOG score 0 \u2264 1 points\nThere is no information provided about the patient's ECOG score.\n\n3. Pathologically confirmed, the core biopsy of breast tumor lesions identified patients with TNBC breast cancer\nThe patient has cytologically confirmed breast cancer, with a 3 cm invasive ductal carcinoma that is HER2-positive and ER/PR negative. This does not meet the criteria for triple-negative breast cancer.\n\n4. Evaluate measurable tumor lesions by ultrasound or magnetic resonance imaging (MRI) within 21 days before enrollment, size \u22652cm\nThe tumor size is 3 cm, meeting this criterion.\n\n5. The main organs function normally, meeting certain criteria for blood tests, biochemical tests, coagulation tests, echocardiography, and ECG\nThere is no information provided about the patient's organ function or test results.\n\n6. No evidence of distant metastases\nThe patient has metastatic lesions on CXR, indicating distant metastases, which excludes the patient from this trial.\n\n7. Provide core biopsies from tumor lesions before treatment begins to confirm TNBC status and biomarker analysis\nThe patient has already had a core biopsy confirming the tumor type and biomarker status.\n\n8. For non-menopausal women, agree to abstinence or use contraception\nThe patient is postmenopausal, so this criterion does not apply.\n\n9. Sign the informed consent\nThere is no information about whether the patient has signed informed consent.\n\nBased on the information provided, the patient does not meet the inclusion criteria for triple-negative breast cancer and has evidence of distant metastases, which would exclude her from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "456": {
        "output": "Okay, let's go through the inclusion criteria for the CIMER clinical trial step-by-step:\n\nFemale \u2265 18 years of age pre and post-menopausal\n- The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\nOligometastatic disease (\u2264 5 sites of disease)\n- The patient has metastatic lesions noted on CXR, but the number of sites is not specified. More information is needed.\n\nBiopsy proven diagnosis of HR+HER2- metastatic breast cancer. ER expression is >10%\n- The patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, so this criterion is not met.\n\nThe other criteria relate to performance status, lab values, willingness to sign consent, etc. which are not provided in the patient note.\n\nSince the key eligibility criterion of HR+HER2- disease is not met for this patient, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "457": {
        "output": "To determine the patient's eligibility for the clinical trial \"Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy\", let's go through the inclusion criteria one by one:\n\n1. Women, aged \u2265 18 years\nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Invasive HER2+ (HR+/-) or TN breast cancer\nThe patient has a HER2-positive invasive ductal breast carcinoma, so this criterion is met.\n\n3. Primary tumor (T), clinical stage T1-3\nThe tumor size is 3 cm, which falls within the T1-3 range, so this criterion is met.\n\n4. Neoadjuvant systemic therapy (NST), at least 3 cycles\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. There is no information provided about whether the patient has received neoadjuvant systemic therapy or not.\n\n5. Tumor stage assessed with breast MRI before start NST\nThere is no information provided about whether the patient had an MRI before starting neoadjuvant systemic therapy.\n\n6. Clinically node-negative before start NST (no suspect ALNs on ultrasound and FGD-PET/CT, or negative cyto-/histopathology in case of suspect nodes)\nThe patient had 5 positive lymph nodes, so this criterion is not met.\n\n7. MRI after or during NST shows radiologic complete response\nThere is no information provided about whether the patient had an MRI after or during neoadjuvant systemic therapy.\n\n8. Written and signed informed consent\nThere is no information provided about whether the patient has provided written and signed informed consent.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criterion of being clinically node-negative before starting neoadjuvant systemic therapy. Additionally, there is insufficient information to determine if the patient meets several other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "458": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Sacituzumab Govitecan In TNBC\" and assess the eligibility of the patient based on the provided patient note.\n\n1. \"Female or male patients \u2265 18 years of age.\"\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. \"Histologically confirmed diagnosis of invasive breast cancer, previously untreated.\"\nThe patient has a cytologically confirmed 3 cm invasive ductal breast carcinoma, which meets this criterion. It is not mentioned if she has received any prior treatment.\n\n3. \"Participants must have biopsy proven ER negative (ER-), PR negative (PR-), HER2 negative (HER2-), invasive breast cancer.\"\nThe patient's tumor is HER2-positive and ER/PR negative, so she does not meet this criterion for triple-negative breast cancer (TNBC).\n\n4. \"Primary tumor (at least one lesion) 1 cm or greater measured by radiological imaging.\"\nThe patient's tumor is 3 cm, so she meets this criterion.\n\n5. \"Regional lymph node AJCC (v7) TNM stages N0-N2.\"\nThe patient has 5 positive lymph nodes, which would likely fall under the N1 or N2 stage, meeting this criterion.\n\n6. \"Absence of distant metastatic disease (AJCC TNM stage M0).\"\nThe patient's CXR was remarkable for metastatic lesions, indicating the presence of distant metastatic disease (M1), so she does not meet this criterion.\n\n7. Other criteria related to performance status, ability to provide informed consent, and adequate organ function are not addressed in the patient note.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial due to her HER2-positive status and the presence of metastatic disease. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "459": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Female: The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Age 18 years or older: The patient is 45 years old, so this criterion is met.\n\n3. Invasive ductal breast carcinoma and ductal carcinoma in situ having undergone breast conservation surgery: The patient has a 3 cm invasive ductal breast carcinoma and is a candidate for tumor resection (breast conservation surgery), so this criterion is met.\n\n4. May include neo-adjuvant treated subjects (chemotherapeutic, endocrine therapy, or radiation): The patient has not received any neo-adjuvant treatment, but this criterion is not mandatory.\n\n5. Ability to understand and the willingness to sign a written informed consent document: There is no information provided about the patient's ability to understand and willingness to sign an informed consent document.\n\nBased on the information provided, the patient meets the first three inclusion criteria, and the fourth criterion is not mandatory. However, there is no information about the fifth criterion regarding the ability to understand and willingness to sign an informed consent document.\n\nIf we assume that the patient has the ability to understand and is willing to sign an informed consent document, then the patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "460": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Pathologically proven diagnosis of invasive breast cancer, cT1-T3, cN0-N3, cM0, HR+ (ER+ and/or PR+) HER2 negative or HR- (ER- and PR-) HER2 negative/triple negative breast cancer.\n- The patient has cytologically confirmed invasive ductal breast carcinoma, which is a type of invasive breast cancer. The tumor is 3 cm (cT2) and has 5 positive lymph nodes (cN1). It is also HER2-positive and ER/PR negative, meeting this criteria.\n\n2. Tumors with positive PD-L1 and/or PD-L1 protein expression. Positivity is defined as PD-L1 and/or PD-L2 expression of \u2265 1% of immune cells within the stroma or in cancer cells.\n- There is no information provided about PD-L1/PD-L2 expression.\n\n3. Estrogen and/or progesterone receptor positive tumor defined \u22651% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines.\n- The tumor is ER/PR negative, so this criteria is not met.\n\n4. HER2/neu must be negative by immunohistochemistry (IHC) defined as IHC 0 or 1+ or fluorescence in situ hybridization (FISH) or other ISH methods with a ratio of < 2 according to current ASCO (American Society of Clinical Oncology)/CAP guidelines.\n- The tumor is HER2-positive, so this criteria is not met.\n\n5. Candidate for neoadjuvant chemotherapy due to their clinical stage or subtype of breast cancer as decided by the treating physician.\n- The patient is a candidate for tumor resection and chemotherapy, so this criteria is likely met.\n\n6-19. Various other criteria related to imaging, cardiac function, demographics, prior treatments, menopausal status, contraception, and adequate organ function.\n- There is insufficient information provided to assess many of these criteria.\n\nOverall, while the patient meets some of the key inclusion criteria like having invasive breast cancer and being a candidate for neoadjuvant chemotherapy, she does not meet other critical criteria like having a HER2-negative and ER/PR-positive tumor.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "461": {
        "output": "To determine the patient's eligibility for the clinical trial \"Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity\", let's go through the inclusion criteria one by one:\n\n1. \"Breast cancer patients with DCIS or invasive breast cancer\"\nThe patient note mentions that the patient has \"cytologically confirmed breast cancer\" and a \"3 cm invasive ductal breast carcinoma\", which satisfies this criterion.\n\n2. \"Undergoing breast conserving surgery and adjuvant radiation\"\nThe patient note states that the patient \"is a candidate for tumor resection and agrees to do so prior to chemotherapy\". This implies that the patient will undergo breast conserving surgery followed by adjuvant radiation therapy.\n\n3. \"Subjects must be willing and able to provide breast skin samples\"\nThere is no information provided in the patient note about the patient's willingness or ability to provide breast skin samples. However, this criterion can likely be satisfied if the patient agrees to participate in the trial.\n\nSince the patient meets the first two inclusion criteria, and the third criterion can potentially be met, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "462": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Women with histological confirmed ER/PR positive, HER2-negative MBC\"\n   - The patient note states that the patient has \"cytologically confirmed breast cancer\" and that the tumor is \"HER2-positive and ER/PR negative\". This does not meet the inclusion criteria of ER/PR positive and HER2-negative.\n\n2. \"Age >18 years old\"\n   - The patient is a 45-year-old woman, so she meets this criterion.\n\n3. \"Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC\"\n   - The patient note does not specify if this is the first or second line therapy, but it does mention that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This suggests that the patient has not yet received any therapy for the metastatic breast cancer.\n\n4. \"Adequate hematologic, renal and hepatic function\"\n   - There is no information provided about the patient's hematologic, renal, and hepatic function.\n\n5. \"Signed informed consent (ICF)\"\n   - There is no information provided about whether the patient has signed an informed consent form.\n\nSince the patient does not meet the key inclusion criterion of having ER/PR positive and HER2-negative metastatic breast cancer, the patient would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "463": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adults aged 18 years or greater: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. All patients or legal guardians are willing and able to sign a written informed consent and HIPAA authorization in accordance with local and institutional guidelines: There is no information provided about this, so we cannot determine if this criterion is met or not.\n\n3. Histologically confirmed invasive lobular carcinoma within the past 12 weeks confirmed from biopsy of primary tumor or metastasis: The patient has a histologically confirmed invasive ductal breast carcinoma, not invasive lobular carcinoma. Therefore, this criterion is not met.\n\n4. Patient is willing to have their clinical records reviewed for at least 24 months after enrollment: There is no information provided about this, so we cannot determine if this criterion is met or not.\n\nSince the patient does not meet the third inclusion criterion of having invasive lobular carcinoma, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "464": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criteria of 18-75 years old.\n\nThe tumor is invasive ductal carcinoma, which is breast cancer confirmed by pathology as required.\n\nThe tumor is HER2-positive, which does not meet the HER2-negative criteria for this trial.\n\nThe tumor is ER/PR negative, which does not meet the ER and/or PR positive criteria for this trial.\n\nThe patient has metastatic lesions seen on CXR, indicating metastatic breast cancer not suitable for curative surgery/radiation as required.\n\nThe patient has not received any prior chemotherapy yet, so does not meet the criteria of having received 4-8 cycles of first-line chemotherapy with stable disease or better response.\n\nBased on the information provided, this patient does not meet all of the key inclusion criteria for this clinical trial due to being HER2-positive and ER/PR negative.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "465": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. This meets the age criteria of \u226518 years.\n\nShe has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. This meets the criteria for HR+/HER2- locally advanced, recurrent, or metastatic breast cancer for Phase 2a Cohort A, as the tumor is ER/PR negative (hormone receptor negative).\n\nAxillary sampling revealed 5 positive lymph nodes, indicating metastatic disease. The patient has metastatic lesions seen on CXR as well. This satisfies the criteria of locally advanced, recurrent or metastatic disease not amenable to curative treatment.\n\nThe patient is a candidate for tumor resection prior to chemotherapy, but it is not clear if she has received any prior systemic therapy like endocrine therapy. This is a key piece of information needed to determine eligibility for Phase 2a Cohorts A or B.\n\nThe other criteria like ECOG performance status, adequate organ function, life expectancy etc. are not provided but can potentially be met.\n\nOverall, based on the information given, the patient appears to be potentially eligible for this clinical trial, but clarification is needed on whether she has received any prior systemic therapy like endocrine therapy for her metastatic breast cancer.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "466": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note states that this is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is titled \"Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.\"\n\nThe inclusion criteria for the trial are:\n- Ovarian germ cell tumors\n    - 20 benign (mature cystic teratoma)\n    - 22 malignant ones (5 dysgerminoma, 8 immature teratoma, 9 yolk sac tumor)\n- 20 normal ovaries\n\nBased on the patient note, this patient does not have an ovarian germ cell tumor. She has breast cancer.\n\nTherefore, this patient does not meet the inclusion criteria for this clinical trial on ovarian germ cell tumors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "467": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female breast cancer patients at the age of >= 18 years and <= 65 years who received first treatment\nThe patient is a 45-year-old postmenopausal woman, so she meets this criteria.\n\n2. Pathologically confirmed HER2-positive invasive breast cancer\nThe patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive, so she meets this criteria.\n\n3. Tumor is larger than 2 cm per 2019 CSCO BC guidelines for neoadjuvant therapy\nThe patient's tumor is 3 cm, so she meets this criteria. \n\n4. ECOG physical status score \u2264 1\nNo ECOG status is provided, so there is not enough information to assess this.\n\n5. Meeting certain lab value requirements for blood counts, liver/kidney function, etc.\nNo lab values are provided, so there is not enough information to assess this.\n\n6. Left ventricular ejection fraction \u2265 55%\nNo LVEF value is provided, so there is not enough information to assess this.\n\n7. Women of childbearing age must have negative pregnancy test\nThe patient is postmenopausal, so this does not apply.\n\n8. Provide written informed consent and be willing to comply with follow-up\nNo information is provided about consent or willingness to comply.\n\nIn summary, the patient meets some of the key inclusion criteria related to breast cancer type, HER2 status, and tumor size. However, there is not enough information provided about ECOG status, lab values, LVEF, and consent to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "468": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is for acute myeloid leukemia (AML) patients.\n\n2. The inclusion criteria specifically state that patients must be newly diagnosed with de novo AML according to the 2016 WHO classification.\n\n3. Since the patient has breast cancer and not AML, she does not meet the key inclusion criteria for this clinical trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "469": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. This meets the age criteria of \u226518 years old.\n\n2. The cancer is invasive ductal carcinoma of the breast, which is metastatic (has spread to lymph nodes and lungs based on positive lymph nodes and CXR findings). This meets the criteria of having histologically/cytologically confirmed metastatic breast cancer.\n\n3. The tumor is HER2-positive and ER/PR negative, which meets the criteria of hormone receptor negative, HER2+ breast cancer.\n\n4. The patient has measurable disease based on the 3 cm primary tumor size.\n\n5. The patient has not yet received any treatment, so the criteria about prior therapies in the metastatic setting does not apply yet. \n\n6. The patient's ECOG performance status is not mentioned, but she is a candidate for surgery so likely has good functional status.\n\n7. There is no information provided about bone marrow, renal, hepatic or cardiac function, so those criteria cannot be assessed.\n\n8. Assuming the patient is not pregnant based on being postmenopausal, the criteria about pregnancy/contraception would be met.\n\n9. There is no information provided about HIV, hepatitis B/C status to assess those criteria.\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria of having metastatic HER2+ hormone receptor negative breast cancer with measurable disease and being an adult \u226518 years old. However, there is insufficient information to definitively assess all eligibility criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "470": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. This meets the age criteria of \u226518 years old.\n\nThe tumor is HER2-positive and ER/PR negative. This does not meet the inclusion criteria of having hormone receptor positive (HR+) breast cancer that expresses ER and/or PR by immunohistochemistry.\n\nThe patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes and metastatic lesions on CXR. This meets the criteria of loco-regional breast cancer (Stage I, II, III).\n\nHowever, there is no information provided about whether the patient developed a local recurrence while on adjuvant endocrine therapy or has molecular evidence of endocrine resistance.\n\nThe patient's ECOG performance status is not mentioned, but she is a candidate for tumor resection, suggesting a relatively good performance status.\n\nHer menopausal status of being postmenopausal is stated.\n\nThere is no information about measurable disease per RECIST 1.1 criteria.\n\nNo details are provided about organ function or ability to swallow oral medications.\n\nNo information is given about prior radiotherapy, chemotherapy, or markers of response/resistance to CDK 4/6 inhibitors.\n\nIn summary, while some criteria are met, there is insufficient information provided to definitively determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "471": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female: The patient is described as a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Age \u2265 18 years old: The patient is 45 years old, so this criterion is met.\n\n3. Invasive ductal carcinoma proved by core needle biopsy: The patient has a 3 cm invasive ductal breast carcinoma confirmed by core biopsy, so this criterion is met.\n\n4. Lump can be detected by ultrasound: This is not explicitly stated, but can be reasonably inferred since the tumor size and location are described.\n\n5. Image results prove the lump is single-center, with maximum diameter <2cm (for stage 1) or <1.5cm (for stage 2): The tumor is described as 3 cm, which exceeds the size criteria for both stage 1 and stage 2.\n\n6. With enough breast tissue and enough space from lump to skin: This is not explicitly stated in the patient note.\n\n7. Not pregnant and no plan for pregnancy in 2 years: The patient is described as postmenopausal, so this criterion is likely met.\n\n8. ECOG level 0-2: The patient's performance status is not provided.\n\n9. Serum creatinine \u22641.1 mg/dl: No information is provided about the patient's serum creatinine level.\n\n10. Accessible for follow-up and mentally healthy: No information is provided about the patient's ability to follow up or mental health status.\n\nBased on the information provided, while the patient meets some of the key criteria like gender, age, and tumor type, the tumor size exceeds the maximum allowed for this trial. There is also insufficient information about several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "472": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients provided written informed consent - This is not mentioned in the patient note, so cannot be evaluated.\n\n2. Postmenopausal or premenopausal or perimenopausal women aged 18-75 years - The patient is a 45-year-old postmenopausal woman, so she meets this criteria.\n\n3. Histologically or cytologically confirmed HR-positive (ER/PR\u226510%), HER2-positive breast cancer - The patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, so she meets this criteria.\n\n4. At least one measurable non-visceral metastatic lesion - The patient has metastatic lesions noted on CXR, but it's not specified if they are visceral or non-visceral. This criteria cannot be definitively evaluated.\n\n5. Previous treatment criteria - It is not mentioned if the patient had any previous treatments, so these criteria cannot be evaluated.\n\n6. ECOG performance score of 0 to 2 - This is not mentioned, so cannot be evaluated.\n\n7. Life expectancy > 24 weeks - This is not mentioned, so cannot be evaluated.\n\n8. LVEF \u2265 50% at baseline - This is not mentioned, so cannot be evaluated.\n\n9. Previous treatments allowed as specified - See point 5.\n\n10. Good compliance expected - This is not mentioned, so cannot be evaluated. \n\n11. Recovered from prior treatment side effects - See point 5.\n\n12. No HIV infection - This is not mentioned, so cannot be evaluated.\n\n13. Laboratory values within specified ranges - These are not provided, so cannot be evaluated.\n\n14. Contraceptive use for women of child-bearing age - The patient is postmenopausal, so this does not apply.\n\nIn summary, while the patient meets some key inclusion criteria like age, menopausal status, cancer type and HER2 status, there is insufficient information provided to definitively determine eligibility for this trial based on the other criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "473": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female or male sex.\nThe patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Diagnosis (confirmed by clinical review) of A/MBC, defined as breast cancer at stage IIIB, stage IIIC, stage IV or identified as having distant metastasis.\nThe patient has cytologically confirmed breast cancer with metastatic lesions on CXR, so this criterion is met.\n\n3. Age \u226518 years at A/MBC diagnosis.\nThe patient is 45 years old, so this criterion is met.\n\n4. Initiated a CDK4/6i in combination with an AI as initial endocrine-based therapy after A/MBC diagnosis on or after 2/3/2015 and before 4/1/2019.\nThere is no information provided about the patient's treatment, so this criterion cannot be evaluated.\n\n5. Evidence of ER or PR positive disease, or absence of any indication of ER and PR negative disease closest to A/MBC diagnosis.\nThe patient's tumor is ER/PR negative, so this criterion is not met.\n\n6. Evidence of HER2 negative disease, or absence of any indication of HER2 positive disease closest to A/MBC diagnosis.\nThe patient's tumor is HER2-positive, so this criterion is not met.\n\nSince the patient does not meet criteria 5 and 6, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "474": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Stage II or III invasive breast cancer: The patient has a 3 cm invasive ductal breast carcinoma, which meets this criterion.\n\n2. Minimum tumor size of 1.5 cm: The patient's tumor is 3 cm, meeting this criterion.\n\n3. HER2-positive breast cancer: The patient's tumor is HER2-positive, meeting this criterion. \n\n4. ER/PR status determined: The patient's tumor is ER/PR negative, meeting this criterion.\n\n5. Bilateral breast cancers allowed if both are HER2-positive: The patient has only one breast cancer, so this criterion is met.\n\n6. Multifocal/multicentric disease allowed if treated as HER2-positive: No information provided, but likely meets this criterion based on the HER2-positive status.\n\n7. Breast imaging and lymph node sampling: The patient has 5 positive lymph nodes, meeting this criterion.\n\n8. Age \u2265 18 years: The patient is 45 years old, meeting this criterion.\n\n9. ECOG performance status 0 or 1: No information provided, but likely meets this criterion based on the patient's overall health status.\n\n10. Laboratory values within specified ranges: No information provided, but likely meets this criterion based on the patient's overall health status.\n\n11. Left ventricular ejection fraction \u2265 50%: No information provided, but likely meets this criterion based on the patient's overall health status.\n\n12. Pregnancy test for women of childbearing potential: The patient is postmenopausal, so this criterion is not applicable.\n\n13. Contraception requirements: The patient is not sexually active, so this criterion is not applicable.\n\n14. History of DCIS or LCIS allowed: No information provided, but likely meets this criterion.\n\n15. Breast conservation therapy allowed: The patient is a candidate for tumor resection, meeting this criterion.\n\n16. Non-English speakers allowed: No information provided, but likely meets this criterion.\n\n17. Willing to sign informed consent: No information provided, but likely meets this criterion based on the patient's agreement to tumor resection.\n\n18. Willing to undergo breast biopsy for research: No information provided, but likely meets this criterion based on the patient's overall health status and agreement to treatment.\n\nBased on the information provided, the patient appears to meet all the relevant inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "475": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Tumor is HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n- Candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n- cT2 cN0/1 breast cancer (The patient has cT2 based on 3 cm tumor size and cN1 based on positive axillary nodes)\n- Scheduled for neoadjuvant chemotherapy (The patient is a candidate for chemotherapy after tumor resection)\n- Informed consent (Not mentioned but can be obtained)\n\nBased on the information provided, the patient meets the key inclusion criteria of having cT2cN1 breast cancer and being scheduled for neoadjuvant (pre-operative) chemotherapy after tumor resection.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "476": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients with histologically confirmed invasive adenocarcinoma of the breast.\nThe patient note confirms this criterion is met - \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\"\n\n2. Triple negative breast cancer: hormone receptor negative (ER < 10% and PgR < 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory.\nThe patient note states \"The tumor is HER2-positive and ER/PR negative.\" So this criterion is not met.\n\n3. Clinical stage at presentation: T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy.\nThe patient note mentions \"Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\" This suggests the patient has metastatic disease (M1), which excludes them from this trial focused on non-metastatic disease.\n\n4. Patient must have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred.\nThere is no information provided about the patient receiving neoadjuvant chemotherapy.\n\n5. Patients should have undergone adequate tumor excision in the breast and lymph nodes after neoadjuvant chemotherapy. \nThe note states \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\" So this criterion is not met yet.\n\n6. Residual invasive disease must be \u22651cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy.\nThere is no information about residual disease after neoadjuvant chemo.\n\n7. ECOG Performance Status: 0-1.  \nNo performance status mentioned.\n\n8. Patients without severe heart, lung, liver and kidney disease.\nNo information provided about comorbidities.\n\n9. Adequate hematologic and end-organ function. \nNo lab values given.\n\n10. No more than 6 weeks may elapse between definitive breast surgery and randomization.\nThe patient has not had surgery yet.\n\nBased on the information provided, this patient does not meet some of the key inclusion criteria (triple negative status, non-metastatic disease) and there is insufficient information to assess many of the other criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "477": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female subject aged \u2265 18 years.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Her2 negative on immunohistochemistry or nonamplified breast cancer\nThe patient's tumor is HER2-positive, so she does not meet this criterion.\n\n3. Metastatic or recurrent unresectable breast cancer...\nThe patient has cytologically confirmed metastatic breast cancer, so she meets this criterion.\n\n4. ...Patient with triple-negative breast cancer without prior treatment in the metastatic setting OR Patient with hormone receptor-positive breast cancer that has exhausted or refused all endocrine monotherapy or endocrine therapeutic combinatorial options AND has not yet been treated with chemotherapy in the metastatic settings, but for whom chemotherapy is indicated.\nThe patient's tumor is ER/PR negative and HER2-positive, so she does not have triple-negative or hormone receptor-positive breast cancer. This criterion is not applicable.\n\n5. Willing and capable to undergo baseline tumor collection...\nThe patient is a candidate for tumor resection, so she is likely willing and capable of undergoing tumor collection. This criterion is met.\n\n6. Life expectancy of \u2265 6 months...\nThere is no information provided about the patient's life expectancy, so this criterion cannot be evaluated.\n\n7. ECOG Performance Status \u2264 2.\nThere is no information provided about the patient's ECOG Performance Status, so this criterion cannot be evaluated.\n\n8. Evidence of post-menopausal status or negative pregnancy test...\nThe patient is described as postmenopausal, so she meets this criterion.\n\n9. Able to provide informed consent...\nThere is no information about whether the patient is able to provide informed consent, so this criterion cannot be evaluated.\n\n10. At least one lesion that can be assessed at baseline...\nThe patient has metastatic lesions visible on CXR, so she likely meets this criterion.\n\nOverall, the patient meets some of the key inclusion criteria like being postmenopausal, having metastatic breast cancer, and being willing to undergo tumor collection. However, her tumor is HER2-positive, which excludes her based on the second criterion. There is also insufficient information to evaluate a few other criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "478": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HER2-positive status based on pretreatment biopsy material: The patient note states that the tumor is HER2-positive, so this criterion is met.\n\n2. Known hormone receptor (HR) status: The patient note states that the tumor is ER/PR negative, so this criterion is met.\n\n3. Clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively: The patient had a 3 cm invasive ductal carcinoma and 5 positive lymph nodes, so this criterion is met.\n\n4. Residual HR-negative, HER2-positive disease in the breast and/or lymph nodes: The patient has HR-negative, HER2-positive disease, so this criterion is met.\n\n5. Received neoadjuvant chemotherapy with specific regimens: The patient note does not mention the neoadjuvant chemotherapy regimen, so it is unclear if this criterion is met.\n\n6. No prior receipt of T-DM1 in the neoadjuvant setting: The patient note does not mention prior T-DM1 treatment, so this criterion is likely met.\n\n7. Prior treatment duration and regimen requirements: The patient note does not provide details on the prior treatment duration and regimen, so it is unclear if this criterion is met.\n\n8. No prior experimental HER2-targeted therapy/therapies: The patient note does not mention any experimental HER2-targeted therapies, so this criterion is likely met.\n\n9. Allowed to receive \u2264 1 cycle of T-DM1 in the adjuvant setting: The patient note does not mention any adjuvant T-DM1 treatment, so this criterion is likely met.\n\n10. Time interval between last definitive treatment and registration: The patient note does not provide dates, so it is unclear if this criterion is met.\n\n11. Registration within \u2264 180 days of most recent definitive breast cancer surgery: The patient note does not provide dates, so it is unclear if this criterion is met.\n\n12. Completion of systemic chemotherapy preoperatively, with some exceptions: The patient note does not provide details on the timing of chemotherapy, so it is unclear if this criterion is met.\n\n13. Toxicities related to prior systemic treatment resolved or at baseline: The patient note does not mention any toxicities, so it is unclear if this criterion is met.\n\n14. Adequate excision of disease: The patient note mentions that the patient is a candidate for tumor resection, but does not provide details on the extent of surgery, so it is unclear if this criterion is met.\n\n15. ECOG performance status 0-1: The patient note does not mention the performance status, so it is unclear if this criterion is met.\n\n16. Laboratory values within specified ranges: The patient note does not provide any laboratory values, so it is unclear if these criteria are met.\n\n17. Screening LVEF requirements: The patient note does not mention LVEF values, so it is unclear if this criterion is met.\n\nBased on the information provided in the patient note, there are several inclusion criteria for which it is unclear if the patient meets them or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "479": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Triple-negative or HER2-positive invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration or core needle biopsy.\"\nThe patient note states that the patient has a HER2-positive invasive ductal breast carcinoma with 5 positive axillary lymph nodes confirmed by core biopsy. This meets the inclusion criterion.\n\n2. \"Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy.\"\nThere is no information provided about whether the patient underwent CT scans before and after neoadjuvant chemotherapy. This criterion cannot be evaluated based on the given information.\n\n3. \"Attend the study voluntarily, sign the informed consent.\"\nThere is no information provided about whether the patient has agreed to participate in the study and sign the informed consent. This criterion cannot be evaluated based on the given information.\n\nSince one of the inclusion criteria cannot be evaluated due to lack of information, and there is no information provided about exclusion criteria, the most appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "480": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is 3 cm, HER2-positive, ER/PR negative, with 5 positive lymph nodes and metastatic lesions on CXR.\n\nThe clinical trial is studying the use of automated breast ultrasound (ABUS) as an alternative to breast MRI for assessing response to neoadjuvant chemotherapy in breast cancer patients.\n\nThe inclusion criteria are:\n1) Female participants eligible for neoadjuvant chemotherapy and planning surgical treatment\n2) Able to give informed consent\n\nBased on the information provided, this patient meets both of those inclusion criteria. She has breast cancer and is a candidate for neoadjuvant chemotherapy prior to surgery. There is no information provided that would suggest she is unable to give informed consent.\n\nTherefore, assessing against the inclusion criteria alone, this patient would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "481": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Written patient informed consent must be obtained prior to start of treatment. (No information provided)\n2. Patient is an adult female (\u2265 18 years of age) with advanced breast cancer - Met (45-year-old woman with advanced breast cancer)\n3. Hormone receptor-positive, HER2-negative breast cancer - Partially met (HER2-positive, ER/PR negative)\n4. Documented evidence of a mutation in the PIK3CA gene - No information provided\n5. Postmenopausal status - Met (45-year-old and postmenopausal)\n6. Evidence of recurrence or progression during or after AI therapy - No information provided\n7. Histologically/cytologically confirmed ER+ and/or PgR+ breast cancer - Not met (ER/PR negative)\n8. Adequate bone marrow and organ function as defined by laboratory values - No information provided\n\nExclusion Criteria:\n1. Prior treatment with any PI3K, mTOR or AKT inhibitor - No information provided\n2. Known hypersensitivity to alpelisib or its excipients - No information provided\n3. Major surgery within 14 days prior and not recovered from side effects - No information provided\n4. Diagnosis of diabetes mellitus type I or uncontrolled type II - No information provided\n5. Impairment of gastrointestinal function/disease altering absorption - No information provided\n6. Documented pneumonitis/interstitial lung disease - No information provided\n7. Child Pugh score B or C - No information provided\n8. Uncontrolled hypertension - No information provided\n9. Clinically significant, uncontrolled heart disease/recent cardiac events - No information provided\n10. Other severe/uncontrolled medical conditions contraindicating participation - No information provided\n11. Currently receiving strong CYP3A4 inducers or BCRP inhibitors - No information provided\n12. History of acute pancreatitis within 1 year or chronic pancreatitis - No information provided\n13. Unresolved osteonecrosis of the jaw - No information provided\n14. History of severe cutaneous reaction - No information provided\n15. Recent radiotherapy and not recovered from side effects - No information provided\n16. Currently receiving or recently received systemic corticosteroids - No information provided\n17. Not recovered from toxicities of prior anticancer therapies - No information provided\n18. Concurrent malignancy or malignancy within 3 years - No information provided\n19. Central nervous system involvement not meeting certain criteria - No information provided\n20. Other severe/uncontrolled medical conditions contraindicating participation - No information provided\n21. Unable to understand/comply with instructions - No information provided\n22. Pregnant or lactating - No information provided\n23. Woman of child-bearing potential not using highly effective contraception - No information provided\n24. Sexually active male unwilling to use condom during treatment - No information provided\n\nBased on the information provided in the patient note, the patient does not meet all the inclusion criteria (specifically criteria 3 and 7) and there is insufficient information to assess many of the exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "482": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 45-year-old postmenopausal woman\n- Diagnosed with invasive ductal breast carcinoma\n- Tumor is 3 cm, HER2-positive, ER/PR negative\n- Has 5 positive lymph nodes\n- Has metastatic lesions seen on CXR\n\nThe inclusion criteria are:\n1) Early-stage invasive breast cancer positive for estrogen receptor and/or progesterone receptor is pathologically confirmed\n   - The patient's tumor is ER/PR negative, so this criterion is not met\n\n2) Patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis\n   - No information given about prior endocrine therapy\n\n3) Age 18-70 years old\n   - The patient is 45 years old, so this is met\n\n4) Patients with one of the following:\n    - KI67 \u2265 30% \n      - No information given\n    - Tumor size > 2 cm\n      - The tumor is 3 cm, so this is met  \n    - Positive lymph nodes\n      - The patient has 5 positive nodes, so this is met\n    - Histological grade III\n      - No information given\n    - Vascular cancer thrombus  \n      - No information given\n    - HER-2 gene overexpression or amplification\n      - The tumor is HER2-positive, so this is met\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "483": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- The patient is a 45-year-old postmenopausal woman\n- She has cytologically confirmed invasive ductal breast cancer\n- The tumor is 3 cm, HER2-positive, ER/PR negative\n- She has 5 positive axillary lymph nodes and metastatic lesions on CXR\n- She is a candidate for tumor resection prior to chemotherapy\n\nThe inclusion criteria for the clinical trial are:\n1) Newly diagnosed women with biopsy-verified invasive breast cancer planned for breast conserving surgery\n2) Age > 18 years\n\nBased on the information provided, the patient meets both of the inclusion criteria:\n1) She is newly diagnosed with invasive breast cancer and is planned for tumor resection (breast conserving surgery)\n2) She is 45 years old, which is greater than 18 years\n\nThere is no information provided about exclusion criteria, so we cannot determine if she would be excluded based on any other factors.\n\nTherefore, given the available information, this patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "484": {
        "output": "To determine the patient's eligibility for the clinical trial \"Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions\", let's go through the inclusion criteria one by one:\n\n1. \"first occurrence breast cancer diagnosed from Jan 1, 2020\"\n   - The patient note does not mention the diagnosis date, so we cannot confirm if this criterion is met.\n\n2. \"non-metastatic cancer stage 0-III\"\n   - The patient note mentions \"CXR was remarkable for metastatic lesions\", which suggests metastatic disease (stage IV). This criterion is not met.\n\n3. \"Invasive tumors must be: HER2 positive (regardless of ER, PR) or ER negative\"\n   - The patient note states that the tumor is \"HER2-positive and ER/PR negative\", so this criterion is met.\n\nSince the patient has metastatic disease (stage IV), which is an exclusion criterion for this trial, the patient would be considered ineligible despite meeting the tumor subtype criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "485": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Ability to understand and willingness to sign informed consent: No information provided, so cannot assess this criteria.\n\n2. Female (regardless of menopausal status) or male: The patient is a 45-year-old postmenopausal woman, so meets this criteria.\n\n3. Biopsy proven ER/PR positive breast cancer: The patient has ER/PR negative (HER2-positive) breast cancer, so does not meet this criteria.\n\n4. HER2 non-amplified: The patient has HER2-positive breast cancer, so does not meet this criteria. \n\n5. Clinical T1-T3, any N, M0 invasive breast cancer: The patient has metastatic lesions on CXR, so likely does not meet the M0 criteria.\n\n6. Planned for neoadjuvant chemotherapy: The patient is a candidate for tumor resection prior to chemotherapy, so meets this criteria.\n\n7. No prior anti-cancer therapy except allowable endocrine therapy: No information provided, so cannot assess.\n\n8. Able to provide research biopsies: Agrees to tumor resection, so likely able to provide biopsies. Meets this criteria.\n\n9. ECOG 0-1: No information provided, so cannot assess.\n\n10. Able to swallow oral medications: Likely meets this criteria based on information provided.\n\nThe remaining criteria relate to laboratory values and contraceptive use which there is no information provided about.\n\nSince the patient does not meet the ER/PR positive and HER2 non-amplified criteria, which are key eligibility criteria for this trial, the overall assessment is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "486": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is titled \"Prospective Breast Cancer Biobanking\" and is studying early stage breast cancer.\n\nThe inclusion criteria for the trial are:\n1. Early stage Breast Cancer\n2. DCIS gr III\n\nFrom the patient note, we know that the patient has:\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma (early stage)\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nBased on the information provided, the patient meets the first inclusion criteria of having early stage breast cancer. However, there is no mention of DCIS gr III in the patient note.\n\nWithout information on whether the patient has DCIS gr III, we cannot definitively determine eligibility. There is insufficient information to fully assess against the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "487": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adult over 19 years-old: The patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Breast Ductal Carcinoma in-situ patients who diagnosed preoperative tissue biopsy: The patient has a 3 cm invasive ductal breast carcinoma, which is not the same as Ductal Carcinoma in-situ (DCIS). Therefore, she does not meet this criterion.\n\n3. A person who understands this study and agrees with willingness to participate: There is no information provided about the patient's willingness to participate in the study.\n\nSince the patient does not meet the second inclusion criterion of having DCIS diagnosed by preoperative tissue biopsy, she is not eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "488": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- Invasive ductal breast carcinoma, 3 cm, left upper outer quadrant\n- HER2-positive, ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is comparing two different biopsy needle techniques for sampling axillary lymph nodes in women with suspected breast cancer.\n\nThe inclusion criteria are:\n1) Women aged 18 or older\n2) With breast masses scored as M3-M5, MRI5, or U3-U5 (suspicious for malignancy)\n3) Histologically proven breast cancer\n4) Ipsilateral axillary lymph nodes indeterminate or suspicious for metastatic disease, requiring biopsy\n5) Able to provide informed consent\n\nLooking at the patient details, she meets criteria 1, 3, and 4. Her breast cancer is confirmed by biopsy, she has suspicious axillary lymph nodes, and she is 45 years old.\n\nThere is no information provided about whether her breast mass was scored as M3-M5, MRI5, or U3-U5, so criterion 2 cannot be definitively assessed.\n\nShe also agrees to tumor resection prior to chemotherapy, which aligns with the trial procedures.\n\nOverall, based on the information given, this patient appears eligible for the clinical trial, assuming her breast mass met the radiologic scoring criteria in point 2.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "489": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient volunteers and signs an informed consent form;\n   - No information provided about consent.\n\n2. Age \u226518 years old, female;\n   - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n3. The patient was diagnosed as triple-negative breast cancer by histopathology (ER negative, PR negative, HER2 negative), and there is no evidence of metastasis;\n   - The patient has cytologically confirmed invasive ductal breast carcinoma that is HER2-positive and ER/PR negative, so this criterion is not met.\n\n4. Patients underwent radical or breast conserving surgery combined with sentinel lymph node biopsy for primary breast cancer. Margins free of disease and ductal carcinoma in-situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.\n   - The patient is a candidate for tumor resection, so this criterion is potentially met pending surgery.\n\n5. For patients who have previously received neoadjuvant therapy for triple-negative breast cancer containing anthracyclines and taxanes, the postoperative efficacy evaluation did not reach pathological complete remission (non-PCR)...\n   - There is no mention of the patient receiving neoadjuvant therapy, so this criterion does not apply.\n\n6. For patients who have not received neoadjuvant therapy for triple-negative breast cancer, \u22651 ipsilateral axillary lymph nodes have pathological tumor involvement after surgery...\n   - The patient had 5 positive axillary lymph nodes, so this criterion is met.\n\n7. Physical condition ECOG PS: 0-1;\n   - No information provided about ECOG performance status.\n\n8. Previously received adjuvant chemotherapy consisting of a minimum of 6 courses with anthracyclines combined taxanes;\n   - There is no mention of the patient receiving prior adjuvant chemotherapy.\n\n9. Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks...\n   - This criterion does not apply since there is no mention of prior adjuvant chemotherapy.\n\n10. Laboratory tests meet the specified criteria for bone marrow, liver, and renal function;\n    - No laboratory values are provided.\n\nBased on the information given, the key criteria that are not met are:\n- The patient has HER2-positive breast cancer, while the trial requires triple-negative disease.\n- There is no information about whether the patient provided informed consent.\n- The ECOG performance status is not provided.\n- Prior adjuvant chemotherapy regimen is not specified.\n- Laboratory values are not provided to assess eligibility criteria.\n\nTherefore, there is insufficient information to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "490": {
        "output": "To determine the trial-level eligibility for this patient, let's go through the inclusion criteria one by one:\n\n1. Brain tumor subjects (27)\n   - The patient note does not mention a brain tumor, so this criterion is not met.\n\n2. Informed consent\n   - There is no information about whether the patient has provided informed consent.\n\n3. Age equal to or greater than 19 years\n   - The patient is 45 years old, so this criterion is met.\n\n4. Brain tumor that requires surgery\n   - The patient has breast cancer, not a brain tumor requiring surgery.\n\n5. Primary or metastatic brain tumor\n   - Again, the patient does not have a brain tumor.\n\n6. Healthy subjects (3)\n   - This criterion is for healthy subjects, which the patient is not.\n\n7. Informed consent (for healthy subjects)\n   - Not applicable since the patient is not a healthy subject.\n\n8. Age equal to or greater than 19 years (for healthy subjects)\n   - Not applicable since the patient is not a healthy subject.\n\nSince the patient does not have a brain tumor and the trial is specifically for brain tumor patients or healthy subjects, the patient does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "491": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of 18-65 years)\n- Has cytologically confirmed HER2-positive invasive ductal breast cancer (meets criteria of HER2+ invasive breast cancer)\n- 3 cm tumor size (meets criteria of T2-T4d or T1c with axillary nodes positive)\n- 5 positive axillary lymph nodes (meets criteria of axillary node positive)\n- No specific details on ECOG performance status, but is a candidate for surgery (likely meets ECOG 0-1)\n- No details provided on organ function tests like neutrophil count, hemoglobin, platelets, liver/kidney function (unable to assess these criteria)\n- No details on left ventricular ejection fraction (unable to assess this criteria)\n- No mention of pregnancy status \n- Agrees to surgery prior to chemotherapy (likely willing to sign informed consent)\n\nBased on the information provided, the patient meets several key inclusion criteria like age, HER2 status, tumor size/nodal status. However, there are some criteria like ECOG status, organ function tests, LVEF that cannot be definitively assessed from the note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "492": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of over 20)\n- Has breast cancer\n- The tumor is HER2-positive and ER/PR negative (does not meet triple negative criteria)\n\nThe inclusion criteria state:\n1. Over 20 years old (patient meets this)\n2. Patients with triple negative breast cancer diagnosed at Seoul National University Hospital (patient does not have triple negative breast cancer, so does not meet this)\n3. Patients who decided to perform neoadjuvant chemotherapy under clinical judgement (unclear if patient meets this)\n\nSince the patient does not have triple negative breast cancer, which is a key inclusion criteria, they likely do not qualify for this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "493": {
        "output": "Okay, let's go through the inclusion criteria for the ROSALINE clinical trial step-by-step:\n\n1. Female - The patient is a 45-year-old postmenopausal woman, so this criterion is met.\n\n2. Age \u2265 18 years - The patient is 45 years old, so this criterion is met. \n\n3. Histological diagnosis of invasive lobular breast adenocarcinoma that is ER+, and HER2- - The patient has invasive ductal breast carcinoma, which is not lobular carcinoma. This key inclusion criterion is not met.\n\n4. ER positive and HER2 negative - While the patient's tumor is HER2-positive, the trial requires ER-positive and HER2-negative status. This criterion is not met.\n\n5. A primary non metastatic or locally advanced tumour of 15 mm or more, cN0 or cN1 without prior treatment candidate for preoperative treatment - The patient has a 3 cm tumor and positive lymph nodes, meeting this size/stage criterion. However, the metastatic lesions noted on CXR would likely exclude the patient.\n\n6. ECOG Performance Status 0 or 1 - No performance status is given, so this cannot be assessed.\n\n7. Adequate bone marrow, renal and liver function - No labwork is provided to assess this.\n\nSince the key eligibility criteria of invasive lobular carcinoma histology and ER+/HER2- status are not met, this patient would not be eligible for the ROSALINE trial despite potentially meeting some other criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "494": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age and gender criteria.\n\nShe has cytologically confirmed breast cancer, which is metastatic with lesions seen on CXR. This meets the criteria of metastatic disease with \u22645 sites of measurable disease.\n\nThe tumor is HER2-positive and ER/PR negative, which meets the criteria of hormone receptor (HR) positive, HER2-negative metastatic breast cancer.\n\nHer ECOG performance status is not mentioned, but she is a candidate for tumor resection, suggesting a relatively good performance status of 0-1.\n\nNo other relevant details about hematological, renal, hepatic or coagulation parameters are provided.\n\nOverall, based on the information given, the patient appears to meet the key inclusion criteria for this clinical trial of combined immunotherapies in metastatic ER+ breast cancer.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "495": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Male or female patients (\u226518 years of age)\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Patients with stage IV breast cancer\nThe patient has cytologically confirmed breast cancer with metastatic lesions on CXR, indicating stage IV disease. This criterion is met.\n\n3. Patients with HER2+ status in metastatic setting\nThe patient's tumor is HER2-positive, so this criterion is met.\n\n4. Patients that received at least two lines of active anti-cancer drugs due to disease progression.\nThe patient note does not mention any prior lines of therapy, so there is not enough information to determine if this criterion is met.\n\n5. Patients that began third-line therapy prior to October 31, 2018.\nAgain, there is no information about the patient's treatment timeline, so it is unclear if this criterion is met.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "496": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n4.1.1. The patient has stage II or III, HER2-negative, ER-positive invasive breast cancer. This matches the given information.\n4.1.2. The patient is currently taking an aromatase inhibitor as adjuvant endocrine therapy and has completed at least 6 months but no more than 7 years. This is not mentioned in the patient note.\n4.1.3. The patient meets the clinical and pathological high risk criteria with a 3 cm tumor size and 5 positive lymph nodes.\n4.1.4. The patient has FFPE tissue from the primary tumor available for submission. This is not mentioned.\n4.1.5. Signed informed consent is not mentioned.\n\nExclusion Criteria:\n4.1.5. The patient has not received prior fulvestrant, CDK4/6 inhibitor, or participated in PENELOPE/PALLAS trials. This matches the given information.\n4.1.6. The patient is not participating in another therapeutic trial. This is not mentioned.\n4.1.7. The patient does not have a current or past invasive cancer other than breast cancer. This matches the given information.\n4.1.8. The patient does not have a second HER2-positive or triple-negative breast cancer. This matches the given information.\n\nBased on the available information in the patient note, the patient meets some of the key inclusion criteria like cancer stage, subtype, and risk factors. However, there is not enough information provided about adjuvant endocrine therapy duration, tissue availability, informed consent, or participation in other trials.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "497": {
        "output": "Okay, let's go through the inclusion criteria for the NAOMI clinical trial and assess the patient's eligibility:\n\n1. Histologic documentation of invasive breast cancer by core needle or incisional biopsy. \nThe patient note mentions \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n2. The invasive cancer must be estrogen receptor alpha (ER)-positive, with ER staining present in greater than 50% of invasive cancer cells by IHC.\nThe patient note states that the tumor is \"ER/PR negative\", so this criterion is not met.\n\n3. The invasive cancer must be HER2-negative.\nThe patient note states that the tumor is \"HER2-positive\", so this criterion is not met.\n\n4. Clinical Stage I-III invasive breast cancer with the intent to treat with surgical resection of the primary tumor. Baseline tumor must be \u22651 cm to provide adequate tissue.\nThe patient note mentions a \"3 cm invasive ductal breast carcinoma\" and that \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\", so this criterion is met.\n\n5. Patients with multicentric or bilateral disease are eligible if the subject is a candidate for clinically indicated neoadjuvant endocrine therapy.\nThere is no mention of multicentric or bilateral disease, so this criterion is not applicable.\n\n6. Women over 18 years of age, for whom neoadjuvant treatment with an aromatase inhibitor would be clinically indicated. Women must be surgically, medically, or naturally post-menopausal.\nThe patient note states that the patient is a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n7. Patients must meet the clinical laboratory criteria for ANC, platelet count, bilirubin, ALT, and AST.\nThere is no information provided about the patient's laboratory values, so this criterion cannot be assessed.\n\n8. Ability to give informed consent.\nThere is no information provided about the patient's ability to give informed consent, but this is generally assumed unless stated otherwise.\n\nSince the tumor is ER/PR negative and HER2-positive, which are exclusion criteria for this trial, the patient would be excluded from participating.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "498": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The key details are:\n- 3 cm invasive ductal breast carcinoma in the left breast\n- HER2-positive and ER/PR negative\n- 5 positive axillary lymph nodes\n- Metastatic lesions on CXR\n\nThe clinical trial is comparing different tumor biopsy methods for sentinel lymph node biopsy in breast cancer patients.\n\nThe inclusion criteria state:\n\"clinically lymph node negative breast cancer patients T1-T3\"\n\nSince the patient has 5 positive axillary lymph nodes, she does not meet the \"clinically lymph node negative\" criteria for this trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "499": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer. The tumor is HER2-positive and ER/PR negative.\n\nThe clinical trial inclusion criteria state:\n1. Patients diagnosed with metastatic HER2-negative breast cancer\n2. AR expression of \u2265 10%\n\nSince the patient's tumor is HER2-positive, she does not meet the first inclusion criteria of having HER2-negative breast cancer.\n\nThere is no information provided about the patient's AR expression status.\n\nGiven the available information, the patient does not fully meet the stated inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "500": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Female participants who are at least 40 years of age on the day of signing the informed consent form with histologically confirmed diagnosis of breast cancer.\nThe patient note states that the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, so this criterion is met.\n\n2. A participant is eligible to participate if she is not pregnant, not breastfeeding.\nThere is no information about pregnancy or breastfeeding in the patient note, but since the patient is postmenopausal, it can be assumed that she is not pregnant or breastfeeding.\n\n3. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\nThere is no information about consent in the patient note.\n\n4. Histologically confirmed invasive adenocarcinoma of the breast, with all of the following characteristics:\n   a. HER2-positive status by local determination according to 2018 ASCO/CAP guidelines.\n   The patient note states that the tumor is HER2-positive, so this criterion is met.\n   b. PAM50 HER2-enriched subtype and ERBB2-high as predefined cutoff as per central determination.\n   There is no information about PAM50 subtype or ERBB2 expression in the patient note.\n   c. Unifocal invasive carcinoma: only 1 invasive focus can be observed (the tumor focus containing or not containing an in situ component)\n   The patient note does not provide information about the number of invasive foci.\n   d. Tumor largest diameter \u22644 cm as defined by breast MRI.\n   The patient note states that the tumor is 3 cm, so this criterion is met.\n   e. No nodal involvement (i.e. cN0). Any suspicious axillary node by ultrasound must be biopsied. If the biopsy or the FNA is negative of tumor cells, patient is eligible.\n   The patient note states that axillary sampling revealed 5 positive lymph nodes, so this criterion is not met.\n   f. No evidence of distant metastasis (M0) by routine clinical assessment.\n   The patient note mentions metastatic lesions on CXR, so this criterion is not met.\n   g. Patient must have known ER and PR status locally determined prior to study entry.\n   The patient note states that the tumor is ER/PR negative, so this criterion is met.\n\n5. Eligible for taxane therapy.\nThere is no information about the patient's eligibility for taxane therapy in the patient note.\n\n6. Willingness of the patient to omit surgery if all criteria are met following neoadjuvant therapy.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so this criterion is not met.\n\n7. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast cancer.\nThere is no information about the patient's life expectancy in the patient note.\n\n8. Breast cancer eligible for primary surgery\nThe patient note states that the patient is a candidate for tumor resection, so this criterion is met.\n\n9. Have provided archival tumor tissue sample or newly obtained core. Formalin-fixed,paraffin embedded (FFPE) tissue blocks are mandatory. Available pre-treatment FFPE core biopsy evaluable for PAM50 or possibility to obtain one.\nThe patient note mentions that a core biopsy was performed, but there is no information about the availability of FFPE tissue blocks or the possibility of obtaining a core biopsy for PAM50 evaluation.\n\n10. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\nThere is no information about the patient's ECOG performance status in the patient note.\n\n11. Ability and willingness to comply with study visits, treatment, testing and to comply with the protocol.\nThere is no information about the patient's willingness or ability to comply with the study requirements in the patient note.\n\n12. Have adequate organ function.\nThere is no information about the patient's organ function in the patient note.\n\nBased on the information provided in the patient note, the patient does not meet all the inclusion criteria for this clinical trial, as she has positive lymph nodes and evidence of metastatic disease, which are exclusion criteria. Additionally, there is not enough information to determine if she meets several other",
        "label": 1
    },
    "501": {
        "output": "To determine the patient's eligibility for the clinical trial \"Trendelenburg Positioning and External Cephalic Version Outcome\", I will compare the patient note with the inclusion criteria provided.\n\nThe inclusion criteria states:\n\"Women interested in having external cephalic version at a gestational age of 37+0/7 or more.\"\n\nFrom the patient note, we can see that the patient is a \"45-year-old postmenopausal woman with cytologically confirmed breast cancer.\" There is no mention of pregnancy or gestational age.\n\nSince the patient does not meet the inclusion criteria of being a pregnant woman interested in external cephalic version at 37 weeks or more of gestation, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "502": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- 45 years old (meets age criteria of 18+)\n- Has metastatic breast cancer (meets criteria of metastatic breast cancer)\n- Has measurable disease with positive lymph nodes and metastatic lesions on CXR (meets criteria of measurable disease involving lymph nodes and visceral organs)\n- Is willing to undergo tumor resection prior to chemotherapy, which would require a biopsy (meets criteria of willingness to undergo biopsy)\n\nBased on the information provided in the patient note, this patient meets all of the listed inclusion criteria for the clinical trial \"Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "503": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the \"women\" inclusion criteria.\n\nShe has cytologically confirmed invasive ductal breast carcinoma, which meets the \"invasive ductal carcinoma of the breast\" inclusion criteria. \n\nThe tumor size is 3 cm (30 mm), which meets the criteria of \"tumor measuring 50mm or smaller\".\n\nHowever, the patient note mentions \"Axillary sampling revealed 5 positive lymph nodes\", which does not meet the criteria of \"no axillary lymph node metastasis or Ipsilateral grade I and II axillary lymph node metastasis\".\n\nThe patient note also mentions metastatic lesions on CXR, which would exclude the patient from the trial as the criteria specifies \"movable(pT0-2N0-1M0)\".\n\nTherefore, based on the inclusion criteria provided, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "504": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prediction Model for Lateral Lymph Node Metastasis\", I will go through the inclusion criteria one by one:\n\nInclusion Criteria:\n1) \"middle to low-lying rectal adenocarcinoma patients with enlarged lateral lymph node \u22655mm for short diameter in CT and/or MRI\"\n\nThe patient note does not mention the location of the cancer (whether it is rectal or breast cancer). It also does not provide any information about enlarged lateral lymph nodes or their size on CT/MRI scans.\n\nSince the patient does not have sufficient information to determine if they meet the key inclusion criteria, I would assess their eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "505": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Refining Local-Regional Therapy for IBC\" and see if the patient meets them:\n\n1. \"Stage III IBC (cT4d cN0-2). Inflammatory breast cancer is defined as the following constellation of symptoms (all of the following must be met):\"\n   - The patient note mentions that the patient has \"cytologically confirmed breast cancer\" and that it is an \"invasive ductal breast carcinoma\", which suggests it is inflammatory breast cancer. However, the stage is not explicitly stated.\n\n2. \"Rapid onset symptoms (6 months or less from time of diagnosis)\"\n   - There is no information about the onset of symptoms in the patient note.\n\n3. \"Breast erythema, edema and/or peau d'orange and/or warm breast with or without an underlying palpable mass\"\n   - No mention of these symptoms in the patient note.\n\n4. \"Erythema occupying at least one-third of the breast\"\n   - No mention of erythema in the patient note.\n\n5. \"Pathologic confirmation (biopsy-proven) invasive breast carcinoma\"\n   - The patient note states that a \"core biopsy revealed a 3 cm invasive ductal breast carcinoma\", so this criterion is met.\n\n6. \"Women age \u226518 years\"\n   - The patient is described as a \"45-year-old postmenopausal woman\", so this criterion is met.\n\n7. \"ECOG performance status \u22642\" \n   - There is no information about the patient's ECOG performance status.\n\n8. \"Ability to understand and willingness to sign informed consent document and comply with study procedures, including baseline research biopsy. If the research biopsy is not felt to be reasonably safe or feasible, a waiver must be obtained from the Principal Investigator. A formal exception would not be required in this case.\"\n   - There is no information about the patient's ability to understand or willingness to sign informed consent.\n\nBased on the information provided in the patient note, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for the clinical trial. Some key details like disease stage, symptom onset, and certain clinical characteristics are missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "506": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer\" and assess the patient's eligibility:\n\n1. Participants must be \u2265 18 years old.\nThe patient is a 45-year-old postmenopausal woman, so she meets this criterion.\n\n2. Participants with a clinical T1 or T2 invasive ductal or lobular breast carcinoma, regardless of estrogen/progesterone/human epidermal growth factor receptor 2 (HER2) receptor status.\nThe patient has a 3 cm invasive ductal breast carcinoma, which falls under the T2 category, and her HER2 status is positive, so she meets this criterion.\n\n3. Participants with clinical (on palpation) N0 and up to two suspicious lymph nodes on axillary ultrasound.\nThe patient had 5 positive lymph nodes on axillary sampling, which exceeds the limit of up to two suspicious lymph nodes on imaging. Therefore, she does not meet this criterion.\n\n4. Participant with biopsy-proven positive axillary disease made by core needle biopsy or fine-needle aspiration.\nThe patient had a core biopsy that revealed 5 positive lymph nodes, so she meets this criterion.\n\n5. Participants must have an Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status less than 2.\nThere is no information provided about the patient's performance status, so it is unclear if she meets this criterion.\n\n6. Participants must understand, accept, and have signed the approved consent form.\nThere is no information provided about whether the patient has signed the consent form, so it is unclear if she meets this criterion.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. Specifically, she does not meet the criterion of having up to two suspicious lymph nodes on axillary ultrasound.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "507": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer - this matches the inclusion criteria of having a histologically proven diagnosis of breast cancer.\n\nA core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative - this matches the criteria of having a known hormonal and HER2Neu status.\n\nAxillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions - this indicates the patient has primary confirmed distant metastatic breast cancer (M1), matching another inclusion criteria.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy - this matches the criteria of having a resectable T4 status and performance status/comorbidity that allows surgery.\n\nBased on the information provided, the patient meets all the key inclusion criteria for this clinical trial on the benefit of surgery in stage IV breast cancer.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "508": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 45-year-old postmenopausal woman with breast cancer. The clinical trial is about evaluating the safety and performance of a biodegradable biliary and pancreatic stent.\n\n2. The inclusion criteria for the trial are:\n- Patient eligible for implantation of a pancreatic or biliary stent prior to participate in the study and according to current guidelines\n- Patient has provided signed informed consent\n\n3. From the patient note, there is no mention of the patient needing a biliary or pancreatic stent implantation. The note focuses on the breast cancer diagnosis, tumor details, and planned treatment of tumor resection followed by chemotherapy.\n\n4. Since there is no information about the patient requiring a biliary/pancreatic stent, we cannot determine if they meet the first inclusion criteria for the trial.\n\n5. There is also no information provided about whether the patient has provided informed consent to participate in the trial.\n\nTherefore, based on the information given, there is insufficient evidence to conclude if the patient is eligible or not for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "509": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman with breast cancer, which meets the age criterion of \"Age over 19 years old\".\n\nShe has cytologically confirmed invasive ductal breast carcinoma in the left breast, which is an \"ipsilateral breast tumor recurrence\" as she had prior breast cancer surgery.\n\nThe note mentions she had a prior \"core biopsy\", suggesting she likely had a prior lumpectomy/partial mastectomy and sentinel lymph node biopsy for the initial breast cancer diagnosis.\n\nThere is no mention of systemic metastasis, only axillary lymph node involvement, so she is \"considered to be axillary lymph node negative from clinical findings\".\n\nThe note states she \"agrees to do\" surgery prior to chemotherapy, suggesting she understands and is willing to participate in the trial procedures.\n\nBased on the information provided, this patient appears to meet all the listed inclusion criteria for the \"Repeat Sentinel Lymph Node Biopsy in Ipsilateral Breast Tumor Recurrence\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "510": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Pathologically confirmed HER2 positive breast cancer\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and that the tumor is \"HER2-positive\", so this criterion is met.\n\n2. Treated with Pyrotinib in the metastatic settings\nThe patient note does not mention if the patient has been treated with Pyrotinib or not. However, it does state that the patient has metastatic lesions on CXR, indicating metastatic disease.\n\n3. Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study\nThe patient note does not provide any information about whether the patient underwent a whole-body FDG PET/CT scan or not.\n\nSince there is insufficient information to determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "511": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 45-year-old postmenopausal woman, which meets the age criteria of 20-65 years old.\n\nShe has cytologically confirmed invasive ductal breast carcinoma, which is an invasive carcinoma confirmed by core biopsy as required.\n\nThe tumor is 3 cm in size, meeting the criteria of a single breast tumor with a maximum diameter of 3 cm.\n\nThere are metastatic lesions noted on CXR, which would exclude her based on the criteria of no distant metastasis.\n\nHer functional status in terms of blood counts, liver and kidney function, and cardiac function are not mentioned, so it's unclear if she meets those criteria.\n\nBased on the information provided, while she meets some of the key inclusion criteria, the presence of distant metastases would likely exclude her from this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "512": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Histology-confirmed epithelial cancer of the mammary gland.\nThe patient note confirms that the patient has cytologically confirmed breast cancer, which is an epithelial cancer of the mammary gland. This criterion is met.\n\n2. Pre and post menopausal patients with early breast cancer and involved axillary lymph nodes (T 1-3 N1 M0) or high-risk N0 patients.\nThe patient note states that the patient is a 45-year-old postmenopausal woman with a 3 cm invasive ductal breast carcinoma and 5 positive axillary lymph nodes. This meets the criteria of early breast cancer with involved axillary lymph nodes (T1-3 N1 M0).\n\n3. White Blood Cell count (WBC) > 4 x 109 / l, platelets > 100 x 109 / l.\nThe patient note does not provide information about the patient's WBC or platelet count.\n\n4. Serum creatinine, Aspartate aminotransferase (AST/SGOT), Alanine aminotransferase (ALT/SGPT), gamma-glutamyltransferase, serum bilirubin 1.3 mg/ml inside the normal range of the participating hospital.\nThe patient note does not provide information about the patient's serum creatinine, liver enzymes, or bilirubin levels.\n\n5. Performance status (WHO) 0 or 1.\nThe patient note does not provide information about the patient's performance status.\n\n6. Age >=18 years\nThe patient note states that the patient is 45 years old, which meets this criterion.\n\n7. Previous surgical treatment: Either radical surgery or, for a partial mastectomy, a histologically confirmed safe margin of 2 cm or more and the results of the axillary node dissection available.\nThe patient note indicates that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This meets the criterion of previous surgical treatment.\n\n8. No evidence of significant cardiac disease\nThe patient note does not provide information about the patient's cardiac status.\n\nBased on the information provided in the patient note, some of the inclusion criteria are met, while others cannot be determined due to lack of information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "513": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast, treated with partial mastectomy.\n- The patient has a 3 cm invasive ductal breast carcinoma, which meets this criteria.\n\n2. Axillary sampling is required only for cases of invasive cancers. Tumor size is determined by the pathologist. Clinical size may be used if the pathologic size is indeterminate. Patients with invasive cancer must have no positive axillary lymph nodes with at least 6 axillary lymph nodes as assessed by axillary ultrasound, axillary sampling, or axillary sentinel node procedure.\n- The patient had axillary sampling which revealed 5 positive lymph nodes, so this criteria is not met.\n\n3. Negative histologic margins of partial mastectomy or re-excision specimen. \n- There is no information provided about the margin status.\n\n4. Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen and/or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm) that are estrogen and/or progesterone receptor positive.\n- The tumor is a 3 cm invasive ductal carcinoma that is HER2-positive and ER/PR negative, so this criteria is not met.\n\n5. Neoadjuvant hormone therapy, chemotherapy, or biologic therapy is not allowed prior to APBI, but adjuvant hormone therapy may have been started after surgery. \n- There is no mention of any prior neoadjuvant therapy.\n\n6. Good candidate for treatment per protocol in the judgment of the PI and/or treating physician following simulation.\n- Assuming the patient is deemed a good candidate by physicians.\n\n7. Postmenopausal status. \n- The patient is described as a 45-year-old postmenopausal woman, so this criteria is met.\n\n8. Age \u2265 50 years at diagnosis.\n- The patient is 45 years old, so this criteria is not met.\n\n9. Able to understand and willing to sign IRB-approved written informed consent document.\n- No information provided, but can assume the patient is able to provide informed consent.\n\n10. All radiation therapy must be planned for delivery at BJH or a BJH/Siteman satellite location with the following stipulations...\n- Assuming this criteria regarding treatment location can be met.\n\nOverall, while the patient meets some of the key criteria like having early stage breast cancer treated with partial mastectomy and being postmenopausal, there are several criteria that are not met - such as having node positive disease, the tumor being HER2-positive/ER/PR-negative, and being under age 50.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "514": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) but normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination reveals a systolic murmur and carotid ultrasound shows severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is the Harvard Atherosclerosis Reversibility Project (HARP), which aims to determine if a lipid-lowering diet with or without lipid-lowering drugs can reverse coronary artery disease in normocholesterolemic patients.\n\n5. The inclusion criteria for the Cholesterol-Lowering Agent Trial are: Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary artery lumen as revealed by angiography.\n\n6. While the patient has severe carotid artery stenosis, the trial specifically requires coronary artery stenosis of 30% or greater as revealed by angiography. The patient's coronary artery status is not mentioned in the note.\n\n7. Additionally, the patient has very high LDL-C levels (545 mg/dL), which would likely exclude him from the \"normocholesterolemic\" criteria of the trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the HARP trial due to the lack of information on coronary artery stenosis and the presence of very high LDL-C levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "515": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is 46 years old, which meets the age criteria of being 40 years or older.\n\n2. The patient has no history of cardiovascular disease (CVD) mentioned, such as heart attack, stroke, or coronary revascularization. However, the inclusion criteria state that for participants aged 55 years or older, a history of CVD is not required if they are considered at high risk for experiencing a CVD event due to existing CVD, subclinical disease, or 2+ CVD risk factors.\n\n3. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could be considered subclinical disease or a CVD risk factor.\n\n4. The patient has a family history of coronary artery disease (CAD), which is another CVD risk factor.\n\n5. The patient's LDL-C level of 545 mg/dL is extremely high, which is another major CVD risk factor.\n\n6. The patient's fasting glucose level of 85 mg/dL is within normal limits, but there is no information provided about whether the patient has been diagnosed with type 2 diabetes mellitus, which is a key inclusion criterion.\n\nBased on the information provided, the patient meets some of the inclusion criteria, such as being 55 years or older and having multiple CVD risk factors, but there is not enough information to determine if the patient has been diagnosed with type 2 diabetes mellitus, which is a critical inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "516": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient is being investigated for dizziness, headaches, and carotid artery stenosis, which could be related to coronary artery disease or other cardiovascular issues. This aligns with the trial's inclusion criteria of patients being investigated for chest pain syndrome or coronary artery disease.\n\n3. The patient has no history of recent myocardial infarction, unstable angina, or significant left main disease, which are exclusion criteria for the trial.\n\n4. There is no mention of the patient having renal failure, pregnancy/lactation, or allergy to losartan, which are also exclusion criteria.\n\n5. The only potential exclusion criterion is the patient's ability to withdraw ACE inhibitors, as there is no mention of the patient being on any medications.\n\nBased on the information provided, the patient appears to meet most of the inclusion criteria and does not seem to be explicitly excluded based on the listed exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "517": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe does not have multiple sclerosis, so the inclusion criteria of \"Multiple sclerosis (MS) diagnosis\" is not met.\n\nThere is no mention of lower urinary tract symptoms or treatment for them, so the criteria \"Lower urinary tract symptoms with or without treatment\" is not met.\n\nThe Expanded Disability Status Scale score is not provided, so we cannot assess if he meets the criteria \"Expanded Disability Status Scale score between 1 and 6.5\".\n\nOverall, while the patient meets the age criteria, there is insufficient information to determine if he meets the other inclusion criteria related to having multiple sclerosis and lower urinary tract symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "518": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18-40 years old for this trial.\n\n2. The patient has no history of hypertension, diabetes mellitus, or coronary artery disease based on the note. However, the note mentions he has a family history of CAD.\n\n3. The note does not explicitly state whether the patient is a smoker or not.\n\n4. Based on the information provided, the patient seems to meet most of the inclusion criteria except for the potential smoking history which is not clearly stated.\n\nTherefore, there is not enough information to definitively determine eligibility. The smoking status needs to be clarified.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "519": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\n4. The clinical trial is the \"Carotid Atherosclerosis Follow-up Study\" which aims to determine if the degree of carotid artery atherosclerosis predicts the development of myocardial infarction, stroke, and all-cause mortality in patients with angiographically defined coronary status. It also aims to quantify the rate of progression of carotid artery disease and evaluate the risk factors associated with progression.\n\n5. The inclusion criteria for the trial are not specified, which means there are no specific eligibility requirements.\n\nBased on the information provided, this patient appears to be eligible for the \"Carotid Atherosclerosis Follow-up Study\" as he has carotid artery atherosclerosis with severe stenosis in the LICA and moderate stenosis in the RICA, as well as plaque in the carotid arteries. The trial does not have any specific inclusion criteria, so the patient meets the eligibility requirements.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "520": {
        "output": "To determine the patient's eligibility for the clinical trial \"Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia\", let's go through the information provided:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors (smoking, high blood pressure, diabetes)\n- Physically active\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL (normal)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe inclusion criteria for the trial are:\n\"No eligibility criteria\"\n\nSince there are no specific inclusion or exclusion criteria mentioned for this trial, and the trial aims to study genetics of LDL subclasses in individuals with hypercholesterolemia, this patient with a very high LDL-C level of 545 mg/dL would likely be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "521": {
        "output": "To determine the patient's eligibility for the clinical trial \"Intimal Thickening and Antioxidants in Hispanics and Anglos (Los Angeles Atherosclerosis Study)\", let's go through the information provided:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors (smoking, high blood pressure, diabetes)\n- Physically active\n- LDL-C: 545 mg/dL (high)\n- HDL-C: 53 mg/dL (normal)\n- Fasting glucose and triglycerides within normal limits\n- No use of lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe clinical trial aims to investigate the role of antioxidants and pro-oxidants on the progression/regression of carotid intima-media thickness (IMT).\n\nThe inclusion criteria for the trial are: \"No eligibility criteria\"\n\nSince there are no specific inclusion or exclusion criteria mentioned, and the patient has carotid artery stenosis (which is relevant to the study of carotid IMT), the patient can be considered eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "522": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD).\n\n2. His lipid profile shows very high LDL-C (545 mg/dL) and low HDL-C (53 mg/dL), which are risk factors for premature atherosclerotic vascular disease.\n\n3. The clinical trial is titled \"Molecular & Clinical Evaluation of Low HDL Syndromes\" and aims to study the genetic cause of low HDL-C, a risk factor for premature atherosclerotic vascular disease.\n\n4. The inclusion criteria for the trial are not specified, which means there are no explicit eligibility requirements.\n\n5. Given the patient's low HDL-C level and the trial's focus on studying low HDL-C, the patient appears to be eligible for this trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "523": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man with no major cardiovascular risk factors except for a family history of CAD.\n2. His LDL-C level is very high at 545 mg/dL, indicating potential hyperlipidemia.\n3. Ultrasound revealed severe stenosis (\u226580%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n4. The trial inclusion criteria for cases are: \"Either had a history of surgical carotid endarterectomy or carotid or CT angiogram showing greater than or equal to 80% stenosis in one or more internal carotid artery.\"\n5. Since the patient has \u226580% stenosis in the LICA, he meets the inclusion criteria for being a case in this trial.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "524": {
        "output": "To determine the patient's eligibility for the clinical trial \"The MI-HEART Project,\" let's go through the inclusion and exclusion criteria:\n\nInclusion Criteria:\n1. Patients at high-risk for an acute myocardial infarction, including any 2 of these risk factors:\n   - Males age > 45 (Yes, the patient is a 46-year-old man)\n   - Females age > 55 (Not applicable)\n   - Family history of premature coronary heart disease (CHD) (Yes, the patient has a family history of CAD)\n   - Current cigarette smoker (No information provided)\n   - Hypertension (No information provided)\n   - Elevated total cholesterol with low HDL and/or high LDL (Yes, the patient has an LDL-C level of 545 mg/dL, which is elevated)\n\nThe patient meets at least two of the high-risk factors for an acute myocardial infarction.\n\n2. OR have:\n   - Active angina (No information provided)\n   - History of coronary heart disease according to the treating physician (No information provided)\n   - Past history of myocardial infarction documented by electrocardiogram or arteriography (No information provided)\n   - Diabetes Mellitus (No information provided)\n   - Renal dialysis (No information provided)\n\nExclusion Criteria:\n- Hospitalization within previous 4 weeks (No information provided)\n- Persons living in a home with previously enrolled patients (No information provided)\n- Patients disoriented to person, place, or time at onset of study (No information provided)\n\nBased on the information provided, the patient meets at least two of the high-risk factors for an acute myocardial infarction, and there is no information indicating that the exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "525": {
        "output": "Okay, let's go through the inclusion criteria for the Carotid Occlusion Surgery Study step-by-step:\n\n1. Vascular imaging demonstrating occlusion of one or both internal carotid arteries.\nThe patient note mentions \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\" This suggests occlusion of at least one internal carotid artery, meeting this criterion.\n\n2. Transient ischemic attack (TIA) or ischemic stroke in the hemispheric carotid territory of one occluded carotid artery. \nThe patient note does not mention any TIA or ischemic stroke, so this criterion is not met.\n\n3. Most recent qualifying TIA or stroke occurring within 120 days prior to projected performance date of PET.\nSince there is no mention of TIA or stroke, this criterion is not applicable.\n\n4. Modified Barthel Index > 12/20 (60/100).\nThere is no information about the Modified Barthel Index in the patient note.\n\n5. Language comprehension intact, motor aphasia mild or absent.\nThere is no information about language comprehension or motor aphasia in the patient note.\n\n6. Age 18-85 inclusive.\nThe patient's age is given as 46 years old, which falls within this range.\n\n7. Competent to give informed consent.\nThere is no information about the patient's competency to give informed consent.\n\n8. Legally an adult.\nThe patient is described as a 46-year-old man, so he is legally an adult.\n\n9. Geographically accessible and reliable for follow-up.\nThere is no information about the patient's geographic location or reliability for follow-up.\n\nBased on the information provided, the patient meets some of the inclusion criteria (occlusion of internal carotid artery and age range), but there is not enough information to determine if he meets all the criteria. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "526": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being at least 45 years old.\n\nHe has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which would qualify as \"Asymptomatic carotid stenosis >= 70%\" under the major atherothrombotic risk factors.\n\nHis LDL-C level of 545 mg/dL would likely qualify as \"Primary hypercholesterolemia\" under the minor atherothrombotic risk factors.\n\nThe patient does not seem to have any of the exclusion criteria listed.\n\nBased on the information provided, this patient appears to meet the inclusion criteria by having at least 1 major atherothrombotic risk factor (carotid stenosis) and 1 minor risk factor (hypercholesterolemia).\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "527": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being >18 years old.\n\nHe has dizziness, frequent headaches, and carotid artery stenosis, but the trial is specifically looking at renal artery stenosis and hypertension/renal dysfunction.\n\nHis LDL-C is very high at 545 mg/dL, but lipid levels are not mentioned in the inclusion/exclusion criteria.\n\nHe does not have documented hypertension on two or more medications or renal dysfunction/CKD based on the information given.\n\nThe ultrasound showed severe stenosis in the left internal carotid artery and moderate 40-50% stenosis in the right internal carotid artery, but no information is provided about renal artery stenosis.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having hypertension on multiple medications, renal dysfunction/CKD, or severe renal artery stenosis documented by imaging.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "528": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)\" and determine the patient's eligibility.\n\n1. The subject must be > 18 and < 80 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. Female subjects of child bearing potential must have a documented negative pregnancy test within 30 days prior to the study procedure.\nThis criterion is not applicable as the patient is a male.\n\n3. Subject must be asymptomatic, defined as no stroke or Transient Ischemic Attack [(TIA);(hemispheric or ocular)] within the 180 days prior to the procedure.\nThe patient presents with dizziness and frequent headaches, but there is no mention of stroke or TIA, so this criterion is likely met.\n\n4. Subjects taking warfarin may be included if their dosage is reduced before the procedure to result in an International Normalized Ratio (INR) of 1.5 or less. Warfarin may be restarted after the procedure.\nThere is no mention of the patient taking warfarin, so this criterion is not applicable.\n\n5. The subject must sign a written informed consent prior to the procedure, using a form that is approved by the local institutional review board (IRB).\nThis criterion cannot be assessed based on the provided information.\n\n6. The subject must agree to return for all required follow-up visits.\nThis criterion cannot be assessed based on the provided information.\n\n7. Subject has a discrete lesion located in the internal carotid artery (ICA); the contiguous common carotid artery (CCA) may be involved.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), so this criterion is met.\n\n8. Carotid stenosis \u2265 70% and \u2264 99% by carotid ultrasound or \u2265 70% and \u2264 99% stenosis (visual estimate) by angiography, without significant (> 60% by ultrasound or angiography) ICA/CCA contralateral stenosis.\nThe patient has severe stenosis (likely \u2265 70%) in the LICA and moderate stenosis (40-50%) in the RICA, so this criterion is met.\n\n9. Target ICA vessel diameter must be visually estimated to be:\n> 2.5 mm and < 7.0 for the Emboshield Pro or for the Emboshield NAV6, > 2.8 mm and < 6.2 for the Emboshield Gen 3 And > 4.0 mm and < 9.0 mm for the Xact stent treatment segment.\nThere is no information provided about the vessel diameter, so this criterion cannot be assessed.\n\n10. Based on the subject's anatomy, the Investigator should expect to successfully deliver the stent to the target lesion (absence of extreme tortuosity, etc.).\nThere is no information provided about the anatomy or tortuosity of the vessels, so this criterion cannot be assessed.\n\n11. De novo target lesion that can be treated with a single stent.\nThere is no information provided about whether the lesion is de novo or can be treated with a single stent, so this criterion cannot be assessed.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there are several criteria that cannot be assessed due to lack of information. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "529": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older for the clinical trial.\n\n2. The patient does not have sickle cell anemia, which is a requirement for inclusion in this trial. The note mentions he has a family history of CAD but no other details about sickle cell disease.\n\n3. The patient has high LDL cholesterol (545 mg/dL) and carotid artery stenosis, but these conditions are not exclusion criteria for the non-invasive procedures in the trial.\n\n4. There is no mention of the patient having any of the exclusion criteria listed, such as pregnancy, lactation, known coronary artery disease, significant renal insufficiency, recent stroke or pulmonary embolism, retinal detachment, or intolerance to MRI.\n\nBased on the information provided, while the patient does not have sickle cell anemia required for inclusion, there is also no clear exclusion criteria mentioned that would prevent participation in at least the non-invasive procedures of the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "530": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age at least 18 years.\nThe patient is 46 years old, so this criterion is met.\n\n2. Presence of symptoms of an ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) scale of one up to 20 or due to an ipsilateral atherosclerotic >50% stenosis of the extracranial internal carotid artery (ICA) as shown by ultrasonography.\nThe patient presents with dizziness and frequent headaches, which could be symptoms of an ischemic stroke. Additionally, the ultrasonography revealed severe stenosis in the left internal carotid artery (LICA), estimated to be >50%. So this criterion is met.\n\n3. Latency between the onset of stroke symptoms and intended administration of the study drugs is not more than 24 hours.\nThere is no information provided about the latency between symptom onset and intended drug administration.\n\n4. Latency between the intended administration of the study drugs and intended carotid endarterectomy is at least three days.\nThere is no information provided about the intended timing of drug administration or carotid endarterectomy.\n\nSince there is insufficient information to determine if criteria 3 and 4 are met, the overall trial-level eligibility cannot be definitively assessed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "531": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of at least 18 years old.\n\n2. The patient has elevated LDL-C levels of 545 mg/dL, which is indicative of hypercholesterolemia.\n\n3. The patient reports a family history of CAD, which could suggest familial hypercholesterolemia.\n\n4. There is no mention of the patient being diagnosed with heterozygous familial hypercholesterolemia specifically.\n\nBased on the information provided, while the patient exhibits signs of hypercholesterolemia and a family history of CAD, there is no explicit diagnosis of heterozygous familial hypercholesterolemia mentioned.\n\nTherefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "532": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man with no major cardiovascular risk factors except for a family history of CAD.\n2. His LDL-C level is extremely high at 545 mg/dL, indicating a potential genetic disorder of high cholesterol.\n3. The clinical trial is studying the effect of a lipid-lowering drug combination (torcetrapib/atorvastatin) in patients with a genetic disorder causing extremely high cholesterol levels.\n4. One of the inclusion criteria for the trial is a diagnosis of Homozygous Familial Hypercholesterolemia.\n\nBased on the patient's extremely high LDL-C level of 545 mg/dL and the trial's inclusion criteria of a genetic disorder causing high cholesterol, it seems likely that this patient may have Homozygous Familial Hypercholesterolemia, making them potentially eligible for this clinical trial.\n\nHowever, the patient note does not explicitly state a diagnosis of Homozygous Familial Hypercholesterolemia.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, as a diagnosis of Homozygous Familial Hypercholesterolemia is not provided).",
        "label": 0
    },
    "533": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of at least 18 years old.\n\n2. However, the patient does not have a diagnosis of heterozygous familial hypercholesterolemia mentioned in the note. The note mentions high LDL-C levels and carotid artery stenosis, but does not explicitly state a diagnosis of heterozygous familial hypercholesterolemia.\n\n3. Since the patient does not have the specific diagnosis required for inclusion in this trial, they would not be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "534": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u2265 40 years old.\n\nHe has no diagnosis of diabetes mentioned, so the criteria \"Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or WHO criteria)\" is not met.\n\nHowever, his LDL cholesterol level is 545 mg/dL, which meets the criteria of LDL \u2265 100 mg/dL within the previous 12 months.\n\nThere is no blood pressure value mentioned, so the criteria \"Systolic BP >= 130 mm Hg within the previous 12 months\" cannot be confirmed.\n\nSince the patient does not have a clear diagnosis of Type 2 diabetes, and the blood pressure criteria cannot be confirmed, there is insufficient information to determine if the patient is fully eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "535": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients,\" let's go through the inclusion and exclusion criteria:\n\nInclusion Criteria:\n1. Untreated dyslipidemic (LDL cholesterol >110 mg/dl): The patient's LDL-C level is 545 mg/dL, which meets this criterion.\n2. Documented atherosclerosis in at least 1 vascular territory:\n   - The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA), which meets this criterion.\n\nThe patient meets all the inclusion criteria.\n\nExclusion Criteria:\n1. Acute illness, infection, inflammation or major systemic diseases: Not mentioned in the patient note.\n2. T-Bil >3 mg/dl: Not mentioned in the patient note.\n3. Creatinine >3 mg/dl: Not mentioned in the patient note.\n\nBased on the information provided, there is no evidence that the patient meets any of the exclusion criteria.\n\nTherefore, considering the inclusion and exclusion criteria, the patient appears to be eligible for the clinical trial \"The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "536": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The subject must be > 18 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. The subject should have a stenosis in the common or internal carotid artery of at least 70% determined by one of the listed modalities.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). The LICA stenosis meets this criterion.\n\n3. The subject should be considered a relatively high risk for carotid endarterectomy, based on certain conditions listed.\nThere is no information provided about the patient's risk factors for carotid endarterectomy, so this criterion cannot be evaluated.\n\n4. Subjects can be either clinically symptomatic or asymptomatic (less than 80 years of age).\nThe patient is 46 years old and presents with dizziness and frequent headaches, which could potentially be considered symptoms. However, it is not clear if these symptoms are related to the carotid artery stenosis.\n\n5. If an angiogram is performed to qualify the subject, it should be as recent as feasible and will not be acceptable if done > 120 days from study entry.\nThe patient had an ultrasonography of the carotid arteries, which revealed the stenosis. There is no mention of an angiogram.\n\n6. Female subjects of childbearing potential must have a documented negative pregnancy test during the index hospitalization.\nThis criterion is not applicable as the patient is male.\n\n7. The subject must sign a written informed consent.\nThere is no information provided about whether the patient has signed an informed consent.\n\n8. If a patient's creatinine is 3.5 or greater, their nephrologist must clear them to participate in the trial.\nThere is no information provided about the patient's creatinine levels.\n\nBased on the information provided, the patient meets at least one of the inclusion criteria (carotid artery stenosis of at least 70%). However, there is not enough information to determine if the patient meets all the inclusion criteria, particularly regarding being at high risk for carotid endarterectomy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "537": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being > 18 years old.\n\n2. The patient is symptomatic with dizziness and frequent headaches, which could potentially be related to the carotid artery stenosis. However, the inclusion criteria specifically mentions symptoms like TIA or stroke in the ipsilateral carotid artery distribution within the previous 120 days. The patient's symptoms are not clearly specified as such.\n\n3. The patient has severe stenosis (>60%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the criteria for stenosis >60% in the common or internal carotid artery.\n\n4. The patient has undergone ultrasonography of the carotid arteries, which is required for screening as per the inclusion criteria.\n\n5. The stenosis is presumed to be of atherosclerotic origin, which meets the inclusion criteria.\n\n6. The target lesion is in the native internal carotid artery, which is acceptable as per the inclusion criteria.\n\nWhile the patient meets some of the key inclusion criteria, there is not enough information provided to determine if they meet all the criteria, particularly regarding the specific nature of their symptoms and whether they are related to the carotid artery stenosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "538": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >=18 years old for the trial.\n\n2. The patient does not have multiple sclerosis, which is one of the target diseases for this trial. \n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the anatomic inclusion criteria #2 of carotid stenosis >= 50% by angiography for the LICA.\n\n4. The LICA reference diameter is not provided, but the criteria is >=4.0 mm and <=9.0 mm, which the severe stenosis likely meets.\n\n5. For the ACCUNET system, there needs to be a straight/mildly angulated >=4 cm segment in the distal ICA with diameter >=3.25 mm and <=7.5 mm to place the embolic protection device. This information is not provided.\n\n6. The other inclusion criteria regarding cardiac/pulmonary disease, diabetes, prior procedures, etc. are not met based on the patient note.\n\nIn summary, while the patient meets some of the key anatomic inclusion criteria for carotid artery stenosis, there is insufficient information provided about the distal ICA segment to place the ACCUNET device. Additionally, the patient does not have multiple sclerosis which is one of the target diseases.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "539": {
        "output": "Okay, let's go through the inclusion criteria for the \"Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)\" clinical trial and assess the eligibility of the patient based on the provided note.\n\n1. The patient must be > 18 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as:\n- one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or\n- one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR\nThe patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms.\n\nThe patient note mentions that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (between 40% and 50%) in the right internal carotid artery (RICA). The PSV and EDV values provided also indicate significant stenosis in the LICA. However, the note does not mention any recent TIAs, strokes, or other neurological symptoms related to the carotid artery stenosis. Therefore, this criterion is partially met.\n\n3. The patient must have one or more of the listed conditions (e.g., congestive heart failure, recent MI, unstable angina, etc.).\nThe patient note does not mention any of these conditions, so this criterion is not met.\n\n4. The qualifying ultrasound or angiogram was performed less than 30 days prior to study entry.\nThe note does not provide the date of the ultrasound, so it is unclear if this criterion is met.\n\n5. The target vessel is in the native common or internal carotid artery. The arterial segment to be treated has a diameter between 4 mm and 9 mm as the largest diameter either proximal or distal to the lesion.\nThe note mentions that the stenosis is in the internal carotid arteries, so this criterion is likely met, but there is no information about the vessel diameter.\n\nBased on the provided information, the patient partially meets the inclusion criteria for the clinical trial, but there is not enough information to determine eligibility conclusively.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "540": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being > 18 years old.\n\nHe has severe stenosis (>50%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, as determined by ultrasound. This meets the criteria of having \u226550% stenosis of the internal or common carotid artery.\n\nHowever, the patient is described as being asymptomatic, with no mention of TIAs, strokes, or other neurological symptoms related to the carotid stenosis. This does not meet the criteria of being clinically symptomatic within the previous 180 days.\n\nThe patient also does not appear to have any of the listed high-risk conditions like congestive heart failure, recent MI or open heart surgery, unstable angina, etc.\n\nTherefore, based on the information provided, this patient does not fully meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "541": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His LDL-C level is very high at 545 mg/dL, indicating potential hyperlipidemia.\n3. Ultrasound revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n4. The inclusion criteria for the clinical trial are: \"Coronary artery stenosis >50% and either carotid or brain artery stenosis > 50%\"\n\nBased on the patient's ultrasound findings of severe LICA stenosis and the inclusion criteria requiring either carotid or brain artery stenosis >50%, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "542": {
        "output": "To determine the patient's eligibility for the \"Office Practice Assessment of Carotid Atherosclerosis Using Handheld Ultrasound (OPACA) Study\" clinical trial, let's go through the inclusion criteria:\n\n1. Males over 45 years and females over 55 years of age with at least one additional risk factor for coronary artery disease.\n\nThe patient is a 46-year-old man, so he meets the age criterion. He has a family history of CAD, which is considered a risk factor for coronary artery disease.\n\n2. Females 45-54 years old may be enrolled if they have a family history of CHD (myocardial infarction, coronary artery bypass graft surgery, angioplasty, sudden cardiac death) in a male first degree relative <55 or a female first degree relative <65 years old AND at least one additional risk factor for coronary artery disease.\n\nThis criterion is not applicable since the patient is male.\n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "543": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 46-year-old man, which meets the inclusion criteria of being an adult.\n\nHe has no history of coronary heart disease or CHD-risk equivalent mentioned. The trial requires participants to have stable CHD or CHD-risk equivalent.\n\nHis LDL-C level is 545 mg/dL, which is very high and outside the allowed range of <130 mg/dL for those on a stable statin dose or <160 mg/dL for those not on a statin.\n\nHe is not reported to be on any lipid-lowering medications like a statin.\n\nNo other relevant inclusion/exclusion criteria are mentioned about antiplatelet therapy, cardiovascular events/procedures, hypertension, diabetes, triglyceride levels, etc.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having stable CHD or CHD-risk equivalent, and his LDL-C level is too high to qualify.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "544": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age >18 years: The patient is 46 years old, so this criterion is met.\n\n2. Patient must be symptomatic with lesions \u226550% stenosis, or asymptomatic with lesions \u226575% stenosis in at least one carotid artery: The patient has severe stenosis (>50%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Since the patient is symptomatic with dizziness and headaches, this criterion is met.\n\n3. Lesions must be specific to the internal carotid artery, common carotid artery, or bifurcated region: The note mentions that plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, so this criterion is met.\n\n4. Acceptable ultrasound studies completed within 30 days of recruitment: The note does not specify when the ultrasound was done, so we cannot confirm if this criterion is met.\n\n5. For bilateral disease, procedures need to be staged >30 days apart: This criterion is not applicable since the trial is assessing the feasibility of the catheter system and not staging procedures.\n\n6. Women of childbearing potential must have a negative pregnancy test within 7 days: The patient is a man, so this criterion is not applicable.\n\n7. The patient is able to give informed consent: There is no information about the patient's ability to provide informed consent.\n\nBased on the information provided, the patient meets most of the key inclusion criteria, except for the timing of the ultrasound study and the ability to provide informed consent, which are not specified.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 2
    },
    "545": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin for gastrointestinal cancer.\n\n5. The inclusion criteria for the trial are:\n   - Diagnosis of gastrointestinal cancer\n   - Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy\n   - No pre-existing neuropathy\n   - No CNS disease or cerebral metastases\n   - WHO performance status 0-1\n   - Life expectancy \u2265 12 weeks\n   - No biliary or gastro-duodenal obstruction\n   - No conditions that would preclude study treatment\n   - No other concurrent potentially neurotoxic drugs or agents\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as he does not have a diagnosis of gastrointestinal cancer and is not receiving or planning to receive oxaliplatin-based chemotherapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "546": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 60 years or greater.\n\nThere is no information provided about the patient's testosterone levels, so it is unclear if he meets the hypogonadism/low testosterone criteria.\n\nThe note mentions he is generally physically active with no major cardiovascular risk factors like smoking, high blood pressure, or diabetes, suggesting he is in generally good health.\n\nThere is no information about his education level or ability to pass screening tests for dementia/provide informed consent.\n\nOverall, based on the information provided, there is not enough evidence to definitively determine if the patient meets all of the inclusion criteria. More information is needed, particularly regarding his testosterone levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "547": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The inclusion criteria for the clinical trial are:\n   - Syncope, pre-syncope, or palpitations less frequently than every 24 hours\n   - Non-diagnostic 24 hours of monitoring related to symptoms within 45 days of enrollment\n   - Ability to understand, assent to, and willing to sign the informed consent form\n\n6. Based on the patient's presentation of dizziness and the carotid artery stenosis findings, it is possible that the patient is experiencing pre-syncope or syncope episodes related to the carotid artery disease.\n\n7. However, there is no information provided about the frequency of these episodes or whether the patient has undergone any prior monitoring.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "548": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of > 18 and < 90 years old.\n\nHe has severe stenosis (>50%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, which meets the inclusion criteria of carotid stenosis of > 30% by ultrasound criteria.\n\nHis LDL cholesterol level is 545 mg/dL, which is well above the required level of > 100 mg/dL.\n\nThere is no information provided about his blood pressure, pregnancy status, or capacity to give informed consent.\n\nOverall, based on the information given, the patient appears to meet the key inclusion criteria related to age, carotid stenosis, and LDL cholesterol level. However, there is insufficient information to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "549": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Males or females greater than or equal to 18 years of age\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception.\nThe patient is male, so this criterion is not applicable.\n\n3. LDL-C level greater than the NCEP goals, as determined by patients' risk category according to NCEP ATP III criteria\nThe patient's LDL-C level is 545 mg/dL, which is significantly higher than the NCEP goal of <100 mg/dL for high-risk patients. So, he meets this criterion.\n\n4. Risk category for coronary heart disease and coronary heart disease equivalent with LDL goal of < 100 mg/dL\nThe patient has a family history of CAD, which puts him in the high-risk category for coronary heart disease. His LDL-C level of 545 mg/dL is much higher than the goal of <100 mg/dL for high-risk patients. So, he meets this criterion.\n\n5. Baseline lipid criteria: LDL-C = 100 to160 mg/dL and triglyceride level = 100 to 500 mg/dL\nThe patient's LDL-C level of 545 mg/dL is higher than the specified range of 100 to 160 mg/dL. However, his triglyceride level of 158 mg/dL falls within the specified range of 100 to 500 mg/dL. So, he partially meets this criterion.\n\n6. Normal thyroid function tests (total T3, total T4, and thyroid-stimulating hormone [TSH])\nThere is no information provided about the patient's thyroid function tests.\n\n7. Hemoglobin A1C < 8.5% on a stable oral hypoglycemic or insulin regimen\nThere is no information provided about the patient's hemoglobin A1C levels or diabetes treatment.\n\n8. On stable lipid modification pharmacotherapy (including a statin) for at least 2 weeks prior to study entry. Patients must be on at least half of the maximal doses of statins (as assessed by the Investigator), or be intolerant to statins such that the doses are not achievable.\nThe patient reported no use of lipid-lowering medications, so he does not meet this criterion.\n\n9. Able to give informed consent\nThere is no information provided about the patient's ability to give informed consent.\n\nBased on the information provided, the patient meets some of the inclusion criteria (age, LDL-C level, risk category for coronary heart disease) but does not meet others (lipid modification pharmacotherapy, thyroid function tests, hemoglobin A1C levels). There is also insufficient information to determine if he meets the remaining criteria (informed consent, thyroid function tests, hemoglobin A1C levels).\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "550": {
        "output": "To determine the patient's eligibility for the clinical trial \"Evaluation of Atorvastatin Treatment on Carotid Plaque\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Subjects with measurable carotid plaque with lipid\n\nBased on the patient note, the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces. This suggests the presence of lipid in the carotid plaque.\n\n2. Subjects are eligible for statin therapy\n\nThe patient has an LDL-C level of 545 mg/dL, which is very high and would likely qualify for statin therapy based on current guidelines.\n\nSince the patient meets both inclusion criteria, they would be considered eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "551": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-85 years old for the clinical trial.\n\n2. The patient has symptomatic ischemic heart disease, as evidenced by the dizziness, frequent headaches, and carotid artery stenosis findings. This meets the inclusion criteria of \"Symptomatic ischemic heart disease (CCS class 1-4, Braunwald class IB, IC, and/or objective evidence of myocardial ischemia)\".\n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the criteria of \"Treatment of 1 or 2 de novo lesions\" and \"Target lesion(s) is(are) located in a native coronary artery, which can be covered by one single stent of maximum 33 mm\".\n\n4. The reference vessel diameters are not explicitly stated, but the stenosis findings suggest they are within the 2.5-3.75 mm range required.\n\n5. There is no information provided about the patient being an acceptable candidate for CABG surgery.\n\n6. The stenosis percentages meet the criteria of \"Target lesion stenosis is \u226550% and <100%\".\n\n7. There is no information about the patient's willingness to comply with follow-up or providing informed consent.\n\nBased on the information provided, the patient appears to meet most of the key inclusion criteria, except for a couple of missing details about CABG candidacy and willingness to participate.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "552": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating carotid artery disease and atherosclerosis. This meets the inclusion criteria of \"Any adult patient with carotid artery disease or known atherosclerosis capable of giving informed consent.\"\n\n3. There is no information provided about the patient's ability to give informed consent, but we can assume they are capable unless stated otherwise.\n\n4. The exclusion criteria do not seem to apply based on the information provided.\n\nTherefore, based on the inclusion and exclusion criteria provided for this clinical trial, this patient appears to be eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "553": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of >18 years old.\n\nHe has no documented diagnosis of type 2 diabetes, which is required per the inclusion criteria \"Patients must be previously diagnosed with type 2 diabetes with documented treatment with insulin, oral hypoglycemics, or diet controlled by medical history.\"\n\nHe does have angina pectoris symptoms like dizziness and headaches, as well as carotid artery stenosis, which could qualify under \"Diagnosis of angina pectoris defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;\"\n\nHis LDL-C level of 545 mg/dL is very high, suggesting he may have undiagnosed diabetes or metabolic syndrome, but this is not explicitly stated.\n\nHe has no documented exclusion criteria like liver disease, renal impairment, recent MI, etc.\n\nHowever, the key inclusion criteria of having type 2 diabetes is not met based on the information provided.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial focused on type 2 diabetic patients)",
        "label": 1
    },
    "554": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female subjects, \u2265 30 years old with either known atherosclerotic coronary or vascular disease OR coronary risk equivalents defined as either: diabetes mellitus, multiple coronary risk factors with a Framingham Risk Score > 2% per year, or an elevated coronary calcium score (> 400 for men, > 200 for women)\n\nThe patient is a 46-year-old man, so he meets the age criteria. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which indicates atherosclerotic vascular disease. So this criterion is met.\n\n2. Currently being treated with a statin (Simvastatin 20 mg/d or its equivalent) as monotherapy for treatment of hyperlipidemia\n\nThe patient note does not mention if the patient is currently taking a statin or any other lipid-lowering medication. This information is missing.\n\n3. Recent lipids (within the past 3 months without interval change in the statin regimen) showing both: LDL-C < 100 mg/dL and HDL-C < 50 mg/dL (men) or < 55 mg/dL (women)\n\nThe patient's LDL-C level is 545 mg/dL, which is much higher than the required <100 mg/dL. However, his HDL-C level of 53 mg/dL meets the criteria of <50 mg/dL for men.\n\nSince the patient meets some but not all of the inclusion criteria, and there is missing information about statin use, I would assess his trial eligibility as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "555": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult patient.\n\n2. The patient has severe stenosis (>80%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria for asymptomatic carotid artery stenosis of >80%.\n\n3. The patient has no reported neurological symptoms like stroke or TIA, so he would be considered asymptomatic.\n\n4. The patient has risk factors like family history of CAD that could make him high risk for carotid endarterectomy, though this is not explicitly stated.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria of having asymptomatic carotid artery stenosis >80% and potentially being at high risk for carotid endarterectomy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "556": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C 545 mg/dL (very high)\n- HDL-C 53 mg/dL (normal)\n- Fasting glucose 85 mg/dL (normal) \n- Triglycerides 158 mg/dL (normal)\n- No lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe clinical trial inclusion criteria are:\n- Type 2 diabetes mellitus \n- Age 50-75 years (patient is 46, so does not meet this)\n- Diabetes duration > 5 years (no information given)\n- At least 2 of: dyslipidemia, hypertension, smoking, family history of premature CAD\n\nThe patient does not have diabetes, which is a core inclusion criteria. He also does not meet the age criteria.\n\nWhile he has dyslipidemia (very high LDL-C) and family history of CAD, there is insufficient information about diabetes duration and he lacks at least 2 other risk factors listed.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "557": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) but normal HDL-C, fasting glucose, and triglycerides.\n\n2. He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA) based on ultrasound findings.\n\n3. The clinical trial is looking at patients with 30-69% carotid artery stenosis who have had neurological symptoms due to ischemia in the carotid artery territory.\n\n4. The inclusion criteria specifically state \"Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% as detected by ultrasound examination.\"\n\n5. This patient meets the inclusion criteria as he has dizziness and headaches (potential neurological symptoms) and has a RICA stenosis between 40-50% based on ultrasound.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "558": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of >= 40 years and <= 75 years.\n\nThere is no information provided about the patient's blood pressure readings, so the criteria of SBP >= 130 mmHg and < 140 mmHg or DBP >= 85 mmHg and < 90 mmHg cannot be evaluated.\n\nThe patient's fasting glucose level is 85 mg/dL, which falls within the range of >= 100 mg/dL and < 126 mg/dL specified in the inclusion criteria.\n\nThere is no information provided about the patient's waist circumference, so the criteria of >= 102 cm for men and >= 88 cm for women cannot be evaluated.\n\nSince there is insufficient information to determine if the patient meets all of the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "559": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age (<50 years) and gender (male) criteria for the trial.\n\n2. The patient's BMI is not provided, but it is stated that he has no cardiovascular risk factors like smoking, high blood pressure, and diabetes mellitus, and is physically active. This suggests his BMI is likely <30 kg/m2, meeting that inclusion criteria.\n\n3. It is stated that the patient has no personal history of cardiovascular diseases, meeting that criteria.\n\n4. There is no mention of the patient taking any medications that could interfere with glucose, lipid metabolism or blood pressure.\n\n5. It is stated that the patient reported no use of lipid-lowering medications, meeting that criteria.\n\n6. There is no mention of previous growth hormone treatment for the patient.\n\nBased on the information provided in the patient note, the patient appears to meet all the inclusion criteria listed for this clinical trial studying the effect of 5 years of growth hormone replacement on atherosclerosis in men with severe growth hormone deficiency.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "560": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Cardiovascular Risk Factors and LCH in Adults\", the patient does not meet the inclusion criteria for the trial.\n\nThe key points are:\n\n1. The patient note does not mention a diagnosis of Langerhans-cell histiocytosis (LCH), which is the sole inclusion criterion for the trial.\n\n2. The patient note describes the patient's symptoms, family history, and test results related to cardiovascular risk factors, but does not indicate a diagnosis of LCH.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "561": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. No other major cardiovascular risk factors are mentioned.\n\n2. His LDL-C level is very high at 545 mg/dL, indicating potential atherosclerosis. His other lipid levels are within normal limits.\n\n3. He has a systolic murmur and ultrasonography revealed severe stenosis (>80%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying stenting versus best medical treatment for asymptomatic high-grade (>80%) carotid artery stenosis.\n\n5. The inclusion criteria specifically mention atherosclerosis as the underlying disease, asymptomatic stenosis >80% (which the patient has in the LICA), and neurologist's consent to potentially perform stenting.\n\nBased on the information provided, this patient meets the key inclusion criteria of having asymptomatic high-grade (>80%) carotid artery stenosis due to underlying atherosclerosis. No explicit exclusion criteria are mentioned that would exclude the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "562": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Levels of LDL-c between >130 mg/dl and <189 mg/dl\nThe patient's LDL-C level is 545 mg/dL, which is higher than the allowed range. This criterion is not met.\n\n2. Presence of at least 1 cardiovascular risk factor defined as:\n   - Age above 45 years in men: The patient is 46 years old, so this criterion is met.\n   - Smoker: The note does not mention if the patient is a smoker or not.\n   - High blood pressure: The note does not mention if the patient has high blood pressure.\n   - HDL-c < 40 mg/dl in men: The patient's HDL-C level is 53 mg/dL, which is higher than the cutoff.\n   - Family background of early heart disease: The patient has a family history of CAD, so this criterion is met.\n\nSince the patient meets at least one cardiovascular risk factor (age above 45 years in men and family history of early heart disease), this inclusion criterion is satisfied.\n\n3. Patients who have given informed consent: The note does not mention if the patient has given informed consent or not.\n\n4. Patients who will be capable of following diet guidelines: The note does not provide information about the patient's ability to follow diet guidelines.\n\nOverall, while the patient meets some of the inclusion criteria (age and family history of heart disease), the LDL-C level is too high, and there is not enough information about informed consent and ability to follow diet guidelines.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "563": {
        "output": "To determine the patient's eligibility for the clinical trial \"Additional Neurological Symptoms Before Surgery of the Carotid Arteries - A Prospective Study (ANSYSCAP)\", I will check if the patient meets the inclusion criteria provided.\n\nThe inclusion criteria is:\n\"Carotid stenosis >50% according to NASCET criteria\"\n\nFrom the patient note, we have the following relevant information:\n- Ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\n- For the LICA, the peak-systolic velocity (PSV) was 208.5 cm/s and end-diastolic velocity (EDV) was 54.5 cm/s.\n\nThe NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria for determining carotid stenosis severity based on ultrasound velocities is:\n- >70% stenosis if PSV > 230 cm/s and EDV > 100 cm/s\n- 50-69% stenosis if PSV 230 cm/s and EDV < 100 cm/s\n\nBased on the PSV of 208.5 cm/s and EDV of 54.5 cm/s for the LICA, this patient has a 50-69% stenosis in the left internal carotid artery according to NASCET criteria.\n\nTherefore, this patient meets the inclusion criteria of \"Carotid stenosis >50% according to NASCET criteria\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "564": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effect of Exercise Training on the Function of the High Density Lipoprotein (HDL)-Cholesterol, Endothelial Function and Endothelial Progenitor Cells in Patients With Metabolic Syndrome(HERMET-Study)\", let's go through the inclusion criteria:\n\n1. Reduced HDL-Cholesterol levels in blood: < 40 mg/dl (1.03 mmol/L) in male, < 50 mg/dl (1.29 mmol/L) in female\nThe patient's HDL-C level is 53 mg/dL, which does not meet this criterion.\n\n2. Plus two of the following criteria:\na) Elevated waist circumference: \u2265 102 cm (\u2265 40 inches) in men or \u2265 88 cm (\u2265 35 inches) in women\nThe patient's waist circumference is not provided.\n\nb) Elevated triglycerides: \u2265 150 mg/dL (1.7 mmol/L)\nThe patient's triglyceride level is 158 mg/dL, which meets this criterion.\n\nc) Elevated blood pressure: \u2265 130 mmHg systolic blood pressure or \u2265 80 mmHg diastolic blood pressure or anti-hypertensive treatment\nThe patient's blood pressure is not provided.\n\nd) Elevated fasting glucose: \u2265 100 mg/dL or on drug treatment for elevated fasting glucose\nThe patient's fasting glucose level is 85 mg/dL, which does not meet this criterion.\n\nBased on the information provided, the patient meets only one of the required criteria (elevated triglycerides) and does not have reduced HDL-C levels, which is a mandatory criterion for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "565": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he does not have other cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus, and is physically active.\n\nHis lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose (85 mg/dL), and triglycerides (158 mg/dL). He is not taking any lipid-lowering medications.\n\nThe physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\nThe clinical trial is looking for participants with diabetes, hypertension, or coronary artery disease.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this trial as he does not have diabetes, hypertension, or a confirmed diagnosis of coronary artery disease. The carotid artery stenosis and high LDL-C levels suggest potential cardiovascular issues, but do not explicitly meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "566": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 46-year-old man\n- No cardiovascular risk factors except family history of CAD\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL (normal)\n- No lipid-lowering medications\n- Carotid artery stenosis\n\nThe inclusion criteria for the clinical trial are:\n- Moderately obese with hyperlipidemia\n\nBased on the information provided, the patient does have hyperlipidemia with a very high LDL-C level of 545 mg/dL. However, there is no mention of the patient being moderately obese.\n\nWithout knowing the patient's body mass index (BMI) or weight status, it is difficult to definitively determine if they meet the inclusion criteria of being moderately obese with hyperlipidemia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "567": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 or older.\n\n2. The patient note mentions that he has a history of childhood scalp irradiation, which meets one of the inclusion criteria.\n\n3. There is no mention of the patient not providing written informed consent.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the \"Carotid Atherosclerotic Disease Following Childhood Scalp Irradiation\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "568": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, so he does not meet the inclusion criteria of being a woman.\n\n2. His LDL-C level is 545 mg/dL, which is much higher than the inclusion criteria range of 90-135 mg/dL.\n\n3. His triglyceride level is 158 mg/dL, which meets the inclusion criteria of > 150 mg/dL.\n\n4. There is no information provided about whether the patient is on stable statin therapy, which is an inclusion criteria.\n\nSince the patient does not meet at least two of the key inclusion criteria (being a woman and having LDL-C in the specified range), and there is insufficient information about statin therapy, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "569": {
        "output": "To determine the patient's eligibility for the clinical trial \"GORE Embolic Protection With Reverse Flow\", let's go through the inclusion criteria one by one:\n\n1. Carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis \u2265 50% OR asymptomatic status with carotid stenosis \u2265 80%\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the criteria for symptomatic status with carotid stenosis \u2265 50%.\n\n2. Target lesion is located in one of the following: (a) internal carotid artery (ICA) (b) bifurcation (c) common carotid artery (CCA) proximal to the bifurcation\n- The patient has stenosis in the left and right internal carotid arteries, which meets this criterion.\n\n3. At Anatomic risk for adverse events from CEA (e.g. restenosis after a prior CEA) OR at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)\n- There is no information provided about the patient's risk for adverse events from CEA or any comorbidities that would increase this risk.\n\nBased on the information provided, the patient meets the first two inclusion criteria for the clinical trial. However, there is not enough information to determine if the patient meets the third inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "570": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe does not have a diagnosis of type 2 diabetes mellitus, which is required for this trial.\n\nHis LDL-C level is 545 mg/dL, which is much higher than the required <2.5 mmol/L (approximately 97 mg/dL).\n\nHis total cholesterol:HDL-C ratio is not provided, but with an HDL-C of 53 mg/dL, it is likely higher than the required <4.0.\n\nHe has no reported history of cardiovascular disease, proteinuria, or renal failure.\n\nHis blood pressure is not mentioned, so it is unclear if he meets that criteria.\n\nHe is not taking any lipid-lowering medications like statins.\n\nHis risk for coronary heart disease, fatal CHD, stroke, and fatal stroke is not calculated using the UKPDS Risk Engine, so his eligibility for the \"low risk\" criteria cannot be determined.\n\nOverall, while he meets some of the inclusion criteria, he does not have a diagnosis of type 2 diabetes and his LDL-C level is too high. There is also insufficient information about his blood pressure and calculated cardiovascular risk.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "571": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of >18 years old.\n\nHe has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating he has evaluable carotid plaques.\n\nHis LDL-C level is 545 mg/dL, which is very high, suggesting he could benefit from lipid-lowering treatment like atorvastatin.\n\nHe reported no use of lipid-lowering medications for more than 6 months.\n\nThere is no mention of contraindications for atorvastatin or unstable cardiovascular health.\n\nHe is not reported to be claustrophobic.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria for the clinical trial on the effect of short-term atorvastatin treatment on carotid artery atherosclerotic lesions.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "572": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis: The patient has primary hypercholesterolemia with LDL-C of 545 mg/dL (>180 mg/dL) and triglycerides of 158 mg/dL (<350 mg/dL), along with coronary heart disease indicated by carotid artery stenosis. This meets the diagnosis criteria.\n\n2. Age: The patient is 46 years old, which falls within the 18-75 years age range. \n\n3. LDL-C level: The patient's LDL-C of 545 mg/dL is above the required range of 130-180 mg/dL.\n\n4. Triglyceride level: The patient's triglyceride level of 158 mg/dL is within the required limit of <350 mg/dL.\n\n5. Documented coronary heart disease: The patient has carotid artery stenosis, which indicates coronary heart disease.\n\n6. Not currently taking a statin: The patient reported no use of lipid-lowering medications.\n\n7. Liver and muscle enzyme levels: No information provided.\n\n8. Other lab tests: No information provided. \n\n9. Failed cholesterol-lowering diet and exercise: No information provided.\n\n10. Stable weight: No information provided.\n\n11. Hormonal therapy: No information provided.\n\n12. Birth control for women of childbearing potential: Not applicable as the patient is a man.\n\n13. Free of other significant diseases: No information provided.\n\n14. Ability to adhere to study requirements: No information provided.\n\nWhile the patient meets some of the key inclusion criteria like diagnosis, age, lipid levels and documented coronary heart disease, there is insufficient information provided about other criteria like lab tests, diet/exercise, weight stability, and ability to adhere to the study.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "573": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. He has no other cardiovascular risk factors and is physically active.\n3. His LDL-C level is high at 545 mg/dL, but other lipid levels (HDL-C, triglycerides) are within normal limits.\n4. He is not taking any lipid-lowering medications.\n5. Physical examination revealed a systolic murmur and carotid artery stenosis (severe in left, moderate in right).\n\nNow let's look at the inclusion criteria for the clinical trial:\n\"Inclusion Criteria: \nPatients suffering from stable CAD, on chronic ASA therapy\nPatients willing to participate in the study and to sign the informed consent form\"\n\nBased on the information provided, the patient seems to have stable CAD based on the carotid artery stenosis findings. However, there is no mention of him being on chronic ASA (aspirin) therapy.\n\nAdditionally, his willingness to participate in the study and sign the informed consent form is not stated.\n\nTherefore, there is not enough information to definitively determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "574": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being 18 years or older.\n\nHe has severe stenosis (>70%) in the left internal carotid artery, which makes him eligible for carotid endarterectomy surgery.\n\nThere is no information provided about whether he has given informed consent to participate in the study.\n\nBased on the information provided, the patient appears to meet at least some of the key inclusion criteria for the clinical trial evaluating contrast-enhanced ultrasound and MRI for detecting plaque neovascularization in carotid artery stenosis patients scheduled for endarterectomy.\n\nHowever, since there is no explicit mention of whether he has provided informed consent, I cannot definitively conclude that he is fully eligible.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "575": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients with Type II hyperlipidaemia\nThe patient note mentions that the patient has an LDL-C level of 545 mg/dL (which is very high) and an HDL-C level of 53 mg/dL (which is low), indicating hyperlipidemia. This criterion is met.\n\n2. Patients having lipid values as indicated below:\n   a) HDL-C < 1.6 mmol/l (1.6 mmol/l = 62 mg/dL)\n      The patient's HDL-C level of 53 mg/dL is less than 62 mg/dL, so this criterion is met.\n   b) TG < 4.5 mmol/l (4.5 mmol/l = 398 mg/dL) \n      The patient's triglyceride level of 158 mg/dL is less than 398 mg/dL, so this criterion is met.\n\n3. Male and females between 18 and 65 years old\nThe patient is a 46-year-old man, so this criterion is met.\n\n4. If female must be post-menopausal, or pre-menopausal and surgically sterile or using an acceptable form of contraception\nThis criterion is not applicable since the patient is male.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "576": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male subject aged 45 years or above, or female subject aged 55 years or above (age-related CVD risk factor)\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. At least another of the following risk factors for CVD: cigarette smoking, hypertension, low HDL cholesterol or high LDL cholesterol, family history of premature coronary heart disease, elevated waist circumference\nThe patient has a family history of CAD and high LDL-C level of 545 mg/dL, so he meets this criterion as well.\n\n3. Willingness to participate in the survey and complying with the study by signing a written informed consent\nThis is not mentioned in the patient note, so we cannot determine if this criterion is met or not.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria of age and cardiovascular risk factors. However, since there is no mention of the patient's willingness to participate, we cannot definitively conclude eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "577": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Clinically established coronary artery disease or carotid artery disease with greater than 15% stenosis by ultrasound\n- The patient has severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, so this criterion is met.\n\n2. Family history of cardiovascular disease  \n- The patient has a family history of CAD, so this criterion is met.\n\n3. Apolipoprotein B level greater than or equal to 120 mg/dL (LDL level should be between 100 and 190 mg/dL without medication)\n- The patient's LDL-C level is 545 mg/dL, which is above 190 mg/dL, but the criterion specifies being without medication, which the patient is.\n\n4. Has been undergoing lipid therapy for no more than 12 months before study entry\n- The patient reported no use of lipid-lowering medications, so this criterion is met.\n\n5. Medically stable\n- There is no information provided about the patient's overall medical stability.\n\n6. Medically able to undergo MRI procedure\n- There is no information provided about any contraindications for the patient to undergo an MRI.\n\nBased on the information given, the patient meets criteria 1-4, but there is insufficient information to determine if criteria 5 and 6 are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "578": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Development of Outcome-measures for Physically Active Patients With Hip and Groin Pain\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of hip or groin pain, which is one of the inclusion criteria for the trial.\n\nAdditionally, the patient's physical activity level is not specified in the note, which is another inclusion criterion for the trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "579": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man with:\n- Family history of CAD (meets inclusion criteria for familiar history of early-onset cardiovascular disease)\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- LDL-C 545 mg/dL (meets inclusion criteria for primary hyperlipidemia)\n- HDL-C 53 mg/dL (does not meet criteria for low HDL)\n- Normal fasting glucose and triglycerides\n- Not taking any lipid-lowering medications\n- Carotid ultrasound showing severe stenosis in left ICA and moderate stenosis in right ICA\n\nBased on the high LDL-C level and family history of early CAD, this patient meets at least one of the inclusion criteria for the clinical trial on early detection of atherosclerosis.\n\nThe carotid ultrasound findings also suggest the presence of subclinical atherosclerosis, which is the main focus of this trial.\n\nTrial-level eligibility: 2) Eligible",
        "label": 1
    },
    "580": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n2. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n3. The clinical trial is titled \"EEG, Cerebral Oximetry, and Arterial to Jugular Venous Lactate to Assess Cerebral Ischemia During Carotid Endarterectomy.\"\n\n4. The inclusion criteria for the trial are: \"All adult patients undergoing carotid endarterectomy will be approached in the Pre-Anesthetic Clinic.\"\n\n5. Based on the patient's presentation of carotid artery stenosis and the trial's inclusion criteria of recruiting patients undergoing carotid endarterectomy, this patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "581": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial \"Proximal Protection With The Mo.Ma Device During Carotid Stenting\" step-by-step:\n\nThe patient is a 46-year-old man, meeting the age criteria of \u226518 years old.\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the angiographic inclusion criteria of \u226580% stenosis for asymptomatic subjects or \u226550% stenosis for symptomatic subjects, with the target lesion being in the internal carotid artery.\n\nThere is no mention of the patient being symptomatic from the carotid stenosis, so he would likely be considered asymptomatic based on the information provided.\n\nThe external carotid artery diameter and common carotid artery diameter where the Mo.Ma device would be positioned are not provided, so it's unclear if those criteria are met.\n\nNone of the general or angiographic exclusion criteria are mentioned as applying to this patient based on the information given.\n\nIn summary, the patient meets some of the key inclusion criteria based on age, carotid stenosis location and severity. However, there is insufficient information to fully determine eligibility, as the external and common carotid artery diameters are not provided.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "582": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is 46 years old, which meets the age criteria of \u226518 years.\n\n2. The patient has carotid artery stenosis, which is not coronary artery disease as required by the inclusion criteria \"Patient with coronary artery disease, eligible for percutaneous coronary intervention (PCI)\".\n\n3. There is no information provided about the patient's left ventricular ejection fraction (LVEF), so we cannot determine if they meet the criteria \"Patient demonstrates a LVEF of \u2265 25%\".\n\n4. There is no information about whether the patient provided informed consent.\n\n5. The inclusion criteria specify angiographic criteria for the target lesion, such as lesion length, vessel diameter, and degree of stenosis. However, the patient note does not provide any information about a target lesion for PCI.\n\n6. The exclusion criteria list several conditions that would exclude the patient, but there is no information provided about most of these conditions.\n\nBased on the information provided in the patient note, we cannot determine if the patient meets all the inclusion criteria or any of the exclusion criteria for this clinical trial. There is insufficient information to assess eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "583": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\nHe does not have a diagnosis of multiple sclerosis, which is one of the inclusion criteria for the example trial provided earlier. However, the current trial is for evaluating treatments for severe asymptomatic carotid stenosis.\n\nThe patient has severe stenosis (>70%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, which meets the inclusion criteria of \"Stenosis of 70% or more by carotid artery duplex, CTA or MRA.\"\n\nThere is no mention of the patient having any recent TIA or stroke symptoms, which meets the criteria of \"No evidence of TIA or CVA originating in area of the brain supplied by the carotid artery under study, in the four months preceding treatment.\"\n\nThe note does not provide information about the patient's suitability for operative treatment or endovascular procedure, which are part of the inclusion criteria.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria related to the carotid artery stenosis and absence of recent neurological symptoms. However, there is not enough information to determine if the patient is eligible for both treatment options.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "584": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. However, the patient does not have a histologically and/or cytologically confirmed solid malignant tumor or malignant lymphoma. The patient's condition appears to be related to carotid artery stenosis and high cholesterol levels.\n\n3. The trial is specifically for patients with advanced refractory malignancies, which this patient does not have.\n\n4. The other inclusion criteria related to prior treatments, performance status, organ function, etc. are not relevant since the patient does not have a malignancy.\n\nTherefore, based on the information provided, this patient does not meet the key inclusion criteria for this clinical trial of the investigational drug P1446A-05 for advanced refractory malignancies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "585": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 21-75 years specified in the inclusion criteria.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This suggests the presence of an intracranial aneurysm (IA) in the internal carotid artery region, which is one of the included regions specified in the criteria.\n\nHowever, the inclusion criteria specifically mention that the IA should have a neck >4 mm or no discernible neck AND a size (maximum fundus diameter) >10 mm. The patient note does not provide information about the neck size or maximum fundus diameter of the IA.\n\nThe parent vessel diameter range of 2.5-5.0 mm is also not mentioned in the patient note.\n\nWhile the patient seems to meet some of the inclusion criteria, there is not enough information provided in the note to definitively determine eligibility for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "586": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226521 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). However, the trial is specifically looking for patients requiring coronary artery bypass graft (CABG) surgery for the right coronary artery and circumflex artery due to atherosclerotic coronary artery disease with \u226575% stenosis.\n\n3. There is no mention of the patient requiring CABG surgery or having stenosis in the right coronary artery and circumflex artery specifically.\n\n4. The other inclusion criteria regarding appropriately sized and accessible target coronary arteries, ability to provide informed consent, etc. cannot be determined from the given patient note.\n\nTherefore, based on the information provided, the patient does not meet the key inclusion criteria of requiring CABG surgery for the specified coronary arteries with \u226575% stenosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "587": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of >14 years old.\n\nHe presents with dizziness and frequent headaches, which are the required symptoms listed in the inclusion criteria.\n\nThe duration of symptoms is not explicitly stated, but it is mentioned that he has a family history of CAD, implying these symptoms have been present for some time.\n\nThere is no mention of him being evaluated by another doctor previously for these symptoms, which is an inclusion criteria.\n\nHe does not have any neuroimaging results mentioned, which is also an inclusion criteria.\n\nOverall, there is not enough information provided in the patient note to definitively determine eligibility based on the listed inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "588": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\nDiabetes: The patient note does not mention diabetes, so this criterion is not met.\n\nCurrent Smoking: The patient note states that the patient has no cardiovascular risk factors such as smoking, so this criterion is not met.\n\nHypertension: The patient note does not mention hypertension, so this criterion is not met.\n\nFamily history of heart disease: The patient note mentions that the patient has a family history of CAD, so this criterion is met.\n\nHigh LDL Cholesterol (>130 mg/dl): The patient's LDL-C level is 545 mg/dL, which is very high, so this criterion is met.\n\nLow HDL Cholesterol (<40 mg/dl): The patient's HDL-C level is 53 mg/dL, which is not low, so this criterion is not met.\n\nBody Mass Index of 30 kg/m^2: The patient note does not provide information about the patient's BMI, so this criterion cannot be evaluated.\n\nWaist circumference greater than 40 inches for men and 35 inches for women: The patient note does not provide information about the patient's waist circumference, so this criterion cannot be evaluated.\n\nReport intake of at least one drink in the last month: The patient note does not provide information about the patient's alcohol intake, so this criterion cannot be evaluated.\n\nPost-menopause (if woman): The patient is a man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, the patient meets two of the inclusion criteria (family history of heart disease and high LDL cholesterol), but there is not enough information to determine if the patient meets the other criteria related to BMI, waist circumference, and alcohol intake.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "589": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria (>18 years old) for the trial.\n\n2. The patient does not have diabetes mellitus, which is one of the inclusion criteria for the trial. However, he does have high LDL-C levels (545 mg/dL) and carotid artery stenosis, which could be indicative of early coronary artery disease.\n\n3. The trial is specifically looking for patients with type 2 diabetes mellitus and metabolic syndrome to study early detection and treatment of coronary artery disease.\n\n4. While the patient does not have diabetes or metabolic syndrome, he does have risk factors for coronary artery disease (high LDL-C, carotid artery stenosis) and is willing to attend frequent clinic visits (implied by presenting to the clinic).\n\n5. The inclusion criteria state that patients should not have coronary stenosis greater than 50%. The patient has severe stenosis in the left internal carotid artery, but the criteria specifically mention coronary stenosis, not carotid stenosis.\n\nBased on the information provided, the patient does not meet all the inclusion criteria for the trial, but he does have some relevant risk factors and conditions that could make him eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "590": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u2265 18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%, which meets the inclusion criteria of \"A significant stenosis in symptomatic patients with \u2265 50% Diameter Stenosis (%DS) or asymptomatic \u2265 80 %DS as defined by angiography.\"\n\n3. The patient is symptomatic with dizziness and frequent headaches, which could be considered as symptoms related to the carotid artery stenosis.\n\n4. There is no information provided about the patient's suitability for DW-MRI or whether they have provided written informed consent.\n\nBased on the available information, the patient appears to meet the key inclusion criteria of age, carotid artery stenosis, and being symptomatic. However, there is not enough information to determine if the patient meets the criteria for DW-MRI suitability and informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "591": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \"men and women over the age of 50y\".\n\n2. However, the trial is specifically looking at improving components of the metabolic syndrome, which this patient does not appear to have based on the provided information. \n\n3. The patient has high LDL cholesterol (545 mg/dL) and carotid artery stenosis, but no other metabolic syndrome risk factors like high blood pressure, high triglycerides, high fasting glucose, or abdominal obesity are mentioned.\n\n4. Therefore, while the patient's age meets the inclusion criteria, there is insufficient information to determine if they would qualify for this particular trial aimed at improving metabolic syndrome components.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "592": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD but no other cardiovascular risk factors.\n\n2. His LDL-C level is very high at 545 mg/dL, indicating potential hyperlipidemia or familial hypercholesterolemia.\n\n3. Ultrasound revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The inclusion criteria for the clinical trial require:\n   - Unilateral or bilateral carotid artery stenosis considered severe (70-79% diameter reduction on ultrasound)\n   - No stroke, transient ischemic attack, or other relevant neurological symptoms in the past 6 months\n   - Uncertainty between immediate carotid endarterectomy (CEA) or deferral\n   - No circumstances precluding long-term follow-up\n   - Neurologist's consent for potential CEA\n\n5. While the patient has severe stenosis in the LICA, the degree of stenosis is not specified as falling within the 70-79% range required for the trial.\n\n6. Additionally, there is no mention of whether the patient has had any recent neurological symptoms or if there is uncertainty regarding immediate CEA versus deferral.\n\nBased on the information provided, there is insufficient evidence to determine if the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "593": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Carotid ultrasound revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n5. The clinical trial is investigating the use of carotid ultrasound as a screening test for severe coronary artery disease (CAD) as a cause of left ventricular systolic dysfunction (LVEF \u2264 40%).\n\n6. The inclusion criterion for the trial is LVEF \u2264 40%.\n\nBased on the information provided, the patient's LVEF is not mentioned. Therefore, there is not enough information to determine if the patient meets the inclusion criterion for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "594": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Carotid With Bivalirudin Angioplasty\" and assess the patient's eligibility:\n\n1. The patient must be at least 18 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. The patient must have a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as \u226550% stenosis for symptomatic patients or \u226580% stenosis for asymptomatic patients determined by carotid duplex ultrasound scan and/or carotid angiography.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Since the patient is symptomatic (dizziness and frequent headaches), the \u226550% stenosis criterion is met.\n\n3. Female patients with child bearing potential must have a negative pregnancy test.\nThis criterion is not applicable as the patient is male.\n\n4. The patient and the patient's physician must agree to have the patient return for a 30-day and one-year clinical and ultrasound imaging follow-up evaluations as indicated in the protocol.\nThere is no information provided about the patient's or physician's agreement to follow-up evaluations.\n\n5. Reference vessel diameter \u2265 3.5 mm - \u2264 9.0 mm diameter.\nThere is no information provided about the reference vessel diameter.\n\nBased on the available information, the patient meets criteria 1 and 2, but there is not enough information to determine if criteria 4 and 5 are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "595": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years in the inclusion criteria.\n\n2. The patient does not have a histologically and/or cytologically confirmed solid malignant tumor or hematologic malignancy, which is required by the inclusion criteria.\n\n3. The patient's ECOG performance status is not mentioned, so it's unclear if they meet the criteria of \u22642.\n\n4. The patient's life expectancy is not mentioned, so it's unclear if they meet the criteria of \u22654 months.\n\n5. The patient's hemoglobin, neutrophil count, platelet count, bilirubin, AST/ALT, and creatinine levels are not provided, so it's unclear if they meet those criteria.\n\n6. The patient's ability to understand and provide informed consent is not mentioned.\n\n7. The patient does not seem to meet any of the exclusion criteria based on the information provided.\n\nSince the patient does not have a confirmed malignancy as required by the key inclusion criteria, and several other criteria cannot be assessed due to lack of information, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "596": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, so he meets the age criteria of being over 18 years old.\n2. The patient does not have a diagnosis of type 2 diabetes mellitus mentioned in the note. The note focuses more on his high LDL cholesterol levels and carotid artery stenosis.\n3. There is no information provided about the patient's HbA1c levels or whether he is being treated with oral anti-diabetic drugs or diet.\n\nSince the patient does not have a clear diagnosis of type 2 diabetes mellitus and there is no information about his HbA1c levels or treatment, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "597": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows very high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying the impact of antiretroviral therapy on metabolic, skeletal, and cardiovascular parameters in HIV-infected individuals who have never received anti-HIV therapy.\n\n5. The inclusion criteria for the trial are enrollment in the parent study A5257, intent to enroll in A5001 (ALLRT), and signed informed consent.\n\nBased on the information provided, this patient does not appear to be HIV-infected and is not enrolled in the parent study A5257. Therefore, he does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "598": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18 years or older.\n\nThere is no mention of heart failure or left ventricular ejection fraction in the patient note, so the criteria related to heart failure history, NYHA class, and left ventricular ejection fraction <50% cannot be assessed.\n\nThe patient note does not provide information about the patient's glomerular filtration rate (GFR) or kidney function, so the criterion of GFR \u2264 40 ml/min/1.73m\u00b2 cannot be evaluated.\n\nSince there is not enough information provided in the patient note to determine if the patient meets all the inclusion criteria for this clinical trial, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "599": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range specified in the inclusion criteria for males (45-75 years old).\n\n2. The patient does not have a spinal cord injury (SCI), which is a requirement stated in the inclusion criteria.\n\n3. While the patient has high LDL-C levels and carotid artery stenosis, which are risk factors for cardiovascular disease, the trial is specifically looking at risk factors in the spinal cord injured population.\n\nSince the patient does not have a spinal cord injury, there is not enough information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "600": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria (\u226518 years).\n\nThere is no information provided about the patient's body mass index (BMI). The criteria requires a BMI between 25-35 kg/m^2.\n\nThe note does not mention if the patient is willing to use a cell phone to take pictures of food, wear an activity monitor, weigh themselves daily on a provided scale, or accept random assignment to the treatment or control group.\n\nThe note does not indicate if the patient's weight has been stable (no more than 4.4 lbs change) over the past 60 days.\n\nSince there is insufficient information about the patient's BMI, willingness to use the required technology, and weight stability, I cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "601": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"A Relative Bioavailability Study Between Two Formulations Of Sildenafil Citrate\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe inclusion criteria for the trial are:\n1. Body mass index between 18.5 and 29.9 kg/m2 (the patient's BMI is not provided in the note)\n2. Good health conditions or without significant disease (the patient has severe carotid artery stenosis, which is a significant disease)\n3. Able to understand the study nature and objective, and willing to cooperate (not mentioned in the patient note)\n\nSince the patient has a significant medical condition (severe carotid artery stenosis), they would likely be excluded from this trial based on the provided inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "602": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. 40-80 years of age: The patient is 46 years old, so this criterion is met.\n\n2. Right hand dominant: There is no information provided about the patient's handedness.\n\n3. Asymptomatic: defined as no symptoms of TIA/stroke in the previous 6 months: The patient presents with dizziness and frequent headaches, but there is no mention of TIA or stroke symptoms. This criterion is likely met, but more information would be needed to confirm.\n\n4. Baseline doppler study with a peak systolic velocity of 400cm/sec: The patient's LICA peak systolic velocity was 208.5 cm/s, which is below the cutoff of 400 cm/s. This criterion is not met.\n\n5. Patient is deemed a candidate for carotid artery stenting: There is no information provided about whether the patient is a candidate for carotid artery stenting.\n\n6. TIMI flow of 1, 2, or 3: There is no information provided about the patient's TIMI flow.\n\n7. 80% or greater stenosis of distal common or internal carotid artery, as determined angiographically, as defined in ACAS: The patient has severe stenosis in the LICA and moderate stenosis (40-50%) in the RICA. This criterion is likely met for the LICA but not the RICA.\n\n8. Subjects are able to give informed consent: There is no information provided about the patient's ability to give informed consent.\n\n9. Subjects are willing/able to complete follow-up visits: There is no information provided about the patient's willingness or ability to complete follow-up visits.\n\nBased on the information provided, the patient does not meet all the inclusion criteria, specifically the criterion related to the peak systolic velocity cutoff of 400 cm/s. However, there are several criteria for which information is lacking, so a definitive determination of eligibility cannot be made.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "603": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Males aged 45 years or above or females aged 55 years or above (age related CVD risk factor).\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. At least two other risk factors for CVD: cigarette smoking, diabetes mellitus, hypertension, low HDL or high LDL cholesterol, strong family history of coronary heart disease, elevated waist circumference, Aboriginal and/or Torres Strait Islander.\nThe patient has a family history of CAD and high LDL-C level of 545 mg/dL, so he meets this criterion as well.\n\n3. Willingness to participate in study and sufficient command of the English language to read and complete study questionnaire.\nThere is no information provided about the patient's willingness to participate or English proficiency, so we cannot determine if this criterion is met.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria of age and cardiovascular risk factors. However, since there is no information about the third criterion, we cannot definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "604": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient has no explicit diagnosis of diabetes mentioned in the note. However, the note does provide information about the patient's lipid profile and cardiovascular risk factors.\n\n3. The inclusion criteria state that the trial is open to patients diagnosed with diabetes, either type 1 or type 2.\n\nSince there is no clear mention of the patient having diabetes, there is not enough information to determine if the patient meets the primary inclusion criteria for this trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "605": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a type 2 diabetic patient with cardiovascular risk factors (family history of CAD).\n\n2. The patient has atypical symptoms of dizziness and frequent headaches, which could be related to the carotid artery stenosis mentioned in the note.\n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which would be relevant for investigating advanced atherosclerosis.\n\n4. The patient's LDL-C level of 545 mg/dL is very high, indicating a significant cardiovascular risk factor.\n\nBased on the information provided in the patient note, this patient appears to meet the inclusion criteria for the clinical trial investigating carotid intima-media thickness (IMT) and large-vessel atherosclerosis by multidetector computed tomography (MDCT) in type 2 diabetic patients with cardiovascular risk factors.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "606": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a patient undergoing coronary intervention via the radial artery.\n\n2. The patient note mentions that he has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), indicating he likely underwent or will undergo a coronary intervention.\n\n3. There is no information provided about whether the intervention was specifically done via the radial artery, but it is a common approach for coronary interventions.\n\nBased on the information provided, it seems reasonable to assume that this patient would be eligible for the clinical trial studying the effect of statins on radial intima-media thickness after transradial angioplasty.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "607": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years for both the DAPT and Non-DAPT groups.\n\n2. The patient does not have a diagnosis of multiple sclerosis or any mention of lower urinary tract symptoms, so he does not meet the inclusion criteria for the previous trial example.\n\n3. For the current CYPRESS trial:\n   - There is no mention of the patient undergoing percutaneous coronary intervention (PCI) or stent deployment, which is required for the DAPT group.\n   - However, the patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could potentially qualify for the Non-DAPT group.\n\n4. Checking the Non-DAPT group inclusion criteria:\n   - The patient meets the age criteria of \u226518 years.\n   - There is no information provided about the lesion length, number of lesions, ejection fraction, or target lesion stenosis percentage to confirm eligibility.\n   - There is no mention of the patient's childbearing potential or pregnancy status.\n   - It is assumed the patient or legally authorized representative has consented to participate.\n\n5. Checking the Non-DAPT group exclusion criteria:\n   - There is no information provided about the target lesion characteristics (bifurcations, calcification, restenosis, etc.) to confirm eligibility.\n   - There is no mention of the patient having left main stenosis, lesions in bypass grafts, chronic total occlusions, or recent myocardial infarction.\n   - There is no information provided about the patient's renal function, presence of clot, prior brachytherapy, left ventricular ejection fraction, or pretreatment with devices.\n   - There is no mention of the patient being a heart transplant recipient or having a life expectancy less than 1 year.\n   - There is no information provided about allergies or contraindications to the listed medications or materials.\n   - There is no mention of the patient having a significant medical condition that would interfere with participation.\n   - There is no information provided about the patient's participation in other investigational studies.\n   - There is no information provided about the investigator's opinion on the lesion's suitability for stenting.\n   - There is no mention of the patient having a bleeding or hypercoagulable disorder, active infection, pregnancy, or being a prisoner, mentally incompetent, or drug/alcohol abuser.\n   - There is no information provided about planned surgeries necessitating discontinuation of antiplatelet therapy.\n\nBased on the information provided in the patient note, there is insufficient information to confirm eligibility for the Non-DAPT group of the CYPRESS trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "608": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 20-79 years old.\n\nHe has no diagnosis of diabetes mellitus or atherosclerotic vascular disease mentioned. However, he does have high LDL-C (545 mg/dL) and carotid artery stenosis, which could be considered an atherosclerotic vascular disease.\n\nHe meets the metabolic syndrome criteria of high triglycerides (>150 mg/dL) and low HDL-C (<40 mg/dL for men).\n\nThere is no mention of contraindications like liver enzyme elevations, pregnancy, nephrotic syndrome, uncontrolled diabetes, hypothyroidism, recent coronary event, heart failure, etc.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria of being 20-79 years old, having atherosclerotic vascular disease (carotid stenosis) and metabolic syndrome components (high triglycerides, low HDL-C), and no clearly documented exclusion criteria.\n\nTrial-level eligibility: 2) Eligible",
        "label": 1
    },
    "609": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, so he meets the age criteria of being an adult.\n\n2. The patient does not have a diagnosis of multiple sclerosis or any other condition mentioned in the inclusion criteria. The note describes symptoms related to carotid artery stenosis and high cholesterol levels.\n\n3. There is no mention of the patient being in a rehabilitation program or having the capability to exercise on their own.\n\n4. There is no information provided about the patient's German language ability.\n\nBased on the information given in the patient note and the inclusion criteria for the clinical trial, there is not enough evidence to determine if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "610": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. The patient is being admitted for a left heart catheterization or scheduled angioplasty, which meets the inclusion criteria of being an in- or out-patient admitted for these procedures.\n\n3. There is no information provided about the patient's ability to provide informed consent, so we cannot definitively determine if this criterion is met.\n\nBased on the information provided, the patient appears to meet at least two of the three inclusion criteria. However, without knowing if the patient is able to provide informed consent, we cannot say definitively if they are eligible or not.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "611": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL\n- Normal fasting glucose and triglyceride levels\n- Not taking any lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe inclusion criteria for the clinical trial are:\n1) Patients who can provide informed consent\n2) Patients with indications for lipid-lowering therapy\n3) Patients with CHD and high risk of CV complications (diabetes, MI, heart failure, hypertension, etc.)\n4) Patients with LDL levels > 3.5 mmol/L (135 mg/dL)\n\nBased on the information provided, this patient meets criteria 2 and 4, as he has very high LDL levels and would likely be indicated for lipid-lowering therapy. However, it is not explicitly stated that he has coronary heart disease or any of the listed high-risk conditions like diabetes, MI, heart failure, etc. The carotid artery stenosis suggests cardiovascular disease, but may not qualify as CHD.\n\nTrial-level eligibility: 1) Not relevant.\n\nThere is insufficient information to definitively determine if the patient meets all the inclusion criteria, specifically having CHD and high CV risk conditions. More details on his cardiac history and risk factors would be needed.",
        "label": 1
    },
    "612": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches. This matches the inclusion criteria of \"Minimum age of 18 years\" and \"Clinical history of TTH, according to the criteria of the International Classification of Headache of the International Headache Society, in face of crisis.\"\n\n2. However, the patient note mentions a family history of CAD, severe stenosis in the left internal carotid artery, and moderate stenosis in the right internal carotid artery. These cardiovascular conditions are not explicitly mentioned in the inclusion/exclusion criteria.\n\n3. There is not enough information provided in the inclusion/exclusion criteria to determine if these cardiovascular conditions would exclude the patient from the trial.\n\nBased on the information given, the patient appears to meet the listed inclusion criteria, but there is not enough information to definitively determine eligibility or exclusion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "613": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female subjects \u2265 18 years and <75 years of age\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Weight \u2265 60 kg\nThere is no information provided about the patient's weight, so this criterion cannot be evaluated.\n\n3. On aspirin therapy (81 mg to 325 mg daily) at the time of screening and able to maintain a consistent aspirin dosing regimen from the baseline visit through the final study visit\nThere is no information provided about whether the patient is on aspirin therapy, so this criterion cannot be evaluated.\n\n4. Subjects who do not have contraindications for a thienopyridine (ie, prasugrel, clopidogrel or ticlopidine), and have a history of stable atherosclerosis represented by Coronary Artery disease, defined as any of the following:\n   - chronic stable angina\n   - Prior history of acute coronary syndrome (\u2265 30 days before screening) including unstable angina or acute myocardial infarction (STEMI or NSTEMI), not currently prescribed or currently on thienopyridine therapy;\n   - Previous coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA), stent, or coronary artery bypass grafting (CABG) coronary artery disease (\u2265 50% obstruction) in at least one coronary vessel after angiography\n\nThe patient note does not mention any history of coronary artery disease, angina, myocardial infarction, or coronary revascularization procedures. Therefore, this criterion is not met.\n\n5. Female subjects meeting specific criteria (not applicable since the patient is male)\n\n6. Subjects with a competent mental condition to provide written informed consent before entering the study.\nThere is no information provided about the patient's mental condition, so this criterion cannot be evaluated.\n\nSince the patient does not meet the key inclusion criterion of having a history of stable atherosclerosis represented by coronary artery disease, he would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "614": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He has no other cardiovascular risk factors and is physically active.\n\nThe clinical trial is the Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D) study, which is looking at myocardial blood flow reserve in type 1 diabetics and non-diabetic controls with high coronary artery calcification (CAC) scores.\n\nThe inclusion criteria are:\n1. Non-diabetic controls with high CAC score (>100), no history of MI/revascularization/angina\n2. Type 1 diabetics with high CAC score (>100), no history of MI/revascularization/angina, preferably with microproteinuria \n3. Type 1 diabetics with low CAC score (<100), no history of MI/revascularization/angina\n\nBased on the patient note, this 46-year-old man does not have type 1 diabetes, which is a key requirement for the study groups. His CAC score is also not mentioned.\n\nTherefore, there is insufficient information to determine if he meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "615": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age inclusion criteria of 18-55 years old.\n\n2. There is no mention of the patient's health status, so we cannot determine if he is in good health as required by the inclusion criteria.\n\n3. There is no information provided about the patient's willingness to abstain from physical therapy, hard physical work, exercise, or sauna during the study observation period.\n\n4. There is no information provided about the patient's gender or use of birth control methods if applicable.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "616": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\n2. The patient is not documented as having HIV-1 infection, which is a requirement for this trial.\n\n3. There is no information provided about the patient's viral load or antiretroviral treatment history.\n\n4. The patient does not have end-stage liver disease or require a liver transplant, which are key criteria for this trial.\n\n5. There is no information about the patient's alcohol or drug use history.\n\n6. There is no information about any opportunistic infections the patient may have.\n\n7. There is no information about the patient's HIV drug resistance profile or antiretroviral treatment history.\n\n8. There is no information about the patient's social security or insurance coverage.\n\n9. There is no information about contraceptive use, as the patient is male.\n\nBased on the lack of information provided about the patient's HIV status, liver disease status, and other key criteria, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "617": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C and normal HDL-C, fasting glucose, and triglycerides. He has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial is titled \"Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients\" and has the following inclusion criteria:\n1. Medically recommended influenza A(H1N1) immunization\n2. Signed informed consent\n\nBased on the information provided in the patient note, there is no mention of the patient being recommended for influenza A(H1N1) immunization or signing an informed consent. The note focuses on the patient's cardiovascular health and carotid artery stenosis.\n\nTherefore, there is not enough information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "618": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Efficacy and Safety of Aripiprazole in First Episode Psychosis\", the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of the patient experiencing a first episode of psychosis or meeting the DSM-IV diagnostic criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS, which are the inclusion criteria for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "619": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- The patient does not have metastatic melanoma, so this criterion is not met.\n\nPRIOR/CONCURRENT THERAPY:\n- No information is provided about prior therapies, so unable to assess this criterion.\n\nPATIENT CHARACTERISTICS:\nLife expectancy > 3 months: No information provided, so unable to assess.\nPerformance status ECOG 0 or 1: No information provided, so unable to assess.\nBone marrow reserve criteria: No information provided, so unable to assess.\nRenal function criteria: No information provided, so unable to assess.\nHepatic function criteria: No information provided, so unable to assess.\nCardiovascular criteria: The patient has no reported cardiovascular issues, so these criteria are likely met.\nPulmonary criteria: No information provided, so unable to assess.\nOther criteria: No information provided about autoimmune disease, HIV status, psychiatric illness, CNS disease, systemic infection, steroid use, prior transplants, asthma medication, or pregnancy/fertility, so unable to assess these.\n\nOverall, the key inclusion criteria of having metastatic melanoma is not met based on the information provided. There is insufficient information to assess many of the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "620": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 40-70 years specified in the inclusion criteria.\n\nThe patient has elevated LDL-C levels (545 mg/dL) and is not on any lipid-lowering medications, suggesting uncontrolled hypertension or high blood pressure. This aligns with the inclusion criteria of \"Untreated patients or those on monotherapy of antihypertensive drugs but with uncontrolled blood pressure in the ranges of 140-160/90-100 mmHg.\"\n\nHowever, the patient note does not provide any specific blood pressure readings or mention if the patient discontinued antihypertensive treatment for 4 weeks during the run-in period, as required by the inclusion criteria.\n\nAdditionally, there is no information about 24-hour mean blood pressure or whether the patient can visit the outpatient clinic on their own and adhere to the study design.\n\nBased on the available information, there is not enough evidence to determine if the patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "621": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur in the neck, and ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nThe clinical trial is looking at using an electronic stethoscope to detect carotid artery stenosis, with ultrasound confirmation.\n\nThe inclusion criteria for the trial are:\n1) Age 40-80 years\n2) Indicated for diagnostic ultrasound related to carotid artery stenosis\n\nBased on the information provided, the patient meets both inclusion criteria:\n1) Age 46 years (between 40-80 years)\n2) Indicated for diagnostic ultrasound, which was performed and showed carotid artery stenosis\n\nTherefore, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "622": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe has a family history of CAD, indicating he may have coronary artery disease (CAD), which is an inclusion criterion.\n\nHis LDL-C level is 545 mg/dL, which is very high and exceeds the exclusion criteria of LDL-C > 100 mg/dL.\n\nHis HDL-C level is 53 mg/dL, which meets the inclusion criteria of HDL-C < 40 mg/dL for males.\n\nHe is not on any lipid-lowering medications like statins, which is an exclusion criterion.\n\nThere is no information provided about his left ventricular systolic function or ejection fraction, which is an inclusion criterion.\n\nThere is also no information about his diabetes status, which could be an exclusion criterion if he has type 2 diabetes with HbA1C > 7%.\n\nBased on the available information, while the patient meets some inclusion criteria, he is excluded due to the very high LDL-C level and not being on statin therapy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "623": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being over 18 years old.\n\nHe has evidence of carotid artery disease based on the ultrasound findings of \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\" This meets the inclusion criteria of having ultrasound evidence of carotid artery disease.\n\nThe patient note does not explicitly mention angiographic evidence of coronary artery disease. However, it states that he has a family history of CAD and an LDL-C level of 545 mg/dL, which is very high and indicative of high cardiovascular risk.\n\nThe note does not mention if the patient is being treated for dyslipidemia or not.\n\nOverall, based on the information provided, the patient appears to meet at least two of the four inclusion criteria (age and carotid artery disease). There is not enough information to definitively determine if he meets the other two criteria regarding coronary artery disease and lipid treatment.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "624": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult male.\n\n2. The patient does not have prostate cancer or a history of radical prostatectomy, which are required for inclusion in this trial.\n\n3. The patient's symptoms and medical history are related to carotid artery stenosis and high cholesterol levels, which are not relevant to this trial on post-prostatectomy erectile dysfunction.\n\n4. There is no information provided about the patient's erectile function or penile vascular status, which are key criteria for inclusion.\n\nBased on the information given, this patient does not meet the inclusion criteria for this clinical trial on intracavernous bone marrow stem-cell injection for post-prostatectomy erectile dysfunction.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "625": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. High-risk for carotid endarterectomy due to anatomical or co-morbid conditions and either has neurological symptoms and \u2265 50% stenosis, via angiography or is asymptomatic and has \u2265 80% stenosis, via angiography\n- The patient has severe stenosis (>50%) in the left internal carotid artery, so this criterion is met.\n\n2. Target lesion located in the common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation\n- The stenosis is located in the left and right internal carotid arteries, so this criterion is met.\n\n3. Arterial segment to be stented has a diameter between 4mm and 9mm\n- There is no information provided about the arterial diameter, so this cannot be assessed.\n\n4. Age \u2265 18 years\n- The patient is 46 years old, so this criterion is met.\n\n5. Life expectancy > 12 months from the date of the index procedure\n- There is no information about the patient's life expectancy, so this cannot be definitively assessed. However, given their age and lack of major comorbidities mentioned, it seems reasonable to assume their life expectancy exceeds 12 months.\n\nOverall, the patient meets the key inclusion criteria of having severe carotid artery stenosis and being at high risk for endarterectomy. The arterial diameter is unknown, but the other criteria are met or can reasonably be assumed to be met based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "626": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has elevated LDL-C levels (545 mg/dL) but normal fasting glucose and triglyceride levels. He is not taking any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nThe clinical trial is an observational study looking at the clinical course of coronary artery disease in patients with known or suspected coronary artery disease.\n\nGiven the inclusion criteria of \"Patients with known or suspected coronary artery disease,\" and the patient's presentation with carotid artery stenosis and elevated LDL-C levels, which are risk factors for coronary artery disease, this patient would likely be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "627": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. The trial is studying fractional flow reserve (FFR) and intravascular ultrasound in coronary lesions.\n\nInclusion criteria:\n- Clinical presentation of stable angina, unstable angina, NSTEMI or recent STEMI (>48 hours) - The patient does not seem to have any of these, so this criterion is not met.\n- Scheduled for coronary catheterization with or without PCI - No mention of this for the patient.\n- Age \u226518 years - Met, patient is 46 years old.\n- Able to provide informed consent - Not mentioned, but presumably met.\n- Agrees to follow-up through 3 years - Not mentioned.\n- Has at least one intermediate coronary lesion 40-80% stenosis, 2.75-4.0mm diameter - The patient has carotid not coronary stenosis, so this is not met.\n\nExclusion criteria:\n- Prior CABG - Not mentioned\n- Likely to undergo PCI/CABG within 1 year - Not mentioned\n- STEMI within 48 hours - Not mentioned\n- Cardiogenic shock - Not mentioned\n- Heart failure class III/IV - Not mentioned \n- Respiratory failure requiring oxygen - Not mentioned\n- LV ejection fraction <30% - Not mentioned\n- Moderate/severe valve disease - Not mentioned\n- Stroke/TIA within 60 days - Not mentioned\n- Renal insufficiency - Not mentioned\n- Unlikely to comply with follow-up - Not mentioned\n- Expected survival <2 years - Not mentioned\n- Pregnant/nursing - Not mentioned for this male patient\n- Participating in another study - Not mentioned\n- Recent caffeine intake - Not mentioned\n\nBased on the information provided, the patient does not seem to meet the key inclusion criteria about having an intermediate coronary lesion being studied. There is insufficient information to fully assess all eligibility criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "628": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients referred for elective Carotid Artery Stenting were participate in the study at the time of scheduling for operation.\n- The patient note mentions the patient is being evaluated for carotid artery stenosis, so this criterion is likely met.\n\n2. Symptomatic patient, as evidenced by transient ischemic attack (TIA), amaurosis fugax, minor or non-disabling stroke(in the hemisphere supplied by the target vessel), within 180 days of the randomization date.\n- The patient note mentions dizziness and frequent headaches, but does not specify if these are symptoms of TIA or stroke. This criterion cannot be definitively assessed based on the information provided.\n\n3. Discrete lesion located in the internal carotid artery(ICA), and the degree of carotid stenosis \u226550% defined as:\nStenosis \u226570% by ultrasound. Stenosis \u226550% by angiography (based on NASCET Criteria)\n- The patient note states there is severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery based on ultrasound findings. This criterion appears to be met.\n\n4. Appropriate for carotid stenting. Candidates for Carotid Artery Stenting meet all other inclusion requirements.\n- Based on the stenosis findings, the patient may be a candidate for carotid artery stenting, but there is insufficient information to definitively assess appropriateness.\n\nIn summary, while the patient appears to meet some of the key inclusion criteria based on carotid stenosis, there is not enough information provided to make a definitive assessment of eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "629": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age inclusion criteria of being greater than 12 years old.\n\n2. There is no information provided about the patient's upper arm circumference, so we cannot determine if they meet that inclusion criteria.\n\n3. The note does not mention if the patient went through an informed consent process or was willing to do so.\n\n4. The note also does not mention if the patient was willing and able to participate for up to 60 minutes.\n\nSince there is not enough information provided to definitively determine if the patient meets all of the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "630": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\nInclusion Criteria: Patients, with 30 to 70% carotid artery stenosis on ultrasound duplex, who will not go for endarterectomy.\n\nFrom the patient note, we have the following information:\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\n- There is no mention of the patient undergoing endarterectomy.\n\nBased on this information, the patient meets the inclusion criteria of having 30 to 70% carotid artery stenosis on ultrasound duplex and not going for endarterectomy.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "631": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n2. He has no other cardiovascular risk factors and is physically active. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur in the neck, and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The inclusion criteria for the clinical trial are:\n   - Neurological symptoms due to ischemia in the carotid artery territory\n   - Carotid artery stenosis < 70% (based on NASCET criteria, with a lower cut-off of an atherosclerotic plaque thickness of at least 2-3 mm, corresponding to an ECST stenosis of 30%)\n   - Written informed consent\n\n5. Based on the information provided, the patient meets the inclusion criteria for the clinical trial:\n   - He has neurological symptoms (dizziness and headaches) that could be due to ischemia in the carotid artery territory.\n   - He has severe stenosis in the LICA and moderate stenosis (40-50%) in the RICA, which falls within the inclusion criteria of < 70% stenosis.\n\n6. There is no information provided about whether the patient has given written informed consent, but this can be obtained if he is eligible and willing to participate.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "632": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis (severe in the left internal carotid artery and moderate in the right internal carotid artery).\n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. The trial is studying postural tachycardia syndrome (POTS) in patients aged 14-29 years.\n2. Patients must have at least 3 of the listed symptoms (dizziness, nausea, palpitations, fatigue, headache, exercise intolerance, blurred vision, abnormal sweating) for at least 3 months.\n3. Patients must have a diagnosis of symptomatic postural tachycardia made during a screening tilt table test.\n4. Patients must have normal physical examination, ECG, and echocardiogram.\n5. Patients must be free from heart disease and systemic illnesses.\n6. Patients must refrain from vasoactive drugs for two weeks before testing.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial:\n\n1. The patient is 46 years old, which is outside the age range of 14-29 years.\n2. There is no mention of the patient having POTS or undergoing a tilt table test.\n3. The patient has carotid artery stenosis, which may be considered a cardiovascular disease.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "633": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u2265 55 years old.\n\n2. The patient has high LDL-C levels (545 mg/dL) and is a candidate for lipid-lowering therapy according to NCEP ATP III guidelines. This meets inclusion criteria B.\n\n3. There is no mention of the patient being unwilling to modify therapy or travel for follow-up visits, so we can assume criteria C and D are met.\n\n4. There is no information provided about the patient's ability to understand and sign informed consent, so criterion E cannot be evaluated.\n\n5. The patient's eGFR is not provided, so criterion F cannot be evaluated.\n\n6. None of the exclusion criteria seem to apply based on the information given (no contraindications to statins, not currently on maximum statin dose, no relevant medical conditions listed, etc.)\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria of age and being a candidate for lipid-lowering therapy. However, there is insufficient information to fully evaluate all criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "634": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Sorafenib in Urothelium Cancer of Bladder\", the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.\n\nThe patient note does not mention any information related to bladder cancer or urothelial carcinoma. The note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. Since the patient does not have the target disease (urothelial carcinoma of the bladder or upper urinary tract) specified in the inclusion criteria, the patient is not relevant for this particular clinical trial.",
        "label": 0
    },
    "635": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. The patient does not have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder mentioned in the note. The note only mentions dizziness, headaches, and carotid artery stenosis.\n\n3. The patient is not currently on antipsychotic therapy, as the note states \"The patient reported no use of lipid-lowering medications.\"\n\nSince the patient does not have a diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder, and is not currently on antipsychotic therapy, there is not enough information to determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "636": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Waist circumference > 94cm\n   - The patient's waist circumference is not provided, so this criterion cannot be evaluated.\n\n2. Triglyceride concentration between 150mg/dL and 400mg/dL\n   - The patient's triglyceride level is 158 mg/dL, which falls within this range.\n\n3. HDL-c < 60mg/dL\n   - The patient's HDL-C level is 53 mg/dL, which meets this criterion.\n\n4. Body mass index: 27 to 35 kg/m\u00b2\n   - The patient's BMI is not provided, so this criterion cannot be evaluated.\n\nSince the patient meets at least two of the inclusion criteria (triglyceride and HDL-C levels), but there is not enough information to determine if they meet the other two criteria (waist circumference and BMI), the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "637": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Differential Diagnosis of STA-PSV in Thyrotoxicosis\", here is my assessment:\n\nThe patient note mentions a 46-year-old man presenting with dizziness, frequent headaches, and abnormal lipid levels (high LDL-C and low HDL-C). The note also mentions carotid artery stenosis and plaque buildup detected through ultrasonography.\n\nHowever, the inclusion criteria for the clinical trial focus on patients with thyrotoxicosis (low TSH levels) who are newly diagnosed and have not taken any antithyroid drugs or beta-blockers.\n\nThere is no information provided in the patient note about the patient's thyroid function, TSH levels, or any symptoms related to thyrotoxicosis.\n\nTherefore, based on the available information, the patient does not seem to meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "638": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This meets the criteria of having a documented severe (70%) symptomatic intracranial stenosis.\n\nThe stenosis is located in the internal carotid arteries, which are intracranial arteries, meeting the criteria of the target lesion being located in an intracranial internal artery.\n\nThe patient is presenting with symptoms of dizziness and frequent headaches, indicating the stenosis is symptomatic.\n\nThe diameter stenosis of the LICA is severe at >70%.\n\nThe reference vessel diameters are not explicitly stated but are likely between 2.0-6.0 mm based on typical internal carotid artery sizes.\n\nThe lesion length is not stated but is likely \u226430 mm to be coverable by one stent.\n\nBased on the information provided, the patient appears to meet all the key inclusion criteria for this clinical trial of atorvastatin for preventing restenosis after intracranial artery stenting.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "639": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 45-80 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of 50% or more symptomatic carotid artery stenosis.\n\n3. The patient is scheduled to undergo carotid artery stenting, which is a requirement for this trial.\n\n4. There is no information provided about the patient's ability to take oral antiplatelet agents or their ability to follow up for 2 years after the procedure. However, these are likely not issues for most patients.\n\n5. There is no information about the patient's modified Rankin Scale score or whether they have provided informed consent, but again, these are likely not major issues.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the \"Carotid Artery Stenting With Cilostazol Addition for Restenosis\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "640": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject must be > 21 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. Subject has the ability to understand and cooperate with study procedures and agrees to return for all required follow-up visits, tests and exams. \nThere is no information provided about the patient's ability to understand/cooperate or willingness to return for follow-ups, so this cannot be assessed.\n\n3. Subjects taking warfarin may be included if their dosage is reduced before the procedure to result in an International Normalized Ratio (INR) of 1.5 or less. Warfarin may be restarted to therapeutic dose after the procedure.\nThe patient note does not mention warfarin use, so this is not applicable.\n\n4. The subject must sign a written informed consent prior to the procedure, using a form that is approved by the local medical ethics committee (EC).\nThere is no information about whether the patient has provided informed consent.\n\n5. The life expectancy of the subject is at least one year.\nNo information is provided about the patient's life expectancy.\n\n6. The subject has a lesion located in the internal carotid artery (ICA); the carotid bifurcation may be involved.\nThe patient note mentions \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA)\", so this criterion is met.\n\n7. The subject must have a minimum distance of 5 cm between the clavicle and bifurcation, as assessed by duplex Doppler ultrasound, computed axial tomographic (CT) angiography or magnetic resonance (MR) angiography.\nThere is no information provided about the distance between the clavicle and bifurcation.\n\nIn summary, while the patient meets some of the key inclusion criteria related to carotid artery stenosis, there is insufficient information to fully assess eligibility based on the provided patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "641": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 45-65 years specified in the inclusion criteria.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating the presence of atherosclerosis and coronary artery disease (CAD).\n\n3. The patient is not currently on any lipid-lowering medications, suggesting that this is a de novo (newly diagnosed) case.\n\n4. There is no mention of the patient having indications for coronary artery bypass surgery (CABG) or the New York Heart Association (NYHA) functional class of heart failure.\n\n5. The patient's hypertension status is not explicitly stated, but it is mentioned that the patient has no cardiovascular risk factors other than a family history of CAD.\n\nBased on the information provided, the patient appears to meet most of the inclusion criteria for the clinical trial, except for the hypertension status, which is not clearly specified.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to the lack of information on hypertension status).",
        "label": 1
    },
    "642": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nOn examination, he has a systolic murmur in the neck radiating to the skull. Ultrasound reveals severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). The plaque is described as bulky, predominantly echogenic and hyperechoic, with less than 50% being echolucent with uneven surfaces.\n\nThe clinical trial inclusion criteria state:\n\"Inclusion Criteria:\n-patients with monolateral, significant, soft carotid stenosis\"\n\nBased on the patient note, the patient has severe stenosis in the LICA and moderate stenosis in the RICA, which meets the \"monolateral, significant\" part of the inclusion criteria. However, the plaque is described as predominantly echogenic and hyperechoic, which suggests it is calcified rather than soft.\n\nTherefore, while the patient has significant carotid stenosis, the plaque characteristics do not meet the \"soft\" criteria for this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "643": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating the presence of atherosclerosis.\n\n3. The trial is looking for patients with atherosclerosis who are scheduled for or have undergone coronary angiography within the past 5 years.\n\n4. While the patient note does not explicitly mention coronary angiography, the presence of carotid artery stenosis and the patient's age suggest that coronary angiography may be recommended or has been performed.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "644": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\nAge > 49 years old: The patient is 46 years old, so this criterion is not met.\n\nAcute ischemic stroke or transient ischemic attack (TIA): The patient is presenting with dizziness and frequent headaches, but there is no mention of an acute ischemic stroke or TIA.\n\nNeurological symptoms compatible with a stroke or TIA in the anterior circulation (territory of the internal carotid artery): Again, there is no mention of symptoms compatible with a stroke or TIA.\n\nOnset of symptoms within the last 7 days: No information is provided about the onset of symptoms.\n\n1 or more acute ischemic lesion(s) visible on MR diffusion-weighted imaging (DWI) in the territory of a single internal carotid artery: No MRI information is given.\n\nPresence of carotid artery plaques in the ipsilateral or contralateral carotid artery as defined by ultrasound (criteria: plaque thickness at least 2mm; located within 1cm proximal or distal to the carotid bifurcation): The patient does have severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nWritten informed consent: No information is provided about consent.\n\nBased on the information given, the patient does not meet several of the key inclusion criteria, such as having an acute ischemic stroke or TIA, and the age criterion. There is also not enough information provided about some of the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "645": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18-70 years old.\n\nHe is undergoing a non-cardiac surgery, which is included in the trial criteria.\n\nThere is no mention of his ASA class, cardiac insufficiency, BMI, daily urine output, hemodialysis status, liver/renal function abnormalities, coagulation abnormalities, hemoglobin/hematocrit levels, electrolyte abnormalities, diabetes history, neurological/mental disorders, hypertension/beta-blocker use, or hypersensitivity to HES.\n\nHowever, the note does not specify if general anesthesia will be used for his surgery, which is an inclusion criterion.\n\nAdditionally, there is no mention of whether the patient has provided voluntary consent to participate.\n\nOverall, based on the information provided, there is insufficient evidence to definitively determine eligibility, as key criteria like anesthesia type and consent are unknown.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "646": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 46-year-old man, which meets the inclusion criteria of being a male at least 18 years old.\n\nHe has dizziness, frequent headaches, and severe stenosis in the left and right internal carotid arteries, but no history of myocardial infarction or acute coronary syndrome. This suggests he has evidence of myocardial ischemia, meeting that inclusion criteria.\n\nThere is no mention of him being an unacceptable candidate for CABG surgery, so we can assume he meets that criteria as well.\n\nThe note does not indicate if he agrees to follow-up visits or avoiding other clinical trials for 2 years, so those criteria are unclear.\n\nAngiographically, he has severe stenosis in the left internal carotid artery and moderate 40-50% stenosis in the right internal carotid artery. The diameters and lesion lengths are not provided, so it's unclear if he meets the angiographic inclusion criteria for target lesion characteristics.\n\nThere is no mention of him having a smooth non-target vessel to act as a self-control vessel, so that criteria is not met based on the note.\n\nHe does not appear to meet any of the general exclusion criteria listed, based on the information provided.\n\nHowever, without details on the specific lesion dimensions and presence of a smooth non-target vessel, it's difficult to fully assess if he meets the angiographic inclusion criteria.\n\nOverall, based on the information given, there is insufficient detail to definitively determine if he is eligible or not for this specific trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "647": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Dietary Protein Requirements on Unbalanced Diets\", I will assess the patient's eligibility for the trial.\n\nThe patient note mentions the following relevant details:\n- 46-year-old man\n- No cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus\n- Physically active\n- LDL-C level of 545 mg/dL (high)\n- HDL-C level of 53 mg/dL\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Carotid artery stenosis\n\nThe inclusion criteria for the clinical trial are:\n- BMI between 18-35 kg/m2 (BMI not provided in the patient note)\n- Age between 18-70 years (the patient is 46 years old, which meets this criterion)\n- Healthy (the patient has carotid artery stenosis, which may not be considered healthy)\n- Non-smoking (the patient is not mentioned as a smoker, so this criterion is likely met)\n- Not using more than a moderate amount of alcohol (no information provided about alcohol consumption)\n- Weight stable (no information provided about weight stability)\n- Not using medication or supplements except for oral contraceptives in women (no information provided about medication or supplement use)\n\nBased on the available information, there is not enough evidence to determine if the patient meets all the inclusion criteria for the clinical trial. The patient's BMI, alcohol consumption, weight stability, and medication/supplement use are not mentioned in the note.\n\nAdditionally, the presence of carotid artery stenosis may exclude the patient from being considered \"healthy\" as per the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "648": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial (not stated, but typically trials allow adults 18 years and older).\n\n2. The patient does not have prostate cancer, which is a key inclusion criteria for this trial. The note mentions he has carotid artery stenosis and high LDL cholesterol levels.\n\n3. There is no mention of the patient being refractory to hormone therapy or previously treated with docetaxel, which are also inclusion criteria for this trial.\n\n4. The note does not provide enough information about the patient's performance status, organ function, neutrophil/platelet counts, etc. to determine if he meets the other inclusion/exclusion criteria.\n\nTherefore, based on the information provided in the patient note, this patient does not appear eligible for this particular clinical trial studying cabazitaxel in hormone refractory prostate cancer patients previously treated with docetaxel.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "649": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. The patient has no history of coronary heart disease, ischemic cerebrovascular disease, or peripheral vascular disease mentioned in the note.\n\n3. The note mentions the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This suggests the presence of atherosclerotic cardiovascular disease.\n\n4. The note does not mention any contraindications to the components of the polypill (aspirin, statins, or ACE inhibitors).\n\n5. There is no information provided about the patient's calculated 5-year CVD risk score.\n\nBased on the information provided, the patient appears to meet the inclusion criteria of having established atherothrombotic cardiovascular disease (carotid artery stenosis). However, there is insufficient information to determine if the patient meets the 5-year CVD risk criteria for inclusion.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial based on the 5-year CVD risk criteria, but likely eligible based on carotid artery stenosis).",
        "label": 1
    },
    "650": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18-60 years old.\n\nThe patient has dizziness and frequent headaches, but no explicit mention of hypertension or being on antihypertensive medications. This does not clearly meet the \"mild to moderate hypertension\" criteria.\n\nThe patient's uric acid level is not mentioned, so it's unclear if he meets the uric acid \u22655.8 mg/dL criteria.\n\nBased on the information provided, there is insufficient evidence that the patient meets all of the inclusion criteria for the \"Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "651": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being \u226518 years old.\n\nHis LDL-C level is 545 mg/dL, which is very high and meets the high LDL-C lipid criteria of LDL-C \u2265100 mg/dL for any risk factor category.\n\nHis HDL-C level is 53 mg/dL, which does not meet the low HDL-C criteria of <45 mg/dL for men.\n\nHis fasting triglyceride level is 158 mg/dL, which meets the criteria of <400 mg/dL.\n\nThere is no mention of the patient having diabetes, so he likely does not fall into the 3+ risk factor category based on the given information.\n\nThe patient is male and there is no mention of him being surgically sterile or using birth control, but this is likely not relevant since he meets the other inclusion criteria.\n\nBased on the information provided, this patient meets the key inclusion criteria of having high LDL-C levels while having triglyceride levels <400 mg/dL.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "652": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-50 years for this trial.\n\n2. The patient's BMI is not provided, so we cannot determine if he meets the BMI criteria of 18-30 kg/m^2.\n\n3. The patient's weight is not provided, so we cannot determine if he meets the weight criteria of less than 100 kg.\n\n4. The patient's health status is not clearly stated, so we cannot determine if he would be considered in good health by the investigator based on physical examination, vital signs, ECG, and laboratory findings.\n\n5. The patient's cardiac troponin I level is not provided, so we cannot determine if it meets the criteria of being less than the upper limit of the laboratory reference range.\n\n6. The patient has not undergone a screening echocardiogram, so we cannot determine if he meets the criteria of normal cardiac function, ejection fraction between 40-70%, and no significant valvular regurgitation or stenosis.\n\nSince there are multiple inclusion criteria that cannot be determined from the provided patient note, we do not have sufficient information to assess the patient's eligibility for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "653": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The clinical trial is a registry study for patients with suspected coronary artery disease (CAD) who underwent computed tomography coronary angiography (CTCA).\n\n6. The inclusion criteria for the trial are:\n   - Patients with suspected CAD\n   - Calcium score available\n   - 64-slice CT technology (or 16-slice CT with >4 year follow-up)\n   - At least 100 patients with complete clinical file and follow-up\n   - Minimum follow-up of 12 months\n\n7. Based on the patient note, this patient has suspected CAD due to the carotid artery stenosis and high LDL-C levels. However, there is no mention of a calcium score or CTCA being performed.\n\nTherefore, based on the available information, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "654": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18 years or older.\n\nHe has dizziness and frequent headaches, but no mention of disabling claudication as defined by the surgeon based on the patient's history. This inclusion criteria is not met.\n\nThere is no mention of an Ankle/Brachial Index (ABI) measurement or exercise test result, so this criteria cannot be evaluated.\n\nHowever, the patient does have severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA) based on ultrasonography findings. The PSV and EDV values provided indicate hemodynamically significant stenosis.\n\nThere is no mention of the patient being able to walk at least 2 minutes on a treadmill at 3.2 km/h and 10% incline, or having a Maximum Walking Distance less than 300 meters.\n\nBased on the information provided, the patient does not seem to meet all the key inclusion criteria for this clinical trial on intermittent claudication due to iliac artery obstruction.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "655": {
        "output": "To determine the patient's eligibility for the clinical trial \"Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease\", let's go through the inclusion criteria one by one:\n\n1. The subject is greater than or equal to 18 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. The subjects has highly suspected or established carotid artery disease.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which indicates established carotid artery disease. This criterion is met.\n\n3. The subject has undergone or been referred for either unilateral or bilateral intra-arterial X-ray carotid angiography for the determination of subject management (within 30 days before or after the U/S procedure).\nThere is no mention of the patient undergoing or being referred for carotid angiography in the given information. This criterion is not met.\n\n4. The subject has non-diagnostic U/S of the carotids as defined by institutional standards.\nThe patient underwent ultrasonography of the carotid arteries, which revealed the stenosis in the LICA and RICA. There is no indication that the ultrasound was non-diagnostic. This criterion is not met.\n\nSince the patient does not meet criteria 3 and 4, they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "656": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The clinical trial is titled \"Early Percutaneous Mitral Intervention in Asymptomatic Moderate Mitral Stenosis.\"\n\n6. The inclusion criteria for the trial are \"asymptomatic patients with moderate mitral stenosis who are potential candidates for early percutaneous mitral commissurotomy.\"\n\nBased on the information provided, this patient does not have mitral stenosis or any mention of mitral valve disease. The patient's presentation and findings are related to carotid artery stenosis and dyslipidemia.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "657": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being at least 18 years old.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the criteria of having carotid stenosis \u226550% for symptomatic patients or \u226580% for asymptomatic patients.\n\nThe target lesion is located in the internal carotid artery (ICA), and the reference vessel diameter of the common carotid artery (CCA) is not mentioned, so we cannot confirm if it meets the criteria of <10mm based on the information given.\n\nThe patient's symptoms of dizziness and frequent headaches could potentially be considered symptomatic, but it is not explicitly stated if these are related to the carotid stenosis or if the patient has had a recent TIA or stroke.\n\nThere is no information provided about the patient's willingness to comply with the study protocol, provide informed consent, or use an acceptable method of birth control if applicable.\n\nOverall, based on the information provided, the patient appears to potentially meet some of the key inclusion criteria related to carotid stenosis and location, but there are some missing details that would be needed to fully confirm eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "658": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient is presenting with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which indicates he has an internal carotid stenosis requiring surgery.\n\n3. There is no information provided about the patient's Mini Mental State Examination score or whether they provided informed written consent.\n\n4. There is also no information about the exclusion criteria such as renal failure, liver failure, heart failure, pregnancy status, contraindication to MRI, or allergies.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria and does not meet any of the exclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "659": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226521 years for both Group A and Group B.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria for Group A of \"Prior clinical ultrasound exam showing a carotid stenosis of greater than or equal to 50 percent.\"\n\n3. There is no information provided about the patient having symptoms or a clinical recommendation for carotid endarterectomy, so the inclusion criteria for Group B cannot be confirmed.\n\n4. There is no information provided about the patient having atrial fibrillation, contraindications for ultrasound contrast agents, pacemakers/defibrillators, cerebral aneurysm clips, neural stimulators, ear implants, or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m^2. Therefore, the exclusion criteria cannot be confirmed.\n\n5. There is no information provided about the patient being pregnant or lactating.\n\nBased on the available information, the patient meets the inclusion criteria for Group A but there is not enough information to confirm eligibility for Group B or to confirm the exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "660": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man with dizziness, frequent headaches, and a family history of CAD. No other major cardiovascular risk factors are mentioned.\n\n2. His LDL-C level is very high at 545 mg/dL, while his HDL-C level is 53 mg/dL (which is within the normal range).\n\n3. The patient is not currently taking any lipid-lowering medications.\n\n4. Carotid artery ultrasound revealed severe stenosis (>50%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n5. The inclusion criteria for the clinical trial state that patients must have at least 50% stenosis of one major coronary artery and be on statin therapy.\n\nBased on the information provided, this patient meets the inclusion criteria of having at least 50% stenosis of a major artery (the LICA). However, the patient is not currently on statin therapy, which is also an inclusion criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "661": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur in the neck, and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\n4. The clinical trial is examining the correlation between the enzyme paraoxonase 1 (PON1) and carotid artery atherosclerotic plaque content and stability.\n\n5. The inclusion criterion for the trial is \"Patients undergoing carotid endarterectomy (CEA).\"\n\nBased on the information provided, this patient appears to have significant carotid artery stenosis, particularly in the LICA, which may warrant surgical intervention such as CEA. Therefore, this patient would likely be eligible for the clinical trial examining the relationship between PON1 and carotid artery plaque.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "662": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. There is no mention of any condition that would limit his anticipated survival to less than 3 years.\n\n3. It is not mentioned if written informed consent was provided, so we cannot determine if this criteria is met.\n\n4. The patient has severe stenosis (>70%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery based on ultrasound findings. This meets the inclusion criteria for stenosis levels.\n\n5. The target vessel characteristics are met:\n   - Discrete lesion in internal carotid artery\n   - Vessel diameter is not provided but likely meets 4.0-9.0 mm range\n   - No mention of excessive vessel tortuosity\n\n6. There is no information provided about participating in another clinical trial.\n\nBased on the information given, the patient appears to meet most of the key inclusion criteria for the carotid artery stenting trial, except for the written informed consent which is not mentioned.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to lack of information on written informed consent)",
        "label": 1
    },
    "663": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 40-99 years for Group A.\n\n2. The patient has not had a CT scan mentioned, so there is no information to determine if he would meet the criteria for Group A. \n\n3. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which would likely qualify him for the Group B criteria of \"patients with severe carotid artery stenosis, that indicated for treatment.\"\n\n4. However, there is no explicit mention that this patient is actually indicated for treatment of the carotid artery stenosis.\n\nBased on the information provided, there is insufficient evidence to definitively conclude that the patient meets the inclusion criteria for either Group A or Group B of this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "664": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 18-65 years specified in the inclusion criteria.\n\n2. The patient has no reported issues with blood pressure, which meets the \"normal blood pressure\" inclusion criterion.\n\n3. The patient is presenting with frequent headaches, which could potentially be episodic tension-type headaches based on the description provided. However, there is no specific mention of the headache characteristics required by the inclusion criteria (bilateral location, pressing/tightening, mild or moderate intensity, not aggravated by routine physical activity, no nausea/vomiting, and at most one of photophobia or phonophobia).\n\n4. There is no information provided about the duration of the headaches, which is required to be between 30 minutes and 7 days according to the inclusion criteria.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria for episodic tension-type headache, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "665": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226521 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), indicating significant carotid artery disease and likely ischemic heart disease.\n\n3. The trial is specifically looking for patients with stable ischemic heart disease (SIHD) and moderate or severe ischemia on stress testing.\n\n4. While the patient note does not explicitly mention a stress test being performed, the carotid ultrasound findings of severe LICA stenosis and moderate RICA stenosis suggest the patient likely has moderate to severe ischemia.\n\n5. The inclusion criteria do not specify any exclusions based on carotid artery disease, so the patient's carotid stenosis should not exclude them from eligibility.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria of being \u226521 years old and having SIHD with likely moderate to severe ischemia.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "666": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >18 and <79 years old.\n\n2. The patient is being referred for diagnostic coronary angiography and has lesions in native coronary arteries that will be treated with PCI, which meets the inclusion criteria for lesion characteristics.\n\n3. The patient has an angiographic stenosis >50% in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA), meeting the criteria of angiographic stenosis >50%.\n\n4. The reference vessel diameter is not explicitly stated, but the LICA and RICA are major arteries, so it's reasonable to assume their diameters fall within the 2.5-4.0 mm range.\n\n5. There is no information provided about successful PCI and OCT imaging, so we cannot confirm that inclusion criteria.\n\n6. There is no information provided about the exclusion criteria, such as comorbidities, heart failure, recent MI, pregnancy, allergies, or renal failure.\n\nBased on the information provided, the patient appears to meet several of the key inclusion criteria, but there is not enough information to definitively confirm eligibility or exclusion.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "667": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient does not have head and neck squamous cell carcinoma, which is a requirement for this trial. The patient's condition is related to carotid artery stenosis and high cholesterol levels.\n\n3. The trial is specifically for patients with previously untreated head and neck squamous cell carcinoma, which this patient does not have.\n\n4. Based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "668": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 46-year-old man\n- Presenting with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C 545 mg/dL, HDL-C 53 mg/dL (high cholesterol)\n- Normal fasting glucose and triglycerides\n- No lipid-lowering medications\n- Carotid artery stenosis (narrowing) - severe in left, moderate in right\n\nThe clinical trial inclusion criteria are:\n1) Stable antiretroviral therapy for at least 12 months, and have no immediate plans to alter therapy.\n2) All plasma HIV RNA levels within the past year must be below conventional levels of detection (< 50 copies RNA/mL)\n3) Ability to provide reliable history of HIV medications or has received majority of medical care from San Francisco General Hospital\n\nBased on the information provided in the patient note, there is no mention of the patient having HIV or being on antiretroviral therapy. The note focuses on cardiovascular issues like high cholesterol and carotid stenosis.\n\nTherefore, this patient does not meet the key inclusion criteria for this HIV clinical trial studying inflammation and atherosclerosis in treated HIV patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "669": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with a family history of coronary artery disease (CAD) but no other cardiovascular risk factors. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the carotid arteries.\n\nThe clinical trial is studying the natural history of carotid atherosclerosis in patients with coronary artery disease over 3 years.\n\nThe key inclusion criterion is \"Consecutive patients with coronary artery disease admitted in our hospital\".\n\nGiven that the patient has carotid atherosclerosis and stenosis, which is closely related to coronary artery disease, and meets the age criteria, he seems to fulfill the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "670": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n5. The clinical trial is looking for patients presenting for the first time to a cardiologist with suspected coronary artery disease, no documented prior history of CAD, intermediate pre-test likelihood of CAD, referred for invasive coronary angiography, and age above 40 years.\n\n6. Based on the information provided, this patient meets the inclusion criteria for the clinical trial as he is presenting for the first time with suspected CAD (based on carotid stenosis and lipid profile), has no documented prior history of CAD, and is above 40 years of age.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "671": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age inclusion criteria of being 18 or greater.\n\n2. However, the patient note does not mention multiple sclerosis or any urinary tract symptoms. The trial is specifically looking at the relationship between urinary tract symptoms in multiple sclerosis patients and risk of falls.\n\n3. Since the patient does not have multiple sclerosis or urinary tract symptoms mentioned, there is not sufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "672": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL-C levels (545 mg/dL) but normal fasting glucose and triglyceride levels. Ultrasonography revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nThe clinical trial is titled \"Prevalence of Allergic Diseases and Atopy in Subjects With Coronary Artery Disease\" and aims to estimate the prevalence of allergic diseases and atopy among patients with angiographically confirmed coronary artery disease.\n\nThe inclusion criteria for the trial are:\n1. Available result of coronary angiography\n2. Able to express written informed consent for study participation\n3. Able to perform forced expiratory maneuver for spirometry\n\nBased on the patient note, the patient has angiographically confirmed coronary artery disease (CAD) with severe stenosis in the LICA and moderate stenosis in the RICA. This meets the first inclusion criterion.\n\nThere is no information provided about the patient's ability to express written informed consent or perform forced expiratory maneuvers for spirometry. Therefore, we cannot definitively determine if the patient meets the other two inclusion criteria.\n\nGiven the available information, the patient appears to meet at least one of the inclusion criteria, but there is not enough information to confirm eligibility for all criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "673": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >40 years old.\n\n2. The patient has undergone ultrasonography of the carotid arteries, which revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%.\n\n3. For the LICA, the peak systolic velocity (PSV) was 208.5 cm/s and end-diastolic velocity (EDV) was 54.5 cm/s. These values suggest stenosis >50% based on the inclusion criteria.\n\n4. For the RICA, the PSV was 91.72 cm/s and EDV was 37.37 cm/s. These values do not clearly indicate stenosis >50% based on the provided criteria.\n\n5. The trial inclusion criteria specifically mention stenosis of 50-99% in the middle cerebral artery (MCA) M1 segment or basilar artery (BA), but do not provide criteria for internal carotid artery stenosis.\n\nBased on the information provided, the patient meets the age criteria and has evidence of severe left internal carotid artery stenosis, but the trial inclusion criteria are focused on middle cerebral artery and basilar artery stenosis. Therefore, there is insufficient information to determine eligibility for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "674": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and abnormal lipid levels (high LDL-C and low HDL-C). The note also mentions carotid artery stenosis, but no diagnosis of plaque psoriasis.\n\n2. The clinical trial is titled \"An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis\".\n\n3. The inclusion criteria for the trial are:\n   - Adult patients diagnosed with plaque psoriasis for at least 6 months prior to screening\n   - Patients receiving conventional systemic agents, topical therapy, phototherapy, or biologic therapy for moderate to severe plaque psoriasis\n   - Have a peak historical or current physician's global assessment (PGA) of \u22653 (range 0-5)\n   - Ability to read and speak English\n   - Reside in the US\n\n4. Based on the patient note, there is no mention of the patient having plaque psoriasis or receiving any of the listed treatments for moderate to severe plaque psoriasis.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "675": {
        "output": "To determine the patient's eligibility for the clinical trial, I will go through the inclusion criteria provided:\n\nInclusion Criteria: total fasting cholesterol > 200mg/dl\n\nFrom the patient note, we have the following information:\n\"The patient's LDL-C and HDL-C levels were 545 and 53 mg/dL, respectively.\"\n\nSince the total cholesterol level is not explicitly stated, we can calculate it from the given LDL-C and HDL-C levels using the following formula:\n\nTotal Cholesterol = LDL-C + HDL-C + (Triglycerides/5)\n\nWe know that the patient's triglyceride level is 158 mg/dL, so:\n\nTotal Cholesterol = 545 + 53 + (158/5)\n            = 545 + 53 + 31.6\n            = 629.6 mg/dL\n\nThe patient's total fasting cholesterol level of 629.6 mg/dL is greater than 200 mg/dL, which meets the inclusion criteria for the clinical trial.\n\nTherefore, based on the information provided, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "676": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 40-80 years specified in the inclusion criteria.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meets the inclusion criterion of \"stenosis of internal carotid artery\".\n\n3. The patient is indicated for carotid endarterectomy or stenting, as evidenced by the severe and moderate stenosis in the LICA and RICA, respectively. This meets the inclusion criterion of \"indication to endarterectomy or stenting\".\n\n4. There is no information provided about the patient's modified Rankin score or whether they have a sufficient temporal bone window for TCD monitoring. However, since the patient is presenting with symptoms and seeking medical attention, it can be reasonably assumed that they are independent (modified Rankin score 0-2).\n\n5. There is no information provided about whether the patient has signed an informed consent form.\n\nBased on the available information, the patient meets most of the inclusion criteria, except for the lack of information about the temporal bone window and informed consent. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "677": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man with no major cardiovascular risk factors except for a family history of CAD.\n\n2. His LDL-C level is very high at 545 mg/dL, while his HDL-C is 53 mg/dL. His fasting glucose and triglycerides are within normal limits.\n\n3. He is not currently taking any lipid-lowering medications.\n\n4. He has carotid artery stenosis, with severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery.\n\n5. The clinical trial is evaluating a new subcutaneous LDL-C lowering medication in patients with high LDL-C levels despite statin therapy.\n\n6. The inclusion criteria require patients to be on a stable statin dose for at least 6 weeks, have LDL-C \u2265 80 mg/dL, and triglycerides \u2264 400 mg/dL.\n\n7. This patient meets the LDL-C and triglyceride criteria, but is not currently on a statin.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "678": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 19-90 years specified in the inclusion criteria.\n\n2. The patient has undergone ultrasonography of the carotid arteries, which revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This satisfies the inclusion criterion of \"having clinical ultrasound evaluation of carotid or femoral artery.\"\n\n3. Based on the information provided, the patient meets both of the inclusion criteria for the clinical trial.\n\n4. There is no information provided about any exclusion criteria that the patient might meet.\n\nTherefore, based on the available information, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "679": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Participant is a female or male of any race / ethnicity >18 years old at the time of the investigational product administration\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Participant or participant's legally acceptable representative provides written informed consent\nThere is no information about whether the patient provided informed consent, so this criterion cannot be evaluated.\n\n3. Participant is capable of complying with study procedures\nThere is no information about the patient's ability to comply with study procedures, so this criterion cannot be evaluated.\n\n4. Participant has known carotid artery stenosis of >69% luminal diameter as based on carotid ultrasound and who is deemed to be a surgical candidate for endarterectomy as determined by the vascular surgeon\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, so he likely meets this criterion.\n\n5. Participant has had a carotid ultrasound and the report is available for collection\nThe patient has had a carotid ultrasound, and the report is available, so he meets this criterion.\n\n6. Participant has had or is scheduled to have a carotid CT angiogram for plaque localization within 30 days of signing ICF (or else scheduled Carotid CT angiogram) CTA must be performed on a separate day and prior to the investigational PET procedure)\nThere is no information about whether the patient has had or is scheduled for a carotid CT angiogram, so this criterion cannot be evaluated.\n\n7. Participant has consented to have an endarterectomy\nThere is no information about whether the patient has consented to have an endarterectomy, so this criterion cannot be evaluated.\n\n8. Participant will be scheduled for an investigational [F-18]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy\nThere is no information about whether the patient will be scheduled for the investigational PET/CT scan, so this criterion cannot be evaluated.\n\n9. Participant must have renal function values as defined by laboratory results within the following ranges:\nSerum creatinine \u2264 1.5 mg/dL\nEstimated glomerular filtration rate (eGFR) \u2265 45mL/min\nThere is no information about the patient's renal function values, so this criterion cannot be evaluated.\n\nIn summary, the patient meets at least one inclusion criterion (age and carotid artery stenosis), but there is not enough information to determine if he meets all the other criteria. Therefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "680": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\n2. The patient does not have a diagnosis of aortic stenosis mentioned in the note. The note mentions carotid artery stenosis, but not aortic stenosis.\n\n3. The inclusion criteria specifically state that the patient must have asymptomatic aortic stenosis documented by prior echocardiographic examination.\n\nSince the patient note does not mention aortic stenosis or provide information about a prior echocardiogram showing asymptomatic aortic stenosis, there is not sufficient information to determine if the patient meets the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "681": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Use of a standard-of-care statin at a stable dose, or intolerance of statins, without use of other lipid modifying therapies\n- The patient note does not mention the use of any lipid-lowering medications, so this criterion is satisfied.\n\n2. Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above\n- The patient's LDL-C level is 545 mg/dL, which is above the specified range.\n\n3. At least one of the following:\n    a) Coronary heart disease (CHD) with a history of myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or prior coronary angiography demonstrating coronary atherosclerosis\n    - The patient note does not mention any history of MI, PCI, CABG, or prior coronary angiography.\n    b) A CHD risk equivalent condition, including diabetes mellitus (type 1 or 2), chronic kidney disease, prior stroke, carotid disease, peripheral arterial disease, or abdominal aortic aneurism\n    - The patient has carotid disease, as evidenced by the severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n    c) \u22652 CHD risk factors (age \u2265 45 years for men or \u2265 55 years for women; smoking; hypertension; low HDL cholesterol; family history of premature CHD) and a high risk of a CV event based on risk estimation systems\n    - The patient is 46 years old (satisfying the age criterion) and has a family history of CAD (satisfying the family history criterion). However, the patient note does not mention any other risk factors like smoking, hypertension, or low HDL cholesterol.\n\nBased on the information provided in the patient note, the patient meets the inclusion criteria for the clinical trial due to having carotid disease, which is a CHD risk equivalent condition.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "682": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being \u2265 18 years old.\n\n2. The patient has elevated LDL-C levels of 545 mg/dL, which is well above the exclusion criteria of LDL-C < 70 mg/dL with cardiovascular disease or LDL-C < 100 mg/dL without cardiovascular disease.\n\n3. The patient's fasting triglyceride level of 158 mg/dL is within the acceptable range (< 400 mg/dL).\n\n4. There is no mention of the patient having homozygous familial hypercholesterolemia, which is an exclusion criterion.\n\n5. The patient reports no use of lipid-lowering medications, which is relevant for assessing the efficacy of the study drug.\n\n6. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests the presence of cardiovascular disease.\n\nBased on the information provided, the patient appears to meet the inclusion criteria of having heterozygous familial hypercholesterolemia and not being adequately controlled with their lipid-modifying therapy (since they are not on any lipid-lowering medications). Additionally, the patient does not seem to meet any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "683": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is focused on estimating the long-term effectiveness of cardiac shock wave therapy (CSWT) in treating coronary heart disease (CHD) compared to other medical and surgical treatments.\n\n5. The inclusion criteria for the trial are: age 18 years and older, diagnosed or suspected CHD, and willingness to participate in the study.\n\nBased on the information provided, the patient meets the age criterion and has suspected CHD based on the carotid artery stenosis findings. However, there is no explicit mention of a CHD diagnosis or the patient's willingness to participate in the study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "684": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Symptomatic or asymptomatic carotid artery stenosis. In symptomatic patients the degree of stenosis should more than 60% (Based on NASCET Criteria), in asymptomatic patients the degree of stenosis should more than 70% (Based on NASCET Criteria);\n\nThe patient note mentions that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis between 40-50% in the right internal carotid artery (RICA). This meets the criteria for symptomatic carotid artery stenosis with >60% stenosis.\n\n2. Tolerance to any of the study medications, including clopidogrel, aspirin and statins;\n\nThere is no information provided about the patient's tolerance to these medications.\n\n3. Can cooperate with and complete brain MRI examination;\n\nThere is no information provided about the patient's ability to undergo an MRI scan.\n\n4. Has a negative pregnancy test within 7 days before randomization and no childbearing potential;\n\nThe patient is a 46-year-old man, so this criterion is not applicable.\n\n5. Vascular ultrasound excluded intravascular thrombosis and unstable plaques in blood vessels of the bilateral upper limbs;\n\nThere is no information provided about ultrasound findings of the upper limb blood vessels.\n\n6. No hemorrhagic tendency;\n\nThere is no information provided about any hemorrhagic tendencies.\n\n7. Stable vital sign, normal renal and hepatic functions;\n\nThere is no information provided about the patient's vital signs, renal or hepatic function.\n\n8. Informed consent.\n\nThere is no information provided about whether the patient has provided informed consent.\n\nBased on the information given, the patient meets the first inclusion criterion for symptomatic carotid artery stenosis >60%. However, there is insufficient information to determine if the patient meets several other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "685": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of \u226518 years.\n\nHe presents with dizziness and frequent headaches, which could be symptoms suggestive of CAD requiring diagnostic/prognostic workup.\n\nThe patient has no history of coronary disease mentioned, so he is suitable for the initial diagnostic imaging tests listed.\n\nThere is no information provided about whether the patient is able and willing to provide consent.\n\nBased on the information given, the patient potentially meets most of the inclusion criteria, except for the consent criterion which is unclear.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to lack of information about ability/willingness to provide consent).",
        "label": 1
    },
    "686": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis of high risk vascular disease (HRVD):\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests cerebrovascular atherosclerotic disease. This meets one of the criteria for HRVD.\n\n2. Must be treated with a statin for at least 30 days prior to screening, or have documented statin intolerance or contraindication:\nThe patient reported no use of lipid-lowering medications, so this criterion is not met.\n\n3. Have a screening HDL-C \u226480 mg/dL:\nThe patient's HDL-C level is 53 mg/dL, which meets this criterion.\n\n4. Have screening triglycerides \u2264400 mg/dL:\nThe patient's triglyceride level is 158 mg/dL, which meets this criterion.\n\n5. Meet one of the following criteria for LDL-C:\n   a) Screening LDL-C no more than 10 mg/dL above the target chosen by the investigator (either <100 mg/dL or <70 mg/dL), or\n   b) If LDL-C is greater than target, the participant must be on maximum tolerated statin dose, have documented statin intolerance, or contraindication to statin.\n\nThe patient's LDL-C level is 545 mg/dL, which is significantly higher than both targets. Since the patient is not on any lipid-lowering medication, the second criterion (b) does not apply.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "687": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He has carotid artery stenosis, with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial is titled \"Building Resiliency and Increasing Community Hope\" and aims to evaluate the effectiveness of a community-based Resiliency Class in reducing depressive symptoms in a low-income, minority population.\n\nLooking at the inclusion criteria for the trial:\n\n1. Age 18 or older: The patient is 46 years old, so he meets this criterion.\n\n2. Endorse one of the first two items on the PHQ-8 (little interest or pleasure in doing things, feeling down, depressed, or hopeless): There is no information provided about the patient's responses to the PHQ-8 or any other depression screening tool.\n\n3. Able to be contacted by phone, email, or Facebook: There is no information provided about the patient's contact information or ability to be reached.\n\n4. Able to participate in the weekly Resiliency Classes: There is no information provided about the patient's availability or ability to attend the weekly classes.\n\n5. English or Spanish speaker: There is no information provided about the patient's language proficiency.\n\nSince there is insufficient information to determine if the patient meets several of the inclusion criteria, I would assess the patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "688": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\n1) The patient is a 46-year-old man, which meets no specific age criteria mentioned in the inclusion criteria.\n\n2) The patient has carotid artery stenosis and plaque, which indicates the presence of atherosclerosis. This meets the first inclusion criteria of \"carotid ultrasound examination: presence of carotid plaque or abnormal CIMT of between 0.9 and 1.2mm\".\n\n3) The patient's LDL-C level is 545 mg/dL, which converts to approximately 14.1 mmol/L. This exceeds the criteria of \"LDL\u22663.12mmol/L\".\n\n4) The patient reported no use of lipid-lowering medications, meeting the criteria of \"no lipid-lowering treatment within the past 6 months\".\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "689": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 18-75 specified in the inclusion criteria.\n\n2. The patient does not have a diagnosis of coronary heart disease (CHD) or stable angina mentioned in the note. The note mentions dizziness, frequent headaches, and carotid artery stenosis, but no CHD or angina diagnosis.\n\n3. The inclusion criteria specifically state that patients must be diagnosed with stage II or III CHD according to the western medical diagnosis standard.\n\nSince the patient note does not mention a CHD or angina diagnosis, which is a requirement based on the inclusion criteria, there is not enough information to determine eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "690": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\n1. Patients with LDL-C greater than or equal to 70 mg/dL at the screening visit and who are not adequately controlled with a stable daily dose of rosuvastatin, with or without other LMT.\n\nThe patient's LDL-C level is 545 mg/dL, which is well above the threshold of 70 mg/dL. The patient is not currently taking any lipid-lowering medications, including rosuvastatin. Therefore, this criterion is met.\n\n2. OR Patients with screening LDL-C greater than or equal to 100 mg/dL who are not adequately controlled with a stable daily dose of rosuvastatin before the screening visit, with or without other LMT.\n\nThe patient's LDL-C level of 545 mg/dL is also above the threshold of 100 mg/dL. As mentioned earlier, the patient is not taking any lipid-lowering medications, including rosuvastatin. Therefore, this criterion is also met.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "691": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis, but there is no mention of postural tachycardia syndrome (POTS) or the characteristic symptoms and heart rate changes associated with POTS.\n\nThe inclusion criteria for the trial specifically require patients to be diagnosed with POTS, with the presence of characteristic orthostatic symptoms for at least six months and an increase in heart rate of at least 30 beats per minute within 10 minutes of standing or during a tilt test, on at least three separate occasions.\n\nSince the patient note does not provide any information related to POTS or the required diagnostic criteria, there is insufficient information to determine if the patient is eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "692": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-99 years old.\n\n2. The patient has hypercholesterolemia, with an LDL-C level of 545 mg/dL, which is very high.\n\n3. The patient is not currently on any lipid-lowering medication like a statin.\n\n4. The patient has carotid artery stenosis, which could be considered an acute cardiovascular event.\n\n5. The inclusion criteria do not specify anything about excluding patients with carotid artery stenosis.\n\nBased on the information provided, this patient seems to meet the key inclusion criteria of being an outpatient, having hypercholesterolemia, not currently on a statin, having an acute cardiovascular event (carotid stenosis), and being able to provide consent.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "693": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. There is no mention of the patient having aortic stenosis or being listed for aortic valve replacement surgery. The patient's condition seems to be related to carotid artery stenosis and high cholesterol levels.\n\n3. The exclusion criteria specifically exclude patients with conditions like previous myocardial infarction, cardiomyopathy, congenital heart disease, and previous cardiac surgery. While the patient has a family history of CAD, there is no mention of them having any of these excluded conditions.\n\n4. However, since the patient does not have aortic stenosis or is not listed for aortic valve replacement surgery, they do not meet the key inclusion criteria for this particular clinical trial.\n\nTherefore, based on the information provided, the patient does not seem to be eligible for this specific clinical trial on aortic stenosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "694": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is evaluating the performance of the NanoCross\u2122 .014 Balloon Catheter in infrapopliteal lesions (below the knee) in patients with critical limb ischemia (Rutherford class 4 or 5).\n\n5. The inclusion criteria for the trial include:\n   - Rutherford class 4 or 5 (rest pain or minor tissue loss)\n   - Age > 18 years\n   - Willing to comply with follow-up evaluations\n   - Provides informed consent\n   - Life expectancy of at least 12 months\n   - Eligible for treatment with the NanoCross\u2122 .014 Balloon Catheter\n   - Meets specific criteria for the target lesion (length, diameter, run-off)\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial, as the patient's condition is related to carotid artery stenosis and not critical limb ischemia or infrapopliteal lesions.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "695": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of \u226518 years.\n\nHe does not have severe aortic stenosis based on the information provided. The note mentions carotid artery stenosis but does not give details about aortic valve stenosis or aortic valve area/gradients.\n\nHis NYHA functional class is not mentioned.\n\nThere is no information provided about a logistic EuroSCORE or comorbidities that would contraindicate conventional aortic valve replacement surgery.\n\nThe ascending aortic dimensions are not provided.\n\nBased on the information given, there is insufficient detail to determine if this patient meets the inclusion criteria for severe aortic stenosis and surgical risk factors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "696": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 or over.\n\n2. The patient is presenting with dizziness, which could potentially be a symptom of orthostatic intolerance (dizziness or lightheadedness in the standing position that disappears when supine).\n\n3. However, there is no clear mention of the patient being referred to any of the participating consortium sites for this trial.\n\n4. Additionally, the patient's symptoms seem to be more related to carotid artery stenosis and potential cardiovascular issues, rather than being indicative of a synucleinopathy.\n\nBased on the information provided, there is not enough evidence to determine if the patient meets the inclusion criteria for this particular clinical trial on synucleinopathies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "697": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 18-60 years specified in the inclusion criteria.\n\n2. The patient has elevated LDL-C levels (545 mg/dL) and carotid artery stenosis, which are indicative of familial hypercholesterolemia, as mentioned in the inclusion criteria.\n\n3. The patient is not currently on any lipid-lowering medications, but the inclusion criteria do not explicitly state that the patient must be on statin treatment. It only mentions being on statin treatment for at least 12 months.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial titled \"Effect of Omega-3 Fatty Acid on Endothelial Function.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "698": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which indicates a clinical diagnosis of coronary artery disease (CAD).\n\n3. The inclusion criteria specifically state that CAD patients must have at least 50% stenosis of one major coronary artery, which this patient meets.\n\n4. There is no information provided about the patient's ability to swallow tablets, which is one of the inclusion criteria.\n\nBased on the information provided, the patient meets the age and CAD diagnosis inclusion criteria, but there is not enough information to determine if they meet the criteria of being able to swallow tablets.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "699": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-65 years old.\n\n2. There is no information provided about whether the patient is on maintenance hemodialysis or not. This is a key inclusion criteria that is missing.\n\n3. There is no information provided about the patient's dialytic vintage (how long they have been on dialysis), iPTH levels, or serum calcium levels. These are also key inclusion criteria that are missing.\n\n4. Based on the information provided in the patient note, there is not sufficient information to determine if the patient meets all of the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "700": {
        "output": "To determine the patient's eligibility for the clinical trial \"Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery\", I will go through the inclusion criteria provided:\n\nInclusion Criteria: patients with carotid plaques size more than 2mm by carotid ultrasound\n\nBased on the patient note, it is mentioned that ultrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. Additionally, plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs).\n\nSince the patient has carotid plaques observed through ultrasound, and the size of the plaques is not explicitly stated but described as \"bulky plates\", it can be reasonably assumed that the plaque size is more than 2mm, meeting the inclusion criteria.\n\nTherefore, based on the information provided, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "701": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 46-year-old man with dizziness, frequent headaches, family history of CAD, high LDL-C level (545 mg/dL), and carotid artery stenosis (severe in left internal carotid artery and moderate in right internal carotid artery).\n\n2. The clinical trial is about evaluating the impact of a \"limitations\" section in systematic review abstracts on how readers interpret the results.\n\n3. The inclusion criteria for the trial are:\n- Abstract of meta-analysis published in the Annals of Internal Medicine journal between 2006 and 2012\n- About a healthcare intervention\n- With a conclusion in favor of the experimental treatment\n\n4. Based on the patient note, there is no information provided about the patient being an author of a meta-analysis or systematic review abstract. The note is about the patient's medical condition.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "702": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n2. The clinical trial is titled \"MICHI\u2122 Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study).\" It aims to evaluate debris captured in the filter of the MICHI Neuroprotection System during transcarotid stenting procedures.\n\n3. The inclusion criteria for the trial are:\n   - Adequate central venous access\n   - Common carotid artery reference diameter of at least 6 mm\n   - Carotid bifurcation is a minimum of 5 cm above the clavicle as measured by duplex Doppler ultrasound (DUS) or computerized axial tomography (CT) angiography or magnetic resonance (MR) angiography\n\n4. Based on the patient note, the following information is relevant to the inclusion criteria:\n   - The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n   - Ultrasonography findings suggest the presence of plaque in the carotid arteries.\n\n5. However, there is no information provided about the patient's central venous access or the specific measurements of the carotid artery diameter and bifurcation location.\n\nTherefore, based on the available information, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "703": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Family physicians belonging to and sharing data with the Electronic Medical Record Administrative Linked Database in Ontario\n- The patient note does not mention whether the physician belongs to this database, so there is not enough information to assess this criterion.\n\n2. Patients rostered to these family physicians with diabetes or hypertension or ischemic heart disease\n- The patient note mentions that the patient has a family history of CAD (coronary artery disease), which is a form of ischemic heart disease. However, it does not explicitly state that the patient has been diagnosed with ischemic heart disease.\n\nSince there is not enough information to confirm that the inclusion criteria are met, the most appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "704": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nThe clinical trial is a pilot observational study to create a model of carotid plaque composition based on ultrasonic backscattered signals and clinical data.\n\nThe inclusion criteria for the CEA (carotid endarterectomy) cohort are:\n1) Age \u2265 40 years\n2) Scheduled to undergo CEA for clinically significant carotid stenosis\n3) CEA being performed for stenosis of the internal carotid artery (ICA), distal end of the common carotid artery (CCA), and/or CCA bulb.\n\nBased on the information provided, the patient meets all the inclusion criteria:\n1) Age 46 years (\u2265 40 years)\n2) Has clinically significant carotid stenosis (severe stenosis in LICA and moderate stenosis in RICA)\n3) Stenosis involves the ICA\n\nTherefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "705": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Computer Assisted Orthognathic Surgery. Facial Asymmetry\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and carotid artery stenosis, but there is no mention of facial asymmetry or mandibular deviation, which are the primary inclusion criteria for this trial.\n\nThe inclusion criteria specifically state:\n\n1. Facial asymmetry or mandibular deviation (cant of the occlusal plane > 3\u00b0 and/or midline discrepancies > 2.5 mm)\n2. Presence of all central incisors\n3. Pre- and postoperative radiographs and plaster casts (group 1) or cranial CBCT images (group 2)\n4. Pre- and postoperative digital photographs\n\nThe patient note does not provide any information regarding facial asymmetry, mandibular deviation, or the presence of central incisors. Additionally, there is no mention of pre- or postoperative radiographs, plaster casts, CBCT images, or digital photographs.\n\nTherefore, based on the information provided, the patient does not seem to be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "706": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18-65 years old.\n\nThere is no mention of the patient taking opioid pain medication or planning to start a new pain medication regimen for chronic non-malignant pain. The note only mentions dizziness, headaches, and high LDL cholesterol levels.\n\nThe note does not provide any information about the patient's testosterone levels or symptoms of hypogonadism like fatigue, decreased energy, depressed mood, decreased libido, or erectile dysfunction.\n\nSince the patient does not seem to be taking opioid pain medication, does not have documented low testosterone levels, and does not have chronic non-malignant pain conditions listed in the criteria, there is insufficient information to determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "707": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose (85 mg/dL), and triglycerides (158 mg/dL). He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is titled \"Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients\" and aims to investigate the effect of community-based group walks on developing a physically active lifestyle and improving glycemic control in adult diabetes patients.\n\n5. The inclusion criteria for the trial are:\n   - Joslin Clinic patients\n   - 18 years or older\n   - A1C between 7.5% - 12.0%\n   - Received physician clearance indicating safe to participate in the walk club events\n   - Reside within Boston and Greater Boston Area\n   - Ability to communicate in English and/or Chinese\n   - Agree to participate in the intervention walk club for 6 consecutive weeks\n\n6. Based on the information provided, the patient does not meet the inclusion criteria for this clinical trial as he does not have diabetes (no A1C value provided) and is not a Joslin Clinic patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "708": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 30-85 years old.\n\n2. The patient has a family history of CAD, which is listed as one of the inclusion criteria for having at least one traditional cardiovascular risk factor.\n\n3. The patient has high LDL-C levels (545 mg/dL), which indicates dyslipidemia, another inclusion criteria.\n\n4. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating cerebrovascular disease diagnosed by objective testing, which is also an inclusion criteria.\n\nSince the patient meets multiple inclusion criteria and there is no information provided that would exclude them based on the exclusion criteria, I would assess this patient as:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "709": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being > 18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests coronary artery disease.\n\n3. However, there is no mention of the patient being on acetylsalicylic acid (ASA) 100 mg/day, which is one of the inclusion criteria.\n\nSince the patient does not meet all of the inclusion criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "710": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 40-75 years old for the trial.\n\nHe does not have a diagnosis of type 2 diabetes, which is an inclusion criteria for the trial looking at newly diagnosed type 2 diabetes patients.\n\nHe has elevated LDL cholesterol of 545 mg/dL and carotid artery stenosis, which are not exclusion criteria for this trial.\n\nHe has no history of cardiovascular events like myocardial infarction, stroke, etc. which are exclusion criteria.\n\nThere is no mention of congestive heart failure, cancer, anemia, renal disease, organ transplants, HIV/hepatitis, pregnancy, alcohol/drug abuse, psychiatric illness, or debilitating chronic illness that would exclude him.\n\nHowever, the key point is that he does not have a diagnosis of newly diagnosed type 2 diabetes within the last year, which is a core inclusion criteria for this trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "711": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient is at least 18 years old at informed consent\nThe patient is 46 years old, so this criterion is met.\n\n2. Patient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.\nThere is no information provided about the patient's willingness or ability to comply with the study requirements, so this cannot be assessed.\n\n3. Patient is willing to provide written informed consent prior to enrollment in study.\nAgain, there is no information about the patient's willingness to provide informed consent.\n\n4. Patient is either:\n   a) Symptomatic with carotid stenosis \u226550% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR\n   b) Asymptomatic with carotid stenosis \u226580% as determined by angiography using NASCET methodology\n\nThe patient has severe stenosis (narrowing) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, as determined by ultrasonography. However, the inclusion criteria specifically require angiography using the NASCET methodology for determining the degree of stenosis. Since the patient's stenosis was evaluated by ultrasonography and not angiography, it is unclear if this criterion is met.\n\n5. Patient must be considered high risk for adverse events during carotid endarterectomy\nThere is no information provided about the patient's risk for adverse events during carotid endarterectomy.\n\nSince there is insufficient information to determine if the patient meets several of the key inclusion criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "712": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery (LICA) as well as moderate stenosis in the right internal carotid artery (RICA).\n\nThe clinical trial is titled \"Intensive Statin Therapy in Patients With AMI\" and the inclusion criteria states \"All patients with NSTEMI and STEMI\".\n\nNSTEMI refers to non-ST segment elevation myocardial infarction, while STEMI refers to ST-segment elevation myocardial infarction. Both are types of acute myocardial infarction (AMI) or heart attack.\n\nThe patient note does not mention the patient having a myocardial infarction or heart attack. The symptoms and findings are related to carotid artery stenosis.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "713": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. At least 1 of the following vascular risk factors or on treatment for 1 of these conditions determined by the study physicians to be responsible for the mild memory and thinking problems you experience:\n   - The patient has high LDL-C (545 mg/dL) which satisfies the \"poorly controlled cholesterol (LDL > 70 mg/dL)\" criterion.\n\n2. Age > 55 years\n   - The patient is 46 years old, which does not meet this criterion.\n\n3. Memory complaint\n   - The patient complains of dizziness and frequent headaches, but no specific memory complaint is mentioned.\n\n4. Montreal Cognitive Assessment (MoCA) score \u2264 26\n   - No MoCA score is provided for the patient.\n\n5. Either, presence of strategic (caudate, thalamus, subcortical white matter lacunar infarcts or mild to moderate small vessel ischemic changes (T2-positive) felt to be sufficient to explain the cognitive decline (in the clinical judgment of the examining physician)\n   - The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but no specific mention of strategic infarcts or small vessel ischemic changes.\n\n6. English-speaking\n   - No information is provided about the patient's language.\n\nBased on the information provided, the patient meets one of the inclusion criteria (poorly controlled cholesterol) but does not meet the age criterion and lacks information for several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "714": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- High LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL)\n- Normal fasting glucose and triglycerides\n- Not taking any lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe clinical trial is studying the effect of garlic tablets on:\n- Carotid intima media thickness (CIMT)\n- Flow mediated dilation (FMD)\n- Plasma lipid profile\n- C-reactive protein\nIn patients with coronary artery disease (CAD)\n\nThe inclusion criteria are:\n1) Angiography confirmed CAD\n2) Not consistently using garlic in the last month\n\nLooking at the patient details, the patient has carotid artery stenosis which is indicative of atherosclerosis and increased risk of CAD, though CAD is not explicitly confirmed by angiography.\n\nHowever, the patient meets the second inclusion criteria of not using garlic consistently in the last month.\n\nSince the key inclusion criteria of angiography-confirmed CAD is not clearly met based on the patient note, I would assess:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "715": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 40-75 years old.\n\nThe patient is male, which meets the male sex criteria.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. This indicates the presence of coronary artery disease, which meets the inclusion criteria of \"History of known coronary artery disease (by either history of myocardial infarction, angiogram demonstrative >=50% stenosis in at least 1 major epicardial coronary artery, or a previous stress test that showed evidence of ischemia that has not been revealed to be a false positive test by angiography)\".\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial \"Effect of Probiotic Supplementation on Endothelial Function\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "716": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a patient of the outpatient clinic.\n\n2. However, the inclusion criteria specifically mentions patients presenting 12 months after the introduction of the hs-TnT test in June 2009. The patient note does not provide any information about when the patient presented relative to June 2009.\n\n3. Without knowing if the patient presented within the 12 month window after June 2009, there is insufficient information to determine eligibility based on the given inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "717": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being > 21 years old.\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), meeting the criteria of having a lesion located in the internal carotid artery (ICA).\n\nThe note mentions that ultrasonography was performed, suggesting that the minimum distance of 5 cm between the clavicle and bifurcation was likely assessed, meeting that criteria.\n\nThe note does not mention the patient's life expectancy, ability to understand/cooperate with study procedures, willingness to return for follow-ups, or provide informed consent. However, since this is baseline information, we can assume the patient is eligible unless stated otherwise.\n\nThe note also does not provide information about the patient's INR level, which is required to be \u2264 1.5 at the time of the procedure.\n\nOverall, based on the information provided, the patient appears to meet most of the key inclusion criteria, except that the INR level is unknown.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, as the INR level is unknown).",
        "label": 1
    },
    "718": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Participant is a female or male of any race/ethnicity >18 years old at the time of the investigational product administration\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Participant or participant's legally acceptable representative provides written informed consent\nThere is no information about providing consent, so I cannot determine if this criterion is met.\n\n3. Participant is capable of complying with study procedures\nThere is no information about the patient's ability to comply with study procedures, so I cannot determine if this criterion is met.\n\n4. Participant has known carotid artery stenosis of >50% luminal diameter based on carotid ultrasound or computed tomography angiography (CTA), as stated in official clinical report or as measured by PI if no quantitative assessment appears in the report, and who is deemed to be a surgical candidate for endarterectomy\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%, based on ultrasonography. So he meets this criterion.\n\n5. Participant has had a carotid ultrasound and/or computed tomography angiography (CTA) and the report is available for collection\nThe patient has had ultrasonography of the carotid arteries, so this criterion is met.\n\n6. Participant has had or is scheduled to have a carotid CT angiogram for plaque localization within 60 days of signing ICF (or else scheduled CTA must be performed on a separate day and prior to the investigational PET procedure)\nThere is no information about whether the patient has had or is scheduled for a carotid CT angiogram, so I cannot determine if this criterion is met.\n\n7. Participant has consented to have an endarterectomy\nThere is no information about whether the patient has consented to have an endarterectomy, so I cannot determine if this criterion is met.\n\n8. Participant will be scheduled for an investigational[F-18]RGD-K5 PET/CT scan within 4 weeks prior to endarterectomy\nThere is no information about whether the patient will be scheduled for the investigational PET/CT scan, so I cannot determine if this criterion is met.\n\n9. Participant must have renal functions values as defined by laboratory results within the following ranges:\nSerum creatinine \u2264 1.5 mg/dL\nEstimated glomerular filtration rate (eGFR): \u2265 45mL/min\nThere is no information about the patient's renal function values, so I cannot determine if this criterion is met.\n\nSince there are multiple criteria that cannot be determined from the given information, I would assess the patient as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "719": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female 21 - 70 years.\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Have been diagnosed diabetes mellitus and being treated with lifestyle intervention for at least 1 month prior to screening, with or without antidiabetic agents.\nThe patient note does not mention diabetes mellitus or any treatment for it. This criterion is not met.\n\n3. HDL-cholesterol level of < 35 mg/dL.\nThe patient's HDL-C level is 53 mg/dL, which does not meet this criterion.\n\n4. Triglycerides level of < 200 mg/dL.\nThe patient's triglyceride level is 158 mg/dL, so this criterion is met.\n\n5. Adequate liver and renal function.\nThere is no information about the patient's liver and renal function in the note.\n\n6. Statin and/or fenofibrate therapy should have been being regularly taken for >=3 months at stable dose (ONLY for subjects currently under statin and/or fenofibrate therapy).\nThe patient note states that the patient reported no use of lipid-lowering medications, so this criterion is not applicable.\n\n7. Able to take oral medication.\nThere is no information about the patient's ability to take oral medication in the note.\n\nBased on the information provided in the patient note, the patient does not meet at least two of the inclusion criteria (diagnosis of diabetes mellitus and HDL-C level < 35 mg/dL). There is also insufficient information to determine if the patient meets some of the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "720": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 40-65 years old for this clinical trial.\n\n2. The patient does not have acute lymphoblastic leukemia (ALL) or any other form of leukemia mentioned in the note. The trial is specifically for patients with ALL in complete remission.\n\n3. There is no information provided about the patient's organ function (cardiac, pulmonary, renal, hepatic) or performance status, which are required for eligibility.\n\n4. There is no mention of the patient having an HLA-matched sibling or unrelated donor, which is a requirement for this allogeneic hematopoietic stem cell transplant trial.\n\nSince the patient does not have the target disease (ALL) and there is insufficient information about organ function, performance status, and availability of a matched donor, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "721": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. However, the patient does not have breast cancer, which is a key inclusion criterion for this trial. The patient's condition appears to be related to carotid artery stenosis and high cholesterol levels.\n\n3. The other inclusion criteria, such as being a woman, having an invasive breast cancer diagnosed by cytology or histology, and having specific tumor stages, are not met by this patient.\n\n4. Therefore, based on the information provided, this patient does not meet the inclusion criteria for the \"Chronic Toxicities Related to Treatment in Patients With Localized Cancer\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "722": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a case of carotid stenosis.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), confirmed by ultrasonography.\n\n3. The patient has not received any prior revascularization procedures like carotid endarterectomy (CEA) or carotid artery stenting (CAS) based on the information provided.\n\n4. The trial is investigating the current situation and outcomes of CEA and CAS procedures for carotid stenosis in China.\n\n5. Since the patient has carotid stenosis and has not undergone any prior revascularization procedures, they would be eligible for inclusion in this trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "723": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis (i.e., histologically confirmed thyroid cancer (papillary, follicular, or medullary type; TNM classification system);\nThe patient note does not mention a thyroid cancer diagnosis, so this criterion is not met.\n\n2. Willing to participate in the EG meetings;\nThere is no information about the patient's willingness to participate in meetings.\n\n3. >18 years;\nThe patient is 46 years old, so this criterion is met.\n\n4. Alert and capable of giving free and informed consent;\nThere is no information about the patient's alertness or ability to provide consent.\n\n5. Able to speak and read English or French.\nThere is no information about the patient's language abilities.\n\nSince the patient note does not mention a thyroid cancer diagnosis, which is a key inclusion criterion, there is not enough information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "724": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Pain in Women With Chronic Pelvic Pain\", the patient does not seem to be eligible for this trial. The key reasons are:\n\n1. The patient is described as a 46-year-old man, while the inclusion criteria specify \"Women\".\n2. There is no mention of chronic pelvic pain in the patient note. The note describes symptoms related to carotid artery stenosis and high cholesterol levels.\n\nSince the patient does not meet the gender and condition requirements specified in the inclusion criteria, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "725": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients with a diagnosis of noncardioembolic IS that developed between 8 and 180 days before the start of the protocol treatment\n- The patient note does not mention an ischemic stroke diagnosis, so this criterion is not met.\n\n2. Patients with a responsible lesion identified by MRI\n- The patient note mentions severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery identified by ultrasonography, but does not specify if an MRI was done to identify a responsible lesion.\n\n3. Patients aged 20 to 85 years old when providing informed consent\n- The patient is 46 years old, so this criterion is met.\n\n4. Patients taking clopidogrel or aspirin alone as antiplatelet therapy when providing informed consent\n- The patient note states that the patient reported no use of lipid-lowering medications, so this criterion is not met.\n\n5. Patients meeting at least one of the following criteria a-c:\na) at least 50% stenosis of a major intracranial artery (to the level of A2, M2, or P2)\n- This is not mentioned in the patient note.\nb) at least 50% stenosis of an extracranial artery (the common carotid artery, internal carotid artery, vertebral artery, brachiocephalic artery, or subclavian artery)\n- The patient note mentions severe stenosis in the left internal carotid artery, so this criterion is met.\nc) Two or more of the listed risk factors\n- The patient has a family history of CAD, which is not one of the listed risk factors.\n\n6. Patients considered to be able to visit the study site for ambulatory care throughout the observation period\n- There is no information about this in the patient note.\n\n7. Patients who provided written informed consent\n- There is no information about this in the patient note.\n\nBased on the information provided, the patient meets criteria 3 and 5b, but does not meet criteria 1, 4, 5a, and 5c. There is not enough information to determine if criteria 2, 6, and 7 are met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "726": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u2265 18 years\nThe patient is 46 years old, so this criterion is met.\n\n2. Patient with an indication for PCI including angina (stable or unstable), silent ischemia, NSTEMI, or recent STEMI.\nThe patient presents with dizziness and frequent headaches, but there is no mention of angina, silent ischemia, NSTEMI, or recent STEMI. This criterion is not met.\n\n3. Regarding prior non-target vessel PCI, there is no information provided about any prior PCI procedures.\n\n4. Patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule.\nThere is no information provided about the patient's willingness or ability to provide consent and comply with follow-up.\n\n5. Angiographic inclusion criteria (visual estimate):\n   a. Treatment of up to three de novo target lesions, maximum of one de novo target lesion per vessel\n   b. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of \u22652.5 mm to \u22644.25 mm and diameter stenosis \u226550% to <100%.\n   c. Lesion must be \u226428 mm long and can be covered by a single study stent with maximum length of 33 mm.\n   d. TIMI flow 2 or 3\n\nThe patient note mentions severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), but it does not provide information about coronary artery lesions or TIMI flow.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "727": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. The patient must be \u226518 of age;\nThe patient is 46 years old, so this criterion is met.\n\n2. Symptomatic ischemic heart disease and/or objective evidence of myocardial ischemia including chronic stable coronary artery disease, or acute coronary syndrome including non-ST-elevation and ST-elevation myocardial infarction;\nThe patient presents with dizziness and frequent headaches, which could be symptoms of ischemic heart disease. However, there is no explicit mention of a diagnosis of ischemic heart disease or myocardial ischemia.\n\n3. Acceptable candidate for CABG;\nThere is no information provided about whether the patient is a candidate for CABG (coronary artery bypass graft surgery).\n\n4. The patient is willing to comply with specified follow-up evaluations;\nThere is no information provided about the patient's willingness to comply with follow-up evaluations.\n\n5. Patients who agree to accept the follow-up visits.\nSimilar to the previous criterion, there is no information provided about the patient's agreement to accept follow-up visits.\n\n6. Patients can understand the study objectives psychologically and linguistically and show the sufficient compliance to the study protocol. Patients present acceptance of the risks and benefits described in the informed consent form.\nThere is no information provided about the patient's ability to understand the study objectives or their acceptance of the risks and benefits.\n\n7. At least one lesion with a diameter stenosis >50% or more suitable for coronary stent implantation in a vessel with a reference diameter ranging from 2.5 mm to 4.0 mm;\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). However, the inclusion criteria specifically mentions lesions suitable for coronary stent implantation, and the patient's stenosis is in the carotid arteries, not the coronary arteries.\n\nBased on the information provided, there is insufficient evidence to determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "728": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and Female patients who are more than 20 years old or 70 years old or less.\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Patient who voluntarily sign on written informed consent form\nThere is no information provided about whether the patient signed an informed consent form, so this criterion cannot be evaluated.\n\n3. Patient who LDL-C \u2265 100mg/dl or was diagnosed with hyperlipidemia\nThe patient's LDL-C level is 545 mg/dL, which is well above the 100 mg/dL threshold, so he meets this criterion.\n\n4. Patient who was suspected with Impaired Fasting Glucose (IFG) and satisfy FPG level \u2265 100mg/dL and < 126mg/dL when FPG measured twice.\nThe patient's fasting glucose level is 85 mg/dL, which is below the IFG range of 100-125 mg/dL. There is no information about whether his fasting glucose was measured twice.\n\nBased on the information provided, the patient meets criteria 1 and 3, but does not meet criterion 4 and there is insufficient information to evaluate criterion 2.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "729": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial (Brasilia Heart Study) is a cohort study of myocardial infarction (MI) patients admitted within the first 24 hours of symptoms.\n\n5. The inclusion criteria for the trial are:\n   - Less than 24 hours after the onset of MI symptoms\n   - ST-segment elevation of at least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads\n   - Evidence of myocardial necrosis, as indicated by elevated CK-MB and troponin I levels\n\n6. Based on the information provided, the patient does not meet the inclusion criteria for the Brasilia Heart Study, as there is no mention of a myocardial infarction or ST-segment elevation on ECG.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "730": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18 years or older.\n\nHe has elevated LDL-C levels (545 mg/dL) and is not on any lipid-lowering medication, meeting the criteria of \"displaying at least one abnormal plasma lipid parameter and/or receiving a lipid-lowering therapy unchanged for at least 3 months.\"\n\nThe patient has provided informed consent, though this is not explicitly stated in the note.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial \"Identification of CETP as a Marker of Atherosclerosis.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "731": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-80 years old for the clinical trial.\n\n2. The trial is for patients with erectile dysfunction, but the patient note does not mention any issues related to erectile dysfunction. Instead, it describes symptoms of dizziness, headaches, and carotid artery stenosis.\n\n3. The inclusion criteria specifically mention \"penile arterial insufficiency and or venous leakage (doppler) at the time of inclusion: PSV <25 cm/sec, PSV >25 cm/sec, EDV>5cm/sec, RI<0,75.\" However, the patient note does not provide any information about penile arterial or venous measurements.\n\n4. The exclusion criteria mention severe co-morbidities like cardiac insufficiency, congestive cardiac failure, malignancy, infection, sepsis, and bed sores. While the patient has carotid artery stenosis, there is no mention of any of the listed exclusion criteria.\n\nBased on the information provided in the patient note and the inclusion/exclusion criteria for the clinical trial, there is not enough information to determine if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "732": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226535 years old for the trial.\n\n2. The patient has severe stenosis (>70%) in the left internal carotid artery (LICA) based on the peak systolic velocity of 208.5 cm/s and end-diastolic velocity of 54.5 cm/s. This meets the criteria for carotid stenosis defined by Doppler ultrasound.\n\n3. The patient has no history of stroke or TIA ipsilateral to the stenosis within 180 days, as per the inclusion criteria.\n\n4. The patient's modified Rankin Scale score is not mentioned, but he is described as physically active, suggesting a score of 0 or 1.\n\n5. There is no mention of the patient's childbearing potential or pregnancy status.\n\n6. It is not stated whether the patient agrees to comply with follow-up appointments or has signed the consent form.\n\n7. The patient has moderate stenosis (40-50%) in the right internal carotid artery, which is not the target lesion for this trial.\n\n8. There is no mention of intolerance or allergic reactions to study medications.\n\n9. There is no mention of recent GI hemorrhage, prior major ipsilateral stroke, severe dementia, or intracranial hemorrhage.\n\n10. There is no mention of current neurologic illness, objection to blood transfusions, low platelet count, or anticoagulant use.\n\n11. There is no mention of atrial fibrillation or other high-risk cardiac sources of emboli.\n\n12. There is no mention of unstable angina, low ejection fraction, or recent heart failure admission.\n\n13. There is no mention of respiratory insufficiency or low FEV1.\n\n14. There is no mention of known malignancy.\n\n15. There is no mention of recent major surgery, trauma, revascularization, or acute coronary syndrome.\n\n16. Serum creatinine and estimated GFR are not provided.\n\n17. There is no mention of planned major surgery within 3 months.\n\n18. There is no mention of being listed for organ transplantation or participating in another trial.\n\n19. There is no mention of inability to understand or cooperate with study procedures.\n\n20. The carotid stenosis is described as atherosclerotic, not non-atherosclerotic.\n\n21. There is no mention of previous ipsilateral CEA or CAS.\n\n22. There is no mention of ipsilateral internal or common carotid artery occlusion.\n\n23. There is no mention of intra-carotid floating thrombus.\n\n24. There is no mention of ipsilateral intracranial aneurysm >5 mm.\n\n25. There is no mention of extreme morbid obesity.\n\n26. There is no mention of coronary artery disease with multiple severe stenoses.\n\n27. There is no mention of serious adverse reaction to anesthesia, distal/intracranial stenosis greater than index lesion, or adverse neck anatomy that would preclude CEA.\n\n28. There is no mention of allergy to contrast dye, type III aortic arch anatomy, severe angulation or tortuosity of the carotid arteries, proximal/ostial CCA or innominate stenosis, excessive circumferential calcification, small or large reference vessel diameter, inability to use embolic protection device, non-contiguous or long lesions, qualitative characteristics precluding safe sheath placement, occlusive or critical ilio-femoral disease, or severe atherosclerosis of the aortic arch or origin of the carotid arteries that would preclude safe CAS.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for the trial, and there are no clear exclusion criteria mentioned. However, there are some missing details that would be needed to make a definitive determination, such as the patient's modified Rankin Scale score, childbearing potential/pregnancy status, willingness to comply with follow-up and provide consent, serum creatinine/estimated GFR, and specific details about the carotid artery anatomy and suitability for CEA or CAS.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "733": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 45-65 years specified in the inclusion criteria.\n\nHe has cardiovascular disease (CVD), as evidenced by the severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which meets the inclusion criterion of \"patients with \u2265 50% stenosis in at least one coronary angiogram demonstrated.\"\n\nHis body mass index (BMI) is not explicitly stated, but the inclusion criteria specify a BMI range of 18.5-35, which is a common range for most clinical trials.\n\nThere is no information provided about whether the patient has been taking dietary supplements, vitamins, or herbal products in the past 3 months, which is an inclusion criterion.\n\nThere is also no information about the patient's willingness to participate in the trial, which is another inclusion criterion.\n\nBased on the available information, the patient meets some of the inclusion criteria but lacks information on a few key criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "734": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck.\n   - The patient note does not mention a diagnosis of squamous cell carcinoma of the head and neck, so this criterion is not met.\n\n2. Disease must be considered incurable...\n   - There is no information about the patient's disease being incurable.\n\n3. Measurable disease defined as lesions...\n   - No information is provided about measurable lesions.\n\n4. Phase I only criteria, not applicable here.\n\n5. Phase II only criteria, not applicable here since the patient does not have the relevant diagnosis.\n\n6. Minimum of 14 days elapsed since the end of any prior therapy.\n   - No information about prior therapy is given.\n\n7. At least 18 years of age.\n   - The patient is 46 years old, so this criterion is met.\n\n8. Resolution of all acute toxic effects...\n   - No information about toxic effects is provided.\n\n9. ECOG performance status \u2264 2\n   - No information about performance status is given.\n\n10. Adequate bone marrow and organ function as defined...\n    - Some lab values are provided (LDL-C, HDL-C, fasting glucose, triglycerides) but not the required values.\n\n11. Baseline corrected QT interval (QTc) < 480 ms.\n    - No information about QTc is provided.\n\n12. Women of childbearing potential and men must agree to use adequate contraception...\n    - No information about contraception is given.\n\n13. Available archival tumor tissue for the proposed correlative studies.\n    - No information about tumor tissue is provided.\n\n14. Ability to understand and willingness to sign an IRB approved written informed consent document.\n    - No information about consent is provided.\n\nOverall, based on the limited information in the patient note, the patient does not meet the key inclusion criteria of having a confirmed squamous cell carcinoma of the head and neck diagnosis. There is also insufficient information provided to determine if many of the other criteria are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "735": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe has no history of diabetes mellitus mentioned. However, he does have a family history of CAD and his LDL-C level is 545 mg/dL, which is very high. This suggests he is at high risk for a future cardiovascular event based on inclusion criteria 3c \"Male patients >50 years of age or females >60 years of age, with at least one of the risk factors defined in protocol.\"\n\nHis HDL-C level is 53 mg/dL, which meets the criteria of HDL-C <42 mg/dL for men.\n\nHis triglyceride level is 158 mg/dL, which falls within the range of \u2265180 and <500 mg/dL specified in the inclusion criteria.\n\nThe patient is not currently on any lipid-lowering medication, but the criteria state he must be on a stable statin therapy for at least 4 weeks prior to randomization.\n\nBased on the information provided, the patient potentially meets most of the key inclusion criteria, except for being on a stable statin therapy.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial as he is not currently on a stable statin therapy as required).",
        "label": 0
    },
    "736": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226520 years old.\n\n2. The patient has high LDL-C levels of 545 mg/dL, which is well above the exclusion criteria of <100 mg/dL for heterozygous familial hypercholesterolemia or <120 mg/dL for non-familial hypercholesterolemia with risk factors.\n\n3. The patient is not currently on any lipid-lowering medications, which meets the inclusion criteria of not being adequately controlled on stable lipid therapy.\n\n4. There is no mention of the patient having heterozygous familial hypercholesterolemia or documented cardiovascular disease/risk factors that would categorize them into the primary prevention category III.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria of having very high LDL-C levels and not being adequately controlled on lipid therapy. There is no clear exclusion criteria that would prevent them from participating.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "737": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >50 years and <85 years.\n\n2. The patient has no diagnosis of aortic sclerosis or mild aortic stenosis mentioned in the note. The note mentions carotid artery stenosis, but not aortic valve disease.\n\n3. There is no mention of the patient's lipoprotein(a) [Lp(a)] levels in the note.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for aortic sclerosis/mild aortic stenosis and elevated Lp(a) levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "738": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old for the clinical trial.\n\n2. The patient does not have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The note mentions dizziness, headaches, and carotid artery stenosis, but no hematological malignancy.\n\n3. Since the patient does not have CLL/SLL, they do not meet the key inclusion criteria of having a histologically or flow cytometry confirmed diagnosis of B-cell CLL/SLL.\n\n4. The other inclusion criteria related to active disease status, prior treatment regimens, ECOG performance status, and organ function are not relevant since the patient does not have CLL/SLL.\n\nTherefore, based on the information provided in the patient note, this patient does not qualify for the clinical trial studying relapsed/refractory CLL.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "739": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 45-65 years specified in the inclusion criteria.\n\nHe has a family history of CAD (cardiovascular disease), which is relevant to the trial targeting CVD patients.\n\nThe patient has severe stenosis (>50%) in the left internal carotid artery, which meets the inclusion criteria of \"\u2265 50% stenosis in at least one coronary angiogram demonstrated.\"\n\nHis BMI is not mentioned, but the criteria specify a range of 18.5-35, so there is not enough information to determine if he meets this criterion.\n\nThere is no mention of him taking dietary supplements, vitamins or herbal products, so we can assume he meets the criterion of \"avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention.\"\n\nThe note does not mention his willingness to participate in the trial.\n\nOverall, based on the information provided, the patient meets some of the key inclusion criteria (age, CVD diagnosis, stenosis level), but there is not enough information to determine if he meets all the criteria (BMI, willingness to participate).\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "740": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria (no specific age cutoff given in the inclusion criteria).\n\n2. The patient has severe stenosis (>70%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). \n\n3. The inclusion criteria state:\n   - Asymptomatic stenosis of internal carotid artery >70%\n   - Symptomatic stenosis of internal carotid artery >60%\n\n4. The patient has severe (>70%) stenosis in the LICA, which meets the asymptomatic criteria.\n\n5. The patient is also experiencing dizziness and frequent headaches, which could be considered symptoms related to the carotid stenosis. If these are considered symptoms, then the moderate RICA stenosis of 40-50% would also meet the >60% criteria for symptomatic stenosis.\n\n6. The last inclusion criteria is \"planned surgical treatment of the stenosis\". The patient note does not explicitly mention planned surgical treatment, but given the severity of stenosis, it is reasonable to assume surgical treatment would be considered.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "741": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \">21 years\" for the clinical trial.\n\n2. The patient has no reported pregnancy, so the criteria \"If female patient with child bearing potential, patient may not be pregnant at the study entry and must utilize reliable birth control for the duration of her participation into the study\" is not applicable.\n\n3. There is no information provided about the patient's willingness or ability to comply with follow-up evaluations, so the criteria \"Patient is willing and able to comply with the specified follow-up evaluation\" cannot be assessed.\n\n4. The patient does not have critical limb ischemia or any of the Rutherford categories mentioned, so the criteria \"Critical Limb Ischaemia, Rutherford category 4 (ischaemic rest pain), 5 (minor tissue loss) or 6 (major tissue loss)\" is not met.\n\n5. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but the trial specifically requires \"Stenosis (>50% luminal loss) or occlusion of infra-genicular arteries (defined as: distal to the infra-popliteal artery), including the tibiofibular trunk, the anterior tibial artery, the posterior tibial artery and the peroneal artery\". The carotid arteries are not part of the infra-genicular arteries, so this criteria is not met.\n\n6. There is no information provided about the length of the arterial lesions, so the criteria \"Infragenicular arterial lesions with length of <20cm\" cannot be assessed.\n\n7. There is no information provided about the patient having at least one crural artery with expected unobstructed runoff to ankle level after treatment or successful guidewire crossing of the trial lesion.\n\nBased on the information provided, the patient does not meet the critical inclusion criteria related to critical limb ischemia and infra-genicular arterial lesions required for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "742": {
        "output": "To determine the patient's eligibility for the \"Cardiovascular Risk Clinic\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Family history of CAD (first degree relative): The patient has a family history of CAD.\n2. Physician-diagnosed diabetes or stroke: No information provided.\n3. Overweight (BMI\u226525) or obese (BMI\u226530): No information provided about the patient's BMI.\n4. Total cholesterol \u2265200, documented history of hypercholesterolemia, or currently taking lipid-lowering medications: The patient's LDL-C level is 545 mg/dL, which is very high, indicating hypercholesterolemia. The patient is not taking any lipid-lowering medications.\n5. History of smoking: The patient has no history of smoking mentioned.\n6. HDL <44 mg/dl: The patient's HDL-C level is 53 mg/dL, which is within the normal range.\n7. LDL \u2265130 mg/dl or documented history of hyperlipidemia: The patient's LDL-C level is 545 mg/dL, which is very high, indicating hyperlipidemia.\n8. Elevated triglycerides (\u2265200 mg/dl): The patient's triglyceride level is 158 mg/dL, which is within the normal range.\n9. Hypertension (systolic blood pressure \u2265130 mmHg, diastolic blood pressure \u226585 mmHg, documented diagnosis of hypertension, or currently taking antihypertensive medications): No information provided about the patient's blood pressure or hypertension diagnosis.\n10. Diabetes (fasting glucose \u2265100 mg/dl, physician diagnosis of diabetes/pre-diabetes, or currently taking anti-glycemic medications): The patient's fasting glucose level is 85 mg/dL, which is within the normal range, and no information is provided about a diabetes diagnosis or medication.\n11. Post-traumatic stress disorder (PTSD) or at risk for PTSD: No information provided.\n12. Insomnia (five hours of sleep per night or less) or sleep apnea: No information provided.\n\nBased on the information provided, the patient meets at least one inclusion criterion (hypercholesterolemia with LDL-C level of 545 mg/dL) and does not have any exclusion criteria mentioned.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "743": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria for the trial.\n\nHe has no history of high blood pressure, diabetes, or use of hypertension/hyperglycemia drugs, so those criteria are not met.\n\nHis waist circumference is not provided, so we cannot determine if he meets the central obesity criteria.\n\nHis fasting blood glucose of 85 mg/dL is within normal limits, so he does not meet the elevated blood glucose criteria.\n\nHis triglyceride level of 158 mg/dL is slightly elevated but does not meet the >=150 mg/dL criteria.\n\nHowever, his LDL-C level of 545 mg/dL is extremely high, and his HDL-C of 53 mg/dL meets the reduced HDL-C criteria for males (<=40 mg/dL).\n\nTherefore, based on the provided information, this patient meets at least 2 of the 5 criteria for metabolic syndrome (reduced HDL-C and potentially central obesity if waist circumference was high enough).\n\nTrial-level eligibility: 1) Not relevant. While the patient has dyslipidemia, there is insufficient information to definitively determine if he meets 3 or more criteria for metabolic syndrome required for inclusion in this trial.",
        "label": 1
    },
    "744": {
        "output": "Based on the patient note provided, the patient is a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL-C levels (545 mg/dL) and moderate to severe carotid artery stenosis, which suggests the presence of atherosclerosis.\n\nThe clinical trial titled \"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis\" has the following inclusion criteria:\n\n1. Patients with psoriasis\n2. Age and sex-matched patients with CAD, untreated hypertension, and healthy subjects\n\nWhile the patient note does not explicitly mention psoriasis, it does indicate the presence of CAD based on the carotid artery stenosis findings.\n\nTherefore, based on the information provided, the patient appears to meet the inclusion criteria for the clinical trial as an age and sex-matched patient with CAD.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "745": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u2265 20 years and < 75 years.\n\n2. The patient has an LDL-C level of 545 mg/dL, which is very high and indicates hyperlipidemia. This meets the inclusion criteria of having at least one metabolic syndrome-related risk factor.\n\n3. The patient has no history of cerebrovascular or coronary artery disease mentioned in the note, so the exclusion criteria do not apply.\n\n4. There is no mention of the patient currently taking Blopress Tablets or any other hypertension medication.\n\nBased on the information provided, the patient meets the inclusion criteria of having at least one metabolic syndrome-related risk factor (high LDL-C) and does not meet any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "746": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, so he meets the age criteria of \u226512 years old for the concussion cohort.\n\n2. There is no mention of a history of concussion within the prior 6 months in the patient note.\n\n3. The patient has complaints of dizziness and frequent headaches, which could potentially be symptoms of dizziness/balance problems.\n\nHowever, the key inclusion criteria is a history of concussion within the prior 6 months, which is not mentioned in the patient note. Without this crucial piece of information, it is difficult to definitively determine eligibility.\n\nTherefore, my assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "747": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Adult patients > 18 years old who had a successful liver transplant at least 1 year prior to enrollment\nThe patient note does not mention a liver transplant, so this criterion is not met.\n\n2. BMI>30 with previous failed attempts at weight loss via conventional methods\nThe patient's BMI is not provided, so we cannot assess this criterion.\n\n3. In addition to one of the following:\n- Triglyceride (TG)>150 mg/dl or specific treatment for this lipid abnormality\nThe patient's triglyceride level is 158 mg/dL, which meets this criterion.\n- HDL <40 mg/dl in females and <50 mg/dl in males or specific treatment of this lipid abnormality\nThe patient is male, and his HDL-C level is 53 mg/dL, which does not meet this criterion.\n- Systolic BP >130 or diastolic BP >85 mm Hg or treatment for previously diagnosed hypertension\nThe patient's blood pressure is not provided, so we cannot assess this criterion.\n- Fasting plasma glucose >100 mg/dl or previously diagnosed type 12 diabetes\nThe patient's fasting glucose level is 85 mg/dL, which does not meet this criterion, and there is no mention of diabetes.\n\nBased on the information provided, the patient meets one of the inclusion criteria (triglyceride level >150 mg/dL), but we do not have enough information to determine if they meet the other criteria, such as a successful liver transplant at least 1 year prior and BMI>30 with previous failed weight loss attempts.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "748": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) but normal HDL-C, fasting glucose, and triglycerides.\n\n2. The clinical trial is titled \"Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making.\"\n\n3. The inclusion criteria for the trial are:\n   - Symptoms suggestive of CAD, according to the opinion of the site clinician\n   - Age >= 21 years\n\n4. The patient meets the age criterion (46 years old).\n\n5. The patient is presenting with dizziness and frequent headaches, which could be considered anginal equivalent symptoms suggestive of CAD.\n\n6. Additionally, the patient has a family history of CAD and an abnormal lipid profile with high LDL-C levels, which are risk factors for CAD.\n\n7. Based on the information provided, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "749": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This suggests the presence of carotid artery aneurysms, which is an inclusion criterion.\n\n3. The patient has provided relevant clinical details such as LDL-C, HDL-C, fasting glucose, and triglyceride levels, as well as information about the presence of plaques in the carotid arteries.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the Carotid Aneurysm Registry clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "750": {
        "output": "Based on the patient note provided, the patient does not have plaque psoriasis or any indication that they are being treated for psoriasis. The note describes a 46-year-old man with dizziness, headaches, family history of coronary artery disease (CAD), and findings of carotid artery stenosis on ultrasound.\n\nThe inclusion criteria for the clinical trial \"Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis\" specifically require subjects to have moderate to severe plaque psoriasis and be initiating or switching biologic therapy for psoriasis.\n\nSince the patient note does not mention psoriasis or biologic therapy for psoriasis, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "751": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria.\n\nHe has no diagnosis of metabolic syndrome mentioned, but some relevant details are provided:\n- LDL-C level of 545 mg/dL (high)\n- HDL-C level of 53 mg/dL (normal range)\n- Fasting glucose of 85 mg/dL (normal)\n- Triglycerides of 158 mg/dL (normal)\n\nThe inclusion criteria require meeting 3 or more of the following:\n1) Increased abdominal circumference \u2265102 cm (no data provided)\n2) Triglycerides \u2265150 mg/dL (patient's is 158 mg/dL, so meets this)\n3) Low HDL-C (patient's is 53 mg/dL which is normal range for men)\n4) High blood pressure (no data provided)\n5) High blood glucose (patient's is 85 mg/dL which is normal)\n\nSo based on the information given, the patient meets 1 of the 5 criteria for metabolic syndrome required for inclusion.\n\nThere is no definitive diagnosis of metabolic syndrome stated.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "752": {
        "output": "Okay, let's go through the inclusion criteria for the EXTEND Exercise Trial step-by-step:\n\n1. Male age \u2265 18 years - The patient is a 46-year-old man, so he meets this criterion.\n\n2. Histologically-confirmed adenocarcinoma of the prostate - There is no mention of the patient having prostate cancer in the note, so this criterion is not met.\n\n3. Completion of appropriate prior treatment with local therapy - Since there is no mention of the patient having prostate cancer, this criterion is not applicable.\n\n4. Detectable PSA, defined as PSA \u22650.01 ng/ml - No PSA value is provided in the patient note.\n\n5. Appropriate for treatment with ADT in the opinion of the treating physician - Not applicable since the patient does not have prostate cancer.\n\n6. Serum total testosterone \u2265150 ng/dL (5.2 nmol/L) - No testosterone level is provided.\n\n7. ECOG performance status of \u2264 1 - No ECOG performance status is mentioned.\n\n8. Planned treatment with castration therapy for \u22658 months - Not applicable.\n\n9. Must not have any absolute contraindications to exercise testing/training - The patient note does not provide enough information to determine if any contraindications are present.\n\n10-16. Other criteria related to ability to participate in exercise testing/training, life expectancy, birth control, and organ function - Insufficient information is provided.\n\nBased on the information given in the patient note, there is not enough evidence to determine if the patient meets the key inclusion criteria related to having prostate cancer and being a candidate for the specific treatments involved in this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "753": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the \"healthy subjects\" inclusion criteria for Groups 1-3.\n\n2. However, the patient note mentions that he has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This suggests underlying cardiovascular disease or endothelial dysfunction.\n\n3. The inclusion criteria specifically state \"healthy subjects\", which this patient does not appear to be due to the carotid artery stenosis.\n\n4. There is no information provided about whether the patient gave informed consent or not.\n\nBased on the information provided, this patient does not fully meet the inclusion criteria of being a healthy subject for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "754": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His LDL-C level is 545 mg/dL, which is extremely high, indicating potential familial hypercholesterolemia.\n\n3. He is not currently taking any lipid-lowering medications.\n\n4. Carotid ultrasound revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The clinical trial is studying REGN1500 in participants with homozygous familial hypercholesterolemia (HoFH).\n\n6. The inclusion criteria for the trial are:\n   - Men and women \u226518 years of age (the patient is 46 years old, so he meets this criterion)\n   - Diagnosis of homozygous familial hypercholesterolemia (HoFH) (the patient's extremely high LDL-C level and carotid artery stenosis suggest HoFH, but a definitive diagnosis is not provided)\n   - Willing to consistently maintain usual diet for the duration of the study (no information is provided about the patient's willingness to maintain their diet)\n\nBased on the available information, the patient potentially meets the age and diagnosis criteria for the trial, but there is not enough information to determine if he meets the diet criterion.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "755": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is assessing the effect of different radial artery clamp times post-procedure on radial artery occlusion and bleeding in patients undergoing cardiac catheterization via the radial approach.\n\n5. The inclusion criteria for the trial are:\n   - Patients requiring cardiac catheterization via the radial approach for coronary artery disease investigation and treatment.\n   - Evidence of pre-procedural radial artery patency using the Barbeau test.\n   - Ability to provide informed consent.\n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial as he requires cardiac catheterization via the radial approach for the investigation and treatment of coronary artery disease.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "756": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertension (PAH).\n\n5. The inclusion criteria for the trial are:\n   - Evidence of signed informed consent\n   - Willingness to comply with study procedures\n   - Appropriate use of birth control for females of childbearing potential and males\n   - Completion of a previous study (APD811-003) or discontinuation due to clinical worsening while on placebo\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial, as he does not have pulmonary arterial hypertension (PAH). The patient's condition appears to be related to carotid artery stenosis and dyslipidemia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "757": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being \u226518 years old.\n2. There is no mention of the patient having multiple sclerosis or lower urinary tract symptoms, which are required for inclusion.\n3. The patient's BMI is not provided, but his height is not given so we cannot calculate if he meets the BMI <25 kg/m2 criteria.\n4. There is no information about the patient's waist circumference to determine if he meets the <94 cm criteria.\n5. There is no indication if the patient is willing to participate in the entire study or be randomly assigned to groups.\n6. There is no information about the patient passing any psychological/medical screening or being able to provide informed consent.\n7. The patient's nationality/social insurance status is not provided to determine if he meets the Slovenian social insurance criteria.\n8. There is no information about the patient's English language fluency.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "758": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches. This matches the inclusion criteria of \"age >=18 patients who complained of dizziness\".\n\n2. However, there is no mention of the patient having orthostatic hypotension, which is a key inclusion criteria (\"Orthostatic hypotension after 3-minute standing (systolic blood pressure drop >=20 or diastolic blood pressure drop >=10)\").\n\n3. The patient note describes carotid artery stenosis and high LDL cholesterol levels, but these are not relevant to the inclusion criteria for this particular trial on neurogenic orthostatic hypotension.\n\n4. Since there is insufficient information to determine if the patient meets the orthostatic hypotension criteria, we cannot conclude if the patient is eligible or not for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "759": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\nInclusion Criteria: Patients with 50% stenosis of the carotid arteries that are safe to undergo MRI imaging\n\nFrom the patient note, we have the following information:\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\n\nSince the patient has at least 50% stenosis in the LICA, they meet the inclusion criteria for the clinical trial.\n\nThere is no information provided about the patient's safety to undergo MRI imaging, but we can assume that if they were being considered for this trial, they would be safe to undergo the procedure.\n\nTherefore, based on the information provided, the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "760": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which does not match the inclusion criteria of women with overactive bladder symptoms.\n\n2. The patient has an LDL-C level of 545 mg/dL, which is very high, but the trial does not list high LDL-C as an inclusion criterion.\n\n3. The patient has an HDL-C level of 53 mg/dL, which meets the criterion of HDL-C < 50 mg/dL for women.\n\n4. The patient's fasting glucose of 85 mg/dL and triglycerides of 158 mg/dL do not meet the criteria for metabolic syndrome.\n\n5. There is no information provided about the patient's waist circumference, blood pressure, or use of medications for any of the metabolic syndrome components.\n\n6. The patient note does not mention any overactive bladder symptoms like urgency, nocturia or frequency.\n\nBased on the information provided, the patient does not seem to meet the key inclusion criteria of being a woman with overactive bladder symptoms and metabolic syndrome.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "761": {
        "output": "Okay, let's go through the inclusion criteria for the Patient and Provider Assessment of Lipid Management Registry (PALM) clinical trial step-by-step:\n\n1. Prior evidence of clinical atherosclerotic cardiovascular disease (ASCVD):\nThe patient note does not mention any prior ASCVD events like myocardial infarction, unstable angina, coronary revascularization, etc. This criterion is not met.\n\n2. Currently on statin therapy:\nThe patient note states \"The patient reported no use of lipid-lowering medications.\" So this criterion is not met.\n\n3. Low density lipoprotein cholesterol (LDL-C) level \u2265 130 mg/dL within the last 2 years (treated or untreated):\nThe patient's LDL-C level is 545 mg/dL, which meets this criterion.\n\n4. Age \u2265 65 years:\nThe patient is 46 years old, so this criterion is not met.\n\n5. Age \u2265 40 years with at least 1 of the following:\n    a. Diabetes: Not mentioned in the patient note.\n    b. Chronic Kidney Disease (CKD): Not mentioned.\n    c. 10-year ASCVD risk \u2265 5%: Not mentioned.\n    d. 2 or more of the following characteristics:\n        i. Male sex: Yes, the patient is a man.\n        ii. Systolic BP > 140 mmHg or on medication for hypertension: Not mentioned.\n        iii. Current tobacco use: Not mentioned.\n\nSince the patient is 46 years old and meets one of the characteristics (male sex), this criterion is met.\n\nBased on the information provided in the patient note, the patient meets 2 out of the 5 inclusion criteria for the PALM clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "762": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Males, Ages 18 and older\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. Body Mass Index (BMI) between 18 and 35 kg/m^2 (inclusive)\nThe patient's BMI is not provided, so there is not enough information to assess this criterion.\n\n3. Not currently hospitalized\nThe note does not mention if the patient is hospitalized or not, so there is not enough information to assess this criterion.\n\n4. Clinical indication of adenocarcinoma of the prostate evidenced by a biopsy report on record\nThe note does not mention any diagnosis of prostate cancer or a biopsy report, so the patient does not meet this criterion.\n\n5. At present receiving ADT treatment with a GnRH agonist for at least 2 months but not longer than 36 months without interruption\nThe note does not mention the patient receiving any ADT treatment or GnRH agonist, so the patient does not meet this criterion.\n\n6. Able to initiate Screening procedures 2 weeks prior to the next scheduled injection with a GnRH agonist\nSince the patient is not receiving GnRH agonist treatment, this criterion is not applicable.\n\n7. Willing to discontinue current ADT regimen for the duration of the study\nSince the patient is not receiving any ADT regimen, this criterion is not applicable.\n\n8. T level less than 50 ng/dL at Screening\nThe patient's testosterone level is not provided, so there is not enough information to assess this criterion.\n\n9. WHO/ECOG performance status of 0 or 1\nThe patient's performance status is not provided, so there is not enough information to assess this criterion.\n\n10. Life expectancy of at least 1 year\nThe patient's life expectancy is not provided, so there is not enough information to assess this criterion.\n\n11. Adequate renal function demonstrated by having normal blood urea nitrogen (BUN) and Creatinine Screening lab values\nThe patient's BUN and creatinine levels are not provided, so there is not enough information to assess this criterion.\n\nOverall, based on the information provided in the patient note, the patient does not meet the inclusion criteria for adenocarcinoma of the prostate and receiving ADT treatment with a GnRH agonist. There is also not enough information provided to assess several other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "763": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The clinical trial is a registry for chronic total occlusion (CTO) in coronary arteries, aiming to gather data on patient demographics, risk factors, procedural details, and outcomes.\n\n6. The inclusion criteria for the trial are: \"All consecutive patients undergoing an elective attempt at percutaneous revascularization of a chronic total occlusion are eligible for inclusion in the CTO registry. A chronic total occlusion is defined as an occluded coronary artery with TIMI 0 flow that has been occluded for 3 months or more.\"\n\nBased on the information provided, the patient does not seem to have a chronic total occlusion of a coronary artery. The carotid artery stenosis is mentioned, but the trial is specifically focused on coronary artery occlusions.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "764": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches. This matches the inclusion criteria of presenting to the emergency department with a migraine headache.\n\n2. However, there is no information provided about the severity of the headache pain being moderate to severe (at least 4/10 on the Faces Pain Scale - Revised). \n\n3. There is also no information about whether the patient requires IV fluids and IV medication as part of their headache treatment.\n\nSince there is not enough information provided to definitively determine if the patient meets all of the inclusion criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "765": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he does not have any other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglyceride levels. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is a single-center registry trial for patients with stable coronary artery disease.\n\n5. The inclusion criteria for the trial are:\n   - Over 18 years of age\n   - Presenting with stable coronary artery disease\n   - Angiographic lesion not involving side branch (SB) in whom provisional main vessel stenting strategy is planned after reviewing angiogram\n\n6. Based on the information provided, the patient does not meet the inclusion criteria for this clinical trial because:\n   - The patient's presentation is related to carotid artery stenosis and not coronary artery disease.\n   - There is no mention of an angiographic lesion or planned percutaneous coronary intervention (PCI) for the patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "766": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The clinical trial is a Phase II trial for a combination treatment of PEG-T\u03b11 and adefovir for HBeAg-positive chronic hepatitis B.\n\n6. The inclusion criteria for the trial are:\n   - Chronic hepatitis B for more than 6 months\n   - ALT > 2 \u00d7 Upper Limit Normal (ULN)\n   - Serum bilirubin < 2 \u00d7 ULN\n   - Positive HBeAg and HBV-DNA between 1.00E\uff0b05 IU/ml and 9.99E\uff0b09 IU/ml\n   - Signed Informed Consent Form (ICF)\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as he does not have chronic hepatitis B or any of the other required criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "767": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial.\n\n2. The patient does not have a diagnosis of arteriosclerotic cardiovascular disease, type 2 diabetes, or a history of myocardial infarction, stroke, etc. as per the inclusion criteria.\n\n3. However, the patient has an LDL-C level of 545 mg/dL, which is well above the cutoff of 190 mg/dL mentioned in the inclusion criteria.\n\n4. Based on the high LDL-C level alone, the patient meets at least one of the inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "768": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. He has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is a prospective study of patients referred for coronary angiography, assessing the relationship between diet, lifestyle, and the severity of coronary artery disease (CAD).\n\n5. The inclusion criteria for the trial are: patients fluent in English or Spanish who are referred for coronary angiography and are fully able to fill out the baseline questionnaires.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial as he is being referred for coronary angiography (due to the carotid artery stenosis findings) and is presumably able to fill out the baseline questionnaires.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "769": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 45-65 years old specified in the inclusion criteria.\n\nHe has a family history of CAD (coronary artery disease), which suggests he may have cardiovascular disease.\n\nHis LDL-C level of 545 mg/dL is very high, indicating potential cardiovascular issues.\n\nThe patient has severe stenosis (\u226550%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, meeting the criteria of \"\u226550% stenosis in at least one coronary angiogram demonstrated.\"\n\nHis BMI is not provided, but the criteria specifies a range of 18.5-35, so there is not enough information to determine if he meets this criterion.\n\nThere is no mention of him taking dietary supplements, vitamins, or herbal products, so he likely meets the criterion of \"avoidance of dietary supplements, vitamins and herbal products at least 3 months before and throughout the intervention.\"\n\nHis willingness to participate is not explicitly stated, but we can assume he is willing since he is being evaluated for the trial.\n\nBased on the information provided, the patient appears to meet most of the key inclusion criteria, except that his BMI is not specified.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to missing BMI data).",
        "label": 2
    },
    "770": {
        "output": "To determine the patient's eligibility for the clinical trial \"Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease\", let's go through the inclusion criteria one by one:\n\n1. Both sexes: The patient is a 46-year-old man, so this criterion is met.\n\n2. Coronary heart disease (angiographically or clinically approved): The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which suggests the presence of coronary heart disease. This criterion is likely met.\n\n3. Sufficient knowledge of the German language: There is no information provided about the patient's language proficiency, so this criterion cannot be evaluated.\n\n4. At least one not sufficiently controlled risk factor:\n   - Diabetes mellitus (HbA1c > 7.5%): The patient's fasting glucose level (85 mg/dL) is within normal limits, so this risk factor is not present.\n   - Smoking: The patient is reported as not being a smoker, so this risk factor is not present.\n   - Lack of physical activity (less than 60 minutes of light physical exercise per week): There is no information provided about the patient's physical activity level, so this risk factor cannot be evaluated.\n   - Heightened stress level (PSS-4 > 5): There is no information provided about the patient's stress level, so this risk factor cannot be evaluated.\n   - Arterial hypertension (blood pressure despite medication repeatedly heightened > 140/90 or in a 24-hour measurement > 135/85 mmHg): There is no information provided about the patient's blood pressure, so this risk factor cannot be evaluated.\n   - Hypercholesteremia (LDL > 130 mg/dL): The patient's LDL-C level is 545 mg/dL, which is significantly higher than the cutoff of 130 mg/dL. This risk factor is present.\n\n5. Written informed consent to participate: There is no information provided about whether the patient has given written informed consent, so this criterion cannot be evaluated.\n\nBased on the available information, the patient meets at least one inclusion criterion (hypercholesteremia) and potentially another (coronary heart disease). However, there is insufficient information to evaluate some of the other criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "771": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 40-85 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%, which meets the inclusion criteria of having symptomatic or asymptomatic ICA stenosis \u2265 70%.\n\n3. The patient has not undergone carotid endarterectomy (CEA) yet, so he would be indicated for CEA according to the American Heart Association criteria.\n\n4. There is no information provided about the patient's functional independence or modified Rankin score, so we cannot determine if he meets that inclusion criteria.\n\n5. There is also no information provided about whether the patient has a sufficient temporal bone window for TCD monitoring or if he has signed an informed consent.\n\nBased on the available information, the patient potentially meets some of the key inclusion criteria, but there is not enough information to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "772": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe has symptoms of dizziness and frequent headaches, which could be indicative of ischemic heart disease, meeting the criteria of \"Symptomatic ischemic heart disease (CCS class 1-4 , Braunwald class IB, IC, IIB, IIC,IIIB,IIIC) and/or objective evidence of myocardial ischemia.\"\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40% and 50%, meeting the criteria of \"Target lesion stenosis is >50% and <100%.\"\n\nThe lesions appear to be de novo (new) lesions, meeting the criteria of \"Target lesions are de novo.\"\n\nThe lesions are located in the internal carotid arteries, which are major epicardial vessels, meeting the criteria of \"Target lesion located in a major epicardial coronary vessel with reference of \u2265 2.5 - \u2264 3.5mm in diameter (by visual estimation).\"\n\nBased on the information provided, it seems that the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "773": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"diagnosed by a neurologist, with headache characteristics as established by the International Headache Society\"\nThe patient note does not explicitly mention a diagnosis of tension-type headache by a neurologist, but it does state that the patient presents with frequent headaches.\n\n2. \"Controlled pharmacologically\"\nThe patient note does not mention any medication being taken for the headaches.\n\nSince there is no clear information about the patient being diagnosed with tension-type headache by a neurologist or being on medication for it, there is insufficient information to determine eligibility based on the given inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "774": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u2265 18 years old.\n\nHowever, the patient does not have cervical or vaginal cancer. The trial is specifically for \"newly diagnosed stage IB2 (> 4 cm), II, IIIB or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix (FIGO 2009) or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina\".\n\nThe patient has carotid artery stenosis, dizziness, and frequent headaches, which are not relevant to the inclusion criteria of this cervical/vaginal cancer trial.\n\nTherefore, based on the information provided, this patient does not meet the key inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "775": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a male patient.\n\n2. The patient has no diagnosis of prostate cancer mentioned, so he does not meet the inclusion criteria of \"locally advanced or metastatic prostate cancer or high-risk prostate cancer.\"\n\n3. The patient has no mention of being scheduled to start androgen deprivation therapy (ADT) for at least one year.\n\n4. The patient has a family history of coronary artery disease (CAD), which could potentially meet the inclusion criteria of \"history of ischaemic heart disease.\" However, the patient himself does not have a confirmed diagnosis of ischemic heart disease.\n\n5. There is no mention of the patient's life expectancy or performance status.\n\nBased on the information provided, the patient does not meet the key inclusion criteria of having prostate cancer and being scheduled for ADT. Additionally, there is insufficient information to determine if he meets the other inclusion criteria related to cardiovascular history and performance status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "776": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >=18 years old.\n\n2. The patient does not have a diagnosis of multiple sclerosis, so he does not meet that inclusion criteria.\n\n3. The patient has severe hypercholesterolemia with an LDL-C of 545 mg/dL, which is well above the required levels in the inclusion criteria (>=160 mg/dL for heterozygous FH, >=130 mg/dL for other cases).\n\n4. The patient has no reported use of lipid-lowering medications, so he meets the criteria of not being adequately controlled with conventional lipid-modifying therapies.\n\n5. The patient has carotid artery stenosis based on the ultrasound findings, which qualifies as cardiovascular disease under inclusion criteria D.\n\n6. None of the exclusion criteria appear to apply based on the information given.\n\nTherefore, this patient meets the key inclusion criteria of having severe hypercholesterolemia not adequately controlled, as well as cardiovascular disease, while not meeting any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "777": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being > 18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which suggests he is undergoing or being considered for carotid endarterectomy or stenting.\n\n3. There is no mention of previous carotid artery surgery, cervical radiation, impaired consent capacity, contraindication to MRI scans, or prisoner status, which are the exclusion criteria.\n\n4. The patient appears to meet all the inclusion criteria for patients and does not seem to meet any of the exclusion criteria.\n\nTherefore, based on the information provided in the patient note and the inclusion/exclusion criteria of the clinical trial, this patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "778": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The trial is studying the pharmacokinetic properties of macitentan, which is a medication used to treat pulmonary arterial hypertension.\n\n2. The patient note does not mention pulmonary arterial hypertension or any other condition that would require treatment with macitentan.\n\n3. The inclusion criteria specifically state that participants should be healthy adults, whereas the patient note describes a 46-year-old man with dizziness, frequent headaches, and carotid artery stenosis.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "779": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has no other cardiovascular risk factors and is physically active.\n\nThe key findings are:\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL (normal)\n- Normal fasting glucose and triglyceride levels\n- No use of lipid-lowering medications\n- Carotid artery ultrasound showing severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA)\n- Presence of carotid artery plaques\n\nThe clinical trial is looking at subclinical atherosclerosis in individuals free of clinical manifested arterial atherosclerotic disease.\n\nGiven the patient's very high LDL-C level, carotid artery stenosis, and presence of plaques, he likely has subclinical atherosclerosis despite being asymptomatic for arterial atherosclerotic disease.\n\nTherefore, based on the inclusion criteria, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "780": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria (no specific age cutoff given).\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of \"Documented stenotic atherosclerotic lesion located at carotid bifurcation and / or proximal internal carotid artery (ICA)\".\n\nThe patient is described as symptomatic with dizziness and frequent headaches. While not explicitly stated if these symptoms are related to the carotid stenosis, it can be reasonably inferred that they are ipsilateral symptoms within 6 months, meeting the criteria \"Subject is either (A) symptomatic within 6 months of procedure, with an ipsilateral carotid stenosis \u2265 50% by angiography\".\n\nThe stenosis location and severity suggest a stent length \u2264 40mm could cover the lesion.\n\nThe reference vessel diameters of 4.0-7.0mm are not explicitly given but can be reasonably inferred from the peak systolic velocities provided.\n\nNo information is given about landing zones for filter deployment or patient willingness for follow-up visits and consent.\n\nOverall, based on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "781": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Man with transient ischemic attack or recent ischemic stroke (<15j) in the carotid territory, confirmed by MRI\n- The patient note mentions that the patient presented with dizziness and frequent headaches, but does not specify if they had a transient ischemic attack or recent ischemic stroke confirmed by MRI.\n\n2. Man with carotid stenosis > 50% on the side of stroke\n- The patient note states that the patient had severe stenosis in the left internal carotid artery (LICA), which would satisfy this criteria.\n\n3. Male candidate for carotid endarterectomy\n- The patient note does not mention if the patient is a candidate for carotid endarterectomy.\n\n4. Subject affiliated or beneficiary of a social security scheme\n- There is no information provided about the patient's insurance or social security status.\n\n5. Informed written consent\n- There is no mention of whether the patient provided informed written consent.\n\nBased on the information provided in the patient note, the patient meets one of the inclusion criteria (carotid stenosis > 50%), but there is not enough information to determine if they meet the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "782": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial \"MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)\" step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 40-60 years specified in the inclusion criteria.\n\nHe has elevated LDL-C level of 545 mg/dL and no history of coronary heart disease or myocardial infarction, which aligns with the inclusion criteria for patients with familial hypercholesterolemia.\n\nHowever, there is no mention of an identified genetic mutation (LDL-R, ApoB, PCSK9) in the patient note, which is required for inclusion in the trial.\n\nAdditionally, the patient does not have any of the specified high cardiovascular risk factors listed in the inclusion criteria, such as smoking, family history of premature CHD, metabolic syndrome, hypertension, or tendon xanthoma.\n\nThe patient does not have diabetes mellitus or uncontrolled hypertension, which are exclusion criteria.\n\nThere is no information provided about the patient's renal function, claustrophobia, metallic devices, or previous use of Amgen products, which are also exclusion criteria.\n\nBased on the available information, there is insufficient evidence to determine if the patient meets the inclusion criteria for the clinical trial, specifically regarding the genetic mutation and high cardiovascular risk factors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "783": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being greater than 40 years old.\n\nHe has no documented HIV infection, which is an inclusion criteria for this trial.\n\nHe does have dyslipidemia, with an LDL-C of 545 mg/dL and HDL-C of 53 mg/dL, meeting that inclusion criteria.\n\nHis fasting triglyceride level of 158 mg/dL meets the criteria of being \u2264600 mg/dL.\n\nHowever, there is no mention of the patient having documented cardiovascular disease or other listed risk factors like diabetes, smoking, or hypertension.\n\nBased on the information provided, the patient does not clearly meet the criteria of having moderate or high cardiovascular disease risk as defined in the inclusion criteria.\n\nTherefore, there is insufficient information to determine if the patient is eligible for this clinical trial targeting HIV patients with cardiovascular disease risk.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "784": {
        "output": "To determine the patient's eligibility for the Clear-Road Trial, let's go through the inclusion criteria one by one:\n\n1. High risk for carotid endarterectomy due to anatomical or co-morbid conditions and either:\n   - has neurological symptoms and \u2265 50% stenosis via angiography, or\n   - is asymptomatic and has \u2265 80% stenosis via angiography.\n\nThe patient has severe stenosis (>50%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Additionally, the patient has neurological symptoms of dizziness and frequent headaches. Therefore, this criterion is met.\n\n2. Target lesion located in the distal common carotid artery (CCA), internal carotid artery (ICA), or carotid bifurcation.\n\nThe patient has stenosis in the left and right internal carotid arteries, which meets this criterion.\n\n3. Arterial segment to be stented has a diameter between 4mm and 9mm.\n\nThere is no information provided about the diameter of the arterial segment to be stented. However, since the patient meets the other criteria, we can assume that this criterion is also met.\n\n4. Age \u2265 18 years.\n\nThe patient is 46 years old, which meets this criterion.\n\n5. Life expectancy > 12 months from the date of the index procedure.\n\nThere is no information provided about the patient's life expectancy, but since the patient meets the other criteria, we can assume that this criterion is also met.\n\n6. Provides a signed, IRB (Institutional Review Board) / IEC (Institutional Ethical Committee) approved informed consent form prior to participation.\n\nThis criterion cannot be assessed based on the provided information.\n\n7. Willing and able to comply with follow-up requirements.\n\nThis criterion cannot be assessed based on the provided information.\n\nBased on the available information, the patient meets the key inclusion criteria for the Clear-Road Trial, such as having neurological symptoms and significant carotid artery stenosis, being at high risk for carotid endarterectomy, and meeting the age requirement.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "785": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His LDL-C level is 545 mg/dL, which is very high, indicating potential atherosclerotic disease.\n3. Carotid ultrasound revealed severe stenosis (>70%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n4. The clinical trial is studying carotid endarterectomy (CEA) and carotid artery stenting (CAS) in patients with carotid stenosis > 70%.\n\nBased on the inclusion criteria of the clinical trial, which requires patients to have carotid stenosis > 70%, and the patient's ultrasound findings of severe stenosis (>70%) in the LICA, this patient meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "786": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Provision of informed consent prior to any study-specific procedures: The patient note does not mention whether informed consent was provided, so this criterion cannot be evaluated.\n\n2. Male aged \u226545 and <70 years or female aged \u226555 and <70 years: The patient is a 46-year-old man, so he meets this criterion.\n\n3. Subjects with only hypertension (as defined blood pressure \u2265140/90 mmHg or on antihypertensive treatment) and age as CVD risk factors and subjects without hypertension who have 3 or more other risk factors (including age) must have Fasting LDL C of \u2265120 mg/dL (3.1 mmol/L) and <160 mg/dL (4.1mmol/L); Subjects without hypertension who have fewer than 3 other risk factors (including age) must have Fasting LDL-C of \u2265120 mg/dL (3.1 mmol/L) and <190 mg/dL (4.9 mmol/L): The patient's LDL-C level is 545 mg/dL, which is higher than the specified range for both cases.\n\n4. Triglycerides <500 mg/dL (5.65 mmol/L) at Visit 1: The patient's triglyceride level is 158 mg/dL, which meets this criterion.\n\n5. HDL-C levels \u226460 mg/dL (1.6 mmol/L) at Visit 1: The patient's HDL-C level is 53 mg/dL, which meets this criterion.\n\n6. Maximum IMT \u22651.2 mm and <3.5 mm at any location in the carotid ultrasound scans conducted at both Visit 2 and Visit 3: The patient note does not provide information about the carotid intima-media thickness (IMT) measurements, so this criterion cannot be evaluated.\n\n7. Willing to follow all study procedures including study visits, fasting blood draws, and compliance with study treatment regimen: The patient note does not mention the patient's willingness to follow the study procedures, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria but does not meet the LDL-C criterion. Additionally, there is not enough information to evaluate several other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "787": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-30 years old for the clinical trial.\n\n2. However, the patient note does not explicitly state that the patient is a healthy volunteer. The note mentions that the patient has dizziness, frequent headaches, and carotid artery stenosis.\n\n3. The inclusion criteria for the clinical trial specifically state \"Healthy volunteers, male and/or female aged 18-30 years.\"\n\nSince the patient does not appear to be a healthy volunteer based on the information provided in the note, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "788": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1) Type 1 or 2 diabetes: The patient note does not mention if the patient has diabetes, so this criterion cannot be evaluated.\n\n2) Blood glucose controlled well, no effective with oral PDE-5i: There is no information about blood glucose control or use of PDE-5 inhibitors in the patient note.\n\n3) Have a consistent partner willing to engage in sexual activity more than twice per month during the study: No information provided.\n\n4) Males age 20-65 years: The patient is a 46-year-old man, so he meets this criterion.\n\n5) IIEF-5 score is under 16: No IIEF-5 score is provided in the patient note.\n\n6) Penile arterial insufficiency or venous leakage (doppler): PSV <25 cm/sec, or PSV >25 cm/sec, EDV>5cm/sec, RI<0.75: The patient note provides doppler ultrasound values of LICA PSV 208.5 cm/s, LICA EDV 54.5 cm/s, RICA PSV 91.72 cm/s, and RICA EDV 37.37 cm/s. These values do not meet the criteria for penile arterial insufficiency or venous leakage.\n\n7) HbA1c is between 6.5% 10%: No HbA1c value is provided.\n\n8) Physical examination with no abnormalities: The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which would likely be considered abnormalities.\n\n9) Willing to consent to participate in the study follow-up: No information provided.\n\n10) Willing to limit alcohol intake and eliminate use of recreational drugs for sexual encounters: No information provided.\n\nBased on the information given in the patient note, there is insufficient information to determine if the patient meets several of the key inclusion criteria, such as having diabetes, blood glucose control, IIEF-5 score, HbA1c value, and willingness to participate in the study. Additionally, the patient has carotid artery stenosis, which would likely be considered an abnormality on physical examination and could potentially exclude the patient from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "789": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the \"Adult patients\" inclusion criteria.\n\n2. However, the patient does not have pulmonary arterial hypertension. The note mentions carotid artery stenosis and high LDL cholesterol levels, but no mention of pulmonary hypertension.\n\n3. Since the patient does not have the target disease (pulmonary arterial hypertension) required for this clinical trial, he does not meet the key inclusion criteria.\n\nTherefore, based on the information provided in the patient note, this patient would not be eligible for the \"Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "790": {
        "output": "To determine the patient's eligibility for the clinical trial \"Effect of Rosuvastatin Therapy on HDL2 Level\", let's go through the inclusion criteria one by one:\n\n1. Patients with CAD undergoing quantitative coronary angiography:\nThe patient note mentions that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which suggests the presence of carotid artery disease (CAD). However, it is not explicitly stated that the patient underwent quantitative coronary angiography.\n\n2. Patients with hyperlipidemia: TG(Triglyceride)>1.6mmol/L and/or TC(total cholesterol)>4.6mmol/L, and they didn't take antilipemic agents or steroid hormone at least three months before this trial:\nThe patient's triglyceride level (158 mg/dL or 1.78 mmol/L) is above the specified threshold of 1.6 mmol/L, indicating hyperlipidemia. Additionally, the patient reported no use of lipid-lowering medications.\n\n3. Patients between the ages of 30 and 75 years, the functions of liver or kidney are not severe:\nThe patient's age of 46 years falls within the specified age range of 30 to 75 years. There is no information provided about the patient's liver or kidney function.\n\nBased on the available information, the patient meets the inclusion criteria for hyperlipidemia and age range. However, there is insufficient information to determine if the patient underwent quantitative coronary angiography or if their liver and kidney functions are not severely impaired.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 2
    },
    "791": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u22653 years to \u226450 years.\n\n2. The patient presents with dizziness and frequent headaches, but is reported to be in good general health with no major cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus. This suggests he may meet the criteria of \"good general health by medical history physical examination.\"\n\n3. There is no mention of clinically relevant abnormalities in blood pressure and heart rate.\n\n4. The patient has carotid artery stenosis, but there is no information provided about ECG results or QTc intervals to determine if he meets the criteria of \"No clinically relevant abnormalities in 12-lead ECG results.\"\n\nSince there is insufficient information about the patient's ECG results and QTc intervals, which are key inclusion criteria for this trial, I cannot definitively determine if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "792": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. The patient has high LDL-C levels (545 mg/dL) but normal fasting glucose and triglyceride levels. He is not taking any lipid-lowering medications.\n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is titled \"Exercise Rehabilitation in Veterans With PAD\" and is studying the effects of exercise rehabilitation or neuromuscular stimulation on leg blood flow, physical function, quality of life, and general health in patients with peripheral artery disease (PAD) who require revascularization.\n\n5. The inclusion criteria for the trial are:\n   - Diagnosis of peripheral arterial disease; or ankle-brachial index <0.9.\n   - Planned to undergo endovascular revascularization within 6 months.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial. The patient has carotid artery stenosis but does not have a diagnosis of peripheral artery disease or a planned endovascular revascularization procedure.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "793": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C 545 mg/dL (very high)\n- HDL-C 53 mg/dL (normal)\n- Normal fasting glucose and triglycerides\n- Not taking any lipid-lowering medications\n- Carotid ultrasound showed:\n    - Severe stenosis in left internal carotid artery (LICA)\n    - Moderate 40-50% stenosis in right internal carotid artery (RICA)\n    - Plaque in anterior and posterior walls of ICA and common carotid arteries\n\nThe clinical trial inclusion criteria are:\n1) Stable multi-vessel coronary artery disease diagnosed by angiography\n2) Left main disease >50% stenosis OR multi-vessel disease with >70% stenosis in 2+ coronary arteries\n3) At relative equipoise for at least 2 potential treatment options that are anatomically feasible and safe\n\nBased on the information provided, the patient does not have a confirmed diagnosis of multi-vessel coronary artery disease by angiography. The carotid ultrasound findings indicate carotid artery stenosis but do not definitively diagnose coronary artery disease.\n\nTherefore, there is insufficient information to determine if the patient meets the inclusion criteria for this specific clinical trial on treatment decisions for multi-vessel coronary artery disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "794": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n2. There is no mention of the patient having COPD or any other chronic respiratory disease, which is not part of the inclusion criteria.\n3. The patient's BMI is not provided, but the criteria specifies a BMI < 25 kg/m^2.\n4. The patient's height is not provided, but the criteria specifies a range of 158 - 190 cm.\n5. The patient's waist circumference is not provided, but the criteria specifies < 94 cm.\n6. There is no information about the patient's willingness to participate or ability to provide informed consent.\n7. There is no information about the patient's Slovenian social insurance status.\n8. There is no information about the patient's English language fluency.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all of the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "795": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. The patient has symptomatic carotid artery stenosis, as evidenced by the dizziness, headaches, carotid bruit, and ultrasound findings of severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\n3. The patient meets the criteria of having a carotid plaque \u22652 mm on duplex ultrasound.\n\n4. There is no information provided about whether the patient is scheduled for carotid endarterectomy or conservative therapy.\n\n5. The patient has provided informed consent by participating in this study.\n\nBased on the information provided, the patient meets the inclusion criteria for age, symptomatic carotid artery stenosis, and carotid plaque size. However, there is not enough information to determine if the patient is scheduled for carotid endarterectomy or conservative therapy, which is one of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "796": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The inclusion criteria for the clinical trial are:\n   - Adults with ST-elevation myocardial infarction (STEMI) diagnosed within the last 12 hours\n   - Included in the Romanian National Programme of Primary Percutaneous Revascularisation (for whom primary PCI is recommended)\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as there is no mention of a STEMI or myocardial infarction diagnosis. The patient's presentation and findings are related to carotid artery stenosis and dyslipidemia, but not an acute myocardial infarction.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "797": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of >21 and \u226480 years specified in the inclusion criteria.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meets the criterion of being diagnosed with carotid artery stenosis.\n\nThe patient is considered asymptomatic, as there is no mention of any symptoms related to the carotid stenosis. The inclusion criteria state that asymptomatic patients must have carotid stenosis \u226580%, which the patient meets with severe stenosis in the LICA.\n\nThe target lesion is located in the carotid arteries, which meets the criterion of being located at the carotid bifurcation and/or proximal ICA.\n\nThere is no mention of the patient having multiple lesions, so it can be assumed that the patient has a single target lesion, meeting that criterion.\n\nThe patient's vessel diameters are not provided, so it is unclear if they meet the criterion of having reference diameters between 3.0 mm and 9.0 mm at the target lesion.\n\nThere is no information provided about the patient meeting any of the anatomic or co-morbid high-risk conditions listed in the inclusion criteria.\n\nBased on the information provided, the patient meets most of the key inclusion criteria, except for the vessel diameter and high-risk condition requirements, which cannot be determined from the given information.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "798": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying changes in middle cerebral artery velocity and oxygen saturation of the brain during carotid endarterectomy.\n\n5. The inclusion criteria for the trial are:\n   - Patients awaiting carotid artery endarterectomy carried out in regional anesthesia\n   - Age over 18 years\n   - Both female and male patients\n   - Venous catheter and arterial catheter for invasive blood pressure monitoring\n   - Bilateral continuous measurement of middle cerebral arteries with Transcranial Doppler\n   - Bilateral continuous measurement of cerebral saturation with INVOS monitor\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial as he is a 46-year-old man with severe carotid artery stenosis awaiting carotid endarterectomy, and the trial can likely accommodate the necessary monitoring equipment.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "799": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid artery stenosis - severe in the left internal carotid artery (LICA) and moderate (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the carotid arteries.\n\nThe clinical trial is recruiting patients undergoing percutaneous coronary intervention (PCI) for coronary lesions.\n\nBased on the inclusion criteria of the trial, which requires patients undergoing PCI for coronary lesions, this patient does not seem to meet the criteria as the note does not mention any coronary lesions or planned PCI. The carotid artery stenosis and high LDL-C suggest cardiovascular disease, but not specifically coronary artery disease requiring PCI.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "800": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL (normal)\n- Normal fasting glucose and triglyceride levels\n- Not taking any lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe clinical trial is studying familial hypercholesterolemia (FH) in Spain. The inclusion criteria are:\n- Index cases with genetic diagnosis of FH \n- Relatives over 15 years old with genetic diagnosis of FH\n- First-degree relatives of those with genetic diagnosis\n\nWhile the patient has extremely high LDL-C levels suggestive of FH, there is no mention of a genetic diagnosis of FH for the patient or any relatives.\n\nTherefore, based on the provided information:\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "801": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe presents with dizziness and frequent headaches, which could be symptoms of a recent ischemic stroke or TIA.\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which suggests intracranial atherosclerotic stenosis (ICAS).\n\nThe patient has a family history of CAD, which is an atherosclerotic risk factor.\n\nThere is no mention of coexistent \u226550% extracranial carotid or vertebral artery stenosis, potential cardio-aortic embolic sources, or time since the ischemic event.\n\nBased on the available information, this patient appears to meet the key inclusion criteria for the clinical trial on stroke mechanism evolution in intracranial atherosclerotic stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "802": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria (\u226518 years) for the clinical trial.\n\n2. The patient does not have a diagnosis of multiple sclerosis or lower urinary tract symptoms, which are required for the example clinical trial. Therefore, this patient note is not relevant for that particular trial.\n\n3. However, the patient note mentions that the patient has an abdominal perimeter \u2265102 cm (based on the carotid artery stenosis findings), high LDL-C (545 mg/dL), and low HDL-C (53 mg/dL), which meet some of the inclusion criteria for the \"Grape and Pomegranate Polyphenols in Postprandial Glucose and Related Parameters\" clinical trial.\n\n4. While the patient's fasting glucose and triglyceride levels are within normal limits, the inclusion criteria state that subjects presenting some or several of the listed characteristics will be prioritized.\n\nTherefore, based on the information provided in the patient note, this patient would likely be eligible for the \"Grape and Pomegranate Polyphenols in Postprandial Glucose and Related Parameters\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "803": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C level of 545 mg/dL (very high)\n- HDL-C level of 53 mg/dL (normal)\n- Normal fasting glucose and triglyceride levels\n- Not taking any lipid-lowering medications\n- Systolic murmur in the neck radiating to the skull\n- Severe stenosis (>50%) in the left internal carotid artery (LICA)\n- Moderate stenosis (40-50%) in the right internal carotid artery (RICA)\n\nThe clinical trial inclusion criteria are:\n1. Symptomatic patients with internal carotid artery stenosis >50%\n2. Asymptomatic patients with internal carotid artery stenosis >60% \n3. Anatomy of internal carotid artery applicable for stent implantation and use of embolic protection device\n\nBased on the information provided, the patient meets criteria 1 as they are symptomatic (dizziness and headaches) and have severe stenosis (>50%) in the LICA.\n\nThere is no information provided about the anatomy of the internal carotid arteries and whether they are suitable for stent implantation and embolic protection device use. However, this criterion is not a strict requirement for eligibility.\n\nTherefore, the patient appears to be eligible for the clinical trial based on the available information.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "804": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18-35 years old.\n\nThere is no information provided about his birth history (preterm or full-term), so we cannot determine if he meets that inclusion criteria.\n\nHis blood pressure is not explicitly stated, but he is described as having dizziness and frequent headaches, which could be related to elevated blood pressure. However, without a specific blood pressure measurement, we cannot confirm if he meets the criteria of 24-hour awake ABP greater than 115/75 mmHg.\n\nThere is no information provided about his willingness to give informed consent, ability to access and use a computer/internet, or willingness to complete the study requirements and attend study visits.\n\nBased on the information provided, there is not enough evidence to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "805": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18 or older.\n\n2. The patient is being referred for evaluation of coronary artery disease, as evidenced by the carotid artery stenosis findings and the plan for cardiac CT examination.\n\nTherefore, based on the inclusion criteria provided, this patient appears to be eligible for the clinical trial on using cardiogoniometry for detecting coronary artery disease by CT angiography.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "806": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >18 years old.\n\n2. The patient has severe stenosis (\u226550%) in the left internal carotid artery, which meets the criteria of having a carotid plaque \u226550%.\n\n3. The patient is not explicitly stated to be symptomatic (having had a recent ischemic stroke) or asymptomatic. There is no mention of a recent stroke.\n\n4. The other criteria like ability to give informed consent and being affiliated with social security are not mentioned in the patient note.\n\nSince there is not enough information to determine if the patient is symptomatic or asymptomatic, and some other criteria are not mentioned, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "807": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. The note does not mention that the patient is scheduled for a total knee arthroplasty, which is one of the inclusion criteria for the trial.\n\nThe inclusion criteria for the trial are:\n1. Patients scheduled for primary total knee arthroplasty\n2. American Society of Anesthesiologists (ASA) physical status I-III\n3. Mentally competent and able to give consent for enrollment in the study\n\nSince the patient note does not indicate that the patient is scheduled for a total knee arthroplasty, there is not enough information to determine if the patient meets the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "808": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Single Shot vs Catheter Infraclavicular Brachial Plexus Block After Distal Radius Fracture Repair\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of a distal radius fracture or any planned surgery for fracture repair.\n\nThe inclusion criteria for the trial specifically state that eligible participants should be \"Patients scheduled for open reduction and internal fixation of a distal radius fracture\".\n\nSince the patient note does not indicate that the patient has a distal radius fracture or is scheduled for such a surgery, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "809": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 20-65 years.\n\n2. The patient has no history of diabetes mentioned, which is one of the inclusion criteria for this trial.\n\n3. There is no information provided about the patient's IIEF-5 score, which is required to be under 16 for inclusion.\n\n4. The patient has carotid artery stenosis, but the inclusion criteria are specifically looking for penile arterial insufficiency or venous leakage, with certain Doppler criteria. The patient's Doppler findings are not related to the penile vasculature.\n\n5. There is no information about the patient's HbA1c level, which needs to be between 6.5%-10% per the inclusion criteria.\n\n6. There is no mention of the patient's willingness to participate in follow-up, limit alcohol, or eliminate recreational drug use for sexual encounters.\n\nBased on the information provided, there is insufficient evidence to determine if the patient meets all of the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "810": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria (\u226518 years) for the trial.\n\nHe has dizziness and frequent headaches, which could be symptoms of carotid artery stenosis, but the note does not explicitly state if he has had a transient ischemic attack, amaurosis fugax, or minor nondisabling stroke within 180 days.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA) based on ultrasound findings.\n\nFor symptomatic patients, the inclusion criteria require \u226550% stenosis by angiography, \u226570% by ultrasound, or \u226570% by CT/MR angiography if ultrasound is 50-69%.\n\nFor asymptomatic patients, the criteria require \u226560% stenosis by angiography, \u226570% by ultrasound, or \u226580% by CT/MR angiography if ultrasound is 50-69%.\n\nSince the patient has severe (likely \u226570%) stenosis in the LICA based on ultrasound, he would meet the criteria for an asymptomatic patient.\n\nHowever, it is unclear from the note if he has had any recent symptoms that would qualify him as a symptomatic patient.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial based on symptom status).",
        "label": 1
    },
    "811": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and severe stenosis in the left internal carotid artery (LICA) as well as moderate stenosis in the right internal carotid artery (RICA).\n\nThe clinical trial is titled \"Norwegian Carotid Plaque Study\" and aims to assess atherosclerotic carotid artery disease using advanced ultrasound techniques.\n\nThe inclusion criteria are:\n1) Symptomatic carotid artery disease\n2) Asymptomatic carotid artery disease\n\nGiven that the patient has severe stenosis in the LICA and moderate stenosis in the RICA, he meets the inclusion criteria for having symptomatic carotid artery disease (dizziness and headaches could be symptoms).\n\nThere is no information provided about exclusion criteria, so based on the inclusion criteria alone, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "812": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of >18 years.\n\nThe patient is male, which meets the gender criteria. \n\nIt is not explicitly stated whether the patient provided informed consent, so I cannot confirm that criteria.\n\nThe patient has severe stenosis (>75%) in the left internal carotid artery, which meets the criteria of symptomatic carotid stenosis >75%.\n\nBased on the information provided, the patient appears to meet at least 3 out of the 4 inclusion criteria. However, since informed consent is not mentioned, I cannot definitively conclude eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to lack of information on informed consent).",
        "label": 1
    },
    "813": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which indicates he is undergoing open surgical revascularization for internal carotid stenosis.\n\n3. The patient has provided written informed consent (not explicitly stated, but can be assumed for this exercise).\n\nSince the patient meets all the inclusion criteria listed for this clinical trial, the trial-level eligibility assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "814": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being over 18 years old.\n\nHe has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery caused by atherosclerotic plaque, which meets the criteria of \"Carotid artery stenosis caused by atherosclerotic plaque\".\n\nThe stenosis was diagnosed using carotid duplex ultrasonography, which meets the criteria of \"Severe carotid artery stenosis confirmed by [...] carotid duplex ultrasonography\".\n\nThere is no information provided about whether the patient provided informed consent, but we can assume that this would be obtained if the patient was enrolled in the trial.\n\nBased on the information provided, this patient appears to meet all of the stated inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "815": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe key findings are:\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis (40-50%) in the right internal carotid artery (RICA)\n- Presence of atherosclerotic plaque in the carotid arteries\n\nThe clinical trial is investigating the use of the Enterprise stent system for treating carotid artery stenosis in patients with atherosclerotic ischemic stroke.\n\nThe inclusion criteria are:\n1) Atherosclerotic plaque-caused carotid artery stenosis\n2) Severe carotid artery stenosis (unilateral stenosis > 70%) diagnosed by angiography\n3) Age 18-75 years\n4) Either sex\n5) Provision of informed consent\n\nAssessing the patient against the inclusion criteria:\n1) The patient has atherosclerotic plaque-caused carotid artery stenosis (meets criteria)\n2) The patient has severe stenosis (>70%) in the LICA (meets criteria)\n3) The patient is 46 years old (meets criteria)\n4) The patient is male (meets criteria)\n5) Informed consent is not mentioned (cannot be assessed)\n\nBased on the available information, the patient meets the key inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "816": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Comparison Between 3 Solutions of Bupivacaine of Adductor Canal Block for Anterior Cruciate Ligament Reconstruction\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of any knee injury or planned anterior cruciate ligament reconstruction surgery, which is the focus of the clinical trial.\n\nThe inclusion criteria for the trial specify:\n\n1. American ASA I, II (physical status classification system)\n2. Body mass index \u2264 35 kg/m^2\n3. Surgery time \u2264 2 hours\n\nSince the patient note does not provide any information related to these criteria or indicate that the patient is undergoing anterior cruciate ligament reconstruction surgery, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "817": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u2265 18 years of age.\nThe patient is 46 years old, so this criterion is met.\n\n2. Patient is currently on atorvastatin or simvastatin or rosuvastatin or statin na\u00efve (no statins in the last 30 days).\nThe patient reported no use of lipid-lowering medications, so they are statin na\u00efve. This criterion is met.\n\n3. The patient has unilateral or bilateral carotid artery stenosis that is considered severe (carotid artery diameter reduction \u2265 70%) as defined by:\n   - Peak systolic velocity of at least 230 cm/s plus at least one of these:\n     - End diastolic velocity \u2265 100 cm/s OR\n     - CTA showing \u2265 70% stenosis OR\n     - MRA showing \u2265 70% stenosis\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) with a peak systolic velocity of 208.5 cm/s and an end-diastolic velocity of 54.5 cm/s. While the peak systolic velocity is below 230 cm/s, the end-diastolic velocity is above 100 cm/s, meeting this part of the criterion.\n\n4. This stenosis has not caused any stroke, transient cerebral ischemia, or other relevant neurological symptoms in the past.\nThe patient note does not mention any previous stroke or neurological symptoms, so this criterion is met.\n\n5. The patient's attending doctor(s) (PMD, cardiologist, vascular/neurosurgeon) AND the patient have decided to proceed with a CEA to treat the patient's severe carotid stenosis.\nThe patient note does not provide information about the decision to proceed with a CEA, so this criterion cannot be evaluated.\n\n6. The patient has no known circumstance or condition likely to preclude 1 year follow-up or adherence to the study protocol.\nThe patient note does not provide information about the patient's ability to follow up or adhere to the study protocol, so this criterion cannot be evaluated.\n\n7. The patient is independent in their Activities of Daily Living at baseline.\nThe patient note does not provide information about the patient's independence in Activities of Daily Living, so this criterion cannot be evaluated.\n\n8. Patient has the ability to provide informed consent.\nThe patient note does not provide information about the patient's ability to provide informed consent, so this criterion cannot be evaluated.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria but there is not enough information to determine if they meet all of the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "818": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL-C levels (545 mg/dL) but normal HDL-C, fasting glucose, and triglyceride levels. He is not on any lipid-lowering medications.\n\nThe key findings are the severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA) based on ultrasound findings.\n\nThe clinical trial is studying the safety and effectiveness of transcarotid artery revascularization (TCAR) compared to carotid endarterectomy (CEA) in patients undergoing these procedures.\n\nThe inclusion criteria state that all patients undergoing TCAR or CEA, both standard surgical risk and high surgical risk as defined by CMS criteria, are eligible.\n\nGiven the patient's carotid artery stenosis findings, he would likely be a candidate for either TCAR or CEA to treat the carotid stenosis. As the trial includes all patients undergoing these procedures regardless of surgical risk, this patient appears to meet the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "819": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid artery stenosis - severe in the left internal carotid artery (LICA) and moderate (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the carotid arteries.\n\nThe clinical trial is looking at gene polymorphism associated with macroangiopathy (large blood vessel disease) in type 2 diabetes patients.\n\nThe inclusion criteria for the trial are:\n1) Clinical coronary heart disease (CHD) like angina or myocardial infarction\n2) Coronary atherosclerosis confirmed by angiography\n3) Cerebral infarction diagnosed by CT scan\n4) Common carotid artery intima-media thickness \u22651.2 mm on ultrasound\n5) Extensive irregular stenosis or obstruction of lower extremity arteries\n\nBased on the patient note, the patient meets criteria 4 (carotid artery stenosis and plaque observed on ultrasound). However, there is no mention of the other criteria like coronary artery disease, cerebral infarction, or lower extremity artery disease.\n\nTherefore, there is insufficient information to determine if the patient is fully eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "820": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being > 18 years old.\n\n2. The patient presented with dizziness and frequent headaches, which are not necessarily indicative of an out-of-hospital cardiac arrest (OHCA) of assumed cardiac etiology. \n\n3. There is no information provided about the patient's first recorded heart rhythm during a cardiac arrest event.\n\n4. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests underlying cardiovascular disease but does not confirm an OHCA event.\n\nBased on the information provided in the patient note, there is insufficient evidence to determine if the patient meets all the inclusion criteria for this clinical trial, which requires an OHCA of assumed cardiac etiology and documented first recorded heart rhythm.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "821": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he does not have other cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus, and is physically active.\n\nHis lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose (85 mg/dL), and triglycerides (158 mg/dL). He is not taking any lipid-lowering medications.\n\nPhysical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\nThe clinical trial is recruiting HIV-infected patients aged \u226545 years with at least two cardiovascular risk factors, who are on antiretroviral therapy (ART) with suppressed viral load (<50 copies/mL) for at least 12 months, asymptomatic for cardiac symptoms, and on stable ART for more than 6 months.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial as he is not HIV-infected and does not have at least two cardiovascular risk factors (apart from high LDL-C).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "822": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >18 years old.\n\n2. The patient does not have a diagnosis of diabetes mentioned in the note. This is a key inclusion criteria that is not met.\n\n3. While the patient has carotid artery stenosis and plaque buildup described from ultrasonography, there is no mention of a previous carotid duplex ultrasound done specifically in 2012 as required.\n\nSince the patient does not have a diagnosis of diabetes stated, which is a key inclusion criteria, and there is no evidence they had the required carotid ultrasound in 2012, there is insufficient information to determine eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "823": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL-C levels (545 mg/dL) but normal fasting glucose and triglyceride levels. Ultrasonography revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nThe clinical trial is titled \"Coronary Revascularization Assessed by Stress PET\" and aims to assess the effect of mechanical revascularization (PCI or CABG) on regional absolute myocardial blood flow during stress (sMBF) as measured by Positron Emission Tomography (PET).\n\nThe inclusion criteria for the trial are:\n1. Individuals who undergo cardiac stress PET and subsequently undergo coronary angiography and mechanical revascularization.\n2. Adults \u226518 and able to give informed consent.\n\nBased on the information provided, the patient meets the age criterion (\u226518 years old) and is likely to undergo coronary angiography and mechanical revascularization given the severe carotid artery stenosis. However, it is not explicitly stated whether the patient has undergone or will undergo a cardiac stress PET, which is a requirement for inclusion in the trial.\n\nTherefore, there is not enough information to determine if the patient is eligible or not for this specific trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "824": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is focused on revascularization methods for occlusive lesions in the femoral artery, specifically comparing remote endarterectomy and stenting of the superficial femoral artery.\n\n5. The inclusion criteria for the trial are:\n   - Patients with occlusive lesions of C and D type femoral artery\n   - Patients with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford)\n   - Patients who consent to participate in the study\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as the patient's condition is related to carotid artery stenosis and not occlusive lesions of the femoral artery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "825": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age between 25 and 65 years: The patient is 46 years old, which falls within this range.\n\n2. Waist circumference >88 cm for women and >102 cm for men: The patient's waist circumference is not provided, so we cannot determine if this criterion is met.\n\n3. Blood pressure: systolic \u2265 130 mmHg and diastolic \u2265 85 mmHg: The patient's blood pressure is not provided, so we cannot determine if this criterion is met.\n\n4. Fasting glucose level \u2265 110mg/dL: The patient's fasting glucose level is 85 mg/dL, which does not meet this criterion.\n\n5. Triglycerides: \u2265 150 mg/dL: The patient's triglyceride level is 158 mg/dL, which meets this criterion.\n\n6. HDL cholesterol \u226440 mg/dL in men and \u226450 mg/dL in women: The patient's HDL cholesterol level is 53 mg/dL, which does not meet this criterion.\n\nBased on the information provided, the patient does not meet all the inclusion criteria for this clinical trial. Specifically, the patient's fasting glucose level and HDL cholesterol level do not fall within the required ranges.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "826": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age inclusion criteria of 35-85 years old.\n\n2. The patient has a clinical diagnosis of peripheral arterial disease, as evidenced by the carotid artery stenosis and plaque buildup described in the patient note. This meets the inclusion criteria of having a clinical diagnosis of peripheral arterial disease.\n\n3. The patient's LDL-C level is 545 mg/dL, which is extremely high. The trial requires patients to either be on a statin for at least 6 months or be statin intolerant. The patient note does not mention statin use or intolerance.\n\n4. There is no information provided about the patient's ankle brachial index, which is required to be between 0.4-0.9 per the inclusion criteria.\n\nBased on the information provided, while the patient meets some of the inclusion criteria, there is not enough information to definitively determine eligibility due to the lack of ankle brachial index data and statin use/intolerance status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "827": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His LDL-C level is very high at 545 mg/dL, indicating hyperlipidemia.\n3. He has no other cardiovascular risk factors like smoking, high blood pressure, or diabetes.\n4. Neck auscultation revealed a systolic murmur, and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. The coronary artery disease was defined by one of the following criteria:\n   a) Based on WHO criteria in terms of elevations of cardiac enzymes, ECG, and clinical symptoms (angina, chest pressure, or shortness of breath)\n   b) Angiographic evidence of more than 50% stenosis in one or more major coronary arteries\n   c) Previous history of PCI or CABG\n\n2. The patient meets criterion (b) with the angiographic evidence of severe stenosis (>50%) in the LICA and moderate stenosis (40-50%) in the RICA.\n\nTherefore, based on the information provided, the patient meets the inclusion criteria for the clinical trial on the association study to evaluate the TFPI gene in CAD in Han Chinese.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "828": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 50 years or more for both cardiac and psychiatric subjects.\n\nHe has dizziness, frequent headaches, and a family history of CAD, but no other cardiovascular risk factors. His LDL-C level is very high at 545 mg/dL, indicating potential CAD. The carotid ultrasound also revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, confirming the presence of CAD.\n\nHowever, the patient does not report any psychiatric disorders like major depressive disorder, bipolar 1 disorder, or bipolar 2 disorder, which are required for inclusion as a psychiatric subject.\n\nBased on the information provided, the patient meets the inclusion criteria for cardiac subjects with known CAD, but does not meet the inclusion criteria for psychiatric subjects.\n\nThere is no information provided about any exclusion criteria that may apply to the patient.\n\nTherefore, based on the available information:\nTrial-level eligibility: 1) Not relevant.\n\nThe patient does not have sufficient information to qualify for the trial as a psychiatric subject, and while he may be eligible as a cardiac subject, there is not enough information provided to definitively determine his eligibility or exclusion.",
        "label": 0
    },
    "829": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. The note does not mention any upcoming wrist arthroscopy surgery or any condition related to the wrist.\n\nThe inclusion criteria for the trial specifically state that eligible participants should be \"Patients scheduled for wrist arthroscopy\" and have an ASA physical status of I-III.\n\nSince the patient note does not indicate that the patient is scheduled for wrist arthroscopy surgery, which is a key inclusion criterion, the patient cannot be considered eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "830": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18 and older.\n\n2. The patient does not have an infection after fracture fixation or prosthetic joint surgery. The note mentions carotid artery stenosis and high cholesterol levels, but no orthopedic device-related infection.\n\n3. There is no mention of Staphylococcus aureus infection in the patient note.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial titled \"Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients' Clinical Outcome in Orthopedic Device Related Bone Infections\".\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "831": {
        "output": "Based on the provided patient note and the clinical trial information, the patient does not meet the inclusion criteria for the trial titled \"Sono-ease Device for Internal Jaguar Vein Cannulation\". The trial is focused on patients who require internal jugular vein (IJV) catheterization, while the patient note describes a case of carotid artery stenosis with no mention of IJV catheterization.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "832": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur in the neck, radiating to the skull.\n\n4. Ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n5. The clinical trial is the \"Saint Luc Valve Registry,\" which is studying aortic stenosis, mitral regurgitation, and aortic regurgitation.\n\n6. The inclusion criteria for the trial are the presence of aortic stenosis, mitral regurgitation, or aortic regurgitation at the time of an echocardiography at the Cliniques Universitaires Saint Luc.\n\nBased on the information provided, the patient does not seem to have aortic stenosis, mitral regurgitation, or aortic regurgitation. The patient's condition appears to be related to carotid artery stenosis, which is not the focus of this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "833": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Endovascular treatment can be initiated within 6 hours of symptom onset.\n   - The note does not mention the time of symptom onset, so this criterion cannot be evaluated.\n\n2. ASPECTS of >=6 is diagnosed by two or more stroke physicians.\n   - There is no information about the ASPECTS score in the note.\n\n3. The end diastolic velocity in the common carotid arteries or internal carotid artery is evaluated by carotid duplex ultrasound\n   - The note mentions that carotid duplex ultrasound was performed, and it provides the end diastolic velocity values for the left and right internal carotid arteries (54.5 cm/s and 37.37 cm/s, respectively). This criterion is met.\n\n4. NIHSS score of >=6.\n   - The note does not mention the NIHSS score.\n\n5. Age>=18 years.\n   - The patient is 46 years old, so this criterion is met.\n\n6. Written informed consent is obtained.\n   - There is no information about informed consent in the note.\n\nSince some of the inclusion criteria cannot be evaluated based on the information provided in the patient note, the trial-level eligibility cannot be determined as either \"Eligible\" or \"Excluded\". Therefore, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "834": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe has high LDL-C levels of 545 mg/dL, which is well above the required \u226570 mg/dL for subjects unable to tolerate high-intensity statin therapy.\n\nThe patient reported no use of lipid-lowering medications, indicating he is intolerant or unable to take statins.\n\nUltrasonography revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, with plaque observed, meeting the criteria of having significant carotid artery plaque with maximum wall thickness \u22652 mm.\n\nWhile the MRI results are not provided, the presence of plaque suggests the patient likely has a LRNC (lipid-rich necrotic core) that would be visible on the baseline MRI scan, as required.\n\nThere is no information provided about the patient's medical stability or willingness to participate and sign informed consent.\n\nOverall, based on the information given, the patient appears to meet most of the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "835": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%. This suggests multivessel coronary artery disease.\n\n3. The patient is experiencing symptoms of dizziness and frequent headaches, which could be consistent with obstructive coronary artery disease or ischemia.\n\n4. There is no mention of the patient being considered ineligible for coronary artery bypass surgery by a heart team.\n\n5. The patient is able to speak English (assumed since no other language is mentioned).\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. Specifically, the criteria regarding being deemed ineligible for coronary artery bypass surgery by a heart team is not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "836": {
        "output": "Based on the patient note and the inclusion/exclusion criteria provided for the clinical trial \"Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC\", the trial-level eligibility for this patient is as follows:\n\nTrial-level eligibility: 1) Not relevant.\n\nThe patient note does not mention any diagnosis of head and neck squamous cell carcinoma, which is a key inclusion criterion for this trial. The note describes the patient's presentation with dizziness, frequent headaches, and carotid artery stenosis, but there is no information provided about the patient having advanced head and neck cancer or having received prior anticancer therapy, which are also required for eligibility in this trial. Without sufficient information to determine if the patient meets the cancer-related inclusion criteria, the patient cannot be considered eligible or excluded for this particular trial.",
        "label": 0
    },
    "837": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C 545 mg/dL (very high)\n- HDL-C 53 mg/dL (normal)\n- Normal fasting glucose and triglycerides\n- No lipid-lowering medications\n- Carotid artery stenosis (severe in left, moderate in right)\n\nThe inclusion criteria for the trial are:\n1) Stable exertional angina\n2) Type 2 diabetes mellitus without receiving injectable antidiabetic drugs\n\nFrom the patient note, there is no mention of the patient having angina or type 2 diabetes. The high LDL-C and carotid stenosis suggest atherosclerotic cardiovascular disease, but the inclusion criteria are not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "838": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with no history of diabetes mellitus. The clinical trial is looking at coronary artery plaque burden and morphology in patients with type 1 or type 2 diabetes mellitus.\n\nOne of the inclusion criteria is \"Type 1 or 2 diabetes mellitus\". Since the patient note does not mention the patient having diabetes, he does not meet this key inclusion criteria.\n\nWhile the patient does have some relevant findings like high LDL, carotid artery stenosis and plaque, the lack of a diabetes diagnosis makes him ineligible for this particular trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "839": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. The clinical trial is studying the effectiveness of drug-eluting balloons in treating stenosis in bypass vein grafts.\n\nThe key inclusion criterion for this trial is \"Any venous bypass with stenosis warranting intervention\".\n\nFrom the patient note, we can see that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). However, the stenosis is in the carotid arteries, not in a venous bypass graft.\n\nSince the patient does not meet the key inclusion criterion of having stenosis in a venous bypass graft, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "840": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for this trial (no specific age cutoffs given).\n\n2. The patient has severe stenosis (narrowing) in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This meets the inclusion criteria of \"stenotic lesions of the extracranial part of carotid arteries requiring surgical treatment according to national treatment guidelines\".\n\n3. The length of the atherosclerotic plaques in the ICA is not explicitly stated, but it is mentioned that the plaque extends to the middle third of the ICAs, suggesting the plaque length is greater than 1 cm, meeting that inclusion criteria.\n\n4. There is no information given about whether the patient provided informed consent, so we cannot definitively say that criteria is met.\n\nHowever, based on the information provided about the carotid artery stenosis and plaque length, this patient appears to meet the key inclusion criteria for this carotid artery revascularization trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "841": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. No other major cardiovascular risk factors are mentioned.\n\n2. His lipid profile shows very high LDL-C (545 mg/dL) and borderline HDL-C (53 mg/dL). Other relevant labs like fasting glucose and triglycerides are normal.\n\n3. He has carotid artery stenosis - severe in the left internal carotid artery and moderate (40-50%) in the right internal carotid artery based on ultrasound findings.\n\n4. The clinical trial \"Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease\" is studying platelet biomarkers in patients with coronary artery disease undergoing angiography.\n\n5. The key inclusion criteria are: signed informed consent and planned angiography within the next 3 days.\n\nBased on the patient having carotid artery stenosis and being scheduled for an angiogram, he meets the key inclusion criteria for this clinical trial studying platelet biomarkers in coronary artery disease patients undergoing angiography.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "842": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient does not have multiple sclerosis, which is one of the inclusion criteria for the given clinical trial \"Is the Severity of Urinary Disorders Related to Falls in People With Multiple Sclerosis\".\n\n3. The patient note mentions carotid artery stenosis, atherosclerosis, and cardiovascular risk factors like high LDL cholesterol levels. This aligns with the clinical trial \"Haemodynamic and Geometric Factors in Atherosclerosis\" which is studying atherosclerotic alterations in peripheral vessels like the carotid arteries.\n\n4. The inclusion criteria for this trial specifically requires \"asymmetrical (side difference) plaque distribution in carotids/femoral arteries which was tested in at least two prior 3D-ultrasound examinations\".\n\n5. The patient note mentions that ultrasonography revealed \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%\". This suggests an asymmetrical plaque distribution in the carotid arteries.\n\n6. However, the note does not explicitly state that the patient had at least two prior 3D-ultrasound examinations confirming this asymmetrical plaque distribution.\n\nTherefore, based on the information provided, the patient may potentially be eligible for the \"Haemodynamic and Geometric Factors in Atherosclerosis\" clinical trial, but there is not sufficient information to confirm eligibility definitively.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "843": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being between 18-85 years old.\n\n2. The patient has no prognosis-limiting comorbidities mentioned, is not pregnant/lactating, and there is no indication of unwillingness to give informed consent or enter follow-up.\n\n3. The patient has carotid artery stenosis, which is not directly relevant to the trial focused on stress echocardiography applications. However, the trial does include a subproject on \"coronary flow velocity, left ventricular elastance reserve and B-lines in known or suspected CAD.\"\n\n4. The patient's LDL-C level of 545 mg/dL is very high, suggesting potential cardiovascular disease or risk, which could make them eligible for the CAD subproject.\n\n5. There is no specific mention of the patient having an acceptable acoustic window at rest, which is an inclusion criteria.\n\nOverall, while the patient may potentially be eligible for the CAD subproject based on their elevated LDL-C level and possible CAD risk, there is insufficient information provided about their acoustic window to definitively determine eligibility for the full trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "844": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study on Vulnerable Plaque of Carotid Artery With Chinese Herbal and Insects Medicine\", I will go through the inclusion criteria one by one:\n\n1. \"Meet the diagnostic criteria of carotid artery atherosclerosis\"\nThe patient note mentions that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which indicates carotid artery atherosclerosis. This criterion is met.\n\n2. \"Ultrasound of carotid artery atherosclerosis plaque specifies it as unstable plaque (including malacoplakia and mixed plaque)\"\nThe patient note states that \"Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, which were characterized as bulky plates extending to the middle third of the internal coronary arteries (ICAs) and as predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\" This description suggests that the plaque is likely unstable or vulnerable, meeting this criterion.\n\nSince both inclusion criteria are met based on the information provided in the patient note, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "845": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for most clinical trials.\n\n2. The patient has severe stenosis (narrowing) in the left internal carotid artery and moderate stenosis in the right internal carotid artery. This meets the inclusion criteria of \"\u2265 50% stenosis of internal carotid artery in symptomatic patients; or \u2265 70% stenosis of internal carotid artery in asymptomatic patients\".\n\n3. However, there is no information provided about whether the patient has received statin therapy for \u2265 2 weeks before inclusion, which is another inclusion criterion.\n\nSince we don't have complete information to determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "846": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226514 years.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of \"Diameter reduction of renal artery or main branch of renal artery\u2265 60%\".\n\n3. The patient's blood pressure is not mentioned, so we cannot determine if he meets the blood pressure criteria.\n\n4. The patient's serum creatinine level is not provided, so we cannot determine if he meets the criteria of serum creatinine level <264umol/L.\n\n5. The length of the ipsilateral kidney and glomerular filtration rate are not provided, so we cannot determine if he meets those criteria.\n\n6. The patient's urine protein level is not mentioned, so we cannot determine if he meets the criteria of urine protein <2+.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to determine if he meets all of them. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "847": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Comparison Between Partial Nephrectomy and Ablation for Renal Tumor\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of renal cell carcinoma (RCC) or any renal tumor.\n\nThe inclusion criteria for the trial specifically states that patients with RCC of \u22644 cm maximum diameter should be included in the study.\n\nSince the patient note does not indicate the presence of a renal tumor or RCC, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "848": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age ranging from 45 to 80 years of age, both genders\nThe patient is 46 years old and male, so he meets this criterion.\n\n2. Patients diagnosed with an ischemic stroke or TIA before admission and the following requirements should be satisfied as well:\n   - The occurrence of an ischemic stroke within 30 days and with a baseline modified Rankin Scale (mRS) score\u22644.\n   - The occurrence of an TIA within 15 days and with a baseline Oxfordshire Community Stroke Project on the basis of age, blood pressure (BP), clinical features, and duration of TIA symptoms (ABCD2) score\u22654.\nThe patient note does not mention an ischemic stroke or TIA, so this criterion is not met.\n\n3. Patients with symptomatic intracranial atherosclerotic stenosis (sIAS) that is attributed to at least 50% stenosis of the diameter of a major intracranial artery (carotid artery, or middle cerebral artery (M1)) verified by magnetic resonance angiography (MRA) or computed tomographic angiography (CTA).\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, so this criterion is met.\n\n4. Informed consent obtained patients or health care proxy, as appropriate, able to cooperate and participate follow-up visits.\nThere is no information about informed consent or ability to participate in the patient note.\n\nBased on the information provided, the patient meets criteria 1 and 3, but does not meet criterion 2. There is not enough information to determine if criterion 4 is met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "849": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Willing to participate in the trial of dietary interventions for one month\"\nThe patient note does not mention whether the patient is willing to participate in the trial or not. However, this criterion alone does not exclude the patient.\n\n2. \"within the age range\"\nThe patient note states that the patient is 46 years old. The inclusion criteria do not specify the age range, so we cannot determine if the patient meets this criterion or not.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "850": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age inclusion criteria of 35-86 years for the CREST-H trial.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA), which aligns with the CREST-2 inclusion criteria that the patient must be enrolled in.\n\n3. There is no mention of the patient being unable to undergo MRI, having a known allergy to gadolinium contrast dye, having a pre-existing diagnosis of dementia, having contralateral ICA stenosis >70%, having a history of severe head trauma, having major depression, or having less than 8 years of education. Therefore, the patient does not seem to meet any of the exclusion criteria.\n\n4. The patient appears to meet all the inclusion criteria and does not seem to meet any of the exclusion criteria for the CREST-H trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "851": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 35-74 years old for this trial.\n\n2. The trial is looking at the association between coffee consumption and coronary artery calcium (CAC) score. The patient note does not mention anything about the patient's coffee consumption habits.\n\n3. However, the patient note does provide information about the patient's CAC score, indicating severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\n4. The inclusion criteria only state that participants must be from the ELSA-Brasil study in S\u00e3o Paulo who underwent CAC determination, which this patient seems to have done.\n\n5. There is no information provided about whether the patient is part of the ELSA-Brasil study or not.\n\nBased on the information given, there is not enough evidence to determine if the patient meets the inclusion criteria for this trial or not. More information is needed about whether the patient is part of the ELSA-Brasil study.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "852": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being >18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating atherosclerotic disease.\n\n3. However, the trial is specifically looking at coronary artery disease and fractional flow reserve (FFR) measurements, not carotid artery disease.\n\n4. There is no mention of the patient undergoing coronary computed tomography angiography (CCTA) or invasive coronary angiography (ICA) in the patient note.\n\nBased on the information provided, this patient does not seem to meet the inclusion criteria for this particular clinical trial, as the trial is focused on validating FFR-CT software for coronary artery disease, and the patient's condition appears to be related to carotid artery disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "853": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His LDL-C level is 545 mg/dL, which is extremely high, indicating potential familial hypercholesterolemia.\n3. He has carotid artery stenosis, which could be related to the high cholesterol levels.\n4. The clinical trial is focused on registering patients with familial hypercholesterolemia in Taiwan.\n5. The inclusion criteria mention using the Taiwan FH Diagnostic Criteria, which is based on the Dutch Lipid Clinic Network Criteria.\n\nBased on the extremely high LDL-C level and potential familial hypercholesterolemia, this patient seems to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "854": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 6-16 years specified in the inclusion criteria. However, the inclusion criteria specifically mentions \"children and adolescents\", so the patient's age may not qualify.\n\n2. The patient's weight status is not mentioned, so it's unclear if they would meet the criteria for obese or normal weight based on the IOTF criteria.\n\n3. The patient's gender (male) is not an exclusion factor based on the provided inclusion criteria.\n\n4. It's not explicitly stated if the patient is diet naive or not.\n\nSince there is not enough information provided about the patient's age, weight status, and diet history to definitively determine if they meet all the inclusion criteria, I would assess:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "855": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The trial is about evaluating cardiovascular risk in soccer referees. This patient is not mentioned to be a soccer referee, so he does not meet that inclusion criteria.\n\n3. The other inclusion criteria are being an elite referee of the gold series of the Paulista Soccer Federation, being registered for the 2009 Sao Paulo professional soccer championship, and being eligible for pre-participative evaluation.\n\nSince the patient is not mentioned to be a soccer referee at all, he does not meet any of those criteria.\n\nTherefore, based on the information provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "856": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult (age \u2265 18 years).\n\n2. The patient has severe stenosis (70-99%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of having symptomatic, unilateral ICA stenosis 70-99% and irrelevant stenosis <50% of contralateral ICA.\n\n3. The patient presents with dizziness and frequent headaches, which could be symptoms of a TIA or stroke. However, the note does not explicitly state that the patient had a TIA or stroke within 360 days.\n\n4. There is no information provided about the patient's consent for ICA stenting or endarterectomy or any contraindications to MRI.\n\nBased on the available information, the patient meets some of the inclusion criteria but there is not enough information to determine if they meet all of the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "857": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range specified in the inclusion criteria (45-65 years for men).\n\nHe has a family history of CAD, which is considered a cardiovascular risk factor according to the inclusion criteria.\n\nHis LDL-C level of 545 mg/dL indicates dyslipidemia, another cardiovascular risk factor listed in the inclusion criteria.\n\nThe patient is not reported to have hypertension, obesity, or be a current/former smoker within the last 10 years. However, the inclusion criteria state that having at least one cardiovascular risk factor is sufficient.\n\nBased on the information provided, this patient meets the inclusion criteria of being a man aged 45-65 years with at least one cardiovascular risk factor (family history of CAD and dyslipidemia).\n\nThere is no information provided that would exclude the patient based on the trial's exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "858": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 30-85 years specified in the inclusion criteria.\n\n2. The patient has severe stenosis (>60%) in the left internal carotid artery (LICA), which meets the inclusion criteria for the symptomatic group: \"Patients who have a relevant intracranial atherosclerotic stenosis \u226560%\".\n\n3. However, there is no mention of the patient having an acute infarct in diffusion-weighted MRI or microembolic signals (MES) detected by transcranial Doppler (TCD). These are also part of the inclusion criteria for the symptomatic group.\n\n4. The patient does not seem to meet the inclusion criteria for the asymptomatic group either, as there is no information provided about the absence of infarct or MES on TCD.\n\n5. Based on the information provided, there is insufficient evidence to determine if the patient meets all the inclusion criteria for either the symptomatic or asymptomatic group.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "859": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria (\u226518 years) for the clinical trial.\n\n2. The patient does not have a diagnosis of multiple sclerosis or lower urinary tract symptoms, which are required for the example clinical trial provided earlier. \n\n3. The patient note describes symptoms related to carotid artery stenosis, dizziness, headaches, and abnormal lipid levels.\n\n4. The clinical trial titled \"Microembolisation After Carotid Revascularisation\" is focused on studying carotid artery stenosis and the effects of revascularization procedures like carotid stenting or endarterectomy.\n\n5. The inclusion criteria for this trial are:\n   - Patients presenting with symptomatic carotid stenosis between 50% and 99%\n   - Patients presenting with asymptomatic carotid stenosis between 60% and 99%\n   - Patients who accept the informed consent\n\n6. Based on the patient note, the patient has severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery. The patient is also symptomatic with dizziness and headaches.\n\n7. Therefore, this patient meets the inclusion criteria for the \"Microembolisation After Carotid Revascularisation\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "860": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which does not directly match or contradict the inclusion criteria of being a candidate for first bariatric surgery.\n\n2. The patient has dizziness, frequent headaches, and a family history of CAD, but no other cardiovascular risk factors. This information is not directly relevant to the inclusion criteria.\n\n3. The patient has high LDL-C levels (545 mg/dL) and normal HDL-C, fasting glucose, and triglyceride levels. This information is not directly relevant to the inclusion criteria.\n\n4. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, as confirmed by ultrasonography. This information is not directly relevant to the inclusion criteria.\n\n5. The inclusion criteria state that the patient must be a candidate for first bariatric surgery. There is no information provided in the patient note about the patient's weight or whether they are a candidate for bariatric surgery.\n\nBased on the lack of information regarding the patient's weight or candidacy for bariatric surgery, which is the sole inclusion criteria provided, there is not enough information to determine if the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "861": {
        "output": "To determine the patient's eligibility for the clinical trial \"New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques\", let's go through the inclusion criteria:\n\n1. \"Subject has carotid plaque with > 50% stenosis\"\nAccording to the patient note, the patient has severe stenosis (>50%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Therefore, this criterion is met.\n\n2. \"Subject is able to understand the study procedure and provide informed consent\"\nThere is no information provided about the patient's ability to understand the study procedure or provide informed consent. However, we can assume that as a 46-year-old man presenting for medical care, he is likely able to do so unless stated otherwise.\n\nSince both inclusion criteria are met based on the information provided, and there are no exclusion criteria mentioned, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "862": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. He has no other cardiovascular risk factors and is physically active.\n3. His LDL-C level is high at 545 mg/dL, but other lipid levels (HDL-C, triglycerides) are within normal limits.\n4. He is not taking any lipid-lowering medications.\n5. Physical examination revealed a systolic murmur and carotid artery stenosis (severe in the left, moderate in the right).\n\nNow, let's look at the inclusion criteria for the clinical trial:\n1. Recent (within 12 months) first-time coronary artery event, defined as myocardial infarction or unstable angina pectoris, addressed with PCI or CABG.\n2. Depressive symptoms above a score of 8 on the CES-D scale.\n3. Interest in participating in the Mindfulness-Based Stress Reduction (MBSR) program.\n\nBased on the information provided, the patient does not seem to have had a recent myocardial infarction or unstable angina pectoris, which is the primary inclusion criterion for this trial. Additionally, there is no mention of depressive symptoms or interest in the MBSR program.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "863": {
        "output": "To determine the patient's eligibility for the clinical trial \"Assessing Neurocognition After Cerebrovascular Intervention\", let's go through the inclusion criteria one by one:\n\n1. Patients >18 years of age\nThe patient is 46 years old, so this criterion is met.\n\n2. Ultrasound evidence of carotid stenosis; in which the patient has either 50% or greater symptomatic carotid stenosis or 70% or greater asymptomatic carotid stenosis.\nAccording to the patient note, ultrasonography revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\n\nSince the patient has severe stenosis (>50%) in the LICA, this criterion is met.\n\nBased on the information provided in the patient note, the patient meets both inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "864": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a human trial.\n2. The trial is investigating the effect of psyllium fiber on LDL-C, non-HDL-C, and apoB. The patient's LDL-C level of 545 mg/dL is reported, but there is no information provided about non-HDL-C or apoB levels.\n3. There is no mention of the patient being part of a randomized controlled trial (RCT) or receiving psyllium fiber as an intervention.\n4. The patient's lipid levels are reported, but there is no information about a follow-up period or the amount of psyllium fiber consumed.\n\nBased on the information provided in the patient note, there is insufficient data to determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "865": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being a patient presenting for evaluation related to carotid artery stenosis.\n\n2. The patient has severe stenosis (>70%) in the left internal carotid artery, which meets the inclusion criteria for symptomatic patients with plaque \u226570% in at least one carotid artery.\n\n3. The patient also has moderate stenosis (40-50%) in the right internal carotid artery, which may or may not meet the inclusion criteria depending on whether the trial considers this level of stenosis as significant.\n\n4. The patient is presenting with symptoms of dizziness and frequent headaches, which could potentially be related to the carotid artery stenosis, although this is not explicitly stated.\n\n5. The patient does not appear to have had a stroke or TIA based on the information provided, but this is not a strict requirement for the symptomatic arm of the trial.\n\nBased on the information provided, it seems that the patient meets the key inclusion criteria for being a symptomatic patient with severe carotid artery stenosis being considered for carotid endarterectomy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "866": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches, which matches the inclusion criteria of \"Patients arriving to the emergency room with decreased consciousness, severe headaches or dizziness\".\n\n2. The patient has a family history of CAD but no other cardiovascular risk factors, and his lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. This information is not directly relevant to the inclusion criteria.\n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which could potentially be related to the dizziness and headaches.\n\n4. There is no information provided that would exclude the patient from the trial based on the given inclusion criteria.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "867": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 18-80 years\nThe patient is 46 years old, which falls within this range.\n\n2. Carotid artery with 30-70% stenosis by ultrasound and plaque thickness >2.5mm\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery. This meets the stenosis criteria. The plaque thickness is not explicitly stated, but the plaques are described as \"bulky plates\", suggesting they likely exceed 2.5mm.\n\n3. Patients without transient ischemic attack, minor stroke or amaurosis fugax within 6 months\nThere is no mention of the patient having any of these conditions.\n\n4. Patients' LDL-c level below 100 mg/dL (2.6mmol/L), well-controlled blood pressure (systolic BP<140 and diastolic BP<90 under resting conditions) and diabetes (HbA1c<7%)\nThe patient's LDL-C level is 545 mg/dL, which is well above the cutoff of 100 mg/dL. There is no information provided about the patient's blood pressure or diabetes status.\n\n5. Written informed consent\nThis is assumed to be obtained for any clinical trial participation.\n\nBased on the information provided, the patient meets some but not all of the key inclusion criteria. The elevated LDL-C level appears to be a disqualifying factor.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "868": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 40-80 years specified in the inclusion criteria.\n\n2. The patient has no history of hypertension mentioned, so he does not fit into the salt-sensitive hypertension (SSH) or non-SSH, salt-resistant hypertension (SRH) groups.\n\n3. However, the inclusion criteria also mention a control group of patients without hypertension aged 40-80 years.\n\n4. Since the patient falls within this age range and has no reported hypertension, he could potentially fit into the control group.\n\n5. There is no additional information provided about whether the patient meets any exclusion criteria for the trial.\n\nBased on the information given, the patient appears to be eligible for the clinical trial as part of the control group without hypertension.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "869": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Willing to participate in the trial of dietary interventions for one month\n- The patient note does not mention the patient's willingness to participate in a dietary intervention trial, so this criterion cannot be evaluated.\n\n2. Within the age range\n- The patient note states that the patient is 46 years old. The trial does not specify the age range, so we cannot determine if the patient meets this criterion.\n\nSince there is not enough information provided in the patient note to definitively determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "870": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. He has no cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus.\n3. His LDL-C level is high at 545 mg/dL, but other lipid levels like HDL-C, fasting glucose, and triglycerides are within normal limits.\n4. He is not taking any lipid-lowering medications.\n5. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nNow, let's look at the inclusion criteria for the SWIDINEP clinical trial:\n1. Type 2 diabetes\n2. eGFR <60ml/min or albumin/creatinine ratio >3mg/mmol\n3. Can understand French and has signed the consent form\n\nBased on the information provided in the patient note, there is no mention of the patient having type 2 diabetes or any renal function tests like eGFR or albumin/creatinine ratio.\n\nTherefore, there is not enough information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "871": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects who are 18 to 75 years of age, male or female using a highly effective birth control method or not of child-bearing potential, at Visit 1 (screening visit).\nThe patient is a 46-year-old man, so he meets this criterion.\n\n2. LDL-C 130 to 189 mg/dL (inclusive) on a cholesterol lowering diet but no lipid modifying drug treatment for at least 6 weeks.\nThe patient's LDL-C level is 545 mg/dL, which is well above the required range of 130-189 mg/dL. He also reported no use of lipid-lowering medications.\n\n3. A qualifying LDL-C value must be obtained at the beginning and end of the placebo run-in (Visit 2 and Visit 3) and the Visit 3 value must be within 12% of the value at Visit 2, higher or lower; the average of both qualifying values must be in the range of 130 to 189 mg/dL (inclusive) for inclusion in the study.\nThere is no information provided about placebo run-in or Visit 2 and Visit 3 LDL-C values.\n\n4. TG \u2264 350 mg/dL on a cholesterol lowering diet but no lipid modifying drug treatment for at least 6 weeks and TG levels must be \u2264 350 mg/dL at both Visit 2 and Visit 3\nThe patient's triglyceride level is 158 mg/dL, which meets this criterion.\n\n5. Signed written informed consent.\nThere is no information provided about informed consent.\n\nBased on the information given, the patient does not meet the LDL-C criterion for inclusion in this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "872": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. He has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying intracranial artery stenosis (ICAS) and its etiology and progression using MRI.\n\n5. The inclusion criteria for the trial are patients with recent transient ischemic attack or ischemic stroke within two weeks of symptom onset and intracranial artery stenosis (30-99%) in specific arteries determined by CT angiography or MR angiography.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial as he has carotid artery stenosis (severe in LICA and moderate in RICA), which would likely qualify as intracranial artery stenosis. However, the patient note does not mention if he had a recent transient ischemic attack or ischemic stroke within the past two weeks.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "873": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n3. The inclusion criteria for the clinical trial are:\n   - Diagnosed with carotid stenosis\n   - Had indications for carotid revascularization\n\nBased on the information provided in the patient note, the patient meets both of the inclusion criteria for the clinical trial:\n- He is diagnosed with carotid stenosis (severe stenosis in LICA and moderate stenosis in RICA).\n- The presence of severe carotid stenosis would likely indicate the need for carotid revascularization.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "874": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 20-40 years old.\n\nThere is no mention of apical periodontitis or the number of teeth present, so those criteria cannot be evaluated from the given information.\n\nThe patient's LDL-C level of 545 mg/dL is very high, suggesting potential cardiovascular issues, but there is no information provided about left ventricular ejection fraction, hepatic function, or renal function to assess those criteria.\n\nOverall, there is not sufficient information in the patient note to definitively determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "875": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the inclusion criteria of being male or female of any race.\n\nHis LDL-C level is 545 mg/dL, which is well above the required 100 mg/dL for inclusion.\n\nHis triglyceride level of 158 mg/dL is below the exclusion criteria cutoff of 400 mg/dL.\n\nThere is no mention of the patient having coronary heart disease, peripheral artery disease, cerebrovascular disease, uncontrolled hypertension, insulin-dependent diabetes mellitus, or secondary dyslipidemia, which are all exclusion criteria.\n\nThere is also no mention of renal or hepatic diseases, AIDS/HIV, viral hepatitis B or C, cancer within 5 years, high alcohol consumption, or participation in another clinical study recently.\n\nThe only potential exclusion criteria is the carotid artery stenosis mentioned, which could be considered a \"serious disease or medical condition\". However, this is not definitively stated.\n\nOverall, based on the information provided, the patient appears to meet the key inclusion criteria and there are no clear exclusion criteria applying.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "876": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being at least 18 years old.\n\n2. The patient has evidence of myocardial ischemia (dizziness and frequent headaches, carotid artery stenosis).\n\n3. The patient is not reported to have had a recent myocardial infarction or unstable arrhythmias.\n\n4. There is no mention of the patient having a low ejection fraction, organ transplant, cancer, autoimmune disease, or other severe comorbidities that would exclude them.\n\n5. The trial is focused on evaluating a coronary stent, but the patient's condition involves carotid artery stenosis rather than a coronary artery lesion.\n\nBased on the information provided, the patient does not appear to meet the key inclusion criteria of having a coronary artery lesion suitable for stenting. While the patient has evidence of vascular disease, it is not the specific condition being studied in this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "877": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which falls within the age range of 20-40 years specified in the inclusion criteria.\n\n2. The patient presents with dizziness and frequent headaches, but there is no mention of non-specific mechanical neck pain for more than 3 months, which is one of the inclusion criteria.\n\n3. There is no information provided about whether the patient is willing to participate in the study or sign the confirmation form.\n\n4. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, but the inclusion criteria do not mention any requirements related to carotid artery stenosis.\n\nBased on the information provided, the patient does not meet all the inclusion criteria for the clinical trial, as there is no mention of non-specific mechanical neck pain for more than 3 months.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "878": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient is being sent for a carotid duplex examination, which aligns with the inclusion criteria of being an outpatient sent to the vascular laboratory for a carotid ultrasound study.\n\n3. The patient has severe stenosis (>70%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of having at least moderate known stenosis (50-69% or greater) of one or both internal carotid arteries.\n\n4. There is no mention of the patient having fibromuscular dysplasia (FMD) of the internal carotid arteries.\n\nBased on the information provided, this patient meets the inclusion criteria for the clinical trial titled \"Evaluation of a Novel Technique to Diagnose Carotid Artery Stenosis\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "879": {
        "output": "To determine the patient's eligibility for the clinical trial \"Cognitive and Blood Flow Effects of Mountain Tea\", I will go through the inclusion criteria one by one:\n\n1. 50-70 yrs of age\nThe patient's age is given as 46 years old, which does not meet this criterion.\n\n2. No underlying health problem which would prevent engagement with the study\nThe patient note mentions dizziness, frequent headaches, and carotid artery stenosis. These could potentially prevent engagement with the study, but it is not explicitly stated.\n\nSince the patient does not meet the age criterion, and there is uncertainty about whether their health problems would prevent engagement, I would assess their eligibility as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "880": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying the incidence of ventricular arrhythmias in patients with chronic total occlusion (CTO) of a coronary artery, either after successful CTO recanalization, failed CTO recanalization, or untreated CTO.\n\n5. The inclusion criteria for the trial are:\n   - Presence of CTO defined as complete obstruction of the vessel with TIMI flow grade 0 and an estimated duration of \u22653 months\n   - AND one of the following:\n     - Successful percutaneous CTO recanalization for stable angina within the previous 6 months\n     - Failed percutaneous CTO recanalization for stable angina within the previous 6 months\n     - Untreated CTO diagnosed in the previous 6 months\n   - Age \u226518 years\n   - Written informed consent\n   - Agrees to follow-up including implantation of an insertable cardiac monitor (ICM)\n\n6. Based on the information provided, the patient does not appear to have a chronic total occlusion of a coronary artery, as the findings are related to carotid artery stenosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "881": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being able to provide informed consent (implied by no mention of cognitive impairment).\n\n2. The patient has severe stenosis (>50%) in the left internal carotid artery, which meets the inclusion criteria of \"Extracranial carotid stenosis greater than 50% stenosis (NASCET) in the carotid bifurcation or internal carotid artery assessed by means of ultrasound\".\n\n3. There is no information provided that would suggest the patient is unable to follow up for examinations.\n\nBased on the information provided in the patient note, the patient meets all of the listed inclusion criteria for the \"Stratification of Patient With Carotid Disease\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "882": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C 545 mg/dL (very high)\n- HDL-C 53 mg/dL (normal)\n- Normal fasting glucose and triglycerides\n- Not taking any lipid-lowering medications\n- Carotid ultrasound showed severe stenosis in left internal carotid artery and moderate stenosis (40-50%) in right internal carotid artery\n- Atherosclerotic plaques present in carotid arteries\n\nThe clinical trial is looking for patients with low cardiovascular risk based on the AGLA/GSLA risk score to screen for atherosclerotic plaques.\n\nWhile the patient has very high LDL-C levels and carotid artery plaques/stenosis, the inclusion criteria specifically states looking for patients with low cardiovascular risk.\n\nGiven the presence of severe carotid stenosis and very high LDL-C, this patient would likely be considered at high cardiovascular risk, not low risk.\n\nTherefore, based on the inclusion criteria provided, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 2
    },
    "883": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria (\u226518 years).\n\nHis BMI is not provided, so we cannot assess if he meets the BMI \u2265 18.5 kg/m2 criteria.\n\nHis fasting blood glucose of 85 mg/dL (4.7 mmol/L) meets the criteria of \u22647 mmol/L.\n\nThe note mentions that the patient is physically active, meeting that criteria.\n\nHowever, the patient's percent body fat is not provided, so we cannot assess if he meets the 5-25% for men or 12-35% for women criteria.\n\nOverall, while the patient meets some of the inclusion criteria, there is not sufficient information provided to fully determine eligibility, as the BMI and percent body fat are missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "884": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being more than 18 years old.\n\n2. The patient does not have a diagnosis of nasopharyngeal carcinoma (NPC). The note mentions dizziness, frequent headaches, and carotid artery stenosis, but no cancer diagnosis.\n\n3. The patient has not received any prior radiation therapy to the head and neck region.\n\n4. There is no mention of the patient's ECOG performance status or whether they have signed an informed consent form.\n\nSince the patient does not have a diagnosis of NPC, which is a key inclusion criterion for this trial, they would not be eligible to participate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "885": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. This matches the age criteria of being above 18 years old.\n\n2. He has no ischemic ECG changes mentioned, which satisfies the \"no-ischemic ECG changes\" criteria.\n\n3. He is presenting with dizziness and frequent headaches, which could be symptoms of acute chest pain, though it is not explicitly stated as \"ischemic sounding chest pain\". \n\n4. His initial troponin level is not provided, so it is unclear if he meets the \"initial troponin in the intermediate range (5-50ng/L)\" criteria.\n\n5. The note mentions carotid artery stenosis and plaque, but does not provide information about an episode of chest pain within the last 12 hours.\n\nBased on the information provided, there is not enough evidence to definitively determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "886": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 25-70 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests a cervical vascular pathology.\n\n3. The patient has provided the necessary information, such as carotid artery velocities and plaque characteristics, to assess the cervical vascular pathology.\n\n4. There is no mention of the patient not providing informed consent.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial titled \"Blood Flow Measurement Using Quantitative Magnetic Resonance Angiography and Duplex Sonography.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "887": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is studying the use of ultra-high frequency ultrasound in patients with fibromuscular dysplasia (FMD) and vascular Ehlers-Danlos syndrome (V-EDS).\n\n5. The inclusion criteria for the FMD group are: age 18-80 years, diagnosed with FMD of renal, cervical, cerebral arteries or spontaneous coronary dissections, signed informed consent, and affiliated with social security.\n\n6. The inclusion criteria for the V-EDS group are: age 18-80 years, diagnosed with vascular Ehlers-Danlos syndrome, signed informed consent, and affiliated with social security.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial as he does not have a diagnosis of FMD or V-EDS. Therefore:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "888": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge: 18-65 years.\nThe patient's age is 46 years old, which falls within the inclusion criteria of 18-65 years.\n\nThe inclusion criteria does not mention any other requirements related to the patient's medical condition or history.\n\nBased on the information provided in the patient note, the patient meets the age inclusion criteria for this clinical trial on reducing sedentary behavior.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "889": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for most clinical trials.\n\n2. The patient has no diagnosis of atopic eczema mentioned in the note. The trial is specifically for patients with moderate-to-severe atopic eczema.\n\n3. There is no mention of the patient starting any phototherapy or systemic immunomodulating therapy for atopic eczema.\n\n4. The patient note describes symptoms related to carotid artery stenosis and high cholesterol levels, which are not relevant to the inclusion criteria for this atopic eczema trial.\n\nBased on the information provided in the patient note, there is insufficient evidence that the patient meets the key inclusion criteria for the TREAT NL atopic eczema registry trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "890": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-65 years.\n\n2. There is no mention of the patient having Visceral Leishmaniasis or any of the clinical signs and symptoms listed (fever, weight loss, splenomegaly).\n\n3. There is no information provided about the presence of amastigotes detected by the rK39 dipstick test.\n\n4. There is no information about the patient's childbearing potential or willingness to use birth control methods.\n\n5. There is no information about the patient's ability to comply with study requirements.\n\n6. There is no information about the patient's hemoglobin levels.\n\n7. There is no information about the patient's platelet count.\n\n8. There is no information about the patient's white blood cell count or immunocompetence status.\n\n9. There is no information about whether the patient has provided written informed consent.\n\n10. There is no information about the patient's screening laboratory parameters and investigations.\n\nBased on the lack of information provided in the patient note regarding the inclusion criteria for this clinical trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "891": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, so his age meets the inclusion criteria of being 18 years or older.\n\n2. The patient note does not explicitly state that the patient has type 1 diabetes mellitus. It mentions that the patient has no history of diabetes mellitus.\n\nSince the patient does not have type 1 diabetes mellitus, which is the only inclusion criteria listed, he does not meet the eligibility requirements for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "892": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and no history of cardiovascular disease or risk factors except for a family history of CAD.\n\n2. His lipid profile shows very high LDL-C (545 mg/dL) and normal HDL-C, fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\n3. Clinical examination reveals a systolic murmur and carotid ultrasound shows severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\n4. The clinical trial is looking at the relationship between serum oxidative status markers (PON1, TBARS, thiol levels) and the presence/severity of coronary artery disease in patients presenting to the emergency department with acute chest pain but no evidence of acute myocardial infarction or ischemic ECG changes.\n\n5. The inclusion criteria are:\n   - Patients admitted to the chest pain unit after presenting to the ED with acute chest pain suspected to be of cardiac origin\n   - Suitable for further investigation by cardiac CT scan\n   - No previous history of CAD\n   - No signs of myocardial ischemia on admission ECG\n   - Normal cardiac biomarkers\n\n6. Based on the information provided, this patient does not meet the inclusion criteria for the trial as he did not present with acute chest pain and there is no mention of him being admitted to the chest pain unit.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "893": {
        "output": "To determine the patient's eligibility for the clinical trial \"Advanced Ultrasound Methods in the Assessment of Carotid Plaque Instability\", let's go through the inclusion criteria:\n\nInclusion Criteria: Atherosclerotic carotid stenosis >50% with or without cerebrovascular symptoms.\n\nBased on the patient note, the patient has:\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%\n\nSince the patient has severe stenosis (>50%) in the LICA, they meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "894": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years and \u226475 years.\n\n2. The patient has documented stable coronary artery disease (CAD), as evidenced by the severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n3. The patient's gender is not specified, so we cannot determine if the requirement for women to be postmenopausal or surgically sterile is met or not.\n\n4. There is no information provided about whether the patient was previously taking clopidogrel or ticagrelor and had discontinued them at least 14 days before randomization.\n\nBased on the available information, the patient meets some of the inclusion criteria but there is not enough information to determine if they meet all of the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "895": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >17 years old in the inclusion criteria.\n\n2. The patient has hypertension, as evidenced by the carotid artery stenosis and systolic murmur, which meets the inclusion criteria of having hypertension.\n\n3. There is no mention of the patient being on any anti-hypertensive medications, so the requirement of not being on more than two anti-hypertensives is met.\n\n4. The patient's laboratory tests (LDL-C, HDL-C, fasting glucose, triglycerides) are within normal limits, meeting the criteria of normal renal, metabolic, electrolyte, and lipid profile tests.\n\n5. There is no mention of the patient having cardiac disease other than hypertension, renal/circulatory/neurologic diseases, diabetes, or being a smoker, which meets the exclusion criteria.\n\n6. There is no mention of the patient having secondary hypertension or being on any drug therapy other than anti-hypertensives.\n\nBased on the information provided, the patient meets all the inclusion criteria and does not violate any of the exclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "896": {
        "output": "Based on the patient note provided, the patient does not appear to have a prosthetic joint infection or any symptoms related to a prosthetic joint. The note describes a 46-year-old man with dizziness, headaches, family history of coronary artery disease, and abnormal lipid levels. It also mentions carotid artery stenosis and plaque formation.\n\nGiven that the clinical trial titled \"Alpha Defensin and 16S rRNA Gene in Diagnosis of PJI\" is specifically focused on diagnosing prosthetic joint infections, this patient does not meet the inclusion criteria as there is no mention of a prosthetic joint or suspected prosthetic joint infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "897": {
        "output": "To determine the patient's eligibility for the \"Carotid Artery Disease After Stroke (CADAS)\" clinical trial, let's go through the inclusion criteria:\n\n1. Patients with capacity to give informed consent.\nThe patient note does not mention anything about the patient's capacity to give informed consent, so we cannot make a definitive assessment on this criterion.\n\n2. All patients who have suffered a Partial Anterior Circulatory Stroke (PACS) or Transient Ischaemic Attack (TIA).\nThe patient note does not mention that the patient has suffered a stroke or TIA. It only mentions that the patient presents with dizziness and frequent headaches.\n\n3. Carotid Stenosis >50%.\nThe patient note states that the patient has \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%.\" This means that the patient meets the criterion of having carotid stenosis >50% in at least one carotid artery.\n\nBased on the available information, the patient meets one of the inclusion criteria (carotid stenosis >50%) but does not have sufficient information to determine if they meet the other two criteria (capacity to give informed consent and having suffered a stroke or TIA).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "898": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nClinical Criteria:\n1) Age\u226550 years: The patient is 46 years old, which does not meet this criterion.\n2) Asymptomatic carotid stenosis with only dizziness or mild headache: The patient presents with dizziness and frequent headaches, which meets this criterion.\n\nAnatomy Criteria:\n1) Internal carotid artery independent disease: The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), meeting this criterion.\n2) Carotid stenosis satisfies one of the following criteria:\n   a) Ultrasonography suggests stenosis \u226570%, or angiography showed stenosis \u226560%: The ultrasonography revealed severe stenosis in the LICA, which likely meets the \u226570% stenosis criterion.\n   b) Ultrasonography suggests stenosis <70%, but angiography or other examination showed stenosis in an unstable state: Not applicable in this case.\n3) Patients with bilateral carotid stenosis, the treatment time for target vessel contralateral vessels is required 30 days before enrollment or 30 days after completion of study procedure: The patient has bilateral carotid stenosis, but there is no information about treatment timing.\n4) The stent can reach the site of lesion smoothly as expected: There is no information about this criterion.\n\nBased on the available information, the patient meets some of the inclusion criteria, such as having asymptomatic carotid stenosis with dizziness and headache, and having severe stenosis in the LICA. However, the patient's age of 46 years does not meet the age criterion of \u226550 years. Additionally, there is no information about the treatment timing for bilateral carotid stenosis or whether the stent can reach the lesion site smoothly.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "899": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 21-65 years old.\n\n2. There is no mention of the patient's employment status, so we cannot confirm if he is working full-time.\n\n3. There is no mention of the patient having a clinical diagnosis of CHD or other heart diseases, which meets the exclusion criteria.\n\n4. There is no mention of the patient working in a health-relevant environment, which meets the exclusion criteria.\n\n5. There is no mention of the patient having reading difficulties, which meets the exclusion criteria.\n\n6. However, there is no mention of the patient using a smartphone frequently in their daily lives, which is an inclusion criteria.\n\n7. There is also no mention of the patient's ability to read, speak and understand English, which is an inclusion criteria.\n\nSince there is not enough information to confirm that the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "900": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors\", the patient does not appear to meet the eligibility criteria for this trial.\n\nThe patient note mentions that the patient is a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. However, the inclusion criteria for the trial specifically require participants to have histologically or cytologically confirmed renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, or melanoma. The patient note does not mention any of these types of cancer.\n\nAdditionally, the inclusion criteria require participants to have recurrent or metastatic disease that is not amenable to local therapy with curative intent. The patient note does not indicate that the patient has any metastatic or recurrent cancer.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "901": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the inclusion criteria of 60-99% stenosis of the internal carotid artery.\n\n3. The patient is symptomatic, presenting with dizziness and frequent headaches, which could be considered reversible ischemic neurological deficits. This meets the inclusion criteria of a symptomatic lesion.\n\n4. There is no information provided about the diameter of the target internal carotid artery, previous stenting, calcification, tortuosity, occlusion of the contralateral carotid artery, anatomical contraindications for endarterectomy, acute ipsilateral stroke, disabling stroke, other severe brain pathologies, history of hemorrhagic transformation, severe comorbidities, allergies, pregnancy status, or contraindications for MRI.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria for the clinical trial. However, there are some missing details that could potentially exclude the patient, such as the diameter of the target internal carotid artery, anatomical contraindications for endarterectomy, and comorbidities.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "902": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-80 years old.\n\n2. The patient has dizziness and frequent headaches, but there is no clear diagnosis of unilateral lower extremity radiculopathy due to degenerative foraminal stenosis mentioned in the note.\n\n3. There is no information provided about the patient being scheduled for a lumbar foraminotomy procedure.\n\n4. The patient has carotid artery stenosis, but this does not seem to be related to a neurogenic source of pain or radiculopathy.\n\n5. There is no information about the patient's availability for the entire study duration of 12 months.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for this specific clinical trial on lumbar selective nerve root block and lumbar foraminotomy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "903": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is titled \"Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension\" and aims to study the prevalence of hyperventilation syndrome in patients with controlled pulmonary arterial hypertension (PAH).\n\n5. The inclusion criteria for the trial are:\n   - Non-smoker or stopped smoking for 2-10 years\n   - Idiopathic, heritable, or drug/toxin-related PAH, or PAH associated with controlled pulmonary hypertension\n   - Diagnosed and treated for PAH for more than 4 months\n   - Optimal control of PAH (no right heart failure symptoms, NT-proBNP < 300 ng/L or BNP < 50 ng/L, and optimal hemodynamic results from a recent right heart catheterization)\n   - Informed and written consent\n   - Non-affiliation to a social security\n\n6. Based on the patient note, there is no mention of the patient having pulmonary arterial hypertension or any related conditions. The note focuses on carotid artery stenosis and lipid profile abnormalities.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "904": {
        "output": "Based on the patient note provided, the patient does not seem to have diabetes mellitus. The note mentions that the patient's fasting glucose level is within normal limits, and there is no mention of the patient having diabetes.\n\nThe inclusion criteria for the clinical trial \"Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables\" is that the patient must have diabetes mellitus.\n\nSince the patient note does not indicate that the patient has diabetes mellitus, which is the only inclusion criterion mentioned, the patient would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "905": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial.\n2. The trial is looking at arterial function and atherosclerosis in essential thrombocythemia patients with the JAK2 V617F mutation.\n3. The patient note does not mention essential thrombocythemia or the JAK2 V617F mutation.\n4. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating atherosclerosis.\n5. However, without information on whether the patient has essential thrombocythemia or the JAK2 V617F mutation, it is not possible to determine if they meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "906": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. He has no other cardiovascular risk factors and is physically active.\n3. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n4. He is not taking any lipid-lowering medications.\n5. Physical examination revealed a systolic murmur and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n6. The inclusion criteria for the clinical trial are: signed informed consent and significant carotid artery stenosis.\n\nBased on the information provided, this patient meets the inclusion criteria of having significant carotid artery stenosis, as evidenced by the ultrasonography findings of severe LICA stenosis and moderate RICA stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "907": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 18-80 years\nThe patient is 46 years old, which falls within this range.\n\n2. Carotid artery with 30-70% stenosis by ultrasound and plaque thickness >2.5mm\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery. The plaque thickness is not mentioned, but plaque is described as \"bulky plates extending to the middle third of the internal coronary arteries\".\n\n3. Patients without transient ischemic attack, minor stroke or amaurosis fugax within 6 months\nThere is no mention of the patient having any of these conditions.\n\n4. Patients' LDL-c level below 100 mg/dL (2.6mmol/L), well-controlled blood pressure (systolic BP<140 and diastolic BP<90 under resting conditions) and diabetes (HbA1c<7%)\nThe patient's LDL-C level is 545 mg/dL, which is very high and does not meet this criterion. There is no information provided about blood pressure or diabetes status.\n\n5. Written informed consent\nThis is assumed to be obtained if the patient enrolls in the trial.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. The very high LDL-C level excludes the patient from eligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "908": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-65 years old for the clinical trial.\n\n2. There is no mention of the patient having a traumatic brain injury (TBI) or any cognitive deficits related to working memory. The trial is specifically looking for patients with moderate to severe TBI and working memory deficits.\n\n3. The patient's presenting symptoms are dizziness, frequent headaches, and carotid artery stenosis. These do not align with the inclusion criteria for the cognitive rehabilitation trial.\n\n4. There is no information provided about the patient's Glasgow coma score, time since TBI, working memory complaints/deficits, vision, neurological/psychoactive treatment, ability to travel for the trial, or health insurance status.\n\nIn summary, while the patient meets the age criteria, there is insufficient information to determine if they meet the other key inclusion criteria related to TBI, working memory deficits, and clinical stability. Without evidence that the core eligibility requirements are met, this patient cannot be deemed eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "909": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Physically Active During Cancer Treatment (FAKT)\", the patient does not seem to be eligible for this trial. The key reasons are:\n\n1. The patient does not have colorectal cancer or any other type of cancer mentioned in the note. The trial is specifically for patients with colorectal cancer undergoing adjuvant chemotherapy with Oxaliplatin-based combination therapy.\n\n2. The patient's condition appears to be related to carotid artery stenosis and associated symptoms like dizziness and headaches, rather than cancer.\n\n3. There is no mention of the patient undergoing any cancer treatment or scheduled for adjuvant chemotherapy.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "910": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he does not have other cardiovascular risk factors like smoking, high blood pressure, or diabetes.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is focused on assessing the quality of life of patients treated for coronary heart disease.\n\n5. The inclusion criteria for the trial is \"Confirmed coronary disease.\"\n\nBased on the information provided, the patient has carotid artery stenosis and an abnormal lipid profile, but there is no explicit mention of confirmed coronary heart disease or coronary artery disease.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "911": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\nHe has no diagnosis of diabetes mentioned, which is required for inclusion.\n\nHis lipid levels (LDL-C 545 mg/dL, HDL-C 53 mg/dL) and carotid artery stenosis are noted, but these are not part of the inclusion criteria.\n\nThere is no mention of the patient having a coronary artery calcium score done or a toe-brachial index measured, which are required for inclusion.\n\nSince the patient does not have a diagnosis of diabetes mellitus and lacks the required coronary artery calcium score and toe-brachial index measurements, he does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "912": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >21 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This suggests he may have intracranial stenosis, which is a key inclusion criteria.\n\n3. The patient recently had a stroke/TIA, as evidenced by the dizziness and frequent headaches he is experiencing. This meets the inclusion criteria of \"recent stroke/TIA and severe stenosis of intracranial ICA or MCA within previous three months\".\n\n4. There is no information provided about whether the patient's cerebrovascular reserve (CVR) is impaired or not.\n\nSince the key criteria of recent stroke/TIA with severe intracranial stenosis are met, but we don't have information about CVR impairment, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "913": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for this trial. The trial is focused on assessing the relationship between heterotopic ossification (HO) of the elbow joint and serum uric acid levels, while the patient note describes a case of carotid artery stenosis with no mention of elbow trauma or HO.\n\nThe inclusion criteria specifically state that participants should have a history of elbow joint fracture or dislocation, diagnosed heterotopic ossification, and complete clinical and imaging data related to the elbow condition. The patient note does not provide any information relevant to these criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "914": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\nHe has a history of asymptomatic carotid artery stenosis, with severe stenosis (>50%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery. This meets the inclusion criteria of having a stenosis of the internal carotid artery of 50% or higher, without any recent cerebrovascular events.\n\nThe patient also meets the following risk factor criteria:\n- LDL cholesterol > 2.6 mmol/l (his LDL-C was 545 mg/dL, which is very high)\n- HDL cholesterol < 1.2 mmol/l in males (his HDL-C was 53 mg/dL, which is low)\n\nBased on the information provided, the patient meets the inclusion criteria for the clinical trial on the lifestyle modification program for patients with asymptomatic carotid artery stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "915": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u226518 years\nThe patient is 46 years old, so this criterion is met.\n\n2. Sufficient English language ability to adequately understand the study\nNo information is provided about the patient's language ability, so I cannot determine if this criterion is met. \n\n3. Able to give informed consent\nNo information is provided about the patient's ability to give informed consent, so I cannot determine if this criterion is met.\n\n4. Significant carotid artery plaque with 50-70% stenosis on ultrasound or MRI performed prior to screening\nThe patient has severe stenosis (>70%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA), so this criterion is met.\n\n5. Significant asymptomatic carotid artery plaque with >70% stenosis on ultrasound or MRI performed prior to screening, but carotid endarterectomy or carotid artery stenting has been deemed unsuitable by multidisciplinary team during routine clinical care\nNo information is provided about whether carotid endarterectomy or stenting was deemed unsuitable, so I cannot determine if this criterion is met.\n\n6. Lipid-rich necrotic core (LRNC) on baseline MRI scan\nNo information is provided about the presence of an LRNC on MRI, so I cannot determine if this criterion is met.\n\n7. Adequate image quality for MRI analysis\nNo information is provided about the image quality of the MRI, so I cannot determine if this criterion is met.\n\n8. LDL-C \u22652.6 mmol/L (100 mg/dL)\nThe patient's LDL-C level is 545 mg/dL, which is well above the cutoff of 100 mg/dL, so this criterion is met.\n\n9. On stable dose of maximally-tolerated lipid-lowering therapy in accordance with UK national clinical guidelines (NICE CG18120) for \u22652 months prior to screening. Acceptable non-statin lipid-lowering medications include ezetimibe or a fibrate.\nThe patient reported no use of lipid-lowering medications, so this criterion is not met.\n\nIn summary, while some of the inclusion criteria are met (age, carotid stenosis, high LDL-C), there is insufficient information to determine if several other criteria are met. Additionally, the patient is not on lipid-lowering therapy, which is an inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "916": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 or over.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), indicating an indication for carotid revascularization procedure (surgery or angioplasty and stenting).\n\n3. There is no information provided about the patient's acceptance to participate in the protocol.\n\nBased on the available information, the patient meets two out of the three inclusion criteria for the clinical trial. However, there is not enough information to determine if the patient has accepted to participate in the protocol.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "917": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the \"Adult patients\" criteria.\n\n2. The patient has high LDL-C levels (545 mg/dL) and is not on any lipid-lowering medications, indicating primary hypercholesterolemia.\n\n3. The patient is not explicitly stated to be on the ezetimibe-rosuvastatin combination therapy yet. However, the inclusion criteria state \"Adult patient adequately controlled with rosuvastatin and ezetimibe according to ESC / EAS 2019 guidelines.\"\n\n4. Based on the ESC/EAS 2019 guidelines, the target LDL-C level for this patient (with carotid artery disease) should be <55 mg/dL. With an LDL-C of 545 mg/dL, the patient is not adequately controlled.\n\n5. Therefore, while the patient meets some of the inclusion criteria, they do not meet the criteria of being adequately controlled with rosuvastatin and ezetimibe.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "918": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >18 years and <75 years.\n\n2. The patient has severe stenosis (>60%) in the left internal carotid artery, which meets the inclusion criteria of \"evidence of carotid artery atherosclerosis with endoluminal stenosis > 60%\".\n\nBased on the information provided in the patient note, the patient meets both of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "919": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is a reader study to evaluate the performance of radiologists when using SoftVue\u2122 automated breast ultrasound and screening mammography compared to screening mammography alone in women with dense breast parenchyma.\n\n5. The inclusion criteria for the trial are:\n   - Radiologists of any age, sex, race, ethnicity, or institutional affiliation\n   - Hold a current United States medical license\n   - Be American Board of Radiology Certified\n   - Be MQSA-qualified\n   - Be experienced in reading digital mammography (DM) images on a monitor\n   - Be experienced in reading breast ultrasound images on a monitor\n   - Have completed a Financial Disclosure showing no Conflicts of Interest\n   - Have provided a current curriculum vitae (CV)\n   - Have provided a signed Readers' Agreement\n   - Have provided written Informed Consent\n\n6. Based on the information provided, this patient does not meet the inclusion criteria for the clinical trial, as the trial is focused on radiologists and their performance in reading breast imaging studies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "920": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Age \u226518 and \u226460 years: The patient is 46 years old, so this criterion is met.\n\n2. BMI \u226525 - \u226435 kg/m2: There is no information provided about the patient's BMI, so this criterion cannot be evaluated.\n\n3. Waist circumference criteria: There is no information provided about the patient's waist circumference, so this criterion cannot be evaluated.\n\n4. Triglycerides >150 mg/dL: The patient's triglyceride level is 158 mg/dL, so this criterion is met.\n\n5. Blood pressure criteria: There is no information provided about the patient's blood pressure, so this criterion cannot be evaluated.\n\n6. Fasting blood glucose \u2265100 mg/dl: The patient's fasting glucose level is 85 mg/dL, which is below the cutoff, so this criterion is not met.\n\n7. Low HDL level criteria: The patient's HDL-C level is 53 mg/dL, which does not meet the low HDL criteria for either men or women, so this criterion is not met.\n\n8. Ready to give voluntary, written, informed consent: There is no information provided about the patient's willingness to provide consent, so this criterion cannot be evaluated.\n\nSince there are multiple inclusion criteria that cannot be evaluated due to lack of information, and at least one criterion (fasting blood glucose) that is not met, I would conclude:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "921": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria.\n\nHe has severe stenosis (>50%) in the left internal carotid artery and moderate stenosis (40-50%) in the right internal carotid artery, meeting the inclusion criteria for stenosis.\n\nThere is no mention of any stroke, TIA or amaurosis fugax symptoms, so he does not meet that part of the inclusion criteria. \n\nHowever, he does have stenosis >80% in the left ICA without any neurological symptoms in the prior 180 days, which meets another part of the inclusion criteria.\n\nThe target vessel diameter requirements are not mentioned, so I cannot assess that criteria.\n\nThere is no mention of the patient being unwilling to comply with protocol requirements.\n\nHis life expectancy is not mentioned, so I cannot assess if he meets the >=3 year life expectancy criteria.\n\nThere is no information given about him meeting any of the high surgical risk criteria listed.\n\nLooking at the exclusion criteria:\n- No mention of chronic atrial fibrillation\n- No mention of paroxysmal atrial fibrillation episodes\n- No mentioned cardiac sources of emboli\n- No recently implanted heart valves\n- No intracranial or extracranial arterial stenosis greater than the lesion\n- No cerebral aneurysm, AVM or other abnormal angiographic findings mentioned\n- No history of intracranial hemorrhage\n- No hemorrhagic transformation of ischemic stroke\n- No major stroke with neurological deficit \n- No evolving stroke\n- No intracranial tumor\n- No neurological illnesses that could mimic TIA/stroke\n- No TIA/amaurosis fugax within 48 hours\n- No isolated middle cerebral artery supply mentioned\n- No mention of bleeding diathesis/coagulopathy\n- No recent CABG, stent, valve or vascular surgery mentioned\n- No recent myocardial infarction mentioned\n- No occlusion of the carotid arteries\n- No intraluminal filling defects mentioned\n- No carotid string sign mentioned\n- No >50% stenosis of the common carotid artery ostium\n- No open neck stoma mentioned\n- No history of neck irradiation mentioned\n- Patient is male, not pregnant\n- No mentioned intolerance/allergies to medications/stent materials\n- Life expectancy not mentioned to assess <3 years\n- No recent GI bleed mentioned\n- Not mentioned as participating in another trial\n- No inability to understand/cooperate with procedures mentioned\n- No extensive/diffuse atherosclerotic disease in proximal CCA mentioned\n- Not mentioned as otherwise unsuitable by physician\n- No metallic implants preventing MRI mentioned\n\nOverall, based on the information provided, the patient seems to meet the key inclusion criteria of carotid artery stenosis >80% without recent symptoms. There is no clear exclusion criteria that he meets.\n\nHowever, there are some criteria I cannot definitively assess like target vessel diameter, life expectancy, high surgical risk factors.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "922": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient note states:\n- 46-year-old man\n- Presenting with dizziness and frequent headaches\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C 545 mg/dL, HDL-C 53 mg/dL (high cholesterol)\n- Fasting glucose and triglycerides within normal limits\n- No use of lipid-lowering medications\n- Systolic murmur and carotid artery stenosis detected\n\nThe inclusion criteria for the clinical trial are:\n- Ages 25-40 years \n- Active duty service member or veteran\n- Sustained at least 1 TBI >= 6 months and <= 5 years ago\n- Able to provide consent and understand the protocol\n\nThe key exclusion criteria are:\n- Current unstable medical conditions that require treatment \n- Unstable endocrine disorders\n- Major medical illnesses associated with fatigue\n- Use of certain sleep modifying medications\n- Psychiatric conditions requiring immediate treatment\n- Pregnancy\n- Severe obstructive sleep apnea or CPAP use\n\nBased on the information provided, this 46-year-old patient does not meet the age criteria for the clinical trial. There is also no mention of the patient being an active duty service member, veteran, or having a traumatic brain injury history.\n\nWhile high cholesterol is noted, there are no other details provided about unstable medical conditions that would exclude the patient.\n\nTherefore, given the limited information, I would assess:\n\nTrial-level eligibility: 1) Not relevant\n\nThe patient does not have sufficient information provided to qualify for this particular clinical trial on characterizing fatigue in military personnel with traumatic brain injuries.",
        "label": 0
    },
    "923": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides.\n3. He is not taking any lipid-lowering medications.\n4. Neck auscultation revealed a systolic murmur, and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n5. The inclusion criteria for the clinical trial are:\n   - Patients with ocular ischemic syndrome (OIS)\n   - Stenosis of the ipsilateral (to the affected eye) internal carotid artery (ICA) >50%\n   - Abnormal ICA blood flow velocity\n   - Ocular symptoms/signs not explained by other ocular diseases\n\n6. Based on the patient's carotid artery stenosis and abnormal blood flow velocities, it appears that the patient meets the inclusion criteria for ocular ischemic syndrome (OIS) and carotid artery stenosis >50%.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "924": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\nHe has no diagnosis of diabetes mellitus mentioned, which is required for this trial.\n\nHe does have cardiovascular risk factors:\n- Family history of CAD\n- High LDL-C level of 545 mg/dL\n- Carotid artery stenosis (severe in left internal carotid artery, moderate in right internal carotid artery)\n\nHowever, the inclusion criteria specifically require type 2 diabetes in addition to high cardiovascular risk.\n\nSince the patient does not have a diagnosis of type 2 diabetes mentioned, he does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "925": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%, which meets the inclusion criteria of having a carotid atheromatous plaque with \u226550% NASCET stenosis.\n\n3. There is no mention of the patient being from the vascular surgery department of the Louis Pradel Hospital, but this is likely not a strict requirement.\n\n4. There is no mention of any contraindications to physical activity or the patient's performance status, but the patient is described as physically active, which suggests no major limitations.\n\n5. There is no information provided about the patient's availability, ability to understand French, or having a social security system.\n\n6. There is no mention of the patient providing informed consent.\n\nBased on the information provided, the patient meets some of the key inclusion criteria, such as age and carotid stenosis severity. However, there is not enough information to definitively determine eligibility, as several criteria are not addressed in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "926": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has no other cardiovascular risk factors and is physically active.\n\nThe key points from the inclusion criteria are:\n1. Age \u2265 65 years\n2. Scheduled for a diagnostic carotid artery duplex ultrasound study\n3. Having one or more of the following: hypertension, hyperlipidemia, diabetes, tobacco usage, known CAD/PAD, or family history of early onset of atherosclerotic disease.\n\nThe patient is 46 years old, which does not meet the age criteria of \u2265 65 years. However, he has undergone a carotid artery duplex ultrasound study, which revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nAdditionally, the patient has hyperlipidemia (LDL-C of 545 mg/dL) and a family history of CAD, which meets one of the inclusion criteria.\n\nBased on the information provided, the patient meets some of the inclusion criteria but does not meet the age requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "927": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18 years and older.\n\nHe has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating coronary artery disease.\n\nThe note mentions he is physically active, and there are no other medical conditions mentioned that would affect sports participation.\n\nBased on the information provided, this patient seems to meet the inclusion criteria of:\n1) Age 18 years and older\n2) Stable coronary artery disease\n3) No current medical conditions affecting sports participation\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "928": {
        "output": "To determine the patient's eligibility for the \"Vivio AS (Aortic Stenosis) Detection Study\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. Adult subjects (21 years of age or older).\nThe patient is 46 years old, so this criterion is met.\n\n2. Referred for transthoracic echocardiography by physician/primary care provider/cardiologist.\nThe patient note does not explicitly mention a referral for transthoracic echocardiography, but it does state that an ultrasonography of the carotid arteries was performed, which revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\n3. Willing and able to participate in all study evaluations and allow access to medical testing and records.\nThere is no information provided about the patient's willingness or ability to participate in the study evaluations or allow access to medical records.\n\n4. Signed informed consent or have a legally authorized representative who provides informed consent on behalf of the subject.\nThere is no information provided about the patient signing an informed consent or having a legally authorized representative.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria for the \"Vivio AS (Aortic Stenosis) Detection Study\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "929": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Senofilcon A Lenses in Moderate to Severe Dry Eye Disease\", the patient does not appear to have any information related to dry eye disease or ocular conditions. The note describes a 46-year-old man with dizziness, frequent headaches, a family history of coronary artery disease (CAD), and carotid artery stenosis.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria for the dry eye disease clinical trial, the assessment of eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "930": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and carotid artery stenosis. The clinical trial is focused on the effects of whole-body vibration training for patients who have undergone total knee arthroplasty (knee replacement surgery) due to knee osteoarthritis.\n\nThe patient note does not mention knee osteoarthritis or a total knee arthroplasty. Therefore, the patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "931": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Internal Carotid Artery Blood Flow in Pediatric Moyamoya Patients\", the patient does not meet the inclusion criteria for this trial.\n\nThe key reasons are:\n\n1. The patient is a 46-year-old man, while the trial is specifically recruiting pediatric patients.\n2. The patient's condition is related to carotid artery stenosis, not moyamoya disease, which is the focus of the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "932": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is titled \"PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement\" and aims to evaluate the use of the Sentinel\u00ae Cerebral Protection System in reducing the risk of peri-procedural stroke after transcatheter aortic valve replacement (TAVR).\n\n5. The inclusion criteria for the trial are:\n   a. Subject has documented aortic valve stenosis and is treated with an approved TAVR device via transfemoral access.\n   b. Subject has the recommended artery diameter at the site of filter placement per the Sentinel\u00ae Cerebral Protection System Instructions For Use: 9-15 mm for the brachiocephalic artery and 6.5-10 mm in the left common carotid artery.\n   c. Subject (or legal representative) provides written informed consent.\n\n6. Based on the patient note, there is no mention of aortic valve stenosis or the need for TAVR. The patient's presentation and findings are related to carotid artery stenosis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "933": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. The patient does not have a diagnosis of multiple sclerosis or any mention of lower urinary tract symptoms. These are key inclusion criteria for the given clinical trial, which is about assessing the relationship between severity of lower urinary tract symptoms and risk of falling in people with multiple sclerosis.\n\n3. There is no information provided about the patient's Expanded Disability Status Scale score, which is another inclusion criteria.\n\n4. The patient note is focused on describing the patient's cardiovascular health, carotid artery stenosis, and lipid profile. This does not seem relevant to the clinical trial about lower urinary tract symptoms and falls in multiple sclerosis patients.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria of the clinical trial, this patient does not appear to be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "934": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur in the neck, and ultrasonography showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA).\n\n4. The clinical trial is focused on carotid and intracranial arterial stenosis in ischemic stroke patients.\n\n5. The inclusion criteria for the trial are:\n   a) Carotid TIA (transient ischemic attack) or ischemic stroke involving the carotid territory.\n   b) Asymptomatic patients with carotid stenosis or anterior circulation stenosis discovered accidentally during investigations for further risk factors.\n\n6. Based on the patient's presentation with dizziness, headaches, and the presence of severe LICA stenosis and moderate RICA stenosis, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "935": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial.\n2. The patient has no diagnosis of psoriatic arthritis mentioned, which is a key inclusion criteria for this trial. \n3. The patient has carotid artery stenosis, but the inclusion criteria specifically mentions asymptomatic carotid plaques with <50% stenosis. The patient has severe stenosis in the left internal carotid artery, which would likely exclude them.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of having psoriatic arthritis and asymptomatic carotid plaques with <50% stenosis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "936": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of 18-90 years.\n\nHe has a family history of CAD and high LDL-C level of 545 mg/dL, which suggests he has cardiovascular risk factors.\n\nThe patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating he has peripheral vascular disease.\n\nHe does not have a diagnosis of prostate cancer, which is required for inclusion in this trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this specific clinical trial on cardiovascular events in GnRH agonist vs. antagonist treatment for prostate cancer patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "937": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Pain Management for Cystoscopy: A Prospective Randomized Study Focused on Understanding the Role of the Bag Squeeze to Manage Pain for Patients Undergoing Cystoscopy\", the patient does not meet the inclusion criteria for this trial.\n\nThe key points are:\n\n1. The patient is a 46-year-old man, which meets the \"Male\" inclusion criterion.\n2. However, the patient note does not mention that the patient is undergoing a flexible cystoscopy at the University Health Network.\n3. The patient note also does not provide any information about whether the patient has previously undergone a flexible cystoscopy or has any history of pelvic pain.\n\nSince there is insufficient information to determine if the patient meets all the inclusion criteria, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "938": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226520 years and \u226480 years in the inclusion criteria.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meets the inclusion criteria of \"Target lesion located at the carotid bifurcation and/or proximal internal carotid artery (ICA).\"\n\n3. The stenosis is described as \"severe\" for the LICA, which likely meets the criteria of \u226550% stenosis if symptomatic or \u226580% stenosis if asymptomatic.\n\n4. The patient has dizziness and frequent headaches, which could potentially be considered symptoms related to the carotid stenosis, but this is not explicitly stated.\n\n5. There is no information provided about the patient's medical history or comorbidities to determine if they meet the high-risk criteria for carotid endarterectomy (CEA).\n\nBased on the information provided, the patient appears to meet some of the key inclusion criteria for the clinical trial, such as age and carotid artery stenosis location and severity. However, there is not enough information to definitively determine if the patient meets all the inclusion criteria, particularly regarding symptoms related to the stenosis and high-risk factors for CEA.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "939": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur in the neck, and ultrasonography showed severe stenosis (>70%) in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery, extending to the middle third of the ICAs.\n\nThe clinical trial is a prospective comparative randomized single-center non-inferiority trial comparing a modified method of eversion carotid endarterectomy with the standard eversion carotid endarterectomy in patients with extensive atherosclerotic disease of the carotid bifurcation.\n\nThe inclusion criteria for the trial are:\n1. Patients with stenosis of the internal carotid artery (ICA) between 70-99% (as assessed by ultrasound and CT angiography)\n2. Patients with an extensive lesion of the ICA (plaque < 2 cm) by ultrasound and CT angiography\n\nBased on the patient's presentation and the inclusion criteria, this patient meets the criteria for the trial as he has severe stenosis (>70%) in the LICA and moderate stenosis (40-50%) in the RICA, as well as plaque observed in the anterior and posterior walls of the ICA and common carotid artery.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "940": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches. This aligns with the inclusion criteria of being diagnosed with Persistent Postural Perceptual Dizziness (3PD).\n\n2. The patient does not have any other major medical conditions mentioned that would exclude him from the trial.\n\n3. The trial is recruiting patients from the balance clinic at Guy's Hospital, but the patient's location is not specified in the note.\n\nBased on the information provided, there is not enough evidence to definitively determine if the patient meets the inclusion criteria of being diagnosed with 3PD at the balance clinic at Guy's Hospital.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "941": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being at least 18 years old.\n\n2. The patient has carotid artery stenosis, which is not the target disease of coronary artery disease (CAD) required for this trial. \n\n3. The inclusion criteria specifically state that the patient must have evidence of myocardial ischemia and be a candidate for percutaneous coronary intervention (PCI). This patient does not appear to meet those criteria based on the provided note.\n\n4. The angiographic inclusion criteria are very specific about lesion location, length, diameter stenosis, etc. which this patient note does not provide details about for coronary arteries.\n\n5. Some of the exclusion criteria that may apply are: no acute myocardial infarction within 48 hours, no prior PCI within 12 months, and no cerebrovascular events within 6 months (the patient had dizziness and headaches which could potentially indicate a prior event).\n\nIn summary, while the patient's age meets the criteria, there is insufficient information provided about coronary artery disease, myocardial ischemia, or suitability for PCI to determine if they would be eligible for this specific trial targeting long coronary lesions.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "942": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he does not have other cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus, and is physically active.\n\nHis lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose (85 mg/dL), and triglycerides (158 mg/dL). He is not taking any lipid-lowering medications.\n\nPhysical examination revealed a systolic murmur and carotid artery ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nThe clinical trial is aimed at validating the use of micro-electro-mechanical sensors (gyroscope and accelerometer) in detecting hemodynamically significant coronary artery disease (CAD).\n\nThe inclusion criteria for the trial are:\n1. Age > 18 years\n2. Patients visiting the hospital for suspected CAD and undergoing coronary computed tomography angiography (CCTA)\n3. Signed informed consent to participate in the trial\n\nBased on the information provided, the patient meets the age criterion (46 years old) and is visiting the hospital for suspected CAD (as evidenced by the carotid artery stenosis and plaque findings). However, there is no mention of the patient undergoing CCTA or providing informed consent.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "943": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). He has high LDL cholesterol (545 mg/dL) but normal other lipid levels, glucose, and no major cardiovascular risk factors like smoking or diabetes. Ultrasound revealed severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial is investigating brain microcirculation in patients with septic and non-septic shock using contrast-enhanced ultrasound.\n\nThe inclusion criteria are:\n1) Septic shock criteria (refractory hypotension, hypoperfusion, high lactate, oliguria, mental status changes)\n2) Cardiogenic shock following acute MI or post-cardiac surgery with oliguria and mental status changes\n\nBased on the patient note, there is no indication that the patient has septic shock or cardiogenic shock meeting the trial inclusion criteria. The patient's presentation seems to be related to carotid artery stenosis rather than shock.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "944": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-80 years old.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meets the inclusion criteria of \"Occlusion of the common carotid artery or internal carotid artery (mTICI=0) confirmed by DSA\".\n\n3. The occlusion is in the internal carotid arteries, which meets the criteria of \"The origin of occlusive segment is from the common carotid artery or the initial segment of the internal carotid artery to the petrous segment and above, and does not exceed the bifurcation of the internal carotid artery (C7 segment)\".\n\n4. The patient is presenting with dizziness and frequent headaches, which could be associated with the carotid artery occlusion, meeting the criteria of \"Ischemic stroke, TIA or progressive visual/cognition impairment associated with occlusion\".\n\n5. There is no information provided about the duration of the occlusion or the presence of a distinguishable hypoperfusion area indicated by CT perfusion.\n\nBased on the information provided, the patient meets most of the inclusion criteria, but there is not enough information to determine if the occlusion is over 24 hours and if there is a distinguishable hypoperfusion area indicated by CT perfusion.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "945": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis. The clinical trial is investigating brain microcirculation using contrast-enhanced ultrasound in patients who have had successful resuscitation after cardiorespiratory arrest.\n\nThe key inclusion criterion for the trial is \"ICU patients with successful resuscitation after out-hospital or in-hospital cardiorespiratory arrest.\"\n\nBased on the patient note provided, there is no mention of the patient having experienced a cardiorespiratory arrest or being resuscitated. The note describes the patient's carotid artery stenosis and cardiovascular risk factors.\n\nSince the patient does not meet the key inclusion criterion of having had a successful resuscitation after cardiorespiratory arrest, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "946": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226514 years.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%. This meets the inclusion criteria of \"1-2 branches with the stenotic rate < 70% involved\".\n\n3. The patient is experiencing dizziness and frequent headaches, which could be considered \"mildly ischemic manifestation relative to activity but relieve after rest\".\n\n4. There is no information provided about the patient's blood pressure, NYHF class, or eGFR, so we cannot determine if they meet those inclusion criteria.\n\nSince we don't have complete information to definitively determine eligibility, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "947": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226514 years old.\n\n2. There is no information provided about the Kerr score or disease activity, so the \"active: Kerr score\u22652\" criteria cannot be assessed.\n\n3. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). This meets the criteria of \"\u22653 branches with the stenotic rate >70% involved.\"\n\n4. There is no information provided about the patient's blood pressure, New York Heart Association functional classification, or estimated glomerular filtration rate (eGFR). Therefore, the criteria related to these factors cannot be assessed.\n\nSince the patient meets at least one of the criteria for severe disease (\u22653 branches with stenotic rate >70% involved) and the age criteria, but there is insufficient information to assess all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "948": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being 18 years or older.\n\n2. The patient is not undergoing multi-level posterior cervical fusion surgery, which is a key inclusion criterion for this trial. \n\n3. The patient's condition appears to be related to carotid artery stenosis and high cholesterol levels, which is not relevant to this surgical trial.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the \"Cervical Orthosis Versus no Orthosis Following Multi-level Posterior Cervical Fusion\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "949": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man with carotid artery stenosis, which matches the inclusion criteria of \"Clinical diagnosis of carotid artery stenosis\".\n\n2. The trial does not specify any exclusion criteria related to other medical conditions or medications.\n\n3. The trial requires age-gender-race-matched controls, but does not explicitly state that the patient must be included in the study group.\n\nBased on the information provided, there is sufficient evidence to determine that the patient meets the inclusion criteria for the clinical trial on carotid artery stenosis and ocular changes.\n\nHowever, since the trial also requires matched controls, and it is unclear if the patient will be part of the study group or control group, I cannot definitively conclude eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "950": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being > 18 years old.\n\n2. There is no information provided about the patient's ability to understand and sign an informed consent.\n\n3. The patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which suggests eligibility for percutaneous peripheral intervention.\n\n4. There is no information provided about the patient's IIEF-5 score or whether they have tried and failed oral PDE5-I therapy for at least 6 months.\n\n5. The patient's peak systolic velocity (PSV) in the left internal carotid artery is 208.5 cm/s, which is higher than the inclusion criteria of PSV < 25 cm/sec.\n\n6. There is no information provided about the patient's hemodynamic conditions or ejection fraction.\n\n7. There is no information provided about the patient having treatable angiographic lesions of the pudendal arteries.\n\nBased on the information provided, there is not enough evidence to determine if the patient meets all the inclusion criteria for this clinical trial. Specifically, we lack information about the patient's IIEF-5 score, PDE5-I treatment history, hemodynamic conditions, ejection fraction, and pudendal artery lesions.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "951": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria (\u226518 years) for the trial.\n\nThere is no explicit mention of the patient having a ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI) diagnosis in the patient note. However, the note does mention severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, which could potentially lead to a myocardial infarction.\n\nThe patient note also mentions that the patient has not reported using any lipid-lowering medications, which is relevant for a trial assessing the effects of long-term lipid-lowering therapy.\n\nWhile the patient note does not explicitly confirm the presence of an infarct-related artery, the severe stenosis in the left internal carotid artery could potentially be considered as such.\n\nBased on the information provided in the patient note, there is not enough evidence to definitively confirm or exclude the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "952": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is focused on patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic valve stenosis and concomitant coronary artery disease (CAD).\n\n5. The inclusion criteria for the trial are patients who underwent a TAVI procedure at \u00d6rebro University Hospital between 2009 and December 1, 2019.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial, as there is no mention of the patient undergoing a TAVI procedure or having severe aortic valve stenosis. The patient's presentation and findings are related to carotid artery stenosis and dyslipidemia, which are not relevant to the trial's focus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "953": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The inclusion criteria for the clinical trial are:\n   - Admitted ischemic occlusive stroke after successful reperfusion therapy\n   - Stabilized in ICU or the inward\n   - Attack started 48 hours or less\n   - Can be fed by nasogastric tube or by himself\n   - MRI imaging was taken in the first 24 hours and CT\n\n5. Based on the patient note, there is no mention of the patient having an ischemic stroke or being admitted for one. The note primarily focuses on the patient's carotid artery stenosis and lipid profile.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "954": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of >30 years.\n2. The patient does not have diabetes mellitus, which is a key inclusion criterion for this trial.\n3. The patient has high LDL-C levels and carotid artery stenosis, but these are not relevant to the inclusion criteria for this trial.\n\nBased on the information provided, the patient does not meet the inclusion criteria of having diabetes mellitus for at least 10 years and being asymptomatic.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "955": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 46-year-old man presenting with dizziness and frequent headaches. He has a family history of coronary artery disease (CAD) but no other cardiovascular risk factors. His lipid profile shows high LDL-C and normal HDL-C, fasting glucose, and triglycerides. He has no history of lipid-lowering medication use. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\nThe clinical trial titled \"Factors Affecting Outcome of Vestibular Rehabilitation\" is an observational study investigating the relationship between illness perceptions and improvement in dizziness handicap following vestibular rehabilitation.\n\nThe inclusion criteria for this trial are:\n1) Aged above 18 years old\n2) Enrolled in the vestibular rehabilitation program due to chronic dizziness\n\nBased on the patient note, the 46-year-old man meets the age criterion (above 18 years old) and presents with dizziness, which would likely qualify him for enrollment in the vestibular rehabilitation program.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "956": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man presenting with dizziness, frequent headaches, and carotid artery stenosis, but there is no mention of a diagnosis of moderate to severe plaque psoriasis or any treatment with etanercept (Enbrel).\n\nThe inclusion criteria for the trial specifically require:\n\n1. Confirmed diagnosis of moderate to severe plaque psoriasis\n2. Receiving etanercept treatment for a minimum duration of 1 year\n3. No history of using a biological treatment other than etanercept for moderate to severe plaque psoriasis or any other reason\n\nSince the patient note does not indicate that the patient has plaque psoriasis or has been treated with etanercept, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "957": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Adults aged 18 years and older\nThe patient is 46 years old, so this criterion is met.\n\n2. Patient or patient's legal healthcare proxy consents to participation\nThere is no information provided about consent, so this cannot be evaluated.\n\n3. Have an audible heart murmur in at least one auscultation position, as heard by a clinician\nThe patient note states \"Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\" So this criterion is met.\n\n4. Undergoing or have undergone a complete (i.e., not limited) echocardiogram\nThe patient note mentions \"Ultrasonography of the carotid arteries\" but does not specify if a complete echocardiogram was done. So this cannot be definitively evaluated.\n\n5. Willing to have heart recordings done with two different electronic stethoscopes\nThere is no information provided about the patient's willingness, so this cannot be evaluated.\n\nBased on the information given, the patient meets at least one of the inclusion criteria (having an audible heart murmur). However, there is not enough information to determine if the other criteria are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "958": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial (no specific age range given in the inclusion criteria).\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). \n\n3. The patient has at least one atherosclerotic plaque in the carotid artery that is thicker than 2.0 mm (severe stenosis in LICA implies plaque thickness >2.0 mm).\n\n4. The plaque is described as \"predominantly echogenic and hyperechoic, with less than 50% of the area being echolucent with uneven surfaces.\" This meets the inclusion criteria of the plaque being \"uniformly or predominantly echolucent.\"\n\n5. The patient is not currently on any lipid-lowering medication, so they would be eligible for the Elococumab Injection treatment in the trial.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria for the clinical trial titled \"The Changes in Carotid Plaque Neovascularization After Elovocumab Therapy.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "959": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Patients with stable symptoms and low to intermediate probability of coronary artery disease (CAD) referred for evaluation\"\n   - The patient presents with dizziness and frequent headaches, which could be symptoms of CAD. However, the note does not specify the probability of CAD.\n\n2. \"Patients without known history of CAD\"\n   - The note does not mention any known history of CAD for the patient.\n\n3. \"Patients older than 18 years\"\n   - The patient is 46 years old, which meets this criterion.\n\n4. \"Patients giving voluntary written consent to participate in the study\"\n   - There is no information provided about the patient's consent.\n\n5. \"Subject is willing to comply with study follow-up requirements\"\n   - There is no information provided about the patient's willingness to comply with follow-up requirements.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets all the inclusion criteria for the clinical trial. Some key information is missing, such as the probability of CAD, the patient's consent, and willingness to comply with follow-up requirements.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "960": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The patient does not have moderate-to-severe plaque psoriasis, which is a requirement for the trial.\n2. The patient has not been receiving etanercept (Enbrel) treatment for at least 1 year, which is another inclusion criterion.\n\nThe patient note describes a 46-year-old man with dizziness, headaches, and carotid artery stenosis, but there is no mention of psoriasis or any psoriasis treatment.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "961": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and abnormal lipid levels (high LDL-C and low HDL-C). The note also mentions carotid artery stenosis and the presence of plaque in the carotid arteries.\n\nThe clinical trial titled \"Differences in Fat Mass Estimation Formulas in Physically Active Adult Population and Relation With Skinfold Sums\" has the following inclusion criteria:\n\n\"To be between 18 and 50 years old and to practice any sport in a regular basis\"\n\nBased on the information provided in the patient note, there is no mention of the patient practicing any sport or being physically active on a regular basis. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "962": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which could be indicative of a carotid web lesion.\n\n3. The patient has experienced dizziness and frequent headaches, which could be symptoms of a transient ischemic attack or cerebral infarction in the carotid area downstream of a carotid web lesion.\n\n4. The inclusion criteria require validation of the carotid web by a pair of experts (Neurologist and Neuroradiologist), which is not mentioned in the patient note.\n\n5. The inclusion criteria also require the agreement of the patient or the support person after reading the information and non-opposition form, which is not mentioned in the patient note.\n\nBased on the information provided in the patient note, the patient meets some of the inclusion criteria, but there is not enough information to determine if they meet all the criteria, specifically the validation of the carotid web by experts and the agreement of the patient or support person.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "963": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD.\n2. His LDL-C level is very high at 545 mg/dL (normal <130 mg/dL), indicating potential hyperlipidemia.\n3. He has no other cardiovascular risk factors like smoking, hypertension, or diabetes.\n4. Carotid ultrasound revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), indicating the presence of atherosclerosis.\n\nNow let's look at the inclusion criteria for the clinical trial:\n\n1. Healthy participants with LDL <130 mg/dL without evidence of atherosclerosis.\n2. Participants with LDL >160 mg/dL, without evidence of atherosclerosis.\n3. Participants with LDL >160 mg/dL, with evidence of atherosclerosis.\n\nBased on the patient's very high LDL level (545 mg/dL) and the evidence of atherosclerosis from the carotid ultrasound findings, this patient meets the third inclusion criterion for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "964": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His LDL-C level is very high at 545 mg/dL, but his HDL-C, fasting glucose, and triglyceride levels are within normal limits.\n\n3. He is not taking any lipid-lowering medications.\n\n4. Examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery.\n\n5. The clinical trial is focused on lowering blood pressure through lifestyle modifications in a rural area of Bangladesh.\n\n6. The inclusion criteria for the trial are:\n   - Participants with clinic blood pressure \u2265 130/80 mmHg who are not taking medication\n   - Participants with controlled blood pressure (< 130/80 mmHg) using anti-hypertensive medication for a minimum of six weeks\n   - Participants living in Banshgram Union only\n\nBased on the information provided, this patient does not meet the inclusion criteria for the clinical trial, as he is not being treated for high blood pressure and does not live in the specified area (Banshgram Union). Additionally, the trial is focused on lifestyle modifications for lowering blood pressure, while the patient's primary issue appears to be related to carotid artery stenosis and high LDL-C levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "965": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, so he meets the age criteria of being \u226555 years old.\n\nThere is no information provided about whether the patient is willing and able to provide written informed consent or comply with study procedures.\n\nThe key piece of information is that the patient has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery. However, the inclusion criteria do not mention anything about carotid artery stenosis or other cardiovascular conditions.\n\nThe main inclusion criterion is that the patient must have an active Medtronic Reveal LINQ device that has been implanted for at least 60 days but no more than 3 years. There is no mention of the patient having such a device implanted.\n\nBased on the information provided, there is insufficient evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "966": {
        "output": "To determine the patient's eligibility for the clinical trial \"Universal Familial Hypercholesterolemia Screening in Children\", let's go through the inclusion criteria one by one:\n\n1. Elevated total cholesterol (cohort 1) or LDL-cholesterol (cohort 2) at universal screening program in children.\nThe patient's LDL-C level is 545 mg/dL, which is significantly elevated, meeting this criterion.\n\n2. Completed FH genetic analysis (cohort 3).\nThere is no information provided about whether the patient has undergone genetic analysis for familial hypercholesterolemia (FH).\n\n3. Parent or sibling of child with confirmed familial hypercholesterolemia (cohort 4).\nThere is no information provided about whether the patient has a child or sibling with confirmed FH.\n\nSince the patient meets the first inclusion criterion of having an elevated LDL-C level, and there is no information to exclude them based on the other criteria, the patient can be considered potentially eligible for the trial.\n\nHowever, it's important to note that the exclusion criteria for the trial are not provided, and there may be additional factors that could exclude the patient from participating.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "967": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of 18-64 years old for the clinical trial.\n\n2. The patient's BMI is not provided, so we cannot determine if he meets the BMI criteria of 20.0-29.9 kg/m^2.\n\n3. The patient note mentions that he has no cardiovascular risk factors like smoking, high blood pressure, and diabetes mellitus, and is physically active. However, it also mentions that he has a family history of CAD and has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The inclusion criteria state that participants should be \"generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\"\n\n5. While the patient does not have traditional risk factors like smoking or diabetes, the presence of severe carotid artery stenosis and a family history of CAD may disqualify him from being considered \"generally healthy.\"\n\n6. Without additional information from the screening visit, physical examination, vital signs, electrocardiogram, and laboratory tests, it is difficult to determine if the patient would be considered eligible or not.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "968": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of <70 years.\n\nHe has a family history of CAD, indicating stable coronary heart disease, which meets one of the inclusion criteria.\n\nHis LDL-C level is 545 mg/dL, which is considered high and meets the \"high LDL levels\" criteria.\n\nHis HDL-C level is 53 mg/dL, which is considered low and meets the \"low HDL\" criteria.\n\nHis triglyceride level of 158 mg/dL is within normal limits, so it does not meet the \"high triglycerides\" criteria.\n\nThe patient reported no use of lipid-lowering medications, which is not an exclusion criterion.\n\nBased on the information provided, the patient meets most of the inclusion criteria for the clinical trial, except for the \"high triglycerides\" criterion.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "969": {
        "output": "Based on the patient note provided, the patient does not seem to have valvular heart disease. The note mentions carotid artery stenosis and elevated LDL cholesterol levels, but no information about valvular heart disease.\n\nSince the inclusion criteria for the clinical trial \"Epidemiology and Long-term Outcome of Patients With VHD\" specifically requires patients with moderate or severe valvular heart disease, this patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "970": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and non-pregnant female patients or female patients of childbearing age on contraception age 18-80years.\nThe patient note states that the patient is a 46-year-old man, so this criterion is met.\n\n2. Total HDL level 38mg/dL or lower in men and HDL 45 mg/dL or lower in women and a low HDL-P defined as less than 7000 by Spectracell LPP Plus.\nThe patient's HDL-C level is 53 mg/dL, which is higher than the cutoff of 38 mg/dL for men. However, there is no information provided about the HDL-P level.\n\n3. CHL HDL Fx score equal to or greater than 0.9.\nThere is no information provided about the patient's CHL HDL Fx score.\n\n4. Patients will remain on their present diet, exercise program, medications (except for those who alter serum lipids) sleeping habits, alcohol intake, caffeine intake, smoking amount and emotional status as best as possible related to stress and anxiety and maintain body weight at baseline visit as best as possible to avoid confounding variables.\nThere is no information provided about the patient's diet, exercise, medications, sleeping habits, alcohol/caffeine intake, smoking, emotional status, or weight.\n\n5. No other lipid lowering supplement can be taken during the study.\nThe patient note states that the patient reported no use of lipid-lowering medications.\n\n6. All lipid lowering supplements must have been discontinued at least 30 days prior to study entry.\nThere is no information provided about whether the patient has taken any lipid-lowering supplements in the past.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all of the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "971": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for the trial (no specific age range is mentioned in the inclusion criteria).\n\n2. The patient has carotid artery stenosis and plaque, which is relevant to the trial's aim of assessing carotid plaque vulnerability using multiple ultrasound techniques.\n\n3. The patient is suitable for contrast-enhanced ultrasound (CEUS) examination, as mentioned in the inclusion criteria.\n\n4. There is no information provided about whether the patient has voluntarily enrolled in the study or signed an informed consent form.\n\nBased on the available information, the patient appears to meet two out of the three inclusion criteria explicitly stated. However, there is no information about voluntary enrollment or informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "972": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy\", let's go through the inclusion criteria one by one:\n\n1. Age \u2265 40 years old: The patient is 46 years old, so this criterion is met.\n\n2. Significant (70-99%) carotid artery stenosis on one side, as measured by duplex ultrasound or angiogram: The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA), as confirmed by ultrasonography. This criterion is met.\n\n3. Asymptomatic carotid stenosis (no history of ipsilateral stroke or TIA within 180 days): The patient presents with dizziness and frequent headaches, but there is no mention of a history of stroke or TIA. This criterion is likely met, assuming the symptoms are not related to a recent stroke or TIA.\n\n4. Deemed to be fit for carotid endarterectomy: There is no information provided about the patient's fitness for carotid endarterectomy.\n\n5. At least one of the following high-risk features: \n   a) prior stroke >6months prior to randomization: Not mentioned\n   b) peripheral artery disease: Not mentioned\n   c) current smoker: Not mentioned\n   d) type 2 diabetes: Not mentioned\n   e) eGFR \u2265 30 mL/min/1.73m2 and <60 ml/min/1.73m2: Not mentioned\n   f) hsCRP > 2mg/L in the absence of alternative known causes of hsCRP elevations including autoimmune diseases or active infections: Not mentioned\n\n6. On a moderate to high intensity statin therapy: The patient reported no use of lipid-lowering medications.\n\nBased on the information provided, the patient meets criteria 1, 2, and 3, but there is not enough information to determine if criteria 4, 5, and 6 are met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 1
    },
    "973": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of < 18 years and < 80 years specified in the inclusion criteria.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), indicating the presence of carotid plaque. This meets the inclusion criteria of \"At least one imaging examination suggested the presence of carotid plaque\".\n\nThere is no mention of the patient having any allergy to contrast-enhanced ultrasound or other contraindications.\n\nThe note does not explicitly state whether the patient voluntarily enrolled in the study, but we can assume that since the patient underwent the necessary examinations, they likely consented to participate.\n\nBased on the information provided in the patient note, the patient appears to meet all the inclusion criteria for the clinical trial \"Artificial Intelligence Based Comprehensive Assessment System of Carotid Plaque Stability\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "974": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness and frequent headaches. This aligns with the inclusion criteria of having a diagnosis of tension-type headache (TTH).\n\n2. The patient does not have any cardiovascular risk factors like smoking, high blood pressure, or diabetes mellitus, which is good.\n\n3. The patient's LDL-C level is high at 545 mg/dL, but this is not an exclusion criterion for the trial.\n\n4. The patient reported no use of lipid-lowering medications, which is also not an exclusion criterion.\n\n5. The patient has carotid artery stenosis, but this is not mentioned in the inclusion or exclusion criteria for the trial.\n\n6. The trial's inclusion criteria specifically mention:\n   - Diagnosis of TTH based on ICHD-3 beta criteria\n   - Bilateral localization, pressing and tightening pain, mild-moderate intensity (\u22647.0 on VAS)\n   - No increase in pain during physical activity\n   - No photophobia, phonophobia, vomiting or nausea\n   - Symptoms for more than 3 months\n   - At least one segmental dysfunction of the upper cervical spine\n\nBased on the information provided in the patient note, it is unclear if the patient meets all of these specific criteria for TTH diagnosis and symptom presentation.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "975": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur in the neck, and carotid ultrasound showed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\n4. The clinical trial is titled \"Multi-contrast Versus Multi-sequence Carotid MRI,\" and its objective is to validate two multi-contrast sequences for quantifying atherosclerotic plaque components using conventional multi-sequence MRI and histology.\n\n5. The inclusion criteria for the trial are:\n   - Patients with a carotid plaque \u2265 2 mm thick based on ultrasound or CTA\n   - Age 18 years or older (no maximum age)\n   - Informed consent by signing the informed consent form\n\n6. Based on the patient's carotid ultrasound findings of severe stenosis in the LICA and moderate stenosis in the RICA, along with the presence of plaque, the patient meets the inclusion criteria of having a carotid plaque \u2265 2 mm thick.\n\n7. The patient's age of 46 years also meets the age criterion of being 18 years or older.\n\n8. Assuming the patient provides informed consent, they would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "976": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria for this trial (no specific age range given in the inclusion criteria).\n\n2. The trial is for the treatment of lesser toe deformities, specifically hammertoe deformity. The patient note does not mention any toe deformities or foot/ankle issues. \n\n3. The inclusion criteria list several medical conditions that would exclude patients, such as uncontrolled hypertension, previous myocardial infarction, neoplasms, COPD, arrhythmias, morbid obesity, uncontrolled diabetes, peripheral vascular disease, peripheral neuropathy, lumbar disc herniation, and neuromuscular alterations.\n\n4. The patient note mentions the patient has a family history of CAD but no other cardiovascular risk factors. It does not indicate if the patient has any of the other exclusionary conditions listed.\n\n5. The inclusion criteria also require palpable peripheral pulses, ankle-brachial index between 1-1.2, and oxygen saturation \u2265 95%. The patient note does not provide this information.\n\nIn summary, while the patient's age meets the criteria, there is insufficient information in the note to determine if they meet all of the other inclusion criteria related to medical conditions and vascular/neurological status of the lower extremities. More details would be needed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "977": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \"Adults at least 18 years\" for both Aim 1 and Aim 2 of the inclusion criteria.\n\n2. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), with plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery. This indicates the presence of hypoechogenic or echolucent lipid-rich soft plaque, which meets the inclusion criteria for Aim 2.\n\n3. There is no information provided about the patient's ability to provide written informed consent or willingness to participate over 5 years, which are also part of the inclusion criteria for Aim 2.\n\nBased on the available information, the patient meets the inclusion criteria for Aim 1 (Ultrasound only) but there is not enough information to determine eligibility for Aim 2 (Ultrasound and MRI).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "978": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 18-70 years specified in the inclusion criteria.\n\nThe note mentions that the patient is physically active, implying the ability to walk for at least 20 meters without support, as required by the inclusion criteria.\n\nThere is no information provided about the patient's ability to sign an informed consent form, understand instructions, or complete motor tasks. However, the lack of any mention of cognitive impairment suggests that the patient likely meets these criteria.\n\nThe note does not mention any visual acuity issues, so we can assume the patient meets the visual acuity criterion of >10/20 on the worse side.\n\nThe patient does not appear to have any unilateral motor impairments of the lower limb, such as post-stroke hemiparesis, Parkinson's disease, multiple sclerosis, unilateral amputation, surgical orthopedic interventions, or unilateral lesions of peripheral nerves. The note mentions carotid artery stenosis and associated symptoms like dizziness and headaches, but no specific motor impairments.\n\nBased on the information provided, the patient does not seem to meet the inclusion criteria for this particular clinical trial, as there is no evidence of unilateral motor impairment of the lower limb.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "979": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which falls within the age range of 35-80 years old specified in the inclusion criteria.\n\nThe patient has severe stenosis in the left internal carotid artery (LICA), with a peak systolic velocity of 208.5 cm/s and end-diastolic velocity of 54.5 cm/s, indicating severe stenosis (70-99% by NASCET criteria). This meets the inclusion criteria of \"severe carotid stenosis (MRA or CTA confirmed stenosis rate of 70% - 99%, NASCET standard)\".\n\nThe patient is described as asymptomatic, with only dizziness and frequent headaches reported. This meets the inclusion criteria of being \"asymptomatic or mild stroke (NIHSS \u2264 3) or TIA\".\n\nThere is no information provided about whether the patient agrees to participate in the clinical trial and sign the informed consent.\n\nBased on the available information, the patient appears to meet the key inclusion criteria for age, severity of carotid stenosis, and being asymptomatic/mildly symptomatic. However, there is no information about the patient's willingness to participate and provide informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial, as consent is unknown).",
        "label": 1
    },
    "980": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Evaluation of Sedation in COVID-19 ARDS\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 46-year-old man with dizziness, frequent headaches, and carotid artery stenosis. There is no mention of the patient having COVID-19 or acute respiratory distress syndrome (ARDS).\n\nThe inclusion criteria for the trial specifically states \"moderate to severe COVID-19 ARDS\".\n\nSince the patient note does not indicate that the patient has COVID-19 or ARDS, there is not enough information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "981": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of CAD. However, he has no other cardiovascular risk factors and is physically active.\n\n2. His LDL-C level is very high at 545 mg/dL, indicating potential hyperlipidemia or familial hypercholesterolemia. His HDL-C level is within normal limits.\n\n3. The patient reported no use of lipid-lowering medications.\n\n4. Examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n5. The inclusion criteria for the clinical trial are:\n   - Age > 18 years old\n   - CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI\n   - Treated with cangrelor per standard of care\n   - Treated with aspirin prior to the PCI procedure per standard of care\n\n6. Based on the information provided, the patient meets the age criterion (46 years old) and has evidence of CAD (carotid artery stenosis).\n\n7. However, there is no mention of the patient undergoing PCI or being treated with cangrelor or aspirin.\n\nTherefore, based on the available information, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "982": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). However, he has no other cardiovascular risk factors and is physically active.\n\n2. His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose (85 mg/dL), and triglycerides (158 mg/dL). He is not taking any lipid-lowering medications.\n\n3. Physical examination revealed a systolic murmur and carotid artery stenosis, with severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\n4. The clinical trial is titled \"Obesity in Pediatric Sickle Cell Disease: A New Phenomenon\" and aims to determine the prevalence of hypertension, hyperlipidemia, and hyperglycemia in obese pediatric patients with sickle cell disease (SCD) compared to non-obese pediatric patients with SCD.\n\n5. The inclusion criteria for the clinical trial are:\n   - Age 10-19 years\n   - Diagnosed with SCD genotype HbSS, HbS\u03b20, HbSC, or HbS\u03b2+\n   - Regularly followed by the UMMC Pediatric SCD clinic (at least one visit per year in the past two years)\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial because:\na) The patient is 46 years old, which is outside the age range of 10-19 years specified in the inclusion criteria.\nb) There is no mention of the patient having sickle cell disease (SCD), which is a requirement for the trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "983": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of \u226518 years old.\n\n2. The patient does not have a diagnosis of multiple sclerosis, which is one of the inclusion criteria for the given trial. \n\n3. The patient has carotid artery stenosis, which is relevant to the trial titled \"The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study\".\n\n4. The patient has severe stenosis (>60%) in the left internal carotid artery, and moderate stenosis (40-50%) in the right internal carotid artery. This meets the inclusion criteria of \"Asymptomatic carotid artery lesions between 40 and 60%, at carotid artery ultrasound, for which lesions an interventional strategy - beside optimal medical therapy - is not clearly defined.\"\n\nBased on the information provided, this patient meets the key inclusion criteria for the CAMP clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "984": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for this trial. The key points are:\n\n1. The patient note describes a 46-year-old man with carotid artery stenosis and high cholesterol levels, but no mention of pulmonary vein stenosis or any cardiac condition related to the trial.\n\n2. The inclusion criteria specifically state that the trial is for \"Pediatric patients undergoing cardiac catheterization for the indication of known or suspicion for intraluminal pulmonary vein stenosis.\"\n\nSince the patient note does not indicate any known or suspected pulmonary vein stenosis, and the patient is an adult rather than a pediatric patient, they do not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "985": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the age criteria of being over 18 years old.\n\n2. The patient does not have a diagnosis of acute myocardial infarction (STEMI or NSTEMI) within 48 hours from the onset of symptoms. The note mentions dizziness and frequent headaches, but no acute myocardial infarction.\n\n3. The patient's LDL-C level is 545 mg/dL, which is above the 125 mg/dL threshold for those not on consistent lipid-lowering therapy.\n\n4. The note does not mention if the patient was on any lipid-lowering therapy prior to presentation.\n\nSince the patient meets the LDL-C criteria but does not have a clear diagnosis of acute myocardial infarction within 48 hours, there is insufficient information to determine eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "986": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man with:\n- Dizziness and frequent headaches\n- Family history of CAD\n- No cardiovascular risk factors like smoking, high BP, diabetes\n- Physically active\n- LDL-C 545 mg/dL (very high)\n- HDL-C 53 mg/dL (normal)\n- Normal fasting glucose and triglycerides\n- Not taking any lipid-lowering medications\n\nHe has:\n- Systolic murmur in the neck radiating to skull\n- Severe stenosis in left internal carotid artery (LICA)\n- Moderate 40-50% stenosis in right internal carotid artery (RICA)\n\nThe trial inclusion criteria are:\n- Asymptomatic patients \n- Uni- or bilateral carotid artery stenosis \u226550%\n- LDL-C \u2265100 mg/dL despite ongoing lipid lowering therapy\n\nThis patient meets most of the criteria:\n- He is asymptomatic (dizziness/headaches not specified as related to carotid stenosis)\n- He has severe (\u226550%) stenosis in the LICA\n- His very high LDL-C of 545 mg/dL is well above 100 mg/dL\n- He is not on any lipid lowering therapy\n\nThe only potential issue is that the criteria specifies \"despite ongoing lipid lowering therapy\" which this patient is not taking.\n\nHowever, given his extremely high LDL-C level of 545 mg/dL, he would likely still be eligible for the trial aimed at plaque stabilization/regression.\n\nTrial-level eligibility: 2) Eligible",
        "label": 1
    },
    "987": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note does not mention anything about Behcet's disease or the patient having that diagnosis.\n\n2. The inclusion criteria specifically state that patients must fulfill the modified International Criteria for Behcet's Disease.\n\nSince the patient note does not provide any information about the patient having Behcet's disease, there is insufficient information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "988": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u2265 45 years.\n\nHe has no history of coronary artery disease, peripheral artery disease, transient ischemic attack, stroke, diabetes, or atrial fibrillation mentioned.\n\nHowever, the patient has hyperlipidemia with an LDL-C level of 545 mg/dL, which is very high and meets one of the inclusion criteria.\n\nHe also has a history of hypertension, as indicated by the carotid artery stenosis and systolic murmur, meeting another inclusion criterion.\n\nThe patient does not seem to be scheduled for surgery lasting more than 2 hours based on the information provided.\n\nOverall, the patient meets 2 out of the 11 inclusion criteria (hyperlipidemia and history of hypertension), but does not meet the criteria for planned surgery lasting more than 2 hours.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "989": {
        "output": "To determine the patient's eligibility for the \"Pullback Pressure Gradient (PPG) Global Registry\" clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\n1. Consecutive patients with stable coronary artery disease or stabilized acute coronary syndrome\n\nThe patient note does not mention if the patient has stable coronary artery disease or a stabilized acute coronary syndrome. It only mentions that the patient has dizziness, frequent headaches, and a family history of CAD.\n\n2. Invasive FFR measurement \u22640.80\n\nThe patient note does not provide any information about an invasive FFR measurement.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "990": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226545 years old.\n\nHe is not scheduled for major noncardiac surgery, so he does not meet that inclusion criteria.\n\nThere is no information provided about the type of anesthesia he will receive or his expected hospitalization duration.\n\nHis ASA physical status is not mentioned.\n\nHe is not reported to be taking any anti-hypertensive medications chronically.\n\nThere is no information about whether he will have direct blood pressure monitoring with an arterial catheter.\n\nIt is unclear if he will be cared for by clinicians willing to follow the GUARDIAN protocol.\n\nHe does not have a history of peripheral arterial surgery, coronary artery disease, or stroke/TIA mentioned.\n\nHis serum creatinine level is not provided.\n\nHe does not have diabetes mentioned.\n\nHis smoking status is not mentioned.\n\nHe is not scheduled for major vascular surgery.\n\nHis body mass index is not provided.\n\nHis preoperative high-sensitivity troponin T or troponin I levels are not provided.\n\nHis BNP or NT-proBNP levels are not provided.\n\nBased on the information given, there is insufficient evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "991": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria (\u226518 years).\n\nThe patient does not have a diagnosis of metabolic syndrome mentioned. However, some relevant details are provided:\n- LDL-C level of 545 mg/dL (high)\n- HDL-C level of 53 mg/dL (within normal range for men)\n- Normal fasting glucose and triglyceride levels\n- No mention of large waist circumference or high blood pressure\n\nBased on the information given, the patient does not clearly meet the criteria for metabolic syndrome of having 3 or more of the listed traits.\n\nThe note also does not mention the patient's ability to come to the hospital 5 days per week for 3 weeks.\n\nIn summary, there is insufficient information to determine if the patient meets all the inclusion criteria for this metabolic syndrome trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "992": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of > 18 years old.\n\nHe has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA) between 40-50%, as confirmed by ultrasonography. This meets the inclusion criteria of \"Carotid stenosis defined as: Stenosis \u226570% by computer tomography angiography (NASCET criteria); OR by duplex-ultrasound with \u226570% stenosis defined by a peak systolic velocity of at least 230 cm/s\".\n\nThe note mentions that the carotid stenosis is treatable with carotid artery stenting (CAS), which meets the final inclusion criteria.\n\nBased on the information provided in the patient note, this patient meets all the inclusion criteria for the clinical trial \"Digital Variance Angiography for Contrast Media Dose Reduction in Carotid Artery Stenting\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "993": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 46-year-old man, which meets the age criteria of \u226518 years.\n\nHe has severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, indicating stable coronary artery disease (CAD).\n\nThe inclusion criteria specify either stable angina/dyspnea with myocardial ischemia detected on angiogram, or acute coronary syndrome (ACS) with symptoms of ischemia and troponin elevation. This patient seems to have stable CAD based on the information provided.\n\nThe criteria also require at least one de novo lesion in native coronary arteries suitable for PCI, with reference vessel diameter 2.0-5.0mm and lesion length \u226440mm. The patient note doesn't provide these specific details about the lesion characteristics.\n\nAdditionally, the trial has several inclusion criteria related to bleeding risk factors, which are not mentioned in this patient note.\n\nOverall, while the patient meets some of the key inclusion criteria like age and having CAD, there is insufficient information provided about the lesion characteristics and bleeding risk factors to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "994": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe clinical examination revealed a systolic murmur and carotid artery stenosis - severe in the left internal carotid artery (LICA) and moderate (40-50%) in the right internal carotid artery (RICA). Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nThe clinical trial is a registry for patients who have undergone invasive coronary angiography (ICA) or percutaneous coronary intervention (PCI).\n\nThe inclusion criteria are:\n1) Age \u2265 18 years\n2) Has undergone or will undergo a clinically indicated ICA\n3) Has undergone or will undergo a clinically indicated PCI\n\nBased on the patient note, the patient meets the age criteria (46 years old). However, there is no mention of the patient undergoing or planning to undergo ICA or PCI. The note focuses on carotid artery stenosis rather than coronary artery disease.\n\nTherefore, based on the information provided, the patient does not have sufficient information to qualify for this clinical trial registry.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "995": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 46-year-old man, which meets the inclusion criteria of being an adult.\n\n2. The patient has severe stenosis (>60%) in the left internal carotid artery, as evidenced by the peak systolic velocity of 208.5 cm/s and end-diastolic velocity of 54.5 cm/s, which exceeds the criteria for severe stenosis.\n\n3. The patient also has moderate stenosis (40-50%) in the right internal carotid artery, which may or may not meet the inclusion criteria depending on the exact cutoff used.\n\n4. The patient is asymptomatic, as the presenting symptoms of dizziness and headaches are not clearly related to the carotid stenosis.\n\n5. The patient meets the inclusion criteria of having asymptomatic carotid artery stenosis >60% (NASCET criteria) based on the duplex ultrasound findings.\n\n6. There is no information provided about exclusion criteria, so we cannot determine if the patient would be excluded based on any other factors.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "996": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nA. Written informed consent obtained from the patient or his/her legally acceptable representative\n- The patient note does not mention whether informed consent was obtained, so this criterion cannot be evaluated.\n\nB. Acute ischemic stroke within middle cerebral artery or internal carotid artery occlusion\n- The patient note mentions severe stenosis in the left internal carotid artery and moderate stenosis in the right internal carotid artery, so this criterion is met.\n\nC. Patients of both sexes aged \u2265 19 years and \u2264 82 years\n- The patient is a 46-year-old man, so this criterion is met.\n\nD. NIHSS score \u2265 15 points, NIHSS loss of consciousness 1a score \u2265 1 point\n- The patient note does not provide the NIHSS score or loss of consciousness score, so this criterion cannot be evaluated.\n\nE. Patients with proximal cerebral arterial occlusion (such as middle cerebral or internal carotid artery)\n- The patient has severe stenosis in the left internal carotid artery, so this criterion is met.\n\nF. Unilateral ischemic lesion of at least 2/3 of the middle cerebral artery (MCA) territory involving basal ganglia confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)\n- The patient note does not mention any ischemic lesions or imaging findings, so this criterion cannot be evaluated.\n\nG. Decided to perform decompressive hemicraniectomy within 48 hours after symptom onset - Onset time was defined as the time when patients were lastly seen normal\n- The patient note does not mention any plans for decompressive hemicraniectomy or the time of symptom onset, so this criterion cannot be evaluated.\n\nSince some of the inclusion criteria cannot be evaluated based on the information provided in the patient note, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "997": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note does not mention anything about familial partial lipodystrophy type 2 or the R482 codon mutation of the LMNA gene.\n\n2. The note describes the patient's lipid profile, carotid artery stenosis, and some cardiovascular risk factors, but none of this information is relevant to the inclusion criteria of the clinical trial.\n\n3. Since the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria for this specific trial on cortisol metabolism in familial partial lipodystrophy type 2, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "998": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 46-year-old man presenting with dizziness, frequent headaches, and a family history of coronary artery disease (CAD). His lipid profile shows high LDL-C (545 mg/dL) and normal HDL-C (53 mg/dL), fasting glucose, and triglycerides. He is not on any lipid-lowering medications.\n\nThe key findings are:\n- Severe stenosis (\u226550%) in the left internal carotid artery (LICA)\n- Moderate stenosis (40-50%) in the right internal carotid artery (RICA)\n\nThe clinical trial is investigating cognitive decline in patients with asymptomatic intracranial stenosis, defined as \u226550% stenosis in the intracranial segment of the internal carotid artery or middle cerebral artery (MCA).\n\nBased on the inclusion criteria, this patient would be eligible for the trial as he has severe stenosis (\u226550%) in the LICA, which meets the criteria for intracranial stenosis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "999": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has been diagnosed with gallstones, biliary sludge, and CBD stones. The patient does not appear to be HIV-positive or pregnant.\n\nGiven the inclusion criteria for the clinical trial \"A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies\", which requires participants to be HIV-positive pregnant women or their infants, this patient does not meet the eligibility criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1000": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for radiation therapy to relieve symptoms in patients with non-small cell lung cancer.\n\n3. Based on the inclusion criteria, the key requirements are:\n   - Histologically or cytologically proven non-small cell lung cancer\n   - Locally advanced or metastatic disease\n   - Symptoms related to intrathoracic lung cancer that are amenable to radiation palliation\n\n4. The patient note does not mention any diagnosis of lung cancer or symptoms related to lung cancer.\n\n5. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1001": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is a Phase I study evaluating the efficacy and safety of lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator gene to nasal epithelium in patients with cystic fibrosis.\n\nLooking at the inclusion criteria:\n- The patient does not have cystic fibrosis, which is required.\n- There are no details provided about the patient's sweat chloride levels, FEV1, PO2, or homozygous/compound heterozygous delta F508 mutation status.\n- The patient does not seem to have any nasal issues mentioned that would exclude them.\n\nBased on the information provided, there is insufficient evidence that the patient meets the key inclusion criteria of having cystic fibrosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1002": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. History of biliary pain\nThe patient note mentions the patient experienced abdominal pain radiating to the right upper quadrant, getting worse after eating fatty food, and had similar episodes twice in the past year. This suggests a history of biliary pain, so this criterion is met.\n\n2. Evidence of a single noncalcified, radiolucent gallstone between 4 and 20 mm (inclusive) diameter\nThe ultrasound revealed several gallstones, with the smallest being 14mm, which falls within the required range. However, it does not specify if the stones are noncalcified or radiolucent, and it mentions multiple stones rather than a single stone. So this criterion may not be fully met based on the information provided.\n\n3. HIDA scan demonstrating patency of cystic bile duct\nThere is no mention of a HIDA scan or patency of the cystic bile duct in the patient note.\n\n4. No cardiac pacemaker\nThis is not mentioned, but we can assume the patient does not have a pacemaker unless stated otherwise.\n\n5. No allergy to radioopaque dye, iodine, bile acids\nAllergies are not mentioned, so we can assume the patient does not have any relevant allergies.\n\n6. No spontaneous or iatrogenic bleeding disorder\nBleeding disorders are not mentioned, so we can assume the patient does not have any.\n\n7. No current or prior bile duct obstruction, cholangitis, pancreatitis, or cholecystitis\nThere is no mention of these conditions in the patient note.\n\n8. Not pregnant\nThe patient is described as a 54-year-old menopausal woman, so she is not pregnant.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to determine if she fully meets the criteria regarding the type and number of gallstones and the HIDA scan results.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1003": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The clinical trial is studying the use of ginger to control chemotherapy-induced nausea and vomiting.\n\n2. The inclusion criteria for the trial state that participants must have a confirmed cancer diagnosis, be currently receiving chemotherapy, have experienced nausea and vomiting from a previous round of chemotherapy, and be scheduled to receive certain antiemetic medications.\n\n3. Based on the patient note, there is no mention of the patient having a cancer diagnosis or receiving chemotherapy. Therefore, the patient does not meet the key inclusion criteria for this trial.\n\n4. The exclusion criteria mention that patients with clinical evidence of bowel obstruction should be excluded. While the patient has abdominal pain, there is no specific mention of bowel obstruction.\n\n5. Overall, there is insufficient information in the patient note to determine if the patient meets the inclusion criteria for this clinical trial studying ginger for chemotherapy-induced nausea and vomiting.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1004": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers like ESR and leukocytosis with left shift. This matches some of the inclusion criteria of \"at least three of the following signs or symptoms of an acute attack of sigmoid diverticulitis: fever, abdominal tenderness, leukocytosis and left shift.\"\n\nThe ultrasound revealed gallstones, biliary sludge and CBD stones, suggesting the symptoms may be due to biliary disease rather than diverticulitis. However, the trial inclusion criteria do not explicitly exclude patients with concurrent biliary disease.\n\nThere is no mention of a contrast enema or CT scan confirming sigmoid diverticulitis in the patient note. These are listed as inclusion criteria for the trial.\n\nBased on the available information, while the patient meets some of the clinical criteria for acute diverticulitis, there is no definitive imaging confirmation as required by the trial's inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1005": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones, including abdominal pain, nausea, vomiting, and fever. Imaging confirmed the presence of gallstones and common bile duct (CBD) stones.\n\n2. The clinical trial is studying the management of CBD stones at the time of laparoscopic cholecystectomy (gallbladder removal surgery). It is comparing two techniques for removing CBD stones: facilitated endoscopic retrograde cholangiopancreatography (ERCP) and conventional ERCP.\n\n3. The inclusion criteria for the trial are:\n   - The patient must be able to give informed consent preoperatively (i.e., elective procedures only)\n   - Patients at higher than normal risk of having CBD stones identified at the time of cholecystectomy, such as:\n     - CBD stones identified on ultrasound\n     - Wide CBD (>6mm) on ultrasound\n     - Previous, recent, or current cholangitis, jaundice, or biliary pancreatitis\n     - Abnormal AST and ALT levels (>2 times normal)\n\n4. Based on the information provided, this patient meets the inclusion criteria for the trial:\n   - She is presenting for an elective procedure (not an emergency)\n   - She has CBD stones identified on ultrasound\n   - She is at higher risk of having CBD stones due to her symptoms and imaging findings\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1006": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman, which meets the BMI criteria of \u226530 kg/m2 for subjects without additional comorbidities or \u226527 kg/m2 for subjects with comorbidities.\n\nHer past medical history mentions hypercholesterolemia, which is considered a comorbidity of dyslipidemia as defined in the inclusion criteria.\n\nThe patient does not seem to have any other clinically relevant abnormalities mentioned that would exclude her based on the medical history, physical exam, ECG or lab tests specified in the first inclusion criteria.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for the clinical trial evaluating weight loss with CP-945,598 in obese subjects.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1007": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for assessing quality of life and bowel symptoms after treatment for malignant large bowel obstruction with colorectal stents or surgery.\n\n3. The inclusion criteria for the trial are:\n   - Age over 18 years\n   - Presentation of large bowel obstruction based on clinical symptoms and imaging study\n   - Large bowel obstruction due to stage IV colorectal cancer, unresectable local-regional colorectal cancer, or unresectable extra-colonic cancer\n   - Ability to provide informed consent\n\n4. Based on the patient note, there is no mention of the patient having colorectal cancer or any other type of cancer causing a large bowel obstruction. The patient's symptoms and imaging findings suggest gallbladder disease with gallstones and biliary obstruction, but not a malignant large bowel obstruction.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1008": {
        "output": "Based on the patient note provided, there is no mention of Helicobacter pylori infection. The patient appears to be presenting with symptoms of gallstones and cholecystitis. Therefore, this patient does not meet the inclusion criteria for the clinical trial titled \"Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori\", which requires patients to have H. pylori infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1009": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice\".\n\nThe inclusion criteria for the trial states: \"Biliary patients older than 1-year-old status post Kasai operation.\"\n\nBased on the patient note, there is no mention of the patient having biliary atresia or having undergone a Kasai operation. The patient appears to be presenting with symptomatic cholelithiasis (gallstones).\n\nTherefore, this patient does not meet the inclusion criteria for the stated clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1010": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the symptoms of symptomatic gallstone disease.\n\nThe inclusion criteria state:\n1. Age between 18-75 years - The patient is 54, so meets this criteria.\n\n2. Presence of gallbladder stones or sludge on ultrasound, without bile duct stones or bile duct dilatation - The ultrasound revealed gallstones, biliary sludge, and CBD stones. The CBD stones would exclude the patient based on this criteria.\n\n3. At least one episode of severe right upper quadrant/epigastric pain of >=30 mins duration with radiation/movement urge, or at least 3 episodes without radiation/movement urge in the last 12 months - The patient experienced epigastric pain radiating to the right upper quadrant that worsened after eating, meeting this criteria. She also had 2 similar episodes in the past year.\n\nWhile the patient meets most of the inclusion criteria, the presence of the CBD stones would likely exclude them from this particular trial based on the second criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1011": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying esophageal metaplasia and Barrett's esophagus using a novel antibody. The inclusion criteria are:\n   - Dyspeptic symptoms, upper abdominal pain, heartburn, regurgitation\n   - Endoscopically - normal appearing GE junction, irregular z-line, or erosive esophagitis up to Grade 2\n\n3. The patient's symptoms of abdominal pain, nausea, and vomiting could potentially be related to dyspepsia or upper abdominal pain, which meets the first inclusion criterion.\n\n4. However, the patient's condition is likely due to gallstones and biliary disease, rather than esophageal or gastric issues. There is no mention of endoscopic findings related to the esophagus or gastroesophageal junction.\n\n5. Based on the information provided, there is not enough evidence to determine if the patient meets the second inclusion criterion related to endoscopic findings.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1012": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy\".\n\n3. The key inclusion criteria are: \"Biliary atresia patients aged 0 to 3 years, who had a Kasai operation\"\n\n4. Based on the patient note, this 54-year-old woman does not have biliary atresia and has not had a Kasai operation. She appears to have gallstone disease.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1013": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking for children aged 8-17 years with functional gastrointestinal disorders like functional dyspepsia (FD), irritable bowel syndrome (IBS), or a combination of FD/IBS.\n\nGiven the inclusion criteria of the trial, this 54-year-old patient with gallstones does not meet the age criteria nor does she have a functional gastrointestinal disorder diagnosis.\n\nTherefore, based on the information provided, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1014": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones detected on ultrasound.\n\n2. The clinical trial is titled \"Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection\".\n\n3. The only inclusion criteria listed is \"Patients with H. pylori infection\".\n\n4. There is no mention of H. pylori infection in the patient note.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for this clinical trial on H. pylori infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1015": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge 40 to 65 years: The patient is 54 years old, which meets this criterion.\n\nSedentary (exercise less than two times per week): There is no information provided about the patient's exercise habits, so this criterion cannot be evaluated.\n\nOverweight or mildly obese (BMI 25 to 35 kg/m2): The patient is described as obese, which likely meets this criterion, but the exact BMI is not provided.\n\nMild to moderate lipid abnormalities (either LDL cholesterol 130 to 190 mg/dl; or HDL cholesterol < 40 mg/dl for men, or < 45 mg/dl for women): The patient's lipid levels are not provided, so this criterion cannot be evaluated.\n\nWomen were postmenopausal: The patient is a 54-year-old woman and is described as menopausal, so she meets this criterion.\n\nBased on the information provided, the patient meets some of the inclusion criteria, but there is not enough information to determine if she meets all of them. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1016": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has had similar episodes twice in the past year.\n\nThe inclusion criteria for the trial are:\nA. Age 18-55 years (The patient is 54, so meets this criteria)\nB. Diagnosis of moderate to severe epigastric pain/discomfort present at least 3 times per week for 12 weeks (The patient has had recurrent episodes, so likely meets this)\nC. Epigastric pain/discomfort must be the dominant symptom (This seems to be the case for the patient)\nD. Able to give informed consent (Not mentioned, but assume she can)\n\nThe exclusion criteria are:\nA. H. pylori positive (Not mentioned)\nB. Regular NSAID/aspirin use (Not mentioned)\nC. Medications inducing GI symptoms (Not mentioned)\nD. History of esophagitis (Not mentioned)\nE. History of gastric/duodenal ulcer (Not mentioned)\nF. History of duodenal erosions (Not mentioned) \nG. Previous upper GI surgery (Not mentioned)\nH. Symptoms of IBS (Not mentioned)\nI. Other organic disease explaining dyspepsia symptoms (The patient has gallstones/biliary sludge which could explain her symptoms, so this exclusion criteria likely applies)\nJ. Pregnancy/lactation (Not mentioned, assume not pregnant/lactating)\nK. Inadequate contraception (Not mentioned)\nL. Excess alcohol use (Not mentioned)\nM. Substance abuse history (Not mentioned)\nN. Unwillingness to stop antisecretory meds (Not mentioned)\n\nBased on meeting the inclusion criteria but likely being excluded due to having gallstones/biliary sludge that could explain her symptoms (exclusion criteria I), the most appropriate assessment is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "1017": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Functional and Molecular Characterisation of Oesophageal Distal Epithelium: Correlations With Acid and Non Acid Reflux\" and aims to study the esophageal epithelium in patients with GERD symptoms.\n\nThe inclusion criteria for the trial are:\n1. Digestive symptoms suggestive of GORD (heartburn, regurgitation, epigastric pain), or dyspeptic syndrome (nausea, belch, bloating, epigastric discomfort).\n2. Need for upper GI endoscopy and pH monitoring.\n3. Normal propagation of esophageal peristaltic waves (manometry < 6 months).\n4. Age 18-70 years\n5. Signed informed consent\n6. Normal coagulation\n\nBased on the patient note, the patient meets the following inclusion criteria:\n1. She has epigastric pain, nausea, and vomiting, which could be suggestive of GERD or dyspeptic syndrome.\n\nHowever, there is no information provided about:\n- The need for upper GI endoscopy and pH monitoring\n- Esophageal manometry results\n- Signed informed consent\n- Coagulation status\n\nWithout this additional information, it is difficult to determine if the patient is fully eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "1018": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The inclusion criteria specify:\n\n1. Male and females, 18-75 years of age. \n   - The patient is 54 years old, which meets this criterion.\n\n2. Chronic renal failure with hemodialysis 3x/week for at least 6 months and adequate dialysis as judged by a nephrologist who is not a study investigator.\n   - There is no mention of the patient having chronic renal failure or being on hemodialysis, so this criterion is not met.\n\n3. Fasting TG <600 mg/dl, LDL cholesterol <190 mg/dl (off lipid-lowering medication)\n   - No lipid values are provided, so it's unclear if this criterion is met.\n\n4. Willing and able to change Renagel... to another phosphate binder for 1 month prior to the screening visit until the completion of the study.\n   - There is no mention of the patient taking Renagel or other phosphate binders.\n\n5. Willing and able to temporarily stop Sensipar (cinacalcet) for 1 week before the study admission until completion of the study (a total of 2 weeks).\n   - There is no mention of the patient taking Sensipar.\n\n6. Willing and able to stop ASA (except low dose ASA in patients with vascular disease), NSAID, fish oil, psyllium, other nonprescribed vitamins/supplements for 1 week prior to study until completion of study.\n   - No information is provided about the patient's medication/supplement use.\n\n7. Willing and able to sign an informed consent.\n   - No information about willingness to sign a consent.\n\n8. Willing to refrain from participation in an investigational drug study for the duration of the study.\n   - No information about participation in other studies.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1019": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worse after eating fatty foods. She has a history of similar episodes in the past year. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the efficacy of pancrelipase on postprandial belching and bloating. The inclusion criteria are:\n\n1) Bothersome upper abdominal discomfort, bloating or belching following meals for at least 12 months.\n2) Normal upper GI endoscopy and/or upper GI series in the preceding 3 years.\n\nBased on the patient note, the patient does not seem to have chronic postprandial bloating, belching or upper abdominal discomfort as the primary complaint. Her symptoms appear to be related to gallstone disease. There is also no mention of a recent normal upper GI study.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial studying postprandial symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1020": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings point to a diagnosis of acute cholecystitis/cholelithiasis (gallstones and biliary sludge).\n\n2. The clinical trial is studying the use of rifaximin (Xifaxan) versus vancomycin for the treatment of Clostridium difficile-associated diarrhea (CDAD). \n\n3. The inclusion criteria require the patient to be 18 years or older with acute diarrhea and at least one other sign of enteric infection, as well as a positive C. diff toxin assay.\n\n4. Based on the patient note, there is no mention of diarrhea or a positive C. diff toxin test. The symptoms and findings are consistent with gallstone disease, not CDAD.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial studying CDAD treatments.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1021": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the efficacy of a drug (afimoxifene gel) for treating cyclic mastalgia (breast pain) in premenopausal women.\n\nThe inclusion criteria for the trial are:\n1) Premenopausal woman at least 18 years old\n2) History of cyclical mastalgia for 4 months prior\n3) Moderate or severe mastalgia determined by VAS score >40mm for \u22657 days per cycle in the second part of the cycle\n4) Regular menstrual cycles of 28 +/- 3 days\n\nBased on the patient note, there is no information provided about whether the patient meets criteria 2-4 regarding cyclical breast pain and menstrual cycle regularity.\n\nTherefore, there is insufficient information to determine if this patient would be eligible for the cyclic mastalgia clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1022": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever, which is likely due to gallstones and cholecystitis. The clinical trial is titled \"Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache.\"\n\nThe inclusion criteria for this trial is:\n\"Migraine Headache\"\n\nSince the patient is not presenting with a migraine headache, but rather with symptoms related to gallbladder disease, she does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1023": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1. Sedentary (exercises fewer than two times per week)\n2. Overweight or mildly obese (BMI of 25 to 35 kg/m2) \n3. Mild to moderate lipid abnormalities (LDL cholesterol 130 to 190 mg/dl or HDL cholesterol less than 40 mg/dl for men or less than 45 mg/dl for women)\n\nBased on the information provided, the patient's exercise level and BMI are not mentioned, so we cannot determine if she meets criteria 1 and 2. However, her lipid profile is also not provided, so we cannot determine if she meets criterion 3.\n\nTherefore, there is not sufficient information in the patient note to determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1024": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and biliary sludge seen on ultrasound).\n\n2. The clinical trial is studying the use of corticosteroids following a Kasai procedure (portoenterostomy) in infants with biliary atresia.\n\n3. The inclusion criteria for the trial are:\n   - Portoenterostomy or gallbladder Kasai operation for biliary atresia within the previous 72 hours\n   - Post-conception age \u2265 36 weeks\n   - Weight at enrollment \u2265 2000 gm\n   - Written informed consent obtained prior to or within 72 hours of portoenterostomy\n\n4. Based on the patient note, this 54-year-old woman does not meet the inclusion criteria for the trial, as she is not an infant who has recently undergone a Kasai procedure for biliary atresia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1025": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\n2. The clinical trial is a population-based case-control study of biliary tract cancers in Shanghai, China. \n\n3. The inclusion criteria state that cases must be newly diagnosed biliary tract cancers among residents of urban Shanghai, under age 75 at diagnosis.\n\n4. Based on the patient note, there is no mention of the patient being diagnosed with biliary tract cancer. The symptoms and findings point to cholelithiasis (gallstones) and cholecystitis, but no cancer diagnosis.\n\n5. Since the patient does not have a confirmed biliary tract cancer diagnosis, they would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1026": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Biliary Atresia Study in Infants and Children\" and is studying the factors that cause biliary atresia and influence disease progression.\n\n3. The inclusion criteria state that participants need to have a confirmed diagnosis of biliary atresia, be between 6 months and 20 years old, either have their native liver or a confirmed liver transplantation, and provide informed consent.\n\n4. Based on the patient note, this 54-year-old woman does not have a diagnosis of biliary atresia. She has gallstones and other biliary issues, but not specifically biliary atresia.\n\n5. Additionally, she is outside the age range specified in the inclusion criteria (over 20 years old).\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the \"Biliary Atresia Study in Infants and Children\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1027": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Causes and Natural History of Dyslipidemias\" and is studying disorders that affect fat content in the blood, such as high or low cholesterol and triglyceride levels.\n\n3. The inclusion criteria for the trial specify that participants must have dyslipidemia (abnormal lipid levels), with examples given such as high cholesterol (>200 mg/dl), low HDL (<25 mg/dl), high triglycerides (>150 mg/dl), etc.\n\n4. The patient note does not mention any lipid disorder or abnormal cholesterol/triglyceride levels. The focus is on gallbladder disease.\n\n5. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this dyslipidemias trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1028": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying a new anti-inflammatory medication CJ-023,423 and its effect on stomach ulcers compared to naproxen and placebo.\n\nThe inclusion criteria state that participants must be healthy adults aged 18-75 with no clinically relevant abnormalities based on medical history, physical exam, ECG, and lab tests. Female participants must use adequate contraception and have a negative pregnancy test.\n\nBased on the information provided, this patient does not meet the inclusion criteria for this trial as she has an active gallbladder disease with gallstones and is not considered a \"healthy adult\".\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1029": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She was diagnosed with gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is for treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy) using combination chemotherapy regimens.\n\n3. Based on the inclusion criteria, this patient does not have T-ALL or T-LLy. She has gallstone disease, which is not relevant to the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1030": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms suggestive of gallstones and choledocholithiasis (CBD stones). The key details are:\n\n- Abdominal pain radiating to the right upper quadrant, worse after fatty foods\n- History of similar episodes in the past year\n- Elevated inflammatory markers (ESR, leukocytosis)\n- Ultrasound showing gallstones, biliary sludge, and CBD stones (smallest 14mm)\n\nThe clinical trial is comparing two approaches for managing combined gallstones and CBD stones:\n1) One-stage laparoscopic cholecystectomy with intraoperative ERCP and CBD clearance \n2) Two-stage approach with preoperative ERCP/sphincterotomy followed by laparoscopic cholecystectomy\n\nThe inclusion criteria are:\n1) Able to give informed consent\n2) ASA class I-III\n3) High risk of having CBD stones (jaundice, cholangitis, deranged LFTs, CBD stones on imaging)\n\nThis patient meets criteria 2 and 3 based on the information provided. There is no mention about ability to provide consent.\n\nHowever, the key point is that this trial is specifically recruiting patients with combined gallstones and CBD stones requiring treatment.\n\nGiven the clinical presentation and imaging findings, this patient appears to have cholelithiasis with choledocholithiasis and would likely be eligible for this trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1031": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman, which meets the age (19-65 years) and BMI (35-65 kg/m2) inclusion criteria.\n\nHer medical history includes hypercholesterolemia and 2 normal vaginal deliveries, none of which are listed as exclusion criteria.\n\nHer current condition is acute cholecystitis with gallstones and biliary sludge/stones, which is not an exclusion criterion.\n\nHer vital signs show mild fever (38.2C) and elevated BP (150/85 mmHg). The fever is below the exclusion cutoff of 37.5C, but the BP is above the exclusion cutoff of 160/90 mmHg.\n\nHer lab values show leukocytosis with left shift and elevated ESR, which are not listed as exclusion criteria. Other relevant labs like platelet count, hemoglobin, PT/PTT, liver enzymes, and creatinine clearance are not provided.\n\nBased on the information provided, the elevated BP of 150/85 mmHg would exclude her from this clinical trial under the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1032": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and symptoms suggestive of gallstones and cholecystitis.\n\nThe clinical trial is studying the effects of esomeprazole (Nexium) on antioxidant capacity and free radical production in patients taking NSAIDs and experiencing dyspepsia.\n\nLooking at the inclusion criteria:\n1. Age 18 years and older - The patient is 54 years old, so meets this criteria.\n2. Taking NSAIDs on a daily basis - The note does not mention the patient taking NSAIDs, so this criteria is not met.\n3. At least 1 week history of dyspeptic symptoms like epigastric/upper abdominal discomfort or pain - The patient has a 4 day history of abdominal pain, nausea, vomiting, so this criteria is partially met but the duration is less than 1 week specified.\n\nSince the patient is not clearly taking daily NSAIDs and the dyspeptic symptom duration is less than 1 week, the patient does not fully meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1033": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with signs and symptoms of acute cholecystitis, including abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. This meets the inclusion criteria of being over 18 years old and having at least 3 of the following signs of acute cholecystitis:\n- Abdominal pain in the upper right quadrant (present)\n- Murphy's sign (not mentioned)\n- Leukocytosis > 10,000/ml (present) \n- Temperature > 38\u00b0C or < 36.5\u00b0C (present at 38.2\u00b0C)\n- Gallstones/sludge or sonographic signs of cholecystitis (present - ultrasound showed gallstones, biliary sludge and CBD stones)\n\nThe patient was started on antibiotics (not specified if it was moxifloxacin) in the emergency department.\n\nThe inclusion criteria also require that laparoscopic cholecystectomy is possible within 24 hours and that the patient provides informed consent. This is not mentioned in the patient note.\n\nOverall, based on the information provided, the patient appears to meet most of the key inclusion criteria for this trial comparing early laparoscopic surgery versus antibiotic therapy and delayed cholecystectomy for acute cholecystitis.\n\nHowever, there are a couple potential gaps:\n1) It's not clear if laparoscopic surgery could be performed within 24 hours\n2) Informed consent is not mentioned\n\nTrial-level eligibility: 1) Not relevant (patient meets most criteria but there is insufficient information to fully assess eligibility)",
        "label": 0
    },
    "1034": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the use of duloxetine for patients with suspected functional pancreatic/biliary pain (Sphincter of Oddi Dysfunction).\n\n3. The inclusion criteria for the trial are:\n   - Referred for investigation/management of functional upper abdominal pain symptoms\n   - No significant medical conditions\n   - At least 2 pain attacks in the previous month, severity \u2265 4/10\n   - Prior cholecystectomy\n   - Age 18-65\n   - Functional pain characteristics as per Rome III criteria\n   - Structural causes of pain excluded by imaging/labs\n   - No significant ECG abnormalities\n   - Able to give informed consent\n   - Females must use contraception or be postmenopausal/surgically sterile\n   - Geographically accessible for follow-up\n\n4. The exclusion criteria include psychosis, bipolar disorder, suicidal ideation, substance abuse, abnormal liver function tests, hypersensitivity to duloxetine, concomitant MAOI use, serious medical illness, uncontrolled glaucoma, acute liver injury, prior duloxetine intolerance, and pregnancy/breastfeeding.\n\n5. Based on the patient note, this 54-year-old woman has gallstones and biliary sludge, which are structural causes of her abdominal pain. Therefore, she does not meet the inclusion criteria of having functional (non-structural) upper abdominal pain.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1035": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone of 14mm.\n\nThe clinical trial is studying endoscopic treatment of biliary strictures after liver transplantation, comparing balloon dilatation versus stent placement.\n\nThe inclusion criteria for the trial are:\n1. Liver transplanted patients with diagnosis of biliary obstruction based on endoscopic cholangiopancreaticography\n2. Older than 18 years\n3. Male and female\n\nBased on the information provided, this patient does not seem to be a liver transplant recipient and does not have a biliary stricture. Her condition appears to be cholelithiasis (gallstones) with a common bile duct stone.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1036": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This does not match the inclusion criteria for the clinical trial, which is looking for children aged 7-17 with recurrent abdominal pain.\n\n2. The inclusion criteria specifically mention the child having experienced at least 3 episodes of abdominal pain over a 3-month period affecting their activities. The patient note does not provide this level of detail about the frequency and duration of abdominal pain episodes.\n\n3. The inclusion criteria also require the primary caregiver to be willing and able to complete questionnaires, and that the child has lived with the primary caregiver full-time for at least 5 years and half their lifetime. This information is not available in the patient note.\n\n4. Based on the mismatch between the patient details and the inclusion criteria for this particular clinical trial on recurrent abdominal pain in children, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1037": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings are consistent with acute pancreatitis.\n\n2. The clinical trial is studying the recurrence of acute alcoholic pancreatitis.\n\n3. The inclusion criteria state that patients must have survived their first acute alcoholic pancreatitis episode and had high alcohol consumption detected.\n\n4. There is no mention of the patient's alcohol consumption or history of prior pancreatitis episodes in the note provided.\n\n5. Without information on whether this is the patient's first episode of pancreatitis and details about her alcohol use, it is not possible to definitively determine if she meets the inclusion criteria.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1038": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The clinical trial is titled \"Prevention of Narcotic-Induced Nausea\" and aims to study whether additional medication is needed to prevent nausea caused by narcotic pain medication.\n\nThe inclusion criteria for the trial are:\n1. Patient in Christian Care Emergency Department (Satisfied: The patient is admitted to the emergency department)\n2. Require intravenous narcotics for painful condition (Likely satisfied: The patient is experiencing abdominal pain, which may require narcotic pain medication)\n3. \u226518 years of age (Satisfied: The patient is 54 years old)\n4. Able to visually rate amount of pain and nausea (Likely satisfied: No information provided to suggest otherwise)\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1039": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is focused on rapid HIV testing in the emergency department for patients with certain conditions.\n\nLooking at the inclusion criteria for the trial:\n1. Sexually transmitted disease evaluation or prior history of sexually transmitted disease - No mention of this for the patient\n2. Pregnancy - The patient is menopausal, so not pregnant\n3. Clinical condition that suggests possible immunodeficiency - No mention of immunodeficiency\n4. History of illicit drug use - No history mentioned\n5. History of chronic viral hepatitis - No history mentioned\n6. Patients with unexplained pneumonia or recurrent pneumonia - No pneumonia mentioned\n7. Male patients who have a history of sex with men - Patient is female\n8. Abdominal pain in a sexually active woman or urethritis in a man - Patient does have abdominal pain, but no mention of being sexually active\n9. Trauma - No trauma mentioned\n\nThe patient does not seem to meet any of the specific inclusion criteria listed for this rapid HIV testing trial.\n\nAdditionally, the patient's presenting condition of gallstones/biliary disease does not appear directly relevant to the HIV testing trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1040": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Admitted to emergency ward for abdominal pain\"\nThe patient note states that the 54-year-old woman was \"admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\" This meets the first inclusion criterion.\n\n2. \"18 years or older\"\nThe patient note mentions that the patient is 54 years old, which satisfies the age requirement.\n\nSince the patient meets both inclusion criteria and there are no exclusion criteria mentioned, we can conclude that the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1041": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients over the age of 18yr\nThe patient is 54 years old, so this criterion is met.\n\n2. The typical history of abdominal pain for over 24h with raised (>3-fold) serum pancreatic enzymes on admission\nThe patient has abdominal pain that started 4 days ago, and the note does not mention raised pancreatic enzymes, so there is not enough information to determine if this criterion is met.\n\n3. Severe pancreatitis, as defined by:\n   a) The presence of organ failure resistant to early aggressive IV fluid resuscitation as defined by a Marshall score of \u22652 in any one organ\n   b) Pancreatic necrosis >30% on CT scan or a modified CT severity index (CTSI) of \u22658\n   c) APACHE score \u2265 8\n   d) Ranson's criteria \u22653\nThe note does not provide information about organ failure, pancreatic necrosis, APACHE score, or Ranson's criteria, so there is not enough information to determine if this criterion is met.\n\nSince there is not enough information provided in the patient note to determine if all the inclusion criteria are met, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1042": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a Phase II study evaluating temozolomide + O6-benzylguanine in patients with temozolomide-resistant malignant glioma.\n\n3. Based on the inclusion criteria, the key requirements are:\n   - Recurrent/progressive malignant glioma\n   - Temozolomide resistance (defined as \u226525% increase in tumor growth within 8 weeks of last temozolomide dose)\n   - Age \u2265 18 years\n   - Measurable enhancing disease on MRI/CT\n   - Adequate performance status and organ function\n\n4. From the patient note, there is no mention of the patient having a malignant glioma or being treated with temozolomide previously. The presenting symptoms and findings are consistent with cholelithiasis/cholecystitis.\n\n5. Therefore, based on the information provided, the patient does not meet the key inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1043": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and normal vaginal deliveries.\n\n2. The clinical trial is titled \"The Influence of Ezetimibe on Gallbladder Function\" and aims to determine if ezetimibe normalizes resting and residual volume in patients with chronic acalculous cholecystitis.\n\n3. The inclusion criteria for the trial are:\n   - Subjects with typical biliary pain and ejection fraction <30% on a HIDA scan.\n   - Must be > 18 years of age.\n\n4. Based on the patient note, the patient is experiencing abdominal pain, nausea, vomiting, and fever, which could be indicative of biliary pain. However, there is no mention of a HIDA scan or ejection fraction in the patient note.\n\n5. The patient meets the age criterion (54 years old), but there is insufficient information to determine if she meets the other inclusion criterion regarding the ejection fraction on a HIDA scan.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1044": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the safety and efficacy of droxidopa in treating intradialytic hypotension in patients undergoing hemodialysis for end-stage renal disease (ESRD).\n\n3. Based on the inclusion criteria, the key requirements are:\n   - Aged 18 years or over (the patient is 54, so meets this criteria)\n   - Clinical diagnosis of ESRD (not mentioned for this patient)\n   - Requiring maintenance hemodialysis 3 times per week for at least 3 hours (not mentioned)\n   - History of intradialytic hypotension for at least 1 month (not mentioned)\n   - Observed symptomatic intradialytic hypotension in 3 of 6 HD sessions during screening (not mentioned)\n\n4. While the patient's age meets one of the inclusion criteria, there is no information provided about a diagnosis of ESRD, requirement for hemodialysis, or history of intradialytic hypotension.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1045": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the inclusion criteria of \"All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness\".\n\n2. The patient has epigastric tenderness radiating to the right upper quadrant, which gets worse after eating fatty foods. This also matches the inclusion criteria of \"abdominal pain and tenderness to direct palpation in the region anterior to the mid-axillary line bilaterally, and extending from the costal margins to the inguinal ligaments\".\n\n3. The patient does not seem to meet any of the exclusion criteria mentioned in the trial description.\n\n4. Based on the information provided, this patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1046": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is evaluating the safety and immunogenicity of a hepatitis B vaccine (HBV-MPL) compared to Engerix-B in healthy volunteers aged 15 years or older.\n\n3. The inclusion criteria for the trial are:\n   - Male or female aged \u2265 15 years at the time of first vaccination\n   - Free of obvious health problems\n   - Able to provide written informed consent\n   - For females of childbearing potential, abstinent or using adequate contraception\n\n4. Based on the patient note, this 54-year-old woman has gallbladder disease and is not free of obvious health problems. She does not meet the inclusion criteria of being free of health issues.\n\n5. Additionally, her age of 54 years meets the age requirement, but there is no information provided about her ability to provide informed consent or contraceptive use if applicable.\n\nTherefore, based on the limited information provided, this patient does not have sufficient details to be considered eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1047": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is about the safety and immunogenicity of a candidate HBV-MPL vaccine compared to Engerix-B in healthy adolescents aged 11-15 years.\n\n3. The inclusion criteria for the trial are:\n   - Age between 11 and 15 years at the time of first vaccination\n   - Free of obvious health problems\n   - Written informed consent from parents/guardians and subject if 15 years old\n   - For females of childbearing potential, must be abstinent or using contraception, have a negative pregnancy test, and agree to continue contraception for 2 months after vaccination\n\n4. Based on the patient note, this 54-year-old woman with gallstones and other health issues does not meet the age or health status inclusion criteria for this hepatitis B vaccine trial in healthy adolescents.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1048": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Histologically or cytologically confirmed adenocarcinoma of the pancreas\n- The patient note does not mention pancreatic cancer, so this criterion is not met.\n\n2. Metastatic disease\n- The patient note does not mention metastatic disease.\n\n3. Received \u2265 1 prior chemotherapy regimen, preferably gemcitabine hydrochloride-based\n- There is no information about prior chemotherapy in the patient note.\n\n4. For subjects without archival tissue available, must be willing to undergo a fresh needle-core biopsy\n- Not relevant based on the information provided.\n\n5. No known brain metastases\n- There is no mention of brain metastases in the patient note.\n\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%\n- No information about performance status is provided.\n\n7. White blood cell (WBC) \u2265 3,000/mm\u00b3\n- No WBC count is mentioned.\n\n8. Other laboratory criteria (ANC, platelet count, hemoglobin, bilirubin, liver enzymes, creatinine, urine protein)\n- No relevant laboratory values are provided except for leukocytosis with left shift, which is not specific enough.\n\n9. Not pregnant or nursing, fertile patients must use effective contraception\n- No information about pregnancy or fertility is given.\n\n10. Other criteria (HIV status, willingness for biopsies, allergies, QTc interval, ECG, hypertension, cardiac conditions, ability to take oral medication, other illnesses or malignancies, recovery from prior therapy, time since prior therapy, concurrent medications)\n- No relevant information is provided.\n\nBased on the information given in the patient note, there is insufficient information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1049": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\nThe clinical trial is titled \"Acute Pain Episodes in Patients Under Opioid Maintenance Therapy : Clinical Management and Long Term Effects\".\n\nThe inclusion criteria for this trial are:\n1. Patients aged 18 or more (The patient is 54, so meets this criteria)\n2. Patients under opioid maintenance therapy (buprenorphine or methadone) (There is no mention of the patient being on opioid maintenance therapy in the note)\n3. Patients treated by the same drug (buprenorphine or methadone) since at least 3 months (Again, no mention of opioid maintenance therapy)\n\nBased on the information provided in the patient note, there is no indication that the patient meets criteria 2 and 3 for inclusion in this clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1050": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) The subject is a female scheduled to undergo ambulatory breast surgery performed under general anesthesia\n- The patient note does not mention breast surgery, so this criterion is not met.\n\n2) The subject is expected to undergo general inhalation anesthesia.\n- There is no information about the type of anesthesia, so this cannot be determined.\n\n3) The subject presents with two of the three following high-risk factors associated with PONV:\n    a) She is a non-smoker.\n    - The note states the patient does not smoke, so this is met.\n    b) She has documented history of PONV and/or motion sickness.\n    - There is no mention of PONV or motion sickness history.\n    c) She is expected to receive intra-operative and postoperative opioid.\n    - There is no information about planned opioid use.\n\n4) The subject's American Society of Anesthesiologist physical status is ASA I-III\n- There is no ASA status provided.\n\n5) The subject is between 18 to 65 years of age.\n- The patient is 54 years old, so this is met.\n\n6) The subject is expected to be discharged from the hospital/surgical center on the same day as the surgery.\n- This is not a criterion that can be evaluated based on the information provided.\n\n7) The subject has provided written informed consent to participate in the study.\n- There is no mention of consent.\n\nExclusion Criteria:\n1) The subject has a history of allergic reaction to, intolerances of or contraindications for any of the study medications or required anesthetic agents.\n- There is no information about allergies or intolerances.\n\n2) The subject has received or is expected to receive any excluded preoperative drug within 48 hours prior to induction; or is expected to receive any excluded intra-operative or postoperative medications.\n- No information is provided about preoperative/intraoperative/postoperative medications.\n\n3) The subject is pregnant or lactating.\n- The note states the patient is menopausal, so she is not pregnant or lactating.\n\n4) The subject is taking warfarin.\n- There is no mention of warfarin.\n\n5) The subject has a history of alcohol and/or drug abuse within 1 year of study medication, or has a positive screening or pre-study test for alcohol or drugs of abuse.\n- The note states she does not drink alcohol or use illicit drugs.\n\n6) The subject is expected to require the use of a nasogastric tube postoperatively.\n- There is no information about planned nasogastric tube use.\n\n7) The subject has a diagnosed latex allergy. \n- No latex allergy is mentioned.\n\n8) The subject has used oral aprepitant (Emend\u00ae) within the last 30 days.\n- There is no mention of recent aprepitant use.\n\n9) The subject has participated in a randomized study or has been exposed to any experimental drug within 30 days prior to enrollment of this study.\n- No prior study participation or experimental drug use is stated.\n\nBased on the information provided in the patient note, there is insufficient evidence to determine if the patient meets all the inclusion criteria or definitively rule out the exclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1051": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. This meets the inclusion criteria of \"Subjects showing at least one of the 4 symptoms (upper abdominal pain, upper abdominal discomfort, epigastric pain, epigastric burning) for at least 6 months before obtaining informed consent.\"\n\n2. The patient is experiencing epigastric pain radiating to the right upper quadrant, which gets worse after eating fatty foods. This meets the inclusion criteria of \"Subjects showing two or more of the following symptoms: upper abdominal pain, upper abdominal discomfort, post-prandial fullness, upper abdominal bloating, early satiety, nausea, vomiting and/or excessive belching for at least 3 months (one of them should be post-prandial fullness or early satiation).\"\n\n3. The patient's symptoms seem to be related to gallstones and biliary sludge, rather than functional dyspepsia, which is the target condition for this clinical trial.\n\nBased on the information provided, the patient does not appear to be eligible for this particular clinical trial, as her symptoms are likely due to a specific medical condition (gallstones) rather than functional dyspepsia.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1052": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The clinical trial is looking at using transdermal nicotine to reduce post-operative nausea and vomiting (PONV) in non-smoking female patients undergoing general surgery.\n\nLooking at the inclusion criteria:\n1. Age 18-65: The patient is 54, so she meets this criterion.\n2. Female: The patient is female, so she meets this criterion. \n3. Health patient or acute illness: The patient seems to have an acute illness (gallstones/biliary issues), so she may meet this criterion.\n4. Undergoing outpatient-type general surgery: The note doesn't specify if she is having surgery, so this is unclear.\n5. Undergoing general anesthesia for the surgery: Again, unclear if she is having surgery requiring general anesthesia.\n6. Receiving opioids during surgery: Unclear if she will receive opioids during a potential surgery.\n7. Non-smoker: The note doesn't specify if she is a smoker or not.\n\nOverall, there is not enough information provided in the patient note to definitively determine if she meets all the inclusion criteria for the clinical trial. More details about a potential upcoming surgery would be needed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1053": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The clinical trial is looking at uncomplicated nausea and vomiting in the emergency department.\n\nThe inclusion criteria for the trial are:\n1. 18 years or older (the patient is 54, so meets this criteria)\n2. Nausea and at least 1 episode of vomiting in the last 12 hours presenting to the York Hospital Emergency Department\n\nWhile the patient does have nausea and vomiting, the note indicates this is likely due to gallstones and biliary sludge/stones rather than an uncomplicated cause. The abdominal pain radiating to the right upper quadrant, getting worse after eating fatty foods, and the ultrasound findings of gallstones/biliary sludge point to a complicated biliary cause rather than uncomplicated nausea/vomiting.\n\nTherefore, while the patient meets some of the inclusion criteria, she would likely be excluded from this particular trial due to the complicated nature of her nausea/vomiting from gallstone disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1054": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones. This appears to be a case of acute cholecystitis.\n\nThe clinical trial is titled \"Rate of Pelvic Inflammatory Disease at St. Michael's Hospital\" and is looking at women admitted to the emergency department with pelvic inflammatory disease (PID) or tubo-ovarian abscess (TOA) between 1995-2000.\n\nThe inclusion criteria for the trial are:\n\"women admitted to Emergency with pelvic-inflammatory disease or tubo-ovarian abscess from the year range: 1995-2000\"\n\nBased on the patient note, there is no mention of the patient having PID or TOA. The presenting symptoms and diagnosis appear to be related to gallbladder disease.\n\nTherefore, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1055": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis\", the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever, which was diagnosed as gallstones and biliary sludge. The patient's condition is related to gallbladder disease and does not mention any symptoms or diagnosis of lateral epicondylitis (tennis elbow).\n\nThe inclusion criteria for the clinical trial specifically state that eligible participants should have an onset of lateral epicondylitis symptoms no more than 12 weeks prior to study entry. Since the patient note does not mention any symptoms or diagnosis of lateral epicondylitis, the patient does not meet the inclusion criteria for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1056": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is investigating preoperative biliary drainage for resectable hilar cholangiocarcinoma.\n\n3. The inclusion criteria for the trial are:\n   - Newly diagnosed patients\n   - Resectable patients after imaging assessment and evaluation of general condition\n   - TB > 85\u03bcmol/L\n   - WBC > 1.5\u00d710^9/L, PLT > 100\u00d710^9/L, and HB > 100g/L\n   - No serious heart, lung, or kidney disease\n   - Written informed consent\n\n4. Based on the patient note, there is no mention of a diagnosis of hilar cholangiocarcinoma. The patient appears to have gallstones and cholecystitis.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1057": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This does not match the inclusion criteria of children aged 1-18 years.\n\n2. The patient has signs of gallstones, biliary sludge, and CBD stones, which is not an acute abdominal pain condition of less than 5 days duration as required by the inclusion criteria.\n\n3. There is no mention of the patient's pain scores or the need for surgical consultation, which are part of the inclusion criteria.\n\nBased on the information provided in the patient note, this patient does not meet the inclusion criteria for the clinical trial \"The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision\".\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1058": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea and vomiting.\n2. The clinical trial is about treating nausea and vomiting in pregnant women up to 12 weeks gestation.\n3. One of the inclusion criteria is \"Pregnant women until 12th week of gestation\".\n4. The patient note does not mention that the patient is pregnant.\n\nTherefore, based on the information provided in the patient note, the patient does not meet the key inclusion criteria of being pregnant up to 12 weeks gestation for this particular clinical trial on treating nausea and vomiting in pregnancy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1059": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and epigastric tenderness. This matches the inclusion criteria of \"upper abdominal pain, nausea, vomiting and epigastric tenderness\".\n\nShe has no history of ethanol abuse, which satisfies the inclusion criteria of \"absence of ethanol abuse\".\n\nHer laboratory results show elevated amylase and lipase levels, meeting the criteria of \"elevated amylase level to at least twice the upper limit of normal and elevated lipase level to at lease three times the upper limit of normal\".\n\nImaging confirmed the presence of gallstones, satisfying the criteria of \"imaging confirmation of gallstones\".\n\nThe patient has 3 or fewer Ranson's criteria on admission, is clinically stable, has no acute cholangitis, and has a low suspicion for a retained CBD stone based on the total bilirubin level. This meets the criteria for mild to moderate pancreatitis.\n\nBased on the information provided, the patient meets all the inclusion criteria for the clinical trial \"Early Versus Delayed Surgery for Gallstone Pancreatitis\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1060": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever). The imaging confirmed the presence of gallstones and biliary sludge.\n\nThe clinical trial is studying pain levels after single incision laparoscopic cholecystectomy compared to standard laparoscopic cholecystectomy.\n\nThe inclusion criteria for the trial are:\n1. Body Mass Index less than 30\n2. Attacks of cholelithiasis\n\nLooking at the patient details, she meets the second inclusion criteria of having attacks of cholelithiasis (gallstone disease) based on her symptoms and imaging findings.\n\nHowever, the patient note states that she is obese, which would mean her BMI is greater than 30. This excludes her from meeting the first inclusion criteria.\n\nTherefore, based on not meeting all of the inclusion criteria, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "1061": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying pancreaticobiliary reflux in patients without gallstones (cholelithiasis).\n\n3. One of the inclusion criteria for the trial is \"Normal intraoperative cholangiography\". This patient has gallstones and CBD stones, so they would not have a normal cholangiography.\n\n4. Another inclusion criteria is \"Normal preoperative serum amylase and lipase values\". The patient note does not mention these lab values, so we cannot determine if they meet this criteria.\n\n5. Overall, based on the presence of gallstones/CBD stones, this patient would not be eligible for a trial studying pancreaticobiliary reflux in patients without cholelithiasis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1062": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones, suggesting a diagnosis of acute cholecystitis or choledocholithiasis rather than a primary pyogenic liver abscess.\n\nConsidering the inclusion criteria for the clinical trial \"Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess,\" which requires a clinical diagnosis of liver abscess supported by a CT scan and the absence of biliary tract stones (except for gallstones without biliary tract dilatation), this patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1063": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric radiating to the right upper quadrant and worsens after eating fatty foods. She has had similar episodes in the past year.\n\nThe clinical trial is investigating intravenous aspirin for acute coronary syndrome (ACS).\n\nLooking at the inclusion criteria:\n1. Angina pectoris lasting > 20 mins in the last 24 hours (or equivalent acute symptoms like abdominal/epigastric pain, nausea, etc.)\n- The patient does have abdominal/epigastric pain, nausea, and vomiting for the past 4 days, which could potentially qualify as \"equivalent acute symptoms.\"\n\n2. ECG changes suggestive of ischemia or elevated troponin levels\n- There is no mention of ECG changes or troponin levels for this patient.\n\n3. Risk factors for ACS like known CAD, diabetes, impaired renal function, etc.\n- The only risk factor mentioned is obesity.\n\nWhile the patient does have some symptoms that could potentially qualify under the first inclusion criteria, there is no information provided about ECG changes, troponin levels, or clear risk factors for ACS.\n\nTherefore, based on the information given, there is insufficient evidence to determine if this patient would be eligible for the clinical trial investigating intravenous aspirin for ACS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1064": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted with symptoms of biliary disease requiring cholecystectomy (gallbladder removal surgery). This matches the inclusion criteria of \"Diagnosis of biliary disease requiring cholecystectomy\".\n\nShe is female and 54 years old, which falls within the age range of \">25 years old and <65 years old\".\n\nThe note does not explicitly state if she is postmenopausal or does not wish to bear children anymore. However, it mentions she is menopausal, so this inclusion criteria is likely met.\n\nThere is no information provided about her American Society of Anesthesiology (ASA) class, which assesses operative risk. However, her vitals seem relatively stable other than tachycardia.\n\nThe note does not mention if she is able to understand and provide informed consent.\n\nOverall, based on the information provided, this patient seems to meet most of the key inclusion criteria for this clinical trial of a novel minimally invasive cholecystectomy technique.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1065": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy\" and is studying the safety and effectiveness of the H.E.L.P. System for reducing LDL cholesterol levels in patients with familial hypercholesterolemia.\n\n3. The inclusion criteria for the trial are:\n   - Adequate venous access\n   - Hematocrit \u2265 30%\n   - Platelet count between 100,000 and 1,000,000/ml\n   - Premenopausal women must be surgically sterilized or on oral contraceptives and have a negative pregnancy test\n   - Patients have familial hypercholesterolemia and have undergone at least 6 months of optimal diet and drug therapy (fitting into groups A, B, or C)\n\n4. Based on the patient note, there is no mention of the patient having familial hypercholesterolemia or undergoing any specific treatment for it. The note focuses on the patient's gallstone disease.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1066": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is a study of oral Ixazomib in adult participants with relapsed and/or refractory multiple myeloma.\n\n3. Looking at the inclusion criteria:\n- The patient does not have a diagnosis of multiple myeloma, so she does not meet this criteria.\n- There is no information about prior lines of therapy or measurable disease for multiple myeloma.\n- Her ECOG performance status is not mentioned.\n- There is no information about her menopausal status or use of contraception.\n\n4. Based on the information provided in the patient note, there is insufficient information to determine if she meets the inclusion criteria for this multiple myeloma clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1067": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is:\n- A 54-year-old obese woman (meets age and obesity criteria)\n- Non-smoking (meets non-smoking criteria)\n- Undergoing upper gastrointestinal surgery for gallstones (meets surgery requiring postoperative opioid analgesia criteria)\n- At high risk for PONV due to obesity, female gender, and need for opioid analgesia after surgery\n\nBased on the information provided, this patient meets all of the inclusion criteria for the clinical trial \"Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1068": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric, radiating to the right upper quadrant, and worsens after eating fatty foods.\n\n2. The clinical trial is looking for patients with functional dyspepsia (FD), which is defined as chronic abdominal discomfort localized to the upper abdomen, with symptoms like postprandial bloating, pain, nausea, vomiting, belching, and early satiety.\n\n3. However, the patient's ultrasound revealed gallstones, biliary sludge, and CBD stones, suggesting an organic cause for her symptoms.\n\n4. The inclusion criteria for the clinical trial specifically state that there should be \"No evidence of organic disease (including H. pylori detected at time of endoscopy) that is likely to explain the symptoms.\"\n\n5. Since the patient has an organic cause (gallstones and CBD stones) for her symptoms, she does not meet the inclusion criteria for this clinical trial on functional dyspepsia.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1069": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female >=18 years of age.\nThe patient is a 54-year-old woman, so she meets this criterion.\n\n2. American Society of Anesthesiologists (ASA) physical status 1 to 3.\nThere is no information provided about the patient's ASA physical status.\n\n3. Presence of at least 2 of the following PONV risk factors:\n- female gender (meets this)\n- history of PONV and/or currently prone to motion sickness (no information provided)\n- non-smoking status (no information provided)\n\nThe patient meets at least 1 of the PONV risk factors (female gender).\n\n4. Outpatient undergoing elective laparoscopic gynecological or abdominal surgery\nThe patient was admitted to the emergency department with abdominal pain, so this does not seem to be an elective laparoscopic surgery.\n\n5. Surgery for which anesthesia is expected to last at least 30 minutes\nNo information is provided about any planned surgery or anesthesia.\n\n6. General endotracheal anesthesia conducted as outlined in the anesthetic procedures section of the protocol\nNo information is provided about anesthesia procedures.\n\n7. If a subject has a known hepatic, renal or cardiovascular impairment, he/she may be enrolled in this study at the discretion of the Investigator\nNo information is provided about any hepatic, renal or cardiovascular impairment.\n\n8. If a subject has or may develop prolongation of cardiac conduction intervals, particularly QTc, he/she may be enrolled at the discretion of the Investigator.\nNo information is provided about cardiac conduction intervals.\n\n9. If a subject is female of childbearing potential, she must be using reliable contraceptive measures and have a negative serum beta human chorionic gonadotropin (\u03b2-hCG) pregnancy test within 72 hours prior to surgery on Day 1.\nThe patient is described as menopausal, so this criterion does not apply.\n\nBased on the information provided, the patient does not seem to meet all the inclusion criteria for this clinical trial, particularly the criteria related to undergoing elective laparoscopic surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1070": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries. Her lab tests show elevated inflammatory markers and imaging reveals gallstones and bile duct stones.\n\n2. The clinical trial is for patients with relapsed esophageal cancer or stomach cancer, studying symptom control with or without docetaxel chemotherapy.\n\n3. Looking at the inclusion criteria:\n- The patient does not have esophageal cancer or stomach cancer, she likely has gallstone disease/cholecystitis based on her symptoms and imaging findings.\n- She does not meet the criteria of \"Histologically confirmed adenocarcinoma of the esophagus or stomach\" or \"Advanced disease not amenable to curative treatment\" or \"Documented progressive disease while receiving or within 6 months of completion of first-line chemotherapy with a platinum- and fluoropyrimidine-based therapy either for advanced disease or as neoadjuvant/perioperative therapy.\"\n\nTherefore, this patient does not qualify for this particular clinical trial based on the inclusion criteria provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1071": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. This meets the inclusion criteria of being at least 18 years old and having nausea and/or vomiting.\n\n2. However, the patient's condition seems to be related to gallstones and biliary sludge, which is not a terminal diagnosis. The trial is specifically for terminally ill patients with an estimated survival of 6 months or less.\n\n3. There is no mention of the patient being terminally ill or having a terminal diagnosis in the patient note.\n\n4. The other inclusion criteria, such as being able to understand and sign informed consent, are not explicitly mentioned in the patient note.\n\nTherefore, based on the information provided, this patient does not meet the key inclusion criteria of having a terminal diagnosis with an estimated survival of 6 months or less.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1072": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\nThe clinical trial is studying the use of a harmonic scalpel versus traditional methods for laparoscopic cholecystectomy in cirrhotic patients with symptomatic gallbladder stones.\n\nThe key inclusion criterion for this trial is \"patients with liver cirrhosis with symptomatic gall bladder stone\".\n\nFrom the patient note, there is no mention of the patient having liver cirrhosis. While she has gallbladder stones causing symptoms, the lack of information about cirrhosis means she does not definitively meet the inclusion criteria.\n\nTherefore, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1073": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effects of a topical ketoprofen gel and oral celecoxib on muscle pain induced by eccentric exercise.\n\n3. The inclusion criteria for the trial are:\n   - Signed informed consent\n   - Good health as determined by the investigator\n   - Age 18-55\n   - Willing to abstain from physical therapy, hard work, exercise or sauna during the study\n   - For females of childbearing potential, using appropriate birth control\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for the trial as she is presenting with a gallbladder/biliary issue and not muscle pain induced by eccentric exercise.\n\n5. There is insufficient information in the patient note to determine if she meets other criteria like being in good health, age, willingness to abstain from physical activity, or birth control use.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1074": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients\" and is studying the pharmacokinetics of raltegravir in patients with end-stage liver disease and liver transplant recipients.\n\n3. The inclusion criteria for the trial include:\n   - Age \u2265 18 years\n   - Documented HIV-1 infection (hepatitis B or C co-infection allowed)\n   - Plasma viral load < 50 copies/mL for at least 6 months\n   - Severe liver failure (MELD score \u2265 15 and/or refractory ascites, gastrointestinal bleeding, or hepatic encephalopathy) for Period 1\n   - Eligible for liver transplant waiting list or immediate post-transplant for Period 2\n   - Abstinence from alcohol for \u2265 6 months\n   - No intravenous drug use for \u2265 6 months (methadone substitution permitted)\n   - No ongoing opportunistic infection\n   - Able to receive triple therapy with raltegravir + 2 NRTIs or raltegravir + NRTI + enfuvirtide\n   - HIV population sensitive to raltegravir and at least two fully active NRTIs or enfuvirtide\n   - No viral escape during treatment with 3TC, FTC, or raltegravir\n   - Registered with or covered by social security\n   - Women of childbearing potential must use barrier contraception and have a negative pregnancy test\n\n4. Based on the patient note, there is no mention of HIV infection, liver transplant, or end-stage liver disease. The patient appears to have gallstone disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1075": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and common bile duct stones based on the ultrasound findings.\n\nThe clinical trial is about assessing vaccine responses to the influenza A(H1N1) vaccine in high-risk patients.\n\nThe inclusion criteria for the trial are:\n1. Medically recommended influenza A(H1N1) immunization\n2. Signed informed consent\n\nBased on the information provided in the patient note, there is no mention of the patient being recommended for the influenza A(H1N1) vaccine or signing an informed consent for this trial.\n\nTherefore, there is not enough information to determine if the patient meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1076": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Efficacy and Safety of Aripiprazole in First Episode Psychosis\", the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and gallstones. There is no mention of any psychotic disorder or first episode of psychosis.\n\nThe inclusion criteria for the clinical trial specifically state that participants must be aged 18-59 years and meet the DSM-IV diagnostic criteria for first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS.\n\nSince the patient note does not indicate any psychotic disorder or first episode of psychosis, and the patient's presentation is related to gallstones and abdominal pain, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1077": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is for a study evaluating the safety and efficacy of ALT-801 combined with cisplatin in patients with metastatic melanoma.\n\nLooking at the inclusion criteria:\n1. Disease characteristics: The patient does not have metastatic melanoma, so this criterion is not met.\n2. Prior/concurrent therapy: No information provided, but likely not relevant since the patient does not have melanoma.\n3. Patient characteristics: No information provided about HLA status, bone marrow reserve, renal function, hepatic function, cardiovascular status, pulmonary function, autoimmune disease, HIV status, psychiatric illness, CNS disease, systemic infection, steroid use, organ transplant, asthma medication, or pregnancy/fertility status.\n\nSince the patient does not have the target disease of metastatic melanoma, which is a key inclusion criterion, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1078": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This does not seem to match the inclusion criteria for the \"Lansoprazole for Subgroups of Functional Dyspepsia\" trial, which requires patients to have characteristic dyspeptic symptoms according to the Rome III criteria (postprandial fullness, early satiation, epigastric pain, or epigastric burning).\n\n2. The patient's symptoms, along with the ultrasound findings of gallstones, biliary sludge, and CBD stones, suggest a diagnosis of acute cholecystitis or biliary colic, rather than functional dyspepsia.\n\n3. The trial's inclusion criteria specifically require patients to have functional dyspepsia and exclude structural diseases, which this patient appears to have based on the ultrasound findings.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the \"Lansoprazole for Subgroups of Functional Dyspepsia\" trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1079": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and other symptoms suggestive of gallstones/biliary disease. The trial is studying the use of omalizumab (Xolair) in eosinophilic esophagitis (EoE).\n\nInclusion criteria:\n1) Established diagnosis of EoE - The patient does not have a diagnosis of EoE mentioned.\n2) On therapy for EoE with no change during trial - Not applicable since no EoE diagnosis.\n3) One active EoE symptom at least 2 days/week - Her symptoms do not seem to be from EoE.\n4) Failed PPI therapy or negative pH/impedance testing - Not mentioned, likely not relevant.\n5) Age 12-76 years - The patient is 54 years old, so meets this criteria.\n\nExclusion criteria:\n1) Gastrointestinal reflux disease - Not explicitly mentioned, but her symptoms point more towards biliary disease.\n2) Eosinophilic disease in stomach/duodenum - Not mentioned.\n3) Peripheral eosinophil count >1500 - Not mentioned.\n4) Pregnant/breastfeeding woman - No information provided, but likely not relevant.\n5) Known sensitivity to study drug - Not mentioned.\n6) Severe prohibitive medical condition - Her gallstone disease may qualify as this.\n7) Used investigational agent within 30 days - Not mentioned.\n8) Used systemic/inhaled steroids within 1 month - Not mentioned.\n9) History of malignancy - Not mentioned.\n10) Chronic immunosuppressive therapy - Not mentioned.\n11) Prior omalizumab use within 12 months - Not mentioned.\n12) EoE in remission on swallowed steroids - Not applicable.\n13) Asthma on inhaled steroids - Not mentioned.\n14) IgE levels out of range - Not mentioned.\n\nOverall, the patient does not seem to have a diagnosis of eosinophilic esophagitis, which is the primary disease being studied. Her symptoms point more towards biliary/gallstone disease. She may also have a severe prohibitive condition with her gallstone disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1080": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"A Comparison of the Success Rate Of Cannulation Between The Accuvein Apparatus And Standard Technique\". It is studying the success rate of intravenous cannulation using a device called AccuVein AV300 compared to standard techniques.\n\n3. The inclusion criteria for the trial are:\n   - Infants and children under 18 years of age\n   - American Society of Anesthesiologist (ASA) Physical Status I, II or III\n   - Patients undergoing elective surgery, examination under anesthesia, or MRI who do not have existing intravenous access\n   - Able to understand English\n   - Parent/guardian willing to sign consent\n\n4. Based on the patient note and the inclusion criteria, this 54-year-old woman does not meet the age criteria (she is not an infant or child under 18 years old). There is also no information provided about whether she is undergoing elective surgery, examination under anesthesia, or MRI.\n\nTherefore, based on the information given, this patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1081": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is comparing pre-operative vs intra-operative ERCP for the treatment of common bile duct stones in patients with gallstones and common bile duct stones.\n\nThe key inclusion criteria is \"patients with gallstones and common bile duct stones\".\n\nGiven that this patient has gallstones and common bile duct stones, she meets the inclusion criteria for this clinical trial.\n\nThere is no information provided about potential exclusion criteria that could exclude her.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1082": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She was diagnosed with gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is titled \"Kaletra in Combination With Antiretroviral Agents\" and is investigating the tolerability of Kaletra (lopinavir/ritonavir) in combination with new antiretroviral agents in HIV-1 infected patients.\n\n3. The inclusion criteria for the trial are:\n   - Patients \u2265 18 years of age\n   - Written informed consent\n   - HIV-1 infection\n   - Patients treated with Kaletra, independent of participation in this study\n   - Patients treated with novel antiretroviral therapy for at least 8 weeks\n\n4. Based on the patient note, there is no mention of the patient having HIV-1 infection or being treated with Kaletra or any other antiretroviral therapy.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1083": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with acute right-sided abdominal pain, nausea, vomiting, and fever. This matches the inclusion criteria of \"acute right side abdominal pain\".\n\n2. The patient note does not mention if the patient is willing to participate in the study, which is another inclusion criteria. \n\n3. However, since this is a hypothetical case and the patient has not been asked about participating, we cannot definitively exclude them based on lack of willingness to participate.\n\n4. There are no clear exclusion criteria mentioned for this trial.\n\nGiven the information provided, this patient appears to meet the stated inclusion criteria for the \"Endosonography For Right Side Acute Intestinal Mal-Symptoms (EFRAIM- Study)\" clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1084": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a study looking at cells collected from the spinal cavity of patients with low back pain, with or without radiculopathy (pain radiating down the leg).\n\n3. The inclusion criteria for the trial are:\n   - Understand and sign informed consent forms\n   - Age > 18 years\n   - Scheduled for epiduroscopy assisted epidural neurolysis\n   - Diagnosis of low back pain with or without radiculopathy\n\n4. Based on the patient note, this patient does not have a diagnosis of low back pain or radiculopathy. The symptoms and findings are related to gallbladder disease.\n\n5. Therefore, this patient does not meet the inclusion criteria for this clinical trial on low back pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1085": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is looking at the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a primary care setting using ultrasound and liver biopsy.\n\n3. The inclusion criteria for the trial are:\n   - Patients 18 to 70 years of age\n   - Recruited from Primary Care Clinics or Gastroenterology Clinic at Brooke Army Medical Center\n   - Completed a baseline questionnaire\n   - Had a right upper quadrant ultrasound\n   - If fatty liver was identified, then laboratory data and a liver biopsy were obtained\n\n4. Based on the patient note, the patient meets the age criteria (54 years old) and had an ultrasound done that revealed gallstones and biliary sludge, but no mention of fatty liver.\n\n5. Since there is no indication that the patient had fatty liver on the ultrasound, which is a prerequisite for obtaining laboratory data and a liver biopsy in this trial, there is not enough information to determine if the patient would be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1086": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the use of morphine in acute abdominal pain in elderly patients (65 years or older) with non-traumatic abdominal pain of less than 48 hours duration.\n\n3. The inclusion criteria for the trial are:\n   - Age 65 years or older\n   - Non-traumatic acute abdominal pain of less than 48 hours duration\n   - Mild or greater pain intensity\n\n4. Assessing the patient against the inclusion criteria:\n   - The patient is 54 years old, which does not meet the age criteria of 65 years or older.\n   - The patient has acute abdominal pain, meeting that criteria.\n   - The duration of pain is 4 days, which exceeds the 48 hours criteria.\n   - Pain intensity is not specified, so it's unclear if that criteria is met.\n\n5. Since the patient does not meet at least two of the inclusion criteria (age and duration of pain), they would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1087": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nLooking at the inclusion criteria for the clinical trial:\n1. It is for patients with premalignant lesions or treated early-stage head and neck cancers. This patient does not have any head/neck lesions or cancers mentioned.\n2. The trial requires adequate organ function (liver, kidney, lung) which is not clearly stated for this patient.\n3. The trial excludes pregnant/breastfeeding women, which is not mentioned for this patient.\n4. The trial requires abstaining from green tea products, which is not mentioned for this patient.\n\nOverall, there is insufficient information provided about this patient's medical history and current condition to determine eligibility for this specific head/neck cancer prevention trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1088": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis\" and focuses on infants with antenatal hydronephrosis (AHN) and the effectiveness of antibiotic prophylaxis in reducing urinary tract infections.\n\n3. The inclusion criteria for the trial are:\n   - Infants with AHN (one to seven months of age) confirmed postnatally with renal-bladder ultrasound and/or a dilated ureter \u2265 7mm\n   - SFU grade III and IV AHN (high grade hydronephrosis)\n   - Patients without grades II to V VUR determined by voiding cystogram (includes UPJO-like and primary megaureter (hydroureteronephrosis) only)\n   - Parent or legal guardian able to give free and informed consent\n\n4. Based on the patient note, this 54-year-old woman does not meet the inclusion criteria for the clinical trial, as the trial is focused on infants with antenatal hydronephrosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1089": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\n2. The clinical trial is studying the use of self-expandable metallic stents versus multiple plastic stents in the treatment of post-orthotopic liver transplantation biliary stenosis.\n\n3. The inclusion criteria for the trial are:\n   - Post-orthotopic liver transplantation biliary anastomotic stenosis (at least 1 month post-operative)\n   - Jaundice, cholestasis and/or biliary tree dilation on ultrasound\n\n4. Based on the patient note, there is no mention of the patient having had a liver transplant or biliary stenosis. The patient's condition appears to be related to gallstones and a common bile duct stone.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1090": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1) Patients with dyspepsia or epigastric pain and endoscopically proven gastric and duodenal ulcers\n2) Required laboratory parameters and time limits\n3) Age > 18 years\n4) Signed informed consent form\n\nBased on the information provided, the patient meets criteria 1 as she has epigastric pain, though it's not explicitly stated if she has gastric/duodenal ulcers confirmed by endoscopy.\n\nThere is no information about laboratory parameters or if the patient provided informed consent, so criteria 2 and 4 cannot be evaluated.\n\nThe patient does meet criteria 3 as she is 54 years old.\n\nOverall, there is insufficient information to definitively determine eligibility, as key criteria like endoscopic findings and lab values are missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1091": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effect of a supplement called Coltect on Irritable Bowel Syndrome (IBS) symptoms.\n\n3. The inclusion criteria for the trial are:\n   - IBS as defined by the Rome III criteria\n   - For those above age 40, a colonoscopy within the last 5 years\n   - No new treatment in the last 2 weeks\n   - Not receiving any antibiotics in the last 2 weeks\n\n4. Based on the patient note, there is no mention of the patient having IBS or meeting the Rome III criteria for IBS diagnosis.\n\n5. The patient's symptoms and ultrasound findings suggest a diagnosis of cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder), rather than IBS.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial on IBS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1092": {
        "output": "Based on the patient note provided, the 54-year-old obese woman was admitted to the emergency department with symptoms suggestive of gallstones and common bile duct stones. The ultrasound revealed several gallstones, biliary sludge, and common bile duct stones, with the smallest stone being 14mm.\n\nThe clinical trial titled \"Comparison Between Laparoscopic Common Bile Duct Exploration and Intraoperative ERCP for Management of Common Bile Duct Stones\" has the following inclusion criterion:\n\nInclusion Criteria:\n- Preoperatively diagnosed common bile duct stones\n\nSince the patient has been diagnosed with common bile duct stones preoperatively, she meets the inclusion criterion for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1093": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has had similar episodes in the past year. Ultrasound revealed gallstones, biliary sludge, and a 14mm CBD stone.\n\nThe clinical trial is studying indications for gallbladder surgery in gallstone disease. The inclusion criteria are:\n\n1. Symptomatic gallstone disease (SGBS) with episodes of pain >30 mins and ultrasound evidence of gallstones.\n2. Acute cholecystitis with acute abdominal pain >8-12 hours, right upper quadrant tenderness, gallstones, and signs of inflammation on ultrasound/labs.\n3. Patients who participated in a 1983 gallstone screening study in Bergen, Norway and were operated for symptomatic gallstone disease.\n\nThis patient meets the first inclusion criteria for symptomatic gallstone disease with recurrent episodes of pain lasting >30 mins and ultrasound evidence of gallstones/sludge/CBD stone.\n\nThere is no information provided to exclude her based on the exclusion criteria listed.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1094": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\n2. The clinical trial is titled \"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma\".\n\n3. The inclusion criteria for the trial specify that patients must have newly diagnosed standard-risk B-cell acute lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).\n\n4. Based on the patient note, there is no mention of the patient having leukemia or lymphoma. The symptoms and findings are consistent with gallstone disease.\n\n5. Therefore, this patient does not meet the inclusion criteria for the specified clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1095": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). The ultrasound confirmed the presence of gallstones and bile duct stones.\n\nThe clinical trial is comparing different methods of monitoring breathing after surgery in acute care settings. \n\nTo determine the patient's eligibility, we need to look at the inclusion and exclusion criteria:\n\nInclusion criteria:\n1) Age greater than 18 - The patient is 54 years old, so meets this criteria.\n2) Increased Body Mass Index (BMI) > 31 - The patient is described as obese, so likely meets this criteria.\n3) History of chronic obstructive pulmonary disease (COPD) - There is no mention of COPD in the patient note.\n4) History of Sleep Apnea - There is no mention of sleep apnea in the patient note.\n\nExclusion criteria:\n1) Respiratory failure - Not mentioned, so assume this does not apply.\n2) Isolation requirements - Not mentioned, so assume this does not apply. \n3) Surgical patients admitted to 2 West or ICU - The patient is admitted to the emergency department, not these specific units.\n\nBased on the information provided, the patient meets at least the age and BMI inclusion criteria, but does not have the history of COPD or sleep apnea required. There is insufficient information to fully determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1096": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"A Randomised Controlled Trial on LESS Versus Conventional Laparoscopic Appendicectomy.\"\n\nThe inclusion criteria for the trial are:\n1. History of right lower quadrant pain or periumbilical pain migrating to the right lower quadrant\n2. Fever \u2265 38\u00b0C and/or WCC > 10 X 103 cells per mL\n3. Right lower quadrant guarding, and tenderness on physical examination\n4. Age between 18-75 years old\n\nBased on the patient note, the patient does not meet the inclusion criteria for this clinical trial as she is presenting with symptoms of gallstones/biliary disease rather than appendicitis.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1097": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the use of selumetinib and erlotinib hydrochloride in treating locally advanced or metastatic pancreatic cancer that is refractory to chemotherapy.\n\n3. Based on the patient note, there is no mention of the patient having pancreatic cancer, locally advanced or metastatic. The patient appears to be suffering from gallstones and related complications.\n\n4. Therefore, the patient does not meet the inclusion criteria for this clinical trial, which requires histologically or cytologically proven adenocarcinoma of the pancreas, locally advanced unresectable disease or extrapancreatic metastases, and one prior line of systemic therapy for advanced disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1098": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients with histopathological or cytopathological diagnosis of advanced biliary carcinoma (gallbladder cancer, cholangiocarcinoma, ampullary cancer) not amenable to conventional surgical approach are eligible\"\n- The patient note mentions gallstones, biliary sludge and CBD stones, indicating a biliary issue, so this criterion is potentially met.\n\n2. \"Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan\"\n- There is no mention of measurable lesions in the patient note.\n\n3. \"No patients with untreated brain metastases\"\n- No brain metastases are mentioned.\n\n4. \"Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2 (Karnofsky \u2265 60%)\" \n- No ECOG or Karnofsky performance status is provided.\n\n5. Other inclusion criteria related to blood counts, liver/kidney function, pregnancy status, contraception use, heart disease, prior cancers, QTc interval, hypertension, other illnesses, antiretroviral therapy, surgical procedures, medications etc.\n- Insufficient information is provided in the patient note to assess these criteria.\n\nOverall, while the patient seems to have a biliary issue potentially meeting the first inclusion criterion, there is insufficient information provided in the note to definitively assess eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1099": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Conventional SILS vs Harmonic Scalpel SILS\", the patient appears to be eligible for the trial. The key points are:\n\n- The patient is a 54-year-old woman presenting with abdominal pain, nausea, and vomiting.\n- The ultrasound revealed gallstones, biliary sludge, and CBD stones, indicating symptomatic gallbladder stones.\n- The inclusion criteria for the trial are \"patients with symptomatic gallbladder stones\".\n\nSince the patient meets the inclusion criteria of having symptomatic gallbladder stones, and there is no information provided that would exclude the patient based on the trial's exclusion criteria, the patient can be considered eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1100": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"The Impact of Pain Scores on Intrauterine Lidocaine Versus Normal Saline Infusion at the Time of IUD Placement\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever, which was diagnosed as gallstones and biliary sludge. There is no mention of the patient being eligible for or seeking an intrauterine device (IUD) insertion.\n\nThe inclusion criteria for the clinical trial specifically state that eligible participants should be \"Women eligible for IUD insertion\" and \"Willing to give consent\".\n\nSince the patient note does not indicate that the patient is eligible for or seeking IUD insertion, she does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1101": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the effectiveness of laparoscopic fundoplication on extraesophageal manifestations of gastroesophageal reflux disease (GERD).\n\nThe inclusion criteria for the trial are:\n1) Persistent or recurrent symptoms despite continuous medical treatment\n2) At least one typical reflux symptom (heartburn, regurgitation, dysphagia, epigastric pain) and/or at least one atypical reflux symptom (cough, asthma, hoarseness, distortion of taste)\n3) Pathologic esophageal acid exposure as documented by a reflux-related DeMeester score \u226514.7, and symptom correlation \u226550%, and/or reflux episodes >73.\n\nBased on the information provided in the patient note, the patient does not seem to meet the inclusion criteria for this trial. While the patient is experiencing epigastric pain, which could be a typical reflux symptom, the primary issue appears to be gallstones and biliary disease rather than GERD. There is no mention of the patient having persistent or recurrent GERD symptoms despite medical treatment, nor any information about esophageal acid exposure or reflux episodes.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1102": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worse after eating fatty foods. She has a history of similar episodes in the past year.\n\n2. Imaging revealed gallstones, biliary sludge, and CBD stones. The smallest stone is 14mm.\n\n3. The clinical trial is studying acid rebound in functional dyspepsia patients treated with PPIs.\n\n4. The inclusion criteria for the trial are:\n   - Symptoms indicating dyspepsia (epigastric pain/discomfort, postprandial fullness, early satiation, epigastric burning)\n   - Access to internet\n\n5. Based on the patient's presentation with gallstones and CBD stones, her symptoms are likely due to biliary colic rather than functional dyspepsia.\n\n6. Therefore, she does not meet the inclusion criteria for this particular clinical trial studying functional dyspepsia.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1103": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms consistent with gallbladder disease, including abdominal pain, nausea, vomiting, and the ultrasound confirming gallstones.\n\nThe clinical trial inclusion criteria are:\n1) Informed consent (not mentioned in the patient note)\n2) Ages of 18 to 80 years (the patient is 54, so meets this criteria)\n3) Symptoms consistent with gallbladder disease including biliary colic or chronic right upper quadrant pain (the patient has abdominal pain radiating to the right upper quadrant, consistent with this criteria)\n4) Ultrasound confirming gallstones (the ultrasound revealed gallstones, biliary sludge and CBD stones, so meets this criteria)\n\nBased on the information provided in the patient note, the patient meets criteria 2, 3 and 4 of the inclusion criteria for this clinical trial. There is no information about whether the patient provided informed consent (criteria 1).\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to lack of information about informed consent)",
        "label": 1
    },
    "1104": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\n2. The clinical trial is studying the effect of saline irrigation to decrease the rate of residual CBD stones after endoscopic stone removal procedures.\n\n3. The inclusion criteria for the trial are:\n   - Patients treated with CBD stone removal during therapeutic ERCP after finding CBD stones on imaging\n   - Patients treated with CBD stone removal during diagnostic ERCP due to cholangitis or cholecystitis\n\n4. Based on the patient note, this patient meets the inclusion criteria as she has CBD stones identified on imaging and is likely undergoing therapeutic ERCP for stone removal.\n\n5. There is no information provided about exclusion criteria, so we cannot definitively rule out exclusion.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1105": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is for the treatment of gastroesophageal reflux disease (GERD). The inclusion criteria require:\n1) Persistent or recurrent reflux symptoms despite medical treatment\n2) At least one typical reflux symptom (heartburn, regurgitation, dysphagia, epigastric pain) or atypical reflux symptom (cough, asthma, hoarseness, distortion of taste)\n3) Pathologic esophageal acid exposure documented by reflux-related DeMeester score \u226514.7 and symptom correlation \u226550%, and/or reflux episodes >73\n\nBased on the patient note, there is no mention of the patient having GERD or any reflux symptoms. The symptoms described (abdominal pain, nausea, vomiting, fever) seem to be related to gallstone disease rather than GERD.\n\nTherefore, the patient does not meet the inclusion criteria for this GERD clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1106": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings are consistent with gallstone migration and cholecystitis.\n\nThe inclusion criteria for the clinical trial are:\n1. Clinical diagnosis of gallstone migration, defined as right upper quadrant or epigastric abdominal pain and abnormal liver function tests.\n- The patient has right upper quadrant and epigastric pain, as well as elevated liver enzymes (AST, ALT), meeting this criteria.\n\n2. Patients will be included regardless of the presence of associated cholecystitis.\n- The patient has signs of cholecystitis (RUQ pain, gallbladder findings on imaging, fever).\n\n3. Age \u2265 16 years\n- The patient is 54 years old, meeting this criteria.\n\nBased on the information provided, the patient meets all of the inclusion criteria for this clinical trial on cholecystectomy vs sequential imaging for suspected gallstone migration.\n\nThere is no information provided about exclusion criteria, so we cannot definitively rule out exclusion. However, based solely on the inclusion criteria:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1107": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Intracutaneous Sterile Water Injections\" and is studying the use of sterile water injections for managing labor pain in women with neuraxial analgesia (epidural) who have breakthrough pain.\n\nThe inclusion criteria for the trial are:\n1) Multiparous women (the patient's parity is not mentioned, so this is unclear)\n2) Spontaneous labor (the patient is not in labor)\n3) At least 18 years of age (the patient is 54, so meets this criteria)\n4) Presenting for vaginal delivery with cervical dilation of 4 cm or less (the patient is not in labor, so does not meet this criteria)\n\nSince the patient does not meet at least one of the key inclusion criteria (being in spontaneous labor and presenting for vaginal delivery), she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1108": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is evaluating the efficacy of a combination of pregabalin and antioxidants in reducing pain in chronic pancreatitis patients.\n\n3. The inclusion criteria for the trial are:\n   - Epigastric pain +/- radiation at least thrice in one month over the past three months.\n   - Endotherapy/Surgery and ductal clearance\n\n4. Based on the patient note, there is no mention of chronic pancreatitis or endotherapy/surgery for ductal clearance. The patient's symptoms and imaging findings suggest acute cholecystitis/choledocholithiasis.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial on chronic pancreatitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1109": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of acute cholecystitis (gallbladder inflammation) likely due to gallstones. The ultrasound confirmed the presence of gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is investigating the use of intraperitoneal bupivacaine (a local anesthetic) during emergency cholecystectomy (gallbladder removal surgery) for patients with cholecystitis or gallstone pancreatitis.\n\nThe key inclusion criterion for this trial is \"patients undergoing emergency cholecystectomy for cholecystitis or gallstone pancreatitis.\"\n\nBased on the patient note, this patient meets that criterion as she is being evaluated for an emergency cholecystectomy due to acute cholecystitis from gallstones.\n\nTherefore, assuming there are no other exclusion criteria that would disqualify her, this patient appears eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1110": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman, which meets the age criteria of 50-65 years old and obesity criteria of BMI >30 kg/m2 for the obese group.\n\nThere is no mention of diabetes, so she could potentially be non-diabetic.\n\nHer HOMA-IR value is not provided, so it's unclear if she meets the criteria of HOMA-IR <3 for the insulin sensitive obese group.\n\nIt is not mentioned if she is a smoker or not.\n\nThere is no mention of any inflammatory disease, diabetes in first-degree relatives, or treatments that could interfere with insulin sensitivity.\n\nHowever, it is mentioned that she has abdominal pain, nausea, vomiting, and fever, which could indicate an infection or inflammatory condition related to gallstones and biliary sludge.\n\nBased on the available information, there is not enough evidence to determine if she meets all the inclusion criteria or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1111": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. She has a history of hypercholesterolemia and 2 normal vaginal deliveries. Her symptoms and imaging findings suggest gallstones and biliary sludge.\n\n2. The clinical trial is titled \"Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash\" and is studying the use of ketamine mouthwash for the treatment of severe oral mucositis pain in cancer patients receiving chemotherapy or radiation therapy.\n\n3. The inclusion criteria for the trial are:\n   - Patient has oral mucositis pain that is grade 3 or 4 according to the WHO Oral Mucositis Scale\n   - Patient has received at least one prior chemotherapy or radiation treatment\n   - Patient is at least 18 years old\n   - Patient or their legally authorized representative understands and voluntarily signs the written informed consent\n\n4. Based on the patient note, there is no mention of the patient having oral mucositis or receiving chemotherapy or radiation therapy for cancer. The patient's symptoms and diagnosis appear to be related to gallstones and biliary disease.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1112": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Clinical Trials to Reduce the Risk of Antimicrobial Resistance\" and is focused on treating hospitalized patients with pneumonia requiring mechanical ventilation.\n\n3. The inclusion criteria for the trial are:\n   - Written informed consent\n   - Hospitalized males or females \u2265 18 years with respiratory failure requiring mechanical ventilation and clinical suspicion of HABP, HCAP or VABP\n   - Onset or exacerbation of pneumonia at least 48 hours after admission to any patient health care facility or onset of pneumonia in a nursing home or rehabilitation facility with subsequent transfer to an acute care facility\n   - Women of childbearing potential if their pregnancy test is negative\n   - Subjects who have received previous antibacterial therapy within 14 days of pre-treatment bronchoscopy entry may be entered only if the subject has not responded clinically\n   - Patients should have clinical findings that support a diagnosis of HABP/VABP/HCAP, including a new or progressive infiltrate on chest radiograph and a quantitative culture of Bronchoscopic BAL fluid obtained within 36 hours before starting empiric study therapy\n   - Patients with VABP should have a Clinical Pulmonary Infection Score of \u2265 5\n\n4. Based on the information provided, the patient does not meet the inclusion criteria for this trial as she does not have pneumonia or respiratory failure requiring mechanical ventilation. She is presenting with gallbladder-related issues.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1113": {
        "output": "To determine the patient's eligibility for the clinical trial \"Electrohydraulic Versus Laser Lithotripsy for Treatment of Difficult to Remove Biliary Stones\", I will go through the inclusion criteria one by one:\n\n1. \"1 or more gall stones in bile duct which cannot be removed using conventional methods (must be fragmented)\"\n   - The patient note mentions that the ultrasound revealed \"several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\" This indicates that the patient has gallstones in the bile duct that cannot be removed conventionally and require fragmentation.\n\n2. \"Adults able to provide informed consent\"\n   - The patient is described as a 54-year-old woman, which implies that she is an adult capable of providing informed consent.\n\nSince the patient meets both inclusion criteria, she would be considered eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1114": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. She has a history of hypercholesterolemia and 2 normal vaginal deliveries. Her symptoms and imaging findings suggest gallstones and biliary sludge.\n\n2. The clinical trial is titled \"Reletex for Nausea in GERD Patients\" and is investigating the use of a neuromodulation device (Reletex band) for treating nausea and vomiting associated with GERD that is unresponsive to standard treatments like PPIs and anti-emetics.\n\n3. The inclusion criteria for the trial are:\n   - Age over 18\n   - Clinically diagnosed GERD with nausea and/or vomiting\n   - Continued symptoms despite stable PPI therapy (once or twice daily) with or without anti-emetics\n   - Previous gastric emptying study performed as part of standard care\n\n4. Based on the patient note, there is no clear mention of a GERD diagnosis or that the nausea and vomiting are related to GERD. The symptoms appear to be related to gallstones and biliary sludge.\n\n5. Therefore, the patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1115": {
        "output": "To determine the patient's eligibility for the clinical trial \"Scribes in the Emergency Department\", I will go through the inclusion criteria one by one:\n\n1. \"All consecutive patients during the study period\"\nThe patient note does not mention if this patient visit falls within the study period, so I cannot confirm this criterion.\n\n2. \"age > 18 y/o\"\nThe patient note states that the patient is 54 years old, so this criterion is met.\n\nSince there is not enough information to confirm if the patient meets the first inclusion criterion, I cannot definitively determine eligibility. However, based on the available information, the patient appears to potentially be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1116": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying a natural remedy for rheumatoid arthritis (RA). The inclusion criteria require:\n   - Age 18 or older \n   - Active RA defined by specific joint swelling/tenderness criteria\n   - Elevated ESR\n   - Meeting 1987 ACR criteria for RA diagnosis for at least 6 months\n   - No recent NSAID use\n   - Agreement to participate\n\n3. Based on the patient note, there is no mention of the patient having rheumatoid arthritis or meeting any of the specific RA-related inclusion criteria.\n\n4. The patient's symptoms and diagnosis appear to be related to gallstones/biliary disease rather than rheumatoid arthritis.\n\nTherefore:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1117": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and other symptoms suggestive of gallbladder disease.\n\n2. The clinical trial is about determining the prevalence of food allergies in adult patients with eosinophilic esophagitis.\n\n3. The inclusion criteria for the trial are:\n   - Male and female subjects 18 years and older\n   - Previous diagnosis of eosinophilic esophagitis with specific clinical symptoms and >15 eosinophils per high powered field on esophageal biopsy\n   - Previous diagnosis of gastroesophageal reflux with <15 eosinophils per high powered field on esophageal biopsy\n\n4. Based on the patient note, there is no mention of the patient having eosinophilic esophagitis or gastroesophageal reflux disease. The note suggests the patient has gallbladder disease.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1118": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age: The patient is 54 years old, which meets the age criteria of 18 years and above.\n\n2. Attending the medical office and reporting symptoms suggestive of upper gastrointestinal tract symptoms: The patient was admitted to the emergency department with abdominal pain, nausea, and vomiting, which are symptoms suggestive of upper gastrointestinal tract symptoms.\n\nBased on the information provided in the patient note, the patient meets both inclusion criteria for the clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1119": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. This does not seem to match the symptoms of gastroparesis mentioned in the trial inclusion criteria.\n\n2. The patient's ultrasound revealed gallstones, biliary sludge, and CBD stones, suggesting a diagnosis of cholelithiasis (gallstone disease) rather than gastroparesis.\n\n3. There is no mention of the patient having documented abnormal solid phase gastric emptying scintigraphy, which is a requirement for the trial's inclusion criteria.\n\n4. The trial is specifically looking for patients with idiopathic gastroparesis (gastroparesis with no known cause), whereas this patient's symptoms seem to be caused by gallstone disease.\n\nBased on the information provided, this patient does not meet the inclusion criteria for the \"Acupuncture Treatment for Gastroparesis: a Pilot Study\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1120": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This could potentially be acute appendicitis.\n\n2. The inclusion criteria for the clinical trial are:\n   - Age 2 to 20 years old\n   - Right lower quadrant or poorly localized abdominal pain, tenderness including right lower quadrant, nausea, vomiting, anorexia\n   - Onset of abdominal pain within 72 hours\n   - Patient or parent/guardian able to provide informed consent\n\n3. The patient meets some of the inclusion criteria like abdominal pain, nausea, vomiting, and onset within 72 hours.\n\n4. However, the patient is 54 years old, which is outside the age range of 2-20 years specified in the inclusion criteria.\n\n5. Therefore, based on the inclusion criteria provided, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1121": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)\".\n\nThe inclusion criteria for this trial are:\n1. 1 year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and/or 1.2\n2. Migraines typically last between 4 to 72 hours, if untreated\n3. \u2265 2 and \u2264 8 moderate or severe migraine attacks per month in each of the two months prior to screening\n4. Male, female who is not of reproductive potential, or female of reproductive potential with a screening serum \u03b2-human chorionic gonadotropin (\u03b2-hCG) level consistent with a not-pregnant state, and who agrees to use acceptable contraception\n\nBased on the patient note, there is no mention of the patient having a history of migraines or meeting the criteria for migraines as defined by the International Headache Society. The patient's presentation is consistent with gallbladder disease and cholelithiasis.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial on the treatment of acute migraine.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1122": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the side effects and best dose of combining MLN8237 (alisertib) with nab-paclitaxel in treating patients with advanced solid malignancies that are metastatic or cannot be removed by surgery.\n\n3. Looking at the inclusion criteria:\n- The patient does not have a histologically confirmed malignancy that is metastatic or unresectable. The patient has gallstones and related complications.\n- The patient does not have a diagnosis of pancreatic cancer or poorly differentiated neuroendocrine tumor.\n- The patient does not have measurable disease as defined in the criteria.\n- The patient is not required to undergo biopsies.\n- The patient meets the age criteria of \u2265 18 years old.\n- The patient's performance status is not mentioned, so it's unclear if they meet the ECOG 0 or 1 criteria.\n- The patient's bone marrow and organ function are not provided, so it's unclear if they meet those criteria.\n- The patient's childbearing potential and willingness to use birth control are not mentioned.\n- The patient's ability to take oral medication and maintain a fast is not mentioned.\n\nBased on the information provided, the patient does not meet several of the key inclusion criteria for this clinical trial studying advanced solid malignancies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1123": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for patients with relapsed or refractory multiple myeloma who have failed prior IV bortezomib-containing regimens.\n\n3. Based on the inclusion criteria, this patient does not have a diagnosis of multiple myeloma or any plasma cell disorder. She has gallstone disease.\n\n4. Therefore, she does not meet the key inclusion criteria for this multiple myeloma clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1124": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Alternative Approaches for Nausea Control\" one by one:\n\n1. Be female.\nThe patient note states \"A 54-year-old obese woman\", so this criterion is met.\n\n2. Have a diagnosis of breast cancer, any stage.\nThe patient note does not mention breast cancer or any cancer diagnosis. This criterion is not met.\n\n3. Be chemotherapy na\u00efve and about to begin her first course of chemotherapy.\nThere is no information about the patient receiving chemotherapy. This criterion cannot be evaluated.\n\n4. Be scheduled to receive one of the specified chemotherapy regimens with the specified antiemetic regimen.\nSince there is no information about the patient receiving chemotherapy, this criterion cannot be evaluated.\n\n5. Have a response of > 3 or greater on a question assessing expected nausea.\nThere is no information about the patient's expected nausea level. This criterion cannot be evaluated.\n\n6. Be able to read English.\nThere is no information about the patient's ability to read English. This criterion cannot be evaluated.\n\n7. Be 18 years of age or older and give written informed consent.\nThe patient note states \"A 54-year-old obese woman\", so the age criterion is met. However, there is no information about whether the patient has given written informed consent.\n\nIn summary, while the patient meets the gender and age criteria, there is not enough information to determine if they meet the other criteria related to cancer diagnosis, chemotherapy, expected nausea, and ability to read English and provide consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1125": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the inclusion criteria of \"Causes of admission to the ED are acute cholecystitis, biliary colic, acute cholangitis\".\n\n2. The patient's age of 54 falls within the age range of 18-75 years old specified in the inclusion criteria.\n\n3. There is no information provided that would exclude the patient based on the inclusion criteria listed.\n\n4. The patient note does not mention whether the patient is willing and able to provide informed consent, which is one of the inclusion criteria. However, this is likely something that would be determined during the recruitment process.\n\nBased on the information provided in the patient note and the listed inclusion criteria, this patient appears to be eligible for the clinical trial, assuming they are willing and able to provide informed consent.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1126": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones, with the smallest stone being 14mm.\n\nThe clinical trial is studying the natural process of CBD stones \u2264 6mm and complications within 1 year, as well as side effects of surgical removal.\n\nThe key inclusion criterion given is \"cholecystectomy\", which means the patient must have had their gallbladder removed.\n\nBased on the patient note, there is no mention of the patient having a cholecystectomy. The note only states that she has gallstones and CBD stones.\n\nTherefore, there is not enough information to determine if this patient meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1127": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings are consistent with acute cholecystitis/cholelithiasis.\n\n2. The clinical trial is studying the use of sublingual nitroglycerin for treatment of suspected symptomatic cholelithiasis (gallstones causing biliary colic/pain).\n\n3. The inclusion criteria for the trial are:\n   - Patients with right upper quadrant abdominal pain of less than 24 hours' duration\n   - Ages 18-60 years\n\n4. The patient meets the inclusion criteria of having right upper quadrant abdominal pain consistent with biliary colic/cholecystitis.\n\n5. However, the exclusion criteria list several conditions that would exclude the patient, including pregnancy. The patient note does not mention if she is pregnant or not.\n\n6. Since there is not enough information to definitively rule out pregnancy, which is an exclusion criteria, I cannot determine if the patient is fully eligible or excluded.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1128": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Usefulness of Chest Wall Tenderness as Bedside Test to Exclude Acute Coronary Syndrome in Different Demographic Groups.\"\n\n3. The inclusion criteria for the trial are: \"All patients over the age of 18 years presenting with the leading symptom of first time or recurrent acute chest pain in the emergency room of the Department of Internal Medicine, University Hospital of Zurich.\"\n\n4. The patient does not meet the inclusion criteria as she is presenting with abdominal pain, not chest pain.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1129": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of abdominal pain, nausea, vomiting, and fever, which are suggestive of gallbladder disease.\n2. The ultrasound findings of gallstones, biliary sludge, and common bile duct (CBD) stones confirm the presence of choledocholithiasis (common bile duct stones).\n3. The inclusion criteria for the clinical trial is \"common bile duct stones\".\n4. Since the patient has been diagnosed with common bile duct stones based on the ultrasound findings, she meets the inclusion criteria for the clinical trial.\n5. There is no information provided about any exclusion criteria that may disqualify the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1130": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparison of Pantoprazole and Ranitidine in Dyspepsia\", let's go through the inclusion criteria:\n\n1. Epigastric pain: The patient note mentions that the patient has \"epigastric pain that started 4 days ago with nausea and vomiting\". This meets the inclusion criterion of epigastric pain.\n\n2. Older than 18 years old: The patient note states that the patient is a 54-year-old woman, which meets the age requirement of being older than 18 years old.\n\nSince the patient meets both inclusion criteria mentioned in the trial, the patient can be considered eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1131": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers).\n\n2. The clinical trial is titled \"Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia\" and is studying the link between hormonal contraceptive use and the development of a sexual pain disorder called provoked vestibulodynia.\n\n3. The inclusion criteria for the trial are:\n   - Non-pregnant women between 18-35 years old\n   - Naive to hormonal contraceptives or other hormonal medications\n   - Able to provide informed consent and complete questionnaires\n   - Intends to use hormonal contraceptives for at least 1 year\n   - No pre-existing provoked vestibulodynia, pelvic floor hypertonicity, vaginismus or congenital abnormalities on exam\n   - Available for follow-up appointments\n   - Willing to undergo gynecologic examination if dyspareunia develops\n\n4. Based on the patient note, this 54-year-old woman with gallstone disease does not meet the inclusion criteria for the trial, which is specifically looking at younger women starting hormonal contraceptives.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1132": {
        "output": "To determine the patient's eligibility for the clinical trial \"Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients\", let's go through the inclusion criteria:\n\n1. \"Patients with one or more of the following symptoms namely epigastric pain or discomfort, postprandial fullness and early satiety with or without symptoms suggesting GERD\"\n\nThe patient note mentions that the 54-year-old woman was admitted to the emergency department with abdominal pain that started 4 days ago, along with nausea and vomiting. The epigastric pain radiates to the right upper quadrant and gets worse after eating fatty food. This suggests that the patient meets this inclusion criterion.\n\n2. \"Patients able to give informed consent\"\n\nThere is no information provided in the patient note about the patient's ability to give informed consent. However, since the patient is described as a 54-year-old woman admitted to the emergency department, it can be assumed that she is capable of providing informed consent unless stated otherwise.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1133": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. The clinical trial is titled \"DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study\" and is studying techniques for biliary cannulation in patients who initially had pancreatic duct cannulation during ERCP.\n\n3. The inclusion criteria for the trial are: ERCP patient, over 20 years old, pancreatic duct cannulation patients by chance.\n\n4. Based on the patient note, this patient was admitted for suspected gallstone disease and did not undergo an ERCP procedure where pancreatic duct cannulation occurred by chance.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1134": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients must have a histologically confirmed, unresectable pancreatic adenocarcinoma\"\n   - The patient note does not mention pancreatic cancer, so this criterion is not met.\n\n2. \"Patients must have already received or refused 1st-line treatment\"\n   - There is no information about prior treatment in the patient note.\n\n3. \"Measurable disease will be required; biopsiable disease will be required\"\n   - There is no information about measurable or biopsiable disease in the patient note.\n\n4. \"Eastern Cooperative Oncology Group (ECOG) performance status =< 1\"\n   - The patient's performance status is not provided.\n\n5. \"Life expectancy of greater than 16 weeks\"\n   - The patient's life expectancy is not mentioned.\n\n6. \"Leukocytes >= 3,000/mcL\"\n   - The patient has leukocytosis, which suggests this criterion may be met, but the exact value is not provided.\n\n7. \"Absolute neutrophil count >= 1,500/mcL\"\n   - This information is not provided in the patient note.\n\n8. \"Platelets >= 100,000/mcL\"\n   - This information is not provided in the patient note.\n\n9. \"Total bilirubin =< 1.5 institutional upper limit of normal (IULN)\"\n   - Bilirubin levels are not mentioned.\n\n10. \"Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 X IULN if no liver metastasis or =< 5 X IULN if liver metastases are present\"\n    - Liver enzyme levels are not provided, and presence of liver metastases is not mentioned.\n\n11. \"Creatinine not to be above IULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal\"\n    - Creatinine levels are not mentioned in the patient note.\n\n12. Contraception requirements\n    - This information is not provided.\n\n13. \"Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed\"\n    - There is no information about the patient's ability to swallow tablets.\n\n14. \"Ability to understand and the willingness to sign a written informed consent document\"\n    - This is not mentioned in the patient note.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1135": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones detected on ultrasound.\n\n2. The clinical trial is studying the side effects and best dose of vemurafenib when given together with cetuximab and irinotecan hydrochloride in treating patients with solid tumors that are metastatic or cannot be removed by surgery.\n\n3. The inclusion criteria for the trial state that patients must have:\n   - Histologically confirmed malignancy that is metastatic or unresectable\n   - Cancers with positive BRAF V600 mutation\n   - ECOG performance status of 0 to 2\n   - Life expectancy of greater than 3 months\n   - Measurable disease per RECIST 1.1 criteria\n   - K-RAS wild-type tumor\n   - Adequate blood counts and organ function\n   - Negative pregnancy test and use of contraception (for women of child-bearing age)\n   - Signed informed consent\n\n4. Based on the patient note, there is no mention of the patient having a solid tumor or cancer. The note describes a gallbladder issue.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1136": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Development of Applications of the Bravo\u00ae pH Monitoring System and Evaluation of Its Performance (Encore)\". It is designed to evaluate the performance of the Bravo pH monitoring system in symptomatic patients with known or suspected gastroesophageal reflux disease (GERD).\n\nThe inclusion criteria for the trial are:\n1) Age \u2265 18 years old\n2) Received explanation about the study and agrees to provide written informed consent\n3) Referred for pH monitoring to detect acid reflux due to symptoms like heartburn, regurgitation, dysphagia, epigastric pain, non-erosive reflux disease, chest pain, cough, hoarseness, asthma, or lower pharyngeal irritation.\n\nBased on the patient note, the 54-year-old woman meets the age criteria (\u2265 18 years old). However, her presenting symptoms (abdominal pain, nausea, vomiting, fever) and diagnosis (gallstones, biliary sludge, CBD stones) do not align with the inclusion criteria of suspected GERD or related symptoms.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1137": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This suggests a possible gallbladder issue.\n\n2. The ultrasound revealed gallstones, biliary sludge, and CBD stones, confirming a gallbladder problem.\n\n3. The inclusion criteria for the clinical trial state that patients with acute cholecystitis, cholangitis, biliary and hepatic tumors, Crohn's disease, and previous gastric surgery are not suitable for evaluation.\n\n4. Based on the patient's symptoms and ultrasound findings, she likely has acute cholecystitis (inflammation of the gallbladder) due to gallstones.\n\n5. Therefore, according to the inclusion criteria, this patient would be excluded from the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1138": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of biliary colic (abdominal pain, nausea, vomiting) and signs of cholecystitis/choledocholithiasis (epigastric tenderness, right upper quadrant tenderness, leukocytosis, elevated ESR, gallstones and CBD stones on ultrasound).\n\n2. The clinical trial is evaluating the patency rate of a new winged biliary stent (Viaduct) in patients with biliary obstruction due to stones or benign strictures.\n\n3. The inclusion criteria are:\n   - Age 18 or older\n   - Biliary obstruction from stones or benign strictures confirmed clinically, by labs, and imaging\n   - Indication for plastic stent placement\n   - Expected survival of at least 90 days\n   - High likelihood of follow-up\n   - Able to provide informed consent\n   - Willing and able to comply with study procedures\n\n4. This patient meets all the inclusion criteria:\n   - She is 54 years old\n   - She has biliary obstruction from stones confirmed clinically, by labs, and ultrasound imaging\n   - She would likely need a biliary stent placed for the CBD stones\n   - As this is a benign condition, her expected survival is likely >90 days\n   - As an inpatient, follow-up would be feasible\n   - No issues mentioned regarding ability to consent or comply with procedures\n\n5. There is no information provided about exclusion criteria, so based on the inclusion criteria alone, this patient would be eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1139": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the efficacy of choleretic agents (drugs that promote bile flow) in patients with an acalculous gallbladder (no definite gallstones) after complete removal of CBD stones.\n\n3. The inclusion criteria for the trial are:\n   - Complete clearance of CBD stones\n   - No definite gallbladder stones\n   - Agreement with the study protocol\n\n4. Based on the patient note, the patient has gallstones, biliary sludge, and CBD stones. Therefore, the patient does not meet the inclusion criteria of \"no definite gallbladder stones\" and \"complete clearance of CBD stones.\"\n\n5. There is no information provided about whether the patient agrees with the study protocol.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1140": {
        "output": "To determine the patient's eligibility for the clinical trial \"Single Site Robotic Cholecystectomy in Non Selected Patients\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\n- presence of symptomatic gallstones\n\nBased on the patient note, the key information is:\n- The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting.\n- The ultrasound revealed several gallstones, biliary sludge, and CBD stones.\n\nSince the patient has symptomatic gallstones, as evidenced by the abdominal pain and ultrasound findings, the patient meets the inclusion criteria for this clinical trial.\n\nThere is no information provided about exclusion criteria, so I cannot determine if the patient would be excluded based on any other factors.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1141": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Evaluating a Microfinance Intervention for High Risk Women in Mongolia\" and aims to reduce unprotected sex and increase income from sex work among women engaged in high-risk sexual activity.\n\n3. The inclusion criteria for the trial are:\n   - At least 18 years of age\n   - Reports engaging in vaginal or anal sexual intercourse in the past 90 days in exchange for money, alcohol, or other goods\n   - Reports engaging in unprotected vaginal or anal sexual intercourse in the past 90 days with a paying sexual partner\n   - Reports being interested in learning about and developing her own small business\n\n4. Based on the patient note, there is no information provided about the patient engaging in sex work or having unprotected sexual intercourse with paying partners. The note is focused on her medical condition related to gallstones and biliary issues.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1142": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is studying the safety and efficacy of celecoxib for acute pain relief in patients with traumatic pain, post-surgical pain, and tooth extraction pain.\n\nBased on the inclusion criteria of the trial, which specifies patients with traumatic pain, post-surgical pain, and tooth extraction pain, this patient does not seem to meet the criteria as her pain is due to gallstones and biliary disease.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1143": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a 15-year follow-up study comparing outcomes between total abdominal hysterectomy (TAH) and subtotal abdominal hysterectomy (SAH) in women who underwent these procedures for benign uterine disease.\n\n3. The key inclusion criterion for this trial is \"Women undergoing abdominal hysterectomy for benign uterine disease at a gynaecological department in Denmark (15 years ago)\".\n\n4. Based on the patient note provided, there is no mention of the patient having undergone a hysterectomy 15 years ago in Denmark. The current presentation appears to be related to gallstone disease.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1144": {
        "output": "To determine the patient's eligibility for the clinical trial \"Improving Pain Management for Older Adults in the Emergency Department (ED)\", let's go through the inclusion criteria one by one:\n\n1. Resident physicians will be included if: they provide care to adult patients in the Icahn School of Medicine at Mount Sinai's ED.\n   - This criterion is not applicable to the patient, as the patient is not a resident physician.\n\n2. Patients will be enrolled for survey and/or medical record review if:\n   - All adult (\u226520 years) patients seen in the Icahn School of Medicine at Mount Sinai's ED\n     - The patient note does not specify the hospital, so we cannot determine if this criterion is met.\n   - with severe pain (\u226510 on a verbal pain scale of 0-10, 0=none, 10=severe)\n     - The patient note does not mention the patient's pain score, so we cannot determine if this criterion is met.\n   - and chief complaints of abdominal pain will be eligible for retrospective and/or medical record review and prospective survey at ED discharge.\n     - The patient note mentions that the patient was admitted to the emergency department with abdominal pain, so this criterion is met.\n\nSince we do not have sufficient information to determine if the patient meets all the inclusion criteria, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1145": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The pain is epigastric radiating to the right upper quadrant, worse after eating fatty foods. She has had similar episodes in the past year. Relevant findings include mild fever, elevated blood pressure, tachycardia, epigastric and right upper quadrant tenderness, leukocytosis, and gallstones/biliary sludge/CBD stones on ultrasound.\n\nThe clinical trial is evaluating the efficacy of lansoprazole for symptomatic improvement in gastroesophageal reflux disease (GERD) patients with dyspepsia symptoms.\n\nThe inclusion criteria are:\n1) Patients with heartburn or acid regurgitation at start of lansoprazole therapy\n2) Patients without heartburn/acid regurgitation, but with endoscopic findings of GERD (Los Angeles grade A-D) at start of therapy\n3) Patients with dyspepsia symptoms (postprandial fullness, early satiation, epigastric pain, epigastric burning, upper abdominal bloating, nausea/vomiting, or belching) at start of therapy\n\nThis patient does not appear to have typical GERD symptoms of heartburn or acid regurgitation mentioned. There is also no endoscopic evidence provided about GERD findings. However, she does have dyspepsia symptoms of epigastric pain, nausea, and vomiting.\n\nBased on the information given, while the patient may meet some of the inclusion criteria for dyspepsia symptoms, there is insufficient information to definitively determine if she meets all the criteria for enrollment in this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1146": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not appear to be eligible for the trial. The key points are:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and findings suggestive of gallstones and biliary sludge.\n\n2. The inclusion criteria for the clinical trial is \"Patients with acute osteoporosis fractures\".\n\nSince the patient note does not mention any osteoporotic vertebral fractures, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1147": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is for acute lymphoblastic leukemia (ALL) patients undergoing allogeneic hematopoietic stem cell transplantation (allo HCT) with a fludarabine/total body irradiation (FluTBI) conditioning regimen.\n\nLooking at the inclusion criteria:\n1. Disease criteria: The patient does not have ALL, so this criterion is not met.\n2. Age criteria: The patient is 54 years old, which falls within the 40-65 year age range. However, this is for ALL patients, which the patient does not have.\n3. Organ function criteria: There is no information provided about the patient's organ function.\n4. Performance status: No information is provided about the patient's performance status.\n5. Consent: No information is provided about the patient's ability to provide consent.\n6. Donor criteria: No information is provided about the availability of a donor.\n\nSince the patient does not have ALL, which is a key inclusion criterion for this clinical trial, the patient would not be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1148": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries. Imaging shows gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"User Evaluation of the MiniMed 640G Insulin Pump\" and is evaluating the usability and acceptance of a new insulin pump in patients with type 1 or type 2 diabetes who are current insulin pump users.\n\n3. The inclusion criteria for the trial are:\n   - Age 7 years or older\n   - Current insulin pump user for at least 3 months\n   - Experience with inserting/changing CGM sensor, recharging transmitter, and reading sensor data on pump screen\n   - Willing to sign informed consent and comply with study procedures\n   - Willing to complete study questionnaires\n   - Clinical diagnosis of type 1 diabetes for at least 6 months\n\n4. The patient does not meet the inclusion criteria for this trial as she does not have a diagnosis of type 1 or type 2 diabetes and is not currently using an insulin pump.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1149": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Chronic Toxicities Related to Treatment in Patients With Localized Cancer\" and is focused on studying chronic toxicities in patients with non-metastatic cancer, specifically localized breast cancer.\n\n3. The inclusion criteria for the trial are:\n   - Women\n   - Aged 18 years and over\n   - With an invasive breast cancer diagnosed by cytology or histology\n   - Tumors cT0 to cT3, CN0-3\n   - No clinical evidence of metastasis at the time of inclusion\n   - Untreated including scored for breast cancer surgery in progress\n   - Patient receiving a social security system\n   - Patient mastering the French language\n   - Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage\n   - (Since February 2022) Patient age < 45 years at diagnostic or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-\n\n4. Based on the patient note, this patient does not have breast cancer or any other localized cancer. She has gallstones and related complications.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1150": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients\".\n\n3. The inclusion criteria for the trial are:\n   - Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis\n   - Willing to participate in the study meetings\n   - Age >18 years\n   - Alert and capable of giving informed consent\n   - Able to speak and read English or French\n\n4. Based on the patient note, there is no mention of the patient being diagnosed with thyroid cancer. The note describes symptoms and findings related to gallstones and biliary disease.\n\nTherefore, the patient does not meet the inclusion criteria for this thyroid cancer clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1151": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Pain in Women With Chronic Pelvic Pain\" and the inclusion criteria are:\n1) Women\n2) Clinical diagnosis of chronic pelvic pain\n3) More than eighteen years old\n4) Non-menstrual or noncyclic pelvic pain\n5) Duration of pain of at least 6 months\n\nLooking at the inclusion criteria:\n1) The patient is a woman, so this criterion is met.\n2) The patient does not have a clinical diagnosis of chronic pelvic pain, but rather acute abdominal pain likely due to gallstones/biliary disease.\n3) The patient is 54 years old, so this criterion is met.\n4) The patient's pain is not described as non-menstrual or noncyclic, but rather acute abdominal pain.\n5) The duration of pain is 4 days, not at least 6 months.\n\nSince the patient does not meet criteria 2, 4, and 5 for chronic pelvic pain, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1152": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound.\n\n2. The clinical trial is studying the BioNIR Ridaforolimus Eluting Coronary Stent System for percutaneous coronary intervention (PCI) in patients with coronary artery disease.\n\n3. The inclusion criteria for the trial specify:\n   - Age \u2265 18 years (the patient meets this)\n   - Indication for PCI including angina, silent ischemia, NSTEMI, or recent STEMI (the patient does not seem to meet this, as she is presenting with gallstone disease)\n   - Other criteria related to previous PCIs and angiographic findings\n\n4. Based on the information provided, the patient does not appear to meet the key inclusion criteria of having an indication for PCI. Her presentation is due to gallstone disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1153": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and biliary sludge on ultrasound).\n\nThe clinical trial is titled \"Preoperative Glucocorticoid Use in Major Hepatectomy\" and aims to evaluate if giving glucocorticoids (steroids) before a major liver resection surgery can reduce post-operative complications and hospital length of stay.\n\nThe key inclusion criteria for this trial are:\n1) Adult patients (which the 54-year-old patient satisfies)\n2) Undergoing elective hepatectomy (liver resection surgery)\n\nFrom the patient note, there is no mention that the patient is scheduled for a hepatectomy or liver resection surgery. The symptoms and findings point towards a diagnosis of gallstone disease requiring a cholecystectomy (gallbladder removal surgery), not a major liver resection.\n\nTherefore, based on the information provided, this patient does not meet the key inclusion criteria for the stated clinical trial on preoperative glucocorticoids for hepatectomy patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1154": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Peri-operative Psychology and Post-operative Pain Study\", here is my assessment:\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever, likely due to gallstones and biliary sludge. The note does not mention any recent orthopaedic surgery or plans for elective orthopaedic surgery.\n\nThe inclusion criteria for the clinical trial state that it includes \"All inpatients on Sharp, Shaugh or Stannon ward following elective orthopaedic surgery carried out on Monday to Thursday each week.\"\n\nSince the patient note does not indicate that the patient has undergone or is scheduled for elective orthopaedic surgery, there is insufficient information to determine if the patient meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1155": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman with a history of hypercholesterolemia, which is relevant to the inclusion criteria of the clinical trial on familial hypercholesterolemia.\n\nHowever, the patient note does not mention any family history of high cholesterol or heart disease, nor any abnormal growth on tendons or accumulation of fatty material in the eye, which are part of the clinical diagnostic criteria for familial hypercholesterolemia listed in the inclusion criteria.\n\nWithout more information on whether the patient meets the specific clinical diagnostic criteria for familial hypercholesterolemia, it is difficult to determine if she would be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "1156": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa.\"\n\n3. The inclusion criteria for the trial state:\n   - Age \u2265 18 years\n   - Both males and females are eligible\n   - No current or former diagnosis of cancer (with some exceptions)\n   - No use of certain medications\n   - No chronic anticoagulation or steroid use\n   - Karnofsky Performance Scale \u226590%\n   - Able to provide written informed consent\n   - Negative pregnancy test for women of childbearing potential\n   - No history of food intolerance to broccoli, pineapple, or lime juices\n   - Willing to avoid certain foods and medications during the study\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for the trial. She has an active medical condition (gallstones, biliary sludge, and CBD stones) and is not a healthy volunteer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1157": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients diagnosed with FD according to the ROME III criteria:\n   i) Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to obtaining informed consent\n   - The patient note does not mention how long the symptoms have been present, so this cannot be confirmed.\n   ii) Have not received upper endoscopy within the last 6 months prior to enrollment and do not have evidence of structural/organic disease\n   - The patient note mentions an ultrasound showing gallstones, biliary sludge, and CBD stones, which would be considered an organic disease. This exclusion criterion is not met.\n   iii) Must have one or more of the following symptoms: Bothersome postprandial fullness, Early satiation, Epigastric pain, Epigastric burning\n   - The patient note mentions epigastric pain that gets worse after eating fatty food, which could be considered bothersome postprandial fullness or epigastric pain. This criterion is likely met.\n\n2. At least one of the FD-related symptoms on the Global Overall Symptom (GOS) scale (bothersome postprandial fullness, early satiation, epigastric pain, epigastric burning) is \u22654, whereas heartburn is \u22643.\n   - The patient note does not provide information about symptom severity scores, so this cannot be confirmed.\n\n3. Total score of depression-related symptoms on Hospital Anxiety and Depression Score (HAD) is \u226410.\n   - The patient note does not provide information about depression scores, so this cannot be confirmed.\n\n4. Type of visit: Outpatient\n   - The patient note mentions the patient was admitted to the emergency department, so this criterion is not met.\n\n5. Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study.\n   - The patient note does not provide information about informed consent, so this cannot be confirmed.\n\nBased on the information provided in the patient note, the patient would likely be excluded from this clinical trial due to the presence of an organic disease (gallstones, biliary sludge, and CBD stones) and being admitted to the emergency department rather than being an outpatient.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1158": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric, radiating to the right upper quadrant, and worsens after eating fatty foods. She has a history of similar episodes in the past year. Her vital signs show mild fever, tachycardia, and hypertension. Physical exam reveals epigastric and right upper quadrant tenderness without rebound. Labs show leukocytosis with left shift and elevated ESR. Ultrasound reveals gallstones, biliary sludge, and CBD stones with the smallest stone measuring 14mm.\n\nThe clinical trial inclusion criteria are:\n1) Age >= 16 years (the patient is 54 years old, so this criterion is met)\n2) Abdominal pain as the main complaint (the patient's main complaint is abdominal pain, so this criterion is met)\n\nBased on the information provided, the patient meets all the inclusion criteria for the clinical trial \"Triage of Abdominal Pain in the Emergency Department.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1159": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She was diagnosed with gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is studying the side effects and best dose of onalespib when given together with dabrafenib and trametinib in treating patients with BRAF-mutant melanoma or solid tumors that are metastatic or cannot be removed by surgery.\n\n3. Based on the inclusion criteria, the key requirements are:\n   - Histologically confirmed, BRAF-mutant (V600E/K) solid tumor that is metastatic or unresectable\n   - Measurable disease\n   - Specific laboratory values within certain ranges\n   - No major organ dysfunction\n   - Able to swallow oral medication\n\n4. The patient note does not mention anything about the patient having a BRAF-mutant solid tumor or metastatic disease. The note is focused on gallbladder/biliary issues.\n\n5. Since there is no information provided about the patient meeting the key inclusion criteria of having a BRAF-mutant solid tumor, the patient cannot be considered eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1160": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings suggest gallbladder disease with gallstones and cholecystitis.\n\n2. The clinical trial is studying the effect of timing of dexamethasone administration on pain scores and quality of recovery in patients undergoing elective cesarean section.\n\n3. The inclusion criteria for the trial are:\n   - Over 18 years of age\n   - American Society of Anesthesiologists class I-III\n   - Presenting for elective cesarean section\n\n4. Based on the patient note, this 54-year-old woman is not presenting for an elective cesarean section. She is being treated for gallbladder disease.\n\nTherefore, this patient does not meet the inclusion criteria for the stated clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1161": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Gastropanel for Gastric Atrophy and Cancer Risk Assessment\" and is looking at evaluating a blood test for detecting gastric atrophy and conditions associated with increased gastric cancer risk.\n\n3. The inclusion criteria for the trial are:\n   - Adult females and males over 45 years of age\n   - With dyspeptic symptoms (epigastric pain, bloating and epigastric discomfort)\n\n4. The patient meets the age criteria (54 years old) and has epigastric pain, which could be considered a dyspeptic symptom.\n\n5. However, the patient's symptoms and imaging findings suggest a gallbladder/biliary issue rather than a primary gastric condition.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1162": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Cramer Sports Motion Tape and Low Back Pain EMG\" and is studying the effectiveness of a taping technique on low back pain.\n\nThe inclusion criteria for the trial are:\n1) Must be recruited within the first 2 to 3 therapy visits\n2) Have a diagnosis of chronic mechanical low back pain\n3) Age 18-65\n\nBased on the patient note, there is no mention of the patient having low back pain or being recruited for physical therapy. The presenting complaint is related to gallstones and biliary issues.\n\nTherefore, this patient does not meet the inclusion criteria for the \"Cramer Sports Motion Tape and Low Back Pain EMG\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1163": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is studying risk factors for recurrence of primary bile duct stones. The inclusion criteria state:\n\n\"Patients who were performed ERCP due to CBD stone or calculous cholangitis\"\n\nSince the patient has CBD stones and is likely undergoing or being evaluated for ERCP, she meets the inclusion criteria for this trial.\n\nThere is no information provided about exclusion criteria, so based on the available information, this patient would be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1164": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n\"emergency department's patients undergoing CT evaluation for acute abdominal pain and tenderness (acute is defined as onset of current episode within 7 days of emergency department presentation).\"\n\nFrom the patient note, we know that:\n- The patient is a 54-year-old obese woman admitted to the emergency department\n- She has abdominal pain that started 4 days ago (within 7 days)\n- She is experiencing abdominal tenderness (\"epigastric tenderness and tenderness in the right upper quadrant\")\n- She is undergoing imaging evaluation (ultrasound revealed gallstones and she is likely going for a CT scan)\n\nBased on the information provided, this patient meets all the inclusion criteria for the clinical trial titled \"Limited Abdominal CT in ED Patients With Abdominal Pain\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1165": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. At least 19 years of age\nThe patient note states the patient is 54 years old, so this criterion is met.\n\n2. Smoking at least 10 cigarettes per day\nThere is no information provided about the patient's smoking status or number of cigarettes smoked per day.\n\n3. Smoked daily for at least the past year  \nAgain, there is no information about the patient's smoking history.\n\n4. Have an intention of quit smoking in the next 30 days\nThere is no mention of the patient's intention to quit smoking.\n\nSince there is insufficient information in the patient note to determine if the patient meets criteria 2, 3, and 4, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1166": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct stones (CBDS).\n\nThe clinical trial is studying the management of common bile duct stones (CBDS) in patients.\n\nThe inclusion criteria for the trial is:\n- Patients with common bile duct stones (CBDS)\n\nSince the patient has been diagnosed with common bile duct stones based on the imaging findings, she meets the inclusion criteria for this clinical trial.\n\nThere are no explicit exclusion criteria mentioned, so we cannot exclude the patient based on that.\n\nTherefore, based on the information provided, the patient is eligible for this clinical trial studying the management of common bile duct stones.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1167": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Ultrasound revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\nThe clinical trial is looking at the correlation between power Doppler findings of gallbladder wall vascularity and intraoperative findings in chronic and acute cholecystitis patients undergoing laparoscopic cholecystectomy.\n\nThe inclusion criteria are:\n1. Symptomatic chronic cholelithiasis patients accepted for laparoscopic cholecystectomy\n2. Acute cholelithiasis patients accepted for laparoscopic cholecystectomy within 72-96 hours of symptom onset, with acute cholecystitis diagnosed by RUQ pain, positive Murphy's sign, fever, leukocytosis, sonographic gallbladder distention/wall thickening \u22653mm/gallstones or sludge.\n\nThis patient meets the criteria for acute cholecystitis based on her symptoms, fever, leukocytosis, and ultrasound findings of gallstones/sludge and likely gallbladder wall thickening (not explicitly stated but implied). She would be eligible for the trial if undergoing laparoscopic cholecystectomy within 72-96 hours.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1168": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman with abdominal pain, nausea, and vomiting. She has been diagnosed with gallstones, biliary sludge, and common bile duct stones. The clinical trial you provided is a phase I trial studying the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with recurrent solid tumors that are metastatic or cannot be removed by surgery.\n\nThe inclusion criteria for the clinical trial state that patients must have advanced or metastatic cancer that is refractory to standard therapy or relapsed after standard therapy, and have a histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.\n\nBased on the information provided in the patient note, there is no indication that the patient has cancer or a solid tumor. The patient's condition appears to be related to gallstones and biliary issues.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1169": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings point towards gallstone disease and cholecystitis rather than small bowel obstruction.\n\n2. The clinical trial is looking to evaluate the accuracy of ultrasound in diagnosing small bowel obstruction in emergency department patients.\n\n3. The inclusion criteria for the trial are:\n   - 18 years of age or greater (the patient meets this criteria)\n   - Abdominal pain with clinical suspicion for small bowel obstruction (the patient does not meet this criteria based on her presentation)\n\nSince the patient does not meet one of the key inclusion criteria for suspected small bowel obstruction, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1170": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Investigating a Model for Acute Ischemic Pain in Humans\", the patient does not seem to meet the inclusion criteria for the trial.\n\nThe key points are:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, which is likely related to gallstones and biliary sludge.\n\n2. The inclusion criteria for the trial specify patients over 40 years with unilateral femoral-popliteal peripheral artery disease (PAD), Fontaine grade II.\n\n3. There is no mention of the patient having PAD or any other vascular disease in the provided note.\n\nTherefore, based on the available information, the patient does not appear to be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1171": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effect of acetaminophen on non-alcoholic fatty liver disease (NAFLD) patients compared to healthy controls.\n\n3. The inclusion criteria for NAFLD patients are:\n   - Presence of NAFLD defined by imaging, elevated liver enzymes, or metabolic syndrome\n   - Age 18-70 years\n   - Written informed consent\n\n4. The exclusion criteria for NAFLD patients include:\n   - ALT > 3x ULN at baseline\n   - Evidence of other liver diseases\n   - Excess alcohol intake\n   - Liver cirrhosis\n   - Certain medical conditions or medications\n   - Pregnancy\n   - Hepatocellular carcinoma\n\n5. Based on the patient note, there is no mention of NAFLD or metabolic syndrome. The patient's condition appears to be related to gallstones and biliary obstruction.\n\n6. Therefore, the patient does not meet the inclusion criteria for the NAFLD group in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1172": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones on ultrasound.\n\nThe clinical trial is titled \"Restrictive Fluid Therapy in Severe Preeclampsia\" and is studying fluid management in patients with severe preeclampsia undergoing cesarean section.\n\nThe key inclusion criteria are:\n- Severe preeclampsia defined by criteria like high blood pressure, proteinuria, oliguria, cerebral/visual disturbances, pulmonary edema, epigastric pain, impaired liver function, thrombocytopenia, HELLP syndrome, fetal compromise.\n\nThis patient does not meet the inclusion criteria, as there is no mention of her being pregnant or having preeclampsia. Her symptoms appear to be related to gallstone disease.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1173": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her medical history includes hypercholesterolemia and 2 normal vaginal deliveries. Imaging shows gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS\"\n\n3. The inclusion criteria for the trial are:\n   - Male or female adult patients\n   - 18-60 years of age\n   - Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria (2010)\n   - Patients naive to MS therapy or patients switching from an FDA-approved MS therapy\n   - Expanded Disability Status Scale (EDSS) score 0 to 5.5 inclusive\n\n4. Based on the patient note, there is no mention of the patient having multiple sclerosis or meeting any of the other inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1174": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Gut Microbiome in Diverticulitis and Diverticulosis\", let's go through the inclusion criteria:\n\n1. Groups A and B: Patients with acute diverticulitis - patients presenting to A&E at King's College Hospital with new onset abdominal pain, with or without a known diagnosis of diverticulitis.\n\nThe patient note mentions that the 54-year-old woman was admitted to the emergency department with abdominal pain that started 4 days ago, which could be considered new onset abdominal pain. However, the note does not explicitly state that she has been diagnosed with acute diverticulitis.\n\n2. Groups C and D: Patients with asymptomatic diverticulosis and normal controls - Patients being assessed through the 2ww Colorectal Cancer pathway with a chief complaint of fresh PR bleeding and no other 'red flag' symptoms, who are not overly anxious over their diagnosis as assessed by a physician outside the study team.\n\nThe patient note does not mention any information about the patient being assessed through the 2ww Colorectal Cancer pathway or having fresh PR bleeding.\n\nBased on the information provided in the patient note, there is not enough evidence to determine if the patient meets the inclusion criteria for the clinical trial. More information would be needed, such as a confirmed diagnosis of acute diverticulitis or asymptomatic diverticulosis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1175": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the efficacy and safety of Hyoscine Butylbromide tablets for treating occasional or recurrent episodes of gastric or intestinal spasm-like pain or discomfort.\n\n3. The inclusion criteria for the trial are:\n   - Written informed consent\n   - Age 18-70 years\n   - Occasional or recurrent episodes of gastric or intestinal spasm-like pain or discomfort, present for at least 3 months\n   - Pain intensity score of at least 4 cm on VAS upon screening\n\n4. The patient meets the age criteria (54 years old).\n\n5. The patient is experiencing abdominal pain, which could potentially be classified as \"gastric or intestinal spasm-like pain or discomfort.\"\n\n6. However, the patient's pain is likely due to gallstones and biliary sludge, rather than a functional gastrointestinal disorder like irritable bowel syndrome.\n\n7. There is no information provided about the duration of the patient's symptoms or the pain intensity score upon screening.\n\nBased on the available information, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1176": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices\", the patient does not seem to meet the inclusion criteria for this trial.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, which suggests a diagnosis of cholecystitis or biliary colic. There is no mention of esophageal varices or any endoscopic treatment for esophageal varices in the patient note.\n\nThe inclusion criteria for the clinical trial specifically states \"Patient with esophageal varices having upper GIT endoscopy\".\n\nTherefore, based on the information provided, the patient does not qualify for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1177": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The pain is localized to the right upper quadrant and worsens after eating fatty foods. This is consistent with the suspected diagnosis of biliary colic mentioned in the inclusion criteria.\n\nThe inclusion criteria state:\n1. Patients ages 18-55 - The patient is 54 years old, meeting this criterion.\n2. Present to ED with right upper quadrant (RUQ) abdominal pain - The patient has RUQ abdominal pain, meeting this criterion. \n3. Suspected diagnosis of biliary colic - The clinical presentation strongly suggests biliary colic, meeting this criterion.\n4. Negative pregnancy test for women of childbearing potential - The patient is menopausal, so this criterion is not applicable.\n5. No history of cholecystectomy - There is no mention of a prior cholecystectomy, so the patient likely meets this criterion.\n\nBased on the information provided in the patient note, the patient appears to meet all of the stated inclusion criteria for the clinical trial on the analgesic efficacy of intravenous ibuprofen in biliary colic.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1178": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). The ultrasound confirmed the presence of gallstones and biliary sludge.\n\nThe clinical trial is titled \"Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction\" and is studying the effects of bezafibrate on reducing fibrinogen levels and inflammatory response in patients with ST-elevation myocardial infarction (STEMI) and hyperfibrinogenemia.\n\nThe inclusion criteria for this trial are:\n1) Patients >18 years of age\n2) Admitted with ST-elevation acute coronary syndrome (ACS) \n3) Hyperfibrinogenemia (fibrinogen >500 mg/dl) within 72 hours of symptom onset\n\nBased on the patient note, this 54-year-old woman does not meet the inclusion criteria for this trial as she was not admitted with STEMI, but rather with symptoms of gallstone disease. There is no mention of her having an acute myocardial infarction or elevated fibrinogen levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1179": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial titled \"Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial\" is studying meconium levels of fatty acid ethyl esters (FAEE) in infants born to mothers with different types of diabetes mellitus.\n\nThe inclusion criteria for this trial are:\n- Pregnant women expected to deliver between 37 and 41 weeks gestation (controls)\n- Pregnant women with class A1 diabetes mellitus expected to deliver between 37 and 41 weeks \n- Pregnant women with class A2 diabetes mellitus expected to deliver between 37 and 41 weeks\n- Pregnant women with pre-gestational diabetes mellitus expected to deliver between 37 and 41 weeks\n\nBased on the patient note, this 54-year-old woman is not pregnant and does not have any information about diabetes status or expected delivery timing.\n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial studying FAEE levels in infants of diabetic mothers.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1180": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting. She has a history of hypercholesterolemia and has had 2 normal vaginal deliveries.\n\n2. The clinical trial is titled \"Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study.\"\n\n3. The inclusion criteria for the trial are:\n   - Male or female age 18 to 75 years (the patient meets this criterion)\n   - Presence of newly formed gallstones (size up to 6 mm) with or without sludge diagnosed by ultrasound within 3 or 6 months after bariatric surgery following normal ultrasound (the patient does not meet this criterion as she has not had bariatric surgery)\n   - Bariatric surgery conducted during the last 12 months (the patient does not meet this criterion)\n   - Patients with sleeve gastrectomy or laparoscopic banding of the upper stomach will be included (the patient does not meet this criterion)\n   - Other criteria related to informed consent, pregnancy status, contraception, hypertension control, and medication use (unable to assess based on the provided information)\n\n4. Based on the information provided, the patient does not meet the key inclusion criteria related to having recently undergone bariatric surgery and the presence of newly formed gallstones after bariatric surgery.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1181": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and common bile duct stones, including abdominal pain, nausea, vomiting, and fever. The ultrasound confirmed the presence of gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is investigating the rate of duodenal-biliary reflux in patients with recurrent common bile duct stones after undergoing endoscopic retrograde cholangiopancreatography (ERCP) for stone removal.\n\nThe inclusion criteria for the trial are:\n1. Patients with common bile duct stones\n2. Underwent successful stone removal by ERCP at Xijing Hospital of Digestive Diseases\n\nBased on the patient note, this patient meets the inclusion criteria of having common bile duct stones and likely underwent or will undergo ERCP for stone removal at the hospital.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1182": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman, which does not meet the \"non-obese\" criteria specified in the inclusion criteria for this clinical trial.\n\n2. The patient has elevated cholesterol levels (hypercholesterolemia), which could potentially fall under the \"non-obese patients with elevated low-density lipoprotein (LDL)\" inclusion criteria. However, since the patient is obese, she does not meet this criteria.\n\n3. There is no information provided about the patient's HDL levels, so it is unclear if she meets the \"non-obese patients with low high-density lipoprotein (HDL)\" inclusion criteria.\n\n4. The patient has elevated liver enzymes (elevated liver transaminases), but since she is obese, she does not meet the \"non-obese patients with unexplained and persistently elevated liver transaminases\" inclusion criteria.\n\n5. There is no information provided about hepatomegaly or cirrhosis, so it is unclear if the patient meets those inclusion criteria.\n\n6. The patient has gallstones and biliary sludge, which could potentially explain the elevated liver enzymes and steatosis, so she may not meet the \"biopsy-proven microvesicular or mixed micro/macrovesicular steatosis without a known etiology\" inclusion criteria.\n\n7. There is no information provided about familial hypercholesterolemia or genetic testing, so it is unclear if the patient meets those inclusion criteria.\n\nBased on the information provided, the patient does not clearly meet any of the inclusion criteria due to her obesity.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1183": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone of 14mm.\n\nThe clinical trial is looking at the cost-effectiveness of using endoscopic ultrasound (EUS) versus ERCP for diagnosing CBD stones in patients with intermediate risk.\n\nThe inclusion criteria for the trial are:\n1) History of biliary pain or recent cholangitis\n2) Acute pancreatitis  \n3) Abnormal liver function tests\n4) Dilation of CBD and/or CBD stone detected by ultrasound or CT\n\nThis patient meets criteria 1 (biliary pain), 3 (abnormal LFTs with leukocytosis), and 4 (CBD stone detected on ultrasound).\n\nTherefore, based on the information provided, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1184": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct (CBD) stone.\n\nThe clinical trial is investigating the best pathway for evaluating suspected CBD stones - either magnetic resonance cholangiopancreatography (MRCP) or intraoperative cholangiography.\n\nThe inclusion criteria are:\n1. Patients with cholecystolithiasis (gallstones) and suspected CBD stones\n2. At least one of the following:\n    i. Elevated bilirubin\n    ii. Elevated liver enzymes (ASAT/ALAT, gGT, or aP above normal range - 2 of them)\n    iii. Choledocholithiasis (CBD stones) seen on ultrasound\n    iv. Dilated bile ducts on ultrasound\n3. Provide written informed consent\n\nAssessing against the criteria:\n1. The patient has cholecystolithiasis and a confirmed 14mm CBD stone on ultrasound, meeting this criteria.\n2. The patient likely has elevated liver enzymes given the leukocytosis and left shift, meeting this criteria as well.\n3. No information is provided about written informed consent.\n\nSince the patient meets the key inclusion criteria of cholecystolithiasis, suspected CBD stone, and likely elevated liver enzymes, they would be eligible for this trial if they provide written informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial due to lack of information about written informed consent)",
        "label": 2
    },
    "1185": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion and exclusion criteria:\n\nInclusion Criteria:\n1. Elderly patients admitted to the emergency department (aged 75 year old and older)\n   - The patient is 54 years old, which does not meet this criterion.\n\n2. Acute abdominal pain\n   - The patient was admitted with abdominal pain that started 4 days ago, which qualifies as acute abdominal pain.\n\n3. Informed consent\n   - There is no information provided about whether the patient gave informed consent or not.\n\nExclusion Criteria:\n1. Traumatic pain\n   - The patient's abdominal pain is not due to trauma, so this exclusion criterion is not met.\n\n2. Symptom duration of more than a week\n   - The patient's symptoms started 4 days ago, which is less than a week.\n\n3. Inability for the patient to give informed consent\n   - There is no information provided about the patient's ability to give informed consent.\n\nBased on the available information, the patient does not meet the age criterion for inclusion, and there is no information about informed consent. Therefore, there is not enough information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1186": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effect of different hydrocortisone replacement doses on ectopic lipid depots in patients with corticotropic hypopituitarism.\n\n3. Looking at the inclusion criteria for the trial:\n- It requires patients to have corticotropic pituitary insufficiency, which this patient does not appear to have based on the note.\n- It also requires patients to be capable of exercising on a bicycle for 120 minutes, which is not mentioned for this patient.\n\n4. Looking at the exclusion criteria:\n- The patient has obesity, which is not an exclusion criterion.\n- There is no mention of the patient having any of the listed exclusion criteria like abnormal liver/renal/thyroid function, diabetes, severe dyslipidemia, etc.\n\nBased on the information provided, there is insufficient evidence that the patient meets the key inclusion criterion of having corticotropic pituitary insufficiency. Additionally, there is no information about the patient's ability to exercise as required.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1187": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the inclusion criteria of being a non-pregnant female aged 18-80 years old.\n\n2. The patient has a history of hypercholesterolemia, but no other major medical conditions are mentioned that would exclude her.\n\n3. The key piece of information is that the ultrasound revealed gallstones, biliary sludge, and CBD stones. This indicates the patient likely has cholestatic liver disease.\n\n4. The trial is specifically looking for patients with Primary Biliary Cirrhosis (PBC) or PBC-autoimmune hepatitis overlap.\n\n5. While the patient has signs of cholestasis, there is no definitive diagnosis of PBC mentioned in the note.\n\n6. The inclusion criteria require a definite or probable PBC diagnosis based on elevated alkaline phosphatase for >6 months, positive antimitochondrial antibodies, and/or liver biopsy consistent with PBC.\n\n7. None of those diagnostic criteria for PBC are provided in the patient note.\n\nTherefore, based on the information given, there is insufficient evidence to determine if this patient meets the key inclusion criteria of a PBC diagnosis for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1188": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging shows gallstones and biliary sludge.\n\n2. The clinical trial is studying the use of palonosetron for preventing nausea and vomiting induced by radiation therapy.\n\n3. The inclusion criteria state that patients must be receiving radiation therapy to the upper abdomen, upper/half body (moderate risk) or lower thorax/pelvis (low risk).\n\n4. This patient is not receiving radiation therapy, but rather has gallstone disease causing her symptoms.\n\n5. Therefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1189": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. This matches the inclusion criteria of having symptoms like epigastric pain, abdominal discomfort, nausea, and vomiting.\n\n2. The patient's ultrasound revealed gallstones, biliary sludge, and CBD stones, suggesting chronic gallbladder disease rather than chronic gastritis. \n\n3. There is no mention of the patient being diagnosed with chronic gastritis via endoscopy and pathological methods, which is an inclusion criteria.\n\n4. There is also no mention of the patient agreeing to join the clinical trial.\n\nBased on the information provided in the patient note, the patient does not meet all the inclusion criteria for the \"Clinical Effect of Rebamipide on Chronic Gastritis\" trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1190": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of acute cholecystitis (abdominal pain, nausea, vomiting, fever) and imaging findings of gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying endoscopic nasogallbladder drainage versus gallbladder stenting before cholecystectomy in patients with acute cholecystitis and suspected CBD stones.\n\n3. The inclusion criteria for the trial are:\n   - Grade II or III acute cholecystitis meeting Tokyo 13 diagnostic criteria\n   - High suspicion of CBD stone based on laboratory and imaging studies\n   - Informed consent given\n\n4. Based on the patient note, the patient meets the inclusion criteria of having acute cholecystitis (Grade II or III based on symptoms and imaging findings) and a high suspicion of CBD stones (14mm stone seen on ultrasound).\n\n5. There is no information provided about whether the patient has given informed consent, but we can assume this would be obtained if the patient is eligible and agrees to participate.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1191": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Pre-Emptive Analgesia in Ano-Rectal Surgery\" and is studying the use of pre-operative pain medication for reducing post-operative pain in patients undergoing certain anorectal surgeries.\n\n3. The inclusion criteria specify that patients must be undergoing one of the following surgeries at the listed facilities:\n- Anal fistula repair\n- Anal sphincterotomy for chronic anal fissure\n- Hemorrhoidectomy \n- Anal condyloma excision\n\n4. The patient in this case is presenting with gallstones/biliary issues and does not appear to be a candidate for any of the specified anorectal surgeries.\n\nTherefore:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1192": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. JAK2V617F-positive PV or JAK2V617F-positive ET (confirmed by WHO diagnostic criteria)\n- The patient note does not mention polycythemia vera (PV) or essential thrombocythemia (ET), nor does it state the JAK2V617F mutation status.\n\n2. High risk ET/PV [age >60; history of thrombosis] or low risk disease with symptoms [recurrent headaches, paresthesias, pruritus]\n- Again, no mention of PV or ET diagnosis. The patient is 54 years old and has no stated history of thrombosis or symptoms like headaches, paresthesias, pruritus.\n\n3. Previously treated with at least one other agent [hydroxyurea, interferon, anagrelide] and determined to be either intolerant/resistant\n- No mention of prior treatments for PV or ET.\n\n4. \u226518 years of age\n- The patient is 54 years old, so meets this criteria.\n\n5. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2\n- No ECOG performance status provided.\n\n6. Acceptable pre-study organ function...\n- Some lab values like bilirubin, AST, ALT, creatinine are provided but incomplete to assess this criteria.\n\n7. Women of childbearing potential and males must agree to use adequate contraception...\n- The patient is a 54-year-old postmenopausal woman, so this likely applies.\n\n8. Ability to understand and willingness to sign a written informed consent document.\n- No information provided about ability to consent.\n\nIn summary, while the patient meets some criteria like age, there is insufficient information to determine if they have the target diseases (PV or ET) required for this trial. Several other inclusion criteria also cannot be assessed based on the limited information provided.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1193": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery\".\n\n3. The inclusion criteria for the trial are:\n- Term (\u226537 weeks) live singleton gestation in cephalic presentation\n- Admitted to Labor and Delivery Unit\n- In latent phase of labor, admitted for induction, or at prenatal clinic visit\n- Fewer than 4 prior vaginal deliveries\n- No allergy to misoprostol\n\n4. Based on the patient note, this patient does not meet the inclusion criteria as she is not pregnant or admitted for labor/delivery. She is presenting with gallstone disease.\n\nTherefore:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1194": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms suggestive of acute biliary pancreatitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and CBD stones on imaging).\n\n2. The clinical trial is titled \"Early EUS in Acute Biliary Pancreatitis\" and aims to investigate the usefulness of early endoscopic ultrasound (EUS) in the management of acute biliary pancreatitis.\n\n3. The inclusion criteria for the trial are: \"All consecutive patients entering the emergency department for possible acute biliary pancreatitis\"\n\n4. Based on the patient note and the inclusion criteria, this patient meets the criteria for enrollment in the clinical trial as she presented to the emergency department with possible acute biliary pancreatitis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1195": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is titled \"Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones.\"\n\nThe inclusion criteria for the trial are: \"Patients with CBD stone and treated by ERCP\"\n\nBased on the patient note, this patient has CBD stones and would likely undergo ERCP (endoscopic retrograde cholangiopancreatography) for stone removal.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial.\n\nThere is no information provided about exclusion criteria, so we cannot definitively rule out exclusion based on the details given.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1196": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting for 4 days. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has had similar episodes twice in the past year.\n\nHer medical history includes hypercholesterolemia and 2 normal vaginal deliveries. She is menopausal and does not smoke, drink alcohol, or use illicit drugs.\n\nOn examination, she is mildly febrile with epigastric and right upper quadrant tenderness without rebound. Labs show elevated ESR and leukocytosis with left shift. Ultrasound revealed gallstones, biliary sludge, and common bile duct stones with the smallest stone being 14mm.\n\nThe clinical trial is looking at a \"cholecystectomy first\" strategy for patients with acute gallstone-related conditions like cholecystitis, gallstone pancreatitis, ascending cholangitis, suspected gallstone migration, or choledocholithiasis.\n\nGiven that this patient presented with acute abdominal pain likely due to gallstones/cholecystitis and has imaging evidence of gallstones, biliary sludge, and common bile duct stones, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1197": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Systemic Steroids for Peripheral Nerve Blocks\" and is investigating the ability of dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.\n\nThe inclusion criteria for the trial are:\n1. Primary elective total hip arthroplasty surgery\n2. Must be a candidate for placement of a lumbar plexus block under anatomic landmark technique using electrical stimulation\n3. Must give written informed consent for anesthesia\n4. Must be reliable and able to give accurate verbal pain scores postoperatively\n\nBased on the patient note, this patient does not seem to be undergoing a total hip arthroplasty surgery. The note indicates she is being treated for gallstones and related complications.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1198": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking at the accuracy of surgeon-performed ultrasound in detecting gallstones. The inclusion criteria are:\n1) Patients referred to the radiology department for an abdominal ultrasound\n2) Age > 18 years\n\nThis patient meets both of those criteria - she was referred for an abdominal ultrasound and is over 18 years old.\n\nThere are no explicit exclusion criteria listed, so based on the information provided, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1199": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\n3. The clinical trial is studying the role of ursodeoxycholic acid (UDCA) in treating gallstones in patients with hemolytic disorders like spherocytosis, G6PD deficiency, thalassemia, or sickle cell disease.\n\n4. One of the inclusion criteria is \"Diagnosis of a hemolytic disorder including spherocytosis, G6PD deficiency, thalassemia or sickle cell disease.\"\n   - The patient note does not mention any hemolytic disorder diagnosis for this patient.\n\n5. Another inclusion criteria is \"Patients with cholelithiasis or bile sludge.\"\n   - The patient does have gallstones and biliary sludge, meeting this criteria.\n\n6. The age criteria is \">= 4 years\" which the 54-year-old patient meets.\n\n7. There is no information provided about the patient's ability to consent and follow study procedures.\n\nBased on the available information, while the patient meets some of the inclusion criteria (age, gallstones/sludge), the lack of a stated hemolytic disorder diagnosis means there is insufficient information to determine full eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1200": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her symptoms and lab/imaging findings point to cholecystitis/cholelithiasis (gallstones and biliary sludge).\n\n2. The clinical trial is assessing different doses of a drug (OPS-2071) for treating bacterial enteritis caused by specific pathogens like C. difficile, Salmonella, Campylobacter, pathogenic E. coli, etc.\n\n3. Based on the inclusion criteria provided, this patient does not seem to have bacterial enteritis caused by the listed pathogens. Her condition appears to be gallstone disease.\n\n4. There is insufficient information to determine if she meets the other inclusion criteria regarding providing informed consent, willingness to use contraception, etc.\n\nTherefore, based on the information given:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1201": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is looking at the primary symptoms of gastroesophageal reflux disease (GERD) in Chinese outpatients in the gastroenterology department.\n\n3. The inclusion criteria for the trial are:\n   - Patients aged 18-65 years\n   - Presenting with upper gastrointestinal discomfort (heartburn, regurgitation, dysphagia, substernal pain, epigastric pain, epigastric burning, early satiety, postprandial fullness)\n   - Symptoms lasting for at least 3 months and at least 3 days per week with moderate severity\n   - Able to fill in questionnaires\n\n4. Based on the patient note, the patient does not seem to meet the inclusion criteria for this trial. The patient is presenting with symptoms suggestive of gallstones and biliary disease, rather than GERD symptoms.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1202": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for 4 days. This does not match the inclusion criteria of \"abdominal cramps associated with acute gastroenteritis\".\n\n2. The patient's symptoms are more indicative of gallstones and biliary disease, as confirmed by the ultrasound findings of gallstones, biliary sludge, and CBD stones.\n\n3. The inclusion criteria specifically state \"Adult patients presenting to the emergency department with abdominal cramps associated with acute gastroenteritis\".\n\n4. Since the patient's presentation is not due to acute gastroenteritis, but rather gallstone disease, she does not meet the inclusion criteria for this particular clinical trial.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1203": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial:\n\nThe patient is a 54-year-old obese woman, which meets the age criteria of \u226518 years and <66 years old.\n\nShe has gastrointestinal symptoms like abdominal pain, nausea, and vomiting, which are listed as required symptoms in the inclusion criteria.\n\nHer diagnosis is gallstones and biliary sludge, which would likely be considered an acute liver disease based on the elevated liver enzymes mentioned.\n\nThere is no mention of her being pregnant or breastfeeding, HIV positive, having autoimmune hepatitis, fulminant hepatitis, decompensated liver disease, cancer, or being on parenteral nutrition - all of which are exclusion criteria.\n\nHer platelet count and serum creatinine levels are not provided, but assuming they are within normal ranges, she would meet those criteria.\n\nNo mention is made of her using any of the excluded medications like warfarin, metronidazole, oral steroids, etc.\n\nBased on the information provided, this patient appears to meet the key inclusion criteria for gastrointestinal symptoms in an acute liver disease and does not seem to violate any of the major exclusion criteria.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "1204": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones. This patient does not appear to have acute low back pain, which is the primary inclusion criterion for the clinical trial titled \"Acute Low Back Pain: Causes, Mechanisms, Treatment and Followup.\"\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1205": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). \n\nThe clinical trial is titled \"Simplified Medical Abortion Follow-Up\" and is studying the use of a home pregnancy test for follow-up after a medical abortion.\n\nLooking at the inclusion criteria:\n1. She has not been determined eligible for a medical abortion, as she is presenting with gallstone disease, not for an abortion.\n2. She is not willing to use the home pregnancy test, as this was not mentioned.\n3. Her willingness to comply with study procedures is unknown.\n4. It is unknown if she speaks and reads English.\n5. She has not signed an informed consent form for this study.\n\nBased on the information provided in the patient note, she does not meet the inclusion criteria for this clinical trial on medical abortion follow-up.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1206": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation\".\n\n3. The inclusion criteria for the trial are:\n   - Patients eligible for chemoradiation therapy of the head and neck\n   - Baseline creatinine no greater than 1.5 times the upper limit of normal\n   - Clinical stage II-IV head and neck carcinoma\n   - Pathologic diagnosis of squamous cell carcinoma of the head and neck region\n   - ECOG performance status \u2264 2\n   - Ability to swallow and retain oral medication or take through a feeding tube\n   - Patients of child-bearing potential must agree to use adequate contraceptive methods\n   - Patient or legal representative must understand the study and sign informed consent\n\n4. Based on the patient note, this patient does not have head and neck cancer, which is a key inclusion criterion for the trial. Therefore, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1207": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\nThe clinical trial is looking at using a hemostatic powder (TC-325) to control acute upper gastrointestinal bleeding from non-variceal causes like peptic ulcers.\n\nThe key inclusion criteria are:\n1) Overt signs of upper GI bleeding (hematemesis, melena, circulatory instability)\n2) Documented active bleeding (Forrest I) from a non-variceal upper GI source at endoscopy\n\nBased on the patient note, there is no mention of overt upper GI bleeding signs like hematemesis or melena. The symptoms and findings point more towards biliary colic/cholecystitis from gallstone disease.\n\nWhile the patient could potentially develop an upper GI bleed from something like a bleeding ulcer in the future, there is insufficient information currently to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1208": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone measuring 14mm.\n\nThe clinical trial is studying the use of laser lithotripsy for difficult large bile duct stones >1.5cm that cannot be removed by conventional endoscopic methods.\n\nThe key inclusion criterion for this trial is:\n\"Bile duct stone >1.5cm demonstrated on ultrasound, computed tomography, or magnetic resonance imaging\"\n\nGiven that the patient has a 14mm (1.4cm) CBD stone seen on ultrasound, they meet this main inclusion criterion.\n\nThere is no other information provided about exclusion criteria that could potentially exclude the patient.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "1209": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery\".\n\nLooking at the inclusion criteria:\n1) Primary breast cancer without known extension beyond the breast and axillary nodes (i.e. believed to be Tumor Stage 1-3, Nodes 0-2)\n- The patient note does not mention breast cancer, so this criterion is not met.\n\n2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated lumpectomy will not qualify)\n- The patient note does not mention any scheduled breast surgery, so this criterion is not met.\n\n3) Isolated lumpectomy with axillary node dissection (anticipated removal of at least five nodes)\n- Again, no mention of planned lumpectomy or node dissection, so this criterion is not met.\n\n4) Written informed consent, including willingness to be randomized to opioids or regional analgesia\n- No information about consent is provided.\n\n5) Dutch speaking\n- No information about language is provided.\n\nBased on the information given in the patient note, there is not sufficient evidence that the patient meets any of the inclusion criteria for this breast surgery clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1210": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction\". \n\nLooking at the inclusion criteria:\n1. Pregnant women at \u226537 weeks gestation - The patient note does not mention pregnancy, so this criterion is not met.\n2. Scheduled induction of labor - There is no mention of scheduled labor induction for this patient.\n3. Singleton gestation - No information provided.\n4. Cephalic presentation - No information provided. \n5. Amniotic fluid index \u22655 cm - No information provided.\n6. Formal prenatal ultrasound documenting absence of placenta previa - No information provided.\n7. Bishop score <6 and cervical dilation <3cm - No information provided.\n8. Able to give consent - Presumed able but not explicitly stated.\n9. Maternal age \u226518 years - Met, patient is 54 years old.\n\nSince the patient does not meet the key criteria of being pregnant and scheduled for labor induction, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1211": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Ultrasonography in the Emergency Department\" and aims to investigate if focused ultrasonography examination (f-US) can improve diagnostic accuracy in the emergency department for patients presenting with respiratory symptoms.\n\n3. The inclusion criteria for the trial are:\n   - Patient is 18 years or older\n   - Arrived acutely to the emergency department\n   - Presenting with one or more of the following symptoms: cough, dyspnea, chest pain, respiratory rate > 20, or peripheral oxygen saturation < 95%\n   - Able to provide written informed consent\n\n4. Based on the patient note and the inclusion criteria, this patient does not meet the criteria for this trial as she is presenting with abdominal pain and gallstones, rather than respiratory symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1212": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and common bile duct stones, confirmed by ultrasound.\n\nThe inclusion criteria for the clinical trial are:\n1) Age between 18-80 years (the patient is 54, so meets this criteria)\n2) Diagnosed with gallstones (the patient has gallstones, so meets this criteria) \n3) Diagnosed with common bile duct stones by MRI, MRCP, CT or intraoperative cholangiography/transcystic exploration (the patient has common bile duct stones confirmed by ultrasound, so meets this criteria)\n4) Accepted one of the three management options (EST+LC, LCBDE, LTCBDE) (there is no information given about the planned management, so cannot confirm if this criteria is met)\n\nBased on the information provided, the patient meets criteria 1-3, but there is insufficient information to determine if criteria 4 is met regarding the planned management.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1213": {
        "output": "Based on the provided patient note and the inclusion criteria for the \"Solana\u2122 Trichomonas Assay Field Study\" clinical trial, the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever, which is suggestive of a gallbladder-related condition, such as cholecystitis or choledocholithiasis. There is no mention of any symptoms related to a Trichomonas vaginalis infection, such as vaginal discharge, painful urination, vaginal itching, or lower abdominal pain.\n\nThe inclusion criteria for the clinical trial specifically state that female subjects should be recruited from the general population and categorized as either asymptomatic or symptomatic for Trichomonas vaginalis infection.\n\nSince the patient's symptoms and condition do not align with a Trichomonas vaginalis infection, she would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1214": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is titled \"Colonic Motility in Constipation and Ageing\" and is studying bowel contraction patterns, dietary fiber intake, and gut bacteria in young and older adults with and without constipation.\n\n3. Looking at the inclusion criteria for the constipated group:\n- Age does not match (54 years old, not 18-40 or 70-90)\n- No mention of Barthel index score\n- Has co-existing acute disease (gallstones/biliary disease)\n- No mention of Cleveland Clinic Constipation Score or bowel movement frequency/consistency\n\n4. Looking at the inclusion criteria for the non-constipated group:\n- Age does not match (54 years old, not 18-40 or 70-90) \n- Has co-existing acute disease (gallstones/biliary disease)\n- No mention of Barthel index score or Cleveland Clinic Constipation Score\n\n5. Based on the information provided, the patient does not meet the inclusion criteria for either the constipated or non-constipated groups in this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1215": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted with acute abdominal pain, nausea, and vomiting for 4 days. This matches the presentation of acute pancreatitis.\n\nHer lab tests show elevated ESR and leukocytosis with left shift, indicating an inflammatory process. \n\nThe ultrasound revealed gallstones, biliary sludge and CBD stones, confirming a biliary etiology for her pancreatitis.\n\nThe inclusion criteria state:\n1) Age 18-70 years - The patient is 54, so meets this criteria\n2) First episode of gallstone acute pancreatitis - The note mentions she had similar pain twice in the past year, so this may not be her first episode. More clarity is needed.\n3) Diagnosis based on Atlanta criteria - The patient meets at least 2 of the 3 criteria (abdominal pain, elevated amylase/lipase, imaging evidence)\n4) Biliary etiology confirmed on imaging - This is confirmed by the ultrasound findings\n\nThe main potential exclusion is whether this represents her first episode of acute pancreatitis or not. If it is not her first episode, she may be excluded.\n\nOverall, based on the information provided, there is not enough clarity to definitively determine eligibility. More information is needed about whether this is truly her first episode of acute gallstone pancreatitis.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1216": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone measuring 14mm.\n\nThe clinical trial is comparing endoscopic sphincterotomy plus large-balloon dilatation (ESLBD) versus conventional treatment (endoscopic sphincterotomy +/- mechanical lithotripsy) for the treatment of large CBD stones \u2265 13mm.\n\nThe key inclusion criteria is:\n\"Patient with CBD stones with a smaller diameter \u2265 13mm on cholangiogram\"\n\nGiven that this patient has a 14mm CBD stone seen on imaging, she meets this key inclusion criteria.\n\nThere is no other exclusion criteria mentioned that would exclude this patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1217": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods.\n\n2. The clinical trial is looking to validate a new point-of-care troponin I test in patients presenting to the emergency department with symptoms suggestive of acute coronary syndrome (ACS).\n\n3. The inclusion criteria for the trial are:\n   - Signed informed consent\n   - Age 21 years or older\n   - Presenting to the ED with symptoms suggestive of ACS/myocardial ischemia, such as chest pain, pressure, burning sensation across the precordium and epigastrium, pain radiating to neck, shoulder, jaw, back, upper abdomen, and either arm.\n\n4. Based on the patient note, the patient is presenting with abdominal pain, nausea, and vomiting, which are not typical symptoms of ACS. The pain is localized to the epigastric and right upper quadrant regions, worsening with fatty foods, which suggests a biliary/gallbladder issue rather than ACS.\n\n5. Therefore, this patient does not meet the inclusion criteria for the clinical trial, as they are not presenting with symptoms suggestive of ACS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1218": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her labs show elevated inflammatory markers and imaging reveals gallstones, biliary sludge, and a 14mm common bile duct (CBD) stone.\n\n2. The clinical trial is studying the clinical characteristics of patients with choledocholithiasis (CBD stones) who have markedly elevated aminotransferase levels (>400 IU/L).\n\n3. The inclusion criteria are:\n   - Patients diagnosed with CBD stones by ERCP\n   - Patients showing aminotransferase >400 IU/L on admission\n   - A control group with normal AST/ALT levels\n\n4. Based on the patient note, it does not explicitly state the aminotransferase levels. It only mentions the patient had leukocytosis and elevated ESR, which are non-specific inflammatory markers.\n\n5. Without the specific aminotransferase values, it is difficult to determine if this patient meets the inclusion criteria of having aminotransferases >400 IU/L.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1219": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This meets the age criteria of 18 years or older.\n\nHer symptoms of epigastric pain, nausea, and vomiting could potentially be indicative of functional dyspepsia according to the Rome III criteria mentioned in the inclusion criteria.\n\nHowever, the ultrasound revealed gallstones, biliary sludge, and CBD stones, which suggests a structural/organic cause for her symptoms. This would exclude her from the trial based on the criteria \"no evidence of structural disease (including upper GI endoscopy) that is likely to explain the symptoms.\"\n\nAdditionally, her BMI is not provided, but she is described as obese, which may put her BMI above the required range of 18.5-30.\n\nThere is no information provided about a Helicobacter pylori test, endoscopy within the last 3 months, or symptom duration.\n\nBased on the available information, the patient does not meet all the inclusion criteria and has at least one exclusion criterion (structural disease explaining symptoms).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1220": {
        "output": "To determine the patient's eligibility for the clinical trial \"Comparing the Effects of EST and EPBD in Patients With Acute Biliary Pancreatitis\", let's go through the inclusion criteria one by one:\n\n1. Patients with age \u2265 20 years: The patient is 54 years old, so this criterion is met.\n\n2. Acute biliary pancreatitis concomitant with either signs of acute cholangitis or bile duct obstruction:\n   a. Abdominal pain typical of pancreatitis: The patient has abdominal pain that radiates to the right upper quadrant, which is typical of pancreatitis.\n   b. Elevation of serum amylase and/or lipase up to three times above normal: No information is provided about amylase or lipase levels.\n   c. Imaging studies (abdominal ultrasound or abdominal computed tomography) showed evidence of pancreatitis: The ultrasound revealed gallstones, biliary sludge, and CBD stones, which can cause pancreatitis.\n   d. Common bile duct stones, acute cholangitis (Charcot's triad), total bilirubin (total bilirubin) > 4mg/dL, bile duct dilatation (diameter > 6mm with intact gallbladder, or > 10mm when the gallbladder has been removed) plus total bilirubin 1.8 \u2264 4mg/dL: The patient has CBD stones, but no information is provided about cholangitis, total bilirubin levels, or bile duct dilatation.\n   e. Exclude other causes of acute pancreatitis: No information is provided about other potential causes.\n\nBased on the information provided, the patient meets criteria a and c, but there is not enough information to determine if criteria b, d, and e are met.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1221": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for this trial. The trial is focused on evaluating the use of smoke evacuation systems during head-neck, breast, or abdominal laparoscopic surgeries, while the patient note describes a case of gallstones and biliary sludge, which does not align with the surgical procedures mentioned in the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1222": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for evaluating the efficacy and safety of CUDC-907 in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including those with MYC alterations.\n\n3. The inclusion criteria for the trial are:\n   - Age \u2265 18 years\n   - 2-4 prior lines of therapy for de novo DLBCL and ineligible for or failed autologous or allogeneic stem cell transplant\n   - Histopathologically confirmed diagnosis of relapsed/refractory DLBCL, high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, or transformed follicular lymphoma to DLBCL\n\n4. Based on the patient note, there is no mention of the patient having any form of lymphoma or cancer. The patient is presenting with symptoms related to gallstones and biliary disease.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial, as they do not have the target disease (relapsed/refractory DLBCL).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1223": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note is about a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a case-control study looking at the association between vitamin D deficiency and preeclampsia.\n\n3. The inclusion criteria for the trial are:\n   - Parity: primigravida (first pregnancy)\n   - Age: 18 - 35 years\n   - Singleton pregnancy\n   - Gestational age: 36-40 weeks\n   - No past history of any medical disorder and no other medical complications during pregnancy\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for the trial because:\n   - She is not pregnant (the trial requires pregnant women)\n   - She is 54 years old (the trial requires ages 18-35)\n   - She has a medical condition (gallstones, biliary sludge, CBD stones)\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1224": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the efficacy of a surgical procedure called SASI bypass for obese patients with type 2 diabetes.\n\nThe inclusion criteria state that eligible participants must be type 2 diabetic obese patients.\n\nWhile the patient note mentions obesity, there is no information provided about whether the patient has type 2 diabetes or not.\n\nTherefore, based on the information given, there is not enough evidence to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1225": {
        "output": "Okay, let's go through the patient note and inclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, elevated blood pressure, and leukocytosis. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the POCUS-1 arm of the trial are:\n- RUQ mass/pain/tenderness (patient has this)\n- Murphy's sign (not mentioned)\n- Fever (patient has this)\n- Elevated WBC (patient has this)\n- Elevated CRP (not mentioned)\n- Deranged liver function tests (not mentioned)\n- Jaundice (not mentioned)\n\nThe patient meets some but not all of the POCUS-1 inclusion criteria.\n\nThe exclusion criteria include:\n- Age under 18 (patient is 54, so not excluded)\n- Pregnancy (not mentioned, but patient is menopausal so likely not pregnant)\n- Obesity with BMI \u2265 30 (patient is obese, so potentially excluded)\n- Previously documented gallstones within 2 months for non-critical presentations (not mentioned)\n- Previous cholecystectomy (not mentioned)\n\nBased on the information provided, the patient potentially meets some of the POCUS-1 inclusion criteria but may be excluded due to obesity.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1226": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders\", the patient does not seem to be eligible for this trial. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, which does not align with the inclusion criteria for the trial, which requires patients to have Deep Brain Stimulation (DBS) for Obsessive-Compulsive Disorder (OCD) or Major Depression (MD) and be experiencing a beneficial effect of DBS on their psychiatric symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1227": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Radiofrequency Ablation of Genicular Nerves for Advanced Osteoarthrosis of the Knee Joint 1 Year Follow-up.\"\n\nThe inclusion criteria for the trial are:\n1. Patients suffering from pain caused by osteoarthrosis of the knee joint\n2. Osteoarthrosis of the knee joint (grade 3-4 according to the Kellgren Lawrence classification)\n3. Pain of moderate to severe intensity (VAS\u22655, on a 10-point scale) during >3 months\n4. Pain resistant to conservative treatments\n\nBased on the patient note, there is no mention of the patient suffering from osteoarthrosis of the knee joint or knee pain. The note focuses on abdominal pain and gallstones.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1228": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Sedentary, i.e., have not participated regularly in moderate-to-vigorous physical activity (MVPA) for 90 minutes per week or more for more than 6 weeks of the past 12 weeks.\n- There is no information provided about the patient's physical activity levels, so this criterion cannot be evaluated.\n\n2. Medically cleared for MVPA, documented by a note from their primary care provider.\n- There is no mention of the patient being medically cleared for physical activity.\n\n3. No significant medical condition or physical disability that would interfere with physical activity or study participation.\n- The patient has abdominal pain, nausea, vomiting, and gallstones, which could potentially interfere with physical activity.\n\n4. Elevated depression symptoms. To meet criteria for elevated symptoms, participants must have a QIDS score of 8 or greater (i.e., at least moderate depression levels), and must have a score of 1 or greater on at least one of the two core DSM-V depressive symptoms, i.e., sad mood or anhedonia.\n- There is no information provided about the patient's depression symptoms or QIDS score.\n\n5. No current bulimia or anorexia (past 3 months); no MDD with psychotic symptoms (past 6 months); no history of bipolar disorder, schizophrenia, or a chronic psychotic condition.\n- There is no information provided about the patient's mental health history or conditions.\n\n6. No hazardous drug or alcohol use in the past 6 months.\n- It is mentioned that the patient does not smoke, drink alcohol, or use illicit drugs.\n\n7. Depression is not very severe, i.e., QIDS score is <= 20.\n- There is no information provided about the patient's QIDS score.\n\n8. No suicidality requiring immediate treatment.\n- There is no information provided about suicidality.\n\n9. Not pregnant or planning on becoming pregnant in the next year.\n- It is mentioned that the patient is menopausal, so she is not pregnant or planning to become pregnant.\n\n10. Understands English sufficiently well to consent and complete study assessments.\n- There is no information provided about the patient's ability to understand English.\n\n11. Aged 18-65.\n- The patient is 54 years old, which falls within the age range.\n\n12. Able to make one of the 2 available exercise class times.\n- There is no information provided about the patient's availability for exercise classes.\n\n13. Able to walk 1 mile.\n- There is no information provided about the patient's ability to walk 1 mile.\n\n14. Weight does not exceed 375 lbs.\n- It is mentioned that the patient is obese, but her exact weight is not provided.\n\n15. If participants are aged 60 or older, or if there is any concern about their cognitive capacity, participants will undergo a brief cognitive functioning screener, the Montreal Cognitive Assessment (MOCA). Participants are required to achieve a score within 1 SD of the mean for their age and education level to participate in the study.\n- This criterion does not apply since the patient is 54 years old.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria for this clinical trial. Some key pieces of information that are missing include the patient's physical activity levels, depression symptoms/QIDS score, mental health history, ability to understand English, availability for exercise classes, ability to walk 1 mile, and exact weight.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1229": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman, which matches the first inclusion criteria of \"Obese patients (body mass index > 35 kg/m2)\".\n\nThe patient is being admitted for abdominal pain and gallstones were found on ultrasound, but the inclusion criteria specifies \"No gallstone disease on initial ultrasounds\". Since the patient already has gallstones, they would not be eligible for this prevention trial.\n\nThe patient has not had a previous cholecystectomy, which matches the third inclusion criteria.\n\nOverall, while the patient meets some of the criteria, the presence of existing gallstones excludes them from participating in this particular clinical trial aimed at preventing gallstone formation after sleeve gastrectomy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1230": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1) Age > 8 years old (the patient is 54, so this criterion is met)\n2) Clinical suspicion of acute appendicitis including:\n   - Direct tenderness in the right lower quadrant (the note mentions epigastric and right upper quadrant tenderness, not right lower quadrant)\n   - Percussion and rebound tenderness (not mentioned in the note)\n   - Pyrexia (the patient is febrile, so this criterion is met)\n   - Anorexia (not mentioned in the note)\n   - Nausea and vomiting (the patient has nausea and vomiting, so this criterion is met)\n\nSince the patient does not have direct tenderness in the right lower quadrant or anorexia, and percussion/rebound tenderness is not mentioned, the clinical suspicion of acute appendicitis is not clearly met based on the information provided.\n\nTherefore, the patient does not have sufficient information to qualify for this particular clinical trial on acute appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1231": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones. There is no mention of sudden onset dizziness or any liver dysfunction.\n\nGiven the clinical trial's inclusion criteria of \"Adult patients who were experiencing sudden onset dizziness of unknown etiology for the first time were included in the study\", this patient does not meet the criteria as the presenting symptoms are related to gallbladder disease and not sudden onset dizziness.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1232": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of acute pancreatitis (abdominal pain, nausea, vomiting, elevated inflammatory markers, gallstones/biliary sludge on imaging).\n\nLooking at the inclusion criteria for the clinical trial:\n\n1. \"At least two episodes of acute pancreatitis in the past 12 months\" - The note mentions the patient experienced similar pain twice in the past year, suggesting at least two episodes of acute pancreatitis, so this criterion is met.\n\n2. ECOG performance status \u22641 - No information provided about performance status.\n\n3. Leukocytes \u22652,500/microliter - The patient has leukocytosis, suggesting this is met.\n\n4. Absolute neutrophil count \u22651,500/microliter - No information provided.\n\n5. Platelets \u2265100,000/microliter - No information provided. \n\n6. Hemoglobin >10 g/dL - No information provided.\n\n7. Total bilirubin \u22643.0 x ULN - No information provided.\n\n8. AST/ALT \u22641.5 x ULN - No information provided.\n\n9. Creatinine <1.5 mg/dL - No information provided.\n\n10. Pregnancy requirements - No information provided about pregnancy status.\n\n11. Ability to consent - No information provided.\n\n12. Willingness to comply with protocol - No information provided.\n\nWhile the patient meets the first inclusion criterion about having recurrent acute pancreatitis episodes, there is insufficient information provided about several other key criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1233": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is about prophylaxis of postoperative nausea and vomiting after cardiac surgery.\n\nLooking at the inclusion criteria for the trial:\n1. Non emergent cardiac surgery - The patient note does not mention any cardiac surgery, so this criterion is not met.\n2. Age > 18 years - The patient is 54 years old, so this criterion is met.\n3. Affiliation to French Social Security - There is no information about this in the patient note.\n4. Approval of participation to the study - There is no information about this in the patient note.\n\nSince the patient does not seem to be undergoing any cardiac surgery, which is a key inclusion criterion, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1234": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\n2. The clinical trial is evaluating gallbladder contractility using CCK and milk during a HIDA scan.\n\n3. The inclusion criteria are:\n   - All patients referred for a HIDA scan to evaluate gallbladder function\n   - No evidence of gallbladder stones on prior imaging\n   - Able to lie flat for an additional 30 minutes after the standard HIDA scan\n\n4. This patient meets the first inclusion criteria of being referred for a HIDA scan to evaluate gallbladder function.\n\n5. However, the patient does have evidence of gallstones on imaging, which excludes them from the second inclusion criteria.\n\nBased on the inclusion criteria provided, this patient would not be eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1235": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and biliary sludge on ultrasound).\n\nThe clinical trial is studying the effects of positive intraoperative messages on postoperative outcomes in patients undergoing laparoscopic cholecystectomy.\n\nThe inclusion criteria for the trial are:\n1. Laparoscopic cholecystectomy\n2. ASA (American Society of Anesthesiologists) physical status classification 1-3\n\nBased on the information provided, this patient meets both of the inclusion criteria:\n1. She is scheduled for a laparoscopic cholecystectomy for gallstone disease.\n2. While her ASA status is not explicitly stated, she appears to have no other major comorbidities besides obesity, which would likely place her in the ASA 1-3 range.\n\nThere is no information provided about potential exclusion criteria, which could potentially exclude her from the trial.\n\nTherefore, based on the available information:\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1236": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for a combination of EP0057 (a nanoparticle camptothecin) and olaparib in patients with relapsed/refractory small cell lung cancer (SCLC). \n\n3. The inclusion criteria specifically mention:\n- Histologically/cytologically confirmed advanced solid tumor resistant/refractory to standard therapy (for Phase I)\n- Histologically/cytologically confirmed SCLC, progressed after platinum-based chemo and/or immunotherapy (for Phase II SCLC cohort)\n- Adequate organ function and bone marrow reserves\n- No active brain metastases requiring enzyme-inducing antiepileptics\n- Use of effective contraception\n\n4. This patient does not have SCLC or any other advanced solid tumor. Her diagnosis appears to be acute cholecystitis/choledocholithiasis.\n\nTherefore, based on the information provided, this patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1237": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking at patients diagnosed with acute mesenteric ischemia who were admitted to the hospital after being seen in the emergency department.\n\nThe inclusion criteria are:\n1) ICD-9 diagnosis of acute mesenteric ischemia in 2014 and 2015\n2) Admitted to hospital after Emergency Department assessment \n3) Age > 18\n\nBased on the patient note, there is no mention of a diagnosis of acute mesenteric ischemia. The symptoms and findings point more towards biliary colic/cholecystitis.\n\nTherefore, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1238": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the use of CO2 vs air insufflation during endoscopic ultrasound (EUS) procedures to assess patient discomfort and image quality.\n\nThe only inclusion criteria listed is \"Consecutive patients referred for EUS\".\n\nSince the patient is being evaluated for gallstones/biliary issues and will likely require an EUS, she meets the broad inclusion criteria of being referred for an EUS procedure.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1239": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the use of pembrolizumab (an immunotherapy drug) in treating desmoplastic melanoma that is either resectable or unresectable.\n\n3. The inclusion criteria for the trial specify that patients must have histologically or cytologically confirmed desmoplastic melanoma that is either resectable (Cohort A) or unresectable (Cohort B), with measurable disease per RECIST 1.1 criteria.\n\n4. Based on the patient note provided, there is no mention of the patient having desmoplastic melanoma. The note describes symptoms and findings consistent with cholelithiasis (gallstones) and cholecystitis.\n\n5. Since the patient does not appear to have the target disease (desmoplastic melanoma) required for this clinical trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1240": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). The ultrasound confirmed the presence of gallstones and biliary sludge.\n\nThe clinical trial is studying post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy (gallbladder removal surgery). \n\nThe inclusion criteria for the trial are:\n1. Female patients aged 20-40 years\n2. Undergoing elective laparoscopic cholecystectomy\n3. ASA Physical Status I & II\n\nLooking at the patient details:\n- The patient is female, which meets the gender criteria.\n- However, the patient is 54 years old, which is outside the age range of 20-40 years specified in the inclusion criteria.\n- The patient is likely undergoing a cholecystectomy based on the symptoms and ultrasound findings, meeting that inclusion criteria.\n- There is no information provided about the patient's ASA Physical Status.\n\nSince the patient does not meet the age criteria for the trial, she would not be eligible to participate.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1241": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms of gallstone pancreatitis - abdominal pain, nausea, vomiting, epigastric tenderness. This matches the first inclusion criteria \"Diagnosis of gallstone pancreatitis\".\n\nHer lab results show elevated lipase level and imaging confirmed gallstones/sludge, further confirming gallstone pancreatitis diagnosis.\n\nThe patient has no evidence of organ failure or local/systemic complications mentioned, suggesting mild pancreatitis which meets \"Diagnosis of mild pancreatitis\" criteria. \n\nIt is mentioned she is scheduled for laparoscopic cholecystectomy prior to discharge, meeting that criteria.\n\nThere is no mention of any strong indicators for choledocholithiasis based on ASGE guidelines.\n\nShe was admitted to a non-monitored floor bed, suggesting clinical stability.\n\nThe patient does not seem to meet any of the exclusion criteria listed.\n\nBased on the information provided, this patient appears to meet all the inclusion criteria for the clinical trial on timing of cholecystectomy for mild gallstone pancreatitis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1242": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis\", the patient does not seem to be eligible for this trial.\n\nThe inclusion criteria for the trial are:\n1. Age \u2265 18 years\n2. Procedure with General Anesthesia\n\nWhile the patient note mentions that the patient is 54 years old, satisfying the age criterion, there is no information provided about the patient undergoing a procedure with general anesthesia. The note describes the patient's presentation with abdominal pain, nausea, vomiting, and findings suggestive of gallstones and biliary sludge.\n\nSince there is no mention of the patient undergoing a procedure with general anesthesia, which is a crucial inclusion criterion for this trial, the patient cannot be considered eligible based on the available information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1243": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has had similar episodes in the past year.\n\n2. Imaging shows gallstones, biliary sludge, and a 14mm CBD stone.\n\n3. The clinical trial is studying the use of pinaverium bromide for post-cholecystectomy sphincter of Oddi dysfunction (SOD).\n\n4. The inclusion criteria are:\n   - Upper right abdominal pain following cholecystectomy (within 2 weeks to 6 months)\n   - No intestinal obstruction, peptic ulcer or duodenal diverticulum\n   - Bile duct dilation on imaging with no other abnormalities\n   - Meeting criteria for biliary-type SOD type II (pain + liver enzyme elevation or CBD dilation) or type III (pain only)\n\n5. This patient meets several of the key inclusion criteria:\n   - She has right upper quadrant abdominal pain\n   - Imaging shows CBD stones/dilation with no other abnormalities\n   - Her symptoms suggest a biliary-type pain pattern\n\n6. However, it's unclear if she has had a prior cholecystectomy, which is a key requirement. Her history only mentions 2 prior normal vaginal deliveries.\n\n7. Based on the available information, there is insufficient evidence to definitively determine eligibility. More details are needed about her surgical history.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1244": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone of 14mm.\n\nThe clinical trial inclusion criteria states:\n\"Patients who had EUS presence of CBDS \u2264 10 mm, and EUS images absence of CBD stricture and CBD narrowing below the stones\"\n\nIn this case, the patient has a CBD stone larger than 10mm (14mm), which excludes them from meeting the inclusion criteria.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "1245": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient has functional dyspepsia, postprandial distress syndrome (PDS) subtype, defined by the Rome III criteria.\n   - The patient note does not mention if the patient meets the Rome III criteria for functional dyspepsia with postprandial distress syndrome subtype. More information is needed.\n\n2. Patient has evidence of impaired gastric accommodation.\n   - There is no information provided about the patient's gastric accommodation.\n\n3. Patient's Rome III Questionnaire results indicates that the intensity of co-existing epigastric pain and/or epigastric burning may be present, but have the same or lesser intensity than the evaluations of postprandial fullness or early satiety (i.e. epigastric pain and burning are not the prominent symptoms of the patient's functional dyspepsia).\n   - Again, there is no information about the patient's Rome III Questionnaire results.\n\n4. Patient recall of symptoms of gastrointestinal reflux over the past 8 weeks has no more than 2 episodes per week of heartburn or regurgitation.\n   - This criterion is not addressed in the patient note.\n\n5. Patient is a male or female between 18 and 65 years of age at the pre-study/screening visit.\n   - The patient is a 54-year-old woman, so she meets this criterion.\n\n6. Patient has a Body Mass Index (BMI) >18 to \u226430 kg/m2 at the pre-study/screening visit.\n   - The patient is described as obese, which typically means a BMI > 30 kg/m2, so she likely does not meet this criterion.\n\n7. Patient is judged to have no unmanaged significant disease or disorder based on medical history, physical examination, vital sign measurements, and laboratory safety obtained at pre-study/screening, and within 36 hours prior to first administration of study drug.\n   - The patient has hypercholesterolemia, which may or may not be considered a significant unmanaged disease. More information is needed.\n\n8. Patient has no clinically significant abnormality of ECG performed at pre study/screening, and prior to first administration of study drug.\n   - There is no information provided about the patient's ECG results.\n\n9. Patient is willing to undergo the nutrient volume tolerance tests.\n   - This is not addressed in the patient note.\n\nBased on the information provided, it is difficult to determine if the patient is eligible or not for this clinical trial. There are several criteria that are not addressed in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1246": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea and vomiting. The ultrasound revealed gallstones, biliary sludge and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1) Adult patient - The patient is 54 years old, so meets this criteria.\n2) Patient admitted to the Emergency department with suspected acute uncomplicated renal colic - The patient was admitted with abdominal pain, but the ultrasound findings suggest gallstones/biliary issues rather than renal colic. So this criteria is not met.\n\nThe exclusion criteria are:\n1) Patient presenting with fever (>38\u00b0C) - The patient has a fever of 38.2C, so meets this exclusion criteria.\n2) Other exclusion criteria do not seem to apply based on the information given.\n\nSince the patient does not meet the key inclusion criteria of having suspected renal colic, and meets one of the exclusion criteria of fever, this patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1247": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial titled \"Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia\" is looking to enroll pregnant women between 20-36 weeks gestation presenting with symptoms of suspected pre-eclampsia such as headache, visual disturbances, epigastric or right upper quadrant pain, increasing edema, hypertension, proteinuria, or suspected fetal growth restriction.\n\nSince the patient in the note is not pregnant and does not have any symptoms of pre-eclampsia, she would not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1248": {
        "output": "To determine the patient's eligibility for the clinical trial \"Daily Ginger Drinking and Platelet Function\", I will go through the inclusion criteria one by one:\n\n1. \"Apparently healthy Saudi volunteers of either sex\"\n   - The patient note does not mention the patient's nationality or ethnicity, so it is unclear if they are Saudi.\n   - The patient is described as having several medical conditions (abdominal pain, nausea, vomiting, hypercholesterolemia, gallstones, biliary sludge, CBD stones), so they do not appear to be \"apparently healthy\".\n\n2. \"Age group = 18-60 years\"\n   - The patient is 54 years old, which falls within the specified age range.\n\nSince the patient does not seem to meet the \"apparently healthy\" criterion and their nationality/ethnicity is unknown, there is insufficient information to determine if they are eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1249": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones and biliary sludge.\n\nThe clinical trial is looking to develop an objective pain scale for chronic pain patients in an outpatient setting.\n\nThe inclusion criteria for the trial are:\n1) Adults aged 18-75 (the patient is 54, so meets this criteria)\n2) Able to self-report pain using a validated pain scale (no information given, so cannot determine eligibility)\n3) Patient of the chronic pain clinic receiving a pain treatment procedure (the patient does not seem to be a chronic pain patient, so likely does not meet this criteria)\n4) English speaking (no information given, but can assume meets this criteria)\n5) Signed consent to participate (no information given, so cannot determine eligibility)\n\nBased on the limited information provided, it does not appear this patient would be eligible for the chronic pain study, as they are presenting with an acute gallbladder issue rather than being a chronic pain patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1250": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She was diagnosed with gallstones, biliary sludge, and common bile duct stones based on ultrasound findings.\n\nThe clinical trial is titled \"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations\". It is studying combination chemotherapy for treating young patients with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL) and Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations.\n\nLooking at the inclusion criteria:\n1) The patient does not need to be enrolled in APEC14B1 or consented for eligibility screening, as this criteria is not relevant for this patient.\n2) There are no details provided about the patient's white blood cell count, so this criteria cannot be assessed.\n3) The patient does not have newly diagnosed B-lymphoblastic leukemia, so this key criteria is not met.\n4) The organ function requirements are not relevant, as the patient does not have leukemia.\n5) The other criteria related to specific tests/assessments are also not relevant.\n\nBased on the information provided in the patient note, this patient does not meet the key inclusion criteria of having newly diagnosed high-risk B-cell acute lymphoblastic leukemia. There is insufficient information to determine if she meets any of the other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1251": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is studying the use of routine nasobiliary insertion during ERCP in high-risk patients with CBD stones undergoing laparoscopic cholecystectomy.\n\nThe inclusion criteria for the trial are:\n1) Patients with gallbladder stones complicated by CBD stones\n2) Accepting to participate in the study\n3) Presence of one or more preoperative predictors for high-risk difficult cholecystectomy\n4) Patient fit for laparoscopic cholecystectomy\n\nBased on the information provided, this patient meets the following inclusion criteria:\n1) She has gallbladder stones and CBD stones\n2) Her eligibility to participate is not mentioned, but we can assume she would accept if asked\n3) She is obese, which is a risk factor for difficult cholecystectomy\n4) No information is provided about her fitness for laparoscopic cholecystectomy, but her presentation does not contraindicate it.\n\nSince the patient meets most of the key inclusion criteria and there is no clear exclusion based on the information given, I would assess her as:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1252": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u226518 years: The patient is 54 years old, so this criterion is met.\n\n2. Histologically confirmed, chemo-refractory, locally advanced, recurrent or metastatic gastric, colorectal, pancreatic adenocarcinoma or biliary cancer: The patient has biliary stones and sludge, which suggests a biliary cancer, so this criterion is potentially met.\n\n3. Patient must not have curative options available: There is no information provided about curative options, so this criterion cannot be evaluated.\n\n4. Chemo-refractory definition: There is no information provided about prior chemotherapy, so this criterion cannot be evaluated.\n\n5. Archived tissue must be available: There is no information provided about availability of archived tissue, so this criterion cannot be evaluated.\n\n6. Measurable disease by RECIST 1.1 criteria: There is no information provided about measurable disease, so this criterion cannot be evaluated.\n\n7. ECOG performance status of 0-1: There is no information provided about the patient's performance status, so this criterion cannot be evaluated.\n\n8. Adequate organ function: The patient has leukocytosis and elevated ESR, which may indicate inadequate organ function, but there is no specific information provided about the laboratory values listed in the criteria, so this criterion cannot be fully evaluated.\n\n9. Ability to adhere to dose and visit schedules: There is no information provided about the patient's ability to adhere to the study requirements, so this criterion cannot be evaluated.\n\n10. Requirements for women of childbearing potential: The patient is a 54-year-old woman, so this criterion is likely not applicable.\n\n11. Ability to provide written informed consent: There is no information provided about the patient's ability to provide informed consent, so this criterion cannot be evaluated.\n\n12. Life expectancy of at least 3 months: There is no information provided about the patient's life expectancy, so this criterion cannot be evaluated.\n\nIn summary, while the patient potentially meets the criterion for having a biliary cancer, there is insufficient information provided in the patient note to determine eligibility for this clinical trial based on the listed inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1253": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Definite or probable PBC as defined by at least 2 of the following:\n   - Serum ALP > ULN (Not mentioned in patient note)\n   - Presence of AMA in serum (Not mentioned)\n   - Liver histological findings consistent with PBC (Not mentioned)\n\n2. Serum ALP > 1.67 x ULN and/or total bilirubin >ULN but \u2264 2 x ULN (Not mentioned)\n\n3. UDCA use at stable dose for \u226512 months or intolerant of UDCA with no use for \u226512 months (Not mentioned)\n\n4. Screening FibroSURE/FibroTest\u00ae < 0.75 unless historical liver biopsy within 12 months doesn't reveal cirrhosis (Not mentioned)\n\nThe patient note does not provide sufficient information to determine if the inclusion criteria are met.\n\nExclusion Criteria:\n1. ALT > 5 x ULN (Not mentioned)\n2. Total bilirubin > 2 x ULN (Not mentioned)\n3. INR > 1.2 unless on anticoagulant therapy (Not mentioned)\n4. Other causes of liver disease including viral, metabolic, alcoholic, and autoimmune conditions (Gallstones and biliary sludge mentioned, which could be an exclusion)\n5. Use of fibrates or obeticholic acid within 3 months (Not mentioned)\n6. Cirrhosis of the liver (Not mentioned)\n\nBased on the information provided, the patient has gallstones and biliary sludge, which could potentially exclude them from the trial due to other causes of liver disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1254": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Antimicrobial Stewardship Program for Clostridium Difficile Infection.\"\n\nThe inclusion criteria for the trial are:\n1. Patients diagnosed with CDI (Clostridium Difficile Infection) in the University Hospital 12 de Octubre, Madrid, Spain\n2. Requiring hospitalization or emergency room admission longer than 48 hours\n3. Patient or their representative signs the informed consent\n\nBased on the patient note, there is no mention of the patient being diagnosed with Clostridium Difficile Infection (CDI). The note describes symptoms and findings related to gallstones and biliary issues.\n\nSince the patient does not appear to have CDI, which is a key inclusion criterion for this trial, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1255": {
        "output": "To determine the patient's eligibility for the clinical trial \"Addressing the Health Concerns of VA Women With Sexual Trauma\", I will go through the inclusion criteria one by one:\n\n1. Female Veterans: The patient note does not mention if the patient is a veteran or not, so there is not enough information to determine eligibility based on this criterion.\n\n2. Lifetime history of ST with at least one risk factor: heavy drinking within the past 3 months, screen positive for current PTSD or for IPV within last 12 months: The patient note does not mention any history of sexual trauma, PTSD, intimate partner violence, or heavy drinking, so there is not enough information to determine eligibility based on this criterion.\n\n3. Age 18-65: The patient's age is given as 54 years old, which falls within the age range specified in the inclusion criteria.\n\n4. Seeking treatment through the Women's Primary Care Clinics at the Central Texas VA Healthcare System: The patient note does not specify where the patient is seeking treatment, so there is not enough information to determine eligibility based on this criterion.\n\n5. Ability to understand study procedures in English: The patient note does not provide any information about the patient's ability to understand English, so there is not enough information to determine eligibility based on this criterion.\n\n6. Not actively in suicidal or homicidal crisis warranting imminent hospitalization: The patient note does not mention any suicidal or homicidal ideation, so there is not enough information to determine eligibility based on this criterion.\n\nOverall, based on the information provided in the patient note, there is not enough information to determine if the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1256": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The workup revealed gallstones, biliary sludge, and a common bile duct stone.\n\nThe clinical trial is evaluating the effectiveness of ondansetron in preventing post-operative nausea and vomiting in cardiac surgery patients after cessation of sedation.\n\nThe inclusion criteria for the trial are:\n1. Elective (outpatient) and urgent (inpatient) cardiac surgery procedures requiring cardiopulmonary bypass, including coronary artery bypass grafting (CABG), valve surgery, or CABG and valve surgery.\n\nBased on the patient note, this patient does not seem to be undergoing any cardiac surgery procedures. The symptoms and findings point towards a biliary/gallbladder issue.\n\nTherefore, this patient does not meet the inclusion criteria for the stated clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1257": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\n2. The clinical trial is evaluating the effectiveness of Digital SpyGlass Cholangioscopy for removing common bile duct stones without fluoroscopy.\n\n3. The inclusion criteria for the trial are:\n   - Patients with clinically suspected/confirmed common bile duct stones (CBDS)\n   - CBD caliber 5-15 mm\n\n4. Based on the patient note, the patient has confirmed common bile duct stones, and the smallest stone is 14 mm, which falls within the CBD caliber range specified in the inclusion criteria.\n\n5. There is no information provided about exclusion criteria, so we cannot determine if the patient meets any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1258": {
        "output": "Based on the given patient note and the clinical trial information, the patient does not seem to be eligible for the trial titled \"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)\".\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever, which was diagnosed as gallstones and cholecystitis. There is no mention of bacterial conjunctivitis or any eye-related condition.\n\nThe inclusion criteria for the clinical trial specifically state that participants must have a diagnosis of bacterial conjunctivitis.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1259": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric radiating to the right upper quadrant, worsened by fatty foods. She has had similar episodes in the past year. Her medical history includes hypercholesterolemia and 2 normal vaginal deliveries. She is menopausal. Vitals show mild fever, tachycardia, and hypertension. On exam, she has epigastric and right upper quadrant tenderness without rebound. Labs show leukocytosis with left shift and elevated ESR. Ultrasound reveals gallstones, biliary sludge, and a 14mm CBD stone.\n\nThe clinical trial is studying the use of ondansetron alone versus ondansetron plus dexamethasone for treating acute nausea in the emergency department.\n\nThe inclusion criteria are:\n1) Chief complaint of nausea or abdominal pain with nausea\n2) Inability to tolerate oral nausea medication  \n3) Negative pregnancy test\n\nThis patient meets criteria 1 and 2 as she has abdominal pain with nausea/vomiting and is unable to tolerate oral intake. Her menopausal status suggests she is not pregnant, but a pregnancy test is not explicitly mentioned.\n\nThere are no clear exclusion criteria provided that would exclude this patient.\n\nBased on the available information, this patient appears eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1260": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Endothelial Dysfunction in Hyperemesis Gravidarum\", the patient does not meet the inclusion criteria for the following reasons:\n\n1. The patient is a 54-year-old woman, which is outside the age range of 18-35 years specified in the inclusion criteria.\n2. The patient is not pregnant, and the inclusion criteria require a gestational age of 6-13 weeks and a single pregnancy.\n3. The patient's condition is related to gallstones and biliary sludge, not hyperemesis gravidarum (severe nausea and vomiting during pregnancy).\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1261": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is about preemptive analgesia for post-tonsillectomy pain in children aged 7-12 years old undergoing tonsillectomy with or without adenoidectomy.\n\n3. Based on the inclusion criteria of the trial, which specifies \"Tonsillectomy procedures in Children aged between 7 and 12 years old\", this patient does not meet the criteria as she is an adult and not undergoing a tonsillectomy procedure.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1262": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Tramadol for Labor Analgesia: a Placebo Controlled Randomised Control Trial\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, which was later diagnosed as gallstones and biliary sludge. There is no mention of the patient being in labor or having any pregnancy-related condition.\n\nThe inclusion criteria for the clinical trial specifically state that the participants should be nulliparous (delivering for the first time), in well-established labor (3 or more contractions in a span of ten minutes), with cervical dilation of 4 cm or more, and at least 80% effacement of the cervix.\n\nSince the patient note does not provide any information related to pregnancy or labor, it is not possible to determine if the patient meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1263": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Pancreatobiliary diseases that are eligible for EUS-guided transenteric drainage\"\nThe patient has gallstones, biliary sludge, and CBD stones, which would likely require transenteric drainage. This criterion is met.\n\n2. \"The patient who aged from 20 to 80 years.\"\nThe patient is 54 years old, which falls within this age range. This criterion is met.\n\n3. \"Legally acceptable representative must be capable of giving written informed consent prior to participation in this study\"\nThere is no information provided about a legal representative, so I cannot determine if this criterion is met or not.\n\n4. \"Target lesion that is accessible through the transenteric approach\"\nThe patient has gallstones, biliary sludge, and CBD stones, which should be accessible through a transenteric approach. This criterion is likely met.\n\n5. \"The woman of child-bearing age must be negative from the pregnancy test in order to participate in this study\"\nThe patient is described as a 54-year-old menopausal woman, so she is not of child-bearing age. This criterion is not applicable.\n\n6. \"The patient who is willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures\"\nThere is no information provided about the patient's willingness or ability to comply with study procedures, so I cannot determine if this criterion is met or not.\n\n7. \"The patients should not have any unacceptable conditions (e.g., physiological, familyism, social, geographical) for medical follow-up and adaptation of the study.\"\nThere is no information provided about any potential unacceptable conditions, so I cannot determine if this criterion is met or not.\n\nBased on the information given, the patient meets at least some of the key inclusion criteria, but there are a few criteria that cannot be determined from the provided note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1264": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with acute abdominal pain for the past 4 days, along with nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has a history of similar episodes in the past year. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking at evaluating the use of venous lactate levels as a predictive factor for surgical emergencies in patients presenting with acute abdominal pain.\n\nThe inclusion criteria for the trial are:\n1) Patients over 18 years old - The patient is 54 years old, so meets this criteria.\n2) Patient presenting acute abdominal pain since 7 days or less - The patient has had abdominal pain for 4 days, so meets this criteria. \n3) Need of blood sample confirmed by physician - This is not explicitly stated but can be reasonably inferred given the patient presented to the ED.\n4) Affiliation to french social security system - This information is not provided.\n5) Informed Consent - This is also not stated explicitly.\n\nBased on the information provided, the patient meets criteria 1 and 2, but there is insufficient information to determine if criteria 3-5 are met.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1265": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and other symptoms suggestive of gallbladder disease. The ultrasound revealed gallstones and bile duct stones.\n\n2. The clinical trial is titled \"Abdominal Ultrasound Examination in Non-celiac Wheat Sensitivity\" and is studying the abdominal ultrasound features of patients with non-celiac wheat sensitivity (NCWS) compared to celiac disease.\n\n3. The inclusion criteria for the trial require:\n   - Negative celiac serology (anti-tTG and anti-EnA antibodies)\n   - No intestinal villous atrophy\n   - Negative IgE-mediated wheat allergy tests\n   - Symptom resolution on elimination diet excluding wheat, cow's milk, egg, etc.\n   - Symptom reappearance on double-blind placebo-controlled wheat challenge\n\n4. Based on the patient note, there is no indication that the patient meets these inclusion criteria for NCWS. The symptoms and findings are consistent with gallbladder disease rather than a wheat sensitivity.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1266": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones and CBD stones.\n\nThe clinical trial is titled \"Treatment Algorithm for Nausea and Vomiting in the Palliative Phase\" and is studying treatment strategies for nausea and vomiting in palliative cancer patients.\n\nLooking at the inclusion criteria:\n1. Patients 18 years or older - The patient is 54 years old, so meets this criteria.\n2. In the palliative phase - There is no mention of the patient having cancer or being in a palliative phase, so this criteria is not met.\n3. Suffering from nausea or vomiting with NRS > 2 - The patient is experiencing nausea and vomiting, so likely meets this criteria.\n4. Wish to be treated - No information provided about the patient's wishes.\n5. No treatable cause assignable - The patient's symptoms seem to be caused by gallstones/CBD stones, which is a treatable cause.\n\nSince the patient does not appear to be in a palliative phase and has an identified treatable cause for her symptoms, she likely does not meet all the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1267": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. Her medical history includes hypercholesterolemia and 2 normal vaginal deliveries (NVDs). She is menopausal.\n\n2. The clinical trial is titled \"Postpartum Readmission\" and is a retrospective chart review of women who were readmitted within 6 weeks postpartum for a hypertensive disorder.\n\n3. The inclusion criteria for the trial are:\n   - Women who labored and delivered at a single hospital\n   - Readmitted within 6 weeks postpartum for a hypertensive disorder (with or without hypertension during pregnancy, gestational hypertension, pre-eclampsia, severe pre-eclampsia, or HELLP syndrome)\n   - Controls: Women with pre-eclampsia but not readmitted, or women without pre-eclampsia\n\n4. Based on the patient note, this patient does not meet the inclusion criteria for the trial because:\n   - There is no mention of her being pregnant or having recently delivered a baby\n   - Her admission is related to abdominal pain, nausea, vomiting, and gallstones, not a hypertensive disorder\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1268": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"The Evaluation of Pro/Antioxidative Profile and Diagnostic Parameters in the Patients With Pancreatic Disease\".\n\n3. The inclusion criteria for the trial state that patients must have acute pancreatitis, diagnosed based on clinical symptoms, laboratory tests (elevated lipase/amylase), and imaging findings.\n\n4. While the patient has abdominal pain and some elevated inflammatory markers, there is no clear indication in the note that she has been diagnosed with acute pancreatitis. The imaging findings point more towards biliary disease (gallstones, etc.) rather than pancreatitis.\n\n5. Since there is insufficient information to determine if the patient meets the inclusion criteria for acute pancreatitis, I would assess her as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1269": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Validation of a Predictive Score of Acute Chest Syndrome\", the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The patient does not have sickle cell disease (SCD), which is a requirement for the trial.\n2. The patient is not experiencing a vaso-occlusive crisis (VOC), which is another requirement for the trial.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, which are not related to sickle cell disease or vaso-occlusive crises.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1270": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations\" and assess the eligibility of the given patient.\n\nThe patient note does not mention pancreatic cancer or any KRAS mutation. It describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones.\n\nThe inclusion criteria for the trial are:\n\n1. Histologically confirmed locally advanced or metastatic pancreatic cancer - Not met (patient has gallstones, no mention of pancreatic cancer)\n2. Received at least 6 months of fluorouracil or gemcitabine-based treatments for pancreatic cancer - Not met (no mention of pancreatic cancer treatment)\n3. Measurable disease - Not met (no mention of measurable disease)\n4. Confirmed somatic KRAS G12R mutation - Not met (no mention of KRAS mutation)\n5. No recent chemotherapy, radiation therapy, or experimental therapy - Likely met (no mention of recent treatments)\n6. ECOG performance status \u2264 1 or Karnofsky \u2265 70% - Likely met (no mention of performance status, but the patient is described as having no acute distress)\n7. Adequate blood counts and liver/kidney function - Likely met (no mention of abnormal lab values)\n8. Willing to return for follow-up visits - Likely met (no mention of unwillingness)\n9. Women of childbearing potential must use contraception and have a negative pregnancy test - Not applicable (patient is menopausal)\n10. Ability to understand and sign informed consent - Likely met (no mention of cognitive impairment)\n11. Able to swallow oral medications - Likely met (no mention of swallowing difficulties)\n\nBased on the information provided in the patient note, the patient does not meet several key inclusion criteria for the clinical trial, such as having locally advanced or metastatic pancreatic cancer and a confirmed KRAS G12R mutation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1271": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever.\n2. The clinical trial is titled \"Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions\".\n3. The inclusion criteria for the trial is \"All adult patients with abdominal pain.\"\n4. The patient meets this inclusion criteria as she is an adult presenting with abdominal pain.\n5. There are no specific exclusion criteria mentioned for this trial.\n\nTherefore, based on the information provided, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1272": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Text Message (SMS) to Help Cancer Patients in Chemotherapy Treatment\", the patient does not appear to be eligible for this trial. The key points are:\n\n1. The patient note does not mention any cancer diagnosis or chemotherapy treatment.\n2. The patient's condition seems to be related to gallstones and biliary issues.\n3. The inclusion criteria specifically states that the trial is for \"Cancer patients who will start chemotherapy treatment in Hospital Escola of Federal University of Pelotas.\"\n\nSince the patient note does not provide any information about the patient having cancer or receiving chemotherapy, there is insufficient information to determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1273": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\n2. The clinical trial is studying the microbiomes in patients with recurrent common bile duct stones after endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (EST).\n\n3. The inclusion criteria for the trial are:\n   - Patients with recurrent common bile duct stones\n   - No antibiotics or probiotics used for nearly three months\n   - Possibly without other digestive diseases in addition to common bile duct stones\n\n4. Based on the patient note, this patient has common bile duct stones, but there is no mention of whether these are recurrent stones or if the patient has previously undergone ERCP and EST.\n\n5. There is also no information provided about the patient's use of antibiotics, probiotics, or the presence of other digestive diseases.\n\nGiven the lack of information to definitively determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1274": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman with a BMI > 40 kg/m2, which meets the inclusion criteria for the obese group in the clinical trial.\n\n2. The patient is within the age range of 18-65 years old, as specified in the inclusion criteria.\n\n3. There is no information provided about the patient's pregnancy status or ability to become pregnant, so we cannot determine if she meets that inclusion criteria.\n\n4. There is no information provided about whether the patient is able and willing to sign the informed consent.\n\n5. The additional inclusion criteria for non-obese subjects do not apply to this patient since she is in the obese group.\n\nBased on the information provided, the patient meets some of the inclusion criteria for the obese group, but there is not enough information to determine if she meets all of the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1275": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\nThe clinical trial is titled \"Practical Advantages of Single-port Over Three-port Laparoscopic Appendectomy in Children\".\n\nThe inclusion criteria state:\n1. Acute appendicitis diagnosed by clinical symptoms, lab findings, and imaging\n2. Perforated appendicitis\n3. Peri-appendiceal abscess confirmed by imaging\n\nBased on the patient note, there is no mention of appendicitis, perforated appendicitis, or peri-appendiceal abscess. The patient's symptoms and findings point towards biliary disease like cholecystitis or choledocholithiasis.\n\nTherefore, this patient does not meet the inclusion criteria for the stated clinical trial on laparoscopic appendectomy techniques.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1276": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. This suggests a possible biliary issue.\n\n2. The ultrasound revealed gallstones, biliary sludge, and CBD stones, with the smallest stone being 14mm. \n\n3. The clinical trial is evaluating techniques for achieving biliary access during ERCP in patients who fail initial cannulation.\n\n4. The inclusion criteria are:\n   - Age 18 and older (the patient is 54, so meets this)\n   - Patient has a clinical indication for ERCP (the patient has gallstones/CBD stones, so meets this)\n   - Willing and able to comply with study procedures and provide consent (no information provided, so cannot assess this)\n\nBased on the available information, this patient appears to meet at least the age and clinical indication inclusion criteria for the trial evaluating biliary access techniques during ERCP.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1277": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection\".\n\nLooking at the inclusion criteria:\n1) Age greater than or equal to 18 years - The patient is 54 years old, so this criterion is met.\n\n2) Patients with dyspeptic symptoms and proven H. pylori infection - The patient has abdominal pain which could be considered a dyspeptic symptom, but there is no mention of a proven H. pylori infection in the patient note.\n\n3) Having been previously prescribed standard triple therapy as eradication treatment (omeprazole, clarithromycin, amoxicillin) but not having started it yet - There is no indication in the note that the patient was prescribed this therapy.\n\n4) Written informed consent - Not mentioned in the patient note.\n\n5) The first 5 patients need routine blood analysis after completing eradication therapy - Not applicable here.\n\n6) Women of childbearing age must use contraception - The patient is menopausal, so this does not apply.\n\nBased on the information provided, the patient does not meet all the inclusion criteria, specifically the requirement of a proven H. pylori infection and having been prescribed the standard triple therapy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1278": {
        "output": "To determine the patient's eligibility for the clinical trial \"Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)\", I will go through the inclusion criteria one by one:\n\nInclusion Criteria:\n1. Patients aged 18-65 years presenting to the emergency department\nThe patient is a 54-year-old woman who was admitted to the emergency department, so she meets this criterion.\n\n2. complaining of current nausea with or without episodes of emesis beginning within the previous 24hrs\nThe patient note mentions that she experienced nausea and vomiting that started 4 days ago, so she does not meet this criterion.\n\nSince the patient does not meet one of the inclusion criteria, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1279": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge and CBD stones.\n\nThis clinical trial is studying the safety and efficacy of stem cell therapy in patients with severe community-acquired bacterial pneumonia (sCABP) requiring ICU management.\n\nLooking at the inclusion criteria:\n1) The patient is between 18-80 years old (meets criteria)\n2) No information on body weight to assess 50-100kg criteria\n3) The patient does not have a clinical diagnosis of acute community-acquired bacterial pneumonia (does not meet criteria)\n4) The patient does not require invasive mechanical ventilation or vasopressors for shock (does not meet criteria)\n5) No information on pregnancy status\n\nLooking at the exclusion criteria:\n1) The patient does not have hospital-acquired, healthcare-acquired or ventilator-associated pneumonia (meets criteria)\n2) The patient likely has a non-bacterial pneumonia cause like gallstones (excluded by criteria)\n3) No information on pneumocystis pneumonia, aspiration pneumonia, tuberculosis, post-obstructive pneumonia, cystic fibrosis, chronic lung disease\n4) No information on infection in another organ by same pathogen\n5) The patient is not expected to have rapidly fatal disease within 72 hours (meets criteria)\n6) No information on inability to maintain mean arterial pressure criteria\n7) No information that patient is not expected to survive 3 months due to other conditions\n8) No history of malignancy in the past 5 years is mentioned (meets criteria)\n9) No information on immunodeficiency disorders or HIV/AIDS\n10) No information on immunosuppressant therapy or chronic steroids\n11) No information on chronic granulocytopenia\n12) No information on recent stem cell therapy or organ/bone marrow transplant\n13) No information on recent biological agent, immunotherapy or plasma exchange\n14) No information on receiving another investigational medication recently\n15) No known allergies to penicillin/streptomycin or cryostor components is mentioned (meets criteria)\n16) No known liver cirrhosis or esophageal varices is mentioned (meets criteria)  \n17) No information on hospitalization within previous 15 days\n18) No information on NYHA/CCS class IV functional status\n19) No information on end-stage neuromuscular or cerebral disorders\n20) No information on quadriplegia\n\nIn summary, while the patient meets some inclusion/exclusion criteria, the lack of a bacterial pneumonia diagnosis and not requiring ICU-level care excludes them from this particular trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "1280": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Men and women, ages of 18-65 years, inclusive.\nThe patient is a 54-year-old woman, which meets this criterion.\n\n2. Participants will have a DSM-5 bipolar disorder that is clinically stable.\nThe patient note does not mention bipolar disorder, so there is not enough information to determine if this criterion is met.\n\n3. Participants will have received a stable major psychotropic drug regimen for at least 3 months prior to study entry.\nThere is no information about the patient's medication regimen, so this criterion cannot be evaluated.\n\n4. Participants will be obese (BMI \u2265 30 kg/m2) or overweight (BMI \u2265 27 kg/m2) with at least one weight-related comorbidity.\nThe patient note states that the patient is obese and has hypercholesterolemia, which is a weight-related comorbidity. This criterion is met.\n\n5. Participants in treatment for a weight-related comorbidity must be on a stable and allowed treatment regimen for at least 3 months prior to study enrollment.\nThere is no information about the patient's treatment regimen, so this criterion cannot be evaluated.\n\n6. Participants will be able to provide informed consent before any trial-related activities.\nThere is no information about the patient's ability to provide informed consent, so this criterion cannot be evaluated.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1281": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Body Versus Machine: Deep Breathing Versus Vagus Stimulation for the Treatment of Fibromyalgia,\" the patient does not appear to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, which is not related to the target condition of the trial, which is chronic widespread pain, including fibromyalgia.\n\nThe inclusion criteria for the trial specifically require:\n\n1. Confirmatory diagnosis of chronic widespread pain, including fibromyalgia\n2. Widespread pain index (WPI) \u2265 7 and symptom severity scale (SSS) score \u2265 5 OR WPI of 4-6 and SSS score \u2265 9\n3. Generalized pain in at least 4 of 5 body regions\n4. Pain symptoms have been generally present for at least 3 months\n5. Average pain intensity \u2265 6 on a 0-10 numerical rating scale\n\nThe patient note does not mention any information related to chronic widespread pain, fibromyalgia, or the required pain indices and scores.\n\nTherefore, based on the provided information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1282": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the efficacy of electroacupuncture on acute abdominal emergencies like intestinal obstruction or ileus with symptoms like nausea, vomiting, abdominal pain, distension, or constipation.\n\nThe inclusion criteria are:\n1) Age 20-90 years (the patient is 54, so meets this)\n2) Diagnosed with intestinal obstruction/ileus with nausea, vomiting, abdominal pain, distension or constipation (the patient has abdominal pain, nausea, vomiting but no clear diagnosis of obstruction/ileus)\n3) ICD-10 code R101-R1012 (not enough information given)\n\nBased on the information provided, the patient does not clearly meet all the inclusion criteria, as there is no definitive diagnosis of intestinal obstruction/ileus.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1283": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. Male and non-pregnant female subjects; female subjects must use 2 reliable methods of contraception\n- The patient note does not mention the patient's gender or pregnancy status, so this criterion cannot be evaluated.\n\n2. 18-70 years\n- The patient is 54 years old, which meets this criterion.\n\n3. BMI less than 30 mg/kg2\n- The patient is described as obese, which typically means a BMI greater than 30, so this criterion is likely not met.\n\n4. Established diagnosis of Alcoholic Steatohepatitis (ASH), based on at least 2 of the following signs and symptoms should be present: nausea, jaundice, anorexia, right upper quadrant abdominal pain, leukocytosis or hepatomegaly AND Elevation of total bilirubin > 3 mg/dL AND Liver biopsy showing ASH OR ultrasound of liver showing increased echogenicity OR CT scan showing decreased attenuation of liver compared to spleen OR MRI showing fatty liver (decreased signaling intensity on T1 weighted images)\n- The patient has abdominal pain, nausea, and leukocytosis, which meets the first part of this criterion. However, there is no mention of elevated total bilirubin or liver imaging/biopsy results, so the second part cannot be evaluated.\n\n5. History of chronic alcohol consumption, i.e. more than 50 g/day for a minimum of 6 months and at least 2 months before enrollment\n- There is no mention of the patient's alcohol consumption history, so this criterion cannot be evaluated.\n\n6. AST/ALT ratio greater than 1.5\n- There are no lab values provided for AST and ALT, so this criterion cannot be evaluated.\n\n7. MELD score between 12 and 19\n- The MELD score is not provided, so this criterion cannot be evaluated.\n\n8. Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects of the trial prior to enrollment\n- This is a procedural criterion that cannot be evaluated from the patient note.\n\n9. Willingness and ability to comply with scheduled visits and trial procedures\n- This is also a procedural criterion that cannot be evaluated from the patient note.\n\nIn summary, while the patient meets the age criterion and has some symptoms consistent with Alcoholic Steatohepatitis, there is not enough information provided to definitively determine eligibility for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1284": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use\", here is my assessment:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones. The patient is scheduled to undergo elective abdominal surgery requiring overnight hospital admission.\n\nThe inclusion criteria for the clinical trial are:\n1. Age 18-65 (the patient is 54 years old, meeting this criterion)\n2. With and without history of chronic muscle-skeletal pain (the patient's pain is related to gallstones, not chronic muscle-skeletal pain)\n3. Scheduled to undergo elective abdominal surgery requiring overnight hospital admission (the patient meets this criterion)\n4. Opioid na\u00efve (there is no information provided about the patient's opioid use history)\n5. Willing to comply with study procedures and provide informed consent (no information provided)\n6. Having an email address and access to a computer or electronic tablet (no information provided)\n\nBased on the available information, the patient meets some of the inclusion criteria but lacks information on others, such as opioid use history, willingness to comply with study procedures, and access to email and electronic devices.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "1285": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effect of obeticholic acid on bile acid transport in patients with primary biliary cholangitis (PBC) who are not responding adequately to ursodeoxycholic acid (UDCA) treatment.\n\n3. The inclusion criteria for the trial are:\n   - Patients with PBC\n   - Not responding adequately to UDCA treatment, defined as ALP > 2 times upper normal level during a time period of 6 months\n\n4. Based on the patient note, there is no mention of the patient having PBC or being on UDCA treatment. The patient appears to have gallstone disease, which is a different condition from PBC.\n\n5. Since the patient does not have the target disease (PBC) and does not meet the inclusion criteria, they would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1286": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has a history of similar episodes in the past year. Relevant labs show leukocytosis and elevated ESR. Ultrasound revealed gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm.\n\nThe clinical trial is looking at prognostic factors in acute pancreatitis patients admitted to the hospital. The inclusion criteria require:\n\n1) Diagnosis of acute pancreatitis confirmed by at least 2 of the following:\n    a) Characteristic abdominal pain\n    b) Elevated amylase/lipase > 3x upper limit\n    c) Radiographic evidence on CT or ultrasound\n\nThis patient meets criteria a) with the characteristic abdominal pain description. Criteria c) is also met with the ultrasound findings of gallstones/biliary sludge/CBD stones which can cause acute pancreatitis. There is no mention of amylase/lipase levels, so criteria b) cannot be confirmed.\n\nHowever, since at least 2 of the 3 criteria are met (a and c), this patient would qualify for inclusion in the acute pancreatitis clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1287": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for the trial. The key reasons are:\n\n1. The patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, likely due to gallstones and biliary sludge.\n\n2. The inclusion criteria for the clinical trial are related to patients undergoing surgery under general anesthesia requiring invasive blood pressure monitoring.\n\n3. There is no mention of the patient undergoing any scheduled surgery in the given note.\n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1288": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman, which does not violate any of the inclusion criteria listed for this clinical trial.\n\n2. The patient was admitted to the emergency department with abdominal pain, nausea, and vomiting, which was diagnosed as gallstones and biliary sludge. This does not appear to be a malignancy or cancer, which is required by the inclusion criteria: \"Subjects must have histologically confirmed malignancy that is metastatic or unresectable and for which there is no available therapy likely to convey clinical benefit.\"\n\n3. Since the patient does not have a confirmed malignancy or cancer, she does not meet the key inclusion criteria for this clinical trial.\n\nTherefore, based on the information provided in the patient note and the inclusion criteria for the clinical trial \"IACS-010759 in Advanced Cancers,\" the patient would not be eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1289": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her medical history includes hypercholesterolemia and 2 normal vaginal deliveries. She is menopausal.\n\n2. The clinical trial is looking to evaluate ultrasound features of the ovaries in women with regular, irregular, or absent menstrual cycles across different body types.\n\n3. The inclusion criteria for the trial are:\n   - Age 18-45 years\n   - At least 2 years post-menarche\n   - BMI > 18.5 kg/m^2\n   - Good visibility of ovaries on ultrasound\n   - Either regular menstrual cycles (21-35 days), irregular cycles (>35 days), or previous PCOS diagnosis\n\n4. Based on the patient note, the 54-year-old woman does not meet the age criteria (she is older than 45 years) and is also menopausal, which implies absence of menstrual cycles.\n\n5. There is no information provided about her BMI or visibility of ovaries on ultrasound.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1290": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Point-of-care Ultrasound in Finland\" and aims to evaluate the cost-effectiveness of 2-point compression ultrasound (2-CUS) for suspected deep vein thrombosis (DVT) and the impact of point-of-care ultrasound (POCUS) on length of stay in the emergency department.\n\n3. The inclusion criteria for the trial are:\n   - Emergency department patient\n   - A suspected medical condition that can be confirmed or excluded by basic POCUS exam, including gallbladder stones, among others\n   - Emergency medicine specialist or resident decides to perform a POCUS exam\n\n4. Based on the patient note and inclusion criteria, this patient meets the criteria for the trial as she is an emergency department patient with gallbladder stones, which can be confirmed by POCUS.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1291": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying a combination of two immunotherapy drugs, nivolumab and lirilumab, as a possible treatment for locoregionally recurrent squamous cell carcinoma of the head and neck.\n\n3. Based on the inclusion criteria provided, the key requirements are:\n   - Histologically or cytologically confirmed locoregionally recurrent squamous cell carcinoma of the head and neck\n   - Candidate for salvage surgery\n   - Specific criteria related to age, performance status, organ function, etc.\n\n4. From the patient note, there is no mention of the patient having squamous cell carcinoma of the head and neck. The patient appears to be presenting with gallbladder/biliary issues.\n\n5. Therefore, based on the information provided, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1292": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of acute pancreatitis, including abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones, indicating that the pancreatitis is likely of biliary origin.\n\nThe inclusion criteria for the clinical trial are:\n1. Patients older than 15 years (the patient is 54 years old, so she meets this criterion)\n2. Patients with a diagnosis of mild acute pancreatitis biliary (the patient has acute pancreatitis of biliary origin, and the case does not mention any severe complications, so she likely has mild acute pancreatitis)\n3. Patients who agree to enter the protocol (this is not mentioned in the case, but we can assume that the patient would agree if asked)\n\nBased on the information provided, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1293": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent obtained before any trial related procedures are performed\n- The patient note does not mention whether informed consent was obtained, so this criterion cannot be evaluated.\n\n2. Aged \u226518 years\n- The patient is 54 years old, so this criterion is met.\n\n3. A documented clinically relevant history of chronic wound with exposed tendon and/or bone. Chronic is defined as a non-healing wound over the past 4 weeks with standard care in a specialized clinic.\n- The patient note does not mention any chronic wounds with exposed tendon or bone, so this criterion is not met.\n\n4. 'Problematic wound area' between 0.25 and 10.0 cm2 measured by Image J at S1- irrespective of the total wound size\n- Since there is no mention of a chronic wound, this criterion cannot be evaluated.\n\n5. The subject must be willing and able to comply with the trial protocol\n- There is no information about the patient's willingness or ability to comply with the trial protocol.\n\nBased on the information provided in the patient note, the patient does not appear to be eligible for this clinical trial as the key inclusion criterion of having a chronic wound with exposed tendon or bone is not met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1294": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is about identifying risk factors for Bacillus species sepsis and meningitis.\n\n3. The inclusion criteria for the trial are:\n   - Cases of Bacillus species sepsis\n   - Cases of Bacillus species meningitis\n   - With significant change in clinical status\n   - Bacillus species is the only organism isolated\n\n4. Based on the patient note, there is no mention of Bacillus species infection, sepsis, or meningitis. The patient appears to have a gallbladder issue.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1295": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is studying the relationship between salt sensitivity hypertension and lens opacities. \n\n3. The inclusion criteria for the trial are:\n- Salt sensitivity hypertension patients\n- Non-salt-sensitive, salt-resistant hypertension patients \n- Control patients without hypertension, aged 40-80 years\n\n4. Based on the patient note, there is no mention of the patient having hypertension or being diagnosed with salt sensitivity hypertension or salt-resistant hypertension.\n\n5. The patient does not seem to meet any of the inclusion criteria for this clinical trial on salt sensitivity hypertension and lens opacities.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1296": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Effectiveness of HILT in Shoulder Osteoarthritis\" and is studying the efficacy of High Intensity Laser Therapy for treating shoulder osteoarthritis.\n\n3. The inclusion criteria for the trial are:\n   - Painful osteoarthritis of the shoulder for at least 6 months\n   - Not engage in any other treatment during the treatment period\n   - Pain \u22654 on the visual analog scale (VAS) in the previous 3 months\n\n4. Based on the patient note, there is no mention of the patient having shoulder osteoarthritis or any shoulder-related issues.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1297": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial \"Analgesic Effect of TAP Block After Laparoscopic Cholecystectomy\", here is my assessment:\n\nThe patient is a 54-year-old obese woman who was admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones, indicating that she likely needs a laparoscopic cholecystectomy.\n\nThe inclusion criteria for the clinical trial state that all patients aged 18-75 years scheduled for laparoscopic cholecystectomy are eligible.\n\nSince the patient is 54 years old and is likely to undergo a laparoscopic cholecystectomy based on her symptoms and ultrasound findings, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1298": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a Phase 1 study evaluating the safety, tolerability, and efficacy of AMG 119 in subjects with relapsed/refractory small cell lung cancer (SCLC).\n\n3. The inclusion criteria for the trial specify:\n   - Age \u2265 18 years old\n   - Histologically or cytologically confirmed SCLC with radiographic disease progression or recurrence after at least one platinum-based regimen\n   - ECOG performance status of 0-1\n   - At least 2 measurable lesions (or 1 lesion with sponsor agreement)\n   - Adequate organ function\n   - Other criteria related to brain metastases and treatment history\n\n4. Based on the patient note, there is no mention of the patient having SCLC or any type of lung cancer. The patient's condition appears to be related to gallstones and biliary issues.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial, which is specifically for relapsed/refractory SCLC.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1299": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is a randomized comparative study of different bariatric surgery procedures for treating type 2 diabetes in obese patients.\n\nThe key inclusion criterion for this trial is \"Type 2 diabetic obese patients\".\n\nFrom the patient note, we know the patient is obese, but there is no mention of her having type 2 diabetes.\n\nWithout information about whether the patient has type 2 diabetes or not, we cannot determine if she meets the key inclusion criterion.\n\nTherefore, the trial-level eligibility assessment would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1300": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones, including abdominal pain, nausea, vomiting, and fever. The ultrasound confirmed the presence of gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is titled \"LaGRA Trial in Laparoscopic Cholecystectomy\" and is investigating the effectiveness of a regional anesthesia technique for laparoscopic cholecystectomy (gallbladder removal surgery).\n\nThe inclusion criteria for the trial are:\n1. Patients undergoing laparoscopic cholecystectomy\n2. ASA (American Society of Anesthesiologists) physical status classification I, II, or III\n\nBased on the information provided, this patient meets both inclusion criteria:\n1. She is undergoing a laparoscopic cholecystectomy for gallstones.\n2. While her ASA status is not explicitly stated, her medical history suggests she is likely ASA II or III due to her obesity and hypercholesterolemia.\n\nTherefore, assuming she does not meet any of the exclusion criteria (which are not provided), this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1301": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Comparative Evaluation of Two Different Post-Operative Analgesia After Hallux Valgus Correction\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones. There is no mention of hallux valgus deformity, pain, or walking difficulty with shoes, which are the inclusion criteria for the given clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1302": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Individuals who express gastrointestinal symptoms more than three times per week as identified through the Gastrointestinal Symptom Questionnaire (such as abdominal pain/ discomfort, heartburn, acid regurgitation, bloating, nausea and vomiting, abdominal distention, eructation (burping), increased gas, decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent need for defecation, or feeling of incomplete evacuation)\"\n\nThe patient note mentions that the patient experienced abdominal pain that started 4 days ago with nausea and vomiting, and experienced similar pain twice in the past year. This suggests that the patient experiences gastrointestinal symptoms more than three times per week, meeting this inclusion criterion.\n\n2. \"Healthy with few health complications\"\n\nThe patient note mentions that the patient's past medical history is remarkable for hypercholesterolemia and 2 NVDs (normal vaginal deliveries). While hypercholesterolemia is a health condition, it is not considered a major complication. The patient does not seem to have any other significant health complications mentioned. Therefore, this inclusion criterion is likely met.\n\n3. \"Adults ages 18 or older\"\n\nThe patient note states that the patient is a 54-year-old woman, meeting the age requirement.\n\nBased on the information provided in the patient note, the patient appears to meet all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1303": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Community Based Doulas for Migrant Women in Labour and Birth in Sweden - a Randomised Controlled Trial.\"\n\nThe inclusion criteria for this trial are:\n1) Nulliparous and multiparous pregnant women\n2) 25-36 weeks gestation \n3) Somali-, Arabic-, Russian- or Tigrinya-speaking\n4) Cannot communicate fluently in Swedish\n5) No contra-indications for vaginal birth\n\nBased on the patient note provided, this patient does not meet any of the inclusion criteria as she is not pregnant and is presenting with gallstone disease.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1304": {
        "output": "To determine the patient's eligibility for the clinical trial \"The Role of Ultrasound in Cholecystitis\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\nAcute cholecystitis according to the Tokyo Guidelines 2013 criteria\n\nFrom the patient note, we can see that the patient has:\n- Abdominal pain that started 4 days ago with nausea and vomiting\n- Epigastric pain radiating to the right upper quadrant, getting worse after eating fatty food\n- Experienced similar pain twice in the past year\n- Mildly febrile (T 38.2)\n- Tenderness in the epigastric and right upper quadrant on palpation\n- Elevated ESR and leukocytosis with a left shift\n- Ultrasound revealed several gallstones, biliary sludge and CBD stones\n\nBased on the Tokyo Guidelines 2013 criteria for acute cholecystitis diagnosis, which includes symptoms like abdominal pain, fever, and laboratory/imaging findings like leukocytosis and gallstones, this patient appears to meet the criteria for acute cholecystitis.\n\nTherefore, this patient would be eligible for the clinical trial \"The Role of Ultrasound in Cholecystitis\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1305": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Adjuncts to IVRA, a Comparison Between Ketorolac and Paracetamol\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, which was later diagnosed as gallstones and biliary sludge. The patient's condition does not appear to be related to hand or forearm surgery, which is the focus of the clinical trial.\n\nThe inclusion criteria for the trial specifically state that participants should be \"American Society of Anaesthesiologists (ASA) physical status I or II, who will be scheduled for surgery of the hand or the forearm.\"\n\nSince the patient's condition is not related to hand or forearm surgery, and there is no mention of her ASA physical status, she does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1306": {
        "output": "Based on the patient note provided, the patient appears to be suffering from gallstones and cholecystitis, which is not relevant to the clinical trial titled \"Pain Modulatory Profiles in Massage for Healthy Participants.\"\n\nThe inclusion criteria for this trial require participants to be pain-free, have blood pressure under 140/90 mmHg, and have trigger points that can be located by the therapist.\n\nThe patient note does not provide information about the patient's pain status, blood pressure, or the presence of trigger points. Additionally, the patient is experiencing abdominal pain related to gallstones, which would exclude them from a trial focused on healthy participants.\n\nTherefore, based on the information provided, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1307": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nLooking at the inclusion criteria for the clinical trial:\n1. Age 18-80 years old - The patient is 54, so meets this criteria.\n2. Diagnosed with Crohn's disease - There is no mention of Crohn's disease in the patient note.\n3. Active small bowel Crohn's disease confirmed within 30 days - No evidence of this.\n4. Elevated inflammatory markers - The patient has elevated ESR and leukocytosis, meeting this criteria.\n5. Ability to provide informed consent - Not mentioned, but can be assumed.\n\nThe patient does not seem to meet the key inclusion criteria of having a diagnosis of Crohn's disease or active small bowel Crohn's disease.\n\nLooking at the exclusion criteria:\n- No history of diabetes, hyperlipidemia, thyroid dysfunction, hepatic/cardiac/renal/endocrine dysfunction, or cancer mentioned.\n- Not taking medications known to alter lipid levels.\n- Not pregnant.\n- No history of abdominal/pelvic surgery mentioned.\n- No complicated small bowel Crohn's disease.\n- No recent surgery within 30 days mentioned.\n\nBased on the information provided, the patient does not meet the key inclusion criteria for Crohn's disease, but also does not seem to meet any of the exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1308": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone of 14mm. The clinical presentation and findings are consistent with an unclear biliary lesion or stricture.\n\nThe inclusion criteria for the clinical trial are \"Patients with unclear lesions or strictures in the biliary tract referred for endoscopy work up\".\n\nGiven that this patient has an unclear biliary lesion (CBD stone) and is being worked up with endoscopic procedures, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1309": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is evaluating the safety and efficacy of apremilast in treating cutaneous disease in patients with recalcitrant dermatomyositis.\n\nLooking at the inclusion criteria:\n1. The patient must understand the risks/benefits and provide informed consent - There is no information about this.\n2. The patient must be 18 years or older - The patient is 54 years old, so this criterion is met.\n3. The patient must be willing to participate in evaluations/procedures and able to swallow pills - There is no information about this.\n4. The patient must have a diagnosis of dermatomyositis based on cutaneous findings or skin biopsy - The patient does not have dermatomyositis, so this criterion is not met.\n5. The patient must be a candidate for systemic therapy for dermatomyositis skin disease - This criterion is not applicable since the patient does not have dermatomyositis.\n6. The patient must have cutaneous disease activity of at least 5 on the CDASI scale despite treatment - This criterion is not applicable.\n7. The patient must be on stable doses of immunosuppressive treatments/steroids for at least 4 weeks - This criterion is not applicable.\n8. The patient must undergo age-appropriate cancer screening - There is no information about this.\n9. Females of childbearing potential must have a negative pregnancy test - The patient is menopausal, so this criterion is not applicable.\n\nSince the patient does not have dermatomyositis, which is the target disease for this clinical trial, the patient does not meet the key inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1310": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Gall Bladder Status Among Children With Chronic Haemolytic Anemia\", the patient does not meet the inclusion criteria for the following reasons:\n\n1. The patient is a 54-year-old woman, while the inclusion criteria specify children between 1 and 18 years of age.\n2. There is no mention of the patient having chronic hemolytic anemia in the patient note.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1311": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the use of tranexamic acid for the treatment of gastrointestinal bleeding.\n\n3. The inclusion criteria for the trial are:\n   - Adults\n   - Patients with acute lower and upper gastrointestinal bleeding (assessed clinically)\n   - Patients agreed to participate in the study and signed the informed consent\n\n4. Based on the patient note, there is no mention of gastrointestinal bleeding. The patient's symptoms and findings are consistent with acute cholecystitis/choledocholithiasis.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1312": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Drug Concentration and Volume on Adequate Labor Analgesia With PIEB\". It is studying the effects of different concentrations and volumes of epidural analgesia solutions on labor pain relief.\n\n3. The inclusion criteria for the trial are:\n- 18 years and above\n- Nulliparous parturients (women who have never given birth)\n- Present to the labor and delivery unit for an induction of labor or spontaneous labor\n- Request neuraxial labor analgesia at \u22645 cm cervical dilation\n\n4. Based on the patient note, this 54-year-old woman is not in labor and does not meet the inclusion criteria for this clinical trial on labor analgesia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1313": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting.\n2. The clinical trial is titled \"The Pre-hospital Evaluation of Sensitive Troponin (PRESTO) Study\" and aims to assess a decision aid for determining if a patient has a serious heart problem.\n3. The inclusion criteria for the trial are:\n   - Adult patients (>18 years)\n   - Called 999 for an emergency ambulance because they have experienced pain, discomfort or pressure in the chest, epigastrium, neck, jaw or upper limb without an apparent non-cardiac source\n   - Treating paramedic suspects these symptoms may be caused by acute coronary syndromes.\n\n4. Based on the patient note, the patient does not meet the inclusion criteria for this trial as she is presenting with abdominal pain, nausea, and vomiting, which are likely related to gallstones and biliary sludge, rather than symptoms suggestive of a heart problem.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1314": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying risk factors for developing incisional hernias after transverse epigastric incisions in patients undergoing abdominal surgery for malignant tumors of the alimentary system.\n\n3. The inclusion criteria for the trial are:\n   - Scheduled operative treatment due to a malignant tumor of the alimentary system (including liver, bile ducts, and pancreas) through a transverse incision in the epigastric region\n   - Provision of informed consent to participate in the study\n\n4. Based on the patient note, this patient does not have a malignant tumor of the alimentary system. She has gallstones and biliary sludge, which are benign conditions. Therefore, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1315": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Her medical history includes hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. The clinical trial is studying the efficacy and safety of larazotide acetate for relief of persistent symptoms in adult celiac disease patients.\n\n3. The inclusion criteria for the trial are:\n   - Male and female adults diagnosed with celiac disease for at least 6 months\n   - On a gluten-free diet for at least 6 months\n   - Experiencing symptoms like abdominal pain, cramping, bloating, gas, diarrhea, loose stool, or nausea\n   - Willing to maintain a gluten-free diet throughout the study\n\n4. Based on the patient note, there is no mention of the patient having celiac disease or being on a gluten-free diet. The symptoms and findings point towards a diagnosis of cholecystitis/cholelithiasis.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1316": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Polymer Clips Vs Endoloop for Appendicular Stump Ligation\" and is studying different methods for ligating the appendicular stump during laparoscopic appendectomy.\n\n3. The inclusion criteria for the trial are:\n   a) Patients of either gender aged 15-60 years\n   b) Patients with a MANTRELS score of 7 or above on admission\n\n4. Based on the patient note, there is no mention of appendicitis or the need for an appendectomy. The patient's symptoms and findings point towards biliary disease (gallstones, biliary sludge, CBD stones).\n\n5. Since the patient does not appear to have appendicitis or require an appendectomy, they would not be eligible for this particular clinical trial studying appendicular stump ligation techniques.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1317": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the inclusion criteria of \"abdominal pain consistent with acute pancreatitis\".\n\n2. Her lab results show elevated ESR and leukocytosis with a left shift, which could indicate pancreatitis. \n\n3. The ultrasound revealed gallstones, biliary sludge, and CBD stones, which can cause pancreatitis.\n\n4. The patient has experienced similar episodes of pain twice in the past year, satisfying the criteria of \"Two or more episodes of acute pancreatitis\".\n\n5. The patient is over 18 years old.\n\n6. While the note doesn't explicitly mention pancreas divisum, it does state that the patient has experienced recurrent pancreatitis with no certain explanation, which aligns with the trial's inclusion criteria.\n\n7. There is no information provided about the patient's ability to understand and participate in the study, but we can assume she meets this criteria unless stated otherwise.\n\nBased on the information provided in the patient note, this patient appears to meet the key inclusion criteria for the clinical trial on sphincterotomy for acute recurrent pancreatitis.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1318": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)\" and assess the patient's eligibility.\n\nThe inclusion criteria state that the patient must meet the clinical criteria for either cUTI or AP.\n\nFor cUTI, the patient must have at least two of the following symptoms:\n- Fever (>38\u00b0C or 100.4\u00b0F)\n- Nausea or vomiting\n- Dysuria, increased urinary frequency, or urinary urgency\n- Lower abdominal, suprapubic, or pelvic pain\n\nThe patient note mentions nausea and vomiting, but does not mention any urinary symptoms or lower abdominal pain. Therefore, the patient does not meet the criteria for cUTI.\n\nFor AP, the patient must have acute flank pain or costovertebral angle tenderness, plus at least one of the following:\n- Evidence of pyuria within 48 hours prior to randomization\n\nThe patient note does not mention any flank pain, costovertebral angle tenderness, or evidence of pyuria. Therefore, the patient does not meet the criteria for AP either.\n\nSince the patient does not meet the inclusion criteria for either cUTI or AP, the patient is not eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1319": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric, radiating to the right upper quadrant, and worsens after eating fatty foods. She has had similar episodes twice in the past year.\n\nThe clinical trial is titled \"A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment.\"\n\nThe inclusion criteria for the trial are:\n1. Stomach pain, swelling or dyspeptic complaints.\n2. Men and women between the ages of 18-60.\n3. Patients with VAS > 5.\n\nAssessing the patient against the inclusion criteria:\n1. The patient has abdominal pain, nausea, and vomiting, which can be considered dyspeptic complaints. This criterion is met.\n2. The patient is 54 years old, which falls within the age range of 18-60. This criterion is met.\n3. The patient's VAS (Visual Analog Scale) score for pain is not provided, so it is unclear if this criterion is met.\n\nSince one of the inclusion criteria (VAS > 5) cannot be definitively assessed based on the information provided, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1320": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Interest of the Equimolar Oxygen Nitride Mixture (MEOPA) in the Treatment of Pain in Patients Presenting to the Emergency Department for Suspected Renal Colic.\"\n\n3. The inclusion criteria for the trial are:\n   - Age greater than or equal to 18\n   - Presenting with suspected renal colic (pain in the lumbar fossa radiating towards the external genital organs, rapidly progressive, non-febrile)\n   - Provided informed consent\n   - Affiliated with social security\n\n4. The exclusion criteria for the trial are:\n   - Patient in shock\n   - Oxygen saturation below 93%\n   - Suspicion of pneumothorax\n   - History of emphysema or COPD\n   - Contraindications to MEOPA administration\n   - Contraindication to NSAIDs\n   - Long-term treatment with stage 3 analgesics\n   - Pregnant or lactating\n   - Participating in another interventional or minimal risk study\n   - Under legal protection or deprived of liberty\n\n5. Based on the patient note, the patient does not meet the inclusion criteria for suspected renal colic. Instead, the patient is presenting with symptoms suggestive of gallbladder disease (abdominal pain, nausea, vomiting, fever, and gallstones on ultrasound).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1321": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Nortriptyline for the Treatment of Functional Dyspepsia\" one by one:\n\nAge 18-65 years: The patient is 54 years old, which falls within this range.\n\nA diagnosis of FD according to the Rome IV criteria: The patient note does not explicitly mention a diagnosis of functional dyspepsia or state that the Rome IV criteria were met. However, it does describe symptoms like upper abdominal pain, nausea, and vomiting that could potentially be consistent with functional dyspepsia.\n\nPredicted CYP2D6 extensive metabolizer phenotype on the basis of CYP genotyping: There is no information provided about the patient's CYP genotype or metabolizer phenotype.\n\nInsufficient effect of first line treatment with proton pump inhibitors (twice daily) or prokinetics: The patient note does not mention any prior treatment.\n\nIn the presence of alarm symptoms, patients are required to have undergone an upper gastrointestinal endoscopy (without evidence of organic disease), and have tested negative for Helicobacter pylori 2 years prior to inclusion: The patient note mentions gallstones, biliary sludge, and CBD stones found on ultrasound, which would likely exclude a diagnosis of functional dyspepsia.\n\nWomen in their fertile age (<55 years old) must use contraception or be postmenopausal for at least two years: The patient is a 54-year-old woman who is described as menopausal, so this criterion is met.\n\nBased on the information provided in the patient note, there is not enough evidence to definitively determine if the patient meets the inclusion criteria for functional dyspepsia. The presence of gallstones and other biliary findings would likely exclude the patient from this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1322": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). Imaging confirmed the presence of gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is studying different approaches for evaluating and treating patients with gallstones and an intermediate risk of common bile duct stones when cholecystectomy is indicated.\n\nThe inclusion criteria are:\n1) Patients with gallstones when cholecystectomy is indicated\n2) Intermediate risk for common bile duct stones, defined as:\n    - VUHI score 2.6 - 6.9 \n    - AND one of the following:\n        - Dilated common bile duct\n        - Elevated total bilirubin\n        - Suspected CBD stone on ultrasound\n\nThis patient meets the first inclusion criteria, as she has gallstones and imaging findings suggestive of cholecystitis requiring cholecystectomy.\n\nFor the second criteria, the VUHI score is not provided, but the patient does have a suspected CBD stone on ultrasound (14mm stone).\n\nTherefore, based on the information provided, this patient meets the inclusion criteria for the clinical trial studying different approaches for evaluating/treating gallstone disease with intermediate CBD stone risk prior to cholecystectomy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1323": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. Imaging revealed gallstones, biliary sludge, and a common bile duct stone of 14mm.\n\n3. The clinical trial is studying the effect of a mare milk supplement on primary biliary cholangitis.\n\n4. The inclusion criteria for the trial are:\n   - Patients with morphologically verified diagnosis of primary biliary cholangitis\n   - Aged 18 to 75 years\n   - Willingness to consent to participate in the study\n   - Consent to adhere to treatment\n\n5. Based on the patient note, there is no mention of the patient having primary biliary cholangitis. The patient appears to have cholelithiasis (gallstones) and a common bile duct stone, which are different conditions from primary biliary cholangitis.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1324": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Spinal Morphine for Postoperative Analgesia in Urology\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting, likely due to gallstones and biliary sludge. The patient is not mentioned to be scheduled for open prostatectomy or open nephrectomy, which are the inclusion criteria for the given clinical trial.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1325": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL\" and is studying a combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL).\n\n3. Looking at the inclusion criteria, the first criterion is \"Cytologically and immunophenotypically confirmed relapsed/refractory CLL\". The patient note does not mention CLL or any hematological malignancy, so this criterion is not met.\n\n4. The other inclusion criteria relate to specific CLL disease characteristics, need for treatment, age, performance status, lab values, etc. Since the patient does not have CLL, these criteria are not relevant.\n\n5. Therefore, based on the information provided, the patient does not qualify for this clinical trial studying CLL therapies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1326": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever, which meets the inclusion criteria of \"suspected gallstone/biliary disease presenting with acute abdominal pain\".\n\nHer laboratory results show elevated bilirubin, ALT, AST, and leukocytosis, meeting the criteria of \"at least one of the following blood test results to reflect abnormal liver function\".\n\nThe ultrasound revealed gallstones, biliary sludge, and CBD stones, further confirming suspected gallstone disease.\n\nThe patient meets all the inclusion criteria:\n1. Willing and able to give informed consent (not mentioned but can be assumed)\n2. Age 16 years or above (54 years old)\n3. Suspected gallstone/biliary disease with acute abdominal pain\n4. Abnormal liver function tests\n\nThere is no information provided about exclusion criteria, so based on the given information, this patient appears eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1327": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Pain Processing and Pain Reporting in Patients With Alzheimer's Disease\", the patient does not seem to have Alzheimer's disease or any mention of cognitive impairment. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones.\n\nThe inclusion criteria for the clinical trial require participants to be either:\n1) Mild to moderate patients with Alzheimer's disease (group 1)\n2) Healthy participants (group 2)\n\nSince the patient note does not indicate that the patient has Alzheimer's disease or is a healthy participant without any medical conditions, there is insufficient information to determine if the patient meets the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1328": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Pain Neuroscience Education for Acute and Sub-Acute Low Back Pain\".\n\n3. The inclusion criteria for the trial are:\n   - A complaint of low back pain with or without leg pain less than 3 months\n   - A willingness to participate\n\n4. Based on the patient note, there is no mention of low back pain or leg pain. The patient's symptoms are related to gallstones and biliary issues.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1329": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This meets the age criteria of being above 18 years old.\n\n2. The patient has gallstones, biliary sludge, and CBD stones, indicating an unresectable malignant biliary obstruction diagnosed by ultrasound. This meets the inclusion criteria of having an unresectable malignant biliary obstruction.\n\n3. There is no mention of the involvement of the tumor with the orifice of the cystic duct or the deployment of a self-expandable metallic plastic stent for distal biliary obstruction.\n\n4. Based on the information provided, there is not enough evidence to determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1330": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Gastric Variceal Ligation Versus Gastric Variceal Obturation for Secondary Prophylaxis of Gastric Varices\", the patient does not seem to meet the inclusion criteria.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, but there is no mention of gastroesophageal variceal hemorrhage or any history related to gastric varices.\n\nThe inclusion criteria for the clinical trial specifically state that patients must have a past history of gastroesophageal variceal hemorrhage confirmed by an endoscopic examination.\n\nSince the patient note does not provide any information about the patient having gastroesophageal variceal hemorrhage or gastric varices, there is insufficient information to determine if the patient is eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1331": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers).\n\n2. The clinical trial is studying the use of a gelatin sponge (Surgicel) loaded with local anesthetics (bupivacaine, lidocaine, epinephrine) for post-operative pain control after laparoscopic cholecystectomy.\n\n3. The inclusion criteria for the trial are:\n   - Age 18-65 years old (the patient is 54, so meets this criteria)\n   - Scheduled for laparoscopic cholecystectomy (the patient likely needs this based on symptoms/findings)\n   - ASA grade I/II (no major systemic diseases mentioned, so likely meets this)\n   - No active inflammatory condition (cholecystitis may exclude her depending on interpretation)\n\n4. Based on the information provided, the patient appears to meet most of the inclusion criteria except potentially the \"no active inflammatory condition\" criteria depending on how strictly that is interpreted for her cholecystitis.\n\nTrial-level eligibility: 0) Excluded (patient likely meets most inclusion criteria but may be excluded based on having an active inflammatory condition of cholecystitis)",
        "label": 0
    },
    "1332": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone of 14mm.\n\nThe clinical trial is looking at performing one-stage endoscopic stone removal in patients with mild to moderate cholangitis (inflammation of the bile duct) associated with choledocholithiasis (CBD stones).\n\nThe key inclusion criteria are:\n1) Na\u00efve papilla (no prior sphincterotomy)\n2) Body temperature \u226537\u00b0C \n3) Diagnosed with mild to moderate cholangitis associated with choledocholithiasis\n\nFrom the patient note, we can determine:\n1) No mention of prior sphincterotomy, so likely na\u00efve papilla\n2) Body temperature 38.2\u00b0C, meeting fever criteria\n3) Cholangitis (biliary inflammation) present based on fever, elevated inflammatory markers\n4) Choledocholithiasis (CBD stone 14mm) present\n\nTherefore, this patient meets all the stated inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1333": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is a Phase 1b/2a study assessing the safety, tolerability, and efficacy of brequinar in subjects with relapsed/refractory acute myeloid leukemia (AML).\n\n3. The inclusion criteria for the trial specify:\n   - Age 18 years or older\n   - Relapsed/refractory AML, T-cell leukemia, bi-lineal leukemia, or mixed phenotypic acute leukemia\n   - ECOG Performance Status 0-2\n   - Adequate cardiac, hepatic, and renal function\n   - Use of adequate contraception\n   - Agree to refrain from sperm donation\n\n4. Based on the patient note, there is no mention of the patient having any form of leukemia. The presenting symptoms and findings are related to gallbladder disease.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1334": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patient requiring intervention for the management of symptoms associated with acute cholecystitis\nThe patient note mentions the patient was admitted with abdominal pain, nausea, vomiting, and was found to have gallstones, biliary sludge and CBD stones on ultrasound. This suggests acute cholecystitis requiring intervention, so this criterion is met.\n\n2. Patients referred for percutaneous drainage of the gallbladder who are not surgical candidates because of advanced age, anesthetic risk, significant co-morbidities and/or overall health\nThe patient note does not mention if the patient is a surgical candidate or not, so there is not enough information to assess this criterion.\n\n3. Eligible for endoscopic intervention\nThere is no information provided about eligibility for endoscopic intervention, so this criterion cannot be assessed.\n\n4. Acute Cholecystitis (AC) Grade I (mild) or II (moderate) per Tokyo guidelines\nThe patient note does not provide enough details to determine the grade of acute cholecystitis based on the Tokyo guidelines, so this criterion cannot be definitively assessed.\n\n5. Pre-drainage imaging confirms sufficient stone-free space to allow AXIOS\u2122 stent deployment and complete flange expansion\nThe ultrasound findings are mentioned, but there are no details about stone-free space for stent deployment, so this criterion cannot be assessed.\n\n6. 18 years of age or older\nThe patient is mentioned as a 54-year-old woman, so this criterion is met.\n\n7. Willing and able to comply with the study procedures and patient or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study\nThere is no information provided about the patient's willingness or ability to comply with study procedures or provide informed consent.\n\nSince there are multiple inclusion criteria that cannot be assessed based on the information provided in the patient note, I would conclude:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1335": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and symptoms suggestive of gallstones and cholecystitis.\n\nThe clinical trial is studying the relationship between gastric accommodation, transient lower esophageal sphincter relaxations (TLESRs), and reflux events in healthy volunteers and patients with GERD, with or without overlapping dyspepsia.\n\nTo be included in the trial, GERD patients must have:\n1) Typical symptoms of reflux like heartburn and/or regurgitation\n2) Confirmed gastroesophageal reflux by 24-hour pH-impedance monitoring or positive symptom association\n3) Esophagitis assessed by upper GI endoscopy with evaluation of hiatal hernia\n\nFor GERD/FD overlap patients, they must additionally have symptoms of functional dyspepsia according to the Rome III criteria.\n\nBased on the patient note provided, there is no mention of the patient having typical GERD symptoms like heartburn or regurgitation. The symptoms described are more consistent with gallstone disease and cholecystitis. There is also no information provided about pH monitoring, endoscopy, or hiatal hernia evaluation.\n\nTherefore, based on the information given, this patient does not meet the inclusion criteria for the clinical trial studying GERD and dyspepsia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1336": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for evaluating the efficacy and safety of pembrolizumab plus lenvatinib in previously treated participants with select solid tumors, including biliary tract cancers (BTC).\n\n3. The inclusion criteria for the BTC cohort are:\n   - Has a histologically or cytologically-documented, advanced (metastatic and/or unresectable) BTC\n   - Must have progressed on or since the last treatment\n   - Has measurable disease per RECIST 1.1\n   - Has provided a PD-L1 evaluable tumor tissue sample\n   - Meets other general inclusion criteria (e.g., contraception, ECOG status, organ function)\n   - Has received 1 prior line of therapy\n   - Child-Pugh Score, Class A: well-compensated disease (Score of 5-6)\n\n4. Based on the patient note, there is no mention of the patient having biliary tract cancer or any other solid tumor. The note describes a case of acute cholecystitis/choledocholithiasis.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1337": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea and vomiting. The clinical trial is looking at patients admitted to the emergency department with moderate to severe pain associated with trauma.\n\nThe inclusion criteria are:\n1) Men and women aged 18 or older - The patient is 54 years old, so meets this criteria.\n2) Patients who signed informed consent - No information provided about this.\n3) Patients admitted to the emergency department due to a trauma - The patient was admitted for abdominal pain, nausea and vomiting, which does not seem to be due to a trauma. This criteria is likely not met.\n4) Patients having a pain score \u2265 4 on a numerical rating scale at admission - No pain score is provided in the note.\n5) Patients having a pain score \u2265 40 on the VAS at the time of randomization - No VAS pain score is provided.\n\nBased on the information given, the patient does not seem to meet criteria 3 about being admitted due to trauma. There is also insufficient information about signed informed consent and pain scores to determine if those criteria are met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1338": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking at evaluating a diagnostic test (Film Array Gastrointestinal Panel) for infectious diarrhea in the emergency department.\n\nTo be included in this trial, the patient must have:\n1) Presumed infectious diarrhea (3 or more loose stools in past 24 hours)\n2) At least one of the following:\n   - Symptoms greater than 24 hours\n   - Dehydration\n   - Inflammation (fever, blood in stool, tenesmus)\n\nBased on the information provided, the patient does not seem to have infectious diarrhea as the primary complaint. The symptoms point more towards biliary colic/cholecystitis due to gallstones.\n\nTherefore, this patient would not be eligible for the clinical trial evaluating the Film Array Gastrointestinal Panel for infectious diarrhea.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1339": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1) Patients >18 years old (the patient is 54, so meets this criteria)\n2) Patients with or at risk of malnutrition (the patient's nutritional status is not mentioned, so it's unclear if they meet this criteria)\n3) Patients expected to require oral nutritional supplementation for at least 2 weeks (it's not mentioned if the patient will require this, so unclear if they meet this criteria)\n4) Patients requiring supplementary intake of approximately 300 kcal/day from an oral nutritional supplement (again, unclear if the patient meets this)\n5) Informed assent/consent obtained (not mentioned if this has been done)\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets all of the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1340": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. This meets the age criteria of \"Person over 19 years old\".\n\nShe is experiencing epigastric pain that radiates to the right upper quadrant and gets worse after eating fatty foods. This aligns with the criteria \"Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week\".\n\nThe symptoms have been present for at least a year, meeting the criteria \"Person with above symptoms that started at least 6 months before and continued for minimum 3 months\".\n\nThe ultrasound revealed gallstones and biliary sludge, which could be causing her symptoms. However, the criteria state \"Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease\". This patient may be excluded based on this criterion.\n\nThere is no information provided about previous treatments for functional dyspepsia or whether her symptoms disrupt daily life.\n\nOverall, while the patient meets some of the inclusion criteria, the presence of gallstones and biliary sludge may exclude her from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1341": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the use of virtual reality for postoperative pain management after laparoscopic hysterectomy.\n\nLooking at the inclusion criteria:\n1. Any patient undergoing laparoscopic hysterectomy\n- This patient is not undergoing a hysterectomy, she likely needs a cholecystectomy for her gallstones/biliary issues.\n\n2. Benign indications \n- Her indications (gallstones) appear to be benign.\n\n3. Dr. Jamal Mourad or Dr. Nichole Mahnert will be performing hysterectomy\n- There is no mention of these doctors treating this patient.\n\nBased on the information provided, this patient does not meet the key inclusion criteria of undergoing a laparoscopic hysterectomy performed by the specified doctors.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1342": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worse after eating fatty foods. She has a history of similar episodes in the past year.\n\nThe clinical trial is looking at evaluating fascioliasis (a parasitic infection) in patients with suspected symptoms.\n\nThe inclusion criteria for the trial are:\n- Vague gastrointestinal disturbances (check - patient has abdominal pain, nausea, vomiting)\n- Intermittent eosinophilia (no information provided)\n- Biliary obstruction (check - ultrasound showed CBD stones)\n- Biliary colic pain (check - right upper quadrant pain)\n- Intermittent jaundice (no information provided) \n- Right upper quadrant abdominal tenderness (check)\n\nBased on the information provided, the patient meets several of the inclusion criteria for suspected fascioliasis, including gastrointestinal symptoms, biliary obstruction, biliary colic pain, and right upper quadrant tenderness.\n\nHowever, there is no information about intermittent eosinophilia or jaundice, which are also listed as inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1343": {
        "output": "To determine the patient's eligibility for the clinical trial \"Opiate Use and Biliary Dilation\", let's go through the inclusion criteria one by one:\n\n1. Referral/consultation for consideration for EUS \u00b1 ERCP\n   - The patient note does not mention if the patient was referred for EUS or ERCP, so this criterion is unclear.\n\n2. Age 18 and older\n   - The patient is 54 years old, so this criterion is met.\n\n3. Evidence of biliary dilation on abdominal imaging without obstructive pattern on liver function tests or imaging.\n   - The patient note mentions that the ultrasound revealed biliary sludge and CBD stones, but it does not explicitly state if there was biliary dilation. However, the presence of CBD stones could potentially cause biliary dilation.\n\n4. Willing and able to comply with the study procedures and provide written informed consent to participate in the study.\n   - There is no information provided about the patient's willingness or ability to comply with the study procedures or provide consent.\n\nSince there is not enough information to definitively determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1344": {
        "output": "To determine the patient's eligibility for the clinical trial \"Internet Tools and Emergency Attendance\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\nAny major patient presenting to the emergency department by their personal way.\n\nBased on the patient note, the 54-year-old obese woman was admitted to the emergency department with abdominal pain, nausea, and vomiting. She presented to the emergency department on her own accord, not by ambulance or other means.\n\nSince the patient meets the inclusion criteria of being a major patient who presented to the emergency department by her own personal way, she would be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1345": {
        "output": "Based on the patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with symptoms of gallstones, including abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n- Gallbladder removal because of biliary pain or gallstones complications\n\nSince the patient is scheduled for gallbladder removal due to gallstones and related complications, she meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1346": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Acute Abdomen in Kawasaki Disease\" and the inclusion criteria are:\n   - Patients with Kawasaki disease\n   - Acute abdomen requiring surgery\n\n3. Based on the patient note, there is no mention of the patient having Kawasaki disease. The patient's symptoms and findings point towards a gallbladder/biliary issue rather than Kawasaki disease.\n\n4. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1347": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Comparison Between the Analgesic Efficacy of Erector Spinae Plane Block and Psoas Compartment Block in Hip Surgery\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever, likely due to gallstones and biliary sludge. The patient's condition appears to be related to gallbladder disease and does not mention any hip surgery or related conditions.\n\nThe inclusion criteria for the clinical trial specifically state \"ASA (American Society of Anesthesiologists) I- ASA II Patients\" undergoing hip surgery. However, the patient note does not indicate that the patient is scheduled for hip surgery or meets the ASA I-II criteria.\n\nTherefore, based on the available information, the patient does not seem to be relevant for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1348": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is for patients with newly diagnosed B-lymphoblastic leukemia (B-ALL) or B-lymphoblastic lymphoma (B-LLy), with specific age criteria and diagnostic criteria related to blast counts, bone marrow findings, or circulating leukemic cells.\n\n3. Based on the patient note, there is no indication that the patient has B-ALL or B-LLy. The patient's presentation and findings are consistent with cholelithiasis (gallstone disease).\n\n4. Therefore, the patient does not meet the inclusion criteria for this clinical trial, which is specifically for patients with B-ALL or B-LLy.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1349": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is comparing outcomes of laparoscopic versus open appendectomy in acute appendicitis.\n\n3. The inclusion criteria for the trial state that patients must have acute appendicitis confirmed clinically by pain in the right iliac fossa, tenderness, elevated white blood cell count, without a palpable mass, and radiological confirmation. Patients must be admitted through the emergency department.\n\n4. Based on the patient note, this patient does not have acute appendicitis. The symptoms and imaging findings point to biliary disease/gallstone pancreatitis instead.\n\n5. Therefore, this patient does not meet the inclusion criteria for the clinical trial on acute appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1350": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting.\n2. The patient has a history of hypercholesterolemia and 2 normal vaginal deliveries (NVDs).\n3. The patient is not diagnosed with gastric cancer, but rather has gallstones, biliary sludge, and CBD stones.\n4. The clinical trial is for a nutrition education program for postoperative patients with gastric cancer.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this clinical trial because:\n\na) The patient is not diagnosed with gastric cancer.\nb) The patient has not undergone an operation for gastric cancer.\n\nTherefore, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1351": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying inotuzumab ozogamicin and post-induction chemotherapy in treating patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy).\n\n3. Based on the inclusion criteria provided, the key requirements are:\n   - Patients with B-ALL, MPAL, or B-LLy\n   - Age between 1 and 25 years\n   - Specific white blood cell count criteria for B-ALL and MPAL\n   - Newly diagnosed B-ALL, MPAL, or B-LLy meeting certain criteria\n\n4. The patient note does not mention any diagnosis of B-ALL, MPAL, or B-LLy. The patient appears to be presenting with gallbladder disease.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1352": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Age 18 to 75 years old, gender is not limited: The patient is 54 years old, which falls within the age range. This criterion is met.\n\n2. Patients with upper abdominal pain, abdominal distension, belching, anorexia, early satiety, hiccup, acid reflux, upper abdomen burning sensation and other upper gastrointestinal symptoms: The patient is admitted with abdominal pain that started 4 days ago, along with nausea and vomiting. The pain is described as epigastric, radiating to the right upper quadrant, and worsening after eating fatty food. This criterion is met.\n\n3. Voluntary acceptance of Hp testing: There is no information provided about whether the patient has agreed to undergo Hp testing or not.\n\n4. Voluntary acceptance of the endoscopy and pathological biopsy: There is no information provided about whether the patient has agreed to undergo endoscopy and pathological biopsy or not.\n\nSince there is insufficient information to determine if the patient meets criteria 3 and 4, the patient cannot be considered fully eligible for the trial based on the provided information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1353": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial \"Sexual Health Empowerment for Women's Health\", the patient does not meet the inclusion criteria as there is no mention of the patient being scheduled to leave jail within 3 days.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1354": {
        "output": "Okay, let's go through the inclusion criteria for the DIGEST I clinical trial step-by-step:\n\nAge \u2265 18 and \u2264 80 years: The patient is 54 years old, which meets this criterion.\n\nBenign biliary stricture with postoperative injury or PSC or anastomotic-stricture; and indicated for ERCP procedure: The patient has gallstones, biliary sludge, and CBD stones, which would likely require an ERCP procedure. However, it is not explicitly stated that the patient has a benign biliary stricture.\n\nRestenosis after plain balloon dilation with at least 2 previous balloon dilation sessions and recurrence of biliary obstructive symptoms/signs or being managed with implantable prosthetics (e.g. plastic stents): There is no information provided about previous balloon dilation sessions or implantable prosthetics.\n\nGreater than 40% stenosis of the biliary tract via ERCP: No information is provided about the degree of stenosis.\n\nTotal serum bilirubin >2 mg/dL. Alkaline phosphatase level >3 times higher than normal level. *Note: This IC is waved if the patient is being managed with implantable prosthetics: No information is provided about the patient's bilirubin or alkaline phosphatase levels.\n\nType I, II, III and IV Benign biliary duct strictures. Dominant stricture being accessible by balloon catheter: No information is provided about the type of biliary duct stricture or its accessibility.\n\nStricture length <4 cm: No information is provided about the length of any stricture.\n\nNot currently listed for liver transplantation: No information is provided about the patient's transplant status.\n\nVoluntary participation and provided written informed consent: Assuming the patient would provide consent if eligible.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1355": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying a drug called CB4211 in healthy non-obese subjects (Part A and B) and subjects with non-alcoholic fatty liver disease (NAFLD) (Part C).\n\n3. For Parts A and B, the inclusion criteria require subjects to be non-obese (BMI 18-30), healthy, and without any significant medical conditions. This patient does not meet these criteria as she is obese and has gallstones/biliary disease.\n\n4. For Part C, the inclusion criteria require subjects to be obese (BMI \u226530) with NAFLD confirmed by imaging or fatty liver index score. The patient's obesity meets this criteria, but there is no mention of NAFLD or fatty liver in her note.\n\n5. Additionally, Part C excludes subjects with significant hepatic disorders other than NAFLD. The patient's gallstones and biliary disease would likely exclude her from this part of the trial as well.\n\nIn summary, while the patient meets the obesity criteria for Part C, she does not have a confirmed diagnosis of NAFLD required for inclusion. More importantly, her gallstone disease would likely exclude her from all parts of this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1356": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis of chronic biliary type abdominal pain (RUQ pain, pain radiates to the right flank, scapula, or shoulder, or pain that stimulates gallbladder symptoms)\n- The patient has abdominal pain that started 4 days ago with nausea and vomiting, with epigastric pain radiating to the right upper quadrant, getting worse after eating fatty food. This meets the criteria for chronic biliary type abdominal pain.\n\n2. Pancreatic pain (epigastric or left upper quadrant pain, pain that is exacerbated by some food, or pain that radiates to the back) for at least 3 months prior to the study\n- There is no mention of pancreatic pain in the patient note.\n\n3. absence of abnormal liver and pancreas chemistry or abnormal abdominal imaging\n- The patient's laboratory analysis is remarkable for elevated ESR and leukocytosis with a left shift, which could indicate an abnormality. However, the ultrasound revealed gallstones, biliary sludge, and CBD stones, which could explain the abdominal pain.\n\n4. average pain score of greater than or equal to 3 out of 10 on the numeric rating scale (NRS) for at least the average of 3 episodes each week\n- There is no mention of the patient's pain score in the note.\n\n5. Subjects on antidepressants for pain control should take the medication for a minimum of one month prior to the baseline assessment.\n- There is no mention of the patient taking antidepressants for pain control.\n\n6. Patients with SOD with depressive and/or anxiety disorders who receive psychopharmacologic treatment must be on stable medication dose for at least 6 weeks.\n- There is no mention of the patient having depressive or anxiety disorders or taking psychopharmacologic treatment.\n\n7. Patients with access to a cell phone, able to speak, read, and write English will be enrolled.\n- There is no information provided about the patient's ability to speak, read, and write English or access to a cell phone.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria for the clinical trial. Some criteria are met, while others are not mentioned or unclear.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1357": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman, which meets the age (50-80 years) and BMI (25-40 kg/m2) criteria.\n\nIt is not explicitly stated if she is post- or peri-menopausal, but it does mention she is menopausal, so this criterion is likely met.\n\nHer smoking status is not mentioned, but the criteria allows for both smokers and non-smokers.\n\nThere is no information provided about her dietary inflammatory index (DII) or fruit/vegetable intake to assess those criteria.\n\nIt is also not mentioned if she would be able to adhere to a 6-week washout period.\n\nOverall, while some criteria are met based on the information provided, there are several key criteria that cannot be assessed due to lack of information in the patient note.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1358": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Carfilzomib in Combination for the Treatment of RR MM\" and is studying carfilzomib combination treatments for relapsed/refractory multiple myeloma patients.\n\n3. The inclusion criteria for the trial are:\n   - 18 years and older\n   - Relapsed/refractory multiple myeloma patients who have received 1 to 3 prior lines of therapy\n   - Willing and able to sign informed consent\n   - Receiving carfilzomib for \u2264 2 months (\u22642 cycles) according to regulatory approvals\n\n4. Based on the patient note, this patient does not have multiple myeloma. She has gallstones and related complications.\n\n5. Therefore, this patient does not meet the inclusion criteria for this clinical trial on relapsed/refractory multiple myeloma.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1359": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Improving Tissue Oxygenation in Breast Reconstruction Surgery\" and is studying the effects of optimal fluid therapy and dobutamine on flap oxygenation in patients undergoing DIEP flap breast reconstruction surgery.\n\n3. The inclusion criteria for the trial are:\n   - American Society of Anesthesiologists' (ASA) Physical Classification I-III\n   - Undergoing elective unilateral or bilateral DIEP flap surgery\n   - Competent to provide informed consent\n\n4. Based on the patient note, this patient does not appear to be undergoing DIEP flap breast reconstruction surgery. She is presenting with symptoms related to gallstones and biliary disease.\n\nTherefore, this patient does not meet the inclusion criteria for the given clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1360": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones. Bloodwork showed elevated inflammatory markers.\n\nThe clinical trial is looking at common bile duct pressures in patients with and without gallstones/cholelithiasis. \n\nThe key inclusion criteria is: \"All patients with normal values of amylase, lipase, and liver function tests measured 24 hours before the intervention\"\n\nFrom the patient note, we don't have information on the patient's amylase, lipase or liver function test values from 24 hours prior to presentation. \n\nTherefore, there is insufficient information to determine if this patient meets the inclusion criteria for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1361": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, fever, and elevated inflammatory markers. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Inhaled Steroids for Acute Pharyngitis\" and is investigating the use of nebulized glucocorticoids for treating acute pharyngitis/tonsillitis.\n\n3. The inclusion criteria for the trial are:\n   - Pediatrics and adults > 5 years of age\n   - Patients complaining of acute sore throat likely due to infective pharyngitis/tonsillitis\n   - Onset of symptoms within 7 days\n   - Patient or caregiver has the capacity and willingness to give consent and complete trial paperwork\n   - Not on antibiotics for acute pharyngitis\n\n4. Based on the patient note, this patient does not have acute pharyngitis or tonsillitis. Instead, they are presenting with symptoms related to gallstones and biliary disease.\n\nTherefore, this patient does not meet the inclusion criteria for the \"Inhaled Steroids for Acute Pharyngitis\" clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1362": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms and imaging findings consistent with acute cholecystitis (gallstones, biliary sludge, right upper quadrant pain, fever, leukocytosis).\n\nThe inclusion criteria are:\n1) Age \u226545 years (the patient is 54, so meets this)\n2) Diagnosis of acute cholecystitis defined by at least 2 of:\n   - Abdominal pain in upper right quadrant (present)\n   - Murphy's sign (not mentioned)\n   - Leukocytosis >10 x 10^3/\u03bcl (present) \n   - Fever (present)\n3) Cholelithiasis/gallstones (present)\n4) Ultrasound signs of cholecystitis (present)\n5) Acute cholecystitis requiring surgery diagnosed during working hours (presumed yes)\n6) Expected overnight hospital admission after surgery (presumed yes)\n7) Provide written informed consent (not mentioned)\n\nThe patient meets the age criteria and has a clear diagnosis of acute cholecystitis with gallstones/sludge based on symptoms, lab findings and imaging. As long as this was diagnosed during working hours and the patient consents, she appears eligible.\n\nNone of the exclusion criteria are mentioned as applying.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1363": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct stones. The smallest stone is 14mm.\n\nThe clinical trial is studying intraoperative spillage of bile and gallstones during laparoscopic cholecystectomy.\n\nThe inclusion criteria are:\n1) All age groups\n2) Only laparoscopic cholecystectomy \n3) All types, numbers, and sizes of gallstones\n\nBased on the information provided, this patient meets all the inclusion criteria:\n1) The patient's age (54 years old) falls within \"all age groups\"\n2) The patient is a candidate for laparoscopic cholecystectomy given the gallstone disease\n3) The patient has gallstones of varying sizes, including a 14mm stone\n\nThere is no information provided about exclusion criteria, so we cannot determine if the patient would be excluded.\n\nTherefore, given the available information, this patient appears eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1364": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. \"Patients with biopsy confirmed, active, steroid dependent CD, without nutrient absorbance problems (Definition of steroid dependency: CD being treated with at least 5 mg/day steroids for the last 3 months; an attempt to reduce the dose induces flare of disease as determined by physician assessment).\"\n- The patient note does not mention Crohn's disease or steroid dependency, so this criterion is not met.\n\n2. \"Age \u226518 years\"\n- The patient is 54 years old, so this criterion is met.\n\n3. \"Steroid treatment of at least 3 months and stable steroid dose for at least 2 weeks .If thiopurines and/or biologics are also being administered, then must be administered at stable dose(s) for at least 3 months.\"\n- There is no mention of the patient being on steroids or other treatments, so this criterion cannot be evaluated.\n\n4. \"Patients will undergo an ECG and QT parameters will be measured for further analysis.\"\n- There is no information about ECG or QT parameters in the patient note.\n\n5. \"Female subjects who are postmenopausal (absence of menses for \u2265 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled.\"\n- The patient is a 54-year-old postmenopausal woman, so this criterion is met.\n\n6. \"Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled.\"\n- There is no mention of breastfeeding, but this criterion can likely be assumed to be met for a postmenopausal woman.\n\n7. \"Subject able to provide written informed consent\"\n- There is no information about the patient's ability to provide informed consent.\n\nIn summary, while the patient meets some of the criteria (age, postmenopausal status), there is insufficient information to determine eligibility for this particular trial focused on Crohn's disease and steroid dependency.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1365": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note is about a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. She was diagnosed with gallstones, biliary sludge, and CBD stones based on an ultrasound.\n\n2. The clinical trial is studying the effects of different doses of sufentanil on anesthesia induction and analgesia after tonsillectomy in children aged 1-12 years.\n\n3. Based on the inclusion criteria of the clinical trial, which requires participants to be aged 1-12 years, undergoing adenotonsillectomy, with a BMI between 18.5 and 23.9, the patient in the given note does not meet the criteria.\n\n4. The patient is an adult (54 years old), not a child within the required age range. Additionally, the patient is being treated for gallstones and related complications, not undergoing an adenotonsillectomy.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1366": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of acute cholecystitis (abdominal pain, nausea, vomiting, fever) and imaging findings consistent with gallstones and acute cholecystitis.\n\nThe clinical trial is studying the use of indocyanine green cholangiography during laparoscopic cholecystectomy for acute gallstone cholecystitis grades 1 and 2.\n\nLooking at the inclusion criteria:\n1. Adult patient (>18 years old) - The patient is 54 years old, so meets this criteria.\n2. Requiring laparoscopic cholecystectomy for grade 1 or 2 acute gallstone cholecystitis - The patient has imaging findings of acute cholecystitis and gallstones, so would likely require cholecystectomy. The grade is not specified but presumably meets grade 1 or 2 based on the clinical picture.\n3. Acute cholecystitis evolving for less than 5 days - The note states the symptoms started 4 days ago, so meets this criteria. \n4. Patient affiliated to a social security scheme - No information provided about this.\n\nOverall, based on the information given, the patient appears to meet the key inclusion criteria of being an adult with acute cholecystitis requiring cholecystectomy within the specified timeframe.\n\nTrial-level eligibility: 1) Not relevant, as there is insufficient information about the patient's social security affiliation.",
        "label": 0
    },
    "1367": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"The Effects of Objective Estimation of Pain Response\" and is studying a method to objectively monitor pain response during and after anesthesia.\n\n3. The inclusion criteria for the trial are: All patients over 18 years old.\n\n4. The patient meets the age criteria of being over 18 years old.\n\n5. However, the trial appears to be focused on patients undergoing anesthesia and surgery, which this patient note does not mention. The patient's condition seems to be related to gallstones and not an upcoming surgical procedure.\n\n6. There is not enough information provided to determine if the patient would be eligible for this particular trial, as their medical condition and treatment plan are not clearly stated.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1368": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days. The pain is epigastric radiating to the right upper quadrant, worsening after eating fatty foods. She has had similar episodes twice in the past year.\n\nThe clinical trial is looking to optimize the diagnosis of acute appendicitis by identifying delta signs (changes in clinical, laboratory, or ultrasound findings) that can confirm or rule out appendicitis without needing a CT scan.\n\nThe inclusion criteria for the trial are:\n1. Symptoms of acute appendicitis (right lower quadrant pain, pain migration from epigastrium, nausea, rebound tenderness, fever)\n2. After initial evaluation, the diagnosis cannot be confirmed or excluded\n3. No other gynecological, urological, or gastrointestinal pathology confirmed\n\nThe exclusion criteria are:\n1. Pregnant patient\n2. Symptoms lasting > 48 hours\n3. Signs of peritonitis\n\nIn this case, the patient does not seem to meet the inclusion criteria for symptoms of acute appendicitis. Her pain is epigastric radiating to the right upper quadrant, which is more suggestive of biliary pathology. The ultrasound also showed gallstones, biliary sludge, and CBD stones.\n\nTherefore, based on the information provided, this patient would not be eligible for the clinical trial on optimizing the diagnosis of acute appendicitis.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1369": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The pain is epigastric radiating to the right upper quadrant, worse after eating fatty foods. She has a history of similar episodes in the past year. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Gastric Electrical Stimulation for Abdominal Pain in Gastroparesis\". The key inclusion criteria are:\n\n1. Able to give informed consent\n2. Has an Enterra GES device in place for at least 2 months\n3. Continues to have moderate to severe abdominal pain on pain questionnaires or VAS score >5 for at least 2 months\n4. Abdominal pain is persistent, chronic for >2 months, and refractory to original Enterra GES settings\n\nBased on the patient note, there is no mention of the patient having a GES device or being diagnosed with gastroparesis. The abdominal pain appears to be related to gallstones and biliary disease, rather than gastroparesis.\n\nTherefore, this patient does not meet the inclusion criteria for this specific clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1370": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia\", the patient does not seem to be eligible for this trial.\n\nThe key points are:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and gallstones, which suggests a diagnosis of cholecystitis or biliary colic.\n\n2. The inclusion criteria for the clinical trial specify that participants should have de novo acute myeloid leukemia (AML) with a white blood cell count greater than 50 G/L (50,000/\u03bcL) and be eligible for intensive chemotherapy.\n\n3. There is no mention of the patient having AML or any other hematological malignancy in the provided note.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1371": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a study of a PD-1 monoclonal antibody in combination with chemotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).\n\n3. Based on the inclusion criteria provided, this patient does not seem to have NHL. The patient note mentions gallstones and related symptoms, but no mention of lymphoma.\n\n4. Since the patient does not have the target disease (NHL) required for this clinical trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1372": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Dexmedetomidine Sedation in Orthopedic Surgery\" and is studying different sedation methods for orthopedic surgery patients.\n\nThe inclusion criteria for the trial are:\n1) Physical status according to American Society of Anesthesiologists (ASA) I-III\n2) Patients scheduled for orthopedic surgery\n\nBased on the information provided, this patient does not meet the inclusion criteria for this orthopedic surgery trial, as she is not scheduled for orthopedic surgery. Her condition appears to be related to gallstones/biliary issues.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1373": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of gallstones and the ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the effectiveness of Abdominal Plane Blocks (APB) in treating Chronic Abdominal Pain (CAP).\n\n3. The inclusion criteria for the trial are:\n   - Age over 18 years\n   - Chronic abdominal pain for above 6 months\n   - Moderate to severe pain in the abdomen: Baseline NRS >4 (worst pain the last 24 hours)\n\n4. Based on the patient note, the patient seems to be experiencing an acute exacerbation of gallstone disease rather than chronic abdominal pain. There is no mention of the duration of her abdominal pain or the severity of her pain on a numerical rating scale.\n\n5. Therefore, there is not enough information provided in the patient note to determine if the patient meets the inclusion criteria for this specific clinical trial on Chronic Abdominal Pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1374": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria:\nPatients over 18yrs of age with suspected choledocholithiasis stratified into intermediate risk of choledocholithiasis as per European Society of Gastrointestinal Endoscopy Guidelines\n\nFrom the patient note, we know that:\n1. The patient is 54 years old, so she meets the age criteria of being over 18 years.\n2. The patient is suspected of having choledocholithiasis (CBD stones) based on the ultrasound findings of \"several gallstones, biliary sludge and CBD stones. The smallest stone is 14mm.\"\n\nHowever, the note does not explicitly state whether the patient falls into the intermediate risk category for choledocholithiasis according to the European Society of Gastrointestinal Endoscopy Guidelines.\n\nSince we do not have sufficient information to determine if the patient meets the risk stratification criteria, we cannot conclusively assess her eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1375": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for this trial. The trial is focused on comparing anesthetic agents for upper limb surgeries, while the patient's condition appears to be related to gallstones and biliary issues.\n\nThe inclusion criteria specifically mention upper limb surgeries such as ganglion removal, K-wiring, and carpal tunnel release. However, the patient note does not indicate any upcoming upper limb surgery. Instead, it describes symptoms and findings related to gallstones and biliary obstruction.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1376": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\nThe clinical trial is titled \"Upper Trunk Block Versus Costoclavicular Block For Arthroscopic Shoulder Surgery\" and is studying different nerve blocks for pain management after shoulder surgery.\n\nThe inclusion criteria for the trial are:\n1. American Society of Anesthesiologists (ASA) physical status I-III\n2. BMI 20 to 35 kg/m2  \n3. Patients scheduled for elective arthroscopic shoulder surgery\n\nLooking at the patient details, there is no information provided about their ASA status or whether they are scheduled for shoulder surgery. The patient's BMI is not given, but they are described as obese which likely puts them outside the BMI range.\n\nBased on the information provided, this patient does not meet the inclusion criteria and does not have sufficient details to be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1377": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\nInclusion Criteria:\n1. Consecutive healthy patients aged \u2265 18 years old\nThe patient is 54 years old, which meets this criterion.\n\n2. Suffering from acute calculous cholecystitis indicated for laparoscopic cholecystectomy\nThe patient note mentions that the patient was admitted with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones, indicating acute calculous cholecystitis. The patient would typically be indicated for a laparoscopic cholecystectomy, meeting this criterion.\n\nSince the patient meets both inclusion criteria, they would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1378": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging showed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"ESM in Functional Dyspepsia\" and is looking at using an electronic patient-reported outcome measure (ePRO) based on the Experience Sampling Method for symptom assessment in functional dyspepsia.\n\n3. The inclusion criteria for patients with functional dyspepsia include:\n   - Diagnosis of functional dyspepsia according to ROME IV criteria\n   - Age between 18-75 years\n   - Ability to understand and speak Dutch\n   - Ability to use the ESM tool\n\n4. The exclusion criteria for patients with functional dyspepsia include:\n   - Any organic explanation for GI complaints\n   - Initiation of regularly used medication from 1 month before inclusion\n   - History of upper digestive surgery or abdominal radiation\n   - Pregnancy\n\n5. Based on the patient note, this patient does not have a diagnosis of functional dyspepsia, but rather has gallstone disease which would exclude them from this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1379": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. Imaging revealed gallstones, biliary sludge, and common bile duct stones, with the smallest stone being 14mm.\n\n3. The clinical trial is for toripalimab plus lenvatinib as second-line treatment in advanced biliary tract cancers.\n\n4. The inclusion criteria include:\n   - Age \u2265 18 years\n   - Diagnosed with advanced biliary tract cancer (intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct cancer, gallbladder cancer)\n   - Failed or intolerant to first-line gemcitabine or platinum-based regimen\n   - At least one measurable lesion\n   - Adequate organ function\n   - No more than 2 organs with metastasis\n\n5. Based on the information provided, the patient meets the inclusion criteria of being an adult and having biliary tract disease (common bile duct stones).\n\n6. However, there is no mention of the patient having received any prior treatment or having metastatic disease, which are required for this trial.\n\nTherefore, there is insufficient information to determine if the patient is eligible or not for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1380": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones and choledocholithiasis (CBD stones).\n\n2. The clinical trial is studying a single setting ERCP and laparoscopic cholecystectomy approach for patients with cholecysto-choledocholithiasis.\n\n3. The inclusion criteria are:\n   - Sonologically proven cases of choledocholithiasis with cholelithiasis\n   - CBD diameter < 2cm\n   - Age > 13 years\n\n4. Based on the patient note, the patient meets the inclusion criteria:\n   - She has gallstones and CBD stones confirmed by ultrasound\n   - Her CBD stone size is 14mm, which is less than 2cm\n   - She is 54 years old, which is above 13 years\n\n5. There is no information provided about exclusion criteria, so we cannot determine if she would be excluded.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1381": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Biliary tract cancer proved by histology or cytology\n   - The patient note does not mention a histological or cytological diagnosis of biliary tract cancer. It mentions gallstones, biliary sludge, and CBD stones, but not cancer.\n\n2. Metastatic advanced or locally advanced unresectable biliary tract cancer, including gallbladder cancer, intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma, decided by hepatobiliary doctor and radiologist.\n   - There is no mention of the patient having metastatic, advanced, or unresectable biliary tract cancer in the note.\n\n3. At least one measurable lesion within liver;\n   - The note does not mention any lesions within the liver.\n\n4. No prior intra-arterial/systemic chemotherapy or other systemic therapies\n   - The note does not mention any prior therapies.\n\n5. Prior resection, TACE or ablation will be allowed.\n   - The note does not mention any prior resection, TACE, or ablation.\n\n6. Age from 18 years old to 80 years old.\n   - The patient is 54 years old, which meets this criterion.\n\n7. The performance of Eastern Cooperative Oncology Group (ECOG) <2\n   - The note does not mention the patient's ECOG performance status.\n\n8. Child-Pugh A or Child-Pugh B (\u2264 score 7).\n   - The note does not mention the patient's Child-Pugh score.\n\n9. Expectant survival time \u2265 3 months.\n   - The note does not mention the patient's expected survival time.\n\n10. Baseline blood count test and blood biochemical must meet following criteria:\n    - Hemoglobin \u2265 90 g/L;\n    - Absolute neutrophil count \u2265 1.5\u00d710^9/L;\n    - Blood platelet count \u2265 100\u00d710^9/L;\n    - Alanine aminotransferase (ALT), aspartate aminotransferase (AST) \u2264 2.5 times of upper limit of normal (ULN);\n    - Total bilirubin \u2264 2 times of ULN;\n    - Serum creatinine \u2264 1.5 times of ULN;\n    - Albumin \u2265 30 g/L.\n    - The note does not provide any of these laboratory values.\n\n11. Patients sign informed consent.\n    - The note does not mention whether the patient has signed informed consent.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1382": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This does not match the inclusion criteria for the malaria drug trial, which requires patients to have confirmed uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection.\n\n2. There is no mention of the patient having malaria or any malarial symptoms in the note. The symptoms and findings point towards a diagnosis of cholecystitis/cholelithiasis (gallstones).\n\n3. The patient's age of 54 years falls within the 6 months to 59 years range specified in the inclusion criteria. However, this is the only criterion she meets.\n\n4. Based on the information provided, this patient does not qualify for enrollment in the antimalarial drug efficacy trial as she does not have a confirmed malarial infection, which is the primary requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1383": {
        "output": "To determine the patient's eligibility for the \"VIRal Hepatitis and GAllstone Disease Study\" clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Acute abdominal pain entailing an abdominal ultrasound or computed tomography for suspected gallstone disease at the emergency room at Sahlgrenska University Hospital, Gothenburg\"\n   - The patient note mentions that the patient was admitted to the emergency department with abdominal pain, and an ultrasound revealed gallstones and CBD stones. This criterion is met.\n\n2. \"Written informed consent\"\n   - There is no information provided about whether the patient has given written informed consent or not. We cannot determine if this criterion is met or not.\n\n3. \"Ability to obtain 9 mL serum for analysis of anti-HAV IgM, HBsAg, anti-HCV, HCV Core antigen and HEV RNA\"\n   - There is no information provided about whether the patient can provide the required serum sample or not. We cannot determine if this criterion is met or not.\n\nSince there is not enough information to confirm that all the inclusion criteria are met, the patient's eligibility cannot be determined conclusively.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1384": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the efficacy and safety of HepaStem in patients with acute-on-chronic liver failure (ACLF) grades 1 or 2.\n\nTo determine eligibility, we need to check if the patient meets the inclusion criteria for the trial:\n\n1. Initial diagnostic of ACLF, at the investigational site, maximum 3 days before signature of the ICF.\n- The patient note does not mention ACLF, so this criterion is not met.\n\n2. Patient with Acute on Chronic Liver Failure Grade 1 or 2 according to the CLIF definition*.\n- Again, the patient note does not mention ACLF or its grading, so this criterion is not met.\n\n3. Bilirubin value \u22655 mg/dL.\n- The patient's bilirubin value is not provided, so this criterion cannot be assessed.\n\nSince the patient does not seem to have ACLF, which is the target condition for this trial, they would not be eligible for enrollment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1385": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Change in Body Weight During Treatment of Advanced Colorectal Cancer\", the patient does not appear to be eligible for this trial. The key reasons are:\n\n1. The patient is described as having abdominal pain, nausea, vomiting, and gallstones, which suggests a diagnosis of cholelithiasis (gallstone disease) rather than colorectal cancer.\n\n2. The inclusion criteria specifically mention \"Histologically proven adenocarcinoma of colorectal origin\" and \"Stage IV disease with systemic treatment\", but the patient note does not indicate any diagnosis or treatment related to colorectal cancer.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1386": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the relationship between post-ERCP choledocholithiasis (remaining CBD stones after ERCP) and gallbladder status.\n\n3. The inclusion criteria for the trial is: \"Routine ERCP for CBD stone patients with gallbladder in situ\"\n\n4. Based on the patient note, this patient has CBD stones and still has her gallbladder in place (\"gallbladder in situ\"). \n\n5. Therefore, this patient meets the inclusion criteria for the clinical trial.\n\n6. There is no information provided about exclusion criteria, so we cannot definitively rule out exclusion.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1387": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and symptoms suggestive of gallstones and cholecystitis.\n\nThe clinical trial is titled \"Risk Assessment After Acute Upper Gastrointestinal Haemorrhage in Cirrhosis\".\n\nLooking at the inclusion criteria:\n1) Patients with histologically proven cirrhosis or clinical and ultrasonographic data compatible with the diagnosis of cirrhosis\n- The patient note does not mention cirrhosis, so this criterion is not met.\n\n2) Above 18 years old patients\n- The patient is 54 years old, so this criterion is met.\n\n3) Clinical evidence of bleeding (hematemesis and/or melena) during the previous 24 hours\n- There is no mention of hematemesis (vomiting blood) or melena (black tarry stools indicating gastrointestinal bleeding) in the patient note, so this criterion is not met.\n\n4) Undergo the emergency endoscopy within 2 hours at admittance to emergency room or in the general ward from the initial evaluation\n- It is not specified if the patient underwent an emergency endoscopy within 2 hours, so this criterion cannot be evaluated.\n\n5) Who agree to participate in the study\n- There is no information about the patient's willingness to participate in the study.\n\nSince the patient does not have cirrhosis or evidence of acute upper gastrointestinal bleeding, which are key criteria for this trial, the patient would not be eligible.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1388": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is looking to perform endoscopic biopsies to detect Helicobacter pylori infection in patients undergoing upper GI endoscopy.\n\nThe inclusion criteria for the trial are:\n1. Older than 18 years (The patient is 54, so meets this criteria)\n2. Have a clinical file (Assumed the patient has a medical record)\n3. Medical indication for upper GI endoscopy and biopsy to detect H. pylori\n\nBased on the patient's symptoms of abdominal pain, nausea, vomiting and imaging findings of gallstones/biliary disease, she likely has a medical indication for an upper endoscopy. However, the main indication appears to be to evaluate her biliary disease rather than specifically to test for H. pylori infection.\n\nTherefore, while the patient meets some of the inclusion criteria, there is not sufficient information provided to determine if she fully meets the criteria of having a medical indication for endoscopy/biopsy specifically to detect H. pylori.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1389": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of hypercholesterolemia and 2 normal vaginal deliveries.\n\n2. Imaging revealed gallstones, biliary sludge, and common bile duct stones, with the smallest stone being 14mm.\n\n3. The clinical trial is looking at whether chronic gallbladder diseases increase the incidence of post-ERCP choledocholithiasis (PEC).\n\n4. The inclusion criteria for the trial is \"ERCP patients with gallbladder in situ\".\n\n5. Based on the patient note, this patient has gallstones and is undergoing ERCP, and her gallbladder is still present (in situ).\n\nTherefore, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1390": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This does not seem directly relevant to the inclusion criteria for the clinical trial, which is about painful diabetic peripheral neuropathy (PDPN) in patients with type 2 diabetes.\n\n2. There is no mention of the patient having type 2 diabetes or PDPN in the note.\n\n3. The inclusion criteria specifically require patients to have:\n   - Type 2 diabetes according to ADA criteria\n   - Diagnosis of PDPN caused by type 2 diabetes with DN4 score \u2265 4\n   - Average pain intensity of \u2265 40 mm on VAS in the last 24 hours\n\n4. Since there is no information provided about the patient meeting these key inclusion criteria, we cannot determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1391": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman, so she does not meet the age criteria of 12-18 years old for this pediatric clinical trial.\n\n2. The patient is presenting with symptoms of gallstones, biliary sludge, and CBD stones, which are not functional gastrointestinal disorders like chronic idiopathic nausea, functional abdominal pain, dyspepsia, or irritable bowel syndrome that are required for inclusion.\n\n3. There is no information provided about whether the patient is English-speaking or not.\n\nBased on the information given, this patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1392": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Efficacy of Low Dose Naltrexone in Psoriasis\" and is studying the use of naltrexone for treating psoriasis.\n\nThe inclusion criteria for the trial are:\n- Minimum age 13 years\n- Maximum age 60 years\n- Both males and females affected with mild, moderate, and severe psoriasis\n\nBased on the patient note, there is no mention of the patient having psoriasis. The note describes symptoms related to gallstones and biliary disease.\n\nTherefore, this patient does not meet the inclusion criteria for the psoriasis clinical trial studying naltrexone.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1393": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is a safety study of the drug SEA-TGT (SGN-TGT) in advanced cancer patients, including solid tumors and lymphomas.\n\n3. Looking at the inclusion criteria for the monotherapy parts (A and B):\n- The patient does not have a histologically or cytologically confirmed advanced or metastatic malignancy like the ones listed (NSCLC, gastric/GE junction carcinoma, etc.). She has gallstones/biliary disease.\n- She does not have lymphoma.\n- She does not meet the measurable disease criteria for solid tumors or lymphomas.\n\n4. Looking at the combination therapy inclusion criteria (Parts C and D):\n- The patient does not have NSCLC, HNSCC, cutaneous melanoma, or classical Hodgkin lymphoma, which are required for Parts C and D respectively.\n\n5. Based on the information provided, the patient does not meet any of the inclusion criteria for this clinical trial studying an investigational cancer drug.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1394": {
        "output": "To determine the patient's eligibility for the clinical trial \"Telemedicine Abdominal Exams & Imaging\", I will go through the inclusion criteria one by one:\n\n1. \"Patient presenting to the MGH Emergency Department with abdominal pain\"\nThe patient note states that the 54-year-old woman was \"admitted to the emergency department with abdominal pain that started 4 days ago with nausea and vomiting.\" This meets the inclusion criterion.\n\n2. \"English-speaking\"\nThe patient note does not explicitly state the patient's language, but since it is written in English, it is reasonable to assume that the patient is English-speaking. This inclusion criterion is likely met.\n\nSince both inclusion criteria are met based on the information provided in the patient note, this patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1395": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Noninvasive Brain Stimulation for Pain Relief\" and is investigating the use of transcranial magnetic stimulation (TMS) and transcranial focused ultrasound (FUS) for pain relief in healthy subjects, acute pain patients, and chronic pain patients.\n\n3. The inclusion criteria for the trial are:\n   - Healthy adults between 18 and 80 years of age.\n   - Chronic and acute pain patients: must have an MRI (for ultrasound targeting)\n\n4. Based on the information provided, the patient does not meet the inclusion criteria for this trial as:\n   - She is not a healthy adult, but rather an acute pain patient with gallstones and related complications.\n   - There is no mention of her having an MRI, which is required for acute/chronic pain patients in this trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1396": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting. The clinical trial is studying the use of chewing gum containing vitamin C to treat nausea and vomiting in pregnancy (emesis gravidarum).\n\n2. Looking at the inclusion criteria for the trial:\n- Age \u226518 years: The patient is 54, so meets this criteria.\n- Singleton pregnancy: There is no mention of the patient being pregnant in the note.\n- Signed information sheet: We don't have information about this.\n- Symptoms of nausea and/or vomiting in early pregnancy: The patient is experiencing nausea and vomiting, but it is not specified if this is related to pregnancy.\n- No pre-existing medication for nausea and vomiting: This is not mentioned in the note.\n\n3. Based on the information provided, the patient does not seem to meet the key inclusion criteria of being pregnant and experiencing nausea/vomiting related to pregnancy.\n\n4. Looking at the exclusion criteria, there is no mention of the patient having conditions like gastric band, bariatric surgery, diabetes, or being unable to consent.\n\n5. Overall, there is insufficient information to determine if the patient is eligible or not for this particular pregnancy-related clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1397": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations.\"\n\n3. The inclusion criteria for the trial state that patients must:\n- Be enrolled in a specific study (APEC14B1) and consented to eligibility screening\n- Be less than 22 years of age at enrollment\n- Be newly diagnosed with de novo acute myeloid leukemia (AML) according to WHO criteria, with or without extramedullary disease\n- Meet specific bone marrow blast percentage or genetic criteria for AML\n- For certain arms, have FLT3 mutations, not have congenital long QT syndrome or heart block, and agree to use contraception\n- For neuropsychological testing, be enrolled in certain arms, be 5 years or older, speak English/French/Spanish, have no neurodevelopmental disorders, and no visual/motor impairments\n\n4. Based on the patient note, this 54-year-old woman with gallstones does not appear to have AML or meet any of the other inclusion criteria for this clinical trial on AML therapies.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1398": {
        "output": "To determine the patient's eligibility for the clinical trial \"Scoring System in Acute Calculous Cholecystitis\", let's go through the inclusion criteria:\n\n1. Clinically and Radiologically diagnosed with acute cholecystitis\nThe patient note mentions that the ultrasound revealed gallstones, biliary sludge, and CBD stones, which is consistent with a diagnosis of acute cholecystitis. Additionally, the patient's symptoms (abdominal pain, nausea, vomiting, fever) and physical examination findings (epigastric tenderness, right upper quadrant tenderness) are also indicative of acute cholecystitis.\n\n2. be over 18 years old\nThe patient note states that the patient is a 54-year-old woman, which meets the age requirement.\n\nSince the patient meets both inclusion criteria based on the information provided in the patient note, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1399": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Management and Evolution of Acute Diverticulitis With Pericolic Free Gas\".\n\nLooking at the inclusion criteria for the trial:\n1. Patients over 18 years old - The patient is 54 years old, so this criterion is met.\n2. Informed consent - There is no information about informed consent being provided.\n3. Diagnosed of acute diverticulitis - The patient is diagnosed with gallstones and CBD stones, not diverticulitis.\n4. CT scan reported as 1-2 pericolic bubbles with or without free fluid - There is no mention of pericolic bubbles or free fluid in the patient note.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial as they do not have a diagnosis of acute diverticulitis or the specific CT scan findings required.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1400": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers). The ultrasound confirmed the presence of gallstones and bile duct stones.\n\nThe clinical trial is studying the effects of preoperative endoscopic treatment with antibiotics (fosfomycin and metronidazole) in patients with right-sided colon cancer or right-sided colon adenomas.\n\nLooking at the inclusion criteria:\n1. Age \u2265 18 years - The patient is 54 years old, so this criterion is met.\n2. Right-sided colon cancer or right-sided adenoma \u2265 2 cm - The patient does not have colon cancer or adenoma. She has gallstones and cholecystitis.\n3. Scheduled for surgery/endoscopic mucosal resection - There is no mention of the patient being scheduled for these procedures for colon cancer/adenoma.\n\nSince the patient does not have right-sided colon cancer or a right-sided colon adenoma \u2265 2 cm, and is not scheduled for the respective procedures, she does not meet the key inclusion criteria for this clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1401": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of acute cholecystitis (abdominal pain, nausea, vomiting, fever). The imaging shows gallstones, biliary sludge and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1) Patients with mild acute cholecystitis (grade I) or moderate acute cholecystitis without evidence of gallbladder perforation (grade II)\n2) Cholecystitis with gallbladder wall thickness \u2265 4mm on preoperative imaging\n3) Inflammation of gallbladder and surrounding organs\n4) Age between 19-70 years\n\nBased on the patient note, the patient meets criteria 1, 2, 3 and 4. There is no mention of gallbladder perforation, the gallbladder wall is likely thickened given the acute cholecystitis, and there are signs of surrounding inflammation. The patient's age of 54 years falls within the accepted range.\n\nTherefore, this patient appears eligible for the clinical trial studying empirical antibiotics in acute inflammatory gallbladder disease.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1402": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Expedited Versus Restrictive: Limitations on Activity Following Surgical Treatment of Prolapse\". It is studying postoperative activity levels after prolapse surgery.\n\n3. The inclusion criteria for the trial are:\n- Stage II-IV pelvic organ prolapse\n- Bothersome bulge symptoms  \n- At least 725 MET-minutes/week on International Physical Activity Questionnaire Short Form\n- English-speaking\n- Undergoing treatment of prolapse\n- Surgery occurring at least 7 days from date of randomization\n- Able and willing to follow up at 3 months for in-office exam\n\n4. Based on the patient note, there is no mention of the patient having pelvic organ prolapse or undergoing prolapse surgery. The patient seems to be presenting with gallbladder/biliary issues.\n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial on postoperative activity after prolapse surgery.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1403": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and biliary sludge on ultrasound).\n\n2. The clinical trial is comparing the quality of recovery using two different drugs (sugammadex vs neostigmine) for reversing neuromuscular blockade in patients undergoing laparoscopic cholecystectomy.\n\n3. The inclusion criteria for the trial are patients aged 20-70 undergoing laparoscopic cholecystectomy.\n\n4. Based on the patient note, this 54-year-old woman is a potential candidate for laparoscopic cholecystectomy due to her gallstone disease.\n\n5. Her age of 54 falls within the 20-70 year age range specified in the inclusion criteria.\n\nTherefore, based on the information provided, this patient meets the inclusion criteria for the clinical trial comparing sugammadex vs neostigmine in laparoscopic cholecystectomy patients.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1404": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 54-year-old obese woman\n- Admitted to ER with abdominal pain, nausea, vomiting for 4 days\n- Pain worsens after eating fatty foods\n- Past history of similar pain twice in the past year\n- Medical history of hypercholesterolemia and 2 normal vaginal deliveries\n- No smoking, alcohol, or illicit drug use\n- Mild fever, elevated BP, tachycardia\n- Epigastric and right upper quadrant tenderness on exam\n- Leukocytosis with left shift\n- Ultrasound showed gallstones, biliary sludge, CBD stones with smallest stone 14mm\n\nThe inclusion criteria for the trial are:\n1) 19 years old to under 75 (Patient is 54, meets this criteria)\n2) Patients with dyspepsia in patients with cholelithiasis (Patient has abdominal pain, nausea, vomiting consistent with dyspepsia and gallstones seen on ultrasound, meets this criteria)\n3) Patients who consented to this study and conducted questionnaires and tests during follow up (Cannot assess this from the patient note)\n\nBased on the available information, this patient meets the age and diagnosis inclusion criteria for the clinical trial of comparing motilitone and gasmotin for symptom relief in gallstone patients with functional dyspepsia.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1405": {
        "output": "To determine the patient's eligibility for the clinical trial \"Continuous Alcohol Monitoring for Pancreatitis\", let's go through the inclusion criteria one by one:\n\n1. Aged 18-75 years at the time of eligibility assessment\nThe patient's age is given as 54 years old, which falls within the required age range.\n\n2. History of at least one AP per Revised Atlanta Classification (20) within past 3 years from screening, which requires two of the following evidence of pancreatitis:\n   a) Abdominal pain consistent with AP (acute onset of a persistent, severe, epigastric pain often radiating to the back)\n   The patient is described as having abdominal pain that started 4 days ago with nausea and vomiting. The epigastric pain radiates to the right upper quadrant, which is consistent with pancreatitis.\n   b) Serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal\n   No information is provided about the patient's serum lipase or amylase levels.\n   c) Characteristic findings of AP on contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI) or transabdominal ultrasonography\n   The ultrasound revealed several gallstones, biliary sludge, and CBD stones, which are characteristic findings of acute pancreatitis.\n\n3. Access to a mobile or portable device that has the capability to sync to the BACtrack sensor and internet connection for syncing purposes.\nNo information is provided about the patient's access to a mobile or portable device.\n\nBased on the available information, the patient meets two out of the three criteria for evidence of pancreatitis (abdominal pain and ultrasound findings). However, there is no information about the patient's access to a mobile or portable device for syncing with the BACtrack sensor.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "1406": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the effects of melatonin supplementation in postmenopausal women with H. pylori-associated dyspepsia.\n\nThe inclusion criteria for the trial are:\n1) Epigastric pain of a hunger nature\n2) Pain at night in the epigastric region \n3) Increased appetite\n\nBased on the patient note, there is no mention of H. pylori infection or dyspepsia symptoms like epigastric hunger pain or increased appetite. The patient's symptoms seem to be related to gallstones and cholecystitis.\n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1407": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is evaluating the use of an erector spinae plane block for postoperative analgesia in laparoscopic sleeve gastrectomy.\n\n3. The inclusion criteria for the trial are:\n   - Patients aged between 18 and 65 years\n   - Scheduled to undergo any upper GI laparoscopy surgeries with an ASA score of 1 or 2\n   - Surgeries included are laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic umbilical or epigastric hernia repair\n   - Written informed consent for general anesthesia and all procedures\n\n4. Based on the information provided, the patient meets the age criteria (54 years old) and is scheduled for a laparoscopic cholecystectomy, which is one of the included surgeries.\n\n5. However, there is no information provided about the patient's ASA score or whether they have provided written informed consent.\n\nTherefore, based on the available information:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1408": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, here is my assessment:\n\nThe patient note describes a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones and bile duct stones. The patient's condition appears to be related to gallbladder disease and does not mention any terminal illness or hospice admission.\n\nThe clinical trial titled \"Is Acupuncture Able to Reduce Nausea and Vomiting in the Terminal Ill Patient\" has the following inclusion criteria:\n1. Able to participate due to cognitive ability\n2. Nausea\n3. Admitted to in-bed hospice\n\nWhile the patient in the note experiences nausea, there is no information provided about her cognitive ability or admission to an in-bed hospice for terminal illness.\n\nTherefore, based on the available information, the patient does not meet all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1409": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct stones.\n\nThe clinical trial is titled \"Advanced Endoscopy During COVID-19\" and aims to explore the status of advanced endoscopy procedures like ERCP (endoscopic retrograde cholangiopancreatography) and EUS (endoscopic ultrasound) during the COVID-19 pandemic.\n\nThe inclusion criteria state: \"Patients referred for ERCP or EUS during the study period\"\n\nGiven that the patient has gallstones and common bile duct stones, she would likely be referred for an ERCP procedure to remove the stones.\n\nTherefore, based on the information provided, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1410": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct stones.\n\n2. The clinical trial is for treating pancreatic cancer patients with a specific BRAF V600E mutation using the drugs binimetinib and encorafenib.\n\n3. Based on the patient note, there is no mention of the patient having pancreatic cancer or the BRAF V600E mutation. The symptoms and findings point towards biliary colic/cholecystitis due to gallstones.\n\n4. Therefore, this patient does not meet the key inclusion criteria for this pancreatic cancer trial targeting the BRAF mutation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1411": {
        "output": "To determine the patient's eligibility for the clinical trial \"High Dose IV Lidocaine vs Hydromorphone for Abdominal Pain in the Emergency Department\", let's go through the inclusion criteria one by one:\n\n1. Must be a patient in the emergency department (ED)\nThe patient note states that the patient was \"admitted to the emergency department\", so this criterion is met.\n\n2. Must have acute abdominal pain, defined as abdominal or flank pain of a duration of 7 days or less\nThe patient note mentions that the patient had \"abdominal pain that started 4 days ago\", which falls within the 7-day duration specified in the inclusion criteria.\n\n3. Predicted treatment must include the use of an intravenous opiate\nThere is no explicit mention of the predicted treatment or the use of intravenous opiates in the patient note.\n\nBased on the information provided, the patient meets the first two inclusion criteria, but there is not enough information to determine if the third criterion is met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1412": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a Phase 1 study investigating the tolerability, safety, and pharmacokinetics of Anfibatide (an antiplatelet drug) in healthy volunteers.\n\n3. The inclusion criteria for the trial specify:\n   - Healthy male or female subjects between 18-40 years old\n   - BMI between 19-24\n   - No history of heart, liver, kidney, digestive tract, nervous system, metabolic, ulcer, obvious bleeding, drug allergy, or postural hypotension\n   - Healthy based on medical tests (physical exam, vitals, labs, etc.)\n   - Not taking any medications for the past 2 weeks\n   - Willing to use contraception during the study period\n\n4. Based on the patient note, this 54-year-old woman with gallstone disease and obesity does not meet the inclusion criteria for this healthy volunteer study.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1413": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of acute calcular cholecystitis (ACC) - abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, and gallstones/biliary sludge/CBD stones on ultrasound.\n\nThe clinical trial is studying the timing of early laparoscopic cholecystectomy in patients with ACC.\n\nThe key inclusion criterion is \"ACC patients who underwent early LC\".\n\nBased on the patient note, this patient appears to meet that criterion as she has been diagnosed with ACC and would likely undergo early laparoscopic cholecystectomy.\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1414": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is looking to develop a model to predict choledocholithiasis (presence of gallstones in the common bile duct) using patient characteristics.\n\nThe inclusion criteria for the trial are:\n1) Patients above 18 years old\n2) Clinical suspicion of choledocholithiasis based on biliary-type pain, abnormal liver tests indicating a cholestatic pattern, biliary pancreatitis, or dilated common bile duct.\n\nBased on the patient note, the patient meets both inclusion criteria:\n1) The patient is 54 years old, above 18.\n2) The patient has abdominal pain radiating to the right upper quadrant (biliary pain), abnormal liver tests (leukocytosis with left shift), and imaging showing CBD stones, indicating choledocholithiasis.\n\nTherefore, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1415": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is a phase 1a study investigating the safety and anti-coronavirus response of a drug called brequinar in patients with COVID-19.\n\n3. Looking at the inclusion criteria for the trial:\n- The patient must be willing and able to provide informed consent (no information provided)\n- The patient must be 18 years or older (the patient is 54, so meets this criteria)\n- The patient must be willing to follow up if discharged before study day 15 (no information provided)\n- The patient must have a laboratory-confirmed SARS-CoV-2 infection (the note does not mention COVID-19 or SARS-CoV-2 infection)\n- The patient must be hospitalized (the note states the patient was admitted to the emergency department, so likely hospitalized)\n- The patient must agree to use contraception if of child-bearing potential (no information provided)\n- The patient must have COVID-19 symptoms within 10 days (no COVID-19 symptoms mentioned)\n- The patient must be able to swallow capsules (no information provided)\n- The patient must have at least one COVID-19 symptom (no COVID-19 symptoms mentioned)\n\n4. Based on the information provided in the patient note, there is insufficient evidence that the patient meets the key inclusion criteria of having a confirmed COVID-19 infection and associated symptoms.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1416": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Patients with active CSU for at least 4 months which was treated with anti-histamines as well as at least one course of steroids (ex. Prednisone)\"\nThe patient note does not mention chronic spontaneous urticaria (CSU) or any treatment with anti-histamines or steroids for this condition. This criterion is not met.\n\n2. \"Age \u226518 years\" \nThe patient is 54 years old, so this criterion is met.\n\n3. \"Patients will undergo an ECG and QT parameters will be measured for further analysis.\"\nThere is no information about ECG or QT parameters in the patient note.\n\n4. \"Female subjects who are postmenopausal (absence of menses for \u2265 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled.\"\nThe patient is a 54-year-old woman who is menopausal, so this criterion is met.\n\n5. \"Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled.\"\nThere is no information about breastfeeding in the patient note, but since the patient is menopausal, it can be assumed that she is not breastfeeding.\n\n6. \"Subject able to provide written informed consent\"\nThere is no information about the patient's ability to provide informed consent.\n\nOverall, the patient does not meet the key inclusion criterion of having chronic spontaneous urticaria and being treated with anti-histamines and steroids. There is also insufficient information about ECG/QT parameters and ability to provide informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1417": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Postprandial Glucose, Insulin Responses and Appetite Hormones to Dried Mushrooms\" and is studying the effects of dried mushrooms on postprandial glucose, insulin, and appetite hormones in people with metabolic syndrome.\n\n3. The inclusion criteria for the trial are:\n   - Age between 18 and 75 years\n   - BMI > 25 kg/m2\n   - Metabolic syndrome\n\n4. Based on the patient note, the patient is 54 years old and obese (BMI > 25 kg/m2). However, there is no mention of the patient having metabolic syndrome.\n\n5. Since the patient does not meet all the inclusion criteria (specifically, the metabolic syndrome criterion), there is not enough information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1418": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Low-dose Naltrexone for Bladder Pain Syndrome\" and is studying the use of low-dose naltrexone for treating interstitial cystitis/bladder pain syndrome (IC/BPS).\n\n3. The inclusion criteria for the trial are:\n   - Men and women with non-Hunner and Hunner lesion disease\n   - Meeting AUA definition of BPS: pelvic/bladder pain and lower urinary tract symptoms for >6 weeks with no identifiable cause\n   - Stable treatment for 1 month\n   - Pain scores \u22654/10, urinary frequency \u22658 while awake, nocturia \u22652, BPIC-SS \u226519\n   - Agreement to not take opioids during the trial\n\n4. Based on the patient note, there is no mention of the patient having interstitial cystitis/bladder pain syndrome or meeting the AUA definition of BPS. The patient's symptoms appear to be related to gallstones and biliary disease.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1419": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct (CBD) stone measuring 14mm.\n\n2. The clinical trial is evaluating a disposable endoscope system for the evaluation of bile duct stones or neoplasms.\n\n3. The inclusion criteria for the trial are:\n   - Patients with complicated bile duct stones (stone size > 1.5 cm or number of stones > 3)\n   - Patients with indeterminate biliary stricture or obstruction\n\n4. In this case, the patient has a 14mm CBD stone, which meets the inclusion criteria of \"stone size > 1.5 cm\".\n\n5. There is no information provided about biliary stricture or obstruction, but that is not required since the patient meets the first inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1420": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Abdominal Massage to Prevent Postoperative Ileus After Colorectal Surgery\".\n\nLooking at the inclusion criteria:\n1. Adult patients >18 years - The patient is 54 years old, so she meets this criterion.\n2. Elective Patients undergoing colorectal surgery with intestinal anastomosis - The patient note does not mention any planned colorectal surgery, so this criterion is not met.\n3. Able to give consent - There is no information about the patient's ability to provide consent.\n4. Affiliated to Social Security - There is no information about the patient's social security affiliation.\n\nSince the patient does not appear to be undergoing a colorectal surgery, which is a key inclusion criterion for this trial, she would not be eligible.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1421": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion criteria:\n- More than 18 years old: The patient is 54 years old, so this criterion is met.\n- Between 2007 and 2019: The note doesn't specify the year, but let's assume it falls within this range.\n- Montpellier University Hospital: The note doesn't mention the hospital, so we can't confirm this criterion.\n- Laparoscopic cholecystectomy for symptomatic cholelithiasis associated with common bile duct stones: The patient has gallstones, biliary sludge, and CBD stones, so this criterion is likely met.\n- Common bile duct stones highlighted on preoperative imaging or intraoperative cholangiography: The ultrasound revealed CBD stones, so this criterion is met.\n- Common bile duct stones treated during the same hospital stay surgically or endoscopically: The note doesn't mention if the stones were treated, so we can't confirm this criterion.\n\nExclusion criteria:\n- Laparotomy: The note doesn't mention a laparotomy, so this criterion is likely not met.\n- Previous ERCP: The note doesn't mention a previous ERCP, so this criterion is likely not met.\n- Less than 18 years old: The patient is 54 years old, so this criterion is not met.\n- Lost to follow up: The note doesn't mention any follow-up, so we can't confirm this criterion.\n- Lack of data > 10%: The note seems to provide sufficient data, so this criterion is likely not met.\n- Other surgical procedure associated at the same time: The note doesn't mention any other procedures, so this criterion is likely not met.\n- Previous cholecystectomy: The note doesn't mention a previous cholecystectomy, so this criterion is likely not met.\n- Caroli's disease: The note doesn't mention Caroli's disease, so this criterion is likely not met.\n- Severe cholangitis or acute pancreatitis: The note doesn't mention cholangitis or pancreatitis, so this criterion is likely not met.\n- Pigmentary or hydatic lithiasis: The note mentions gallstones and CBD stones, but not pigmentary or hydatic lithiasis, so this criterion is likely not met.\n- Laparoscopic cholecystectomy for other indication than symptomatic cholelithiasis: The note mentions the cholecystectomy is for symptomatic cholelithiasis, so this criterion is likely not met.\n\nBased on the information provided in the patient note, it seems that some of the inclusion criteria are met, and none of the exclusion criteria are clearly met. However, there are a few criteria that cannot be confirmed due to lack of information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1422": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is titled \"Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty.\"\n\nLooking at the inclusion criteria:\n1. Provision of signed and dated informed consent form (Unable to assess from note)\n2. Stated willingness to comply with all study procedures and availability for the duration of the study (Unable to assess from note)\n3. Male or female, age 18-80 (Patient is 54 years old, meets this criteria)\n4. Undergoing primary unilateral TKA for primary osteoarthritis (Patient is not undergoing a knee arthroplasty, does not meet this criteria)\n5. English speaking (Assuming patient is English speaking based on note)\n6. Patients whose primary residence is in a home and not a facility or rehabilitation center. (Unable to assess from note)\n\nSince the patient is not undergoing a knee arthroplasty, which is a key inclusion criteria for this trial, the patient would not be eligible.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1423": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and common bile duct (CBD) stones.\n\nThe clinical trial is studying early versus delayed laparoscopic cholecystectomy following ERCP (endoscopic retrograde cholangiopancreatography) in patients with concomitant gallstones and CBD stones.\n\nThe inclusion criteria for the trial are:\n\"patients who underwent laparoscopic cholecystectomy after clearance of CBDs by ERCP\"\n\nBased on the patient note, this patient has gallstones and CBD stones, and will likely undergo ERCP to clear the CBD stones, followed by a laparoscopic cholecystectomy.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1424": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge and CBD stones.\n\n2. The clinical trial titled \"Suloexide in the Treatment of Early Stages of COVID-19\" is studying the use of sulodexide in patients with early COVID-19 symptoms to potentially mitigate disease progression.\n\n3. The inclusion criteria for the trial are:\n   - 3 days or less with clinical COVID-19 symptoms (fever, cough, sore throat, headache, body ache, anosmia, diarrhea, vomiting)\n   - Sign informed consent\n   - >50% risk of developing severe COVID-19 according to a risk calculator\n\n4. Based on the patient note, there is no mention of the patient having COVID-19 symptoms or being at risk for severe COVID-19. The presenting symptoms appear to be related to gallbladder disease.\n\nTherefore, based on the information provided:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1425": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones based on ultrasound findings.\n\n2. The clinical trial is studying the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL).\n\n3. Based on the inclusion criteria, the key requirements are:\n- Age between 1 and 30 years\n- First relapse of CD19+ B-ALL\n- Specific performance status criteria\n- No prior hematopoietic stem cell transplant\n- Meeting certain renal function and cardiac function criteria\n\n4. The patient note does not mention anything about B-ALL or relapsed leukemia. The patient appears to be presenting with symptoms related to gallstones and cholecystitis.\n\n5. Therefore, based on the information provided, this patient does not meet the inclusion criteria for the specified clinical trial on relapsed B-ALL.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1426": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the effectiveness of mirtazapine versus dexamethasone in preventing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.\n\nThe inclusion criteria for the trial are:\n1. ASA physical status I or II\n2. Body weight 60-100 kg\n3. Scheduled for laparoscopic cholecystectomy under general anesthesia\n\nBased on the patient note, the patient meets criteria 2 and 3 as she is obese (implying weight over 60 kg) and is likely scheduled for a laparoscopic cholecystectomy given her gallstone disease.\n\nHowever, there is no information provided about her ASA physical status, which assesses operative risk. As an obese patient with gallstone disease, she may not meet the ASA I or II criteria.\n\nTherefore, there is insufficient information to definitively determine eligibility. More details about her overall health status and operative risk would be needed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1427": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone of 14mm.\n\nThe clinical trial is studying the use of an intraintestinal extended biliary stent to prevent duodenobiliary reflux and stent occlusion in patients with malignant or benign extrahepatic biliary strictures requiring biliary stent placement.\n\nThe inclusion criteria state:\n\"Malignant or benign extrahepatic biliary stricture, available for insertion of biliary stents in ERCP to alleviate biliary stricture\"\n\nBased on the patient note, this patient has gallstones, biliary sludge, and a common bile duct stone causing biliary obstruction. She would likely require ERCP with biliary stent placement to relieve the obstruction.\n\nTherefore, this patient meets the inclusion criteria for the clinical trial studying the intraintestinal extended biliary stent.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1428": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever, elevated inflammatory markers, gallstones and biliary sludge on ultrasound).\n\n2. The clinical trial is studying the effectiveness and safety of an LED light source system for endoscopes.\n\n3. The inclusion criteria for the trial are:\n   - Subjects who should receive laparoscopic cholecystectomy on a selected day\n   - Symptoms of gallstone, cholecystitis, or gallbladder polyp \u22650.8 cm\n   - Age between 18 and 75\n   - Voluntarily participate and sign informed consent\n\n4. Based on the patient note, this 54-year-old woman meets the inclusion criteria of having symptoms of gallstones/cholecystitis and being a candidate for laparoscopic cholecystectomy. Her age of 54 falls within the 18-75 range.\n\n5. There is no information provided about whether she has voluntarily agreed to participate or signed an informed consent, but we can assume this would be obtained if she was enrolled.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1429": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair\". It aims to study the effectiveness of oral antibiotics in preventing infection and improper healing in women who suffer severe vaginal lacerations during childbirth.\n\n3. The inclusion criteria for the trial are:\n   - 18 years old and older\n   - 3rd or 4th degree laceration upon delivering vaginally at Prentice Women's Hospital\n   - English-speaking\n   - Administered Ancef during wound repair\n   - First Delivery\n   - Single child being born\n   - Term Delivery (i.e. at least 37 weeks gestation)\n\n4. Based on the patient note and the inclusion criteria, this patient does not meet the criteria for the clinical trial as she is not presenting with a severe perineal laceration following childbirth.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1430": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Clinical Pathways and Patients' Attitudes in Acute Low Back Pain\".\n\n3. The inclusion criteria for the trial are:\n   - Men and women\n   - Aged between 18 and 65 years old\n   - Living in France\n   - Have ever had an acute low back pain\n   - Accepting to participate in the study\n\n4. The patient note does not mention anything about low back pain or the patient's location.\n\n5. Based on the information provided in the patient note, there is not sufficient evidence to determine if the patient meets the inclusion criteria for this clinical trial on acute low back pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1431": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial titled \"Effects of Transcranial Direct Current Stimulation on Pain Control in Chronic Painful Total Knee Arthroplasty\" has the following inclusion criteria:\n\n1. Signed informed consent\n2. Able to independently walk (with or without walk aids)\n3. Chronic painful total knee arthroplasty (more than 3 months)\n4. Visual Analogic Scale for pain more than 3/10\n5. No cognitive impairments (MMSE>24 or =24/30)\n\nBased on the patient note, there is no mention of the patient having a total knee arthroplasty or chronic knee pain. The note focuses on abdominal pain and gallstones.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1432": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and symptoms suggestive of gallstones and cholecystitis.\n\nThe clinical trial is titled \"SEMS and Gastroenterostomy\" and is studying quality of life in patients with stage IV gastric cancer and gastric outlet obstruction syndrome (GOOS) who undergo either self-expandable metal stent (SEMS) placement or stomach-partitioning gastrojejunostomy (SPGJ) surgery.\n\nThe inclusion criteria for the trial are:\n1) Age less than 85 years\n2) Pre-treatment histological diagnosis of gastric adenocarcinoma\n3) Computed tomographic (CT) evidence of gastric cancer\n4) Received adjuvant/neoadjuvant chemotherapy\n5) Symptoms of GOOS\n6) 70-99% luminal reduction on gastroscopy\n\nThe patient note does not mention a diagnosis of gastric cancer or GOOS. The symptoms and findings are consistent with gallstone disease/cholecystitis.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial studying interventions for gastric cancer patients with GOOS.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1433": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a 14mm common bile duct stone.\n\nThe clinical trial is studying a magnetically controlled capsule endoscopy compared to conventional upper endoscopy for diagnosing patients with upper abdominal symptoms.\n\nThe inclusion criteria are:\n1) Patient is able to provide informed consent\n2) Patient has appropriate indications for upper endoscopy including symptoms of upper abdominal pain, acid reflux, heartburn, iron deficiency anemia, weight loss, bloating, belching, nausea, vomiting and atypical chest pain.\n\nThis patient meets both inclusion criteria:\n1) No information provided to suggest she cannot provide informed consent\n2) She has upper abdominal pain, nausea, and vomiting which are indications for upper endoscopy\n\nNo exclusion criteria are provided, so based on the information given, this patient would be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1434": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease\", the patient does not appear to have coronary heart disease verified by coronary angiography. The patient note describes symptoms and findings related to gallstones and biliary disease, but there is no mention of coronary artery disease or a coronary angiography being performed.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1435": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones. This does not appear to be a case of diffuse large B-cell lymphoma (DLBCL).\n\nLooking at the inclusion criteria for the clinical trial:\n1. Age \u226518 years - The patient is 54 years old, so this criterion is met.\n2. Pathologically confirmed relapsed/refractory DLBCL - The patient does not have DLBCL based on the note. This is a key criterion that is not met.\n3. Prior lines of systemic therapy for DLBCL - Not applicable since the patient does not have DLBCL.\n4. PET positive measurable disease - Not applicable.\n5. Adequate bone marrow, liver, and kidney function - No information provided.\n6. ECOG performance status \u22642 - No information provided.\n7. Estimated life expectancy >6 months - No information provided, but likely met given her age and condition.\n8. Primary refractory disease allowed - Not applicable.\n9. Contraception requirements - Not applicable.\n10. Negative pregnancy test for females of childbearing potential - Not applicable.\n11. Hepatitis B, C, and HIV status requirements - No information provided.\n\nSince the patient does not have DLBCL, which is a key inclusion criterion, she would not be eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1436": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, fever, and gallstones/biliary sludge/CBD stones found on ultrasound. There is no mention of headaches or any neurological symptoms.\n\nThe clinical trial is studying different treatment approaches for tension-type headaches. The inclusion criteria specify that patients must:\n1) Be between 18-65 years old\n2) Report having frequent episodic tension-type headaches or chronic tension-type headaches as defined by specific criteria related to headache frequency, duration, location, quality, intensity, and associated symptoms.\n\nSince the patient note does not mention the patient having any type of headache disorder, there is insufficient information to determine if they would meet the inclusion criteria for this particular clinical trial on tension-type headaches.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1437": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Magnesium Oral Supplementation for Acute Non-specific Low Back Pain\", the patient does not seem to be eligible for this trial.\n\nThe key points are:\n\n1. The patient is presenting with abdominal pain, nausea, and vomiting, which is likely related to gallstones and biliary sludge, as indicated by the ultrasound findings.\n2. There is no mention of low back pain or any musculoskeletal complaints in the patient note.\n\nThe inclusion criteria for the trial specifically require:\n1. Patients aged > 18 years old (the patient is 54 years old, so this criterion is met)\n2. Initiation of acute low back pain in the 10 days prior to study entry\n3. Functionally impairing low back pain, defined as a score of > 5 on the Roland-Morris Disability Questionnaire (RMDQ)\n\nSince the patient note does not mention any low back pain or functional impairment related to low back pain, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1438": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"E-health for Self-Management of Chronic Pain\" and aims to validate a digital tool for self-management of chronic pain.\n\n3. The inclusion criteria for the trial are:\n   - Have complex, prolonged axial neck pain or lower back pain\n   - Have been followed by a pain management specialist for at least 3 months or have a history of chronic pain for at least 3 months\n   - Be >18 years of age\n   - Have adequate goal and motivation for the program\n   - Be medically prepared\n   - Have no major change in interventional treatment or be a surgical candidate\n   - Own or have knowledge to use a smart device\n\n4. Based on the patient note, there is no mention of chronic neck or back pain. The patient's primary complaint is related to gallstones and biliary issues.\n\n5. Therefore, the patient does not meet the inclusion criteria for this clinical trial on chronic pain management.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1439": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial, the patient does not seem to be eligible for the trial. Here's my analysis:\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever, who was diagnosed with gallstones, biliary sludge, and CBD stones.\n\nThe inclusion criteria for the clinical trial are:\n1. Medically free children who will be able and cooperative in all steps of the study.\n2. Asymptomatic primary molars with a deep carious lesion.\n3. Vital pulp due to dental caries with no clinical sign of pulpal degeneration.\n4. Preliminary radiographs indicating absence of pathologic internal or external root resorption, or any evidence of inter-radicular bone destruction.\n5. Absence of pre-operative pain or they will only have a short-term pain.\n6. No tenderness to percussion.\n7. Age ranging 4-6 years.\n\nThe patient in the note is an adult woman, while the trial is looking for children aged 4-6 years old. Additionally, the patient's condition is related to gallstones and abdominal pain, which does not match the inclusion criteria related to dental caries and primary molars.\n\nTherefore, based on the information provided, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1440": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of gallstones (abdominal pain, nausea, vomiting, fever) and imaging findings confirming gallstones and biliary sludge.\n\n2. The clinical trial is about evaluating the effectiveness of video editing training for novice trainees performing laparoscopic cholecystectomy (gallbladder removal surgery). \n\n3. The inclusion criteria for the trial are:\n- Trainees in general surgery\n- No experience with laparoscopic cholecystectomy \n- Less than 5 experiences of laparoscopic surgery\n- Uncomplicated symptomatic gallstone disease\n\n4. This patient does not meet the inclusion criteria, as she is not a trainee surgeon. She is a patient with symptomatic gallstone disease requiring surgery.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1441": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with symptoms of acute cholecystitis (abdominal pain, nausea, vomiting, fever). The ultrasound findings of gallstones, biliary sludge and CBD stones confirm the diagnosis.\n\nThe inclusion criteria for the clinical trial are:\n1) Patients with mild acute cholecystitis (grade I by Tokyo guidelines) or moderate acute cholecystitis without evidence of gallbladder perforation (grade II)\n2) Cholecystitis with gallbladder wall thickness \u2265 4mm on preoperative imaging\n3) Inflammation of gallbladder and surrounding organs\n4) Age between 19-70 years\n\nBased on the patient note, the following criteria are met:\n- The patient likely has moderate acute cholecystitis without gallbladder perforation (grade II) given the symptoms and ultrasound findings.\n- The gallbladder wall thickness is not mentioned but can be assumed to be \u22654mm given the acute inflammation.\n- There is inflammation of the gallbladder and surrounding organs (right upper quadrant tenderness).\n- The patient's age of 54 years falls within the 19-70 year range.\n\nTherefore, this patient appears to meet all the listed inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1442": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae\", the patient does not seem to be eligible for this trial.\n\nThe patient note describes a 54-year-old obese woman with abdominal pain, nausea, vomiting, and fever, who was diagnosed with gallstones, biliary sludge, and CBD stones. There is no mention of a urinary tract infection (UTI) or the presence of ESBL-producing Enterobacteriaceae in the patient's urine culture.\n\nThe inclusion criteria for the clinical trial specifically require:\n\n1. Adults (which the patient meets)\n2. Diagnosis of UTI defined by at least two specific symptoms (not present in the patient note)\n3. Positive urine culture with \u2265 103 CFU/mL of a single strain of ESBL-E (not mentioned in the patient note)\n4. Confirmed ESBL-producing Enterobacteriaceae (ESBL-E) susceptible to carbapenems (not mentioned in the patient note)\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria related to UTI and ESBL-producing Enterobacteriaceae, the patient cannot be considered eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1443": {
        "output": "Based on the patient note provided, the patient is a 54-year-old obese woman who presented with symptoms suggestive of gallstone disease, including abdominal pain, nausea, vomiting, and an ultrasound showing gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial titled \"Major Surgery as a Risk of Gall Stone Disease?\" is investigating whether major surgery is a risk factor for developing gallstone disease.\n\nConsidering the inclusion criteria of the trial, which states \"Must be above 18 years of age,\" the patient meets this criterion as she is 54 years old.\n\nTherefore, based on the available information, the patient appears to be eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1444": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days.\n2. The clinical trial is titled \"Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide.\"\n3. The inclusion criteria for the trial are: \"Patients with watery stools starting in the last 2 weeks and 3 times in 24 hours and abdominal pain.\"\n\nBased on the patient note, there is no mention of the patient having watery stools or gastroenteritis. The patient's symptoms seem to be related to gallstones and biliary sludge, as evidenced by the ultrasound findings.\n\nTherefore, this patient does not meet the inclusion criteria for the clinical trial on managing abdominal pain in acute gastroenteritis patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1445": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. She has a history of gallstones and the ultrasound revealed gallstones and bile duct stones.\n\n2. The clinical trial is titled \"Evaluation of Pressure Algometry in the Clinical Assessment of Acute Abdominal Pain in Children\" and the inclusion criteria states \"all children referred with abdominal pain from January 2000 to June 2006 to one surgeon on the pediatric general surgery service at the Health Sciences Centre (HSC)-Children's Hospital in Winnipeg.\"\n\n3. Based on the inclusion criteria, this patient does not qualify for the trial as she is an adult and the trial is specifically looking at children referred to a particular hospital during a specific time period.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1446": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is studying the benefit of eradicating Helicobacter Pylori in patients with functional dyspepsia.\n\n3. The inclusion criteria for the trial are:\n   - Age > 18 years\n   - Patients fulfilling the ROME-IV criteria of Functional Dyspepsia\n   - Signed informed consent\n\n4. Based on the patient note, this patient does not seem to have functional dyspepsia. Instead, she has symptoms and imaging findings consistent with cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder).\n\n5. Therefore, this patient does not meet the inclusion criteria for this clinical trial on functional dyspepsia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1447": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)\" and assess the eligibility of the patient based on the provided note.\n\nThe inclusion criteria are:\n\n1. Covid-19 positive by polymerase chain reaction (PCR) testing;\n- The patient note does not mention if the patient has tested positive for COVID-19, so this criterion cannot be evaluated.\n\n2. Participant must be able to evaluate their symptoms and report them in the symptoms diary;\n- The patient note does not provide information about the patient's ability to evaluate and report symptoms, so this criterion cannot be evaluated.\n\n3. Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials;\n- The patient note does not mention if the patient is capable of taking their oral temperature daily, so this criterion cannot be evaluated.\n\n4. Males and females, at least 18 years of age, capable and willing to provide informed consent;\n- The patient note states that the patient is a 54-year-old woman, so she meets the age and gender requirements. However, there is no information about her ability to provide informed consent.\n\n5. Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study;\n- The patient note mentions that the patient is menopausal, so she meets this criterion.\n\n6. Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms;\n- The patient note does not mention if the patient has received a diagnosis of COVID-19 infection or if she has any symptoms related to COVID-19.\n\n7. Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization);\n- The patient note states that the patient was admitted to the emergency department, but it does not specify if she was hospitalized or not.\n\n8. Patient must be able and willing to comply with the requirements of this study protocol.\n- The patient note does not provide information about the patient's ability or willingness to comply with the study protocol.\n\nBased on the information provided in the patient note, there is insufficient information to determine if the patient meets the inclusion criteria for the clinical trial \"Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)\".\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1448": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and a common bile duct stone.\n\nThe clinical trial is studying the effectiveness of prophylactic antibiotics in laparoscopic cholecystectomy on infection rates.\n\nThe inclusion criteria for the trial are: \"patients who have diagnosed -cholecystitis with / without GB stone, GB polyp\"\n\nBased on the patient's presentation and imaging findings of gallstones, biliary sludge, and a common bile duct stone, it appears she would meet the inclusion criteria of having cholecystitis with gallbladder stones.\n\nTherefore, my assessment is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1449": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms of acute cholecystitis (abdominal pain, nausea, vomiting, fever) and imaging findings of gallstones, biliary sludge, and common bile duct stones.\n\n2. The clinical trial is studying acute calculous cholecystitis with concomitant choledocholithiasis (common bile duct stones).\n\n3. The only inclusion criteria listed is age \u2265 18 years.\n\n4. The patient meets this age criteria.\n\n5. There are no explicit exclusion criteria listed that would exclude the patient.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1450": {
        "output": "To determine the patient's eligibility for the clinical trial, I will need the title of the trial and the inclusion criteria. Without that information, I cannot make an assessment. Please provide the missing details about the clinical trial, and I will evaluate the patient's eligibility based on the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1451": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. This matches the clinical presentation of biliary colic with or without jaundice as per the inclusion criteria.\n\n2. The laboratory findings show elevated ESR and leukocytosis with a left shift, which could indicate inflammation/infection related to gallstones/CBD stones.\n\n3. The ultrasound revealed gallstones, biliary sludge, and CBD stones with the smallest stone being 14mm in size. This matches the radiological findings suggestive of gallstones and concomitant CBD stones as per the inclusion criteria.\n\n4. The patient's age of 54 years falls within the 16-70 years age range specified in the inclusion criteria.\n\n5. The MRCP evidence of CBD stone(s) is not explicitly mentioned, but the ultrasound findings of CBD stones satisfy this requirement.\n\nBased on the information provided, this patient meets all the inclusion criteria for the clinical trial \"Management for Concomitant Gallstones and Common Bile Duct Stones.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1452": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, and vomiting for the past 4 days.\n2. The clinical trial is recruiting patients presenting to the emergency department with a chief complaint of nausea or vomiting.\n3. The patient meets this inclusion criteria as she presented to the emergency department with nausea and vomiting.\n4. There are no other inclusion/exclusion criteria mentioned for the trial.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1453": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\n2. The clinical trial is titled \"Clinical Trial of Ruxian Zengsheng No. 1 Decoction\" and is studying a treatment for liver-qi stagnation type breast hyperplasia.\n\n3. The inclusion criteria for the trial are:\n   - Healthy women over 18 years of age\n   - Diagnosed with breast hyperplasia for over 3 months\n   - Meet criteria for liver-stagnation and qi stagnation syndrome\n   - Breast imaging shows BI-RADS 2-3\n   - NRS pain score \u2265 4\n   - Voluntarily participate and sign informed consent\n\n4. Based on the patient note, this patient does not appear to have breast hyperplasia or meet the syndrome criteria for liver-stagnation and qi stagnation. Her symptoms are related to gallstones and biliary disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1454": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. Imaging revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is studying the timing of endoscopic intervention for acute variceal hemorrhage in cirrhotic patients.\n\nLooking at the inclusion criteria:\n1) The patient does not have any evidence of cirrhosis mentioned in the note.\n2) The patient is not presenting with symptoms of acute variceal hemorrhage like hematemesis, melena or hematochezia.\n3) There is no mention of the patient being hemodynamically stable or unstable.\n\nSince the patient does not meet the key inclusion criteria of having cirrhosis and acute variceal bleeding, there is insufficient information to determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1455": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 54-year-old obese woman presenting with abdominal pain, nausea, vomiting, and fever. The ultrasound revealed gallstones, biliary sludge, and CBD stones.\n\nThe clinical trial is focused on acute-on-chronic liver failure in cirrhotic patients.\n\nThe inclusion criteria for the trial are:\n\"Cirrhotic patients whether compensated or decompensated with an acute decompensation of cirrhosis which is defined by the recent development of ascites, encephalopathy, GI haemorrhage, bacterial infection, or any combination of these\"\n\nBased on the patient note provided, there is no mention of the patient having cirrhosis or any of the conditions listed in the inclusion criteria (ascites, encephalopathy, GI hemorrhage, bacterial infection).\n\nTherefore, the patient does not meet the inclusion criteria for this particular clinical trial on acute-on-chronic liver failure in cirrhotic patients.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1456": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman presenting with symptoms suggestive of gallstones and cholecystitis (abdominal pain, nausea, vomiting, fever). Imaging confirmed the presence of gallstones, biliary sludge, and common bile duct stones.\n\n2. The clinical trial is investigating a one-step laparoscopic cholecystectomy with common bile duct exploration versus the conventional two-step approach for patients with common bile duct stones.\n\n3. The inclusion criteria are:\n   - Common bile duct stones identified by MRCP\n   - Age 18 years or older\n   - Both interventions possible within a reasonable timeframe\n   - Informed consent\n\n4. This patient meets the inclusion criteria:\n   - She has common bile duct stones confirmed by ultrasound\n   - She is 54 years old\n   - No information provided suggests the interventions would not be possible\n   - Consent status is not mentioned, but can be obtained\n\n5. There is no information provided about potential exclusion criteria that may make the patient ineligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1457": {
        "output": "Based on the patient note provided, the 54-year-old obese woman was admitted to the emergency department with abdominal pain, nausea, and vomiting. The ultrasound revealed several gallstones, biliary sludge, and CBD stones, with the smallest stone being 14mm.\n\nGiven the clinical trial's inclusion criteria of \"Adult patients who have gall bladder stone(s),\" this patient meets the inclusion criteria for the trial titled \"RISK FACTORS OF GALL BLADDER STONE.\"\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1458": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 54-year-old obese woman with a BMI likely over 30 kg/m2 based on the description of being obese. This meets the BMI inclusion criteria of \u226530 kg/m2.\n\n2. The patient has symptomatic gallstones and biliary sludge/CBD stones, which would qualify as \"symptomatic uncomplicated gall stones\" per the inclusion criteria. \n\n3. There is no mention of the patient's ASA status, so we cannot definitively determine if they meet the ASA 1-3 inclusion criteria.\n\nBased on the information provided, the patient appears to meet at least some of the key inclusion criteria for the \"Bikini Scarless Laparoscopic Cholecystectomy for Morbid Obesity as a Day Case\" trial related to BMI and gallstone disease. However, without the ASA status, there is insufficient information to fully determine eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1459": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Age \u226518 years old\nThe patient is 54 years old, so this criterion is met.\n\n2. Scheduled to undergo elective surgery under general anesthesia\nThere is no mention of the patient being scheduled for surgery in the note, so this criterion cannot be evaluated.\n\n3. Judged to be at high risk of postoperative nausea and vomiting according to the Apfel's simplified score, with 3 or more of the following factors: women, non-smokers, history of PONV, postoperative use of opioids.\n\nThe patient is a woman and a non-smoker, so she meets 2 of the 4 factors. There is no mention of a history of PONV or postoperative use of opioids in the note.\n\nSince there is not enough information to determine if the patient meets the high-risk criteria for PONV, and it is unclear if she is scheduled for surgery, I would assess her eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1460": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial \"Lamivudine for Chronic Hepatitis B\" step-by-step:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) 2 years ago and recently co-infected with hepatitis B virus (HBV). This matches the inclusion criteria of being 18 years or older and having chronic hepatitis B infection.\n\nHe has no significant past medical history besides the viral hepatitis. His recent biopsy was negative for hepatocellular carcinoma and showed chronic inflammation compatible with chronic viral hepatitis, meeting the inclusion criteria of liver biopsy histology showing chronic hepatitis with or without cirrhosis.\n\nThere is no mention of previous interferon therapy or intolerance, so he may or may not meet that inclusion criteria. \n\nHis vital signs are stable, and he has no ascites, edema or other signs of decompensated liver disease, so he likely does not meet the exclusion criteria of irreversible severe cirrhosis (Child's stage C).\n\nHe is not pregnant and there is no mention of HIV or HCV co-infection, meeting those exclusion criteria.\n\nThere is no information provided about his renal function, hematological parameters, or history of pancreatitis to assess those exclusion criteria.\n\nOverall, based on the available information, this patient appears eligible for the lamivudine clinical trial, but some key lab values and past medical details are missing to make a definitive assessment.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1461": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Age above 18 years: The patient is 55 years old, so this criterion is met.\n2) Male or female: The patient is male, so this criterion is met. \n3) Serum ALT or AST above upper limit of normal: The note doesn't mention specific ALT/AST values, but it does state the patient has chronic viral hepatitis, so this criterion is likely met.\n4) Presence of anti-HCV and HCV RNA: The note states the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n5) Evidence of chronic hepatitis on liver biopsy: The recent biopsy showed chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n6) Written informed consent: This is not mentioned in the note, so we cannot assess this criterion.\n\nExclusion Criteria:\n1) Previous lack of sustained virological response to interferon/ribavirin: This is not mentioned, so this exclusion criterion may not apply.\n2) Decompensated liver disease: There is no mention of the clinical signs listed, so this likely does not apply.\n3) Pregnancy/inability to use contraception: The patient is male, so this does not apply.\n4) Significant systemic illnesses: None are mentioned, so this likely does not apply.\n5) Pre-existing anemia: This is not mentioned, so may not apply.\n6) Recent antiviral/immunosuppressive therapy: The note states the patient is on IFN, RBV and direct antivirals for 6 months, so this may exclude the patient depending on the trial's definition of \"recent\".\n7) Evidence of another liver disease: The note states there is no evidence of other liver diseases, so this does not apply.\n8) Coronary/cerebrovascular disease: This is not mentioned, so likely does not apply.\n9) Active substance abuse: This is not mentioned, so likely does not apply.\n10) Evidence of hepatocellular carcinoma: The recent biopsy was negative for this, so this does not apply.\n11) Clinical gout: This is not mentioned, so likely does not apply.\n\nIn summary, the patient meets all of the inclusion criteria mentioned in the note. The only potential exclusion is the recent antiviral therapy, depending on the trial's definition of \"recent\". More information may be needed on that point.\n\nTrial-level eligibility: 2) Eligible (assuming the recent antivirals do not exclude based on the trial definition)",
        "label": 1
    },
    "1462": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients with chronic hepatitis C.\nThe patient note states that the patient was diagnosed with HCV 2 years ago, so this criterion is met.\n\n2. Age 18 to 70 years, male or female. \nThe patient is a 55-year-old man, so this criterion is met.\n\n3. HCV infection indicated by the presence of anti-HCV (by ELISA and recombinant immunoblot assay [RIBA]).\nThe patient note mentions previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n4. Written informed consent.\nThere is no information about this in the patient note, so we cannot determine if this criterion is met or not.\n\n5. Women must not be pregnant.\nThe patient is a man, so this criterion is not applicable.\n\n6. Patients must not have significant systemic illnesses other than liver disease, including congestive heart failure, renal failure, uncontrolled diabetes mellitus.\nThe patient note states that his past medical history is non-significant, so this criterion is likely met.\n\n7. Patients must not have antiviral or immunosuppressive therapy within the last 6 months.\nThe patient note mentions that the patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, so this criterion is not met.\n\n8. Patients must not have HIV infection.\nThere is no mention of HIV infection in the patient note, so we can assume this criterion is met.\n\n9. Patients must not have contraindications to liver biopsy (mainly clotting abnormality (coumadin therapy, platelet count less than 50,000/cubic millimeter, prothrombin time more than 4 seconds beyond control)).\nThere is no information about clotting abnormalities or contraindications to liver biopsy in the patient note, so we cannot determine if this criterion is met or not.\n\nOverall, based on the information provided in the patient note, the patient meets some of the inclusion criteria but is excluded due to being on antiviral therapy within the last 6 months.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1463": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDisease Characteristics:\n- The patient does not have pathologically confirmed primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC). He is diagnosed with HCV and HBV co-infection.\n\nPrior/Concurrent Therapy:\n- No information provided about prior therapies the patient has received.\n\nPatient Characteristics:\n- The patient is 55 years old, so meets the age criteria of \u226518 years.\n- No information provided about life expectancy.\n- No information provided about hematological parameters.\n- The patient has HCV and HBV infections, which are exclusion criteria for this trial.\n- No information provided about cardiovascular disease.\n- No information provided about concurrent advanced malignancy, inflammatory bowel disease, anticipated need for transplantation, pregnancy status, or other liver diseases mentioned.\n\nBased on the information provided, the patient does not meet the inclusion criteria for pathologically confirmed PSC or PBC. Additionally, the patient has HCV and HBV infections, which are exclusion criteria for this trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1464": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\nInclusion criteria: Persistent infection with mild hepatitis that is non-progressive.\n\nFrom the patient note, we know that:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago and a recent coinfection with HBV.\n- He is on IFN, RBV, and direct antiviral drugs for the past 6 months, suggesting an active treatment for hepatitis.\n- The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\n- There is no evidence of other liver diseases like alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n\nBased on this information, the patient appears to have a persistent hepatitis C infection with mild hepatitis that is non-progressive, as evidenced by the lack of complications and the absence of other liver diseases.\n\nTherefore, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1465": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of being an adult (>18 years old).\n\n2. The patient is diagnosed with HCV and HBV co-infection, which aligns with the inclusion criteria of having HCV infection.\n\n3. The patient's medical history shows positive HCV RNA tests and anti-HCV antibodies, confirming HCV infection.\n\n4. The biopsy ruled out hepatocellular carcinoma, but showed chronic inflammation compatible with chronic viral hepatitis, which fits the inclusion criteria of active liver disease.\n\n5. There is no mention of the patient's hematocrit level, so we cannot determine if they meet the exclusion criteria related to low hematocrit.\n\n6. The patient is not a child younger than 2 years old, so they do not meet the exclusion criteria related to age.\n\nBased on the information provided, the patient appears to meet the key inclusion criteria of having HCV infection and active liver disease, and there is no clear evidence that they meet any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1466": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial \"Tenofovir Disoproxil Fumarate to Treat Pediatric HIV\" step-by-step:\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for 6 months for HCV/HBV\n- No other significant medical history\n- Recent biopsy negative for hepatocellular carcinoma\n- No evidence of other liver diseases\n- Vitals within normal range\n\nThe inclusion criteria state:\n- HIV-infected children between 4-18 years old\n- Meeting certain CD4 count/viral load/clinical criteria for antiretroviral treatment\n- Failing at least second antiretroviral regimen\n- HIV RNA >= 10,000 copies/mL within past 3 months\n- Able to swallow tablets\n- Acceptable hematologic, hepatic, and renal function\n- Able to use birth control if sexually active\n- Provide informed consent\n\nThe exclusion criteria state:\n- Use of nephrotoxic agents, immunomodulators, chemotherapy, radiation, or investigational agents\n- Significant unrelated systemic illness\n- Weight < 10kg\n- Pregnant or breastfeeding\n\nBased on the information provided, this 55-year-old patient with HCV/HBV coinfection does not meet the inclusion criteria for this pediatric HIV trial, as he is not between 4-18 years old and does not have HIV infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1467": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection;\nThe patient is a 55-year-old man with chronic hepatitis B infection, so he meets this criterion.\n\n2. Documentation of positive Hepatitis B e antigen (HBeAg) status.;\nThere is no information provided about the patient's HBeAg status, so this criterion cannot be evaluated.\n\n3. The absence of coinfection with immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV);\nThe patient note states that the patient has a recent coinfection with HCV, so he does not meet this criterion.\n\n4. The absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease;\nThe patient note mentions that there is no evidence of alcoholic liver disease, autoimmune hepatitis, or metabolic liver disease, so he meets this criterion.\n\n5. Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)\nThe patient has been on IFN, RBV and direct antiviral drugs for the past 6 months, but it is unclear if these are nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B. Therefore, this criterion cannot be fully evaluated.\n\nSince the patient does not meet the criterion of the absence of coinfection with HCV, he would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1468": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of chronic hepatitis B infection;\nThe patient is a 55-year-old man with chronic hepatitis B infection, so he meets this criterion.\n\n2. HBeAg negative, anti-HBeAb positive;\nThere is no information provided about the patient's HBeAg or anti-HBeAb status.\n\n3. Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis D virus (HDV);\nThe patient note states that the patient has a recent coinfection with HCV, so he does not meet this criterion.\n\n4. Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease;\nThe patient note mentions that there is no evidence of alcoholic liver disease, autoimmune hepatitis, or metabolic liver disease, so he meets this criterion.\n\n5. Less than 12 weeks prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, famciclovir and lamivudine)\nThe patient has been on IFN, RBV and direct antiviral drugs for the past 6 months, but it is unclear if these include nucleoside/nucleotide analogues active against hepatitis B.\n\nSince the patient has a coinfection with HCV, which is an exclusion criterion, he would be excluded from this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1469": {
        "output": "Okay, let's go through the inclusion criteria one by one:\n\n1. Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of HBeAg-positive chronic hepatitis B infection;\nThe patient is a 55-year-old man, so he meets the age criteria. However, the note does not mention if he has a history of HBeAg-positive chronic hepatitis B infection.\n\n2. Incomplete response to current lamivudine therapy;\nThe note does not mention if the patient is on lamivudine therapy or has an incomplete response to it.\n\n3. HBeAg-positive;\nThe note does not mention the patient's HBeAg status.\n\n4. Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV);\nThe note mentions that the patient has a coinfection with HCV, so this criterion is not met.\n\n5. Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease.\nThe note states that there is no evidence of alcoholic liver disease, autoimmune hepatitis, or metabolic liver disease, so this criterion is met.\n\nSince the patient has a coinfection with HCV, which is an exclusion criterion, and there is not enough information to determine if he meets some of the other inclusion criteria, I would assess the patient as:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1470": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Age over 18 years old - The patient is 55 years old, so this criterion is met.\n2) Presence of HCV RNA - The patient has a positive HCV RNA test, so this is met. \n3) Non-responder to previous IFN or IFN+RBV therapy for at least 3 months - The patient has been on IFN, RBV and direct antiviral drugs for 6 months, so this is likely met.\n4) Washout period of at least 6 months from previous therapy - This is not clearly stated, but the patient has been on current therapy for 6 months, so a washout period is possible.\n5) Liver biopsy showing cirrhosis within last 12 months - A recent biopsy showed chronic inflammation but no cirrhosis, so this criterion is not met.\n6) Cirrhosis classified as Child-Pugh A - Since cirrhosis is not confirmed, this is not applicable.\n7) Compensated liver disease - Based on the clinical details provided, this seems to be met.\n8) Imaging negative for hepatocellular carcinoma within 3 months - The recent biopsy was negative for HCC, so this is met.\n9) Adequate hematologic and renal function - This appears to be met based on the lab values provided.\n10) Normal TSH or controlled thyroid function - This is not mentioned, so cannot be assessed.\n11) Females using birth control - The patient is male, so this is not applicable.\n\nExclusion Criteria:\n1) Systemic corticosteroid use within 6 months - Not mentioned, so assumed not met.\n2) Evidence of drug-induced liver injury - Not mentioned, so assumed not met.  \n3) Use of hepatitis C therapeutics or immunosuppressants - The patient is on IFN, RBV and antivirals, so this exclusion may apply.\n4) Evidence of other liver diseases - No evidence provided, so assumed not met.\n5) Elevated alpha-fetoprotein - Not mentioned, so cannot be assessed.\n6) Child-Pugh B/C cirrhosis - Since cirrhosis not confirmed, this is not applicable.\n7) Decompensated liver disease - No evidence provided, so assumed not met.\n8) HIV infection - Not mentioned, so assumed not met.\n9) History of malignancy - Not mentioned, so assumed not met.\n10) Active infectious process other than HCV - Coinfection with HBV mentioned, so this exclusion may apply.\n11) Autoimmune disease - Not mentioned, so assumed not met.\n12) Pregnancy - The patient is male, so not applicable.\n13) Substance abuse within 1 year - Not mentioned, so assumed not met.\n14) Chronic methadone use - Not mentioned, so assumed not met.\n15) Poor medical risk - No details provided to assess this.\n16) Severe depression history - Not mentioned, so assumed not met.\n17) Significant cardiac/pulmonary disease - Not mentioned, so assumed not met.\n18) Transplant recipient - Not mentioned, so assumed not met. \n19) Uncontrolled seizures - Not mentioned, so assumed not met.\n20) Concerns about compliance - No details to assess this.\n21) Previous thymosin alpha 1 treatment - Not mentioned, so assumed not met.\n22) IFN hypersensitivity - Not mentioned, so assumed not met.\n23) Concurrent clinical trial - Not mentioned, so assumed not met.\n24) Family history of intracerebral hemorrhage - Not mentioned, so assumed not met.\n\nIn summary, while some inclusion criteria are potentially met, the lack of confirmed cirrhosis on biopsy appears to exclude the patient. Additionally, the use of hepatitis C therapeutics and coinfection with HBV may fall under the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "1471": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Signed written informed consent - Not mentioned in patient note\n2) Age over 18 years old - Patient is 55 years old, meets criteria\n3) Presence of HCV RNA measured by qualitative PCR - Patient has positive HCV RNA tests, meets criteria\n4) Nonresponder to previous IFN or IFN+RBV therapy for at least 12 weeks - Patient is on IFN, RBV and direct antivirals for 6 months, suggesting previous non-response, meets criteria\n5) 6 month washout from previous IFN/IFN+RBV therapy - Meets criteria as on current treatment for 6 months\n6) Liver biopsy with chronic hepatitis C within 12 months - Recent biopsy showed chronic inflammation from viral hepatitis, meets criteria\n7) No cirrhosis (METAVIR score 0-3) - Biopsy negative for cirrhosis, meets criteria\n8) Compensated liver disease - No mention of decompensation, meets criteria\n9) Imaging negative for HCC within 3 months - Recent biopsy negative for HCC, meets criteria\n10) Adequate hematologic parameters - No values given, not enough information\n11) Adequate renal function - No values given, not enough information\n12) Normal TSH or controlled thyroid - No information given\n13) Females using birth control - Not applicable \n\nExclusion Criteria:\n1) Systemic corticosteroid use within 6 months - No mention, assumed no use\n2) Hepatotoxic drugs - No mention of other medications\n3) Other liver diseases - No mention of other liver diseases\n4) Alpha-fetoprotein >200 ng/mL - No value given\n5) Cirrhosis - Biopsy negative for cirrhosis\n6) Portal hypertension - No mention\n7) Decompensated liver disease - No mention \n8) HIV infection - No mention\n9) Other malignancies - No mention\n10) Active infections other than HCV - No mention of other infections\n11) Autoimmune diseases - No mention\n12) Pregnancy - Not applicable\n13) Substance abuse within 1 year - No mention\n14) Chronic methadone use - No mention\n15) Poor medical risk - No contra-indications mentioned\n16) Severe depression history - No mention\n17) Significant cardiac/pulmonary disease - No mention\n18) Concerns about compliance - No mention\n19) Prior thymosin alpha 1 use - No mention\n20) IFN hypersensitivity - No mention\n21) Other clinical trials within 3 months - No mention\n22) Family history of ICH - No mention\n\nBased on the information provided in the patient note, the patient meets several of the key inclusion criteria like age, HCV infection, previous non-response to IFN/RBV, and lack of cirrhosis. However, there is insufficient information provided about some other criteria like hematologic/renal parameters, thyroid status, substance use, depression history etc.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1472": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Men or women 18 to 75 years\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Chronic hepatitis C infection based on a history of positive anti-HCV antibody and/or HCV RNA\nThe patient note mentions that he was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so he meets this criterion.\n\n3. History of prior treatment with interferon-a-based therapies or an assessment by the investigator that the patient would not benefit from interferon-a-based therapy or that treatment with interferon-a is contraindicated\nThe patient note states that he is on IFN (interferon), RBV (ribavirin) and direct antiviral drugs for the past 6 months, so he meets this criterion.\n\n4. Stage 4, 5 or 6 liver fibrosis according to the Ishak scoring system.\nThe patient note does not provide information about the stage of liver fibrosis, so it is unclear if he meets this criterion.\n\n5. Cannot have presence of clinically evident ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding within the last 2 years (diuretic therapy of stable mild-to-moderate peripheral edema is permitted)\nThe patient note states that there is no evidence of ascites, so he meets this criterion.\n\n6. Must meet minimum blood chemistry requirements\nThe patient note does not provide information about his blood chemistry, so it is unclear if he meets this criterion.\n\n7. Cannot have unstable or uncontrolled thyroid disease\nThe patient note does not mention any thyroid disease, so assuming he does not have any, he would meet this criterion.\n\n8. Cannot have a variety of other diseases (listed in protocol)\nThe patient note does not provide enough information to determine if he meets this criterion.\n\nBased on the information provided in the patient note, the patient appears to meet some of the inclusion criteria, but there is not enough information to determine if he meets all of them.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1473": {
        "output": "Okay, let's go through the inclusion criteria for the clinical trial \"Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta\" and assess the patient's eligibility.\n\n1. Be positive for both anti-HDV and HBsAg for more than 6 months\n- The patient note mentions he was diagnosed with HCV 2 years ago and recently co-infected with HBV, so this criterion is likely met.\n\n2. Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment\n- There is no information about ALT levels in the patient note.\n\n3. Be HDV RNA positive by PCR (sensitivity: 103 copies/mL)\n- There is no information about HDV RNA levels in the patient note.\n\n4. Be HBV DNA positive by PCR\n- The patient note does not mention HBV DNA levels.\n\n5. Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to enrollment)\n- The recent biopsy was negative for hepatocellular carcinoma and only remarkable for chronic inflammation compatible with chronic viral hepatitis.\n\n6. Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A)\n- There is no information about the Child-Pugh score in the patient note.\n\n7. Present with WBC \u22653000/mm3, ANC \u22651500/mm3, and platelet \u226580,000/mm3\n- There is no information about WBC, ANC, or platelet counts in the patient note.\n\n8-11. Other criteria related to attending follow-ups, providing consent, pregnancy tests, and contraception use.\n- There is no information about these in the patient note.\n\nIn summary, while the patient meets some criteria like having chronic viral hepatitis and being co-infected with HBV, there is insufficient information provided in the patient note to definitively determine eligibility for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1474": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HIV infection (Western Blot +)\nThe patient note does not mention the patient's HIV status, so there is not enough information to determine if this criterion is met.\n\n2. C hepatitis (RNA viral hepatitis C [VHC] +)  \nThe patient note states that the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\n3. Chronic active C hepatitis on liver histological score METAVIR (A over or equal to 1 and F over or equal to 2) on biopsy performed at least 18 months before the expected date of inclusion\nThe patient note mentions a recent biopsy that was negative for hepatocellular carcinoma but remarkable for chronic inflammation compatible with chronic viral hepatitis. However, it does not provide the METAVIR score, so it is unclear if this criterion is met.\n\n4. Previous treatment for C hepatitis for at least 3 months including peg-interferon and ribavirin or peg-interferon alone if counterindication for ribavirin occurred\nThe patient note states that the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is met.\n\n5. Failure to eradicate C hepatitis virus after well conducted treatment\nThe patient note does not explicitly state whether the treatment failed to eradicate the HCV, so there is not enough information to determine if this criterion is met.\n\n6. The liver biopsy should have been realised at least 18 months before inclusion...\nThe patient note mentions a recent biopsy but does not provide the date, so it is unclear if this criterion is met.\n\n7. Regular follow up in an outpatient clinic for HIV\nThe patient note does not mention if the patient is receiving regular follow-up for HIV, so there is not enough information to determine if this criterion is met.\n\n8. Unchanged antiretroviral treatment the last 3 months before inclusion\nThe patient note does not mention if the patient is on antiretroviral treatment or if it has been unchanged, so there is not enough information to determine if this criterion is met.\n\n9. Inform consent\nThe patient note does not mention if the patient has provided informed consent, so there is not enough information to determine if this criterion is met.\n\nIn summary, while some of the inclusion criteria are met based on the information provided in the patient note, there are several criteria for which there is not enough information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1475": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. At least 18 years of age\nThe patient is 55 years old, so this criterion is met.\n\n2. Chronic hepatitis C infection based on history and detectable serum HCV RNA\nThe patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\n3. Documented failure to respond to or relapse after treatment with pegylated interferon and ribavirin combination therapy\nThe patient note does not mention any previous treatment failure or relapse, so there is not enough information to determine if this criterion is met.\n\n4. Adequate hematologic function (specific criteria listed)\nThe patient note does not provide complete hematologic lab values, so there is not enough information to determine if this criterion is met.\n\n5. Adequate renal function (serum creatinine <= 1.5 mg/dL or calculated creatinine clearance > 60 mL/min)\nThe patient note does not provide renal function tests, so there is not enough information to determine if this criterion is met.\n\n6. Normal coagulation profile and D-dimer within limits\nThe patient note does not provide coagulation tests or D-dimer, so there is not enough information to determine if these criteria are met.\n\n7. Female patients must have a negative pregnancy test, all reproductive patients must use contraception\nThe patient is male, so this criterion is not applicable.\n\nSince several key criteria cannot be evaluated due to lack of information in the patient note, I would assess:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1476": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female patients between 18-70 years of age\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Evidence of chronic hepatitis C by detectable serum HCV-DNA\nThe patient note mentions that he was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so he meets this criterion.\n\n3. Hepatitis C genotype 1, 2, 3 or 4\nThe patient note does not specify the hepatitis C genotype, so there is not enough information to determine if he meets this criterion.\n\n4. Indication for antiviral therapy of hepatitis C according to current clinical guidelines\nThe patient note states that he is on IFN, RBV and direct antiviral drugs for the past 6 months, which suggests he meets this criterion.\n\n5. Written informed consent\nThere is no information about whether the patient has provided written informed consent, so this cannot be determined from the patient note.\n\nSince there is insufficient information to confirm that the patient meets all of the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1477": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronic viral hepatitis C, genotype 1 or 4\nThe patient note does not specify the hepatitis C genotype, so this criterion cannot be evaluated.\n\n2. Fibrosis F3 or F3-F4, assessed by the scoring Metavir system\nThe patient note mentions a recent biopsy that was \"only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\" It does not provide information about the fibrosis stage or Metavir score.\n\n3. Initial treatment against HCV\nThe patient note states that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months,\" which suggests that the patient is currently undergoing treatment for hepatitis C.\n\nSince there is not enough information provided in the patient note to determine if the patient meets all the inclusion criteria, particularly regarding the hepatitis C genotype and fibrosis stage, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "1478": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Cellulose Sulfate and HIV Transmission Among Women\", the patient does not appear to be eligible for this trial.\n\nThe key reasons are:\n\n1. The patient is a 55-year-old man, while the trial requires participants to be women.\n2. There is no mention of the patient's HIV status, but the trial requires participants to be HIV negative.\n3. The trial requires participants to have an average of at least three vaginal sex acts per week and at least three different partners in the last three months, which is not applicable to this patient based on the provided information.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1479": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female patients >= 18 years of age will be recruited.\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Patients with dual chronic hepatitis C and B must be positive for both anti-HCV and HBsAg for more than 6 months and HCV RNA quantifiable at 600 IU/mL (by the COBAS AMPLICOR HCV MONITOR\u00ae Test version 2.0). \nThe patient is diagnosed with HCV 2 years ago and has a recent coinfection with HBV. His medical records show previous positive HCV RNA tests, so he likely meets this criterion.\n\n3. Patients must not be positive for HBeAg.\nThere is no mention of the patient's HBeAg status, so we cannot determine if he meets this criterion.\n\n4. Patients with monoinfected chronic hepatitis C must be positive for anti-HCV for more than 6 months and HCV RNA quantifiable at 600 IU/mL (by the COBAS AMPLICOR HCV MONITOR\u00ae Test version 2.0). Patients must not be positive for HBsAg.\nThis does not apply since the patient has dual HCV/HBV infection.\n\n5. All patients must:\n- Be treatment na\u00efve for the hepatitis disease or have had treatment failure to previous interferon monotherapy or treatment failure to previous lamivudine therapy.\nThe patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so he does not meet this criterion.\n\n- Present with elevated serum ALT levels at least 1.5 times the upper limit of normal, documented on two occasions (at least one month apart), within six months prior to enrollment\nThere is no information about the patient's ALT levels, so we cannot determine if he meets this criterion.\n\n- Present with liver biopsy findings compatible with the diagnosis of chronic liver disease (the liver biopsy needs to be taken within 52 weeks prior to the first dose of study drug)\nThe recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis, so he likely meets this criterion.\n\n- Have adequate liver reserve (defined as equal to or better than Child-Pugh Class A)  \nThere is no information about the patient's Child-Pugh score, so we cannot determine if he meets this criterion.\n\n- Present with WBC 3500/mm3, ANC 1500/mm3, and platelets 90,000/mm3\nThere is no information about the patient's WBC, ANC or platelet counts, so we cannot determine if he meets this criterion.\n\nSince there are multiple criteria that cannot be evaluated based on the information provided, I would output:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "1480": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On treatment with IFN, RBV and direct antiviral drugs for 6 months\n- Positive HCV RNA tests and anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, shows chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases like alcoholic liver disease, bleeding varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease\n\nThe inclusion criteria for the clinical trial are:\n- Patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada\n- Hepatitis C\n- Hepatitis B\n- Autoimmune Hepatitis\n- Primary Biliary Cirrhosis\n- Primary Sclerosing Cholangitis\n\nBased on the patient note, this patient meets the inclusion criteria of having Hepatitis C and Hepatitis B coinfection.\n\nThere is no information provided about whether the patient is attending the specific Liver Clinic at Toronto Western Hospital, so we cannot confirm that inclusion criteria.\n\nHowever, since the patient meets at least two of the disease inclusion criteria (HCV and HBV), I would assess this patient as:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "1481": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria for most clinical trials.\n\n2. The patient is diagnosed with HCV and HBV co-infection, which is relevant to the trial's focus on HCV and HIV co-infection.\n\n3. The patient is HIV negative based on the information provided, which does not meet one of the inclusion criteria of being HIV positive.\n\n4. The patient has documented HCV infection with positive HCV RNA tests and anti-HCV antibodies, meeting that inclusion criteria.\n\n5. There is no information provided about the availability of serial sera samples over time for retrospective analysis, which is one of the inclusion criteria.\n\nBased on the information provided, the patient does not fully meet the inclusion criteria due to being HIV negative and lacking information about serial sera samples.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1482": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HCV infected and uninfected (controls)\nThe patient note states that the patient is a 55-year-old man diagnosed with HCV 2 years ago, so he meets this inclusion criterion.\n\n2. Women\nThe patient is described as a man, so this criterion does not apply.\n\n3. Minorities\nThere is no information provided about the patient's ethnicity or race, so it is unclear if he meets this criterion.\n\n4. Exclusion Criteria\n   a. Children\n      The patient is described as a 55-year-old man, so he is not a child and does not meet this exclusion criterion.\n   b. Individuals who cannot or will not provide informed consent\n      There is no information provided about the patient's ability or willingness to provide informed consent.\n\nBased on the information given in the patient note, the patient meets at least one of the inclusion criteria (being HCV infected) and does not meet any of the stated exclusion criteria. However, there is not enough information to definitively determine if he meets all the inclusion criteria, such as being a minority.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1483": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients attending Liver Clinic at Toronto Western Hospital, Toronto, ON, Canada\n   - The patient note does not mention the location, so this cannot be confirmed.\n\n2. Fluent in English \n   - This is not mentioned in the patient note.\n\n3. Men and women between the ages of 18 and 65\n   - The patient is a 55-year-old man, so he meets this criteria.\n\n4. Subjects must provide written informed consent to participate\n   - This is not mentioned in the patient note.\n\n5. Control subjects: negative for both HBV, HCV, and HIV\n   - This does not apply since the patient has HCV and HBV co-infection.\n\n6. Additional criteria for HCV and HBV patients:\n   - Patient is a candidate for antiviral treatment\n     - The note mentions the patient is on IFN, RBV and direct antiviral drugs, so he meets this.\n   - Non-cirrhotic as determined by recent liver biopsy (<2 years prior to assessment)\n     - The note states the recent biopsy was negative for hepatocellular carcinoma, so he likely meets this.\n   - HCV subjects: positive for HCV RNA, negative for HBV and HIV\n     - The patient is positive for HCV RNA but also has HBV co-infection, so he does not fully meet this.\n   - HBV subjects: positive for HBV RNA and negative for HCV and HIV\n     - This does not apply since the patient has HCV.\n\nOverall, the patient meets some of the key criteria like age, being a candidate for antiviral treatment, and likely being non-cirrhotic. However, there are some criteria that cannot be confirmed from the note, like location and English fluency. Additionally, the patient has HBV co-infection which may exclude him.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1484": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) and recent coinfection with hepatitis B virus (HBV). This matches the inclusion criteria of being a patient attending the Toronto Western Hospital Liver Clinic.\n\nHe has serologic evidence of chronic HCV infection by a positive anti-HCV antibody test and detectable HCV RNA, which meets the inclusion criteria.\n\nHis recent biopsy was negative for hepatocellular carcinoma, indicating no cirrhosis, which is required for the second phase of the trial.\n\nThere is no mention of pregnancy status, contraceptive use, or insulin resistance assessment, which are required for inclusion.\n\nOverall, based on the information provided, there is insufficient evidence to determine if the patient meets all the inclusion criteria, particularly regarding pregnancy status/contraceptive use and insulin resistance.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1485": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronic hepatitis C. This is defined as the documentation of the presence of circulating hepatitis C virus by a positive hepatitis C PCR test and a positive HCV genotype test for genotype 1, and a liver biopsy (within the previous 5 years) that is compatible with chronic hepatitis. In the case of patients that have refused liver biopsies a clinical diagnosis of chronic hepatitis C is required.\n- The patient note mentions the patient was diagnosed with HCV 2 years ago and has a recent coinfection with HBV. It also mentions a recent biopsy was negative for hepatocellular carcinoma but remarkable for chronic inflammation compatible with chronic viral hepatitis. This criterion is met.\n\n2. Positive HCV RNA by PCR, Genotype 1, treatment naive\n- The patient note does not specify the HCV genotype, so this criterion cannot be fully assessed.\n\n3. Age 18-65 years.\n- The patient is 55 years old, so this criterion is met.\n\n4. Patient must be able to give informed consent.\n- There is no information about ability to give informed consent.\n\n5. Eligible for interferon alfa and ribavirin-based antiviral treatment...\n- The patient is already on IFN, RBV and direct antiviral drugs for the past 6 months according to the note. The other sub-criteria about contraception, AFP levels, liver function, etc. cannot be fully assessed based on the information provided.\n\nSince the HCV genotype is not specified and some other criteria cannot be definitively assessed, I would say:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1486": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n5.1.1 Adult male or female, age of 18 or older.\nThe patient is a 55-year-old man, so he meets this criterion.\n\n5.1.2 Serums positive for hepatitis C virus by RT-PCR or other assay (bDNA). \nThe patient note states that he was diagnosed with HCV 2 years ago and had previous positive HCV RNA tests, so he meets this criterion.\n\n5.1.3 HCV genotype result must be available at screening.\nThere is no information about the patient's HCV genotype in the note.\n\n5.1.4 Previous antiviral therapy with interferon or interferon plus ribavirin for at least 12 weeks with the failure to obtain a sustained virologic response.\nThe patient note states that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", so he meets this criterion.\n\n5.1.5 No therapy with interferon alfa or interferon alfa-2b plus ribavirin or other specific anti-HCV medications within 6 weeks of the Entry visit.\nThe patient is currently on these medications, so there is no information about whether he meets this criterion or not.\n\n5.1.6 Compensated liver disease with specific laboratory parameters...\nThe patient note provides some of these lab values (BP, HR, BMI) which appear to be within range, but does not provide all the required lab values.\n\n5.1.7 Alpha-fetoprotein (AFP) value requirements\nThere is no information about the patient's AFP value.\n\n5.1.8-5.1.11 Other criteria related to contraception, cardiac testing, liver biopsy, and informed consent.\nThere is no information about these criteria in the patient note.\n\nIn summary, while the patient appears to meet some of the key inclusion criteria related to HCV diagnosis and previous treatment, there is insufficient information in the note to fully determine eligibility for this particular trial.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1487": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Serum ALT at least 1.5x the upper limit of normal\n   - The patient note does not mention the ALT level, so this criterion cannot be evaluated.\n\n2. For chronic HBV: Known positive serum HBeAg for at least 6 months; Presence of HBV DNA in serum\n   - The patient note states that the patient has a recent coinfection with HBV, but does not provide information about HBeAg or HBV DNA levels.\n\n3. For chronic HCV: Presence of anti-HCV in serum within 6 months of enrollment; Positive serum HCV RNA (enrollment)\n   - The patient note mentions that the patient was diagnosed with HCV 2 years ago, and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. This satisfies the criteria for chronic HCV.\n\n4. Written informed consent\n   - The patient note does not mention whether the patient has provided written informed consent.\n\nSince the patient note does not provide complete information to evaluate all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "1488": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Hepatitis C virus (HCV) genotype 1\nThe patient note mentions that the patient is diagnosed with HCV, but it does not specify the genotype. This criterion cannot be evaluated based on the given information.\n\n2. Previous therapy with pegylated interferon and ribavirin\nThe patient note states that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months.\" This suggests that the patient has received previous therapy with pegylated interferon and ribavirin, satisfying this criterion.\n\n3. Documented previous treatment failure\nThe patient note does not provide any information about whether the previous treatment with pegylated interferon and ribavirin was a failure or not.\n\nSince there is not enough information to determine if the patient meets all the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1489": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Hepatitis C infection for \u2265 1 year. \nThe patient note states that the patient was diagnosed with HCV 2 years ago, so this criterion is met.\n\n2. Male or female ages 18-65 years, inclusive.\nThe patient is a 55-year-old man, so this criterion is met.\n\n3. Plasma hepatitis C RNA of >105 copies/mL (or equivalent international units)\nThere is no information about the patient's viral load in the note, so this cannot be assessed.\n\n4. Laboratory values within specified ranges.\nThere is some information about the patient's lab values (BP, HR, BMI), but not enough to fully assess this criterion.\n\n5. Female subjects must have a negative pregnancy test and use contraception.\nThis does not apply since the patient is male.\n\n6. Karnofsky performance score >= 80 within 30 days prior to study entry.\nThere is no information about the patient's Karnofsky score.\n\n7. Ability and willingness to give written informed consent.\nThis is typically assumed unless stated otherwise.\n\n8. Willingness to return for follow-up visit.\nThis is typically assumed unless stated otherwise.  \n\n9. Stable medication doses for >8 weeks prior.\nThe patient is only taking IFN, RBV and direct antiviral drugs for 6 months, so this criterion is likely met.\n\nOverall, while some criteria are met, there is not enough information provided in the patient note to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1490": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile\", I will go through the inclusion criteria one by one:\n\nInclusion Criteria:\nPATIENTS COMPLETING TREATMENT WITH PEGINTERFERON AND RIBAVIRIN FOR CHRONIC HCV INFECTION AND UNDERWENT LIVER BIOPSY PRIOR THERAPY ONSET\n\nFrom the patient note, we know that:\n1. The patient is a 55-year-old man diagnosed with HCV 2 years ago.\n2. He is on IFN, RBV and direct antiviral drugs for the past 6 months, which implies he has completed treatment with PEGINTERFERON and RIBAVIRIN.\n3. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis, which means he underwent a liver biopsy prior to therapy onset.\n\nSince the patient meets all the inclusion criteria mentioned in the trial, he is eligible for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1491": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial titled \"Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B\".\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests and positive anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, chronic inflammation compatible with chronic viral hepatitis\n- No evidence of other liver diseases\n- Vitals: BP 130/75, HR 90/min, BMI 27\n- No ascites, tenderness or edema\n\nThe inclusion criteria state:\n- Adult male or female, 18 to 60 years of age (Patient is 55, meets this)\n- Chronic hepatitis B patients with positive HBsAg for minimum 6 months (Patient has recent HBV coinfection, unclear if positive for 6+ months)\n- Positive HBV-DNA within 3 months (No HBV-DNA level given)\n- Positive HBeAg within 3 months (No HBeAg status given)\n- Abnormal ALT 2-10x upper limit within 3 months (No ALT level given)\n- Liver biopsy shows chronic hepatitis without cirrhosis (Biopsy matches this)\n- Meets minimum hematologic/biochemical criteria (No relevant labs given)\n- Negative HCV antibody (Patient is positive for HCV antibodies)\n- Negative HIV antibody (No HIV status given)\n- Written informed consent (Not mentioned)\n\nBased on the information provided, there are several inclusion criteria that cannot be definitively met or ruled out, such as HBV-DNA/HBeAg status, ALT levels, HIV status and ability to provide consent.\n\nHowever, the patient is noted to be positive for HCV antibodies, which is an exclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "1492": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HCV positive subjects documented by serum HCV RNA concentration > 100,000 IU/mL within 21 days of first study treatment\n- The patient note mentions the patient is HCV positive and has had previous positive HCV RNA tests, so this criterion is likely met.\n\n2. Receipt of adequate previous PEG-IFN and RBV therapy for a minimum of 12 weeks (null responders) or 24 weeks (partial responders) with specific dosing requirements\n- The patient note states the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", so this criterion is met.\n\n3. HCV genotype 1 only\n- There is no mention of the patient's HCV genotype in the note.\n\n4. Adults, 18+ years old\n- The patient is 55 years old, so this is met.\n\n5. Written informed consent\n- Not mentioned in the patient note.\n\n6. Liver biopsy within 5 years documenting changes consistent with hepatitis C\n- The note mentions a recent biopsy was \"only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\"\n\n7. Adequate bone marrow, liver, and renal function based on specific lab value criteria\n- Some relevant labs are provided (BP, HR, BMI) but key ones like bilirubin, albumin, creatinine are not mentioned.\n\n8. Negative pregnancy test for females of childbearing potential, use of contraception\n- The patient is male, so this does not apply.\n\n9. Normal thyroid stimulating hormone (TSH) levels\n- Not mentioned in the note.\n\nIn summary, while some of the key inclusion criteria are met based on the information provided, there are several important criteria that cannot be evaluated due to missing details in the patient note.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1493": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of being > 18 years old.\n\n2. The patient is diagnosed with HCV and HBV co-infection, but not hepatocellular carcinoma (HCC). The trial is specifically for patients with resectable HCC.\n\n3. The patient has not undergone hepatic resection, which is a requirement for this trial of adjuvant therapy after resection.\n\n4. The other inclusion criteria regarding performance status, lab values, pregnancy status, etc. cannot be evaluated based on the provided patient note.\n\nBased on the information given, this patient does not meet the key inclusion criteria of having a pathologically diagnosed and resected HCC. Therefore, he would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1494": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection.\n2. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n3. The patient has a history of positive HCV RNA tests and positive anti-HCV antibodies.\n4. A recent biopsy showed chronic inflammation consistent with chronic viral hepatitis, but no evidence of hepatocellular carcinoma or other liver diseases.\n5. The patient's vital signs and physical examination are unremarkable.\n\nNow, let's look at the inclusion criteria for the clinical trial:\n\n1. Subjects participating in this study should have received three-dose primary vaccination with combined hepatitis A/hepatitis B vaccine in the primary study.\n2. Written informed consent will be obtained from each subject before the blood sampling visit of each year.\n\nBased on the information provided in the patient note, there is no mention of the patient receiving a combined hepatitis A/hepatitis B vaccine in the past. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1495": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection.\n2. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n3. The patient has no other significant medical history or medications.\n4. Recent biopsy showed chronic inflammation compatible with chronic viral hepatitis, but no evidence of hepatocellular carcinoma or other liver diseases.\n5. The clinical trial is evaluating the long-term persistence of hepatitis A and B antibodies after receiving the combined hepatitis A/B vaccine.\n\nThe inclusion criteria for the trial state:\n1. Subjects must have participated in the primary study with the combined hepatitis A/B vaccine.\n2. Written informed consent is required.\n\nBased on the information provided, the patient does not meet the inclusion criteria for this trial, as there is no mention of him previously participating in a study with the combined hepatitis A/B vaccine.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1496": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection.\n2. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n3. The clinical trial is evaluating the long-term persistence of hepatitis A and B antibodies after receiving a combined hepatitis A/B vaccine.\n\n4. The inclusion criteria for the trial are:\n   - Subjects who had consented to participate in the long-term follow-up studies at the previous long-term blood sampling time points\n   - Written informed consent obtained before the blood sampling visit of each year\n\n5. Based on the information provided, the patient does not meet the inclusion criteria for this trial as he has not received the combined hepatitis A/B vaccine previously and is not being followed up from a previous long-term study.\n\n6. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1497": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial one by one:\n\n1. \"male or female patients between 18 and 65 years of age\" - The patient is a 55-year-old man, so he meets this criterion.\n\n2. Requirements for female patients regarding pregnancy/contraception - Not applicable since the patient is male.\n\n3. \"patient has been persistently HCV RNA-positive and remains HCV RNA-positive at screening\" - The note mentions the patient was diagnosed with HCV 2 years ago, so he likely meets this.\n\n4. \"patient is negative for human immunodeficiency virus (HIV), hepatitis delta virus (HDV), and has no evidence of chronic hepatitis B virus (HBV) infection\" - The note mentions a recent coinfection with HBV, so the patient does not meet this criterion.\n\n5. \"patient is in reasonably good health, as determined by the Investigator based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests, except for findings related to their hepatitis C positive status\" - The patient seems to be in reasonably good health based on the details provided.\n\n6. \"subject's private physician has been informed of the subject's planned participation in the study\" - No information provided about this.\n\n7. \"capable of understanding and complying with the protocol, willing to reside in the study unit during the study period and to cooperate fully with the Investigator and site personnel, and must have signed the informed consent document prior to performance of any study-related procedures\" - No information provided about this.\n\n8. \"infected with HCV genotype 1\" - No information provided about the HCV genotype.\n\n9. \"failed previous treatment for HCV infection with an approved regimen of IFN/RBV or pegylated IFN/RBV\" - The note mentions the patient is currently on treatment with IFN, RBV and direct antiviral drugs, but does not specify if he failed a previous treatment regimen.\n\nSince the patient has a recent coinfection with HBV which is an exclusion criterion, he would likely be excluded from this trial based on the information provided.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1498": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with HCV and HBV co-infection.\n2. He is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n3. The clinical trial is titled \"BASTA Study on STI in HIV Infected Patients.\"\n4. The inclusion criteria for the trial are:\n   i. Age > 17 years (The patient is 55, so he meets this criterion)\n   ii. Informed consent signed (No information provided)\n   iii. Effective ongoing treatment (HIV-RNA < 50 copies/ml). Treatment must be based on any triple drug therapy. Patients must be on the same steady therapy for at least 3 months. (The patient is not on HIV treatment, so he does not meet this criterion)\n   iv. Current CD4 cell count above 800 cells/L (No information provided on CD4 count)\n\nBased on the information provided, the patient does not meet the inclusion criteria for the \"BASTA Study on STI in HIV Infected Patients\" clinical trial because he is not infected with HIV and is not on HIV treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1499": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HIV-infected patients confirmed by HIV-RNA level\nThe patient note does not mention the patient's HIV status, so there is not enough information to determine if this criterion is met.\n\n2. HCV-infected patients confirmed by PCR(polymerase chain reaction) or branched DNA (b-DNA)  \nThe patient note states that the patient was diagnosed with HCV 2 years ago and had previous positive HCV RNA tests, so this criterion is met.\n\n3. Scheduled to commence combination IFN/RBV therapy on Day 1\nThe patient note mentions that the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is met.\n\n4. Normal serum creatinine\nThere is no information provided about the patient's serum creatinine levels.\n\n5. On stable antiretroviral regimen (for HIV) for at least 4 weeks\nAgain, there is no information about the patient's HIV status or antiretroviral regimen.\n\n6. Life expectancy > 6 months\nThere is no information about the patient's life expectancy.\n\nSince there is not enough information provided to determine if the patient meets all of the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1500": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients with a chronic HCV infection (HCV antibodies and HCV RNA positive)\nThe patient note states that the patient was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. This criterion is met.\n\n2. Presence of a HCV genotype 1 infection\nThe patient note does not specify the HCV genotype, so this criterion cannot be evaluated.\n\n3. Presence of a compensated liver disease satisfying following hematological and biochemical minimum criteria...\nThe patient note provides some relevant lab values like BP, HR, BMI which are within normal ranges. It also mentions no evidence of other liver diseases. However, it does not provide complete details on all the listed lab criteria, so this cannot be fully evaluated.\n\n4. Exclusion of an autoimmune hepatitis\nThe patient note states there is no evidence of autoimmune hepatitis, so this criterion is met.\n\n5. Alpha-Fetoprotein in the normal range \nThis lab value is not provided in the patient note.\n\n6. Negative HIV test\nThe patient note does not mention the HIV status.\n\n7. Negativity of Hepatitis B surface antigens (Hbs-Ag)\nThe patient note mentions a recent coinfection with HBV, so this exclusion criterion is not met.\n\n8. Normal or elevated ALT/GTP values at screening\nThese lab values are not provided.\n\n9. Other criteria related to diabetes, hypertension, liver biopsy, contraception\nThese are not discussed in the patient note.\n\nIn summary, while some criteria are met, there is insufficient information to fully evaluate eligibility based on the inclusion/exclusion criteria. The HCV genotype is unknown, some key lab values are missing, and the HBV coinfection may exclude the patient.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1501": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) and recently co-infected with hepatitis B virus (HBV).\n2. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct-acting antiviral drugs for the past 6 months.\n3. The clinical trial is studying the effect of lamivudine in adult patients with chronic hepatitis B alone.\n\nChecking the inclusion criteria:\n- Confirmed active liver disease due to Hepatitis B virus: The patient has HBV co-infection, so this criterion is met.\n- Patients must have adequate blood & liver functions: The patient's vitals (BP, HR) and lack of ascites/tenderness suggest adequate liver function. Blood function is not explicitly mentioned but can be assumed to be adequate based on the information provided.\n- Female patients must follow contraceptive requirements: Not applicable as the patient is male.\n- Patients without serious concurrent illnesses like cancer, severe heart disease, uncontrolled diabetes mellitus, or AIDS: The patient's medical history is non-significant, and no such conditions are mentioned, so this criterion is likely met.\n\nBased on the information provided, the patient appears to meet the inclusion criteria for the clinical trial studying the effect of lamivudine in adult patients with chronic hepatitis B.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1502": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection.\n2. He has been treated with interferon, ribavirin, and direct antiviral drugs for the past 6 months.\n3. The clinical trial is assessing the long-term effects of peginterferon alfa-2a plus ribavirin treatment for chronic HCV/HBV co-infection and chronic HCV.\n4. One of the inclusion criteria is: \"Patients who were randomized, treated and returned for follow up in the ML17862 protocol will be eligible for inclusion in this protocol\"\n\nBased on the information provided, it seems that the patient meets this inclusion criterion as he has been treated with interferon and ribavirin for chronic HCV/HBV co-infection.\n\nHowever, there is no explicit mention of whether the patient was part of the ML17862 protocol or not.\n\nIf the patient was part of the ML17862 protocol, then he would be eligible for this clinical trial.\n\nIf the patient was not part of the ML17862 protocol, then there is not enough information to determine his eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial based on the inclusion criteria provided).",
        "label": 2
    },
    "1503": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Long Term, Safety Study of Apricitabine in HIV-infected Subjects\", I will go through the inclusion criteria one by one:\n\n1. Completed AVX-201 protocol: The patient note does not mention whether the patient completed the AVX-201 protocol or not.\n\n2. Plasma HIV RNA <5000 copies/ml: The patient note does not provide any information about the patient's HIV viral load or HIV RNA levels.\n\n3. CD4 cells >50: The patient note does not mention the patient's CD4 cell count.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria for this HIV clinical trial, I would assess the eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1504": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 55-year-old man, so he meets the age criteria of being 18 years or older.\n\nHe has detectable HCV RNA and is coinfected with HBV, which is not an exclusion criteria.\n\nHe does not require a liver or kidney transplant, which is one of the key inclusion criteria for this trial. The trial is studying accelerated progression of hepatitis C in transplant patients.\n\nSince he does not meet that key inclusion criteria of requiring a liver or kidney transplant, he would not be eligible for this particular trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1505": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Chronic HBV infection, with either HBeAg-positive or HBeAg-negative disease - The patient note mentions the patient has HBV infection, so this criterion is met.\n2. Black/African American Race and/or Hispanic ethnicity - The patient's race/ethnicity is not mentioned, so we cannot determine if this criterion is met.\n3. Nucleoside/tide-naive - It is not mentioned if the patient has received prior nucleoside/tide treatment, so we cannot determine if this criterion is met.\n4. Males or females \u2265 16 years of age - The patient is a 55-year-old man, so this criterion is met.\n5. Compensated liver function - The patient note does not provide enough information to determine if the patient has compensated liver function.\n6. ALT of 1.3 to 10 x upper limit of normal (ULN) - The patient's ALT level is not provided.\n7. No Co-infection with HIV, HCV or HDV - The patient note mentions the patient has a coinfection with HCV, so this criterion is not met.\n\nExclusion Criteria:\n1. Women of childbearing potential unwilling/unable to use contraception - Not applicable as the patient is a man.\n2. Pregnant or breastfeeding women - Not applicable.\n3. Evidence of decompensated cirrhosis - No mention of decompensated cirrhosis in the patient note.\n4. Recent history of pancreatitis - No mention of pancreatitis.\n5. Currently abusing illegal drugs or alcohol - No mention of drug/alcohol abuse.\n6. Other serious medical conditions that might preclude study completion - No other serious conditions mentioned.\n7. Serum creatinine > 1.5 mg/dL - Creatinine level not provided.\n8. Hemoglobin < 10.0 g/dL - Hemoglobin level not provided.\n9. Platelet count < 70,000/mm3 - Platelet count not provided.\n10. Absolute neutrophil count < 1200 cells/mm3 - Neutrophil count not provided.\n11. Serum AFP level > 100 ng/mL - AFP level not provided.\n12. Known allergy to nucleoside analogues - No mention of allergies.\n13. Any prior therapy with Entecavir - No mention of prior Entecavir use.\n14. Prior/concomitant nucleoside/tide analogues - No mention of prior use.\n15. Recent interferon/immunostimulator use - No mention of recent use.\n16. Requiring medications that cause immunosuppression/nephrotoxicity/hepatotoxicity - No mention of such medications.\n17. Unable to tolerate oral medication - No issues with oral medication mentioned.\n18. Poor peripheral venous access - No mention of venous access issues.\n19. Prisoners or involuntarily incarcerated individuals - No mention of incarceration.\n\nIn summary, while the patient meets some inclusion criteria like age and HBV infection, there is insufficient information to determine if several other key criteria are met. Additionally, the patient has a HCV coinfection which is an exclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1506": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria step-by-step:\n\nThe patient is a 55-year-old man, satisfying the age criteria of at least 18 years.\n\nHe is diagnosed with HCV and HBV coinfection. The inclusion criteria specify patients with Hepatitis C virus (HCV). However, the coinfection with HBV is not explicitly mentioned as an exclusion criteria.\n\nHe has abnormal ALT levels, satisfying the criteria of ALT > 65 IU/L. \n\nHe was previously treated with IFN, RBV and direct antiviral drugs without sustained virological response, meeting the criteria for previous IFN-based therapy without sustained response.\n\nHe has a positive HCV RNA test within 1 year of screening and after end of therapy.\n\nHe has not received antiviral therapy for at least 6 months prior to screening.\n\nThere is no mention of him consuming alcohol, satisfying the criteria of not consuming alcohol 48 hours prior to PK sampling days or while on study.\n\nThe exclusion criteria he does not meet are:\n- No use of silymarin or other antioxidants within 30 days of screening\n- No positive test for HBsAg within 3 years (he is HBV co-infected)\n- No evidence of decompensated liver disease\n- No history of immunologically mediated diseases\n- No history of solid organ or bone marrow transplantation\n- No thyroid disease\n- No use of oral steroids within 30 days\n- No concurrent CYP3A4 inducer medications\n\nBased on the information provided, the patient meets the key inclusion criteria for the Hepatitis C cohort and does not seem to be excluded based on the listed exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1507": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u226518 years: The patient is 55 years old, so this criterion is met.\n\n2. Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA: The patient note mentions that the patient was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n3. Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis: The patient's recent biopsy was remarkable for chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n\n4. HCV genotype 4: There is no information provided about the patient's HCV genotype, so it is unclear if this criterion is met or not.\n\n5. Patients that have not previously received peginterferon: The patient note states that the patient is currently on IFN, RBV, and direct antiviral drugs for the past 6 months, so it is unclear if the patient has previously received peginterferon or not.\n\nSince there is not enough information to determine if the patient meets criteria 4 and 5, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1508": {
        "output": "To determine the patient's eligibility for the clinical trial \"Study of Nitazoxanide in the Treatment of Chronic Hepatitis C\", let's go through the inclusion criteria one by one:\n\n1. Age \u2265 18 years: The patient is 55 years old, so this criterion is met.\n\n2. Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA: The patient note mentions that the patient was diagnosed with HCV 2 years ago, and his medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. This criterion is met.\n\n3. Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis: The patient note states that the recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. This criterion is met.\n\nBased on the information provided in the patient note, the patient meets all the inclusion criteria for the clinical trial \"Study of Nitazoxanide in the Treatment of Chronic Hepatitis C\".\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1509": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age \u226518 years.\nThe patient is 55 years old, so this criterion is met.\n\n2. Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA.\nThe patient note mentions that the patient was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n3. Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis. \nThe patient's recent biopsy was remarkable for chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n\n4. HCV genotype 4.\nThe patient's HCV genotype is not mentioned in the note.\n\nSince the patient meets criteria 1-3 but there is not enough information to determine if criterion 4 is met, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1510": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection. He is currently on treatment with interferon, ribavirin, and direct antiviral drugs for the past 6 months.\n\nThe clinical trial is titled \"Long Term Treatment Interruptions\" and is a phase III study looking at continuing conventional HIV treatment versus structured treatment interruptions guided by CD4 count in chronically infected HIV patients.\n\nTo be eligible for this trial, the inclusion criteria state:\n1. Age > 17 years (The patient is 55, so meets this criteria)\n2. Informed consent signed (No information provided)\n3. Effective ongoing treatment (HIV-RNA < 50 copies/ml) with triple drug therapy for at least 3 months (The patient does not have HIV, he has HCV/HBV co-infection and is on different treatment)\n4. Current CD4 cell count above 600 cells/mcL and nadir of CD4 cell count > 200 cells/mcL (No CD4 count information provided for this patient)\n\nBased on the information given, the patient does not meet the key inclusion criteria of having HIV infection and being on effective HIV treatment.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1511": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Willing to adhere to study requirements as evidenced by providing written informed consent before initiation of any study-related procedures\n- No information provided about patient's willingness to consent\n\n2. Aged between 18-65 years\n- Patient is 55 years old, meets this criteria\n\n3. Documented history of chronic HCV infection (for at least 6 months prior to study entry) as diagnosed by either: Anti-HCV positive or HCV RNA viral load positive by PCR\n- Patient was diagnosed with HCV 2 years ago and has positive HCV RNA tests, meets this criteria\n\n4. Be a non-responder to or unsuitable for interferon based therapy.\n- Patient is on IFN, RBV and direct antiviral drugs for the past 6 months, suggesting he may have been a non-responder to interferon therapy alone. Meets this criteria.\n\n5. Have liver inflammation, as defined by either AST and/or ALT levels 2-10 x ULN on at least 1 previous occasion within the past 6 months and at Pre-treatment visit\n- No information provided about AST/ALT levels\n\n6. alpha-fetoprotein (AFP) less than/equal to 50\u00b5g/L\n- No information provided about AFP level\n\n7. Hemoglobin \u2265100g/L, platelet count \u226575x109/L, and white blood cell count \u22651.5x109/L\n- No lab values provided\n\n8. Males, or females who are not of child-bearing potential or who are taking adequate contraceptive measures...\n- Patient is a 55-year-old male, meets this criteria\n\n9. Liver biopsy within past 3 years showing stage 2 fibrosis only; or within past 6 years showing stage 0 or 1\n- Recent biopsy negative for hepatocellular carcinoma and only showed chronic inflammation, no information about fibrosis staging\n\nIn summary, the patient meets some of the key inclusion criteria like HCV diagnosis, age, and being a non-responder to interferon. However, there is insufficient information provided about liver enzyme levels, AFP, blood counts, and liver biopsy fibrosis staging to fully assess eligibility.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1512": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of \u2265 14 years.\n\n2. The patient has been diagnosed with HCV and HBV co-infection, which are not solid tumors. This does not meet the inclusion criteria of \"Histologically or cytologically confirmed malignant solid tumor\".\n\n3. The patient's medical history does not mention any solid tumors or cancers.\n\n4. The other inclusion criteria related to blood pressure, performance status, lab values, etc. cannot be assessed based on the given patient note.\n\nSince the patient does not have a confirmed malignant solid tumor, which is one of the key inclusion criteria for this trial, there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1513": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1) Subject is >18 years old - The patient is 55 years old, so this criterion is met.\n\n2) Subject has given written informed consent - There is no information about this in the patient note, so this criterion cannot be evaluated. \n\n3) Subject has a confirmed diagnosis of HIV and HCV infection - The patient is diagnosed with HCV 2 years ago and has a recent coinfection with HBV, but there is no mention of HIV infection. This criterion is not met.\n\n4) Subject is naive for HCV-infection treatment - The patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is not met.\n\n5) Subject has chronic hepatitis and/or subject has compensated cirrhosis (Child class A) - The patient has chronic viral hepatitis according to the biopsy, so this criterion is met.\n\n6) Subject has a CD4+ count of > 350 cell/mmc - There is no information about the patient's CD4+ count.\n\n7) Subject is HIV-RNA negative during the previous six month - There is no information about the patient's HIV status.\n\n8) Subject is on stable HAART including r/LPV for > 6 months - There is no mention of the patient being on HAART or any HIV treatment.\n\n9) Subject has genotype available at baseline and no mutations associated with resistance to PI or no virologic failure on PI treatment, defined as a confirmed HIV-RNA level>50 cp/mL after 24 weeks, > 50 cp/ml after 48 weeks, or a repeated HIV RNA level > 50 cp/mL after prior suppression of viremia to< 50 cps/mL. - There is no information about the patient's HIV genotype or treatment history.\n\n10) Free of any clinically significant disease (other than HIV and HCV) that would interfere with study evaluations. - The patient seems to be free of other significant diseases based on the information provided.\n\n11) Subject will use effective contraceptive methods for the duration of the study - There is no information about this.\n\nSince the patient does not have a confirmed HIV diagnosis and is already on HCV treatment, which are violated inclusion criteria, I would determine:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1514": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices\", let's go through the inclusion criteria one by one:\n\n1. Age older than 18 years: The patient is 55 years old, so this criterion is met.\n\n2. Positive anti-HCV and HCV RNA for more than 6 months: The patient note mentions that the patient was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests, so this criterion is met.\n\n3. Alanine aminotransferase level more than twice the upper limit of normal (ULN): There is no information provided about the patient's alanine aminotransferase level, so it is unclear if this criterion is met or not.\n\nSince one of the inclusion criteria cannot be confirmed based on the information provided in the patient note, there is not sufficient information to determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1515": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection.\n2. He is currently on treatment with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n3. There is no evidence of other liver diseases such as alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\n4. The patient does not have any significant past medical history and is not taking any other medications.\n5. The clinical trial is investigating a new drug (OPC-41061) for the treatment of hepatic edema (ascites) in patients with cirrhosis.\n\nNow, let's check the inclusion criteria for the clinical trial:\n\n1. Subjects with ascites despite taking either of the following combinations of loop diuretics and an anti-aldosterone agent (spironolactone) for at least 7 days prior to start of the study drug administration.\n   - The patient note does not mention if the patient is taking diuretics or spironolactone, so we cannot determine if this criterion is met.\n\n2. Patients who have been hospitalized or are able to stay at the study site from the start of the run-in observation period until completion of postdosing observation.\n   - The patient note does not provide information about the patient's ability to stay at the study site, so we cannot determine if this criterion is met.\n\n3. Subjects capable of giving informed consent to participate in the study of their own free will.\n   - The patient note does not provide information about the patient's ability to give informed consent, so we cannot determine if this criterion is met.\n\nBased on the information provided in the patient note and the inclusion criteria for the clinical trial, there is not enough information to determine if the patient is eligible or not. Therefore, the trial-level eligibility would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1516": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Age greater than or equal to 18 years - The patient is 55 years old, so meets this criteria.\n2) Documentation of HIV-1 infection - No mention of HIV infection in the patient note.\n3) Documentation of hepatitis C infection - The patient is diagnosed with HCV 2 years ago, so meets this criteria. \n4) Histopathologic features consistent with chronic hepatitis C - Recent biopsy was negative for hepatocellular carcinoma but remarkable for chronic inflammation compatible with chronic viral hepatitis, so meets this criteria.\n5) Patients infected with genotype 1 - No mention of HCV genotype in the patient note.\n6) Patients with CD4+ cell counts greater than 100 cells/mm3 - No CD4 count mentioned.\n7) Ability to sign informed consent and comply with study requirements - Can be assumed unless mentioned otherwise.\n8) Neutrophil count >1000, Platelets >75,000, Hemoglobin >10.5 g/dL - No lab values given.\n9) ALT < 7x ULN, Serum lipase <1.5x ULN - No lab values given.\n10) Not pregnant or breastfeeding - Patient is a man, so meets this.\n11-13) Contraception requirements - Not applicable for a male patient.\n14-16) Regarding addictions/supervised treatment - No mention of addictions.\n17) Has a primary doctor outside of study - Can be assumed unless mentioned otherwise.  \n18-22) Able to comply with study procedures - Can be assumed unless mentioned otherwise.\n\nExclusion Criteria:\n1) Cannot be on other experimental therapies - No mention of this.\n2) Cannot have used IFN/peg-IFN previously for HCV - Patient is on IFN, RBV and direct antivirals for 6 months, so excluded.\n3-16) Various exclusion criteria related to co-morbidities, lab values, etc. - Insufficient information provided.\n\nSince the patient has previously received interferon treatment for HCV, which is an exclusion criteria, he would be excluded from this trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "1517": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Written informed consent has been obtained - There is no information about this in the patient note.\n2. Adults 18 years of age or older - The patient is 55 years old, so this criterion is met.\n3. HIV infection documented by detectable HIV RNA PCR - The patient note does not mention HIV infection.\n4. Absolute CD4+ > 300 cells/mm3 - There is no information about CD4+ count in the patient note.\n5. Chronic hepatitis C infection based on history and detectable serum HCV RNA - The patient is diagnosed with HCV 2 years ago and has positive HCV RNA tests, so this criterion is met.\n6. Serum alanine aminotransferase (ALT) above normal limits and/or historical biopsy consistent with hepatitis C - There is no information about ALT levels, but the recent biopsy is compatible with chronic viral hepatitis.\n7. Complete blood counts within normal limits - There is no information about complete blood counts in the patient note.\n8. Normal renal function (serum creatinine within normal limits) - There is no information about renal function or serum creatinine in the patient note.\n9. PT/INR and aPTT within normal limits - There is no information about PT/INR and aPTT in the patient note.\n10. All patients of reproductive potential must agree to use an approved form of barrier contraception or agree not to become pregnant while taking study medications and for 30 days after study completion. Female patients must have a negative serum pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal) - The patient is a 55-year-old man, so this criterion is not applicable.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1518": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man diagnosed with HCV and HBV co-infection.\n2. The inclusion criteria for the clinical trial is \"Patients with laboratory tests positive for hepatitis B and/or C\".\n3. Based on the patient note, the patient has positive laboratory tests for both HCV and HBV.\n4. Therefore, the patient meets the inclusion criteria for this clinical trial.\n5. There is no information provided about exclusion criteria, so we cannot determine if the patient would be excluded.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1519": {
        "output": "Okay, let's go through the inclusion criteria for the \"Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection\" one by one:\n\n1. Chronic hepatitis C infection diagnosed by presence of hepatitis C ribonucleic acid (RNA) in serum by test of hepatitis C virus (HCV) RNA\n- The patient note mentions the patient was diagnosed with HCV 2 years ago and has positive HCV RNA tests, so this criterion is met.\n\n2. No significant alcohol use (7 or fewer drinks per week) for the past 12 months\n- There is no mention of alcohol use in the patient note, so we can assume this criterion is met.\n\n3. Serum AFP (at screening) within certain ranges based on the assay system used\n- There is no information provided about the patient's serum AFP level, so this criterion cannot be evaluated.\n\n4. Evidence of advanced liver disease based on low platelet count, high AST/ALT ratio, or liver biopsy showing bridging fibrosis or cirrhosis\n- The patient note does not provide platelet count, AST/ALT ratio, or liver biopsy results, so this criterion cannot be definitively evaluated. However, it does mention a recent biopsy was \"only remarkable for chronic inflammation compatible with a chronic viral hepatitis\" which suggests no evidence of advanced liver disease.\n\n5. No hepatitis C treatment for at least 4 months prior, and not anticipated to start treatment during the study\n- The patient has been on IFN, RBV and direct antiviral drugs for 6 months, so this criterion is not met.\n\n6. Ultrasound/CT/MRI showing no liver masses suggestive of hepatocellular carcinoma within 6 months\n- The recent biopsy was negative for hepatocellular carcinoma, so this criterion is met.\n\n7. Willing to refrain from over-the-counter SAMe and vitamin B supplements during the study\n- There is no information about this in the patient note.\n\n8. ECOG performance status 0-2\n- There is no information about the patient's performance status.\n\n9. Leukocytes > 1,000/mm^3 \n- There is no information about the patient's leukocyte count.\n\n10. Adequate contraception if child-bearing potential\n- There is no information about the patient's fertility status.\n\n11. Ability to understand and sign informed consent\n- This is typically assumed unless mentioned otherwise.\n\nSince there is insufficient information to evaluate several of the key inclusion criteria (e.g. serum AFP level, evidence of advanced liver disease, performance status, leukocyte count), I would determine the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1520": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronic genotype 1 Hepatitis C infection\nThe patient note mentions that the patient is diagnosed with HCV (Hepatitis C Virus) 2 years ago, so this criterion is met.\n\n2. Never been treated for Hepatitis C Viral (HCV) infection\nThe patient note does not explicitly state whether the patient has been treated for HCV before. It only mentions that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", which suggests the patient is currently being treated.\n\n3. No clinically significant lab abnormalities\nThe patient note does not provide any information about lab abnormalities.\n\n4. Amount of HCV Ribonucleic acid (RNA) in the blood more than 10,000 international units/milliliter (IU/mL) at entry\nThe patient note mentions previous positive HCV RNA tests, but does not specify the viral load.\n\n5. Liver biopsy or Fibroscan test performed during screening or in the past 3 years\nThe patient note mentions that a recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\n\nBased on the information provided in the patient note, there is not enough information to determine if the patient meets all the inclusion criteria, particularly regarding the previous treatment history and the HCV viral load.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1521": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection 2 years ago and recently co-infected with hepatitis B virus (HBV). He meets the inclusion criteria of having chronic HCV infection.\n\nHe has been on interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months. This suggests he may be a treatment-experienced patient, but it's not clearly stated if he has relapsed after previous treatment or is treatment-naive.\n\nHis medical records show positive HCV RNA tests and anti-HCV antibodies, meeting the criteria for documented HCV infection.\n\nThe recent biopsy was negative for hepatocellular carcinoma, meeting that inclusion criteria.\n\nThere is no evidence of other liver diseases like alcoholic liver disease, autoimmune hepatitis, etc., which would likely exclude him.\n\nHis vital signs and physical exam findings are within normal limits.\n\nBased on the information provided, there is insufficient evidence to determine if he meets the criteria of being a treatment-naive or relapsed patient for the different parts of the trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "1522": {
        "output": "Okay, let's go through the inclusion criteria one by one for this 55-year-old male patient with chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection:\n\n1. Diagnosis of chronic hepatitis C - Yes, the patient was diagnosed with HCV 2 years ago.\n\n2. Non-response to or relapse from primary standard HCV therapy - It's not explicitly stated, but the patient is currently on IFN, RBV and direct antiviral drugs, suggesting previous non-response or relapse.\n\n3. HLA A2 positive - This information is not provided in the patient note.\n\n4. HCV-RNA positive - Yes, the patient has previous positive HCV RNA tests.\n\n5. HCV antibodies positive - Yes, the patient had a positive enzyme immunoassay for anti-HCV-antibodies.\n\n6. Liver biopsy within 30 months prior to inclusion - Yes, the recent biopsy was negative for hepatocellular carcinoma.\n\n7. Hematology and biochemistry laboratory results within limits - No abnormal values provided, so assumed to be within limits.\n\n8. Male and female - The patient is male.\n\n9. From 18 to 65 years - The patient is 55 years old.\n\n10. Written informed consent obtained prior to study entry - This is not mentioned in the patient note.\n\nBased on the information provided, the patient meets most of the inclusion criteria except for the HLA A2 status and informed consent, which are not mentioned. However, there is insufficient information to definitively determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1523": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with:\n- Hepatitis C virus (HCV) 2 years ago\n- Recent coinfection with Hepatitis B virus (HBV)\n- He is currently on treatment with IFN, RBV and direct antiviral drugs for the past 6 months.\n\nThe clinical trial inclusion criteria are:\n1) Alcohol excess intake and suspected liver disease\n2) Alcohol excess intake and clinical liver cirrhosis \n3) Chronic hepatitis C virus infection and suspected liver disease\n4) Chronic hepatitis C virus infection and clinical liver cirrhosis\n\nBased on the patient note, the patient meets inclusion criteria 3) as he has chronic hepatitis C virus infection and suspected liver disease (chronic viral hepatitis).\n\nThere is no mention of alcohol excess intake or clinical liver cirrhosis in the patient note.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible",
        "label": 2
    },
    "1524": {
        "output": "To determine the patient's eligibility for the clinical trial \"Genetic Polymorphisms of Interleukin-1B and TNF-A and HBV-Related Hepatocellular Carcinoma\", let's go through the inclusion criteria:\n\nInclusion Criteria:\n- HBsAg-positive patients\n\nFrom the patient note, we can see that the patient is a 55-year-old man diagnosed with HCV and a recent coinfection with HBV. The note mentions that the patient is HBsAg-positive, which means he meets the inclusion criteria for the trial.\n\nThere is no mention of any exclusion criteria in the trial information provided, so we can assume that the patient is not excluded based on the available information.\n\nTherefore, based on the given patient note and the inclusion criteria for the clinical trial, the patient appears to be eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1525": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with:\n- Hepatitis C virus (HCV) 2 years ago\n- Recent coinfection with Hepatitis B virus (HBV)\n\nThe clinical trial is titled \"Genetic Polymorphisms of TNF-\u03b1 Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease\"\n\nThe key inclusion criteria is:\n\"HBV-positive patients\"\n\nSince the patient note mentions the patient has a recent coinfection with HBV, he meets this key inclusion criteria.\n\nThere is no other exclusion criteria mentioned that would exclude the patient.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1526": {
        "output": "To determine the patient's eligibility for the clinical trial \"Genetic Polymorphisms of Interleukin-10 and TNF-\u03b1 on Outcome of HCV-Related Chronic Liver Disease\", I will go through the inclusion criteria provided:\n\nInclusion Criteria:\nAnti-HCV-positive patients\n\nFrom the patient note, we can see that the patient has a positive enzyme immunoassay for anti-HCV-antibodies, indicating that the patient is anti-HCV-positive.\n\nSince the only inclusion criterion provided is being anti-HCV-positive, and the patient meets this criterion, the patient can be considered eligible for this clinical trial.\n\nThere is no information provided about exclusion criteria, so we cannot assess if the patient would be excluded based on any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1527": {
        "output": "To determine the patient's eligibility for the clinical trial \"Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis\", let's go through the inclusion criteria one by one:\n\n1. Clinical diagnosis of cystic fibrosis\nThe patient note does not mention a diagnosis of cystic fibrosis. This criterion is not met.\n\n2. Colonized with Pseudomonas aeruginosa\nThe patient note does not mention any colonization with Pseudomonas aeruginosa. This criterion is also not met.\n\n3. Informed consent\nThere is no information about whether the patient has provided informed consent or not.\n\nSince the patient does not meet the first two inclusion criteria, which are essential for this clinical trial, the patient is not eligible for this trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1528": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is 55 years old and has been diagnosed with chronic hepatitis C virus (HCV) infection for 2 years, as well as a recent co-infection with hepatitis B virus (HBV).\n\n2. The clinical trial is focused on preventing graft reinfection after liver transplantation in HCV patients using monoclonal antibodies.\n\n3. One of the inclusion criteria is \"Resolved HCV infection (HCV RNA negative since more than 6 months)\". Based on the patient note, the patient is currently being treated for HCV with antivirals, but it does not mention if the HCV infection has been resolved or not.\n\n4. Another inclusion criterion is \"HCV chronically infected (RNA positive)\". The patient note states that the patient has had positive HCV RNA tests in the past, indicating chronic HCV infection.\n\n5. The patient also meets the criterion of being anti-HCV antibody positive, as mentioned in the note.\n\nBased on the available information, the patient does not clearly meet the \"Resolved HCV infection\" criterion, but does meet the \"HCV chronically infected\" and \"Anti-HCV antibodies positive\" criteria.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 1) Not relevant.\n\nThe patient does not have sufficient information to definitively qualify or be excluded from the trial based on the provided inclusion criteria.",
        "label": 0
    },
    "1529": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial.\n\nThe patient is a 55-year-old man diagnosed with HCV and HBV co-infection. He has been on antiviral treatment for 6 months.\n\nLooking at the inclusion criteria:\n\n1. Liver transplantation performed for non-autoimmune liver disease performed at least 3 years before IS weaning.\n- The note does not mention if the patient has had a liver transplant, so this criterion cannot be evaluated.\n\n2. Absence of acute and/or chronic rejection episodes during the 12 months before weaning.\n- There is no information about liver transplant rejection episodes.\n\n3. Basal liver biopsy without signs of acute and/or chronic rejection. \n- The recent biopsy was negative for hepatocellular carcinoma but showed chronic inflammation from viral hepatitis.\n\n4. No evidences of autoimmune liver disease.\n- This is satisfied as the note states there is no evidence of autoimmune hepatitis.\n\n5. Low dose immunosuppression (monotherapy with calcineurin inhibitors, mTOR inhibitors or mycophenolate mofetil, or combined therapy with 2 drugs at very low doses).\n- There is no information about the patient's immunosuppression regimen.\n\n6. Absence of medical or psychological disturbances that preclude the safe performance of the trial.\n- This cannot be evaluated from the given information.\n\n7. Stability of liver graft function, defined as normal liver function tests or minor alterations that have not changed over 6 months.\n- There are no details provided about the patient's recent liver function tests.\n\n8. Patients exhibiting certain characteristics like side effects from immunosuppressants, risk of neoplasm, or chronic HCV infection not on treatment.\n- The patient has chronic HCV infection and is on antiviral treatment, so this criterion is partially met.\n\n9. Signature of informed consent.\n- This is not mentioned in the note.\n\nIn summary, there is insufficient information provided in the patient note to definitively determine eligibility for this clinical trial according to all the inclusion criteria listed.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1530": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with:\n- HCV 2 years ago\n- Recent coinfection with HBV\n- On treatment with IFN, RBV and direct antiviral drugs for the past 6 months\n\nThe inclusion criteria for the clinical trial are:\n1. HIV and either HBV or HCV co-infection\n2. 18 years and older\n3. Able to give informed consent\n\nBased on the information provided, the patient meets the following inclusion criteria:\n1. HIV and either HBV or HCV co-infection (The patient has HCV and HBV co-infection)\n2. 18 years and older (The patient is 55 years old)\n\nThere is no information provided about whether the patient is able to give informed consent or not.\n\nOverall, the patient meets 2 out of the 3 inclusion criteria explicitly stated. There is not enough information to determine if the patient meets the third criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1531": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Opioid-dependent patients on current stable agonist maintenance therapy (for at least 6 months prior to study enrolment) with methadone, buprenorphine, or suboxone.\n- The patient note does not mention any opioid dependence or maintenance therapy, so this criterion is not met.\n\n2. Patients need to be infected with chronic hepatitis C and must have indication for therapy with peginterferon alfa and ribavirin.\n- The patient note states that the patient is diagnosed with HCV 2 years ago and is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is met.\n\n3. Patients with informed written consent with respect to a follow-up of psychiatric side effects and in particular neurocognitive performance.\n- There is no information about consent in the patient note, so this criterion cannot be evaluated.\n\n4. Patients with baseline monitoring of emotional state and neurocognitive performance.\n- There is no information about baseline monitoring in the patient note, so this criterion cannot be evaluated.\n\nSince the patient does not meet the first inclusion criterion about being on opioid maintenance therapy, and there is not enough information to evaluate the other criteria, I would assess the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1532": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Previously untreated chronic hepatitis C with HCV-RNA positive in plasma.\nThe patient note mentions that the patient was diagnosed with HCV 2 years ago and has been on treatment for 6 months, so this criterion is met.\n\n2. Must have finished the detoxification phase of a drug rehabilitation program and abstained for at least 6 weeks from using abused substance (alcohol, I.V. drugs and inhaled drugs) before starting therapy.\nThere is no mention of the patient using any abused substances, so we can assume this criterion is met.\n\n3. Liver transaminases (alanine aminotransferase [ALT]) 1.5-fold above the upper limit of normal.\nThere is no specific mention of the patient's ALT levels, so we cannot confirm if this criterion is met.\n\n4. Controlled HIV infection with a viral load <10,000 copies/mL and a CD4 cell (T-cell) count >200 x 10^6 cells/L, in response to a stable antiretroviral treatment (ART) or without ART if it is not required.\nThe patient note mentions that the patient is coinfected with HBV, but there is no information about HIV infection or viral load/CD4 count, so we cannot confirm if this criterion is met.\n\n5. Compensated liver disease with protocol-specified minimum hematologic, biochemical, and serologic criteria at the Entry visit.\nThe patient note mentions that the recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation, so this criterion is likely met.\n\n6. Alpha-fetoprotein value within normal limits obtained within one year prior to entry. Results above the upper limit of normal but <=50 ng/mL require both of the following: Alpha-fetoprotein value <=50 ng/mL obtained within 3 months prior to entry in the study and Ultrasound obtained within 3 months prior to entry in the study or that is negative for evidence of hepatocellular carcinoma.\nThere is no information provided about the patient's alpha-fetoprotein value, so we cannot confirm if this criterion is met.\n\n7. Liver biopsy (optional) within 12 months prior to study entry with a pathology report confirming that the histologic diagnosis is consistent with chronic hepatitis.\nThe patient note mentions that a recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n\n8. Women of childbearing potential must be using an acceptable method of birth control or be surgically sterilized.\nThe patient is a 55-year-old man, so this criterion is not applicable.\n\n9. Reconfirmation that sexually active males must be practicing acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.\nThere is no information provided about the patient's sexual activity or contraceptive practices, so we cannot confirm if this criterion is met.\n\n10. Subjects must be free of any clinically significant diseases other than hepatitis or HIV infection that would interfere with study evaluations.\nThe patient note does not mention any other clinically significant diseases, so this criterion is likely met.\n\nSince there are some criteria that cannot be confirmed based on the information provided in the patient note, we cannot definitively determine if the patient is eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 0
    },
    "1533": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests and positive anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, shows chronic inflammation from viral hepatitis\n- No evidence of other liver diseases\n- Vitals within normal range\n\nThe inclusion criteria for the clinical trial are:\n1) Chronic hepatitis C patients with positive anti-HCV for more than 6 months and HCV RNA\n2) No overt hepatic failure or decompensated liver cirrhosis (Child-Pugh class B or C) or hepatocellular carcinoma\n\nBased on the information provided, the patient meets both of the inclusion criteria:\n1) He has chronic hepatitis C with positive anti-HCV for over 6 months and HCV RNA\n2) He does not have hepatic failure, decompensated cirrhosis, or hepatocellular carcinoma\n\nTherefore, there is sufficient information to determine eligibility, and the patient appears to meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1534": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of \u226518 years for the clinical trial.\n\n2. The patient has been diagnosed with HCV and HBV co-infection, which is not relevant to the inclusion criteria for a trial on chronic prostatitis/chronic pelvic pain syndrome.\n\n3. There is no mention of the patient having chronic prostatitis/chronic pelvic pain syndrome or any related symptoms like pelvic pain, penile pain, etc.\n\n4. The patient's laboratory values like hemoglobin, hematocrit, WBC count, platelets, creatinine, bilirubin, AST, and ALT are not provided, so it's unclear if he meets those criteria.\n\n5. There is no information about the patient's contraceptive use or willingness to use barrier contraception during the trial.\n\nBased on the lack of information about the key inclusion criteria of having chronic prostatitis/chronic pelvic pain syndrome and meeting the required laboratory values, as well as no details about contraceptive use, I would assess that this patient does not have sufficient information to be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1535": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of being older than 12 years.\n2. The patient is diagnosed with HCV and has positive HCV RNA tests, meeting the criteria of being HCV RNA positive.\n3. The patient does not have thalassemia, which is not explicitly mentioned as an inclusion criterion.\n\nBased on the information provided, the patient meets the two stated inclusion criteria of being HCV RNA positive and being older than 12 years of age.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1536": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for the clinical trial step-by-step:\n\nThe patient is a 55-year-old man, so he meets the age criteria of being 18 years or above.\n\nHe has chronic hepatitis C virus (HCV) infection, as mentioned in the note \"diagnosed with HCV 2 years ago\". His HCV RNA levels are not explicitly stated but it is mentioned that he had previous positive HCV RNA tests, so he likely meets the criteria of HCV RNA levels \u2265 10,000 IU/ml.\n\nHe is willing to undergo liver biopsy, as mentioned \"The recent biopsy was negative for hepatocellular carcinoma\".\n\nHe has not received previous adequate interferon treatment, as there is no mention of prior interferon therapy in his medical history.\n\nHe does not have decompensated liver disease, as evidenced by the normal lab values (bilirubin, albumin, prothrombin time) and absence of ascites, bleeding varices or hepatic encephalopathy.\n\nHis ALT/AST levels are not provided but are likely below the exclusion criteria of >1000 micro/L, given the lack of mention of elevated liver enzymes.\n\nHe is not pregnant or breastfeeding (being a man).\n\nHe does not have significant systemic illnesses like HIV, psychiatric disease, heart failure etc. based on the medical history provided.\n\nHe does not have pre-existing anemia, as there is no mention of it.\n\nHe is not on immunosuppressive therapy like corticosteroids.\n\nThere is no evidence of other forms of liver disease like autoimmune, alcoholic, hemochromatosis etc. The note specifically states \"no evidence of alcoholic liver disease, hemochromatosis, autoimmune hepatitis, or metabolic liver disease.\"\n\nNo mention of coronary artery disease, cerebrovascular disease or abnormal stress tests.\n\nNo active substance abuse mentioned.\n\nNo evidence of hepatocellular carcinoma, as mentioned \"The recent biopsy was negative for hepatocellular carcinoma\".\n\nNo mention of gout.\n\nNo mention of autoimmune diseases like lupus, rheumatoid arthritis etc.\n\nBased on the information provided in the patient note and the inclusion/exclusion criteria, this patient appears to meet all the inclusion criteria and does not have any of the exclusion criteria mentioned.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1537": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Treatment naive (no prior treatment with IFN-a +/- RBV regimens. Subjects who have discontinued IFN-a containing regimens after <2 weeks of therapy due to tolerability issues are considered treatment naive.\n- The patient note states that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months.\" This means the patient has received prior treatment with IFN-a and RBV for longer than 2 weeks, so they do not meet this criteria.\n\n2. HCV RNA > 100,000 IU/mL at screening.\n- There is no information provided about the patient's HCV RNA level, so it's unclear if they meet this criteria or not.\n\n3. Genotype 1. \n- The patient's HCV genotype is not mentioned, so again it's unclear if they meet this criteria.\n\n4. A diagnosis of chronic HCV infection for at least 6 months.\n- The patient note states the patient was \"diagnosed with HCV 2 years ago\", so they do meet this criteria.\n\nSince the patient does not meet at least one of the inclusion criteria (being treatment naive) and there is insufficient information to determine if they meet some of the other criteria, I would assess:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "1538": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Diagnosis of HCV with detectable HCV RNA in serum\nThe patient note states that the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\n2. Meets clinical criteria for initiating HCV therapy\nThe patient note mentions that the patient is currently on IFN, RBV and direct antiviral drugs for HCV treatment for the past 6 months, so this criterion is met.\n\n3. Lives in the community and not in a board and care, nursing home, hospice, or other residential setting in which a professional caregiver would dispense necessary medication.\nThere is no information provided about the patient's living situation, so this cannot be determined from the note.\n\n4. Responsible for administering own medications\nThere is no information provided about who administers the patient's medications, so this cannot be determined.\n\n5. Diagnosis of HIV-associated neurocognitive disorder (HAND) will not be cause for exclusion, so long as participant is able to demonstrate the ability to grant full informed consent\nThe patient is not mentioned to have HAND, so this is not an issue.\n\n6. HIV or HCV disease severity will not be cause for exclusion...\nThe patient does not seem to have severe HIV or HCV disease based on the information provided.\n\n7. Able to read English at the 6th grade level\nThere is no information about the patient's reading level.\n\nSince there is insufficient information to determine if the patient meets criteria 3, 4, and 7, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1539": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. \"Medical inclusion criteria were a detectable serum HCV-RNA level in a PCR-based assay (AMPLICOR\u00ae, Roche Diagnostics, Branchburg, NJ) for more than 6 months\"\n   - The patient note states that the patient has had a positive HCV RNA test, satisfying this criteria.\n\n2. \"and an elevated alanine aminotransferase (ALT > 30 U/L, normal <24 U/L).\"\n   - There is no mention of the patient's ALT levels in the note, so this criteria cannot be definitively assessed.\n\nSince one of the inclusion criteria cannot be fully evaluated based on the information provided in the patient note, I would determine the trial-level eligibility as:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 0
    },
    "1540": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria:\n\nInclusion Criteria: History proven HCC patients\n\nFrom the patient note, we can see that the patient is a 55-year-old man diagnosed with HCV and HBV co-infection. The recent biopsy was negative for hepatocellular carcinoma (HCC). There is no mention of a history of HCC.\n\nSince the patient does not have a history of HCC, which is the only inclusion criterion mentioned, the patient does not meet the eligibility requirements for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1541": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HCV infection confirmed on a positive test for anti-HCV antibody and HCV RNA detectable in serum by Polymerase Chain Reaction.\nThe patient note mentions positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n2. Histological diagnosis of chronic hepatitis. \nThe patient note states that the recent biopsy was remarkable for chronic inflammation compatible with chronic viral hepatitis, so this criterion is met.\n\n3. Patients who were non-responders to previous treatment with pegylated interferon and ribavirin or who had contraindicated the antiviral treatment.\nThe patient note mentions the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, suggesting he may have been a non-responder to previous pegylated interferon and ribavirin treatment. This criterion is likely met.\n\n4. Age between 18 and 65 years.\nThe patient is 55 years old, which falls within this age range. This criterion is met.\n\n5. Ability to provide informed consent.\nThere is no information about the patient's ability to provide informed consent, so we cannot determine if this criterion is met or not.\n\n6. Absence of significant alcohol ingestion (weekly ethanol consumption of less than 40 g)\nThe patient note states there is no evidence of alcoholic liver disease, suggesting the patient likely does not have significant alcohol ingestion. This criterion is likely met.\n\nOverall, based on the information provided, the patient appears to meet most of the key inclusion criteria. However, there is not enough information to definitively determine if the patient can provide informed consent.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1542": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of \u226518 years old.\n\n2. The patient is diagnosed with HCV and HBV co-infection, but the trial is specifically looking for HBV and HIV co-infection patients.\n\n3. There is no mention of the patient having HIV infection.\n\n4. The other inclusion criteria like being followed at the RHSP or IDI clinic, willingness to provide consent, and ability to follow study instructions are not addressed in the patient note.\n\n5. There is no information provided about pregnancy status, cardiac devices, or willingness to allow sample storage (the exclusion criteria).\n\nBased on the information provided in the patient note, there is insufficient evidence to determine if the patient meets all the inclusion criteria or any of the exclusion criteria for this particular clinical trial on HBV and HIV co-infection.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1543": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria for this osteoarthritis trial (no specific age cutoffs given in the inclusion criteria).\n\n2. The patient note does not mention osteoarthritis of the knee or hip, which is a key inclusion criteria for this trial. There is no information provided about the patient having osteoarthritis.\n\n3. The patient note mentions the patient has hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfection and is being treated with interferon, ribavirin, and direct antiviral drugs. However, the trial is specifically for osteoarthritis patients.\n\n4. There is no information provided about the patient's pain levels, function levels, willingness to discontinue non-study medications, or ability to comply with the trial procedures.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the key inclusion criteria of having osteoarthritis of the knee or hip, as well as details about pain/function levels and willingness to follow trial procedures:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1544": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1) Male and female, 18 years of age or older\n- The patient is a 55-year-old man, so he meets this criteria.\n\n2) HBsAg positive for more than 6 months  \n- The patient is recently co-infected with HBV, so it's unclear if he meets this criteria based on the information given.\n\n3) Serum HBV DNA > 2,000 IU/ml\n- No serum HBV DNA level is provided, so unable to assess this criteria.\n\n4) Serum ALT < 2 X ULN on two consecutive occasions at least 3 months apart\n- No ALT levels provided.\n\n5) Na\u00efve to nucleoside or nucleotide therapy\n- It mentions the patient is on IFN, RBV and direct antiviral drugs for 6 months, so he does not meet this criteria.\n\n6) On liver biopsy, fibrosis score \u2265 3 according to METAVIR scoring system (within 2 years of Day 0)\n- The recent biopsy was only remarkable for chronic inflammation, no fibrosis score given.\n\n7) If no biopsy, must have 2 of: radiologic cirrhosis evidence, varices, platelets <100K, splenomegaly\n- No evidence of cirrhosis, varices or splenomegaly mentioned. Platelet count not given.\n\n8) Able to provide written informed consent\n- Not mentioned, but can generally be assumed for clinical trials.\n\nExclusion Criteria:\n1) History of SBP, variceal bleeding, HEP, HCC\n- No history of these mentioned.\n\n2) Decompensated liver disease (Child-Pugh >10)\n- No Child-Pugh score given.\n\n3) Co-infected with HCV or HIV\n- The patient is co-infected with HCV, so meets this exclusion criteria.\n\n4) History of any other forms of liver disease\n- No other liver diseases mentioned.\n\n5) Pregnant/breastfeeding \n- No mention of this, but likely does not apply as patient is male.\n\n6) Immunosuppressive/antiviral agents within 6 months\n- The patient is currently on antivirals, so meets this exclusion.\n\n7) History of liver transplant or planned transplant\n- No mention of liver transplant.\n\n8) Other medical conditions making patient unsuitable\n- No other conditions mentioned.\n\n9) Current alcohol/illicit drug abuse or history within 2 years\n- No mention of alcohol or drug abuse.\n\n10) Enrolled in another clinical trial\n- No mention of this.\n\nIn summary, based on the information provided, the patient meets at least one of the inclusion criteria (age) but also meets two of the exclusion criteria (co-infected with HCV and currently on antivirals).\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1545": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Chronic HCV infection: The patient note mentions that the patient was diagnosed with HCV 2 years ago, indicating a chronic HCV infection. This criterion is met.\n\n2. Must undergo liver biopsy: The patient note states that a recent biopsy was performed and was negative for hepatocellular carcinoma but showed chronic inflammation compatible with chronic viral hepatitis. This criterion is met.\n\n3. Must undergo antiviral treatment: The patient note mentions that the patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, indicating that the patient is undergoing antiviral treatment. This criterion is met.\n\nSince all the inclusion criteria are met, and there is no information provided about any exclusion criteria, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1546": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Patients must be chronic alcohol users, defined by a history of ethanol consumption on average > 40g/day for women and 60g/day for men for at least 1 year before inclusion.\n- The patient note does not mention alcohol consumption, so this criterion cannot be evaluated.\n\n2. The presumptive diagnosis for alcoholic hepatitis will be: recent binge drinking; compatible physical findings (one or more: jaundice, enlarged liver, hepatic bruit, abdominal pain, loss of appetite, nausea); and a compatible biochemical profile (moderate elevation of AST over ALT, elevated total serum bilirubin); or a liver-spleen colloid scan suggestive of reticulo-endothelial redistribution and hepatic arterialization.\n- The patient has HCV and HBV co-infection, but no mention of alcoholic hepatitis diagnosis.\n\n3. The diagnosis of alcoholic hepatitis must be confirmed on liver biopsy, showing typical features of acute sclerosing hyaline necrosis 70.\n- The recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation from viral hepatitis.\n\n4. The degree of portal fibrosis as determined on liver biopsy, graded according to the Knodell score-modified by Ishak 71 must be less than or equal to 5 out of a possible score of 6, 6 indicating cirrhosis.\n- No information about fibrosis score is provided.\n\n5. The alcoholic hepatitis must be stable, i.e. not requiring treatment by either pentoxifylline 72 or prednisone, with a Maddrey Score 73 {(PTpatient - PTcontrol) x 4.6 + TBmg/dL} < 32.\n- This criterion relates to alcoholic hepatitis, which the patient does not seem to have.\n\n6. Patients must be willing to participate in the trial, remain abstinent to alcohol, and compliant to the treatment regimen, and undergo a post-treatment liver biopsy.\n- No information about willingness to participate or remain abstinent is provided.\n\nBased on the information given, the patient does not seem to meet the key inclusion criteria of having alcoholic hepatitis confirmed by biopsy. There is also insufficient information to evaluate some other criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1547": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. \"Patients with liver disease followed at the liver unit at Hadassah Medical Center.\"\nThe patient note mentions that the patient is a 55-year-old man diagnosed with HCV (Hepatitis C Virus) and a recent coinfection with HBV (Hepatitis B Virus). This indicates that the patient has liver disease, satisfying this criterion.\n\n2. \"Patients who have given their informed consent for participation in the study.\"\nThere is no information provided about whether the patient has given informed consent or not. We cannot determine if this criterion is met or not.\n\nSince one of the inclusion criteria cannot be evaluated based on the given information, the patient's eligibility cannot be fully determined.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "1548": {
        "output": "To determine the patient's eligibility for the clinical trial \"Prediction of Hepatitis C Recurrence in Liver Transplant Recipients\", let's go through the inclusion criteria one by one:\n\n1. Patients must be >18 years of age\nThe patient is 55 years old, so this criterion is met.\n\n2. Chronic HCV infection (and cirrhosis) - group 1\nThe patient is diagnosed with HCV 2 years ago, indicating chronic HCV infection. However, there is no mention of cirrhosis in the patient note.\n\n3. HCV RNA positive pre-transplant - group 1\nThe patient note mentions previous positive HCV RNA tests, satisfying this criterion.\n\n4. Liver cirrhosis not due to HCV infection - group 2\nSince the patient has chronic HCV infection, this criterion is not applicable.\n\nBased on the information provided in the patient note, the patient meets criteria 1 and 3 but does not have enough information to confirm criterion 2 (presence of cirrhosis). Therefore, there is not sufficient information to determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1549": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subject must be willing to give informed consent and be able to adhere to dose and visit schedules.\n   - There is no information provided about whether the patient is willing/able to do this, so I cannot determine eligibility for this criterion.\n\n2. History of chronic hepatitis C, genotype 1, non-responders or relapsers as documented by genotype testing and HCV RNA levels at 12 weeks ( < 2 log change) during therapy or at 3 - 12 months post therapy, respectively.\n   - The patient note states the patient has HCV genotype 1 and has been on antiviral therapy for 6 months, so he likely meets this criterion.\n\n3. Adult subjects 18-70 years of age, of either gender\n   - The patient is a 55-year-old man, so he meets this age/gender criterion.\n\n4. Liver biopsy within 3 years prior to the screening 1 visit with a pathology report confirming that the histological diagnosis is consistent with chronic hepatitis C.\n   - The patient had a recent biopsy that was negative for hepatocellular carcinoma but showed chronic inflammation compatible with chronic viral hepatitis, so he likely meets this criterion.\n\n5. Compensated liver disease with specific hematologic, biochemical and serologic criteria listed.\n   - The patient's BP, HR, BMI, and lack of ascites/edema suggest compensated liver disease, but his lab values are not provided to confirm he meets the listed criteria.\n\n6. Fasting glucose 70-140 mg/dl or HbA1c <8.5% if 116-140 mg/dl.\n   - No information on fasting glucose or HbA1c is provided.\n\n7. TSH within normal limits.\n   - No information on TSH is provided.\n\n8. Subjects with mild depression may be considered if clinically stable.\n   - No mention of depression.\n\n9. Substance abuse - must have abstained for 1 year prior.\n   - No mention of substance abuse history.\n\n10. ANA < 1:320\n    - No ANA value provided.\n\n11. No radiologic evidence of hepatoma or ascites.\n    - Recent biopsy negative for hepatocellular carcinoma and no mention of ascites, so he likely meets this.\n\nIn summary, the patient appears to potentially meet several of the key inclusion criteria related to his HCV diagnosis, genotype, treatment history, and lack of hepatocellular carcinoma. However, there is insufficient information provided about some laboratory values and other medical details to definitively determine full eligibility.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1550": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male and female subjects, 18-65 years of age, inclusive.\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Cases will be genotype 1 (confirmed by standard testing). Enrollment of controls will not be restricted by genotype.\nThere is no information provided about the patient's HCV genotype, so this criterion cannot be evaluated.\n\n3. All patients must show evidence of chronic hepatitis C, confirmed by detectable plasma HCV RNA. Chronic disease status must be confirmed by at least one of the following standard criteria:\n   a) History of a remote risk factor\n   b) Abnormal ALT levels for >6 months prior to screening period\n   c) Detectable HCV RNA for at least 6 months before the screening period\nThe patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so he meets this criterion.\n\n4. Liver biopsy obtained within 24 months of study enrollment demonstrating absence of cirrhosis (stage 0-3) for cases. Enrollment of controls will not be restricted by stage of fibrosis.\nThe recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation, so the patient likely meets this criterion.\n\n5. Judged to be in good health on the basis of medical history and physical examination (including vital signs and ECG), with any chronic medical conditions under stable medical control.\nThe patient's medical history is non-significant, and his vital signs (BP, HR, BMI) are within normal ranges, so he appears to meet this criterion.\n\n6. Screening Visit laboratory values must be within the specified ranges.\nThere is no information provided about the patient's laboratory values, so this criterion cannot be evaluated.\n\n7. Subjects (or their female partners) must not be pregnant, planning to become pregnant within the next 72 weeks, or they must be permanently sterile or otherwise of non-childbearing potential. They must also not be breastfeeding. If of child-bearing potential, subjects must agree to use 2 effective methods of contraception from screening through 6 months after the last dose of RBV. Male subjects who have a female partner of childbearing potential must agree to use 2 effective methods of contraception from Screening through 7 months after the last dose of RBV unless vasectomized.\nThere is no information provided about the patient's fertility status or use of contraception, so this criterion cannot be evaluated.\n\n8. Female subjects must have a negative pregnancy test at all visits (screening and predose Day 1) before the first dose of study drugs.\nThis criterion is not applicable since the patient is male.\n\n9. Willing to refrain from the concomitant use of any medications, substances or foods.\nThe patient is currently taking IFN, RBV, and direct antiviral drugs, so he may not meet this criterion.\n\n10. Able to read and understand the Informed Consent Form (ICF) and willing to sign the ICF and abide by the study requirements and restrictions.\nThere is no information provided about the patient's ability to understand and sign the informed consent form, so this criterion cannot be evaluated.\n\nBased on the information provided, the patient appears to meet some of the inclusion criteria, but there are several criteria that cannot be evaluated due to lack of information. Additionally, the patient may not meet the criterion regarding concomitant medication use.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1551": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge over 18 years - The patient is 55 years old, so this criterion is met.\n\nWeight 85 kg below the pre-inclusion visit - No weight is provided, so this cannot be assessed. \n\nDocumented HIV infection (HIV positive) - The note does not mention HIV status, so this cannot be confirmed.\n\nHCV infection documented by a positive PCR - The note mentions the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\nHCV Genotype 1 or 4 - The genotype is not provided, so this cannot be assessed.\n\nCompensated liver disease (Child-Pugh below/equal to 6) - No Child-Pugh score is given, but the note mentions no evidence of decompensated liver disease, suggesting compensated disease. This criterion is likely met.\n\nLymphocytes CD4 above 200/mm3 - No CD4 count is provided, so this cannot be confirmed.\n\nPatient not answering a treatment for hepatitis C - The note states the patient is on IFN, RBV and direct antiviral drugs for HCV for the past 6 months, so this criterion is not met.\n\nPatient not covered by dual by Peg-IFN + riba for at least three months (wash out) - As the patient is currently on this treatment, the wash out period criterion is not met.\n\nIn summary, while some criteria are met, there is insufficient information to fully assess eligibility, and the patient is currently receiving the treatment being studied.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1552": {
        "output": "Based on the provided patient note and the inclusion/exclusion criteria for the clinical trial titled \"OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects\", the patient does not appear to be eligible for this trial.\n\nThe key reasons are:\n\n1. The patient is being treated for hepatitis C virus (HCV) and hepatitis B virus (HBV) coinfection, and there is no mention of osteoarthritis (OA) or chronic non-malignant pain requiring around-the-clock opioid therapy, which is one of the inclusion criteria for this trial.\n\n2. The trial is specifically studying the effects of two different oxycodone formulations in patients with moderate to severe OA pain, whereas this patient's condition is related to viral hepatitis.\n\n3. While the patient's liver function appears to be normal based on the provided information, the trial excludes subjects with evidence of impaired liver/kidney function, and the patient's kidney function is not mentioned.\n\nTherefore, based on the available information, this patient does not meet the inclusion criteria and may potentially be excluded due to the lack of relevant medical condition (OA) and the possibility of impaired kidney function (not mentioned).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1553": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with:\n- HCV 2 years ago\n- Recent coinfection with HBV\n- On treatment with IFN, RBV and direct antiviral drugs for the past 6 months\n- No evidence of hepatocellular carcinoma on recent biopsy\n\nThe clinical trial is studying the use of GP73 as a tumor marker for hepatocellular carcinoma (HCC) in patients with HBV and HCV.\n\nThe inclusion criteria state:\n1) Patients with no history of liver disease (this patient has HCV and HBV)\n2) Patients with HCC (this patient does not have HCC based on the biopsy)\n3) Patients with HBV & HCV matched to HCC patients (this patient has HBV and HCV but no HCC)\n\nBased on the information provided, this patient does not fully meet the inclusion criteria as he has HBV/HCV but no documented HCC. He may potentially be included in the trial as a matched control to HCC patients, but there is insufficient information to determine eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1554": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Signed patient consent form - Not mentioned in the patient note, so cannot determine eligibility based on this.\n\n2. Genotype 1 chronic HCV with detectable HCV RNA - The note mentions the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\n3. No previous treatment for HCV infection - The note states the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", indicating previous/current treatment, so this criterion is not met.\n\n4. Hepatitis B and human immunodeficiency virus negative at screening visit - The note mentions the patient has a recent coinfection with HBV, so this criterion is not met.\n\n5. Able and willing to follow contraception requirements - Not mentioned, so cannot determine eligibility.\n\n6. Screening laboratory values, test, and physical exam within acceptable ranges - The note provides some lab values like BP, HR, BMI which seem normal, but does not give full details, so cannot fully assess this criterion.\n\n7. Weight between 40 kg and 125 kg - Not mentioned, so cannot determine eligibility. \n\n8. Proficiency in the use of the external pump infusion system - Not mentioned, so cannot determine eligibility.\n\nSince the patient does not meet criteria 3 and 4 due to previous HCV treatment and HBV coinfection, and there is insufficient information to assess some other criteria, I would determine:\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "1555": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Serologic evidence of HCV infection by an anti-HCV antibody test.\nThe patient note states that the patient has \"previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies\", so this criterion is met.\n\n2. Serum HCV RNA quantifiable > 20,000 copies/mL at screening period and demonstrate abnormal ALT > 40 for 6 months.\nThere is no information provided about the patient's HCV RNA viral load or ALT levels, so it is unclear if this criterion is met.\n\n3. No clinical suspicion or radiological evidence of hepatocellular carcinoma and a serum AFP < 50 ng/mL.\nThe patient note mentions that \"The recent biopsy was negative for hepatocellular carcinoma\", so this criterion is met.\n\n4. Negative urine pregnancy test for women of childbearing potential documented within the 24-hour period prior to the first dose for test drug.\nThe patient is a 55-year-old man, so this criterion is not applicable.\n\nSince there is insufficient information to determine if the second inclusion criterion is met, I would assess the patient's eligibility as:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1556": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Written informed consent - Not mentioned in the patient note, so cannot assess this criteria.\n\n2. Age > 18 years - The patient is 55 years old, so meets this criteria.\n\n3. Positive HBsAg for at least 6 months, positive anti-HDV for at least 3 months and positive for HDV-RNA by PCR within screening period - The note mentions the patient has HBV and HDV co-infection, so likely meets this criteria.\n\n4. Elevated serum ALT \u2265 ULN but \u2264 10X ULN with two abnormal values taken > 1 month apart in last 12 months - No information provided about ALT levels, so cannot assess this criteria. \n\n5. Liver biopsy in last 12 months showing chronic hepatitis, and imaging to rule out hepatocellular carcinoma if cirrhotic - The note mentions a recent negative biopsy for hepatocellular carcinoma with chronic inflammation, so meets this criteria.\n\n6. Negative pregnancy test for females - Not applicable as patient is male.\n\n7. Use of contraception - Not mentioned, so cannot assess.\n\n8. Creatinine clearance \u2265 70 mL/min - No information provided, so cannot assess.\n\nIn summary, the patient meets some of the key inclusion criteria like age, HBV/HDV co-infection and recent negative biopsy. However, there is insufficient information to fully assess eligibility based on the criteria provided.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1557": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Males or females, 18 to 55 years of age who are diagnosed with HCV by PCR\nThe patient is a 55-year-old male diagnosed with HCV, so this criterion is met.\n\n2. HCV treatment-na\u00efve patients who have already committed to undergo standard of care therapy (SOC) for HCV (pegylated interferon and ribavirin), and who wish to participate in a study immediately prior to the initiation of SOC\nThe patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so he is not treatment-naive. This criterion is not met.\n\n3. Chronic hepatitis C infection, genotype 1 or genotype 2, two documented tests (PCR or HCV Ab; if one of the tests is HCV Ab, then the second test must be PCR and the PCR test must be at least 6 months after the HCV Ab test) at least 6 months apart\nThe patient has positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so this criterion is met.\n\n4. Liver biopsy within the last two (2) years (biopsy can be done at the Screening Visit)\nThe patient had a recent biopsy that was negative for hepatocellular carcinoma, so this criterion is met.\n\n5. Positive viral load of <1,000,000 IU/mL as measured by quantitative PCR\nThere is no information provided about the patient's viral load, so this criterion cannot be assessed.\n\n6. Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality and a QT/QTc interval <450 milliseconds - using Bazett's correction: QTc =QT/RR0.5 (ICH Guidance E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs)\nThere is no information provided about the patient's ECG or QT/QTc interval, so this criterion cannot be assessed.\n\n7. Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable birth control methods throughout the study: ...\nThis criterion is not applicable since the patient is male.\n\n8. Willing and able to comply with study procedures and provide written informed consent\nThere is no information provided about the patient's willingness or ability to comply with study procedures or provide informed consent, so this criterion cannot be assessed.\n\nSince the patient is not treatment-naive and there is insufficient information to assess some of the other criteria, the overall trial-level eligibility cannot be determined definitively.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1558": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man, which meets the age criteria of being born before 1985/01/01.\n\nHe is diagnosed with HCV and has a recent coinfection with HBV, which meets the criteria of being an HBV or HCV carrier.\n\nBased on the inclusion criteria provided, this patient appears to be eligible for the clinical trial investigating hepatitis B and hepatitis C genotypes in Taiwan.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1559": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Willing to consent to data being collected and provided to the Duke Clinical Research Institute (DCRI) and Three Rivers Pharmaceuticals\n- No information provided, so cannot determine eligibility for this criteria\n\n2. Able and willing to give written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, and to comply with the requirements of the registry protocol\n- No information provided, so cannot determine eligibility for this criteria\n\n3. Anti-HCV antibody-positive\n- The patient note states \"His medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\" So this criteria is met.\n\n4. HCV RNA concentration >100,000 IU/mL on reverse transcriptase-polymerase chain reaction (RT-PCR) assay at baseline or >90 days before the baseline visit\n- No information on HCV RNA concentration provided, so cannot determine eligibility for this criteria\n\n5. Deemed by the investigator to be an appropriate patient for treatment with Infergen and other prescribed medications\n- No information provided about investigator assessment, so cannot determine eligibility\n\n6. Baseline CD4 count >200 cells/mm3 (human immunodeficiency virus [HIV]-HCV coinfected patients)\n- No information on CD4 count provided, but it does not mention HIV co-infection, so this may not apply\n\n7. Women reproductive criteria\n- The patient is a man, so these criteria do not apply\n\n8. Age >18 years\n- The patient is 55 years old, so meets this criteria\n\nIn summary, the patient meets some of the key inclusion criteria like being anti-HCV antibody positive and being over 18 years old. However, there is insufficient information provided to fully determine eligibility based on criteria like HCV RNA concentration, investigator assessment, ability to consent, etc.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 2
    },
    "1560": {
        "output": "To determine the patient's eligibility for the clinical trial \"PEG-IFN Plus Ribavirin Combination Therapy for Older Patients\", let's go through the inclusion criteria:\n\n1. Age: The patient is 55 years old, which meets the age requirement of 18 years or older.\n\n2. Japanese ethnicity: The patient's ethnicity is not mentioned, but this criterion is not essential for determining eligibility.\n\n3. Positive for antibody to HCV and HCV-RNA for over six months: The patient note states that the patient was diagnosed with HCV 2 years ago and had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, meeting this criterion.\n\n4. Treated with PEG-IFN alpha-2b plus RBV: The patient note mentions that the patient is on IFN, RBV, and direct antiviral drugs for the past 6 months, which aligns with the treatment requirement.\n\nBased on the information provided in the patient note, the patient meets all the essential inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1561": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago\n- Recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- Previous positive HCV RNA tests and positive anti-HCV antibodies\n- Recent biopsy negative for hepatocellular carcinoma, shows chronic inflammation from viral hepatitis\n- No evidence of other liver diseases\n- Vitals within normal range\n\nThe inclusion criteria for the clinical trial state:\n- Adult patients of First Nations, Metis and non-First Nations descent\n- Referred for treatment at one of the three study centers\n\nBased on the information provided, the patient meets the inclusion criteria of being an adult referred for HCV treatment. There is no exclusion criteria mentioned that would exclude this patient.\n\nTherefore, the trial-level eligibility for this patient would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1562": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Age 18-55 years: The patient is 55 years old, which meets this criterion.\n\n2. Enrolled at the participating methadone maintenance clinic for the past 2 months: There is no information provided about the patient being enrolled in a methadone maintenance clinic, so this criterion cannot be evaluated.\n\n3. Moderate to heavy alcohol users within the last 3 months: There is no information provided about the patient's alcohol use, so this criterion cannot be evaluated.\n\nSince there is not enough information to determine if the patient meets all of the inclusion criteria, the appropriate assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1563": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 55-year-old man, which meets the age criteria of 18-60 years old.\n\nHe is diagnosed with HCV genotype 2 years ago, which meets the criteria of being chronically infected for at least 3 months.\n\nThe patient note mentions he is positive for anti-HCV antibodies, which meets that inclusion criteria. \n\nHowever, the inclusion criteria specifies \"Biopsy proven infection with Hepatitis C genotype 1\", while the patient has genotype 2 HCV infection based on the note.\n\nThe patient's ECOG performance status is not mentioned, so we cannot determine if he meets that criteria.\n\nHe has received treatment with IFN, RBV and direct antiviral drugs, which aligns with the criteria of previous therapy with interferon +/- ribavirin or being ineligible for this type of therapy.\n\nBased on the information provided, the main exclusion factor is that the patient does not have a biopsy-proven genotype 1 HCV infection, which is an inclusion criteria for this particular trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "1564": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 55-year-old man, which meets the age criteria of > 18 and \u2264 70 years.\n\nHe has been diagnosed with HCV and HBV co-infection. The trial is specifically looking for chronic hepatitis B patients.\n\nHis HBV viral load is stated to be low, which meets the criteria of HBV DNA < 20,000 IU/mL.\n\nHe is HBeAg negative for more than 6 months, which meets that criteria.\n\nHis ALT levels are not explicitly stated, but it is mentioned that his recent biopsy was only remarkable for chronic inflammation compatible with chronic viral hepatitis, suggesting his ALT is likely < 5 * ULN.\n\nThere is no mention of him being cirrhotic or having a Child Pugh class B or C, so he likely does not meet those exclusion criteria.\n\nBased on the information provided, this patient appears to meet all the key inclusion criteria for this hepatitis B clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1565": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Treatment na\u00efve\nThe patient note does not explicitly state if the patient is treatment naive or not. It mentions that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", which suggests he is not treatment naive.\n\n2. Age 18 and older\nThe patient is 55 years old, so he meets this criterion.\n\n3. Anti-HCV positive > 6 months\nThe patient note states that he was \"diagnosed with HCV 2 years ago\", so he meets this criterion.\n\n4. Detectable serum quantitative HCV-RNA with HCV RNA > 800,000 IU/mL\nThe patient note does not provide the exact HCV RNA level, so this criterion cannot be evaluated.\n\n5. HCV genotype 1\nThe patient note does not specify the HCV genotype.\n\n6. A liver biopsy consistent with the diagnosis of chronic hepatitis C\nThe patient note mentions that the \"recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis.\"\n\nBased on the information provided in the patient note, there is not enough information to definitively determine if the patient meets all the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1566": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with HCV and HBV co-infection. He is currently on treatment with IFN, RBV, and direct antiviral drugs for the past 6 months.\n\nThe clinical trial is evaluating the diagnostic accuracy of the Abbott RealTime HCV Genotype II test for determining HCV genotypes in HCV-infected individuals.\n\nThe inclusion criteria for the trial are:\n1) HCV patients with both positive for anti-HCV and HCV RNA\n2) Patients with signed informed consent\n\nBased on the patient note, the patient meets the first inclusion criteria as he is HCV positive with detectable HCV RNA levels.\n\nHowever, there is no information provided about whether the patient has signed an informed consent to participate in the trial.\n\nTherefore, there is insufficient information to determine if the patient is fully eligible for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1567": {
        "output": "To determine the patient's eligibility for the clinical trial \"A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)\", let's go through the inclusion criteria:\n\n1. Baseline health is stable.\nThe patient note mentions that the patient is \"an alert male with no acute distress\", and his vital signs (BP, HR, BMI) are within normal ranges. There is no indication of unstable health conditions.\n\n2. Has a clinical diagnosis of chronic HCV infection.\nThe patient note clearly states that the patient was diagnosed with HCV 2 years ago and has been receiving treatment for 6 months. Previous positive HCV RNA tests and anti-HCV antibodies are also mentioned.\n\nBased on the information provided in the patient note, the patient meets both inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "1568": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nDISEASE CHARACTERISTICS:\n- Diagnosis of hepatocellular carcinoma (HCC) - The patient is diagnosed with HCV and HBV co-infection, but not explicitly with HCC, so this criterion is not met.\n\nPATIENT CHARACTERISTICS:\n- ECOG performance status 0-1 - No information provided about performance status.\n- Life expectancy \u2265 12 weeks - No information provided about life expectancy. \n- Hemoglobin \u2265 9.0 g/dL - No information provided about hemoglobin levels.\n- ANC \u2265 1,500/mm\u00b3 - No information provided about ANC.\n- Platelet count \u2265 75,000/mm\u00b3 - No information provided about platelet count.\n- Creatinine \u2264 1.5 times upper limit of normal (ULN) OR creatinine clearance \u2265 50 mL/min - No information provided about creatinine levels.\n- Total bilirubin \u2264 3 mg/dL - No information provided about bilirubin levels.\n- ALT and AST \u2264 5 times ULN - No information provided about ALT and AST levels.\n- INR < 1.5 - No information provided about INR.\n- Negative pregnancy test - Not applicable as patient is male.\n- Fertile patients must use effective contraception - Not applicable as patient is male.\n- No other cancer within the past 3 years except specific conditions - Meets this criterion based on information provided.\n- No NYHA class III or IV congestive heart failure - No information provided about heart failure status.\n- No unstable angina or new-onset angina within past 3 months - No information provided about angina.\n- No myocardial infarction within past 6 months - No information provided about myocardial infarction.\n- No cardiac arrhythmias requiring anti-arrhythmic therapy - No information provided about arrhythmias.\n- No uncontrolled hypertension - Blood pressure 130/75 provided, which meets this criterion.\n- No venous thrombotic/embolic events within past 6 months - No information provided about this.\n- No pulmonary hemorrhage/bleeding events > Grade 2 in past 12 weeks - No information provided about this.\n- No other hemorrhage/bleeding events > Grade 3 in past 12 weeks - No information provided about this.\n- No variceal bleeding within past 12 weeks - No information provided about this.\n- No known Grade 2 or 3 esophageal varices - No information provided about this.\n- No evidence or history of bleeding diathesis or coagulopathy - No information provided about this.\n- No significant traumatic injury within past 12 weeks - No information provided about this.\n- No serious non-healing wound, ulcer or fracture - No information provided about this.  \n- No significant proteinuria - No information provided about proteinuria.\n- No HIV positivity - Meets this criterion based on information provided.\n- No active hepatitis B or C, unless stable on medications for \u22652 months - Does not meet this criterion as patient has active HBV and HCV infections.\n- No active clinically serious infections (>Grade 2) - No information provided about infections.\n- No active gastrointestinal malabsorption problem - No information provided about this.\n- No condition that would impair ability to swallow pills - No information provided about this.\n- No active drug or alcohol abuse - No information provided about this.\n- No known severe hypersensitivity to sorafenib or other study drugs - No information provided about allergies.\n- No condition hampering compliance with study - No information provided about this.\n\nPRIOR CONCURRENT THERAPY:\n- No prior systemic therapy, embolic therapy, or radiotherapy for HCC - Meets this criterion based on information provided.\n- At least 4 weeks since prior liver resection or ablation and recovered - No information about prior procedures provided.\n- No prior Raf/MEK/ERK or VEGF-targeted therapy - Meets this criterion based on information provided.  \n- More than 4 weeks since prior investigational drug study - No information provided about this.\n- More than 12",
        "label": 0
    },
    "1569": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection. He is being treated with interferon, ribavirin, and direct antiviral drugs for the past 6 months.\n\nThe clinical trial is titled \"Human Anaplasmosis in Eastern France\" and is studying the epidemiology and clinical symptoms of anaplasmosis, a tick-borne infection.\n\nThe inclusion criteria for the trial are:\n1) Patient with at least one of the following symptoms: fever, muscle pain, joint pain, respiratory signs, neurological signs, meningitis, or erythema occurring within 3 weeks after a tick bite.\n2) Patient with fever and at least one of the following: thrombocytopenia, leukopenia, hepatitis, without any other cause that can explain these abnormalities.\n3) Patient with tick-borne encephalitis or primary stage Lyme borreliosis.\n\nBased on the patient note provided, there is no mention of the patient having any of the symptoms listed in the inclusion criteria, such as fever, muscle pain, joint pain, respiratory signs, neurological signs, meningitis, erythema, thrombocytopenia, leukopenia, tick-borne encephalitis, or Lyme borreliosis.\n\nThe patient note only mentions that the patient has HCV and HBV co-infection and is being treated for it. There is no information provided that would suggest the patient meets the inclusion criteria for the anaplasmosis clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1570": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 55-year-old man diagnosed with:\n- HCV 2 years ago \n- Recent coinfection with HBV\n- On treatment with IFN, RBV and direct antiviral drugs for 6 months\n\nThe inclusion criteria for the HBV arm of the trial are:\n- Patient has been carrying HBsAg for over 6 months (unclear from note if this patient meets this)\n- ALT >= 2x upper limit of normal \n- HBV-DNA level: 10^4 copies/mL for HBeAg(-) or 10^5 copies/mL for HBeAg(+) (HBeAg status not provided)\n\nThere is no mention of the patient having hepatocellular carcinoma (HCC), so they would not meet the inclusion criteria for the HCC arm.\n\nThe exclusion criteria do not seem to apply based on the limited information provided.\n\nOverall, there is insufficient information to determine if the patient meets all the inclusion criteria for the HBV arm of the trial. Key missing details are HBsAg carrier status duration, ALT level, HBV-DNA level, and HBeAg status.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 2
    },
    "1571": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of 18-55 years old.\n\n2. The patient is diagnosed with HCV and HBV co-infection, which is not mentioned in the inclusion/exclusion criteria. However, the trial is studying muscle pain induced by eccentric exercise, so the liver conditions may not be directly relevant.\n\n3. The patient is taking IFN, RBV, and direct antiviral drugs, but there is no mention of these medications being exclusion criteria.\n\n4. The patient's medical history and physical examination do not reveal any conditions that would exclude him from the trial based on the given inclusion criteria.\n\n5. The inclusion criteria specifically state that subjects should be in good health as determined by the investigator, and the patient's vitals and physical examination suggest he is in good health.\n\n6. There is no information provided about the patient's willingness to abstain from physical therapy, hard physical work, exercise, or sauna during the study period.\n\n7. There is no information provided about the patient's gender or potential childbearing status, which is one of the inclusion criteria.\n\nBased on the information provided, there is not enough evidence to definitively determine the patient's eligibility for the trial. Some key information is missing, such as the patient's gender, childbearing potential (if female), and willingness to abstain from physical activity during the study period.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1572": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\nAge \u2265 18: The patient is 55 years old, so this criterion is met.\n\nDocumented HIV-1 infection, hepatitis B or C co-infection is allowed: The patient is documented to have HCV and HBV co-infection, so this criterion is met.\n\nPlasma viral load at screening visit below 50 copies per mL for at least 6 months: The note does not mention the patient's viral load, so there is not enough information to assess this criterion.\n\nPatient with severe liver failure (Meld Score \u2265 15 and/or refractory ascites and/or haemorrhage of digestive tract and/or hepatic encephalopathy) for taking part into period 1: The note does not provide the patient's MELD score or indicate the presence of refractory ascites, hemorrhage, or hepatic encephalopathy, so there is not enough information to assess this criterion.\n\nPatient eligible for the liver transplant waiting list or immediate post transplantation for taking part into period 2: The note does not indicate whether the patient is eligible for a liver transplant waiting list, so there is not enough information to assess this criterion.\n\nAbstinence from alcohol intake for at least 6 months (WHO norm): The note does not mention the patient's alcohol intake, so there is not enough information to assess this criterion.\n\nWithdrawal from intravenous drug use for at least 6 months (methadone substitution is permitted): The note does not mention intravenous drug use, so there is not enough information to assess this criterion.\n\nNo ongoing class C opportunistic infection (1993 CDC classification): The note does not mention any opportunistic infections, so there is not enough information to assess this criterion.\n\nPatient whose clinical and immunovirological condition allows triple therapy with raltegravir + 2 NRTI or raltegravir + NRTI + enfuvirtide: The note does not provide enough details about the patient's clinical and immunovirological condition to assess this criterion.\n\nPatient whose HIV population, according to cumulative genotypes carried out on viral RNA together with treatment history (if available and interpreted as per the ANRS-AC11 algorithm version no.19) does not present a profile of mutations associated with resistance to raltegravir and is sensitive to at least two fully active* agents selected among nucleoside/nucleotide reverse transcriptase analogs NRTI (abacavir, lamivudine, emtricitabine, tenofovir) or enfuvirtide: The note does not provide information about the patient's HIV genotype or resistance profile, so there is not enough information to assess this criterion.\n\nPatient not having experienced viral escape during treatment combining 3TC, FTC or raltegravir: The note does not mention the patient's treatment history or viral escape, so there is not enough information to assess this criterion.\n\nPatient registered with or covered by a social security scheme: The note does not mention the patient's insurance or social security coverage, so there is not enough information to assess this criterion.\n\nFor women of child-bearing potential, use of a barrier contraceptive method during sexual intercourse and negative pregnancy test (plasma \u00df-HCG ) at screening visit: The patient is a man, so this criterion is not applicable.\n\nInformed consent form signed at screening visit at the latest: The note does not mention whether the patient has provided informed consent, so there is not enough information to assess this criterion.\n\nIn summary, while the patient meets the age criterion and has documented HIV and hepatitis co-infection, there is not enough information provided in the note to determine eligibility for most of the other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1573": {
        "output": "To determine the patient's eligibility for the clinical trial \"Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients\", let's go through the inclusion criteria:\n\n1. \"Medically recommended influenza A(H1N1) immunization\"\nThe patient note does not mention whether the patient is recommended for influenza A(H1N1) immunization or not. There is no information about the patient's risk factors for influenza complications.\n\n2. \"Signed informed consent\"\nThe patient note does not provide any information about whether the patient has signed an informed consent or not.\n\nSince there is not enough information in the patient note to determine if the patient meets the inclusion criteria, the assessment would be:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1574": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step to determine the trial-level eligibility for this clinical trial:\n\nThe patient is a 55-year-old man, which meets the age criteria of >18 years.\n\nHe is diagnosed with HCV and HBV co-infection, which falls under the allowed etiologies of \"chronic viral hepatitis B, chronic viral hepatitis C\" for end-stage liver disease.\n\nHis medical history and examination findings do not indicate any contraindications listed in the exclusion criteria.\n\nThe only potential issue is that his MELD score is not provided, which is required to be between 17 and 25 per the inclusion criteria. However, since he is described as having end-stage liver disease, it is reasonable to assume his MELD score likely falls within that range unless stated otherwise.\n\nGiven that he meets the age requirement, has an eligible etiology of end-stage liver disease, and does not have any clearly documented exclusion criteria, the most appropriate assessment would be:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1575": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Efficacy and Safety of Aripiprazole in First Episode Psychosis\", the patient does not seem to be eligible for this trial.\n\nThe patient note indicates that the patient is a 55-year-old man diagnosed with Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) co-infection, and is currently receiving treatment with interferon, ribavirin, and direct antiviral drugs. There is no mention of the patient having a first episode of psychosis or being diagnosed with schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS.\n\nThe inclusion criteria for the clinical trial specifically require participants to be aged 18-59 years and meet the DSM-IV diagnostic criteria for a first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS.\n\nSince the patient note does not indicate that the patient meets these criteria, the patient would not be eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1576": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of \u2265 18 years old.\n\n2. The patient has been diagnosed with HCV and HBV co-infection, but the trial is for metastatic melanoma. So the disease characteristics do not match.\n\n3. The patient is on IFN, RBV and direct antiviral drugs, but the trial excludes patients receiving concurrent chemotherapy or other immunotherapy.\n\n4. There is no information provided about the patient's HLA status or whether their tumor presents HLA-A2.1/p53aa264-272 complexes, which is an inclusion criteria.\n\n5. The patient's medical history and current status suggest they may meet the other patient characteristic criteria like performance status, bone marrow reserve, renal/hepatic function, cardiovascular status, etc. But there are no definitive details provided.\n\nBased on the information given, the patient does not clearly meet all the key inclusion criteria for the metastatic melanoma trial, and is potentially excluded due to receiving concurrent antivirals. There is also insufficient information to definitively assess some criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1577": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient note states:\n- 55-year-old man\n- Diagnosed with HCV 2 years ago and recent coinfection with HBV\n- On IFN, RBV and direct antiviral drugs for the past 6 months\n- No other significant medical history\n- Recent biopsy negative for hepatocellular carcinoma\n- No evidence of other liver diseases\n- Vitals within normal range\n\nThe inclusion criteria for the clinical trial state:\n- Male or female between 18 and 50 years of age, inclusive\n- In general good health, without significant medical illness\n- Demonstrate comprehension of protocol procedures \n- Willing to participate after informed consent\n- Available for all planned follow-up visits\n- Negative pregnancy test for females\n- Effective birth control for females during study\n\nBased on the information provided, this patient does not meet the age criteria as he is 55 years old and the trial requires participants between 18-50 years old. Additionally, the patient has HCV and HBV coinfection, which could be considered a significant medical illness and may exclude him from participating.\n\nWhile there is not enough information to definitively determine if he meets all the other criteria, the age and medical condition alone would likely exclude him from this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1578": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronically infected patients with Hepatitis C virus Genotype 1 (1a or 1b) with detectable viremia (HCV RNA in blood) for more than 6 months and na\u00efve to treatment;\nThe patient note mentions the patient was diagnosed with HCV 2 years ago, so he meets this criteria.\n\n2. Patients must have compensated liver disease, with no history of ascites, jaundice, hepatic encephalopathy or bleeding from esophageal or gastric varices requiring beta-blockers;\nThe patient note does not mention any of those conditions, so he likely meets this criteria.\n\n3. No histological evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 24 months prior to baseline; or on a FibroScan\u00ae performed within 6 months prior to treatment which indicates the absence of liver cirrhosis, i.e., stage < F4 (METAVIR); in case of no available results, a liver biopsy will be performed prior to treatment;\nThe recent biopsy was negative for hepatocellular carcinoma, so he meets this criteria.\n\n4. All laboratory parameters must be grade 0 or 1 (as per CTCAE criteria) except for alanine amino-transferase (ALT), aspartate amino-transferase (AST), gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) for which a grade 2 will be allowed if stated non clinically significant;\nNo information is provided about lab parameters, so this cannot be assessed.\n\n5. No co-infection with Human Immunodeficiency Virus (HIV) or hepatitis B virus (HBsAg positive);\nThe patient note mentions a recent coinfection with HBV, so he does not meet this criteria.\n\n6. No intravenous (IV) drug or alcohol abuse;\nThe patient note does not mention any IV drug or alcohol abuse, so he likely meets this criteria.\n\n7. Serum thyroid stimulating hormone (TSH) levels within normal ranges, regardless of treatment with L-thyroxin;\nNo information about TSH levels is provided.\n\n8. Normal electrocardiogram (ECG); \nNo ECG results are mentioned.\n\n9. Normal retinal examination (eye fundus) within last 12 months for diabetic patients or patients suffering from high blood pressure;\nNo information about retinal exams or diabetes/hypertension is provided.\n\n10. Negative pregnancy test in women of childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential);\nThis does not apply as the patient is a man.\n\n11. Female patients and female partners of male patients (if childbearing potency) must agree to use two effective methods of birth control during the study and for 6 months after the end of treatment. One of the methods needs to be a 'barrier' method (condom or diaphragm);\nNo information about the patient's partner is provided.\n\nBased on the information provided, the patient meets some but not all of the inclusion criteria. The major exclusion is the recent coinfection with hepatitis B virus.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1579": {
        "output": "Okay, let's go through the patient note and inclusion criteria step-by-step:\n\nThe patient is a 55-year-old man diagnosed with chronic hepatitis C virus (HCV) infection 2 years ago and recently co-infected with hepatitis B virus (HBV). This matches the first inclusion criteria of \"proven chronic hepatitis C\".\n\nThe patient's age of 55 falls within the age range of 18-65 specified in the second inclusion criteria.\n\nThe note does not explicitly mention whether the patient has given written informed consent, which is the third inclusion criteria. However, this is likely obtained before enrolling in a clinical trial.\n\nThere is no information provided that would exclude the patient based on the trial's exclusion criteria (which are not given).\n\nBased on the information provided, the patient appears to meet the stated inclusion criteria for the clinical trial on cellular immune responses in chronic hepatitis C patients.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1580": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Subject giving his written informed consent - Not mentioned in the patient note, so cannot determine eligibility for this.\n\n2. Male from 20 to 35 years old and more than 60 - The patient is a 55-year-old man, so he meets this criterion.\n\n3. Affiliated to the French National Health Insurance - Not mentioned, so cannot determine eligibility.\n\n4. Body mass index (BMI) \u2264 25kg/m\u00b2 and waist circumference \u226494cm ; or BMI \u2265 28kg/m\u00b2 and waist circumference \u2265 102cm - The patient's BMI is 27, which falls in between the two ranges specified. However, his waist circumference is not provided, so cannot fully assess eligibility for this criterion.\n\n5. Complete blood count (CBC)-platelet, normal liver function and normal coagulation - Not mentioned, so cannot determine eligibility.\n\n6. Serology of Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) negative - The patient note states he was diagnosed with HCV 2 years ago, so he does not meet this criterion.\n\n7. normal Thyroid Stimulating Hormone(TSH) - Not mentioned, so cannot determine eligibility.\n\nSince the patient does not meet at least one of the inclusion criteria (HCV negative) and there is insufficient information to assess some other criteria, I would determine:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1581": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronic hepatitis C virus (HCV), genotype 1 infection (HCV ribonucleic acid level greater than or equal to 100,000 IU/mL) at screening\n- The patient note mentions the patient was diagnosed with HCV 2 years ago, so this criterion is likely met.\n\n2. Liver biopsy within 3 years with histology consistent with HCV-induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV\n- The recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation compatible with chronic viral hepatitis, meeting this criterion.\n\n3. Treatment na\u00efve male or female between the ages of 18 and 65\n- The patient is a 55-year-old man, meeting the age criterion. However, the note mentions he is on IFN, RBV and direct antiviral drugs for the past 6 months, so he is not treatment-naive.\n\n4. Females must be post-menopausal for more than 2 years or surgically sterile\n- Not applicable as the patient is male.\n\n5. Negative screen for drugs and alcohol\n- No information provided, so cannot assess this criterion.\n\n6. Negative hepatitis B surface antigen (HBsAg) and anti-human immunodeficiency virus antibodies (anti-HIV Ab)\n- The note mentions recent coinfection with HBV, so the patient would not meet this criterion.\n\n7. No use of cytochrome P450 3A (CYP3A) and cytochrome P450 2C8 (CYP2C8) enzyme inducers or inhibitors within 1 month of dosing\n- No information provided, so cannot assess this criterion.\n\n8. Be in a condition of general good health, as perceived by the investigator, other than HCV infection\n- The patient seems to be in generally good health based on the information provided.\n\nOverall, while the patient meets some of the key criteria like having chronic HCV genotype 1 infection and liver damage from HCV, he does not meet the criteria of being treatment-naive and having no HBV coinfection.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1582": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with HCV and recent HBV co-infection. He is currently on treatment with IFN, RBV and direct antiviral drugs for HCV.\n\nThe clinical trial is examining the role of nitazoxanide in preventing recurrence of HCV after liver transplantation.\n\nThe key inclusion criteria are:\n1) Adult patients aged 18-75 \n2) HCV infection identified by positive, quantifiable HCV RNA prior to transplant\n\nThis patient meets the age criteria (55 years old). He also has a confirmed HCV infection with positive HCV RNA tests.\n\nHowever, one of the exclusion criteria not mentioned is HBV co-infection, which this patient has.\n\nTherefore, based on the information provided:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1583": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the inclusion criteria of being an adult.\n2. The patient is diagnosed with HCV and HBV co-infection, not alcoholic liver disease (ALD). Therefore, he does not meet the inclusion criteria of \"Excess alcohol intake\" and \"Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) or a suspicion of cirrhosis related to ALD\".\n3. The patient's ethnicity is not mentioned, so we cannot determine if he meets the \"Caucasian ethnicity\" inclusion criteria.\n\nBased on the information provided, the patient does not seem to meet the key inclusion criteria for this clinical trial on alcoholic liver disease.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1584": {
        "output": "Okay, let's go through this step-by-step:\n\nThe patient is a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection. He is currently being treated with interferon (IFN), ribavirin (RBV), and direct antiviral drugs for the past 6 months.\n\nThe clinical trial is titled \"Role of CCL2 in Alcoholic Liver Diseases\" and is studying the role of the chemokine CCL2 in the pathogenesis of alcoholic liver disease (ALD).\n\nThe inclusion criteria for the trial are:\n1. Excess alcohol intake\n2. Abnormality of liver biopsy compatible with alcoholic etiology\n3. Caucasian ethnicity\n\nBased on the patient note, there is no mention of excess alcohol intake or a liver biopsy compatible with alcoholic liver disease. The patient's liver disease appears to be due to viral hepatitis (HCV and HBV) rather than alcoholic liver disease.\n\nTherefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1585": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. HIV infected patients, age >18 years\nThe patient note states the patient is 55 years old, so this criterion is met.\n\n2. meet Vietnam guideline to begin ART (CD4 count < 350 cells/mm3 and/or WHO stage III or IV disease)\nThere is no information provided about the patient's CD4 count or WHO disease stage, so it's unclear if this criterion is met.\n\n3. Hepatitis C infection as documented by positive HCV antibodies and a detectable serum HCV RNA level\nThe patient note mentions the patient was diagnosed with HCV 2 years ago and has had positive HCV RNA tests, so this criterion is met.\n\n4. AST and ALT \u2264 2 x ULN (\u2264 80 U/L)\nThere is no information provided about the patient's AST and ALT levels.\n\n5. Estimated creatinine clearance \u2265 60 mL/min\nThere is no information provided about the patient's creatinine clearance.\n\nSince there is insufficient information to determine if criteria 2, 4, and 5 are met, I would assess this patient as:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "1586": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial \"A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee\", the patient does not seem to be eligible for this trial.\n\nThe key points are:\n\n1. The patient note does not mention any diagnosis or symptoms related to osteoarthritis of the knee.\n2. The patient is described as having hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection, and is currently undergoing treatment for the same.\n3. The inclusion criteria specifically require patients to have a diagnosis of osteoarthritis of the knee, confirmed by an X-ray.\n\nSince the patient does not have osteoarthritis of the knee, which is the primary condition being studied in this trial, the patient is not eligible for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1587": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Infection with HCV genotype 1 or 4 (subjects infected with multiple genotypes are not eligible)\n- The patient note mentions the patient is diagnosed with HCV, but does not specify the genotype. This criterion cannot be evaluated based on the information provided.\n\n2. BMI greater than 25 Kg/m2  \n- The patient's BMI is given as 27, which meets this criterion.\n\n3. HCV-infected subjects na\u00efve to treatment: subjects who either have never been treated for HCV infection or who previously received HCV treatment ending more than 3 months prior to enrollment for not longer than 2 weeks\n- The patient note states the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months.\" This suggests the patient is currently undergoing treatment and would not meet this criterion.\n\n4. Plasma HCV RNA concentration of >10,000 IU/mL at the screening evaluation\n- There is no information provided about the patient's current HCV RNA levels.\n\nBased on the information in the patient note, the patient meets 1 of the 4 inclusion criteria, does not meet 1 criterion, and there is not enough information to evaluate the other 2 criteria.\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial)",
        "label": 1
    },
    "1588": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria step-by-step:\n\nInclusion Criteria:\nChronic HCV genotype 1 naive patients\n\nFrom the patient note, we know that:\n- The patient is a 55-year-old man diagnosed with HCV 2 years ago.\n- The patient is co-infected with HBV.\n- The patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies.\n- There is no mention of the HCV genotype in the patient note.\n\nSince the patient's HCV genotype is not specified, we cannot determine if they meet the inclusion criteria of having chronic HCV genotype 1. Additionally, the patient is co-infected with HBV, which is not mentioned in the inclusion criteria.\n\nTherefore, based on the information provided, we do not have sufficient information to determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1589": {
        "output": "Okay, let's go through this step-by-step:\n\n1. The patient is a 55-year-old man, which meets the age criteria of being less than 18 years old for this pediatric trial.\n\n2. The patient has chronic hepatitis B, which is required based on the inclusion criteria. This is evidenced by the positive HBsAg tests and clinical history.\n\n3. However, the trial specifically states it is for children and adolescents aged 2 to less than 18 years old. At 55 years old, the patient does not meet this key inclusion criteria.\n\n4. There is no information provided about whether the patient or parent/legal guardian is willing and able to provide written informed consent, which is another inclusion criteria.\n\n5. Based on the age criteria alone, this 55-year-old patient would be ineligible for this pediatric chronic hepatitis B trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "1590": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects chronically infected with HCV genotype 1\nThe patient note does not specify the HCV genotype, so there is not enough information to determine if this criterion is met.\n\n2. Non-responder to prior therapy with peginterferon alfa and ribavirin\nThe patient note states that the patient is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", indicating they have received prior peginterferon and ribavirin therapy. However, it does not specify if they were a non-responder.\n\n3. HCV RNA viral load of 100,00 IU/mL\nThe patient note mentions previous positive HCV RNA tests, but does not provide the specific viral load value.\n\n4. Results of a liver biopsy \u2264 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population)\nThe patient note states that the recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis, meeting this criterion.\n\n5. Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma\nThe patient note mentions that the recent biopsy was negative for hepatocellular carcinoma, satisfying this criterion.\n\n6. Body Mass Index (BMI) of 18 to 35 kg/m2\nThe patient note provides the BMI as 27, which falls within the specified range.\n\nBased on the information provided in the patient note, there is not enough information to definitively determine eligibility for this clinical trial. Some key details, such as the HCV genotype, viral load, and prior treatment response, are missing.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1591": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Males and females, aged 18 years and older\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Chronic hepatitis C genotype 1 (as specified in the protocol)\nThe patient note mentions he was diagnosed with HCV 2 years ago, but does not specify the genotype. More information is needed to assess this criterion.\n\n3. Treatment naive\nThe patient note states he is \"on IFN, RBV and direct antiviral drugs for the past 6 months\", so he does not meet this criterion of being treatment naive.\n\n4. Females criteria\nNot applicable since the patient is male.\n\nSince the patient does not meet the \"treatment naive\" criterion, he would be excluded from this particular clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1592": {
        "output": "Okay, let's go through the inclusion and exclusion criteria for this clinical trial step-by-step:\n\nInclusion Criteria:\n1. Latino ethnicity - The patient note does not mention the patient's ethnicity, so this cannot be evaluated.\n2. Age >= 18 years - The patient is 55 years old, so this criterion is met.\n3. Documentation of hepatitis C infection - The patient note states the patient was diagnosed with HCV 2 years ago, so this criterion is met.\n4. Documentation of HIV-1 infection for co-infected group - The patient note mentions a recent co-infection with HBV, but does not mention HIV, so this cannot be evaluated for the co-infected group.\n5. For HIV patients: CD4+ cell counts >= 100 cells/mm^3 or CD4+ percentage >= 14% - Not applicable since HIV status is unknown.\n6. Ability to provide informed consent and comply with study requirements - Not mentioned in the patient note, so cannot be evaluated.\n7. Has a primary care physician managing medical problems - The patient note does not mention this, so cannot be evaluated.\n8. For HIV patients, care consistent with DHHS guidelines - Not applicable.\n9. Willing to undergo genetic testing - Not mentioned, so cannot be evaluated.\n10. About to start HCV treatment with or without direct-acting antivirals - The patient note states the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is met.\n\nExclusion Criteria:\n1. Unable to comply with research study visits - Not mentioned, so cannot be evaluated.\n2. Any condition contraindicated for study participation - Not mentioned, so cannot be evaluated.\n3. Pregnant or breastfeeding women - The patient is a man, so this does not apply.\n4. Poor venous access - Not mentioned, so cannot be evaluated.\n\nIn summary, the patient meets at least 3 of the inclusion criteria (age, HCV diagnosis, currently on treatment), but there is not enough information to determine if he meets all the other criteria. Some key missing information is the patient's ethnicity and HIV status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "1593": {
        "output": "Okay, let's go through the patient note and inclusion/exclusion criteria for this clinical trial step-by-step:\n\nThe patient is a 55-year-old man, so he meets the age criteria of \u226518 years old.\n\nHe has documented HIV-1 infection and chronic HCV infection, which are required.\n\nHe is co-infected with HCV genotype 1, which is an inclusion criteria. \n\nHe has received previous HCV treatment with IFN, RBV and direct antivirals but did not respond, making him a non-responder which is allowed per the inclusion criteria.\n\nHis CD4 count is not mentioned but is likely >100 cells/mm3 since he is being treated with antivirals. \n\nThere is no mention of him being pregnant or breastfeeding.\n\nHis lab values like neutrophil count, platelets, hemoglobin seem normal based on the limited information provided.\n\nThere is no evidence he has any of the exclusion criteria like cirrhosis, hepatocellular carcinoma, organ transplant, severe cardiac/pulmonary/psychiatric disease, etc.\n\nBased on the information provided, he seems to meet the key inclusion criteria and none of the exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible",
        "label": 0
    },
    "1594": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Subjects chronically infected with HCV genotype 1 as documented by: positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to Screening, and positive for HCV RNA and anti-HCV antibody at Screening\n- The patient note states that the patient was diagnosed with HCV 2 years ago and has had previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies. This criterion is met.\n\n2. HCV RNA \u2265 10^5 IU/mL at Screening\n- There is no information about the patient's HCV RNA level at screening, so this cannot be definitively assessed.\n\n3. Less than 4 weeks total prior therapy with an IFN formulation (ie, IFN\u03b1, pegIFN\u03b1-2a), or RBV and no exposure to IFN or RBV within 24 weeks of Randomization\n- The patient note states that the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is not met.\n\n4. Results of a biopsy obtained \u2264 24 months prior to Randomization showing no evidence of cirrhosis\n- The patient note mentions that the recent biopsy was negative for hepatocellular carcinoma and only showed chronic inflammation, so there is no evidence of cirrhosis. This criterion is met.\n\n5. Body Mass Index (BMI) of 18 to 35 kg/m\u00b2, inclusive. BMI = weight (kg)/ [height (m)]\u00b2 at Screening\n- The patient's BMI is given as 27, which falls within the required range.\n\nSince the patient does not meet criterion 3 due to being on IFN/RBV therapy for over 4 weeks, and there is insufficient information about the HCV RNA level, I would assess:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "1595": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Chronically infected with HCV genotype 1\nThe patient note states that the patient was diagnosed with HCV 2 years ago, so this criterion is met.\n\n2. HCV treatment-na\u00efve\nThe patient note mentions that the patient is on IFN, RBV and direct antiviral drugs for the past 6 months, so this criterion is not met as the patient has received treatment.\n\n3. Not co-infected with HIV or HBV\nThe patient note states that the patient has a recent coinfection with HBV, so this criterion is not met.\n\n4. HCV RNA viral load of at least 100,000 IU/mL\nThe patient note does not provide information about the HCV RNA viral load, so it is unclear if this criterion is met or not.\n\n5. BMI 19 to 35 kg/m2\nThe patient's BMI is 27, which falls within the specified range, so this criterion is met.\n\n6. Subject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male.\nThe patient note does not provide information about the patient's willingness to use contraception, so it is unclear if this criterion is met or not.\n\nSince the patient does not meet at least two of the inclusion criteria (HCV treatment-na\u00efve and not co-infected with HBV), and there is insufficient information to determine if the patient meets the viral load and contraception criteria, the patient cannot be considered eligible for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1596": {
        "output": "Based on the given patient note and the inclusion criteria for the clinical trial titled \"Self Medication With Oral Morphine After Total Knee Arthroplasty,\" the patient does not meet the inclusion criteria for this trial.\n\nThe patient note describes a 55-year-old man diagnosed with hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection, undergoing treatment with interferon, ribavirin, and direct antiviral drugs. There is no mention of the patient requiring or undergoing total knee replacement surgery, which is the primary inclusion criterion for the given clinical trial.\n\nTherefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1597": {
        "output": "Based on the provided patient note and the inclusion criteria for the clinical trial titled \"Efficacy Maxinom\u00ae And Maxitrol\u00ae in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis\", the patient does not seem to be eligible for this trial.\n\nThe key reasons are:\n\n1. The patient note does not mention any eye-related condition or acute bacterial conjunctivitis, which is a requirement for inclusion in this trial.\n\n2. The patient note describes the patient's medical history related to hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, as well as the treatments he is receiving for these conditions.\n\n3. The inclusion criteria specifically state that patients should present with a clinical picture of acute bacterial conjunctivitis at the screening visit, which is not the case for this patient.\n\nTherefore, based on the available information, the patient does not meet the inclusion criteria for this particular clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "1598": {
        "output": "To determine the patient's eligibility for the clinical trial, let's go through the inclusion criteria one by one:\n\n1. Chronic hepatitis C: The patient note mentions that the patient was diagnosed with HCV 2 years ago, so this criterion is met.\n\n2. Chronic hepatitis B: The patient note also mentions a recent coinfection with HBV, so this criterion is met.\n\n3. Alcoholic liver disease: There is no evidence of alcoholic liver disease mentioned in the patient note.\n\n4. Non-alcoholic steatohepatitis: There is no mention of non-alcoholic steatohepatitis in the patient note.\n\nSince the patient meets at least one of the inclusion criteria (chronic hepatitis C and chronic hepatitis B), and there is no information provided that would exclude the patient based on the trial's exclusion criteria, the patient can be considered eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "1599": {
        "output": "Okay, let's go through the inclusion criteria for this clinical trial step-by-step:\n\n1. Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years post-menopausal and are required to take a pregnancy test)\nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Body Mass Index (BMI) 18 - 32 kg/m2\nThe patient's BMI is 27, which falls within this range.\n\n3. Chronically infected with hepatitis C genotype-1 virus\nThe patient is infected with HCV genotype 1, so he meets this criterion.\n\n4. Serum HCV RNA > 5 log10 IU/mL\nThe patient's medical records show positive HCV RNA tests, so he likely meets this criterion (though an exact value is not provided).\n\n5. No previous treatment with interferon, peginterferon, ribavirin or any investigational HCV antiviral agents\nThe patient is currently on IFN, RBV and direct antiviral drugs, so he does not meet this exclusion criterion.\n\n6. No history of signs or symptoms of decompensated liver disease\nThere is no mention of decompensated liver disease in the patient note.\n\n7. No known history of cirrhosis\nThere is no mention of cirrhosis in the patient note.\n\n8. No co-infection with HBV, HIV-1, HIV-2\nThe patient is co-infected with HBV, so he does not meet this exclusion criterion.\n\n9. No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study\nThere is no mention of any such conditions in the patient note.\n\n10. No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)\nThere is no mention of alcohol abuse, illicit drug use, or methadone maintenance in the patient note.\n\nBased on the information provided, the patient does not meet criteria 5 and 8 due to being on current HCV treatment and having a co-infection with HBV.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "1600": {
        "output": "Okay, let's go through the inclusion criteria one by one for this patient:\n\n1. Males and females between 18 and 70 years old. \nThe patient is a 55-year-old man, so he meets this criterion.\n\n2. Subjects diagnosed to have positive HCV antibodies using a third generation test.\nThe patient's medical records show previous positive HCV RNA tests and a positive enzyme immunoassay for anti-HCV-antibodies, so he meets this criterion.\n\n3. Subject is diagnosed to have detectable HCV RNA by PCR.\nThis is not explicitly stated, but it is implied since the patient is on treatment for HCV.\n\n4. Liver biopsy or FibroTest showing a METAVIR score \u2265F2 and/or \u2265A2. \nThe recent biopsy was negative for hepatocellular carcinoma but remarkable for chronic inflammation compatible with chronic viral hepatitis, suggesting he likely meets this criterion.\n\n5. Subject diagnosed to have compensated liver disease.\nThere is no evidence of decompensated liver disease based on the patient note.\n\n6. Subject is non-responder (null or partial) on prior Peg-IFN and RBV based treatment lasting for at least 12 consecutive weeks.\nThis is not explicitly stated, but the patient is on IFN, RBV and direct antiviral drugs, suggesting he may have failed prior Peg-IFN and RBV treatment.\n\n7. Treatment not discontinued due to intolerability to Peg-IFN or RBV.\nThis is not mentioned, so we can assume it was not discontinued due to intolerability.\n\n8. Subjects able to comprehend and give informed consent for participation in this study.\nThis is typically assumed unless stated otherwise.\n\n9. Subject is willing to be treated and commit to all visits.\nThis is typically assumed unless stated otherwise.\n\nBased on the information provided, the patient seems to meet most of the key inclusion criteria. There are a couple of minor criteria that are not definitively stated but can be reasonably inferred.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    }
}